<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Adults and children with known or suspected thyroid neoplasm will be considered for
        participation.  Enrollment will be capped accordingly:

          1. Patients with thyroid nodules requiring evaluation and possible biopsy (no more than
             30 per year);

          2. Patients with recent diagnosis of thyroid cancer requiring consultation and
             counseling about therapeutic options (no more than 10 per year);

          3. Patients with established thyroid cancer requiring specialized studies such as (131)I
             dosimetry (no more than 5 per year);

          4. Enrollment of high risk, non-iodine avid, inoperable thyroid cancer only for purposes
             of screening for eligibility for other specific thyroid cancer protocols.

        EXCLUSION CRITERIA:

          1. Serious underlying medical conditions that restrict diagnostic testing or therapy
             such as renal failure, congestive cardiac failure or active coexisting non-thyroid
             carcinoma;

          2. Patients unable or unwilling to give informed consent
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        On referral, persons of any age will be considered for the inclusion in the study because
        of either:

        A family or personal history of neoplasia of an unusual type, pattern, or number; OR,

        known or suspected factor(s) predisposing to neoplasia, either genetic and/or congenital
        factors (birth defects, metabolic phenotype, chromosomal anomalies or Mendelian traits
        associated with tumors), environmental exposure (medications, occupation, radiation, diet,
        infectious agents, etc.), or unusual demographic features (very young age of onset,
        multiple tumors, etc.).

        Personal and family medical history must be verified through questionnaires, interviews,
        and review of pathology slides and medical records.  For familial neoplasms, two or more
        living affected cases among family members are required. The types of familial tumors that
        we are currently actively accruing include:

        Familial Cancers:  bladder, brain, chordoma, lung, nevoid basal cell carcinoma syndrome
        (NBCC)

        Familial Benign Neoplasms:  meningiomas, neurofibromatosis 2 (bilateral acoustic
        neurofibromatosis)

        The types of familial tumors under active accrual and study are predominantly
        investigator-and hypothesis-driven.  This approach permits GEB investigators to remain
        alert to the opportunities afforded by clusters of rare tumors in families and
        individuals, and to be more responsive to the dynamic research priorities in cancer
        genetics.

        EXCLUSION CRITERIA:

        Referred individuals and families for whom reported diagnoses cannot be verified.

        Inability to provide informed consent.

        Eligible for familial melanoma, lymphoproliferative, breast-ovarian cancer, or testicular
        cancer protocols.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  1 Year
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        CHILDREN DIAGNOSED WITH CANCER.

        -Children 7-17 years of age who are currently being treated for cancer or are up to 3
        years post therapy.

        OR

        Young adults with cancer (YACers) who are acting as counselors at Camp Fantastic.

          -  All children/young adults will be selected for camp after careful screening by a
             multidisciplinary committee consisting of medical and program directors. While the
             state of the child   s health will certainly be considered there will be no
             exclusions for:

          -  Patients who are receiving intramuscular, intrathecal, oral or intravenous
             medications or blood products.

          -  Patients who have had amputations or have other physical defects.

          -  Patients who become febrile and neutropenic at the onset or during the week of camp
             will stay at camp on antibiotic therapy providing their condition remains stable.

          -  At the discretion of the multidisciplinary committee consisting of medical and
             program directors, special exceptions may be made for patients with extenuating
             circumstances.

          -  All children will be officially enrolled and will have an NIH Clinical Center Patient
             Care Number.  The enrollment of a child, signing of protocol consent, and completion
             of admission paperwork is done in person but under extenuating circumstances it may
             be done over the phone after the paperwork has been mailed to the parent/guardian.
             Extenuating circumstances would include a last minute application to camp after the
             trip for camp screenings in Norfolk or Richmond has been completed.

        EXCLUSION CRITERIA:

        -Children with a medical diagnosis other than cancer or their related disorders.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  7 Years
 </minimum_age>
 <maximum_age>
  17 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA - Subject Category A:

        Category A will include patients, and relatives, who may or may not be affected who will
        be evaluated in the Warren G. Magnuson Clinical Center.  Patients in this category will be
        eligible if they or their family members manifest one or more of the following features in
        a pattern suggestive of a heritable urologic malignant disorder:

          -  One or more histologically proven or suspected renal carcinomas and/or cysts

          -  Cerebellar, spinal, medullary or cerebral hemangioblastomas

          -  Retinal angioma

        Pancreatic neuro-endocrine carcinoma, microcystadenoma and/or cysts

          -  Pheochromocytoma

          -  Papillary cystadenoma of the epididymis or broad ligament

          -  Endolymphatic sac tumor

          -  Known or suspected cutaneous fibrofolliculomas or multiple skin-colored papules

          -  History of spontaneous pneumothorax

          -  Lung cysts

          -  Thyroid carcinoma

          -  Intestinal polyposis + / - colon cancer

          -  Cutaneous or Uterine leiomyoma or uterine leiomyosarcoma, sarcoma

        INCLUSION CRITERIA - Subject Category B:

        Category B will include patients, their at-risk relatives and spouses of patients with
        inherited urologic malignancies with the above listed clinical findings who live at a
        distance and who will not be evaluated at the Clinical Center.  In some cases, local
        diagnostic testing may be necessary for these individuals in addition to collection of a
        blood sample for molecular analysis.

        INCLUSION CRITERIA - Subject Category C:

        Category C will include relatives and spouses who enroll in this study primarily for
        genetic linkage studies.  These individuals will contribute a blood sample for DNA
        analysis only.  No imaging diagnostic testing will be performed on individuals from this
        category.

        EXCLUSION CRITERIA:

        Persons unable to give informed consent.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA

        Documentation of plasma glucose below 45 mg/dl is required for enrollment.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  10 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Patients (male or female any age) with known or suspected primary hyperparathyroidism or a
        related disorder (such as familial multiple endocrine neoplasia type 1 [MEN1]) will be
        evaluated.

        The vast majority of patients will be greater than age 18.

        In the rare occasion where special resources might be appropriate (uremic patient, young
        child), the availability of special resources would be confirmed prior to admission.

        EXCLUSION CRITERIA:

        There are no absolute exclusions.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Up to 5,000 subjects will be enrolled in the study at all sites combined. Subjects will be
        enrolled at NEI.

          1. Participants must be undergoing an eye procedure for clinical care of their condition
             which requires the removal of tissue specimens or have agreed pre-mortem to donate
             their eyes after death for research purposes.

          2. Participants must agree to the de-identified storage of their sample for potential
             use in future research projects.

          3. For conditions where blood is needed for analysis, participants must consent to
             having blood drawn for research evaluation, and be able to safely give a blood
             sample.

          4. Participants must be able to give informed consent for themselves and/or their minor
             children who wish to enroll.

        EXCLUSION CRITERIA:

        1.  Participant is unwilling or unable to give informed consent.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Non-Hodgkin's lymphomas in the following categories: diffuse large B cell to include gray
        zone lymphoma and follicular center cell grade IIIB, anaplastic large cell, and aggressive
        T-cell lymphomas and Burkitt Lymphoma.

        Patients with evidence of an underlying low-grade lymphoma will not be eligible for this
        study.  This includes patients who have both indolent and aggressive histologies in the
        same or different biopsy sites (e.g. large cell lymphoma in a node and follicular center
        cell lymphoma in the bone marrow).

        Diagnosis confirmed by staff of the Hematopathology Section, Laboratory of Pathology, NCI.
        Tissue blocks from patients treated in extramural sites must be forwarded to the NCI for
        analysis of bcl-2 by IHC and other markers within 1 month of study entry.

        Patients greater than or equal to 12 years old.

        Stage and Prognosis of Patients: Stages II, III, IV for all subtypes, and stage I bulky
        (greater than 5 cm) primary mediastinal B-cell lymphomas or Burkitt Lymphoma.

        No prior systemic chemotherapy. Patients may be entered if they have had prior
        limited-field radiotherapy, a short course of glucocorticoids and/or cyclophosphamide for
        an urgent problem at diagnosis (e.g. epidural cord compression, superior vena cava
        syndrome).

        HIV negative.

        Not pregnant or nursing.

        Adequate major organ function [in adults: serum creatinine less than or equal to 1.5 mg/dl
        or creatinine clearance greater than 60 ml/min; and in children serum CR less than or
        equal to age-adjusted normal (age 12  to 15 maximum serum creatinine 1.2 mg/dl and age
        greater than 15 maximum serum creatinine 1.5 mg/dl); bilirubin less than 1.5 mg/dl; ANC
        greater than 1,000 and platelets greater than 100,000) unless impairment is due to organ
        involvement by lymphoma or immune-mediated mechanism caused by lymphoma.

        No active symptomatic ischemic heart disease, myocardial infarction or congestive heart
        failure within the past year.  If MUGA is obtained, the LVEF should exceed 40%.

        No other serious concomitant medical illnesses or uncontrolled active infection that would
        jeopardize the patient's ability to receive the regimen with reasonable safety.

        No history of unrelated (non-lymphomatous) neoplasms within past 5 years other than
        non-melanoma skin cancer or in-situ cervix cancer.

        Ability to give informed consent.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  12 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA

        Patients with known or suspected metabolic disorders of such as MEN 1, MEN 1-like states,
        FHH, HPT-JT, FIH, FIC, PHP and their first degree relatives (parents, siblings and
        offspring) and spouses. For the most part only one index case in a family will be tested.

        Pre-test counseling by an NIDDK investigator.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        A.  ALPS Natural History sample size and demographics:

        Study size: up to 1000 patients, patients, relatives and normal controls.

        Sex Distribution: Male and female

        Age range: All ages acceptable

        B.  Eligibility Criteria for Natural History Study:

          1. To be considered as having ALPS, patients must elevated TCR alpha/beta+ CD4-8-
             peripheral blood DNT cells (equal to or greater than 1.5 percent of total lymphocytes
             or 2.5 percent of CD3+ lymphocytes) in the setting of normal or evalted lymphocyte
             counts.

          2. A history of chronic (greater than 6 months) non-malignant, non-infectious
             lymphadenopathy and/or splenomegaly.

          3. Willingness to allow blood, tissue and other samples to be stored.

          4. Patients with RALD (RAS associated leukoproliferative disorders) who present with
             autoimmunity, lymphadenopathy and/or splenomegaly, with elevated or normal DNT   s
             and somatic mutations in NRAS and KRAS

        C.  Eligibility Criteria for Screening potential patients:

          1. A history of chronic (greater than 6 months) lymphadenopathy and/or splenomegaly.

          2. Willingness to allow blood, tissue and other samples to be stored.

        D. Screening criteria for ALPS Relatives:

          1. Extended family members of an ALPS patient are eligible for genetic screening to
             determine if they carry the mutation found in their family.

          2. Willingness to allow blood, tissue and other samples to be stored.

        E.  1.  Apheresis will be done only on healthy volunteers or patients with ALPS who have
        adequate peripheral venous access. Women of childbearing age must have a negative
        pregnancy test within 24 hours of the procedure and must not be breast-feeding.

        EXCLUSION CRITERIA:

        1. Any condition that the Principal Investigator deems to be non-conducive to the research
        goals of the study.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

               1. Positive culture of Cryptococcus neoformans from any body site;

               2. First degree relative (mother, father, sister, brother) of patients with
                  positive Cryptococcus neoformans from anybody site.

               3. Age 18 years or older; and

               4. Ability to provide informed consent.

        EXCLUSION CRITERIA (Apply to patients only):

          1. Known HIV positive serology or other condition predisposing to cryptococcosis,
             including but not limited to corticosteroid therapy equivalent to prednisone 20 mg
             per day or more or acidosis.

          2. Dementia impairing informed consent.

        INCLUSION CRITERIA FOR CONTROLS:

          1. History of ICL without a history of cryptococcosis or

          2. Other conditions which may predispose to cryptococcosis, such as other opportunistic
             infections and autoimmune diseases.

        EXCLUSION CRITERIA FOR CONTROLS:

          1. Iatrogenic immunodeficiency such as concomitant corticosteroid treatment (greater
             than an equivalent of 10 mg of prednisone daily for more than 2 weeks), other
             immunosuppressive medications, total body irradiation or others

          2. Dementia impairing informed consent.

        INCLUSION CRITERIA FOR HEALTHY VOLUNTEERS:

          1. Weight greater than 110 lbs

          2. Hemoglobin level greater than 11 g/dl

          3. Ages 18-70

        EXCLUSION CRITERIA FOR HEALTHY VOLUNTEERS:

          1. History of hepatitis B or hepatitis C

          2. HIV positivity

          3. Any condition which in the opinion of the investigators may alter immune function
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

               1. Individuals referred to the NIH with a possible diagnosis of FMF, TRAPS, HIDS,
                  MWS, FCAS, NOMID, DIRA, PAPA, PFAPA, or other unexplained febrile or
                  inflammatory illnesses.  Individuals may be seen for initial evaluation, genetic
                  studies, and research blood specimens, or may send blood or saliva samples for
                  genetic testing only.  However, we place the following age restrictions on other
                  studies:

                    1. Leukapheresis will only be performed on individuals over the age  of 18
                       years;

                    2. Brief interruption of ongoing therapy for research blood sampling will only
                       be proposed to individuals over the age of 18 years;

                    3. Research bone marrow aspirations and biopsies will only be performed on
                       individuals over the age of 18 years.

               2. Family members of individuals included under item 1: may be seen for initial
                  evaluations, genetic studies, or research blood specimens, or may send blood or
                  buccal samples for genetic testing only.  Unaffected family members will not be
                  asked to undergo leukapheresis, interruption of ongoing therapy, or bone marrow
                  aspirations and biopsies.

               3. Controls for cellular, molecular, biochemical assays and genetic studies:
                  Individuals who undergo phlebotomy specifically to provide a random control
                  specimen will be required to be over the age of 7 years and not pregnant.
                  Individuals providing a control specimen who are already undergoing phlebotomy
                  for other reasons must be greater than 1 year of age and not pregnant.

        EXCLUSION CRITERIA:

          1. In the case of adults, inability to provide informed consent and unavailability of a
             legally authorized representative (LAR) to provide surrogate consent.

          2. In the case of minors, unavailability of a parent or guardian.

          3. Presence of any medical condition that would, in the opinion of the investigators,
             confuse the interpretation of the study.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Patients must have a tissue-diagnosis of grade 1, 2 and/or 3 A/B LYG (or a diagnosis
        consistent with LYG) confirmed by the Laboratory of Pathology, NCI. Final histopathologic
        classification and pathologic grade will be determined by Stephania Pittaluga, M.D. or her
        designee.

        Patients with any stage of disease will be eligible.

        Previously untreated and treated patients are eligible.

        Patients age 12 or older will be eligible.

        Informed consent must be obtained.

        EXCLUSION CRITERIA:

        Female patients who are pregnant or lactating are not eligible to receive treatment but
        can be followed for natural history.

        Patients with a history of coronary artery disease with angina pectoris, or a history of
        congestive heart failure will not be eligible to receive. DA-Epoch-R chemotherapy.

        Patients with significant renal (Cr. greater than 1.5 mg/dl or creatinine less than 40
        cc/min) or hepatic (bilirubin greater than 2.5 u) dysfunction not due to tumor involvement
        will not be eligible to receive DA-EPOCH-R chemotherapy.

        Patients who in the opinion of the principle investigator are poor psychiatric or medical
        risk are not eligible.

        Patients who received &gt;  450 mg/m2 doxorubicin and have a cardiac ejection fraction on
        echocardiogram less than or equal to 40% on protocol entry are not eligible to received
        DA-EPOCH-R.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  12 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Patients (and when appropriate the patient's stem cell donor) may be entered on this
        protocol at the discretion of the Principal and/or Associate Investigators if :

        An investigator decides that it is in the best interest of the patient/donor and the
        Branch for the patient to be enrolled in this protocol while awaiting a decision on
        eligibility for other protocols; or after enrollment on another protocol, or to allow
        careful evaluation of patients with unique or rare disorders of direct interest to the
        Branch; or with more common disorders for fellowship teaching purposes.

        The patient or the patient's guardian is capable of informed consent and signs the consent
        form.  The consent form will be signed by parents or guardians of patients under the age
        of 18.

        Age greater than or equal to 2 and weight greater than 12 kg.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  2 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        For Proteus Patients

        All affected subjects should have the following general criteria:  mosaic distribution of
        lesions, progressive course, and sporadic occurrence.

        In addition, they should have either 1 from A, 2 from B or 3 from C.

        A.  Cerebriform connective tissue nevus.

        B.  Epidermal nevus, Disproportionate overgrowth, specific tumors before the age of 30
        years (bilateral. ovarian cystadenomas or monomorphic parotid adenoma).

        C.  Dysregulated adipose tissue, Vascular malformations, Lung cysts, Facial phenotype.

        The Proteus mail-in and Proteus case review subjects must meet the same eligibility
        standards as those who come to the clinical center and this will be determined by the
        review of the materials.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Subjects with clinical manifestations of a congenital anomaly or craniofacial syndrome, or
        a single congenital anomaly that is also seen as part of a congenital anomaly syndrome
        will be considered eligible for participation in this protocol.

        Blood will also be requested on unaffected relatives that could be informative for linkage
        studies or for determining co-segregation of mutations within families.  Subjects of
        either gender and all ethnic and racial groups will be accepted.

        Prenatal specimens (amniocentesis or CVS) will be accepted if they are previously acquired
        for clinically indicated reasons.  Cord blood or placenta specimens may be accepted if
        they (or a part of them) are not needed for clinical purposes.

        Specimens from patients collected at outside institutions may be accepted into the study
        if they were collected under an IRB-approved protocol at an MPA or FWA institution.

        Coded specimens (specimens linked to identifiers but without personal identifiers attached
        to the sample) may be acquired from other NIH investigators, analyzed, and returned as
        research results to that investigator.

        EXCLUSION CRITERIA:

        Patients with    typical    GCPS or PHS who have demonstrated GLI3 mutations may be
        excluded from this study.  Patients with phenotypes and disorders with a high risk/benefit
        ratio such as late-onset, neurodegenerative, psychiatric, and cancer-predisposition
        disorders will be excluded from participation. Similarly, patients who are medically
        fragile or unable to tolerate travel to the NIH CC will not routinely be eligible for
        participation. Probands who are adults and decisionally-impaired are ineligible if they do
        not have a legal guardian who has authority to sign a consent form on their behalf.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  ELIGIBILITY CRITERIA (EOSINOPHILIC SUBJECTS):

        INCLUSION CRITERIA:

          1. 1-100 years of age

          2. documented peripheral blood eosinophil count &gt; 1500/mm3, tissue eosinophilia
             (abnormal accumulation of eosinophils in the skin or other body tissues) or suspected
             eosinophilic end organ

             involvement

          3. has a primary (non-NIH) physician for routine medical care

        EXCLUSION CRITERIA:

        1) medical conditions or therapies that the investigator feels put the subject at
        unacceptable risk for participation in the study

        ELIGIBILITY CRITERIA (RELATIVES):

        INCLUSION CRITERIA:

          1. 1-100 years of age

          2. extended family member of a study participant in 94-I-0079

        EXCLUSION CRITERIA:

        1) any condition that the investigator feels put the subject at unacceptable risk for
        participation in the study.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  1 Year
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

             1.  All patients with PPNAD and/or Carney Complex by history and their siblings,
             children and parents.  Additional relatives and their families that are suspected to
             have the same disorder on clinical grounds will be recruited:

               1. PPNAD patients will be included if their diagnosis is fully documented.
                  First-degree relatives of patients with the disease will be accepted also for
                  evaluation, or if already conclusively evaluated elsewhere, for DNA linkage
                  analysis only.

               2. Patients with suspected Carney complex will be accepted for evaluation and/or
                  DNA analysis for linkage, if they have at least two of the following:

                    1. cardiac myxoma

                    2. cutaneous myxoma

                    3. breast myxoma

                    4. oral myxoma

                    5. myxoma of the external ear

                    6. spotty mucocutaneous pigmentation (lentigines)

                    7. testicular tumor

                    8. pituitary growth hormone secreting adenoma

                    9. nerve tumor, such as psammomatous melanotic schwannoma

                   10. first-, second-, or third-degree relatives with Carney complex

               3. Patients with one of the familial lentiginosis syndromes:  Peutz-Jeghers and
                  LEOPARD syndrome, other forms of familial lentiginosis.

                  2.  Informed consent, and for children and/ or mentally impaired, parental or
                  legal custodian's consent and subject assent.

                  EXCLUSION CRITERIA:

               1. For DNA analysis and linkage study:

                  1.  Unwillingness to participate.

               2. For clinical evaluation and DNA analysis/linkage study:

                    1. Patients with major illnesses, such as severe renal failure, restrictive or
                       obstructive lung disease, cardiac disease, anemia and/or terminal cancer
                       that will not be able to undergo appropriate testing or the stress of
                       hospitalization.  Also, patients with Carney complex and a known heart
                       tumor (heart myxoma) will not be able to enter the clinical part of the
                       study until after surgical treatment of their tumor.  These patients,
                       however, will be asked to participate in the DNA analysis study.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  3 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        General admission criteria for patients include one or both of the following:

        Findings on lung biopsy diagnostic of LAM;

        Findings on chest x-ray and/or chest computed axial tomography consistent with LAM.

        Patients with TSC and pulmonary LAM will be included in the study.

        Normal non-smokers in the control group are defined as individuals who have not smoked for
        greater than or equal to 1 year and have no systemic or pulmonary disease.

        Normal smokers defined as individuals with no systemic or pulmonary disease, who have
        smoked for greater than or equal to 1 year and have normal chest x-ray and normal
        pulmonary function tests may be included if needed as controls for a similar population of
        patients with LAM.

        EXCLUSION CRITERIA:

        Exclusion criteria for patients include:

        Age less than 16.

        Advanced stage of a pulmonary or a systemic illness in which the risk of the study is
        judged to be significant even in the absence of a clear contraindication to the
        procedures.

        Exclusion criteria for patients for the formal exercise study and the stress
        echocardiogram include patients on continuous oxygen.  Patients may perform an exercise
        test that will assess the patient's exercise capacity with activities of daily living.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  16 Years
 </minimum_age>
 <maximum_age>
  80 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  ELIGIBILITY CRITERIA:

        Patients of any age who were previously enrolled on a CCR protocol.

        Not eligible for or unwilling to participate in an active NCI intramural primary research
        protocol.

        CCR investigator decides it is in the best interests of the patient and the CC for the
        patient to be seen in follow-up visits at the NIH.

        Patient or guardian is able to provide informed consent.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Healthy individuals (including employees and other patients), and patients with selected
        skin or other diseases, including individuals of both genders and all racial/ethnic
        groups.

        Patient volunteers must be willing to undergo blood drawing and/or skin/mucosal
        sampling/monitoring to include non-invasive skin samples.

        EXCLUSION CRITERIA:

        Strong family history and/or evidence of keloid formation following surgery or trauma.

        Children under the age of 18 years.

        Pregnant or nursing women.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Patients of any age, of both genders, and all racial/ethnic groups with dermatologic
        diseases or systemic diseases with cutaneous manifestations.

        Women of childbearing potential, or who are pregnant or lactating, will only undergo tests
        and procedures, and/or receive medications for which data exists proving minimal risk to
        the fetus and/or child.  Only tests that are clinically indicated for diagnosis will be
        performed.

        Patients must be referred by a physician.

        EXCLUSION CRITERIA:

        Patients with cognitive impairment.

        Pregnancy or lactation, if this status precludes proposed diagnostic procedures or
        therapies because of known untoward effects on mother and/or child.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Inclusion criteria for patients with AAT deficiency include:  (1) Diagnosis of AAT with a
        confirmed phenotype considered in the high risk category; (2) Clinical phenotype
        consistent with potential genetic diseases and other genetic causes of lung diseases (3)
        symptoms consistent with pulmonary disease; (4) chest x-ray consistent with pulmonary
        disease; (5) pulmonary function tests consistent with pulmonary disease; (6) smokers,
        defined as individuals who are current smokers (1 pack per day for at least 2 years) and
        nonsmokers, defined as never-smokers or ex-smokers who have quit smoking three or more
        years ago;

        Inclusion criteria for individuals with chronic obstructive pulmonary diseases include:

          1. symptoms consistent with pulmonary disease

          2. chest x-ray consistent with pulmonary disease

          3. pulmonary function tests consistent with pulmonary disease;

          4. smokers, defined as individuals who are current smokers (1 pack per day for at least
             2 years) and nonsmokers, defined as never-smokers or ex-smokers who have not smoked
             for three or more years.

        Inclusion criteria for patients with cystic fibrosis include a defined genetic mutation
        (i.e., any of the known variants of the CFTR gene, such as delta F508 allele) or a cystic
        fibrosis phenotype and clinical features consistent with this disease.  Children with
        cystic fibrosis over eight years of age may be included.

        Patients with established diagnoses of sarcoidosis; mycobacterial infections; TSC
        (definite, probable, or possible); cystic lung diseases including genetic diseases;
        lymphangioleiomyomatosis or diseases associated with lymphatic disorders; history of
        pneumothorax; pulmonary fibrosis; asthma; histiocytosis X and diabetes mellitus will be
        included in this protocol.  Relatives of patients  may also be seen under this protocol.
        Children with lymphangiomatosis who are two years of age or older may be included.

        Research volunteers in the pulmonary control group are defined as individuals with no
        pulmonary disease (e.g. rheumatoid arthritis without evidence of pulmonary disease).
        Research volunteers in the diabetes control group are defined as individuals with no
        history of diabetes, coronary artery disease, or pulmonary disease.

        Because radiation exposure is not required, pregnant women are not excluded from the
        study.

        Patients with abnormalities in ADP-ribosyltransferases, ADP-ribosyl-acceptor hydrolases,
        and their substrates.  Children who are two years of age or older may be studied if they
        have a known defect in ADP-ribosylation, or if they have a family member with a defect in
        ADP-ribosylation and may be affected.

        EXCLUSION CRITERIA:

        Exclusion criteria for all participants include:

          1. age less than 18 or greater than 90 except for NIH patients with diseases /disorders
             as described in this protocol (except cystic fibrosis, lymphangiomatosis or defects
             in ADP-ribosylation) who are 16 years of age or older, patients with cystic fibrosis
             who are over eight years of age, patients who are two years of age or older with
             lymphangiomatosis or a known defect in ADP-ribosylation, or who have a family member
             with a defect in ADP-ribosylation, or unless patient-specific IRB approval is
             obtained and;

          2. inability to obtain reliable pulmonary function testing. As clarification, healthy
             volunteers, relatives of patients (except as noted for an ADP-ribosylation defect),
             and asthmatic patients from Suburban Hospital will be excluded if less than 18 or
             greater than 90 years of age.

        An exclusion criteria for participating in the x-ray portion of the study is pregnancy.

        Exclusion criteria for participating in the bronchoscopy portion of the study are:

          1. presence of any contraindication for fiberoptic bronchoscopy, with lavage and/or
             bronchial brushing;

          2. advanced stage of a pulmonary or a systemic illness such that the risk is judged to
             be significant even in the absence of a specific contraindication to the procedure

          3. allergy to topical anesthetic (e.g., lidocaine)

          4. current or recent respiratory infection (within the last 4 weeks)

          5. pregnancy or lactation

          6. age less than 18 or greater than 65.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  8 Years
 </minimum_age>
 <maximum_age>
  90 Years
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Patient must meet at least one of these criteria:

        Have suspected or known disorder of the immune system or malignancy

        Be a known or potential carrier of genetically determined autoimmune disorder or
        immunodeficiency disease.

        Specific i disorders may include but are not limited to:  X-linked (severe combined
        immunodeficiency) SCID (c gamma deficiency), Autosomal recessive SCID, X-linked CD40
        ligand deficiency, Common variable immunodeficiency, Ataxia-telangiectasia, Wiskott
        Aldrich syndrome, DiGeorge syndrome and Infection with HTLV-1

        Age of birth and above for patients with suspected or known disorders of the immune
        system.

        Patient (or parent/guardian of a minor child) must be able to understand and sign informed
        consent.

        Hematocrit greater than 28%, and platelet count greater than 50,000 necessary for
        apheresis.

        Subjects for whom apheresis is desired but whose counts are lower than those above must be
        evaluated and approved by a Department of Transfusion Medicine consult physician.

        Weight greater than 25 kg is necessary for apheresis.

        EXCLUSION CRITERIA:

        Overall Exclusion Criteria:

        Pregnant or breast feeding women will not be eligible for any aspect of this protocol
        except phlebotomy

        Children less than 18 years old are not eligible for lymph node or bone marrow biopsy

        Exclusion Criteria for skin/parenteral antigen tests:

        Any history of severe reaction or allergy to a particular skin test antigen or other
        ingredients in the formulation (e.g. Thimerosal, eggs or avian protein) will exclude a
        subject from receiving that particular skin test.

        Children under the age of 2 years are not eligible to receive the Pneumococcal polyvalent
        vaccine.

        Subjects under the age of 18 years are not eligible to receive the Candida or mumps skin
        test antigens.

        Exclusion Criteria for Apheresis Alone:

        Any diagnosed medical condition which may be worsened by the apheresis procedure.
        Specifically the patient should not have any of the following:

          1. Congestive Heart Failure

          2. History of angina

          3. Severe hypotension (at the discretion of the patient's physician, the apheresis staff
             and the attending physician from the Department of Transfusion Medicine (DTM) per DTM
             Standard Operating Policies.)

          4. Poorly controlled hypertension (average baseline blood pressure greater than 160/90)

          5. History of a coagulation protein disorder.

        Pediatric normal volunteers (less than 18 years) will not undergo apheresis.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  1 Year
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        A. The following criteria must be met for all, who enter the study:

        Age 3-70 years

        Evidence for the existence of a tumor of the hypothalamic-pituitary unit, as indicated by
        previously obtained imaging studies or biochemical investigation of the
        hypothalamo-hypophyseal function.

        Patients may withdraw from the study at any time.

        B. For family members studied for linkage analysis, the following criteria must be met:

        Any age

        Member of a kindred suspected of having an inherited form of pituitary neoplasia, as
        evidenced by results of a patient studied under A (above).
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  3 Years
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Subjects will be entered on this protocol at the time of their first visit to the NIH
        Clinical Center outpatient clinic or inpatient service if:

        The subject carries the diagnosis of a disorder for which the Hematology Branch has an
        active research protocol, and based on information received from an outside physician,
        he/she appears to meet at least preliminary eligibility criteria for that protocol.

        OR

        The subject is a donor for a subject for which the Hematology Branch has an active stem
        cell transplant protocol and based on information received from an outside physician,
        he/she appears to meet preliminary eligibility as a donor.

        OR

        The subject is a normal volunteer for which the Hematology Branch has an active study
        recruiting healthy normal volunteers and he/she appears to meet preliminary eligibility as
        a normal volunteer.

        Age greater than or equal to 2.

        Weight greater than 12 kg. (Healthy Volunteer greater than or equal to 8)

        The subject or the subject's guardian is capable of informed consent, and willing to sign
        the consent form after initial counseling by clinical staff.  Separate consent forms for
        all interventional or surgical procedures will be obtained after explanation of the
        specific procedure.

        EXCLUSION CRITERIA:

        All subjects not fulfilling the inclusion criteria will be considered inelibible.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  2 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Patients who are evaluated by the Pediatric Oncology Branch and are:

        Children with cancer (or a precancer syndrome), between the age(s) of 3 months to 40
        years.

        Patients between the ages of 30 and 40 years may be evaluated on this protocol if their
        cancer (or precancer syndrome) is of specific interest to the Pediatric Oncology Branch.

        Patients with cancer (or a precancer syndrome), who present with disease manifestations of
        special interest to Pediatric Oncology Branch investigators, including but not limited to,
        lymphoma, brain tumors, Ewings sarcoma, leukemia, neuroectodermal tumors, osteosarcoma,
        rhabdomysarcoma.

        If indicated, availability of a parent or legal guardian to give informed consent.

        Patients, and, when indicated, parent or legal guardian who are deemed sufficiently
        reliable to return for recommended follow-up visits.

        Patients greater than or equal to 18 years of age must be able to give informed consent.

        EXCLUSION CRITERIA:

        Patients younger than 3 months of age.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  3 Months
 </minimum_age>
 <maximum_age>
  40 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  SUBJECT INCLUSION CRITERIA:

        Healthy Volunteers must:

          1. Be 18-70 years of age

          2. Be healthy

          3. Have adequate peripheral venous access

          4. Have normal renal function (creatinine less than or equal to 1.5mg/dL; less than or
             equal to 1 plus  proteinuria)

          5. Have normal hepatic function (bilirubin less than or equal to 1.5 mg/dL)

          6. Have normal hematologic function (WBC greater than or equal to 3000/mm(3);
             granulocytes greater than or equal to 1500/mm(3) ; platelets greater than or equal to
             175,000; hemoglobin greater than or equal to 12.5 g/dL)

        Patients must:

          1. Be 18-70 years of age

          2. Have mast cell hyperplasia compatible with a diagnosis of systemic mastocytosis
             (applicable to systemic mastocytosis patients only) or other allergic, hematologic,
             or immunologic condition

          3. Have adequate peripheral venous access or be willing to have a central line placed.

          4. First be admitted as inpatients under an existing NIH protocol

          5. Have preserved renal function (creatinine less than or equal to 2 mg/dL; less than or
             equal to 2 plus proteinuria)

          6. Have preserved hepatic function (bilirubin less than or equal to 1.5 mg/dL)

          7. Have preserved hematologic function (WBC greater than or equal to 3000/mm(3);
             granulocytes greater than or equal to 1500/mm(3) ; platelets greater than or equal to
             175,000; hemoglobin greater than or equal to 12.5 g/dL)

        All female subjects of childbearing potential:

          1. May be enrolled if using effective contraception

          2. Have a negative serum or urine pregnancy test determined before beginning Plerixafor
             or G-CSF administration

        SUBJECT EXCLUSION CRITERIA:

        All subjects must not meet any of the following criteria:

        Healthy volunteers and patients must not:

          1. Have active bacterial, fungal or viral infections

          2. Have viral screens positive for HIV or hepatitis B or C

          3. Be pregnant or lactating

          4. Have a history of autoimmune disease such as rheumatoid arthritis, vasculitis,
             pyoderma gangrenosum or similar disorder

          5. Have any condition, which in the judgment of the investigator, might place the
             subject at undue risk

        Healthy Volunteers with any of the following will be excluded:

          1. Splenomegaly, pulmonary fibrosis and other related conditions

          2. Use of any investigative drugs within the past 12 months

          3. Have a significant coagulation disorder

        Systemic Mastocytosis and Mast Cell Related Condition Patients with any of the following
        will be excluded:

          1. Patients taking any other growth factors, cytokines or investigative drugs

          2. Patients who are hemodynamically unstable (blood pressure systolic of lower than 105
             or diastolic lower than 65)
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  ELIGIBILITY CRITERIA:

        Patients with XP, XP/CS, CS, or TTD of any age, gender, race or HIV status are eligible
        for this study. Patients will be sought by contacting professional organizations (such as
        the American Academy of Dermatology-XP Task Force), lay support groups (such as the XP
        Society and the Share and Care CS Support Network) or by direct referral.

        INCLUSION CRITERIA:

        On referral, patients will be considered for inclusion in the study:

        If they have clinical documentation of typical features of XP, XP/CS, CS or TDD or;

        If they have laboratory documentation of defective DNA repair, or;

        If they have some suggestive clinical features and are willing to participate in the
        study.

        EXCLUSION CRITERIA:

        Inability or unwillingness to provide tissue (skin, blood, buccal cells or hair) for
        laboratory studies.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  1 Year
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Patients suspected of having, or with biopsy proven malignant disease.

        Patient, parent or guardian (if a minor), is able to provide informed consent.

        EXCLUSION CRITERIA:

        None
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  16 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        All eligible patients are invited to participate in this protocol.  Patients are adults
        with possible ectopic Cushing syndrome.  Since both men and women are affected with
        ectopic Cushing syndrome, both sexes are studied.  All ethnic and racial groups are at
        risk and will be included.  Patients must be willing to return to NIH for follow-up
        studies.

        EXCLUSION CRITERIA:

        Pregnant or lactating women.

        Children (age less than18) are excluded.

        Patients with any severe active infection.

        Patients with clinically significantly impaired cardiovascular (e.g., history of
        abnormally low ejection fraction, the presence of moderate pulmonary fluid overload or leg
        edema, and blood pressure over 190/100), abnormal coagulation (PT and PTT elevated by 30
        percent above the normal values), hematopoietic (hematocrit less than 30 percent,
        hemoglobin below 10 g/dl, white count below 3000 K/UL, and platelets below 100,000
        K/mm(3)), hepatic (liver enzymes elevated by 3-fold above normal values) or renal function
        (plasma creatinine level over 2.0).

        Patients with impaired mental capacity or markedly abnormal psychiatric evaluation that
        precludes informed consent.

        Patients with body weight over 136 kg, which is the limit for the tables used in the
        scanning areas.

        Patients with combined blood withdrawal, during the six weeks preceding the study, of
        greater than 450 ml.

        Patients with known allergy to [111In-DTPA-D-Phe]-pentetreotide or other somatostatin
        analogues.

        Patients more than 70 years of age due to other possible existing diseases which may
        significantly affect appropriate initial work-up and post-operative morbidity and
        mortality.

        Patients with strong evidence for Cushing disease.  This includes those with positive IPSS
        or a lesion on pituitary MRI.

        Patients taking medications that alter CYP3A4 activity will not be eligible for the
        mifepristone study, since this P450 system metabolizes mifepristone.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  90 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Family members of patients admitted to NHLBI allogeneic BMT protocols.

        Ages 18 and older and less than age 65.

        Parent of patient (obligate haplotype match) OR HLA 3/6, 4/6, 5/6, or 6/6 match with
        patient.

        Research apheresis available from patient.

        EXCLUSION CRITERIA:

        Pregnancy or lactation.

        HLA type unknown.

        More than one haplotype mismatch with patient.

        History of any immunosuppressive disease.

        History of chronic viral antigenic stimulus.

        Venous access inadequate.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  65 Years
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Patients will be those already diagnosed with TSC (definite, probable, or possible) based
        on clinical criteria and/or genetic testing, and ranging in age from 18 to 90 years old.

        The clinical features of TSC considered of major significance are:  facial angiofibromas
        or forehead plaque, nontraumatic periungual fibromas, three or more hypomelanotic macules,
        shagreen patch, multiple retinal nodular hamartomas, cortical tuber, subependymal nodule,
        subependymal giant cell astrocytoma, cardiac rhabdomyoma, lymphangioleiomyomatosis, and
        renal angiomyolipoma.

        The minor features of TSC are: multiple randomly distributed pits in dental enamel,
        hamartomatous rectal polyps, bone cysts, cerebral white matter radial migration lines,
        gingival fibromas, nonrenal hamartoma, retinal achromic patch,    confetti    skin
        lesions,  and multiple renal cysts (5).  Definite TSC is diagnosed by the presence of two
        major features or one major feature plus two minor features.  Probable TSC is diagnosed by
        the presence of one major feature and one minor feature.  Possible TSC is diagnosed by the
        presence of either one major feature or two or more minor features.  Patients will not be
        preselected for skin lesions, but about 80% of patients with TSC are expected to have skin
        lesions.

        EXCLUSION CRITERIA:

        Inability to give informed consent.

        Tendency to keloid formation.

        Allergy to anesthetics.

        Bleeding abnormality.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  90 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Patients will be enrolled who are 18 years of age or over who are referred for care.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Pathologically documented Epstein-Barr virus (EBV) antigen-positive at risk or with
             lymphoproliferative disease, lymphoma, or other EBV-associated malignancy

          -  Immunocompromised as a consequence of:

               -  Genetic or acquired immunodeficiency (including AIDS)

               -  Allogeneic bone marrow or organ transplant

          -  Normal lymphocyte donor related to patient or, for organ allografts, to organ*:

               -  Immunocompetent

               -  HLA compatible

               -  EBV seropositive

               -  HIV negative

               -  Organ donors at least HLA haplotype-identical with the lymphoma NOTE: *However,
                  if the HSCT donor is EBV seronegative or not available (e.g., a cord blood
                  transplant), EBV-specific T-cells generated from a normal seropositive related
                  or unrelated donor matched for at least 2 HLA alleles may be used.

               -  Patients who develop other EBV-associated malignancies without pre-existing
                  immune deficiency, including: EBV+ Hodgkin's and Non-Hodgkin's disease, EBV+
                  nasopharyngeal carcinoma, EBV+hemophagocytic lymphohistiocytosis, or EBV+
                  leiomyosarcoma. Normal, EBV specific T-cells from third party seropositive
                  donors who are HLA compatible in at least 2 HLA alleles shared by the patient
                  will be used. Selection of T cells known to be restricted by an HLA allele
                  shared by the patient will be given priority.

        PATIENT CHARACTERISTICS:

        Age:

          -  Not specified

        Performance status:

          -  No moribund patients

        Life expectancy:

          -  At least 9 weeks

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Other:

          -  Pregnant women eligible

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Not specified

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  Not specified

        Surgery:

          -  Not specified
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA - Recipients:

        Group A:  Subjects at high risk for transplant related complications and mortality as
        defined below:

        Ages 10 to 75 (both inclusive) with a history of one of the following:

          -  Treatment with dose intensive chemotherapy and/or radiotherapy

          -  Previous history of allo/auto transplant

          -  History of multiple myeloma or extramedullary plasmacytoma

          -  Chronic disease or co-morbid medical condition including subjects with symptoms or
             signs of significant pulmonary disease, hepatic disease, kidney disease, cardiac
             disease or disease of other organ systems which would result in increased risk of
             morbidity or death from a standard myeloablative transplant.

        Diseases to be included:

          -  CML chronic phase

          -  Acute lymphoblastic leukemia (ALL), all subjects in complete or partial remission.

          -  AML:  AML in first complete or partial remission  Exceptions: AML with good risk
             karyotypes: AML M3 t(15:17), AML M4Eo (inv. 16), AML t(8;21).  All AML in second or
             subsequent complete remission.

          -  MDS:  refractory anemia with excess blasts (RAEB), or chronic myelomonocyte leukemia
             (CMML).

          -  Myeloproliferative diseases associated with either cytopenia or uncontrolled
             proliferation.

          -  CLL or small lymphocytic lymphoma (SLL) with bulky or progressive disease despite
             prior treatment with chemotherapy which includes purine analogs.

          -  NHL

        A) Intermediate or high grade relapsed or progressive despite treatment with standard
        therapy ineligible for autologous PBSC transplant.

        B) NHL intermediate or high grade relapsing despite prior autologous transplant.

        C) Low grade follicular or small lymphocytic lymphoma (1) high risk patients who have
        relapsed following conventional chemotherapy, (2) relapsed following autologous marrow or
        PBSC transplant, or (3) chemo resistant disease.

        D) Mantle cell lymphoma

        E) NHL intermediate or high grade with concurrent BCL2 and MYC translocations who are at
        high risk for relapsed and who have low survival with conventional chemotherapy.

          -  HD, relapsed after prior autologous transplant or after 2 or more combination
             chemotherapy regimens and ineligible for autologous PBSC transplant.

          -  EBV driven lymphoproliferative disorders progressing despite standard therapies.

          -  MM: MM subjects must be between the ages of 8 and 65 (both inclusive)

        Group B:  (Closed to enrollment Oct 2010) Subjects with hematologic diseases associated
        with reasonable longevity, shown to be curable by allogeneic BMT but where concern for a
        high procedural mortality with conventional BMT may delay or prevent such treatment.

        Ages 8 to 80 (both inclusive) with a history of one of the following

          -  PNH associated with either life-threatening thrombosis, cytopenia, transfusion
             dependence or recurrent and debilitating hemolytic crisis.

          -  Aplastic anemia or PRCA (acquired or congenital) in subjects associated with
             transfusion dependence and/or neutropenia who are not candidates for or who have
             failed immunosuppressive therapy

          -  RA or RARS MDS subjects who have associated transfusion dependence and/or
             neutropenia.

        Ability to comprehend the investigational nature of the study and provide informed
        consent.  The procedure will be explained to subjects age 8-17 years with formal consent
        being obtained from parents or legal guardian.

        Availability of HLA identical or single HLA locus mismatched family donor

        INCLUSION CRITERIA - Donor:

        HLA identical or single HLA mismatched family donor

        Age greater than or equal to 2 up to 80 years old

        Weight greater than or equal to 18 kg

        Ability of donor or guardian of donor to comprehend the investigational nature of the
        study and provide informed consent.

        EXCLUSION CRITERIA - Recipient - any of the following:

        Pregnant or lactating

        Group A: age less than 10 or greater than 75 (multiple myeloma age less than 8 or greater
        than 65);

        Group B: Age less than 8 or greater than 80 years.

        ECOG performance status of 3 or more (See NIH Bone and Marrow Consortium Supportive Care
        Guidelines for Allogeneic Hematopoietic Stem Cell Transplant Recipients -
        http://intranet.cc.nih.gov/bmt/_pdf/ECOG_Karnofsky_Lansky_Scales.pdf)

        Psychiatric disorder or mental deficiency severe as to make compliance with the BMT
        treatment unlikely and making informed consent impossible

        Major anticipated illness or organ failure incompatible with survival from PBSC transplant

        Diffusion capacity of carbon monoxide (DLCO) less than 40% predicted.

        Left ventricular ejection fraction: less than 30%.

        Serum creatinine greater than 2.5 mg/dl or creatinine clearance less than 50 cc/min by 24
        hr urine collection

        Serum bilirubin greater than 4 mg/dl,  transaminases greater than 5x upper limit of
        normal,

        Other malignant diseases liable to relapse or progress within 5 years.

        EXCLUSION CRITERIA - Donor - any of the following:

        Pregnant or lactating

        Donor unfit to receive G-CSF and undergo apheresis  (uncontrolled hypertension, history of
        congestive heart failure or unstable angina, thrombocytopenia)

        HIV positive donor.  Donors who are positive for hepatitis B (HBV), hepatitis C (HCV) or
        human T-cell lymphotropic virus (HTLV I/II) will be used at the discretion of the
        investigator following counseling and approval from the recipient
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  2 Years
 </minimum_age>
 <maximum_age>
  80 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Patients are adults or children with known or suspected sporadic or familial
        pheochromocytoma/paraganglioma, on the basis of one or more of the following:

          -  new onset of hypertension or hypertensive episodes and symptoms suggestive of
             pheochromocytoma/paraganglioma (sweating, headache, pallor, palpitations);

          -  high levels of blood or urinary catecholamines or metanephrines.

          -  family history of pheochromocytoma/paraganglioma or genetic mutations known to
             predispose individuals to develop pheochromocytoma/paraganglioma.

          -  patients performing DEXA scan are adults above 25 and below 45 years of age.

        Patients must be willing to return to NIH for follow-up evaluation.

        Patients with pheochromocytoma/paraganglioma will be accepted based on referral from
        clinicians.

        Inclusion criteria for research PET imaging in children

          1. Children over 10 years old with very high suspicion of sporadic or familial
             pheochromocytoma/paraganglioma, in the presence of new onset of hypertension or
             hypertensive episodes and symptoms suggestive of pheochromocytoma/paraganglioma
             (sweating, headache, pallor, palpitations), and family history of
             pheochromocytoma/paraganglioma or genetic mutations known to predispose individuals
             to develop   pheochromocytoma/ paraganglioma, confirmed by conventional imaging
             (ultrasounds, CT, MRI) showing a tumor highly suspicious for
             pheochromocytoma/paraganglioma.

          2. Children must give written informed assent and be willing to return to the NICHD for
             follow-up.

          3. Female subjects of childbearing potential must have a negative pregnancy test within
             1 week of treatment and must use effective contraception (hormonal or barrier
             methods) while in this study.

        EXCLUSION CRITERIA:

        Imaging studies are not done in pregnant or lactating women. A pregnancy test is performed
        in women of child-bearing age (up to age 55). In those with positive results, no PET
        scanning, MIBG scanning, contrast CT, DCE-MRI, vena cava sampling, glucagon and clonidine
        testing is performed.

        Women who are pregnant are excluded from admission to the Clinical Center but may be
        studied as outpatients.

        Imaging studies are not done in patients that have the following exclusion criteria:

          -  Pregnant or lactating women,

          -  Patients with impaired mental capacity that precludes informed consent,

          -  Patients with a body weight of greater than or equal to 400 pounds due to weight
             limitations of the scanner or patients who are not able to enter the bore of the
             PET/CT scanner due to BMI,

          -  Inability to lie still for the entire imaging time (e.g. cough, severe arthritis,
             etc.),

          -  Inability to complete the needed investigational and standard-of-care imaging
             examinations due to other reasons (severe claustrophobia, radiation phobia, etc.),

          -  Any additional medical condition, serious illness, or other extenuating circumstance
             that, in the opinion of the Investigator, may significantly interfere with study
             compliance.

        Additionally DCE-MRI is not done in patients with acute or chronic renal insufficiency
        since gadolinium chelate injection is contraindicated in those patients. In patients where
        DCE-MRI is considered, a creatinine clearance measurement is performed as a clinically
        indicated test by the Department of Laboratory Medicine at the NIH Clinical Center.
        Patients with impaired kidney function will not undergo DCE-MRI. DCE-MRI is also not done
        in patients with severe claustrophobia or the presence of iron or metal in the MRI scan
        site, in patients with pacemakers or defibrillators, and in patients with an allergy to
        gadolinium.

        Exclusion criteria for research PET imaging in children

        Children of less than 10 years of age,

        Children with impaired mental capacity that precludes informed assent,

        Pregnant or lactating female adolescents,

        Inability to lie still for the entire imaging time (e.g. cough, turbulent children, severe
        claustrophobia, etc.).
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  7 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Women at high risk of ovarian cancer due to family or personal medical history, or a
        gynecologic abnormality.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Meets one of the following criteria:

               -  Considered to be at increased risk for developing ovarian cancer, as defined by
                  one of the following:

                    -  Has at least one first-degree relative (mother, sister, or daughter) with
                       ovarian, primary peritoneal, or fallopian tube cancer

                    -  Has at least two first or second degree relatives diagnosed before age 50
                       with either ovarian, primary peritoneal, fallopian tube, and/or pancreatic
                       cancer who have tested positive for hereditary cancer syndrome that
                       includes an increased risk of gynecologic cancer (e.g., BRCA1/2 or Lynch
                       Syndrome)or have increased risk as deemed by a certified genetic counselor

                    -  A personal or family history of a hereditary cancer syndrome that includes
                       an increased risk of gynecologic cancer

                    -  Increased risk as deemed by a certified genetic counselor

               -  Undergoing surgery for a gynecologic condition, including any of the following:

                    -  Diagnosis of a reproductive cancer

                    -  Benign gynecological condition (e.g., uterine leiomyomata, endometriosis,
                       pelvic inflammatory disease, or follicular or corpus luteum ovarian cysts)

                    -  Highly suspicious adnexal mass

                    -  Risk-reducing prophylactic oophorectomy

        PATIENT CHARACTERISTICS:

        Age

          -  Between the ages of 18 and 80
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  80 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients with lymphoma (non-Hodgkin lymphoma [NHL], chronic lymphocytic
             leukemia/small lymphocytic lymphoma [CLL/SLL] or Hodgkin lymphoma) with primary
             refractory or relapsed disease after standard chemotherapy at high risk of relapse
             with conventional autografting; patients with a diagnosis of CLL (or small
             lymphocytic lymphoma) or diagnosis of CLL that progresses to prolymphocytic leukemia
             (PLL), or T-cell CLL or PLL

          -  Must have an HLA genotypically or phenotypically identical related donor or, at a
             minimum, a high likelihood of identifying an HLA-matched unrelated donor; the
             determination of availability of a suitable unrelated donor may be based on a
             World-Book search

          -  Cross-over to other tandem autologous-allogeneic research protocol (#2241) will be
             allowed if the patient loses the suitable HLA-matched related or unrelated donor but
             has an available HLA-haploidentical donor before receiving the allogeneic
             transplantation and if the patient meets the eligibility criteria of the subsequent
             study

          -  Cross-over from other tandem autologous-allogeneic research protocol (#2241) will be
             allowed if a suitable HLA-matched related or unrelated donor is identified before
             receiving the allogeneic transplantation and if the patient meets the eligibility
             criteria of the subsequent study

          -  Signed informed consent

          -  Detectable tumor on radiographic studies or bone marrow biopsy prior to mobilization
             regimen

          -  Expected survival &gt;= 3 months from study entry

          -  DONOR: HLA genotypically or phenotypically identical related donor

          -  DONOR: must consent to granulocyte-colony stimulating factor (G-CSF) (filgrastim)
             administration and leukapheresis for both PBSC allograft and subsequent donor
             lymphocyte infusion (DLI)

          -  DONOR: must have adequate veins for leukapheresis or agree to placement of central
             venous catheter (femoral or subclavian)

          -  DONOR: Age &lt; 75 yrs, older donors may be considered after review at Patient Care
             Conference

          -  DONOR: Fred Hutchinson Cancer Research Center (FHCRC) matching allowed will be Grades
             1.0 to 2.1; unrelated donors who are prospectively: Matched for HLA-A, B, C, DRB1 and
             DQB1 by high resolution typing; only a single allele disparity will be allowed for
             HLA-A, B, or C as defined by high resolution typing

          -  DONOR: Donors are excluded when preexisting immunoreactivity is identified that would
             jeopardize donor hematopoietic cell engraftment; this determination is based on the
             standard practice of the individual institution; the recommended procedure for
             patients with 10 of 10 HLA allele level (phenotypic) match is to obtain a panel
             reactive antibody (PRA) screens to class I and class II antigens for all patients
             before HCT; if the PRA shows &gt; 10% activity, then flow cytometric or B and T cell
             cytotoxic cross matches should be obtained; the donor should be excluded if any of
             the cytotoxic cross match assays are positive; for those patients with an HLA Class I
             allele mismatch, flow cytometric or B and T cell cytotoxic cross matches should be
             obtained regardless of the PRA results; a positive anti-donor cytotoxic crossmatch is
             an absolute donor exclusion

          -  DONOR: patient and donor pairs homozygous at a mismatched allele in the graft
             rejection vector are considered a two-allele mismatch, i.e., the patient is A*0101
             and the donor is A*0102, and this type of mismatch is not allowed

          -  DONOR: Only G-CSF mobilized peripheral blood mononuclear cells (PBMC) only will be
             permitted as a hematopoietic stem cell (HSC) source on this protocol

        Exclusion Criteria:

          -  Life expectancy severely limited by disease other than lymphoma

          -  Prior autologous hematopoietic stem cell transplant

          -  Patients at high risk of veno-occlusive disease of the liver (criteria not yet
             rigorously defined but includes bilirubin &gt; 2.0 mg and serum glutamic oxaloacetic
             transaminase [SGOT] or serum glutamic pyruvate transaminase [SGPT] &gt; 2 x normal);
             patients may be accepted outside of this range if cleared by gastrointestinal (GI)
             consult

          -  Cardiac ejection fraction (EF) &lt; 40% on multi-gated acquisition (MUGA) scan or
             cardiac echo (or if unable to obtain ejection fraction, shortening fraction of &lt;
             26%); patients with active or a history of cardiac disease should be evaluated with
             appropriate cardiac studies and/or consult; ejection fraction is required if age &gt; 50
             years or there is a history of anthracyclines or history of cardiac disease; patients
             with a shortening fraction &lt; 26% may be enrolled if approved by a cardiologist

          -  Baseline serum-creatinine &gt; 2.0 mg/dl and a calculated or measured creatinine
             clearance of &lt; 50 ml/minute

          -  Seropositive for the human immunodeficiency virus (HIV)

          -  Pulmonary dysfunction as measured by a corrected diffusing capacity of the lung for
             carbon monoxide (DLCO) &lt; 50% of predicted total lung capacity (TLC) &lt; 30%, forced
             expiratory volume in 1 second (FEV1) &lt; 30% and/or receiving supplementary continuous
             oxygen; the FHCRC primary investigator (PI) of the study must approve enrollment of
             all patients with pulmonary nodules

          -  Pregnancy or breast-feeding

          -  Patients with poorly controlled hypertension despite hypertensive medication

          -  Karnofsky score &lt; 60; pediatric criteria: Lansky Play-Performance Score &lt; 40

          -  Patients with cluster of differentiation (CD)34 selected auto grafts

          -  Patients with active non-hematologic malignancies (except nonmelanoma skin cancers);
             this exclusion does not apply to patients with non-hematologic malignancies that do
             not require therapy

          -  Patients with a history of non-hematologic malignancies (except nonmelanoma skin
             cancers) currently in a complete remission, who are less than 5 years from the time
             of complete remission, and have a &gt; 20% risk of disease recurrence; this exclusion
             does not apply to patients with non-hematologic malignancies that do not require
             therapy

          -  DONOR: Identical twin

          -  DONOR: Age less than 12 years

          -  DONOR: Pregnancy

          -  DONOR: Human immunodeficiency virus (HIV) seropositivity

          -  DONOR: Inability to achieve adequate venous access

          -  DONOR: Known allergy to G-CSF

          -  DONOR: Current serious systemic illness

          -  DONOR: Failure to meet FHCRC criteria for stem cell donation

          -  DONOR: Donor (or centers) who will exclusively donate marrow
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Patients are adults or children with evidence for the existence of a tumor of the adrenal
        glands, as indicated by previously obtained imaging studies and/or biochemical
        investigation of hormonal secretion.  This condition is meant to include the possibility
        of individuals with "sub-clinical" hormone secretion syndromes, which may be detectable at
        the biochemical level even in the absence of frank clinical signs/symptoms.

        All eligible patients are invited to participate in this protocol, regardless of sex, race
        or ethnic origin.  All populations appear at risk for adrenal tumors, and therefore the
        subject population can include Native Americans, Asian/Pacific Islanders, Caucasian,
        Hispanic, and Black individuals.  Patients will be accepted for evaluation based on
        referral from clinicians, or may be self-referred, if they can provide evidence supportive
        of the diagnosis of hormone over-secretion.

        Patients must be willing to return to the NIH for follow-up evaluation.

        Patients may withdraw from the study at any time.

        EXCLUSION CRITERIA:

          1. Children less than 3 years old will be excluded from the protocol because of the
             limited resources available at the NIH for the care of infants of this age.

          2. Individuals over the age of 70 years of age will be excluded because of the
             possibility of comorbidities that may significantly affect appropriate initial
             work-up and post-operative management. In addition, research data may be compromised
             by the inability to interpret data collected from patients over the age of 70 years
             that may be on multiple medications for a variety for reasons.

          3. Women who are pregnant or nursing will be excluded from the hyperaldosteronism arm of
             the protocol. Women with adrenal tumors secreting cortisol or other adrenal hormones
             may benefit clinically from evaluation and treatment of their tumor, and will be
             considered for enrollment when clinically indicated.

          4. Individuals whose medical status will not allow them, for safety reasons, to
             participate in the provocative testing or who have unacceptably high risk for
             surgical morbidity and mortality will be excluded from the protocol, as they will not
             be able to participate profitably in the research aspects of this protocol.

          5. Individuals found to have an known inherited syndrome as the cause for hormone
             oversecretion will be excluded from participation in this protocol, as the mechanisms
             of hormone oversecretion and tumorigenesis is likely to be distinct in these
             individuals. Specific examples of syndromes to may be excluded from this protocol
             include individuals with Carney Complex, McCune-Albright syndrome, and MEN-1.  If
             inquiries are received from such patients, they will be referred to the appropriate
             ongoing protocols, if possible.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  3 Years
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Patients must be referred to the NIH with a diagnosis or a suspicion of Job Syndrome.
        Family members of probands and patients referred for other immune syndromes that
        demonstrate some the characteristics of Job's syndrome syndrome may also be evaluated
        under this protocol.

        Male and female patients will be accepted.

        EXCLUSION CRITERIA:

        Pregnant women are excluded only from any procedure or test that may endanger the
        pregnancy or the fetus due to the risk from radiographic studies, anesthesia, or certain
        biopsies.

        Coronary CT angiography will not be performed on any patient with contraindication to IV
        contrast media.  This includes patients with: 1) creatinine value of greater than 1.3
        mg/dl, 2) history of multiple myeloma, 3) use of metformin-containing products less than
        24 hours prior to contrast media, and 4) history of significant allergic reaction to CT
        contrast agents despite the use of premedication.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Patients with a clinical history or signs and symptoms suggestive of a primary immune
        deficiency syndrome and their family members are eligible for inclusion in this study and
        they may be referred by their physician or self-referred.  If possible, a local
        physician/clinical immunologist will be identified for self-referred patients to serve as
        primary reference.  If screening of the patients, either by phone interview or review of
        their medical records indicates that the patient may have a primary immunodeficiency
        syndrome and is HIV-negative, the patient will be invited to come to the NIH and sign an
        informed consent.  If family history is positive for immunodeficiency, the patients or
        family members may be asked to invite other relatives to contact the PI to participate in
        the study.

        Adult patient who are unable to provide informed consent are eligible to participate with
        permission obtained from their legal guardian or durable power of attorney.

        EXCLUSION CRITERIA:

        Inability of the subject or the subject   s parent/guardian to provide informed consent.

        Patients infected with the Human Immunodeficiency Virus before enrollment.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Aggressive CD20 positive Diffuse Large B-cell lymphoma confirmed by Laboratory of
        Pathology, NCI.

        HIV + serology.

        All stages (I-IV) of disease.

        ECOG Performance status 0-4

        NHL previously untreated with cytotoxic chemotherapy.

        Age greater than or equal to 18 years

        Laboratory tests (unless impairment due to respective organ involvement by tumor):

          -  Creatinine less than or equal to 1.5 mg/dl or creatinine clearance greater than or
             equal to 50 ml/min

          -  Bilirubin less than 2.0 mg/dl, or total bilirubin less than or equal to 4.5 mg/dl
             with direct fraction less than or equal to 0.3 mg/dl in patients for whom these
             abnormalities are felt to be due to protease inhibitor therapy

          -  AST and ALT less than or equal to 3x ULN (AST and ALT less than or equal to 6x ULN
             for patients on hyperalimentation for whom these abnormalities are felt to be due to
             the hyperalimentation)

          -  ANC greater than or equal to 1000/mm(3)

          -  Platelet greater than or equal to 75,000/mm(3) (unless impairment due to ITP)

        Ability of patient to provide informed consent.

        EXCLUSION CRITERIA:

        Previous rituximab

        Pregnancy or nursing.

          -  Doxorubicin, etoposide, vincristine and cyclophosphamide are teratogenic and may be
             excreted in milk.

          -  Antiretroviral therapy is indicated during pregnancy and nursing.

        Current clinical heart failure or symptomatic ischemic heart disease.

        Serious underlying medical condition or infection other than HIV that would contraindicate
        SC-EPOCH-R.

          -  Examples include, but are not limited to:

          -  Severe AIDS-related wasting

          -  Sever intractable diarrhea

          -  Active inadequately treated opportunistic infection of the CNS

        Concurrent anti-retroviral therapy during EPOCH therapy.

        Primary CNS lymphoma.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Age 18 years or older.

        ECOG performance status less than or equal to 3.

        At least one of the following: Exposure risk to HIV, KSHV, or HPV; HIV seropositive; KSHV
        seropositive; EBV seropositive; HTLV-1 seropositive; Malignancy, Castleman's disease, or
        skin lesions with appearance of Kaposi's sarcoma; Cervical or anal intraepithelial lesion;
        Clinical condition reported or hypothesized to be associated with xenotropic murine
        leukemia virus-relted virus (XMRV)

        Patients not requiring biopsy for a medical indication can be included on the study solely
        for the purpose of obtaining research samples, including blood, pleural fluid, peritoneal
        fluid, or biopsy samples providing the biopsy or aspiration procedure is of low risk: such
        procedure include fine needle aspirates, bone marrow aspirate and biopsy, or excisional
        biopsy. Such biopsies can be completely separate from any other protocol or evaluation
        process.

        EXCLUSION CRITERIA:

        Inability to provide informed consent.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        All patients greater than or equal to 12 months of age with tumors of the CNS of interest
        to the NOB, who may be candidates for another NOB trial at some point in the future.

        Patients with tumors of the CNS that are of particular interest to members of the NOB
        because they pose important clinical and/or scientific questions and/or shed light on
        important aspects of the disease.

        Patients with tumors of the CNS who offer an important educational benefit to
        neuro-oncology trainees and staff.

        Ability of subject or Legally Authorized Representative (LAR) to understand and the
        willingness to sign a written informed consent document.  Availability of a parent or
        legal guardian to give informed consent for children.

        EXCLUSION CRITERIA:

        Patients less than 12 months of age.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  1 Year
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  Diagnosis of human immunodeficiency virus-1 not responsive to highly active
             antiretroviral therapy (HAART); treated with HAART for at least the past 6 months;
             viral load less than 50 copies/mL plasma; CD4 count less than 100/mm3

          -  Lymphoma or other HIV-associated malignancy allowed with the following criteria:
             malignancy is in complete remission or very good partial remission, defined as a
             significant reduction of disease with therapy and no evidence of continued tumor
             growth; viral load has decreased by at least 1.5 logs OR to less than 5,000 copies/mL
             plasma while on HAART; CD4 count is allowed to be greater than 100/mm3

          -  HLA genotypically identical donor available (under 75 years of age)

        --Prior/Concurrent Therapy--

          -  No concurrent growth factors during mycophenolate mofetil administration; concurrent
             continuation of anti-retroviral therapy required

        --Patient Characteristics--

          -  Life expectancy: At least 30 days

          -  Other: No positive serology for Toxoplasma gondii; no other disease or organ
             dysfunction that would preclude survival; not pregnant or nursing; fertile patients
             must use effective contraception during and for 1 year after study
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  64 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Patients at risk. Suspected of having, or with a biopsy proven neoplastic disease of the
        head and neck.

        Patient, parent or guardian (if a minor) able to provide informed consent.

        EXCLUSION CRITERIA:

        Candidates who do not meet the inclusion criteria.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  4 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  All patients must be diagnosed with neuroblastoma, and categorized as high risk at
             the time of diagnosis; exception: patients who are initially diagnosed as
             non-high-risk neuroblastoma, but later converted (and/or relapsed) to high risk
             neuroblastoma are also eligible

          -  All patients must have completed therapy including intensive induction followed by
             ASCT and radiotherapy to be eligible for ANBL0032; radiotherapy may be waived for
             patients who either have small adrenal masses which are completely resected up front,
             or who never have an identifiable primary tumor; examples of such therapies include:

               -  Following treatment per A3973 protocol

               -  Following treatment per Pediatric Oncology Group (POG)-9341/9342 protocol

               -  Following treatment per CCG3891

               -  Following treatment on New Approaches to Neuroblastoma Therapy (NANT) 2001-02

               -  Enrollment on or following treatment per ANBL02P1

               -  Enrollment on or following treatment per ANBL07P1

               -  Tandem transplant patients are eligible:

                    -  Following treatment on or per ANBL0532

                    -  Following treatment per POG 9640

                    -  Following treatment per COG ANBL00P1

                    -  Following treatment per CHP 594/Dana-Farber Cancer Institute (DFCI) 34-DAT

          -  No more than 12 months from the date of starting the first induction chemotherapy
             after diagnosis to the date of ASCT except for the rare occasions as noted below; for
             tandem ASCT patients, this will be the date of the FIRST stem cell infusion;
             exception: for those who are initially diagnosed as non-high risk neuroblastoma, but
             later converted (and/or relapsed) to high risk neuroblastoma, the 12 months
             restriction should start from the date of induction therapy for high risk
             neuroblastoma (not from the initial induction therapy for non-high risk disease), to
             the date of ASCT

          -  At pre-ASCT evaluation patients must meet the International Neuroblastoma Response
             Criteria (INRC) for CR, VGPR, or PR for primary site, soft tissue metastases and bone
             metastases; patients who meet those criteria must also meet the protocol specified
             criteria for bone marrow response as outlined below:

               -  =&lt; 10% tumor (of total nucleated cellular content) seen on any specimen from a
                  bilateral bone marrow aspirate/biopsy

               -  Patient who have no tumor seen on the prior bone marrow, and then have =&lt; 10%
                  tumor on any of the bilateral marrow aspirate/biopsy specimens done at pre-ASCT
                  and/or pre-enrollment evaluation will also be eligible (note that per INRC this
                  would have been defined as "overall" response of progressive disease [PD])

          -  Prior to enrollment on ANBL0032, a determination of mandatory disease staging must be
             performed (tumor imaging studies including computed tomography [CT] or magnetic
             resonance imaging [MRI], MIBG scan, and vanillylmandelic acid [VMA]/homovanillic acid
             [HVA]; bone marrow aspirates are required but biopsy may be omitted if negative prior
             to ASCT); this disease assessment is required for eligibility and should be done
             preferably within 2 weeks, but must be done within a maximum of 4 weeks before
             enrollment

               -  For those with residual disease before radiotherapy, re-evaluation of irradiated
                  residual tumors is preferably performed at the earliest 5 days after completing
                  radiotherapy; patients with residual disease are eligible; biopsy is not
                  required; patients who have biopsy proven residual disease after ASCT will be
                  enrolled on Stratum 07

               -  Patients must not have progressive disease at the time of study enrollment
                  except for protocol specified bone marrow response and except for elevations of
                  catecholamines as the only sign of disease in a patient who had normal
                  catecholamines at pre-ASCT evaluation

          -  Patients must be enrolled before treatment begins; the date protocol therapy is
             projected to start must be no later than ten (10) calendar days after the date of
             study enrollment; patients should be enrolled preferably between day 56 and day 85
             after peripheral blood stem cell (PBSC) infusion (day from 2nd stem cell infusion for
             tandem transplant); patients must be enrolled no later than day 200 after PBSC
             infusion; enrollment must occur after completion of radiotherapy, and after
             completion of tumor assessment post-ASCT and radiotherapy; informed consent should be
             obtained within 3 weeks pre-ASCT up to the time of registration

          -  Patients must not have received prior anti-disialoganglioside (GD2) antibody therapy

          -  Patients must have a Lansky or Karnofsky performance scale score of &gt;= 50% and
             patients must have a life expectancy of &gt;= 2 months

          -  Total absolute phagocyte count (APC = %neutrophils + %monocytes) X white blood cell
             (WBC) is at least 1000/uL

          -  Creatinine clearance or radioisotope glomerular filtration rate (GFR) &gt;= 70
             mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows:

               -  No greater than 0.4 mg/dL (1 month to &lt; 6 months)

               -  No greater than 0.5 mg/dL (6 months to &lt; 1 year)

               -  No greater than 0.6 mg/dL (1 to &lt; 2 years)

               -  No greater than 0.8 mg/dL (2 to &lt; 6 years)

               -  No greater than 1.0 mg/dL (6 to &lt; 10 years)

               -  No greater than 1.2 mg/dL (10 to &lt; 13 years)

               -  No greater than 1.4 mg/dL (&gt;= 13 years [female])

               -  No greater than 1.5 mg/dL (13 to &lt; 16 years [male])

               -  No greater than 1.7 mg/dL (&gt;= 16 years [male])

          -  Total bilirubin =&lt; 1.5 x normal

          -  Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =&lt; 5 x
             normal

          -  Veno-occlusive disease, if present, should be stable or improving

          -  Shortening fraction of &gt;= 27% by echocardiogram, or if shortening fraction abnormal,
             ejection fraction of &gt;= 55% by gated radionuclide study or echocardiogram; note: the
             echocardiogram or gated radionuclide study must be performed within 4 weeks prior to
             enrollment

          -  Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) &gt; 60%
             predicted by pulmonary function test; for children who are unable to do pulmonary
             function tests (PFTs), no evidence of dyspnea at rest and no exercise intolerance
             should be documented; note: the pulmonary function test must be performed within 4
             weeks prior to enrollment

          -  Patients with seizure disorder may be enrolled if on anticonvulsants and
             well-controlled; central nervous system (CNS) toxicity &lt; grade 2

          -  Written informed consent in accordance with institutional and Food and Drug
             Administration (FDA) guidelines must be obtained from parent or legal guardian

          -  Females of childbearing potential must have a negative pregnancy test; patients of
             childbearing potential must agree to use an effective birth control method; female
             patients who are lactating must agree to stop breast-feeding
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  30 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Radiation Oncology Branch investigator deems that it is in the best interests of the
        patient and the NCI/ROB for the patient to be seen in follow-up in the ROB clinic.

        Patient or guardian is able to provide informed consent.

        Patient must have a primary physician in the community to whom records and appropriate
        follow-up management can be given.  Social services will be enlisted for any patients who
        lack health insurance, etc.

        Patients who have received radiotherapy in the ROB and may or may not be officially
        entered on a clinical protocol.  Some patients treated prior to 1993 may not have been
        officially entered on a clinical protocol.

        EXCLUSION CRITERIA:

        Patients who are on another active primary research protocol at NIH.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

               1. Patients 18 years of age and older are eligible.

               2. Patients must have a performance status of ECOG 0, 1, 2, or 3 for admission to
                  this protocol.

               3. Patients with malignancy are eligible.

               4. Patients requiring a surgical procedure for any medical indication can be
                  included on study.

               5. Patients requiring biopsy or any procedure for any medical indication can be
                  included on study.

               6. Patients not requiring biopsy for a medical indication can be included on the
                  study solely for the purpose of obtaining research samples, including blood,
                  pleural fluid, or peritoneal fluid, or biopsy samples, providing the biopsy or
                  aspiration procedure is of minimal risk, i.e. fine needle aspirate, bone marrow
                  aspirate, or excisional biopsy. No radiology tests will be used in the procedure
                  to collect a sample that would not be otherwise used for an appropriate medical
                  indication.

               7. Normal volunteers 18 years of age and older are eligible to enroll. Normal
                  volunteers must be willing to sign informed consent and must be willing to
                  provide samples to be used for research.

        EXCLUSION CRITERIA:

          1. Pregnant individuals will not be eligible due to potential risks to the fetus
             associated with radiologic procedures required for biopsy.

          2. Children will not be eligible because of potential risks from complications due to
             procedures involved in obtaining the biopsies.

          3. Normal volunteers with a history of a clotting disorder may not enroll.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  65 Years
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Patients suspected of having, or with biopsy proven malignant disease or patients with a
        benign condition for whom radiotherapy is a potential treatment.

        Patient or guardian is able to provide informed consent.

        EXCLUSION CRITERIA:

        Candidates who do not meet the inclusion criteria.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  4 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

          -  Patients who are being evaluated for and treated on protocols within the CCR.

          -  All patients or their legal guardians (if the patient is &lt;  18 years of age) must
             sign a document of informed consent indicating their understanding of the research
             nature and the risks of the procedures that will be performed to assess eligibility
             for research protocols.

          -  Patients or their parents/guardians can refuse to participate in the tissue
             procurement portion of this protocol and still participate in the screening
             eligibility on CCR research trials.

          -  A Durable Power of Attorney will be offered to all patients &gt;  18 years of age who
             are potentially cognitively impaired.

        EXCLUSION CRITERIA:

        None
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Children and young adults who are being evaluated for and treated on protocols within the
        Pediatric Oncology Branch.

        All patients or their legal guardians (if the patient is less than 18 years of age) must
        sign a document of informed consent indicating their understanding of the research nature
        and the risks of the procedures that will be performed to assess eligibility for primary
        research protocols.  When appropriate, pediatric patients (less than 18 years of age) will
        be included in all discussions in order to obtain verbal assent.

        Patients or their parents/guardians can refuse to participate in the tissue procurement
        portion of this protocol and still participate in the screening for eligibility on POB
        research trials.

        A Durable Power of Attorney (DPA) will be offered to all patients greater than or equal to
        18 years of age who have a brain tumor or meningeal tumor involvement.

        EXCLUSION CRITERIA:

        None.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  1 Month
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Biopsy proven Kaposi   s sarcoma involving the skin or mucosa.

        Age greater than or equal to 18 years.

        EXCLUSION CRITERIA:

        Unable or unwilling to give informed consent.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

          -  Adult and minor patients with biopsy-proven malignant disease.

          -  Adult and minor patients suspected of having a malignant lesion.

          -  Patients who have or who are suspected of having an inherited urologic malignant
             disorder.

        EXCLUSION CRITERIA:

          -  Subjects whose co-morbidities preclude surgical intervention.

          -  Subjects unable to provide consent.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  1 Year
 </minimum_age>
 <maximum_age>
  65 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Population/Subjects:  Individuals with breast cancer  are identified among the patient
        population at National Naval Medical Center (NNMC).  Patients referred to the NNMC Breast
        Care Center) NNMC-BCC for diagnosis and management (surgical treatment and radiation
        treatment or chemotherapy) of histologically established breast cancer (stage I, II, III,
        or IV) during 2001-2003, are eligible to participate in the study.

        Healthy female individuals will be controls.

        Subjects must be over 18 years of age and post-puberty as breast cancer does not occur
        prior to puberty; and been seen pre-surgical or medical intervention for baseline
        measurements and agree to participate in six follow-up visits of 30-45 minutes in duration
        during the next two-years.

        EXCLUSION CRITERIA:

        Subject chooses to not participate in the study.

        Subjects are unable to complete the clinical examination tests.

        Subjects are unable to complete the questionnaires/surveys.

        Subjects are under age 18.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA - PATIENTS:

          -  Fanconi   s anemia.

          -  Diamond-Blackfan anemia.

          -  Dyskeratosis congenita.

          -  Shwachman-Diamond Syndrome.

          -  Amegakaryocytic thrombocytopenia.

          -  Thrombocytopenia absent radii.

          -  Severe congenital neutropenia.

          -  Pearson   s Syndrome.

          -  Other bone marrow failure syndromes.

          -  First degree relatives of IBMFS-affected subjects as defined here, i.e. siblings
             (half or full), biologic parents, and children.

          -  Grandparents of IBMFS-affected subjects, specifically for Hypothesis 4.

          -  Patients in the general population with sporadic tumors of the types seen in the
             IBMFS (head and neck, gastrointestinal, and anogenital cancer), with none of the
             usual risk factors for those tumors (e.g. smoking, drinking, HPV).

          -  Adult patients and family members who are unable to provide consent.

        INCLUSION CRITERIA - UNAFFECTED SIBLING STUDY:

        Eligibility for this amendment will be assessed only after the subject has been deemed
        eligible for the parent protocol.

        Specific eligibility for the proposed amendment are as follows:

          -  Ability to read, write, and speak in English.

          -  Between the ages of 11 &amp;  21.

          -  Informant has at least one biologically related, living sibling (full or half) who
             has an IBMFS.

        EXCLUSION CRITERIA - PARENT PROTOCOL:

          -  Evidence that the hematologic disorder is acquired rather than genetic.  Such
             evidence includes temporal relation of the aplastic anemia to known marrow
             suppressant drugs, chemicals, toxins, or viruses (in the absence of evidence
             indicative of an inherited marrow failure disorder).

          -  Known causes of cytopenias such as autoantibodies to red cells, platelets, or
             neutrophils, viruses (especially hepatitis), micronutrient deficiencies, transient
             erythroblastopenia of childhood, and cyclic neutropenia.

          -  Assignment of the patient   s physical findings to other syndromes or causes that are
             not part of the IBMFS disease spectrum.

          -  Inability or unwillingness to complete the questionnaires or permit access to medical
             records and pathology specimens.

          -  There are no other exclusion parameters not related to the primary disease.

        EXCLUSION CRITERIA - UNAFFECTED SIBLING STUDY:

          -  Diagnosis of an IBMFS or any other chronic illness.

          -  Cognitive impairment or inability to express feelings or experiences verbally or
             inability to provide informed consent.

          -  Emotional distress at the time of the interview.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

               1. Patients must a candidate for, or currently receiving radiotherapy.

               2. Age greater than or equal to 18 years.

        EXCLUSION CRITERIA:

          1. Inability to provide informed consent.

          2. Patients who have unobtainable data regarding previous radiation therapy.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  90 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Breast Cancer and High Risk Patients:

        Women of any age with a unilateral invasive or noninvasive (DCIS) breast cancer of
        epithelial origin.

        Women without breast cancer, but with a Gail Index greater than 1.67%.

        Women known to be BRCA1/2 mutation carriers.

        Women with cytologic or histologic evidence of ductal hyperplasia, atypical ductal
        hyperplasia, or lobular carcinoma in situ.

        Women may be either premenopausal or postmenopausal. Postmenopausal is defined by the
        absence of menstrual periods for at least 24 months.

        Postmenopausal women who have previously undergone a hysterectomy without oophorectomy
        must have a serum FSH level of greater than 40 IU/ml, and a serum estradiol level of less
        than 40 pg/ml to document postmenopausal status.

        Breast cancer may be invasive or noninvasive, and in the past or the present.

        The contralateral breast of women with breast cancer, or the normal breast of high risk
        subjects, must be free of any suspicious areas by physical examination and mammogram, and
        without past history of invasive ductal or in situ ductal carcinoma. A past history of
        atypia or LCIS on a previous biopsy is acceptable.

        Women who are from a family with heritable breast cancer with a known deleterious BRCA1/2
        mutation, who themselves have been tested and to not carry this mutation.  These women are
        not at increased risk for breast cancer due to the familial mutation and are eligible to
        participate as normal volunteers.

        WBC greater than 2500.

        Platelets greater than 50,000.

        Normal Volunteers

        Women who are premenopausal or postmenopausal with a Gail model risk index less than
        1.67%.

        Women who have previously undergone a hysterectomy without oophorectomy must have a serum
        FSH level of greater than 40 IU/ml, and a serum estradiol level of less than 40 pg/ml to
        document postmenopausal status.

        Both breasts must be free of any suspicious areas by physical examination and, for women
        over 30 years of age by mammogram. There must be no past history of atypical hyperplasia,
        invasive or in situ carcinoma.

        WBC greater than 2500.

        Platelets greater than 50,000.

        EXCLUSION CRITERIA:

        Breast Cancer Patients:

        Contralateral breast prosthesis.

        Pregnancy.

        History of radiation therapy to the contralateral breast.

        Lactating breast.

        Chemotherapy within the past 1 month.

        Current antiestrogen therapy.

        Current hormonal replacement therapy or oral contraceptives.

        Concurrent infection.

        Previous contralateral major duct excision.

        High Risk Subjects

        Bilateral breast prosthesis.

        Pregnancy.

        Lactating breast.

        Current antiestrogen therapy.

        Current hormonal replacement therapy or oral contraceptives.

        Concurrent infection.

        Previous bilateral major duct excision.

        History of therapeutic mediastinal radiation.

        Normal Volunteers

        Bilateral breast prosthesis.

        Pregnancy.

        Lactating breast.

        Current antiestrogen therapy.

        Current hormonal replacement therapy or oral contraceptives.

        Concurrent infection.

        Previous bilateral major duct excision.

        History of therapeutic mediastinal radiation.
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  ELIGIBILITY CRITERIA

        CAEBV PATIENTS

        Study size: up to 150 patients

        Sex distribution: male and female

        Age range:no minimum nor maximum age

        Patients with known or suspected CAEBV and their relatives will be recruited by referrals
        from health care providers.  The rarity of this disease will markedly limit the number of
        patients available to study.

        Patient recruitment is irrespective of racial and ethnic group or gender.  NIAID
        investigators will be available to answer questions and discuss general aspects of CAEBV
        and identified genes or modifier genes with participants or their providers.

        Eligibility criteria:

        To be considered having CAEBV, a patient must have:

          1. a severe progressive illness that began as a primary EBV infection, or associated
             with postive  EBV-specific antibody titers (IgG-VCA greater than or equal to ; EA or
             EBNA not otherwise explained AND

          2. evidence of  major organ involvement such as lymphadenitis, hemophagocytosis,
             meningoencephalitis, persistent hepatitis, splenomegaly, interstitial pneumonitis,
             bone marrow hypoplasia, uveitis AND

          3. detection of elevated levels of EBV DNA, RNA or proteins in affected tissues OR
             elevated levels of EBV DNA in the peripheral blood

        Exclusion Criteria:

        (a) Any other condition that, in the opinion of the investigator, would make the patient
        unsuitable for enrollment or could interfere with the patient participating in the study.

        RELATIVES OF CAEBV PATIENTS

        Study size: up to 150 relatives of CAEBV patients

        Age range:  2 years and above

        To determine the genetic basis for this syndrome, the evaluation of blood, saliva and/or
        previously obtained tissue specimens from healthy relatives of CAEBV patients will serve
        as controls.  No tissue biopsies will be performed on healthy relatives. We will

        perform some or all of the studies listed in section V. on samples from normal relatives.

        UNRELATED VOLUNTEERS

        Study size: up to 300 persons

        Age range: 18 years and above

        Panels of anonymous blood samples will be obtained through NIH Clinical Center Blood
        Transfusion Medicine to determine if identified genetic changes are mutations or
        polymorphisms.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  2 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Patients with known or suspected Birt Hogg Dube Syndrome and their family members of any
        age will be recruited from the dermatology, urology, oncology, and genetics communities
        worldwide.

        Patients with at least one histologically confirmed fibrofolliculomas; or

        Patients with clinical evidence of multiple skin papules (without fibrofolliculoma biopsy
        confirmation) and a personal or family history of spontaneous pneumothorax / or kidney
        cancer; or

        Patients with spontaneous pneumothorax and skin papules or kidney cancer and a positive
        family history of spontaneous pneumothorax, skin papules or kidney cancer; or

        A relative of a patient with a confirmed diagnosis of BHD, or

        Renal tumor histology consistent with BHD, including, but not limited to those suggestive
        of chromophobe, oncocytic neoplasm oroncocytoma.

        EXCLUSION CRITERIA:

        Persons unable to give informed consent.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  4 Years
 </minimum_age>
 <maximum_age>
  65 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Patients 18 years of age and older are eligible.

        Patients must have a performance status of ECOG 0, 1, 2, or 3 for admission to this
        protocol.

        Patients with malignancy are eligible.

        INCLUSION FOR APHERESIS:

        Hemoglobin greater than or equal to 10 mg/dL and platelet count &gt;  75,000/mm(3)

        Weight greater than 25 kg

        HIV negative

        Prothrombin Time     within normal limits

        Partial Thromboplastin Time     within normal limits

        Medically indicated central line in place or adequate peripheral venous access

        EXCLUSION CRITERIA:

        Children will not be eligible.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Study population:

        Patients must be members of families with familial TGCT as defined below.

        Definition of familial TGCT:

        The criterion establishing familial TGCT is the presence of:

        -at least two cases of documented GCT in blood relatives (at least one of which is
        testicular in origin),

        OR

          -  a single family member with bilateral testicular cancer,

          -  men with a history of TGCT who are one in a set of identical siblings will also be
             included in the study.

        Case definition:

        A case will be determined to have TGCT according to the following criteria:

          -  Pathologic confirmation of a germ cell   derived tumor arising in the testis.
             Extragonadal germ cell tumors will also be included.

          -  Germ cell   derived histologies including: seminoma, germinoma, embryonal carcinoma,
             endodermal sinus (yolk sac) tumor, gonadoblastoma, choriocarcinoma, teratoma, and
             mixed germ cell tumor.

          -  A case will be determined to have TIN on the basis of pathologic confirmation of
             intratubular malignant germ cells (ITMGCs) as defined by Burke and Mostofi.

        Individuals from participating families who are eligible for this study include:

        i)   all TGCT cases;

        ii)   All GCT cases (including those of ovarian or extra-gonadal sites);

        iii)  all first-degree relatives of each TGCT case;

        iv) the spouse(s) of every case if the spouse and case had children who are participating
        in the study;

        v)  any blood relative not included in (ii - iii) above who genetically links two cases;
        and

        vi)   any blood relative with cancer other than TGCT

        vii)  family members as described in i) - v) above must be age 12 or greater in order to
        participate

        EXCLUSION CRITERIA:

        Families will be deemed ineligible for participation in this study if:

        There are not at least two proven cases of GCT in the family, one of which is testicular
        in origin, unless there is a family member with bilateral testicular cancer;

        Deceased TGCT cases lacking both archival sources of tissue for DNA extraction AND lacking
        surviving spouses and children who are willing to paricipate in the study (unavailability
        of such persons prohibits inferring the genotype of the deceased individual with TGCT).

        Critical informative family members are unwilling to participate (i.e., unwilling to
        provide written informed consent);
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  12 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Adult patients (greater than or equal to 18 yrs of age) with tumors of the CNS or a
        history of a CNS tumor who are being evaluated for protocols within the National Cancer
        Institute.

        All patients or their previously designated LAR (Legally Authorized Representative) (if
        the patient is deemed by the treating physician to be impaired or questionably impaired in
        such a way that the ability of the patient to give informed consent is questionable) must
        sign an informed consent indicating that they are aware of the investigational nature of
        this study and the risks of the procedures that will be performed to assess eligibility
        for primary research protocols.

        EXCLUSION CRITERIA:

        None
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        On referral, persons of any age will be considered for inclusion in the study because of
        either:

          -  A family or personal medical history of hematologic/ lymphoproliferative malignancy
             of any unusual type, pattern, or number; or,

          -  Known or suspected factor(s) predisposing to hematologic malignancy, either genetic
             and/or congenital factors (birth defects, metabolic phenotype, chromosomal anomalies
             or Mendelian traits associated with tumors), environmental exposure (medications,
             occupation, radiation, diet, infectious agents, etc.), or unusual demographic
             features (very young age of onset multiple tumors, etc.).

        Personal and family medical history must be verified through questionnaires, interviews,
        and review of pathology slides and medical records.  For familial neoplasms, two or more
        living affected cases among family members are generally required, although in selected
        instances exceptions may be made, e.g., for WM, one cases plus a living 1st degree
        relative with an autoimmune condition will qualify a family for further investigations.

        Familial aggregation of any hematologic cancer(s) is eligible for study, our current
        active accrual efforts fall into 5 categories

          1. Chronic lymphocytic leukemia (CLL)

          2. Waldenstrom   s macroglobulinemia (WM)

          3. Non-Hodgkin   s Lymphoma (NHL)

          4. Hodgkin disease (HD)

          5. Mixed hematologic and lymphoproliferative diseases

        EXCLUSION CRITERIA:

          -  Referred individuals for whom reported diagnosis cannot be verified.

          -  Referred individuals who decline informed consent.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  1 Year
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Individuals age 18 and over are considered for inclusion in the study if they have a:

        Family history of neoplasia of an unusual type, pattern, or number which includes breast
        cancer or is consistent with an identified or suspected familial cancer syndrome which
        includes breast and/or ovarian cancer,

        Personal history of neoplasia(s) or benign conditions of an unusual type or with unusual
        demographic features (young age of onset, multiple primary sites, rare tumor type of
        pathologic characteristics) consistent with an identified or suspected familial cancer
        syndrome which includes breast and/or ovarian cancer, or

        A known mutation associated with one of the breast/ovarian cancer family syndromes.

        Eligibility is now restricted to only bloodline individuals age 18 and over from families
        which are already enrolled in 02-C-0212 and in which there is a known BRCA mutation

        Personal and family medical history must be verified through questionnaires, interviews,
        and review of pathology slides and medical records. For known or suspected familial
        syndromes in which no gene has been identified, two or more living affected cases among
        family members are required for participation. The types of familial syndromes under
        active accrual and study are predominantly investigator-and hypothesis-driven. This
        approach permits CGB investigators to remain alert to the opportunities afforded by
        unexpected clusters of rare tumors in families and individuals, and to tailor the accrual
        of families with specific types of syndromes to meet programmatic goals. This requires
        that CGB investigators remain abreast of both general knowledge and state-of the-art
        developments in clinical oncology, genetics, epidemiology and molecular biology, so that
        critical research opportunities can be recognized when they present, and so that
        thoughtful decisions can be made regarding the commitment of the resources needed to
        conduct such studies.

        EXCLUSION CRITERIA:

        Individuals and families referred for evaluation in whom reported diagnoses are not
        verifiable.

        Inability to provide informed consent.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

          -  On referral, persons of any age will be considered for inclusion in the study because
             of either:

          -  A family or personal medical history of melanoma of an unusual type, pattern, or
             number; or

          -  Known or suspected factor(s) predisposing to melanoma, either genetic or congenital
             factors (bathing trunk nevi, dysplastic nevi), or unusual demographic features (e.g.
             very young age of onset, multiple melanomas, previous history of heritable
             retinoblastoma, Hodgkin's disease, lymphoma, or organ transplant).

        EXCLUSION CRITERIA:

          -  Referred individuals and families for whom reported diagnoses cannot be verified;

          -  Inability to provide informed consent.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Birth to 80 years of age.

        Histologic evidence of increased mast cell number by bone marrow and/or skin biopsy.

        Must be under the care of a primary care physician to be enrolled.

        Patients must be able and willing to undergo a bone marrow biopsy. A bone marrow biopsy
        will be pre-empted if, during the procedure, the patient experiences significant flushing,
        pain, hypotension or tachycardia for any reason, which places the patient at risk.  A
        patient may decline to have a bone marrow biopsy if the bone marrow sample is only for
        research purposes.

        Bone marrow biopsy will be performed on children only if medically indicated.  Research
        samples will be collected at that time only if the procedure does not increase the risks
        to the child.

        EXCLUSION CRITERIA:

        No primary care physician.

        Anemia with hemoglobin less than 8 g/dL, hematocrit less than 24.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  80 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        All subjects must meet the established diagnostic criteria for hypereosinophilic syndrome:
        eosinophilia greater than 1,500/mm(3) on two occasions, no secondary etiology for the
        eosinophilia despite careful clinical evaluation, and evidence of end organ damage
        (histologic evidence of tissue infiltration by eosinophils and/or objective evidence of
        clinical pathology in any organ system that is temporally associated with eosinophilia and
        not clearly attributable to another cause).

        All subjects must fit one of the following three categories:

          1. refractory to or intolerant of steroids

          2. presence of FIP1L1/PDGFRA by RT-PCR

          3. presence of greater than or equal to 4 of the following laboratory criteria
             suggestive of a myeloproliferative disorder:

        i.     dysplastic eosinophils on peripheral smear

        ii.    serum B12 level greater than or equal to 1000 pg/ml

        iii.   serum tryptase level greater than or equal to 12

        iv.   anemia and/or thrombocytopenia

        v.    bone marrow cellularity greater than 80% with left shift in maturation

        vi.   dysplastic (spindle-shaped) mast cells on bone marrow biopsy

        vii.  evidence of fibrosis on bone marrow biopsy

        viii. dysplastic megakaryocytes on bone marrow biopsy

        3. All subjects must be at least 2 years of age.

        4. Negative serum beta-hCG within 24 hours prior to drug administration for women of
        childbearing potential to exclude early pregnancy.

        5. All subjects (men and women) must agree to practice abstinence or effective
        contraception during administration of imatinib mesylate and for 6 months after
        discontinuation of drug.

        Of note, failure of the standard chemotherapeutic agents (steroids, hydroxyurea, and
        interferon alpha) will not be a prerequisite for participation in this protocol for the
        following reasons. 1) There is no approved therapy for HES. 2) Steroid therapy in the
        myeloproliferative subset of HES patients is generally ineffective. 3) Although
        hydroxyurea and interferon alpha are initially effective in most cases, a majority of
        patients become refractory to or intolerant of these agents within a relatively short
        period of time (less than 1 year). 4) Data from other myeloproliferative disorders,
        including CML, suggest that interferon and imatinib mesylate, but not hydroxyurea, are
        associated with cytogenetic remission. 5) The reported incidence and severity of side
        effects from imatinib mesylate in patients with CML appears comparable to (or less than)
        those associated with interferon alpha.

        Although a private physician is not required for inclusion in the study, it is strongly
        recommended that all subjects have a physician outside the NIH for routine medical care
        and emergencies.

        EXCLUSION CRITERIA:

          1. Pregnancy or nursing women

          2. HIV positivity or other known immunodeficiency

          3. D816V KIT-positive systemic mastocytosis

          4. Absolute neutrophil count less than 1000/mm(3) or platelet count less than
             10,000/mm(3) or less than 50,000/m(3) with clinical evidence of bleeding.

          5. Elevated transaminases (greater than 5 times the upper limit of normal) or elevated
             bilirubin (greater than 3 times the upper limit of normal)

          6. Any condition that, in the investigator   s opinion, places the patient at undue risk
             by participating in the study
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  2 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

        All patients must meet the following inclusion criteria. All tests and eligibility
        criteria must be completed within four weeks of completion of radiation and chemotherapy,
        following surgery.

          -  Patients must have sufficient tumor lysate protein that was generated from the
             surgically obtained tumor material. Patients must also have sufficient DCVax-L
             product available after manufacturing. These determinations will be made by Cognate
             BioServices, Inc. (Cognate) and communicated to the clinical site through the
             Sponsor, or its designee.

          -  Patients with newly diagnosed, unilateral GBM (Grade IV) are eligible for this
             protocol. An independent neuropathologist will review this diagnosis during the
             enrollment process.

          -  Subjects 18 and 70 years of age at surgery who are capable of informed consent.
             Patients must be able to understand and sign the informed consent documents
             indicating that they are aware of the investigational nature of this study.

          -  Patients must have a life expectancy of &gt;8 weeks.

          -  Patients must have a KPS rating of 70 at the baseline visit (Visit 3).

          -  Primary therapy must consist of surgical resection with the intent for a gross or
             near total resection of the contrast-enhancing tumor mass, followed by conventional
             external beam radiation therapy and concurrent Temodar chemotherapy. Patients having
             a biopsy only will be excluded. These primary treatments must be completed at least
             two weeks prior to first immunization.

          -  Patients may have received steroid therapy as part of their primary treatment.
             Steroid treatment must be stopped at least 10 days prior to leukapheresis.

          -  Patients must not have progressive disease at completion of radiation therapy.
             Patients with suspected pseudoprogression will be enrolled and analyzed separately.

          -  Patients must be willing to forego cytotoxic anti-tumor therapies except temozolomide
             essentially according to the schedule of the Stupp Protocol (Stupp et al. N Engl J
             Med 352: 987-96, 2005) while being treated with DCVax-L. DCVax-L treatment must be
             given as described and temozolomide/Temodar treatment schedules must be given
             essentially according to the Stupp Protocol.

          -  Patients must have adequate bone marrow function (e.g., hemoglobin &gt;10 g/dl, white
             blood count 3600-11,000mm3, absolute granulocyte count 1,500/mm3, absolute
             lymphocyte count 1,000/mm3, and platelet count 100K/mm3. Eligibility level of
             hemoglobin can be reached by transfusion.

          -  Adequate liver function (SGPT, SGOT, and alkaline phosphatase 1.5 times upper limits
             of normals (ULN) and total bilirubin 1.5mg/dl), and adequate renal function (BUN or
             creatinine 1.5 times ULN) prior to starting therapy.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Members of the XP families where the proband has previously been evaluated at the Clinical
        Center or is newly diagnosed under other approved protocols (primarily 99-C-0099) are
        eligible to participate in this study. Families with XP patients of any age, gender or
        race are eligible for this study.

        On referral, families of XP patients will be considered for inclusion in the study if the
        proband has clinical documentation of features of XP and laboratory determination of the
        DNA repair defect. All relatives of XP patients including spouses are eligible to
        participate.

        EXCLUSION CRITERIA:

        Inability or unwillingness to provide family history information or tissue (skin, blood,
        buccal cells or hair) for laboratory studies.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        RECIPIENT:

        Ages 18-70 years (both inclusive)

        Stages IIb to IVb patients with MF (biopsy diagnostic or consistent with MF) who have
        progressed despite at least one treatment regimen and all patients with SS

        AND

        Anticipated median survival less than 5 years or debilitation as a result of their
        disease.

        Recovery from acute toxicity of prior treatment for MF/SS (to less than or equal to grade
        1 [CTCAE v3.0]) or stabilization of toxicity occurring from prior therapy for MF/SS.

        HIV negative

        ECOG performance status of 1 or less.

        No major organ dysfunction precluding transplantation.

        DLCO greater than or equal to 60 percent predicted

        Left ventricular ejection fraction greater than or equal to 40 percent.

        Less than or equal to 25 percent of liver involved with metastatic tumor by CT scan.

        6/6 HLA matched family donor available

        Ability to comprehend the investigational nature of the study and provide informed
        consent.

        &lt; TAB&gt;

        INCLUSION CRITERIA-DONOR:&lt; TAB&gt;

        6/6 HLA- matched family donor

        Age greater than or equal to 18 years

        Ability to comprehend the investigational nature of the study and provide informed
        consent.

        EXCLUSION CRITERIA (ANY OF THE FOLLOWING)-RECIPIENT

        Patient pregnant or lactating

        Age greater than 70 or less than 18 years

        ECOG performance status of 2 or more.

        Psychiatric disorder or mental deficiency of the recipient or donor sufficiently severe as
        to make compliance with the BMT treatment unlikely and making informed consent impossible.

        Major anticipated illness or organ failure incompatible with survival from BMT and where
        survival is considered insufficient to assess transplant outcome (i.e. less than 3
        months).

        DLCO less than 60 percent predicted

        Left ventricular ejection fraction less than 40 percent

        Serum creatinine greater than 2.0 mg/dl

        Serum bilirubin greater than 4 mg/dl, transaminases greater than 5 times the upper limit
        of normal

        HIV positive

        History of other malignancies in the last five years with the exception of basal cell or
        squamous cell carcinoma of the skin

        Evidence for CNS metastatic disease

        &lt; TAB&gt;

        Disease involving greater than 25 percent of the liver radiographically.

        EXCLUSION CRITERIA (any of the following)-DONOR:

        Donor pregnant or lactating

        Age less than 18 years

        HIV positive (donors who are positive for hepatitis B (HBV), hepatitis C (HCV) or human
        T-cell lymphotropic virus (HTLV-1) will be used at the discretion of the investigator
        following counseling and approval from the recipient).

        Sickling hemoglobinopathy including HbSS or HbsC.

        History of malignancy within 5 years except basal cell or squamous carcinoma of the skin.

        Donor unfit to receive G-CSF and undergo apheresis (Uncontrolled hypertension, history of
        stroke, thrombocytopenia).

        Psychiatric disorder or mental deficiency of the donor sufficiently severe as to make
        compliance with the BMT treatment unlikely and making informed consent impossible.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Patients with known or suspected Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome
        and their family members of any age will be recruited from the dermatology, urology,
        oncology, and genetics communities worldwide.

        An individual from a family in which one or more family member have:

          -  Cutaneous leiomyoma and kidney cancer

          -  Cutaneous leiomyoma and uterine leiomyoma

          -  Multiple cutaneous leiomyoma

          -  Kidney cancer and uterine leiomyomata

          -  Renal tumor histology consistent with HRLRCC including, but not limited to:
             Collecting Duct and/or Papillary, Type II

        Spouses enrolled primarily for linkage analysis

        EXCLUSION CRITERIA:

        Persons unable to give informed consent.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Diagnostic Study Protocol

        All adults and children requiring dynamic testing of the hypothalamic-pituitary axis for
        the evaluation of pituitary reserve, inconsistent thyroid function test, inappropriate TSH
        secretion, or pre-and post-operative evaluation of pituitary adenomas (glycoprotein
        hormone secreting tumors, growth hormone secreting tumors and TSH secreting tumors).

        EXCLUSION CRITERIA:

          -  Uncontrolled hypertension;

          -  Uncontrolled seizure disorder;

          -  Unstable coronary disease;

          -  Known allergy to TRH.

        Research protocols

        TRH is available for use in other IRB approved research protocols either using the
        standard diagnostic testing protocol or the modified TRH test.

        EXCLUSION CRITERIA:

          -  Untreated hypertension;

          -  Coronary artery disease;

          -  History of asthma;

          -  History of seizures;

          -  Pregnancy;

          -  Known allergy to TRH.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  2 Years
 </minimum_age>
 <maximum_age>
  65 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Newly diagnosed chronic phase chronic myelogenous leukemia (CML)

               -  bcr-abl positive

               -  No blasts, promyelocytes, myelocytes, or metamyelocytes in the peripheral blood

          -  Availability of a HLA-identical sibling or unrelated donor

        PATIENT CHARACTERISTICS:

        Age

          -  Any age

        Performance status

          -  Not specified

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No second malignancy requiring therapy

          -  No evidence of disease-related symptoms or extramedullary disease (including
             hepatosplenomegaly)

          -  No serious diseases that would preclude study participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No prior interferon

        Chemotherapy

          -  No prior chemotherapy other than hydroxyurea

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  No prior radiotherapy

        Surgery

          -  Not specified

        Other

          -  Prior anagrelide allowed

          -  No participation in another clinical trial
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Inclusion criteria are the availability of radiologic examinations in the clinical PACS
        (picture archiving system) in the Clinical Center. Existing Patient scans with and without
        the target lesion will be included.  Examples of target lesions include subcutaneous and
        bone lesions and pulmonary emboli, although patient scans with other disorders depicted on
        radiologic studies may be included when appropriate.  Patient scans without the target
        lesion may be included to determine the specificity of the computer aided detection or
        diagnosis algorithm.

        EXCLUSION CRITERIA:

        There are no exclusion criteria.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   INCLUSION CRITERIA:

          1. Diagnosis of myelodysplastic disorders; Fanconi's Anemia; Acute Myelogenous Leukemia
             (including secondary); Acute Lymphoblastic Leukemia; Multiple Myeloma; Plasma Cell
             Dyscrasia; lymphoproliferative disorders (Non-Hodgkin Lymphoma, Hairy Cell Leukemia,
             Chronic Lymphocytic Leukemia, and Hodgkin's Disease). Diagnosis of myelodysplastic
             disorders which is not good risk by IPSS: Fanconi's Anemia; Acute Myelogenous
             Leukemia (1st or subsequent relapse, or 2nd or subsequent CR, or refractory disease);
             Acute Lymphoblastic Leukemia in 2nd or subsequent remission or relapse or refractory
             disease; Philadelphia Chromosome-positive Chronic Myelogenous Leukemia (failed STI
             and interferon); Multiple Myeloma (Stage II or III); Lymphoma; Chronic Lymphocytic
             Leukemia (primary refractory or recurrent disease); Hodgkin's Disease (after
             relapse); Hemophagocytic Lymphohistiocytosis (failed chemotherapy and/or anti-viral
             therapy); bone marrow failure such as Aplastic Anemia and Paroxysmal Nocturnal
             Hemoglobinuria; PNH (failed prior therapies).

          2. Conditions that increase treatment related mortality: (need one or more to be
             eligible): Age &gt; / = 50 years; EF of less than 45%; DLCO less than 50% or FEVI 50-75%
             of predicted value; Diabetes Mellitus; Renal Insufficiency (but creatinine clearance
             not less than 25 mL/min); Prior recent history of systemic fungal infection; 3rd or
             greater remission of AML or ALL; Significant Grade III or IV neurologic or hepatic
             toxicity from previous treatment; More than 1 year from diagnosis (CML or Myeloma
             patients ONLY); Multiple types of treatment regimens (equal to or more than 3);
             Significant Grade III or IV neurologic or hepatic toxicity from previous treatment;
             Prior autologous or allogeneic stem cell transplantation.

          3. Haploidentical family member donor. This protocol is open to patients who lack a 5/6
             or 6/6 HLA antigen-matched donor. Due to the increased risk of GvHD, patients with
             Fanconi Anemia and a 5/6 HLA match will also be eligible.

             For this protocol, the "best" donor will be defined as a first-degree haploidentical
             family member who matches at the greatest number of MHC loci. Matching will be
             determined by Class I and Class II DNA typing. The donor should be sufficiently
             healthy as to not be at increased risk from the stem cell mobilization procedure.
             Should more than one "equally" MHC-incompatible donor be identified, other selection
             criteria will include: age and size of donor, CMV status, and sex. The Principal
             Investigator will make final decisions.

          4. Available healthy donor without any contraindications for donation.

          5. Patient and/or legal representative and/or legal guardian able to understand and sign
             consent.

          6. Age between birth and 70 years.

          7. Women of child-bearing potential must have a negative pregnancy test.

        EXCLUSION CRITERIA:

          1. Pregnant, lactating or unwilling to use contraception.

          2. HIV-positive patient.

          3. Uncontrolled intercurrent infection.

          4. Untreated blast crisis for CML.

          5. Uncontrolled high-grade lymphoproliferative disease / lymphoma.

          6. Unstable angina and uncompensated congestive heart failure (Zubrod of 3 or greater).

          7. Severe chronic pulmonary disease requiring oxygen (Zubrod of 3 or greater).

          8. Hemodialysis dependent.

          9. Active hepatitis or cirrhosis with total bilirubin, SGOT, and SGPT greater than 3X
             upper limit of normal.

         10. Unstable cerebral vascular disease and recent hemorrhagic stroke (less than 6
             months).

         11. Active CNS disease from hematological disorder.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

               1. Age 4 and older.

               2. Neurosurgical-related conditions such as brain tumors, pituitary tumors,
                  epilepsy, Parkinson   s disease, other abnormal movement disorders,
                  arteriovenous malformations, and pain disorders, based on Surgical Neurology
                  Branch training and teaching needs.

               3. For adults: able to provide informed consent or having a legally-authorized
                  representative to provide consent, if incapacitated.

               4. For minors: a parent or legal guardian who is able to provide consent.

                  For immediate blood relatives of subjects having genetic testing only:

               5. Blood relative of a subject who is suspected to have a genetic mechanism
                  underlying their neurological disorder (for genetic testing only).

        EXCLUSION CRITERIA:

        1.Medically unstable  or severe organ failure based on clinical evaluation.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  4 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Patients who have been diagnosed with VHL using the following criteria:  either germ line
        analysis (12) or clinical criteria and a family history (8, 12) and who have at least 1
        pancreatic manifestation of VHL as documented on any non-invasive imaging study.  These
        manifestations include:

          1. Pancreatic cyst(s).

          2. Solid lesions suspicious for microcystic adenoma(s).

          3. Solid enhancing lesions suspicious for PNET(s).

          4. Any other solid lesion(s) of the pancreas.

        Age greater than or equal to 12 years of age.

        Patients must be willing to return to NIH for follow-up.

        Patients/parent must be able to sign an informed consent.

        EXCLUSION CRITERIA:

        Patients unwilling to return to the NIH for follow-up.

        Patients unwilling to undergo serial non-invasive imaging.

        Patients without evidence of pancreatic lesions.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  12 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   INCLUSION CRITERIA:

          1. Any patient, regardless of age or sex, with EBV-positive Hodgkin's or non-Hodgkin's
             Lymphoma, or lymphoepithelioma or leiomyosarcoma regardless of the histological
             subtype or EBV (associated)-T/NK-lymphoproliferative disease or Severe Chronic EBV#

             (#SCAEBV is defined as patients with high EBV viral load in plasma or PBMC (&gt;4000
             genomes per ug PBMC DNA) and/or biopsy tissue positive for EBV)

             a - In second or subsequent relapse (or first relapse or with active disease if
             immunosuppressive chemotherapy contraindicated or multiply relapsed patients
             currently in remission who have a high risk of relapse) OR with primary disease or in
             first remission if immunosuppressive chemotherapy is contraindicated, e.g. patients
             who develop Hodgkin disease after solid organ transplantation or if the Lymphoma is a
             second malignancy e.g. a Richters transformation of CLL.(Group A)

             OR

             b - In remission or with minimal residual disease status after autologous or
             syngeneic SCT for Hodgkin's or non-Hodgkin's Lymphoma/Lymphoepithelioma/SCAEBV.
             (Group B)

             OR

             c - Patients after allogeneic SCT for Hodgkin's Lymphoma or Non-Hodgkin's
             Lymphoma/Lymphoepithelioma/SCAEBV. (Group C)

          2. Patients with life expectancy 6 weeks or greater.

          3. Tumor tissue EBV positive

          4. Patients with a Karnofsky/Lansky score of 50 or greater

          5. Donor HIV negative (if autologous product - patient must be HIV negative)

          6. If post allogeneic SCT must not have less than 50% donor chimerism in either
             peripheral blood or bone marrow

          7. Patients with bilirubin 3x normal or less, AST 5x normal or less, and Hgb greater
             than 8.0

          8. Patients with a creatinine 2x normal or less for age

          9. Patients should have been off other investigational therapy for one month prior to
             entry in this study.

         10. Patient, parent/guardian able to give informed consent.

        EXCLUSION CRITERIA:

          1. Patients with a severe intercurrent infection.

          2. Donors who are HIV positive or Patients who are HIV positive if autologous product to
             be used

          3. Patients with greater than Grade II GVHD

          4. Due to unknown effects of this therapy on a fetus, pregnant women are excluded from
             this research. The male partner should use a condom.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Patients who are evaluated by the Radiation Oncology Branch and are:

        Children with cancer (or a precancer syndromes, such as aplastic anemia or other
        myelodysplastic syndromes), between the age(s) of 6 months - 21 years, whose cancer (or
        precancer syndrome) will be treated with radiation therapy in the Radiation Oncology
        Branch, NCI.

        Patients with cancer (or a precancer syndromes, such as aplastic anemia or other
        myelodysplastic syndromes), who present with disease manifestations of special interest to
        Radiation Oncology Branch investigators, because they are likely to shed led light on the
        natural history, pathogenesis, radiation response, and late effects of disease process.

        Patients with cancer (or precancer syndromes, such as aplastic anemia or other
        myelodysplastic syndromes) who offer an important educational benefit to trainees in
        radiation oncology and staff.

        Patient must have a primary physician in the community who specializes in pediatrics
        and/or oncology and is willing to collaborate with the ROB staff in the clinical
        management of the patient

        If indicated, availability of a parent or legal guardian to give informed consent

        Children with cancer (or a precancer syndrome, such as aplastic anemia or other
        myelodysplastic syndrome), between the age(s) of 6 months - 21 years, whose cancer (or
        precancer syndrome) have already been treated with radiation therapy in the Radiation
        Oncology Branch, NCI.

        EXCLUSION CRITERIA:

        Patients, and/or guardians who are in the estimation of the PI, deemed unable or unlikely
        to adhere to protocol treatment and follow-up requirements.

        Patients who are enrolled on a clinical trial (e.g. COG or CNMC) in which one of the
        research objectives is to study the radiation treatment.

        Patients who are pregnant and are to receive radiation treatment on this protocol.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  21 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

               1. Age: greater than or equal to 1 years and less than or equal to 21 years.

               2. Radiographic diagnosis:  Patients must have a brain tumor (including, but not
                  limited to high grade gliomas, low-grade gliomas, primitive neuroectodermal
                  tumors, ependymomas) or residual abnormality (e.g. post-operatively or
                  post-radiation) that is measurable or evaluable on standard MRI or CT.

               3. All patients or their legal guardians (if the patient is less than 18 years of
                  age) must sign a document of informed consent indicating their awareness of the
                  investigational nature and the risks of this study.  When appropriate, the minor
                  patient will be asked for oral assent.  The parent or guardian will sign the
                  consent form on the designated line attesting to the fact that the minor has
                  given assent.

               4. Durable Power of Attorney (DPA): A DPA will be offered to all patients 18-21
                  years of age.

               5. Prior treatment:  Patients will be eligible for this study regardless of prior
                  treatment, as long as they meet other eligibility criteria.  Therefore, patients
                  who are newly diagnosed, post-operative, post-radiation or post-chemotherapy are
                  eligible.

        EXCLUSION CRITERIA:

          1. Patients under age 18 years who weigh greater than 70 kg are excluded because they
             would exceed the standard allowable dosimetry for pediatric patients (i.e. Effective
             Dose greater than 0.5 REM/year).  In addition, patients who weigh greater than 136 kg
             are excluded, as this is the maximum weight allowable on PET scanner tables.

          2. Pregnant women are excluded because the effects from the magnet on the fetus are
             unknown.  In addition, gadolinium is not approved for use in pregnant women, because
             its teratogenic effects have not been studied and we wish to avoid radiation exposure
             to the fetus.

          3. Any patient who is unable (either because of physical or psychological factors) to
             undergo imaging studies without sedation but is not considered an anesthesia
             candidate.

          4. Any patient with a metallic MRI incompatible implant, including cardiac pacemakers,
             neural pacemakers, aneurysmal clips, shrapnel, cochlear implants or ferrous surgical
             clips.

          5. Any patient with a history of a severe reaction (CTC v.4 Grade greater than or equal
             to 2) to Gadolinium or other contrast agents.

          6. Any patient with Diabetes mellitus or steroid-induced hyperglycemia (fasting glucose
             greater than 150) because this may interfere with the interpretation of the
             [(18)F]-FDG PET scan.

          7. Any patient with permanent braces, permanent retainers or nonferrous implant that, in
             the judgment of the Principal Investigator, would interfere with obtaining
             spectroscopy in the area of the tumor.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  1 Year
 </minimum_age>
 <maximum_age>
  21 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  ELIGIBILITY CRITERIA FOR PATIENTS WITH A CURRENT DIAGNOSIS OF CANCER:

        INCLUSION CRITERIA:

          -  Patients must have a form of cancer currently being studied with adoptive cell
             therapies in the Surgery Branch.

          -  Able to understand and sign the Informed Consent Document.

          -  Patients must be greater than or equal to 16 years of age.

          -  Clinical performance status of ECOG 0 or 1.

          -  Life expectancy of greater than three months.

          -  Seronegative for HIV (The experimental treatments being evaluated depend upon an
             intact immune system. Patients who are HIV seropositive can have decreased immune
             competence and thus be less responsive to the experimental treatment and more
             susceptible to its toxicities).

          -  Seronegative for hepatitis B surface antigen and seronegative for antibody to
             hepatitis C. If hepatitis C antibody test is positive, then patients must be tested
             for the presence of antigen by RT-PCR and be HCV RNA negative.

          -  If Surgery is required to obtain TIL for cell acquisition, the expected procedure
             must be associated with minimal morbidity and minimal hospitalization.

        EXCLUSION CRITERIA:

          -  Active systemic infections, coagulation disorders, or other major medial illnesses of
             the cardiovascular, respiratory, or immune system.

          -  Patients who cannot give proper informed consent to the adoptive cell experimental
             therapy due to an active psychiatric disorder or inability to understand the nature
             of the proposed therapy and attendant risk.

        ELIGIBILITY CRITERIA FOR NORMAL DONORS:

        INCLUSION CRITERIA:

          -  Normal donors must be greater than or equal to 18 years of age.

          -  Seronegative for HBsAg, Anti-HBc, Anti-HCV, Anti-HIV-1/2, HIV- 1/HCV/HBV NAT,
             anti-HTLV-1/2, RPR, T. cruzi, and West Nile Virus NAT

          -  Normal donors must meet the strict behavioral and medical history requirements

        EXCLUSION CRITERIA:

          -  Has had babesiosis.

          -  Is at risk or has Creutzfeld-Jakob Disease.

          -  Is on steroid therapy or any other medication or has received vaccination that might
             interfere with cell preparation per Principal Investigator   s discretion.

          -  Has ongoing illness that would cause harm to the volunteer during the apheresis
             procedure as determined by the Principal Investigator.

          -  Has had yellow jaundice, liver disease, or hepatitis since the age of 11

          -  Has uncontrolled diabetes

          -  Has a hematologic malignancy or any bleeding abnormalities

          -  Has received any type of organ transplant in the past 12 months.

          -  Has undergone xenotransplantaion at any time.

          -  Has received a dura mater graft.

          -  If female, has been pregnant in the last six weeks

          -  Has had body piercing or tatoos within the past year

          -  Has spent time outside the United States to a restricted country

          -  Has participated in any high-risk activities

        Eligibility Criteria for Subjects with Spontaneous Vitiligo and for Patients with a
        history of cancer who currently have no evidence of disease.

        INCLUSION CRITERIA:

        - Greater than or equal to 18 years of age.

        EXCLUSION CRITERIA:

        - Has ongoing illness that would cause harm to the volunteer during the apheresis
        procedure as determined by the Principal Investigator.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  16 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients with alopecia areata (AA), both children and adults, who have been diagnosed by a
        physician with alopecia universalis, alopecia totalis, patchy persistent AA, or transient
        mild AA.  Family members (related by blood) of these patients, preferably sib-pairs plus
        parents and multiplex families(persons with at least three family members with AA or
        alopecia universalis and alopecia totalis).

        Also, healthy individuals who are unaffected, non-blood related individuals and do not
        live in the same household with alopecia areata patient are needed as controls.
  </textblock>
 </study_pop>
 <sampling_method>
  Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria

          -  Diagnosed with alopecia areata by a dermatologist

          -  United States resident

        Accepts Health Volunteers: Non blood-related individuals who are unaffected with alopecia
        areata and do not live in the same household with alopecia areata patient.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        The subject carries the diagnosis of malignant solid tumor or a malignant or non-malignant
        hematologic disorder, and is being screened at the NIH for eligibility for an NIH Clinical
        Center treatment protocol.

        OR

        The subject carries the diagnosis of malignant solid tumor or a malignant or non-malignant
        hematologic disorder, and is already enrolled on a clinical protocol at the NIH Clinical
        Center.

        OR

        The subject is a related HLA-compatible family member of a patient (bearing a diagnosis of
        malignant solid tumor or a malignant or non-malignant hematologic) being evaluated for or
        already enrolled on a clinical protocol at the NIH Clinical Center and is identified as a
        potentially suitable donor of allogeneic hematopoietic stem cells for transplantation.

        OR

        The subject carries the diagnosis of malignant solid tumor or a malignant or non malignant
        hematologic disorder or a bone marrow failure condition and is not available to
        participate in an NIH Clinical Center treatment protocol, or travel to the NIH clinical
        center, but is referred for participation through their home health care provider.

        The subject or the subject's guardian is able to understand the investigational nature of
        the study and provide informed consent after initial counseling by clinical staff.
        Separate consent forms for all interventional or surgical procedures will be obtained
        after explanation of the specific procedure.

        Age 2 years and older (no upper limit)

        EXCLUSION CRITERIA:

        Subjects unable to comprehend the investigational nature of the procedure

        Age less than 2 years
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  2 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Diagnosis of B-cell chronic lymphocytic leukemia (CLL) meeting the following
             criteria:

               -  Peripheral blood absolute lymphocyte count greater than 5,000/mm^3

               -  Lymphocytosis must comprise small to moderate size lymphocytes with no greater
                  than 55% prolymphocytes, atypical lymphocytes, or lymphoblasts morphologically

               -  Phenotypically characterized CLL defined by the following:

                    -  Predominant population of cells share B-cell antigens with CD5 in the
                       absence of other pan-T-cell markers (CD3 or CD2)

                    -  B cell expresses either kappa or lambda light chains

                    -  Surface immunoglobulin with low cell surface density expression

          -  Requires chemotherapy, as indicated by any of the following:

               -  Disease-related symptoms

                    -  Weight loss of 10% or more within the past 6 months

                    -  Extreme fatigue

                    -  Fevers greater than 100.5F for 2 weeks without evidence of infection

                    -  Night sweats without evidence of infection

               -  Evidence of progressive marrow failure manifested by the development of or
                  worsening anemia (hemoglobin no greater than 10 g/dL) and/or thrombocytopenia
                  (platelet count no greater than 100,000/mm^3)

               -  Massive (i.e., greater than 6 cm below left costal margin) or progressive
                  splenomegaly

               -  Massive nodes or clusters (i.e., greater than 10 cm in longest diameter) or
                  progressive adenopathy

               -  Progressive lymphocytosis with an increase of greater than 50% over a 2-month
                  period OR an anticipated doubling time of less than 6 months

          -  Demonstrated progression after at least 1 course of either an alkylating agent-based
             or purine nucleoside-based (e.g., fludarabine) regimen OR failed to achieve a
             meaningful response OR relapsed after prior therapy

               -  Patients who have relapsed after a pentostatin-based regimen are eligible
                  provided the response was greater than 12 months prior to study entry

          -  No bone marrow dysplasia related to prior therapy

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  See Disease Characteristics

        Hepatic

          -  Bilirubin no greater than 2 mg/dL (unless secondary to tumor, hemolysis, or Gilbert
             syndrome)

        Renal

          -  Creatinine no greater than 2.0 mg/dL OR

          -  Creatinine clearance  30 mL/min

        Cardiovascular

          -  No New York Heart Association class III or IV heart failure

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use 2 methods of effective contraception (including 1 barrier
             method) for at least 28 days before starting lenalidomide, while participating in the
             study, and for at least 28 days after discontinuation/stopping lenalidomide

          -  No other malignancy within the past 2 years except squamous cell or basal cell skin
             cancer or carcinoma in situ of the cervix

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  See Chemotherapy

          -  At least 8 weeks since prior rituximab

        Chemotherapy

          -  See Disease Characteristics

          -  At least 6 weeks since prior chemotherapy

          -  At least 1 year since prior pentostatin, cyclophosphamide, and rituximab (PCR)
             therapy

               -  PCR therapy at least 1 year prior to study entry allowed

          -  No prior lenalidomide

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified

        Other

          -  No concurrent oral or IV antibiotics for active infection
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA: PATIENT RECIPIENT

               1. Patients with hematologic malignancies, myelodysplasia, or myeloproliferative
                  disorders, as summarized in the following table. The diagnosis must be
                  histologically confirmed by the Laboratory of Pathology of NCI or Hackensack
                  (There will be no central pathology review).

               2. Chronic Lymphocytic Leukemia - Disease Status: a) Relapse post-fludarabine, b)
                  Non-CR after salvage regimen.

                  Hodgkin's and Non-Hodgkin's Lymphoma (all types, including Mantle Cell Lymphoma)
                  - Disease Status: a) Primary treatment failure, b) Relapse after autologous SCT,
                  c) Non-CR after salvage regimen

                  Special Cases of High-Risk Lymphoma, including but not limited to : (1) plasma
                  dendritic cell type, 2) Hepato-splenic T cell type, 3) gamma delta pinniculitic
                  T cell type, 4) Muco-cutaneous NK cell type and 5) stage III-IV nasal NK cell
                  type- Disease Status: a) Primary treatment failure, b) Relapse after autologous,
                  c) Non-CR after salvage regimen, d) In forist CR or any later CR

                  Chronic EBV-associated lymphoproliferative disease a) At any point after
                  diagnosis, including up-front therapy

                  Multiple Myeloma - Disease Status: a) Primary treatment failure, b) Relapse
                  after autologous SCT, c) Non-CR after salvage regimen.

                  Acute Myelogenous Leukemia - Disease Status: a) CR number 1 and high-risk
                  [excludes t(8;21), t(15;17), or inv(16)], b) CR number 2 or greater).

                  Acute Lymphocytic Leukemia - Disease Status: a) CR number 1 plus high-risk
                  [t(9;22) or bcr-abl(+); t(4;11), 1(1;19), t(8;14)], b) In CR number2 or greater.

                  Myelodysplastic Syndrome - Disease Status: a) RAEB, b) RAEB-T (requires marrow
                  and blood blasts less than 10% after induction chemotherapy).

                  Myeloproliferative disorders - Disease Status: a) Idiopathic myelofibrosis, b)
                  Polycythemia vera, c) Essential thrombocytosis, d) Chronic myelomonocytic
                  leukemia.

                  Chronic Myelogenous Leukemia - Disease Status: a) Chronic phase CML, refractory
                  to imatinib treatment b) Accelerated phase CML. b) Accelerated phase CML

                  Patients with myeloproliferative disorders must be end-stage, which is primarily
                  defined as disease severity refractory to splenectomy.

               3. Patient age of 16 to 75 years.

               4. Consenting first degree relative matched at 6/6 HLA antigens (A, B, and DR).

               5. Patient or legal guardian must be able to give informed consent.

               6. All previous therapy must be completed at least 2 weeks prior to study entry,
                  with recovery to less than or equal to non-hematologic grade 2 toxicity of
                  previous therapy.

               7. ECOG performance status equal to 0 or 1.

               8. Life expectancy of at least 3 months.

               9. Acute leukemia must be in hematologic remission (less than 10% blood or marrow
                  blasts).

              10. Left ventricular ejection fraction greater than or equal to 45%, preferably by
                  2-D echo, or by MUGA. However, patients with LVEF of between 35% and 44% may
                  also be eligible provided that such patients are cleared by a Cardiology
                  Consultation that must include a cardiac stress test.

              11. Corrected DLCO greater than 50% of expected value.

              12. Creatinine less than or equal to1.5 mg/dl and creatinine clearance greater than
                  or equal to 50 ml/min.

              13. Serum total bilirubin less than 2.5 mg/dl; serum ALT and AST equal 2.5 times
                  upper limit of normal. Values above these levels may be accepted, at the
                  discretion of the PI or study chairman, if such elevations are thought to be due
                  to liver involvement by malignancy.

              14. Adequate central venous access potential.

              15. Potential patients referred for the study may not be eligible for the
                  experimental protocol therapy due to reasons such as uncertainty about donor HLA
                  typing or need to control malignant disease, infection, or metabolic abnormality
                  such as hypercalcemia on a emergent basis.  Should a referred patient present to
                  us in such a scenario, the patient will be referred back to their primary
                  hematologist-oncologist for treatment.  However, if referral back to the
                  referring physician is not in the best interest of the patient according to the
                  clinical judgement of the PI, then the patient may receive standard treatment
                  for the malignant disease or complicating conditions (infection, metabolic
                  problems under the current study. In other cases, a patient may have reasonable
                  control of malignancy but does not meet the CD4 cell cut-off of 50 cells per
                  microliter required for cohort 3 therapy; in such cases, standard care
                  chemotherapy regimens may be administered for the specific goal of reducing the
                  CD4 count (that is, immune depleting regimens such as the pentostatin plus
                  cyclophosphamide combination, administered similar to the manner that we have
                  developed on protocol 08-C- 0088). If it becomes apparent that the patient will
                  not be able to proceed to experimental therapy, then he/she must come off study.
                   Recipient-Subjects receiving a standard therapy, and availability of receiving
                  the same treatment elsewhere, outside of a research protocol.  Because such
                  standard care therapy is not experimental, it is not necessary to complete the
                  eligibility criteria prior to receiving such standard care; however, prior to
                  initiation of the experimental therapy, the patient must meet each of the
                  eligibility crieteria detailed above. Attempts will be made to standardize such
                  pretransplant

        chemotherapy (by administration of EPOCH-FR chemotherapy, which is detailed later in this
        protocol); however, other regimens using approved agents will be allowed if such regimens
        are thought to be in the best interest of the patient.

        INCLUSION CRITERIA: DONOR

          1. First-degree relative with genotypic identity at 6/6 HLA loci (HLA- A, B, and DR).

          2. Age 11 to 90 years and able to give consent or assent. For donors &lt;  18 years old,
             the legal guardian must be able to provide informed consent.

          3. Adequate venous access for peripheral apheresis, or consent to use a temporary
             central venous catheter for apheresis.

          4. Donors must be HIV negative.

          5. Donors with a history of hepatitis B or hepatitis C infection may be eligible.
             However, eligibility determination of such patients will require a hepatology
             consultation. The risk/benefit of the transplant and the possibility of transmitting
             hepatitis will be discussed with the patient and eligibility will then be determined
             by the principal investigator and LAI.

          6. Lactating donors must substitute formula feeding for her infant during period of
             filgrastim administration (to prevent any filgrastim effect on infant).

        EXCLUSION CRITERIA: PATIENT

          1. Active infection that is not responding to antimicrobial therapy.

          2. Active CNS involvement by malignancy.

          3. HIV infection (treatment may result in progression of HIV and other viral
             infections).

          4. Chronic active hepatitis B. Patient may be hepatitis B core antibody positive. For
             patients with concomitant positive hepatitis B surface antigen, patient will require
             a hepatology consultation. The risk/benefit profile of transplant and hepatitis B
             will be discussed with the patient and eligibility determined by the principal
             investigator and Lead Associate Investigator.

          5. Hepatitis C infection. Patient may have hepatitis C infection. However, each patient
             will require a hepatology consultation. The risk/benefit profile of transplant and
             hepatitis C will be discussed with the patient and eligibility determined by the
             principal investigator and Lead Associate Investigator.

          6. Pregnant or lactating.  Patients of childbearing potential must use an effective
             method of contraception. The effects of the chemotherapy, the subsequent transplant
             and the medications used after the transplant are highly likely to be harmful to a
             fetus. The effects upon breast milk are also unknown and may be harmful to the
             infant.

          7. History of psychiatric disorder which may compromise compliance with transplant
             protocol, or which does not allow for appropriate informed consent.

        EXCLUSION CRITERIA: DONOR

          1. History of psychiatric disorder which may compromise compliance with transplant
             protocol, or which does not allow for appropriate informed consent.

          2. History of hypertension that is not controlled by medication, stroke, autoimmune
             disease, or severe heart disease (donors with symptomatic angina will be excluded).
             Donors with a history of coronary artery bypass grafting or angioplasty who are
             symptom free will receive a cardiology evaluation and be considered on a case-by-case
             basis.

          3. History of prior malignancy. However, cancer survivors who have undergone potentially
             curative therapy may be considered for stem cell donation on a case-by-case basis. In
             addition, donors with localized cancer such as prostate cancer that are on a
             watch-and-wait management due to the low-risk of disease progression may also be
             considered for stem cell donation on a case-by-case basis. The risk/benefit of the
             transplant and the possibility of transmitting viable tumor cells at the time of
             transplantation will be discussed with the patient.

          4. Donors must not be pregnant (unknown effect of filgrastim on fetus).  Donors of
             childbearing potential must use an effective method of contraception.

          5. Anemia (Hb less than 11 gm/dl) or thrombocytopenia (platelets less than 100,000 per
             microliter).  However, potential donors with Hb levels less than 11 gm/dl that is due
             to iron deficiency will be eligible as long as the donor is initiated on iron
             replacement therapy and the case is individually approved by NIH or Hackensack Blood
             Bank.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  11 Years
 </minimum_age>
 <maximum_age>
  90 Years
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   INCLUSION CRITERIA:

          -  Signed written informed consent form in accordance with institutional guidelines

          -  Histologically confirmed high-grade glioma by needle biopsy, open biopsy, or surgical
             resection

          -  Age 18 to 75 years

          -  Performance status Eastern Cooperative Oncology Group (ECOG) 0-2 OR Karnofsky 50-100%

          -  White Blood Cells (WBC) at least 2,500/mm^3

          -  Absolute granulocyte count at least 1,200/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Bilirubin less than 2.0 mg/dL

          -  Serum glutamic oxaloacetic transaminase/serum glutamic-pyruvic transaminase
             (SGOT/SGPT) less than 2.5 times upper limit of normal

          -  Creatinine less than 1.8 mg/dL

          -  Fertile patients must use effective contraception for at least 2 months before and
             during study participation

        EXCLUSION CRITERIA:

          -  Rapidly progressing central nervous system (CNS) disease with associated neurological
             deterioration

          -  Uncontrolled clinically significant confounding medical condition within the past 30
             days such as congestive heart failure

          -  Pregnant or lactating, or positive serum human chorionic gonadotropin (HCG).

          -  Contraindications to the study medications
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients with a diagnosis of primary cancer at age 21 or younger meeting other criteria.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Diagnosis of primary cancer at age 21 or younger, irrespective of current age

          -  No prior history of allogeneic (non-autologous) hematopoietic cell transplant

          -  Development of one of the following key adverse events at any time following
             initiation of cancer therapy:

               -  Cardiac dysfunction; Please Note: case enrollment has been closed due to
                  achievement of target accrual

               -  Ischemic stroke (IS)

               -  Subsequent malignant neoplasm (SMN)

               -  Avascular necrosis (AVN); Please Note: case enrollment has been closed due to
                  achievement of target accrual

          -  Submission of a blood specimen (or in certain cases a buccal cell specimen) to the
             Clinical Pharmacokinetics Laboratory at St. Jude Children's Research Hospital as per
             the requirements; Please Note: if a patient is currently receiving active cancer
             treatment, it is preferable to obtain the blood sample at a time when the patient's
             WBC is &gt; 2,000

          -  Written informed consent from the patient and/or the patient's legally authorized
             guardian, obtained in accordance with institutional policies approved by the U.S.
             Department of Health and Human Services

          -  In active follow up by a COG institution; active follow up will be defined as date of
             last visit or contact by a COG institution within the past 24 months; any type of
             contact, including contact specifically for participation in ALTE03N1, qualifies as
             active follow-up; Please Note: treatment on a COG (or legacy group) therapeutic
             protocol for the primary cancer is NOT required
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  21 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Age greater than or equal to 18 years

        Histologically confirmed supratentorial Glioblastoma multiforme

        Karnofsky performance greater than 60

        Patient must be a candidate for radiotherapy

        EXCLUSION CRITERIA:

        Inability to provide informed consent

        Patients who have had prior radiotherapy to the brain

        Patients with other cancers excluding nonmelanomatous skin cancers or carcinoma in situ

        Gliadel wafer placement at the time of surgery

        &lt; TAB&gt; &lt; TAB&gt;
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Subject Inclusion Criteria:

          -  Patients must have a histologically confirmed diagnosis of a malignancy known to be
             8H9 reactive. 8H9 expression must be confirmed by immunohistochemical staining of
             tumor and assessed by the Department of Pathology or by immunofluorescence of bone
             marrow except for patients confirmed to have neuroblastoma.

          -  Patients must have CNS/ leptomeningeal disease which is refractory to conventional
             therapies or for which no conventional therapy exists OR a recurrent brain tumors
             with a predilection for leptomeningeal dissemination (medulloblastoma, PNET, rhabdoid
             tumor).

          -  Patients must have no rapidly progressing or deteriorating neurologic examination.

          -  Patients must have an absolute neutrophil count (ANC) &gt; 1000/ul and a platelet count
             &gt; 50,000/ul.

          -  Patients may have active malignancy outside the central nervous system.

          -  Both pediatric and adult patients of any age are eligible.

          -  Patients or a legal guardian will sign an informed consent form approved by the IRB
             and obtained by the Principal or a Co- Investigator before patient entry. Minors will
             provide assent.

          -  Patients with stored stem cells will be treated at the escalating dose while patients
             with no stem cells will be treated at the 50 mCi dose. Neuroblastoma patients can be
             treated at the 50 mCi dose with or without stored stem cells.

        Subject Exclusion Criteria:

          -  Patients with obstructive or symptomatic communicating hydrocephalus.

          -  Patients with an uncontrolled life-threatening infection.

          -  Patients who are pregnant: Pregnant women are excluded for fear of danger to the
             fetus. Therefore negative pregnancy test is required for all women of child-bearing
             age, and appropriate contraception is required during the study period.

          -  Patients who have received cranial or spinal irradiation less than 3 weeks prior to
             the start of this protocol.

          -  Patients who have received systemic chemotherapy (corticosteroids not included) less
             than 3 weeks prior to the start of this protocol.

          -  Severe major organ toxicity. Specifically, renal, cardiac, hepatic, pulmonary, and
             gastrointestinal system toxicity should all be less than grade 2. Patients with
             stable neurological deficits (because of their brain tumor) are not excluded.
             Patients with &lt;= 3 hearing loss are not excluded.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Age greater than or equal to 12 years.

        Biopsy proven KSHV-associated MCD, confirmed in the Laboratory of Pathology, CCR.

        Willing to give informed consent.

        -A parent or guardian must be available for giving consent for pediatric subjects under 18
        years of age.

        EXCLUSION CRITERIA:

        Any abnormality that would be scored as NCI CTC Grade IV toxicity that is unrelated to
        HIV, its treatment, or to MCD that would preclude protocol treatment and/or observation
        only.

        Presence of another malignancy requiring current treatment that would preclude the use of
        all of the study treatments or the ability to monitor the natural history of MCD
        untreated.

        Any condition or set of circumstances that in the opinion of the investigators would make
        participation in this study unsafe or otherwise inappropriate for a given individual.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  12 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

               1. Any patient age 1-75 referred by the primary transplant physician for the
                  evaluation of chronic graft-versus-host disease independently of age or
                  underlying diagnosis;

               2. Patient or the patient's legal representative is able and willing to provide
                  consent.

        EXCLUSION CRITERIA:

          1. Significant medical condition or any other significant circumstance that could in the
             PIs assessment affect the patient's ability to tolerate, comply, or complete the
             study;

          2. Patients who in the PIs assessment have a life expectancy less than 3 months.

        Note: Because it is not always possible to make a clear clinical distinction between acute
        and chronic GVHD, patients with acute GVHD are not a-priori excluded until the possibility
        of chronic GVHD is reliably excluded on the basis of the clinical assessments in the cGVHD
        clinic.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  1 Year
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients having received a preceding allogeneic transplantation from either a human
             leukocyte antigen (HLA)-matched related or unrelated donor are eligible for this
             protocol

               -  Related donor: HLA genotypically identical at least at one haplotype and may be
                  phenotypically or genotypically identical at the allele level at HLA A, B, C,
                  DRB1, and DQB1

               -  Unrelated donor who are prospectively:

                    -  Matched for HLA-A, B, C, DRB1 and DQB1 by high resolution typing; OR

                    -  Only a single allele disparity will be allowed for HLA-A, B, or C as
                       defined by high resolution typing

          -  Patients with less than 50% donor CD3 peripheral blood chimerism on two separate,
             consecutive evaluations (the two evaluations must be at least 14 days apart) OR
             patients with absolute decreases of donor CD3 peripheral blood chimerism of &gt;= 20% if
             the second test shows &lt; 50% donor CD3 cells (the two evaluations must be at least 14
             days apart)

          -  Patients with evidence of disease are only eligible if the disease is stable (or
             persistent) in comparison to the status prior to transplantation

          -  Patients must be tapered off systemic steroids to a dosage of less than or equal to
             0.25 mg/kg/day

          -  Patients must have persistent donor CD3 cells (&gt;= 5% donor CD3 cells by a
             deoxyribonucleic acid [DNA]-based assay that compares the profile of amplified
             fragment length polymorphisms [ampFLP] [or fluorescent in situ hybridization (FISH)
             studies or variable number of tandem repeats (VNTR)])

          -  DONOR: Alternatively to a fresh unmodified leukapheresis product, previously
             collected cryopreserved peripheral blood stem cells (PBSC) after mobilization with
             G-CSF or cryopreserved unmodified leukapheresis product from the original donor can
             be used; if cryopreserved product is not available, the following criteria apply for
             the DLI product:

          -  DONOR: Original donor of hematopoietic cell transplantation

          -  DONOR: Donor must give consent to leukapheresis

          -  DONOR: Donor must have adequate veins for leukapheresis or agree to placement of
             central venous catheter (femoral or subclavian)

          -  DONOR: Donor must be medically fit to undergo the apheresis procedure (institutional
             guidelines for apheresis)

        Exclusion Criteria:

          -  Current grade II to IV acute GVHD or extensive chronic GVHD

          -  Karnofsky score &lt; 50%

          -  Lansky Play-Performance Score &lt; 40

          -  Evidence of relapse or progression of disease after transplantation

          -  Prior recipient of cord blood

          -  DONOR: Donor who are not suitable for medical reasons to donate peripheral blood
             mononuclear cells (PBMC) by continuous centrifugation according to the criteria of
             the American Association of Blood Banks (AABB)

          -  DONOR: Pregnancy

          -  DONOR: Human immunodeficiency virus (HIV) or human T-lymphotrophic virus (HTLV)
             infection

          -  DONOR: Recent immunization may require a delay
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

          -  Patients with podocyte diseases, MCD, FSGS (including primary, secondary, and
             adaptive variants), and CG (including HIV-associated variant), who meet the following
             criteria:

          -  An adequate renal biopsy, defined as having minimum 10 glomeruli for light microscopy
             and minimum 3 glomeruli for electron microscopy, unless the podocyte disease is
             diagnostic on fewer glomeruli.  Patients who have non-diagnostic or technically
             inadequate biopsies will be offered the opportunity to undergo a research biopsy to
             determine eligibility.  For some patients who have had a non-diagnostic or
             technically inadequate biopsy, a repeat renal biopsy may be clinically indicated in
             an effort to diagnose and treat a potentially serious kidney disease.

          -  Greater than or equal to 16 years of age. The rationale for excluding younger
             children is that retinoids may carry greater toxicity in children, as there are
             reports of premature epiphyseal closure, development of slender long bones, and
             periostial thickening.

          -  Prior treatment with at least two immunosuppressive agents that have been shown to
             induce remission in MCD and FSGS: glucocorticoids, cyclosporine, tacrolimus,
             cyclophosphamide, chlorambucil, and mycophenolate mofetil. Therapy with each agent
             must last at least 8 weeks. Exemptions will be made for those with contraindications
             to these medications or those who cannot tolerate these medications. The rationale is
             to recruit patients who have failed conventional therapy.  All patients will be off
             immunosuppression for at least 4 weeks before starting retiniods in order to avoid a
             confounding effect.

          -  Three first void urine protein/creatinine ratios &gt;  2 g/g obtained within one month
             prior to enrolling in the study. These urine collections will be obtained after the
             patient has been on a stable dose of ACE inhibitor or ARB for at least 4 weeks (the
             maximal antiproteinuric effect of these medications occurs after 4 weeks). The
             rationale is that patients with nephrotic-range proteinuria are at high risk for
             progressive renal disease, justifying participation in a clinical trial with novel
             agents. Patients with steroid-sensitive frequently relapsing MCD will not be required
             to have used ACE inhibitor or ARB, as steroids alone are typically sufficient therapy
             to induce remission.

          -  If hypertensive: blood pressure of less than or equal to 140/90 on a stable dose of
             ACE inhibitor or ARB for at least 1 month or greater than or equal to 75 percent of
             measurements before the entry of the study. The rationale is that uncontrolled
             hypertension can exacerbate proteinuria.

        EXCLUSION CRITERIA:

          -  Pregnancy, breastfeeding, or unwillingness to use at least two contraceptive methods
             (at least one of which must be primary, including tubal ligation, partner vasectomy,
             oral contraceptives, implanted contraceptives, and intrauterine device). The
             rationale is that retinoids are teratogenic and are excreted in breast milk.

          -  Abnormal liver function test, including AST, ALT, total bilirubin, or protime. The
             rationale is that retinoids can be hepatotoxic. The only exception will be the
             following: if the cause of abnormality of LFTs is felt to be due to a specific
             hepatotoxic drug such as a statin and the levels are less than 2 times the upper
             limit of the normal AND normalize upon holding the offending drug, patients may be
             considered for study participation after consultation with hepatology service.

          -  Hypertriglyceridemia greater than 500 mg/dL despite statin/fibrate therapy. The
             rationale is that retinoids can increase lipids, particularly triglyceride as this
             can lead to pancreatitis.

          -  Any medical conditions requiring concurrent immunosuppression, as this pilot study is
             designed to evaluate the effect of retinoids as a monotherapy.

          -  Any medical conditions requiring concurrent use of tetracycline, minocycline, or
             doxycycline, due to enhanced risk of increased intracranial pressure.

          -  Hypersensitivity to retinoids.

          -  Presence of any unstable cardiovascular disease, uncontrolled diabetes with
             hemoglobin A1c greater than 8 percent, chronic inflammatory or infectious conditions
             except HIV-1 infection. Retinoids have been associated with chest pain of unclear
             etiology, increased serum glucose, myelosuppression and increased risk of infection.
             The etiology of infection is not clear but may be related to myelosuppression.

          -  Those with HIV-1 infection must not have any evidence for opportunistic infectious
             complications and have CD4 count greater than or equal to 200. Both tretinoin and
             isotretinoin have been safely studied in HIV-infected patients for other indications.

          -  GFR less than 40 ml/min/1.73m(2)estimated by 5-variable MDRD equation, as the
             metabolities of retinoids are excreted in part in urine, and there is a concern for
             increased toxicity. In participants less than 18 years of age, we will use Schwartz
             equation.

          -  Expansion of glomerulus or interstitial formation on the biopsy.

          -  Untreated depression, as retinoids have been associated with depression, suicidal
             ideation, and aggressive behavior. If patients manifest significant depressive
             symptoms, they will be included in the study only if assessed and agreed by a
             psychiatrist (either at NIH or other) and if they have regular follow-up visits with
             a psychiatrist.

          -  Factors that increase the risk of renal biopsy. These include the following:
             unwillingness to accept blood transfusion, bleeding diathesis, single kidney, small
             kidneys (less than 9.5 cm).
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  16 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Patients must fulfill all of the following criteria to be eligible for study admission:

          1. All patients must have a CT, MR, or PET scan available in digital format.

          2. Age greater than or equal to 18 years.

          3. No serious concurrent medical illness that would preclude the patient from making a
             rational informed decision on participation.

          4. The ability to understand and willingness to sign a written informed consent form,
             and to comply with the protocol. If in question, an ethics consult will be obtained.

          5. Patients, except for those in enrolling in Cohorts 1 and 9, must be actively enrolled
             in an NIH protocol.

          6. For surgery cohort, patients must be undergoing a surgical procedure and have
             pre-operative imaging.

        PROSTATE BIOPSY COHORT (Cohorts 1 and 9) INCLUSION CRITERIA:

        1. Source of patients will be the community at large as well as patients who have
        undergone prostate MRI and have had abnormalities identified as follows:

          1. PSA &gt; 2.5 or Abnormal digital rectal exam or an abnormality identified on prostate
             MRI witha clinical indication for biopsy.

          2. Pre-biopsy prostate MRI showing targetable lesions.

        EXCLUSION CRITERIA:

        Patients with any of the following will be excluded from study entry:

          1. Patients with an altered mental status that precludes understanding or consenting for
             the biopsy procedure will be excluded from this study.

          2. Patients unlikely able to hold reasonably still on a procedure table for the length
             of the procedure.

          3. Patients with any known allergy to adhesives or latex or skin reactions to dressings
             (since the adhesive fiducials could theoretically induce a rash in these patients),
             if adhesive fiducials are to be used.

          4. Inability to hold breath, if procedure will be performed with conscious sedation, and
             without general anesthesia.

          5. Patients with pacemakers or automatic implantable cardiac defibrillators.

          6. Gross body weight above the CT table limit (375 pounds), if CT table used.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Adults must have either radiological or established histological diagnosis of the
             following general categories: high-grade glioma/CNS lymphoma or brain metastases.

          -  Previously untreated patients must have a lesion on an imaging study

          -  Post treatment patients will have radiographic abnormalities that may or may not be
             recurrent tumor

          -  Patients must be 18 years or older for inclusion in this study.

          -  After entry into the study, patients are expected to be followed for approximately
             4-6 weeks after the final infusion of ferumoxytol.

          -  All patients, or their legal guardians, must sign a written informed consent and
             HIPAA authorization in accordance with institutional guidelines.

          -  Sexually active women of child-bearing potential and men must agree to use adequate
             contraception (hormonal or barrier method of birth control; or abstinence) prior to
             study treatment and for the duration of study treatment. Should a female become
             pregnant or suspect she is pregnant while participating in this study, she should
             inform her treating physician immediately.

          -  Pre-treatment radiological scans/studies for patients receiving ferumoxytol must be
             performed with approximately 16 weeks prior to study entry.

        Exclusion Criteria:

          -  Patients with clinically significant signs of uncal herniation, such as acute
             pupillary enlargement, rapidly developing motor changes (over hours), or rapidly
             decreasing level of consciousness

          -  Patients with known allergic or hypersensitivity reactions to parenteral iron,
             parenteral dextran, parenteral iron-dextran, or parenteral iron-polysaccharide
             preparations (Ferumoxytol Investigator's Drug Brochure, 2009). Patients with
             significant drug or other allergies or autoimmune diseases may be enrolled at the
             investigator's discretion.

          -  Patients who are pregnant or lactating or who suspect they might be pregnant.

          -  Adult patients who require monitored anesthesia for MRI scanning

          -  Patients with renal insufficiency; GFR &lt; 50.

          -  Subjects who have a contraindication for MRI: metal in their bodies (a cardiac
             pacemaker or other incompatible device), are severely agitated, or have an allergy to
             Gd contrast material.

          -  Subjects with known hepatic insufficiency or cirrhosis.

          -  HIV-positive patients on combination antiretroviral therapy are ineligible because of
             the potential for pharmacokinetic interactions with ferumoxytol.

          -  Subjects with known or suspected iron overload (genetic hemochromatosis or history of
             multiple transfusions).
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients with a diagnosis of CLL (or SLL) or diagnosis of CLL that progresses to
             prolymphocytic leukemia (PLL)

          -  Patients with B-Cell CLL or PLL who:

               -  Failed to meet National Cancer Institute (NCI) Working Group criteria 2 for
                  complete or partial response after 2 cycles of therapy with regimen containing
                  fludarabine (or another nucleoside analog, e.g. cladribine [2-CDA], pentostatin)
                  or with disease relapse within 12 months after completing therapy with a
                  fludarabine (or another nucleoside analog) containing regimen

               -  Failed FCR or pentostatin/cyclophosphamide/rituximab (PCR) combination
                  chemotherapy at any time point

               -  Patients with novo or acquired "17p deletion" cytogenetic abnormality; patients
                  should have received induction treatment but could be transplanted in 1st CR

          -  Patients who have suitable human leukocyte antigen (HLA)-matched related or unrelated
             donors willing to receive filgrastim (G-CSF), undergo leukapheresis to collect
             peripheral blood mononuclear cell (PBMC), and to donate stem cells

          -  RELATED DONORS: When more than one potential donor exists, priority should be given
             to donors based on HLA identity &gt; cytomegalovirus (CMV) seronegativity &gt; ABO
             compatibility &gt; sex matching

               -  Donor who is HLA phenotypically or genotypically identical at the allele level
                  at HLA-A, -B, -C, -DRB1, and -DQB1

               -  Must consent to G-CSF administration and leukapheresis;

               -  Must have adequate veins for leukapheresis or agree to placement of central
                  venous catheter (femoral, subclavian);

               -  Only G-CSF mobilized PBMC only will be permitted as a hematopoietic stem cell
                  (HSC) source on this protocol

          -  UNRELATED DONORS:

               -  Fred Hutchinson Cancer Research Center (FHCRC) matching allowed will be Grades
                  1.0 to 2.1; Unrelated donors who are prospectively:

               -  Matched for HLA-A, B, C, DRB1 and DQB1 by high resolution typing

               -  Only a single allele disparity will be allowed for HLA-A, B, or C as defined by
                  high resolution typing

          -  UNRELATED DONORS: Donors are excluded when preexisting immunoreactivity is identified
             that would jeopardize donor hematopoietic cell engraftment; this determination is
             based on the standard practice of the individual institution; recommended procedure
             for patients with 10 of 10 HLA allele level (phenotypic) match is to obtain a panel
             reactive antibody screens to class I and II antigens for all patients before HCT; if
             the PRA shows &gt; 10% activity, then flow cytometric or B and T cell cytotoxic cross
             matches should be obtained; the donor should be excluded if any of the cytotoxic
             cross match assays are positive; for those patients with an HLA Class I allele
             mismatch, flow cytometric or B and T cell cytotoxic cross matches should be obtained
             regardless of the PRA results; a positive anti-donor cytotoxic crossmatch is an
             absolute donor exclusion

          -  UNRELATED DONORS: Patient and donor pairs homozygous at a mismatched allele in the
             graft rejection vector are considered a two-allele mismatch, i.e., the patient is
             A*0101 and the donor is A*0102, and this type of mismatch is not allowed

          -  UNRELATED DONORS: Only G-CSF mobilized PBMC will be permitted as a HSC source on this
             protocol

        Exclusion Criteria:

          -  Infection with human immunodeficiency virus (HIV)

          -  Active diagnosis of central nervous system (CNS) involvement with CLL

          -  Patients unwilling to use contraceptive techniques before and for 12 months after HCT

          -  Pregnant women or females who are breastfeeding

          -  The addition of cytotoxic agents for 'cytoreduction' with the exception of tyrosine
             kinase inhibitors (such as imatinib mesylate), cytokine therapy, hydroxyurea, low
             dose cytarabine, chlorambucil, or rituxan will not be allowed within three weeks of
             the initiation of conditioning

          -  Active bacterial or fungal infections unresponsive to medical therapy

          -  Performance status: Karnofsky score &lt; 60 for adult patients

          -  Cardiac ejection fraction &lt; 40%; ejection fraction is required if age &gt; 50 years or
             there is a history of prior transplant, anthracycline exposure or history of cardiac
             disease; and poorly controlled hypertension despite multiple antihypertensives

          -  Diffusing capacity of the lung for carbon monoxide (DLCO) &lt; 40%, total lung capacity
             (TLC) &lt; 40%, forced expiratory volume in 1 second (FEV1) &lt; 40% and/or requiring
             continuous supplementary oxygen, or severe deficits in pulmonary function testing as
             defined by pulmonary consultant service; and the FHCRC principal investigator (PI) of
             the study must approve of enrollment of all patients with pulmonary nodules

          -  Patients with clinical or laboratory evidence of liver disease would be evaluated for
             the cause of liver disease, its clinical severity in terms of liver function, and the
             degree of portal hypertension; patients will be excluded if they are found to have
             fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension,
             hepatic damage with bridging fibrosis, alcoholic hepatitis, esophageal varices, a
             history of bleeding esophageal varices or hepatic encephalopathy, uncorrectable
             hepatic synthetic dysfunction evidenced by prolongation of the prothrombin time,
             ascites related to portal hypertension, bacterial or fungal liver abscess, biliary
             obstruction, chronic viral hepatitis with total serum bilirubin &gt; 3 mg/dl, or
             symptomatic biliary disease

          -  Patients with active non-hematologic malignancies (except non-melanoma skin cancers);
             this exclusion does not apply to patients with non-hematologic malignancies that do
             not require therapy

          -  Patients with a history of non-hematologic malignancies (except non-melanoma skin
             cancers) currently in a complete remission, who are less than 5 years from the time
             of complete remission, and have a &gt; 20% risk of disease recurrence; this exclusion
             does not apply to patients with non-hematologic malignancies that do not require
             therapy

          -  DONOR: Age &lt; 12 years

          -  DONOR: Identical twin

          -  DONOR: Pregnancy

          -  DONOR: Infection with HIV

          -  DONOR: Inability to achieve adequate venous access

          -  DONOR: Known allergy to filgrastim (G-CSF)

          -  DONOR: Current serious systemic illness
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA-TRANSPLANT RECIPIENTS:

        Patients surviving three years or more from date of first stem cell transplant who have
        been treated.

        -With an experimental allogeneic stem cell transplant on a NHLBI HB protocol

        Or

        -With a standard of care allogeneic stem cell transplant on the NHLBI standard of care
        protocol

        Or

        -As a special exemption to the above protocols

        Age greater than or equal to 10 years old and age less than or equal to 80

        For adults: Ability to comprehend the investigational nature of the study and provide
        informed consent.  For minors: Written informed consent from one parent or guardian and
        informed assent: The process will be explained to the minor on a level of complexity
        appropriate for their age and ability to comprehend.

        EXCLUSION CRITERIA-STEM CELL TRANSPLANT RECIPIENTS:

        None, all patients meeting the inclusion criteria will be eligible

        INCLUSION CRITERIA-DONOR:

        If appropriate clinical management of the recipient or ongoing laboratory research would
        indicate the need for additional stem cell collection or peripheral blood collection, a
        donor may also be accrued to this protocol providing they meet the following criteria:

          -  HLA 5/6 or 6/6 matched family donor

          -  Weight greater than or equal to 18 kg

          -  Age greater than or equal to 2 or less than or equal to 80 years old

          -  Age greater than or equal to 18 years of age (if participating only as a donor of
             peripheral blood cells for laboratory research studies).

          -  For adults: Ability to comprehend the investigational nature of the study and provide
             informed consent.  For minors: Written informed consent from one parent or guardian
             and informed assent: The process will be explained to the minor on a level of
             complexity appropriate for their age and ability to comprehend.

        No additional stem cells will be harvested for research purposes.

        EXCLUSION CRITERIA-DONOR (ANY OF THE FOLLOWING):

          -  Pregnant or actively breastfeeding

          -  Donor unfit to receive filgrastim and undergo apheresis. (Uncontrolled hypertension,
             history of congestive heart failure or unstable angina, thrombocytopenia)

          -  HIV positive. Donors who are positive for HBV, HCV or HTLV-1 may be used if the
             risk-benefit ratio is considered acceptable by the patient and investigator.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  2 Years
 </minimum_age>
 <maximum_age>
  80 Years
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Diagnosis of 1 of the following:

               -  Neuroblastoma (NB)

                    -  Meets 1 of the following criteria:

                         -  Histologically confirmed disease

                         -  Bone marrow involvement with elevated urinary catecholamines

                    -  Progressive or recurrent disease OR failed to achieve a complete response
                       to prior standard therapy

               -  Malignant chromaffin cell tumors (CCT) (i.e., malignant pheochromocytoma or
                  malignant paraganglioma)

          -  Evaluable disease on metaiodobenzylguanidine (MIBG) scan

               -  MIBG-avid disease

          -  Must have  2 x 10^6 CD 34+ autologous peripheral blood stem cells cryopreserved and
             available for reinfusion after study therapy

          -  Ineligible for other Memorial Sloan-Kettering Cancer Center protocols that use
             monoclonal antibody 3F8 (patients with NB only)

        PATIENT CHARACTERISTICS:

        Age

          -  Over 1 (patients with NB)

          -  1 to 21 (patients with CCT)

        Performance status

          -  Not specified

        Life expectancy

          -  At least 8 weeks

        Hematopoietic

          -  See Disease Characteristics

        Hepatic

          -  No hepatic toxicity &gt; grade 2

        Renal

          -  Creatinine clearance &gt; 60 mL/min

          -  No renal toxicity &gt; grade 2

        Cardiovascular

          -  No cardiac toxicity &gt; grade 2

        Pulmonary

          -  No pulmonary toxicity &gt; grade 2

        Other

          -  Not pregnant

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No gastrointestinal toxicity &gt; grade 2

          -  No neurologic toxicity &gt; grade 2

          -  No hearing deficit &gt; grade 3

          -  No other severe major organ toxicity

          -  No active, serious infection not controlled by antibiotics

          -  Able and willing to comply with radiation safety procedures

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  At least 2 weeks since prior biologic therapy

        Chemotherapy

          -  At least 3 weeks since prior chemotherapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  1 Year
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Clinical diagnosis of bilateral intraocular retinoblastoma (RB)

               -  International Intraocular Retinoblastoma Classification (IIRC) Group B, C, or D
                  disease in 1 or both eyes

               -  IIRC Group E disease in 1 eye allowed provided the eye was enucleated at
                  diagnosis AND there is no extraocular RB in the enucleated eye by histologic
                  confirmation AND there is IIRC Group B, C, or D disease in the remaining eye

               -  No IIRC Group A disease in 1 or both eyes

          -  No unilateral RB

          -  No extraocular or metastatic RB

        PATIENT CHARACTERISTICS:

        Age

          -  Over 30 days

        Performance status

          -  Not specified

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  AST and ALT &lt; 2 times upper limit of normal (ULN)

          -  Conjugated and unconjugated bilirubin &lt; 2 times ULN

        Renal

          -  Creatinine &lt; 1.5 times ULN

          -  Glomerular filtration rate (GFR)  100 mL/min* NOTE: *A 4-hour IV hydration is
             allowed if GFR is low due to poor hydration or transient dehydration

        Other

          -  Meets 1 of the following auditory criteria:

               -  Normal audiogram

               -  At least normal responses to speech by audiogram

               -  Documentation of hearing by acoustic emission test

               -  Recording of evoked potentials by auditory brain stem response

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  See Disease Characteristics
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients with hematologic malignancy, lymphoma or other HIV-associated malignancy are
             eligible provided these criteria are met:

               -  The malignancy is in complete remission or very good partial remission, defined
                  as a significant reduction of disease with therapy and no evidence for continued
                  tumor growth in the case of lymphoma or solid tumors

               -  Highly active antiretroviral therapy (HAART) is initiated within one month of
                  hematopoietic cell transplant

               -  Viral load has decreased by &gt;= 1.5 logs or viral load &lt; 5000 copies/ml plasma on
                  HAART therapy

               -  CD4 count is allowed to be &gt; 100 cells/ul

          -  HIV infected patients without malignancy who have failed HAART are eligible provided
             that these criteria are met:

               -  They have been treated with more than one regimen of HAART for a total of at
                  least 6 months duration

               -  The viral load is &lt; 50 copies/ml plasma

               -  The CD4 count &lt; 100 cells/ul

          -  DONOR: Human leukocyte antigen (HLA) genotypically/phenotypically identical donor; if
             more than one HLA-identical sibling is available, priority will be given to donors
             matched for cytomegalovirus (CMV) status, ABO titer, and sex

               -  Peripheral blood stem cells will be collected from donors greater than 12 years
                  of age

               -  Bone marrow will be collected from donors less than 12 years of age

          -  DONOR: HLA phenotypically identical unrelated donor; match grades allowed:

               -  Match grade 1: Matched at allele level for HLA-A, B, C, DRB1, and DQB1

               -  Match grade 2.1: Single allele disparity for HLA-A, B, C, DRB1, and DQB1

        Exclusion Criteria:

          -  Positive serology for toxoplasma gondii on treatment or with evidence of active
             infection

          -  Patients with other disease or organ dysfunction that would limit survival to less
             than 30 days

          -  Patients with medical history of noncompliance with HAART or medical therapy

          -  DONOR: Donors for whom medical or psychologic reasons would make donor procedure
             intolerable

          -  DONOR: Marrow donors who have increased anesthetic risk

          -  DONOR: Donors who are HIV positive

          -  DONOR: Age &gt; 75 years
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  ELIGIBILITY CRITERIA:

        Diagnosis of mantle cell lymphoma (confirmed at NCI). All variants are eligible.

        Age greater than or equal to 18 years.

        No prior treatment except for local radiation or a short course of steroids for control of
        symptoms.

        All stages of disease.

        ECOG performance status less than or equal to 3.

        Adequate major organ function (serum creatinine less than or equal to 1.5 mg/dl or
        creatinine clearance greater than 50 ml/min; bilirubin less than 2 mg/dl (total) except
        less than 5 mg/dl in patients with Gilbert's syndrome as defined by greater than 80%
        unconjugated; ANC greater than 1000 and platelets greater than 75,000) unless impairment
        due to organ involvement by lymphoma.

        No myocardial infarction within 6 months prior to enrollment or New York Hospital
        Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled
        ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active
        conduction system abnormalities.  Prior to study entry, any ECG abnormality at Screening
        has to be documented by the investigator as not medically relevant.

        No grade 2 greater than or equal to peripheral neuropathy within 14 days before
        enrollment.

        Ability to give informed consent.

        HIV antibody negative.

        Female subject is either post-menopausal or surgically sterilized or willing to use an
        acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device,
        diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the
        study.  Female subject is not pregnant or breast-feeding.  Confirmation that the subject
        is not pregnant must be established by a negative serum beta-human chorionic gonadotropin
        (beta-hCG) pregnancy test result obtained during screening.  Pregnancy testing is not
        required for post-menopausal or surgically sterilized women

        Male subject agrees to use an acceptable method for contraception for the duration of the
        study.

        No history of a prior invasive malignancy in past 5 years

        No known involvement of central nervous system by lymphoma

        No history of hypersensitivity to boron or mannitol.

        Patient has not received other investigational drugs with 14 days before enrollment.

        No serious medical or psychiatric illness likely to interfere with participation in this
        clinical study.

        Exclusion for FDG scan is anyone exceeding the weight limit of the scanner (350 lb).
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Biopsy proven prostate cancer

          -  Clinical Tumor Category T1b, T1c, T2a and      PSA greater than (&gt;) 10 or Gleason
             score equal or greater than 4+3=7 or PSA velocity &gt; 2.0 ng/ml per year and also
             eligible patients with tumor category T2c, T3a, T3b, or T4 as per 2002 AJCC
             guidelines. Any minor tertiary grade of Gleason 5; Biopsy Proven or Radiographic
             (erMRI Seminal Vesicle Invasion); Gleason = or &gt; 3+4=7 with 50% or more cores
             positive

          -  Negative bone scan

          -  Lymph node assessment by CT or MR

          -  Adequate hematologic function (Blood Counts)

          -  Adequate liver functions (blood tests)

          -  ECOG performance Status 0 or 1

          -  Peripheral neuropathy must be =&lt; grade 1

          -  PSA obtained within 3 months of entry

        Exclusion Criteria:

          -  Prior history of malignancy that are &lt; 5 years except for cancers found to be
             "in-situ" and would not likely impact a patient's life expectancy with appropriate
             medical management.

          -  Prior pelvic radiation therapy

          -  Prior hormonal therapy (up to 4 weeks prior to enrollment allowed)

          -  Individuals unable to tolerate lying still 5 - 10 minutes

          -  Patients with a history of severe hypersensitivity reaction to docetaxel or other
             drugs formulated with polysorbate 90.
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  30 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Histologically confirmed* de novo B-cell non-Hodgkin's lymphoma (NHL) of 1 of the
             following WHO histologic subtypes:

               -  Diffuse large cell lymphoma, including any of the following morphologic
                  variants:

                    -  Centroblastic

                    -  Immunoblastic

                    -  T-cell/histiocyte rich

                    -  Anaplastic

               -  Mediastinal (thymic) large cell lymphoma

               -  Intravascular large cell lymphoma NOTE: *Fine needle aspirates or core biopsies
                  must not be the only diagnostic material

          -  Stage I primary mediastinal (thymic) OR stage II-IV disease

          -  CD20-positive disease

          -  No underlying low-grade lymphoma (e.g., transformed lymphoma or low-grade lymphoma in
             the bone marrow)

          -  No known lymphomatous CNS involvement

               -  Lumbar puncture required unless there are no neurological symptoms

          -  As of July 1, 2012, the PET/CT imaging companion study CALGB-580603 will be required
             of all patients enrolling onto the treatment study CALGB-50303 NOTE: A new
             classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The
             terminology of "indolent" or "aggressive" lymphoma will replace the former
             terminology of "low", "intermediate", or "high" grade lymphoma. However, this
             protocol uses the former terminology.

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute neutrophil count  1,000/mm^3^*

          -  Platelet count  100,000/mm^3^*

          -  No active bleeding unrelated to NHL NOTE: *Unless due to NHL

        Hepatic

          -  Bilirubin  2 mg/dL* NOTE: *Unless due to NHL or Gilbert's disease

        Renal

          -  Creatinine  1.5 mg/dL^* OR

          -  Creatinine clearance  50 mL/min^* NOTE: *Unless due to NHL

        Cardiovascular

          -  No active ischemic heart disease

          -  No congestive heart failure

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  HIV negative

          -  No active uncontrolled bacterial or viral infection unrelated to NHL

          -  No other active medical process unrelated to NHL

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No prior rituximab

        Chemotherapy

          -  No prior chemotherapy for other malignancies

          -  No prior cytotoxic chemotherapy

          -  No other concurrent chemotherapy

        Endocrine therapy

          -  Prior short course (&lt; 10 days) glucocorticoids allowed for an urgent local disease
             complication (e.g., cord compression or superior vena cava syndrome) at diagnosis

          -  No concurrent hormonal therapy except steroids for adrenal failure or hormones for
             non-disease related conditions (e.g., insulin for diabetes)

          -  No concurrent dexamethasone or other steroidal antiemetics

        Radiotherapy

          -  Prior limited field radiotherapy allowed for an urgent local disease complication
             (e.g., cord compression or superior vena cava syndrome) at diagnosis

          -  No concurrent radiotherapy except for isolated CNS lesions

        Surgery

          -  Not specified

        Other

          -  No other concurrent investigational or commercial agents or therapies for NHL
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Age 18 or more years. No upper limit.

          -  Post total mastectomy or lumpectomy. All planned surgery complete.

          -  Margins clear (no tumour contacting the inked margin)

          -  Tumour oestrogen or progesterone receptor positive

          -  Planned dose to irradiated volumes at least the biological equivalent of 45 Gy in 25
             fractions or more.

          -  ECOG 0-2

          -  Patients post menopausal using same criteria as ATAC study.

          -  Written informed consent

        Exclusion Criteria:

          -  Previous radiotherapy to the area to be treated.

          -  Previous invasive malignancy within 5 years of current breast cancer diagnosis with
             the exception of cervix in-situ or skin cancer other than melanoma.

          -  Patients with clinical evidence of metastatic disease.

          -  Previous hormonal breast therapy.

          -  Ongoing hormone replacement therapy.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   community sample
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  High risk Stage II or III colon cancer

          -  Eastern Cooperative Oncology Group performance status (ECOG P.S.) O or l

          -  No prior chemotherapy

          -  Complete tumor resection

          -  Candidate for and planned to receive standard capecitabine

          -  Adequate bone marrow reserve

        Exclusion Criteria:

          -  Known DED deficiencies
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Diagnosis of Ph-positive or Bcr-positive CML in early chronic phase CML (i.e., time
             from diagnosis 12 months). Except for hydroxyurea, patients must have received no or
             minimal prior therapy, defined as &lt;1 month (30 days) of prior interferon-alpha (with
             or without cytarabine) and/or an FDA-approved TKI. Patients with de novo accelerated
             phase will be treated but analyzed separately.

          2. Age &gt;/= 16 years (Age &gt;18 years to participate in optional symptom burden assessment)

          3. ECOG performance of 0-2.

          4. Adequate end organ function, defined as the following: total bilirubin &lt; 1.5 * ULN,
             SGPT &lt; 2.5 * ULN, creatinine &lt; 1.5 * ULN.

          5. Patients must sign an informed consent indicating they are aware of the
             investigational nature of this study, in keeping with the policies of the hospital.

          6. Reliable telephone access to receive calls from an interactive voice response system
             (IVR) (only applicable to patients who will participate in optional symptom burden
             assessment).

        Exclusion Criteria:

          1. NYHA cardiac class 3-4 heart disease as well as impaired cardiac function defined as:
             LVEF &lt; 45% as determined by MUGA scan or electrocardiogram; Complete left bundle
             branch block; Use of cardiac pacemaker; ST depression of &gt; 1 mm in 2 or more leads
             and/or T wave inversions in 2 or more continuous leads; Congenital long QT syndrome;
             History of, or presence of significant ventricular or atrial tachyarrhythmia's;
             Clinically significant resting bradycardia (&lt; 50 bpm); QTc &gt; 450 msec on screening
             ECG (using the QTcF formula);

          2. (Continued from #1) Right bundle branch block plus left anterior hemiblock,
             bivascular block; Myocardial infarction within 12 months prior to starting AMN107;
             Unstable angina diagnosed or treated within the past 12 months; Other clinically
             significant heart disease (e.g. congestive heart failure, uncontrolled hypertension,
             history of labile hypertension, or history of poor compliance with an
             antihypertensive regimen).

          3. Patients with active, uncontrolled psychiatric disorders including: psychosis, major
             depression, and bipolar disorders.

          4. Female patients of childbearing potential must have negative pregnancy test within 7
             days before initiation of study drug dosing. Postmenopausal women must be amenorrheic
             for at least 12 months to be considered of non-childbearing potential. Surgical
             sterilization is considered non-childbearing potential. Female patients of
             reproductive potential must agree to employ an effective method of birth control
             (hormonal or barrier) throughout the study and for up to 3 months following
             discontinuation of study drug.

          5. Patients with severe and/or uncontrolled medial disease (i.e., uncontrolled diabetes,
             chronic renal disease, or active uncontrolled infection [persistent fever and
             worsening clinical condition]).

          6. Patient with known chronic liver disease (i.e., chronic active hepatitis, and
             cirrhosis).

          7. Patient with known diagnosis of human immunodeficiency virus (HIV) infection.

          8. Patients in late chronic phase (i.e., time from diagnosis to treatment &gt;12 months) or
             blastic phase are excluded. The definitions of CML phases are as follows: A. Early
             chronic phase: time from diagnosis to therapy &lt; 12 months Late chronic phase: time
             from diagnosis to therapy &gt; 12 months.B. Blastic phase: presence of 30% blasts or
             more in the peripheral blood or bone marrow. C. Accelerated phase CML: presence of
             any of the following features: * Peripheral or marrow blasts 15% or more.

          9. (Cont. #8)Peripheral or marrow basophils 20% or more. *Thrombocytopenia &lt; 100 x
             10(9)/L unrelated to therapy. * Documented extramedullary blastic disease outside
             liver or spleen due to past causes D. Clonal evolution defined as the presence of
             additional chromosomal abnormalities other than the Ph chromosome is part of
             accelerated phase CML. Ph chromosome variants or complex Ph chromosome translocations
             are not considered to indicate disease acceleration.

         10. ( Cont # 8) We have recently found clonal evolution to have a variable prognostic
             impact and may be suppressed with IFN-a therapy. Hence these patients, like others
             with de novo accelerated phase, will be eligible, and analyzed separately.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  16 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Group 1: Next of kin of a relative who has died from lymphoma Group 2: Subjects who have a
        next of kin diagnosed with lymphoma and/or CLL Group 3: Subjects who have had or have
        non-Hodgkin's lymphoma, CLL or Hodgkin's disease and had a relative who also had lymphoma
        or CLL
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Any individual diagnosed with non-Hodgkin's lymphoma or Hodgkin's disease or chronic
             lymphocytic leukemia (CLL), who has a 1st degree relative (parent, sibling or child)
             with a lymphoproliferative disorder; or families in which the individual has a
             lymphoproliferative disorder, and an unusual clustering of frequent or premature
             solid tumors is also observed.

          -  Family members of the individual, either affected or unaffected with lymphoma, who
             are contacted by the individual and agree to participate in the study.

          -  Deceased family members may be included in the study. Public records such as death
             certificates may be used to confirm the history. Consent for medical records or
             tissue blocks will be obtained from the deceased family member's next of kin. The
             hierarchy of relatives defined as next of kin is spouse, offspring, parents and
             siblings. Archived tissue samples may be used for genetic research.

          -  Age &gt; 18 years

        Exclusion Criteria:

          -  Subjects without a family history of lymphoma
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  A diagnosis of localized prostate cancer (clinical stage T1-2N0M0) which is treated
             by radical prostatectomy

          -  Pathological stage: pT0/2/3 and pN0/x

          -  Serum level of PSA once reached &lt; 0.1 ng/ml after radical prostatectomy and then
             increased   0.4 ng/ml

          -  Serum level of PSA   1.0 ng/ml  at entry

          -  No clinical recurrence based on abdominal and pelvic computed tomography, and a bone
             scan

          -  No history of chemotherapy or radiation therapy or endocrine therapy for any cancer

          -  Ages  20 to 79 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  No blood transfusion within 28 days of entry

          -  Sufficient organ function within 28 days of entry

          -  Provided written informed consent

        Exclusion Criteria:

          -  Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ

          -  Mental disease or mental symptoms which would affect participant's decision to
             participate

          -  Continuous medication with steroids (exclude external use of steroids for skin)

          -  Ischemic heart disease or arrhythmia which needs medical treatment

          -  Poorly controlled hypertension

          -  Poorly controlled diabetes mellitus

          -  History of cerebral infarction or myocardial infarction within 6 months

          -  Liver cirrhosis

          -  Interstitial pneumonia which requires ventilation assistance, oxygen inhalation,
             steroids, or diuretic medicine
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  20 Years
 </minimum_age>
 <maximum_age>
  79 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Histologically proven carcinoma of the breast, T1-2 (0-5cm) N0-1, M0.

          -  Pure ductal carcinoma in situ accepted if completely excised.

          -  Any receptor status.

          -  Extensive intraductal cancer (EIC) accepted if completely excised.

        Exclusion Criteria:

          -  Unable to consent

          -  Vascular/collagen disorder

          -  Prior malignancy except minor skin squamous cell or basal cell carcinoma or carcinoma
             in-situ of the cervix .

          -  Gross multifocal disease

          -  Involvement of margins.

          -  Bilateral breast cancer
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

        Must have one of the following diagnosis:

          -  AML in remission or relapse (e.g., FAB M7 or biphenotypic  leukemia)

          -  High-risk ALL in first remission (e.g., poor responder to prednisone,  Ph+ ALL)

          -  ALL beyond first remission

          -  Secondary leukemia

          -  Primary myelodysplasia (including RAEB, RAEB-T, CMML, JCML, and JMML)

          -  Chronic myeloid leukemia

          -  Histiocytoses (including multi-system Langerhans' cell histiocytosis and
             hemophagocytic lymphohistiocytosis

        Inclusion criteria Donor research participants

          -  HIV negative (date).

          -  Hepatitis B surface antigen negative (date).

          -  Hepatitis C antibody negative (date).

          -  Syphilis negative (date).

          -  Donor is equal to or greater than 3 on 6 HLA match (date).

          -  Not pregnant (negative pregnancy test).

          -  Not lactating.

          -  At least 18 years of age.

        Exclusion Criteria

          -  Patients greater than 24 months of age at the time of transplant.

          -  HLA-identical sibling donor is available.

          -  Cardiac function: shortening fraction &lt;25%.

          -  Pulse oximetry oxygen saturation &lt;92% on room air.

          -  Glomerular filtration rate less than 40 ml/min/1.73 m2 (may use Technetium-99 result
             for GFR).

          -  Direct bilirubin &gt; 3 mg/dl.

          -  SGPT &gt; 500 U/L.

          -  Patients with previous allergy to mouse proteins.

          -  Patients with previous allergy to rabbit serum products.

          -  Patients with Down's syndrome
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  24 Months
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Tumor(s) are clearly defined on pre-therapy contrast enhanced MRI scans.

          2. Men or women.

          3. Age between 18 and 70 years, inclusive.

          4. Karnofsky rating 70-100.

          5. ASA score 1-2.

          6. Able and willing to give informed consent.

          7. Able to communicate sensations during the ExAblate MRGFUS procedure.

          8. Apparently able to attend all study visits (i.e., life expectancy of at least 3
             months).

          9. At least 14 days passed since last brain surgery, or intracranial radiation
             therapy/radiosurgery

         10. No additional tumor brain surgery nor radiation therapy anticipated for at least 14
             days.

        Exclusion Criteria:

          1. The subject presents with:

             - Symptoms and signs of increased intracranial pressure (e.g., headache, nausea,
             vomiting, lethargy, and papaedema).

             - Unstable hemodynamic status including: i. Documented myocardial infarction within
             six months of enrollment. ii.Symptomatic coronary artery stenosis. iii. Congestive
             heart disease requiring medication. iv. Anti-arrhythmic drug medication. v. Cardiac
             pacemaker. vi. Severe hypertension (diastolic BP &gt; 100 on medication).

          2. Anti-coagulant therapy, on medications known to increase risk of hemorrhage, (e.g.:
             non-steroidal anti-inflammatory drugs (NSAIDs), statins

          3. TIA or stroke in the last 1 month

          4. Insulin-dependent diabetes mellitus

          5. Immunosuppression (corticosteroids to prevent brain edema are permitted)

          6. Known sensitivity to gadolinium-DTPA

          7. Contraindications to MRI such as non-MRI-compatible implanted devices

          8. Large subjects not fitting comfortably into the MRI scanner

          9. Difficulty laying supine and still for up to 4 hours in the MRI unit or
             claustrophobia

         10. Untreated, uncontrolled Sleep apnea

         11. Positive pregnancy test (for pre-menopausal women)

         12. Known life-threatening systemic disease

         13. More than 3 metastatic tumors

         14. History of abnormal bleeding and coagulopathy

         15. Use of Avastin in the preceding two weeks or planned use in the forthcoming two weeks
             and VEGF inhibitors within + 30 days of treatment

         16. Patients with a history of uncontrolled seizures or who are not on anti seizure
             medication (e.g., Phenytoin 100 mg PO t.i.d. or Keppra 500 mg po bid) before the
             procedure
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Surgical candidates with epilepsy or brain tumor(s)
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Surgical candidates with epilepsy or brain tumor(s)
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Helicobacter pylori infection subjects

        Exclusion Criteria:

          -  Prior gastrectomy; pregnant women
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  30 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  squamous cell carcinoma of oral cavity, oropharynx or hypopharynx

          -  Stage III - IV (T1-T4, N0-N2)(UICC 2002)

          -  Not resected

          -  Indication of radiotherapy to bilateral cervical nodes at dose&gt;= 50 Gy

          -  Delineation of target volumes done before randomization

          -  Scintigraphy of parotid gland done before radiotherapy start

          -  Quality of life questionnaires (EORTC-C30 and EORTC-H&amp;N35) filled in by the patient

          -  Informed consent signed

        Exclusion Criteria:

          -  N3 (UICC 2002)

          -  Distant metastasis

          -  Contra-indication to concomitant cisplatin

          -  History of cancer within the last 5 years

          -  History of head and neck radiotherapy

          -  Administration of drugs for treatment or prophylaxis of xerostomia (pilocarpine,
             ethyol)
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients (age &gt; or = 1 years) with a diagnosis of relapse after related or unrelated
             allogeneic stem cell transplantation for a hematological malignancy.

          -  For CML, relapse will be defined as any cytogenetic evidence of a Philadelphia
             chromosome or persistence of BCR/ABL rearrangements by molecular testing on at least
             two measurements over a 6 month interval.  If cytogenetics are normal and there is
             PCR evidence of a BCR/ABL fusion, patients will be eligible if they have evidence of
             a quantitative increase in CML measured either by quantitative PCR or by fluorescent
             in situ hybridization (FISH).

          -  For non-CML, relapse will be defined based on disease specific morphologic criteria
             from a bone marrow biopsy and aspirate or recurrence of disease specific
             cytogenetics.  For disease specific definition of relapse, see appendix 3.  Relapse
             can be determined morphologically with less than 5 percent blasts if definitive
             relapse can be determined.  Equivocal results for relapse should result in a repeated
             test after an appropriate time interval (suggested 1 month) to determine eligibility.

        Post-transplant lymphoproliferative diseases (often referred to as EBV-associated
        lymphomas) are NOT eligible for this protocol.

          -  For Chronic Phase CML patients only

          -  - must have failed (no response in 3 months or incomplete response at 6 months) or
             refused treatment with Gleevec

          -  - if no prior DLI, CML patients will first have DLI- if relapse occurs after DLI, DLI
             with chemotherapy per this protocol will be offered

          -  Patients must be within one year of identification of relapse or if beyond that time
             period, must have at least 10% donor DNA by RFLP or cytogenetics.

          -  Same allogeneic donor (sibling or URD) used for transplantation is available for
             lymphocyte donation.

          -  No severe organ damage (by laboratory or clinical assessment) as measured by:

          -  - blood creatinine  2.0 mg/dL

          -  - liver function tests &lt; 5 x normal

          -  - left ventricular ejection fraction &gt; 40% (testing required only if symptomatic or
             prior known impairment).

          -  - pulmonary functions &gt; 50% (testing required only if symptomatic or prior known
             impairment).  Oxygen saturation (&gt;92%) can be used in child where PFT's cannot be
             obtained.

          -  - chest x-ray without evidence of active infection

          -  Off prednisone and other  immunosuppressive agents (given for any reason) for at
             least 3 days prior to DLI infusions.

          -  Performance status  60%

          -  Women must not be pregnant or lactating. The agents used in this study may be
             teratogenic to a fetus and there is no information on the excretion of agents into
             breast milk All females of childbearing potential must have a blood test or urine
             study within 2 weeks prior to registration to rule out pregnancy

          -  Women of childbearing potential and sexually active males are strongly advised to use
             an accepted and effective method of contraception

          -  Patient must given written informed consent indicating understanding of the nature of
             the treatment and its potential risks

        Exclusion Criteria:

          -  Concurrent signs of acute or chronic graft-versus-host disease requiring ongoing
             treatment at the time of relapse will be ineligible.

          -  Patients being treated for GVHD with  prednisone, cyclosporine, Imuran or other
             immunosuppressive medications are not eligible until these medications are
             discontinued for at least 2 weeks without a flare of GVHD.

          -  Active CNS leukemia

          -  Active fungal infection or pulmonary infiltrates (stable prior treated disease is
             allowable)

          -  HIV positive
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  1 Year
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients must have a diagnosis of JMML and fulfill these minimal criteria
             (International diagnostic criteria for JMML):

               -  Leukocytosis (&gt; 13,000) with absolute monocytosis (&gt; 1,000)

               -  The presence of immature myeloid cells in the peripheral blood

               -  Less than 30% marrow blasts

               -  Absence of t(9:22) or BCR-ABL transcript

               -  Adequate major organ function including:

                    -  Cardiac: ejection fraction &gt; 45%

                    -  Hepatic: no clinical evidence of hepatic failure (e.g. coagulopathy,
                       ascites)

               -  Karnofsky performance status &gt; 70% or Lansky score &gt; 50%

               -  Creatinine must be &lt; 2 x normal for age

          -  Written informed consent.

        Exclusion Criteria:

          -  Active uncontrolled infection within one week of HCT.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  18 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients that are scheduled to begin radiotherapy to the large-field chest region
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients that are scheduled to begin radiotherapy to the large-field chest region are
             eligible if:

               -  Daily radiation dose is between 1.8 and 5 Gy/day

               -  Any single dimension of field size is  15 cm

               -  Provision of written informed consent

        or

          -  Or patients receiving IMRT or Tomotherapy, when low-dose radiation is spread out to
             the normal tissues, irrespective of daily radiation doses.

          -  Or patients receiving radionucleotides as part of the medical treatment (cancer or
             non-malignant conditions)

          -  Or patients who will receive diagnostic CT scans, PET/CT scans, mammograms, or
             diagnostic imaging requiring radionucleotides
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

        All patients who elect to undergo brachytherapy for the treatment of adenocarcinoma of the
        prostate and who are otherwise recommended treatment with LHRH agonist.  All patients must
        have a confirmed histological diagnosis of adenocarcinoma of the prostate and elect to be
        treated with transperineal implantation of the prostate.

        Eligible patients will have confirmed clinical stage T1 or T2 (UICC 1997 staging system)
        with

          1. PSA &gt; 10 but &lt; 15 and Gleason score &lt; 7, OR

          2. PSA &lt; 10 and Gleason score = 7 OR

          3. Prostate volume &gt; 50cc as measured on trans rectal ultrasound

        While criteria 1 and 2 are mutually exclusive, criteria 3 can be present alone or in
        combination with criteria 1 OR 2.

        Otherwise patients should be able to give informed consent and have a life expectancy. 2
        years.

        Exclusion Criteria:

        -
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  The proposal is to include as many patients with PT as possible including previously
             diagnosed patients whether or not they have received treatment. Thus all patients are
             eligible assuming they meet the diagnostic criteria and they do not have any
             exclusion criterion (see below). It will be necessary to stratify patients according
             to their previous treatment. This information will be collected on entry to the
             study. Informed consent is of course required where there is a change of therapeutic
             strategy.

        The diagnostic criteria for primary thrombocythaemia are:

          -  Platelet count &gt; 600x109/l.

          -  No evidence of overt polycythaemia(confirmed by RCM if necessary)or of polycythaemia
             masked by co-existent iron deficiency.

          -  No Philadelphia chromosome.

          -  Absence of peripheral blood and/or marrow appearances of myelodysplasia, or
             myelofibrosis.

          -  No known cause of reactive thrombocytosis. Particular care should be taken to exclude
             iron deficiency in pre-menopausal women.

        Notes:

          -  In asymptomatic patients, the platelet count should be observed for a period of at
             least 2 months to confirm &gt;600x109/l, and to allow any cause of reactive
             thrombocytosis to become overt.

          -  If the PCV is above normal upper limit (that is, males &gt;0.51, females &gt;0.48) or in
             high normal range in a patient with palpable splenomegaly measure RCM. Iron deficient
             primary polycythaemia (polycythaemia vera) is strongly suggested if Hb/PCV is normal
             in the presence of iron deficient red cell changes. In this situation, iron therapy
             is potentially dangerous.

          -  Exceeding rarely, bcr-abl positive Philadelphia chromosome negative patients present
             with high platelet counts with little or no elevation in WBC count. The features that
             suggest it is necessary to examine for bcr-abl, are:- basophilia, left-shift in WBC,
             granulocyte count &gt;16x109/l, difficulty in controlling platelet count, megakaryocytes
             of low ploidy (NAP is usually unhelpful).

          -  A normal ESR, CRP or plasma viscosity is useful in excluding a reactive
             thrombocytosis.

          -  Written informed consent obtained in accordance with NCRI requirements.

          -  Patients with impaired hepatic / renal function are not excluded although the
             respective biochemical tests should be monitored during therapy and reduced doses of
             cytoreductive agent should be used, particularly in the case of hydroxyurea and renal
             dysfunction.

        Exclusion Criteria:

        High risk features (any of the following):

          -  Age &gt;or= 60 years

          -  Platelet count &gt; or= 1500x109/l (current or previous) (a)

          -  History of ischaemia, thrombosis or embolic events (including erythromelalgia) (b)

          -  Haemorrhage considered to be related to PT (b)

          -  Presence of hypertension (c)or diabetes (d)

          -  The manufacturers of hydroxyurea state that it should be avoided in pregnancy and in
             lactating women. Similarly, hydroxyurea  should not be prescribed for women when
             there is doubt about their use of an effective contraceptive method.

          -  Exclude patient from hydroxyurea therapy and, therefore, from the 'intermediate' risk
             randomisation if the patient has current leg ulcers.

        Notes on the definition of high risk:

          -  In patients with borderline counts the allocation of a patient to a high risk group
             based on platelet count alone should rely on at least three samples taken on separate
             occasions over at least 2 months.

          -  Documentation of previous thrombo-embolic, ischaemic and haemorrhagic events should
             be given on the patient's entry proforma.

          -  Hypertension is defined as those patients requiring hypotensive therapy.

          -  Diabetes is defined as those patients requiring therapy with a hypoglycaemic agent.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  40 Years
 </minimum_age>
 <maximum_age>
  59 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients with Sickle Cell Disease/Thalassemia (SCD/THAL) 0-50 years of age with an
             acceptable stem cell donor and disease characteristic defined by the following:

               -  Stroke, central nervous system (CNS) hemorrhage or a neurologic event lasting
                  longer than 24 hours, or abnormal cerebral magnetic resonance imaging (MRI) or
                  cerebral arteriogram or MRI angiographic study and impaired neuropsychological
                  testing

               -  Acute chest syndrome with a history of recurrent hospitalizations or exchange
                  transfusions

               -  Recurrent vaso-occlusive pain 3 or more episodes per year for 3 years or more
                  years or recurrent priapism,

               -  Impaired neuropsychological function and abnormal cerebral MRI scan

               -  Stage I or II sickle lung disease,

               -  Sickle nephropathy (moderate or severe proteinuria or a glomerular filtration
                  rate [GFR] 30-50% of the predicted normal value)

               -  Bilateral proliferative retinopathy and major visual impairment in at least one
                  eye

               -  Osteonecrosis of multiple joints with documented destructive changes

               -  Requirement for chronic transfusions but with red blood cell (RBC)
                  alloimmunization &gt;2 antibodies during long term  transfusion therapy

          -  Patients with transfusion dependent alpha- or beta-thalassemia 0-35 years of age with
             an acceptable stem cell donor as defined in the criteria in section above.

          -  Patients with other non-malignant hematologic disorders that are
             transfusion-dependent or involve other potentially life-threatening cytopenias
             (including but not limited to Severe Congenital Neutropenia, Diamond-Blackfan Anemia
             and Shwachman-Diamond Syndrome) who are 0-35 years of age with an acceptable stem
             cell donor

          -  Second Transplants

               -  Patients with sickle cell disease or thalassemia who have failed to engraft or
                  have autologous recovery after a myeloablative SCT regimen or non-myeloablative
                  regimen are eligible for this protocol.

               -  Regimen A2 will be utilized for patients with sickle cell disease or thalassemia
                  who do not have an HLA-identical sibling donor or for any patient who has
                  pre-existing organ dysfunction making them ineligible for a myeloablative
                  preparative regimen.

               -  Regimen B will be utilized for patients with sickle cell disease or thalassemia
                  who have an HLA-identical sibling donor.

               -  Patients must meet above criteria.

               -  If the patient has received prior radiation therapy, eligibility to receive
                  additional radiation therapy must be determined by Dr. Dusenbery

               -  If first transplant was a non-myeloablative regimen, the second transplant can
                  occur at any time

               -  If the first transplant was a myeloablative regimen, then the second transplant
                  must be &gt; 6 months from the first transplant

        Exclusion Criteria:

          -  Patients with one or more of the following:

          -  Karnofsky or Lansky performance score &lt;70

          -  Acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis on
             biopsy

          -  Stage III-IV lung disease

          -  GFR&lt;30% predicted

          -  Pregnant or lactating females

          -  Active serious infection whereby patient has been on intravenous antibiotics for one
             week prior to study entry.  Any patient with AIDS or ARC or HIV seropositivity

          -  Psychologically incapable of undergoing bone marrow transplant (BMT) with associated
             strict isolation or documented history of medical non-compliance

          -  Patients not able to receive total lymphocytic irradiation (TLI) due to prior
             radiation therapy
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  50 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Donor will be &lt;75 years of age and in good health.

          -  Recipients will be &lt; or = 55 years, will have normal organ function (excluding bone
             marrow) and will have a Karnofsky activity assessment &gt; or = 90%.

          -  Recipients with related or unrelated donor matched at the HLA A, B, DRB1 loci, or
             mismatched related or unrelated (if &lt; 35 years old) at a single HLA A, B, DRB1 locus.

          -  Recipients will be eligible in one of the following disease categories

          -  Chronic myelogenous leukemia in accelerated phase or in post blast crisis second or
             greater chronic phase; or in chronic phase but intolerant of or resistant to tyrosine
             kinase inhibitors.

          -  Acute myelocytic leukemia in first or greater remission, or first, second or third
             relapse.

          -  Acute lymphocytic leukemia in the 2nd or greater bone marrow remission.

          -  High risk children will be transplanted in first remission if they meet criteria

          -  Myelodysplastic syndrome.

          -  Myeloproliferative Diseases - (i.e. myelofibrosis, chronic myelomonocytic leukemia
             (CMML))

          -  Juvenile myelomonocytic leukemia

          -  Chronic lymphocytic leukemia

          -  Advanced non-Hodgkin's (NHL).

          -  Advanced Hodgkin's disease beyond PR2 (&gt; CR3, &gt; PR3).

          -  Multiple Myeloma after initial therapy.

          -  Donors and recipients signed informed consent

        Exclusion Criteria

        donors and recipients should meet the following test criteria.

          -  required for donors:

               -  anti-HIV, Hepatitis B, surface antigen, anti-HCV, CMV, HSV, EBV serologies,
                  pre-priming.

               -  CBC, platelet count each day of apheresis, day 0 (or 1 or 2 as needed)

          -  required for recipients:

               -  anti-HIV, Hepatitis B, surface antigen, anti-HCV, CMV, HSV, EBV serologies,
                  pre-transplant.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  55 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients meeting the Durie and Salmon criteria for initial diagnosis of multiple
             myeloma, requiring therapy and meeting one of the following:

               -  After initial therapy in either first complete or partial remission or no
                  objective response

               -  After achieving initial response and later disease progression, patient will be
                  eligible after subsequent therapy upon achievement of either complete or partial
                  response

          -  Is not eligible or has refused any protocols of higher priority

          -  18 - 75 years of age

          -  Adequate organ function defined as:

               -  Hematologic: hemoglobin  8 gm/dl (untransfused), white blood cells (WBC) 
                  3000/l, absolute neutrophil count (ANC)  1500/l, platelets  100,000/l
                  (untransfused)

               -  Cardiac: no active ischemia, left ventricular ejection fraction &gt; 45% by MUGA
                  scan

               -  Hepatic: bilirubin &lt; 2.0 mg/dl, ALT &lt; 3x the upper limit of normal

               -  Pulmonary: FEV1-Forced Expiratory Volume in One Second AND Forced vital capacity
                  (FVC) &gt;50% predicted and Carbon Monoxide Diffusing Capacity (DLCO) (corrected) &gt;
                  50% predicted

               -  Performance status: Karnofsky performance of &gt; 80%.

          -  Free of active uncontrolled infection at the time of study entry.

          -  At time of study enrollment &gt; 4 weeks from prior myelosuppressive chemotherapy; and &gt;
             6 weeks from prior nitrosoureas.

          -  Patients must exercise informed voluntary consent and sign a consent form approved by
             the University of Minnesota IRB: Human Subjects Committee.

        Exclusion Criteria:

          -  Patients will be ineligible if they have advanced myeloma refractory and unresponsive
             to salvage chemotherapy regimens.

          -  Female patients who are pregnant (positive b-HCG) or breastfeeding will be excluded
             from study entry. In addition fertile men or women unwilling to use contraceptive
             techniques during and for 12 months following treatment, particularly after
             thalidomide will also be excluded from study entry.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Subjects with cutaneous t-cell lymphoma and/or Sezary syndrome
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  18 or older

          -  able and willing to provide informed consent

          -  diagnosed with CTCL

        Exclusion Criteria:

          -  Lack of CTCL diagnosis in medical record
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients with recurrent solid tumors

          -  Patients with malignant melanoma

          -  Patients with hematological malignancies.

               -  Chronic myelogenous leukemia in chronic or accelerated phase, to include chronic
                  myelomonocytic leukemia (juvenile chronic myelogenous leukemia [JCML] or CMML).

               -  Acute lymphoblastic leukemia (ALL)

                    -  First remission high-risk ALL (Ph+ with initial high white blood cell
                       [WBC]; t (4-11) in infants less than 1 year and CALLA negative)

                    -  Second or subsequent remission ALL or isolated extramedullary disease on or
                       off therapy.

               -  Acute non-lymphocytic leukemia (ANLL)

                    -  Patients with ANLL in first remission who have a matched sibling donor.

                    -  ANLL in second remission, or patients who only achieve an initial partial
                       remission &lt; 15% blasts, or early relapse.

               -  Myelodysplastic syndromes (MDS): refractory anemia (RA), refractory anemia with
                  excess blasts (RAEB), refractory anemia with excess blasts in transformation
                  (RAEB-T) and CMML/JCML.

          -  Selected immunodeficiencies:

               -  Wiskott-Aldrich syndrome.

               -  Severe combined immunodeficiency variants that require ablation.

               -  Hyper-IGM syndrome.

               -  Other immune deficiencies after approval from the medical director.

          -  Bone marrow failure syndromes (single or multiple hematopoietic lines)

          -  Venous access: A double lumen central vascular access device or its equivalent will
             be required for all patients entered on the protocol.

          -  Informed consent: The donor and the patient and/or the patient's legally authorized
             guardian must acknowledge in writing that consent to become a study subject has been
             obtained in accordance with the institutional policy approved by the United States
             (U.S.) Department of Health and Human Services.

          -  Patient organ function requirements:

               -  Adequate renal function: serum creatinine &lt; 2 x normal, or creatinine clearance
                  calculated by Schwartz formula, of glomerular filtration rate (GFR) &gt; 40
                  ml/min/1.73m2, or an equivalent GFR as determined by the institutional normal
                  range.

               -  Adequate liver function: total bilirubin &lt;/= 2 x normal; and SGOT (AST) or SGPT
                  (ALT) &lt;/= 4 x normal.

               -  Adequate cardiac function: shortening fraction of &gt; 24% by echocardiogram, or
                  ejection fraction of &gt; 30% by radionuclide angiogram.

               -  Adequate pulmonary function: DLCO, FEV1 / FVC &gt; 30% by pulmonary function test.
                  For children who are uncooperative for pulmonary function tests and have no
                  evidence of dyspnea at rest or exercise intolerance, pulse oximetry &gt; 94% on
                  room air is considered acceptable.

               -  Performance status: Lansky &gt;/= 60% for children &lt;/= 16 years of age; or
                  Karnofsky &gt; 60% status for those &gt; 16 years of age.

        Exclusion Criteria:

          -  Patients who are pregnant

          -  Inability to find a suitable donor for the patient

          -  Patient is HIV-positive

          -  Patient has active Hepatitis B

          -  Disease progression or relapse prior to HPC infusion
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  21 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Community
  </textblock>
 </study_pop>
 <sampling_method>
  Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  18 years of age or older

          -  Identified by the investigator to have a condition of interest (cardiovascular
             disease, cancer, endocrine disease, neurological disease, arthritis, psychiatric
             disease) for exploratory studies related to the patient's illness or other feature
             that offers the possibility of generation of hypotheses for future studies

        Exclusion Criteria:

          -  Unwilling to be subjected to diagnostic and/or therapeutic procedures that are not
             necessary for clinical management

          -  Excessive blood loss in this study plus other research participation and/or clinical
             evaluation that will result in blood loss of greater than 1 unit (400ml or 1 pint)
             over an 8 week period

          -  Inability to give informed consent
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   women in surgery for breast cancer
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Palpable breast cancer lesion
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   All hematopoietic cell transplant recipients and donors who agree to participate
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:- All hematopoietic cell transplant recipients and donors who agree to
        participate

        Exclusion Criteria:- Subject does not agree to participate
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

        Preoperative criteria:

          1. Histologically confirmed adenocarcinoma

          2. Clinical stage II or III

          3. Preoperative findings:

               -  Main lesion of the tumor is located at the rectum

               -  Lower tumor margin is below the peritoneal reflection

               -  No extramesorectal lymph node swelling (Shorter diameter is less than 10 mm)

               -  No invasion to other organ (s)

          4. Patient age is more than 20 and less than 75

          5. PS: 0, 1

          6. No past history of chemotherapy, pelvic surgery or radiation

          7. Written informed consent

             Operative criteria:

          8. Mesorectal excision is performed

          9. Operative findings:

               -  Main lesion of the tumor is located at the rectum

               -  Lower tumor margin is below the peritoneal reflection

         10. R0 after resection

        Exclusion Criteria:

          1. Multiple cancer patients

          2. Pregnant patients

          3. Psychological disorder

          4. Steroid administration

          5. Cardiac infarction within six months

          6. Severe pulmonary emphysema and pulmonary fibrosis

          7. Doctor's decision for exclusion
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  21 Years
 </minimum_age>
 <maximum_age>
  74 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients with biopsy or cytology proven (squamous or adenocarcinoma) esophageal
             cancer

          -  Patients with staging investigations showing operability

          -  Surgical plan of total transthoracic esophagectomy

        Exclusion Criteria:

          -  Patients with low performance status (ECOG score&gt;1)

          -  Past history of malignancy

          -  Staging investigations indicating advanced disease

          -  Patients medically unfit for surgical resection

          -  Patients with pulmonary reserve inadequate to undergo thoracotomy and extensive
             mediastinal lymphadenectomy

          -  Patients considered for salvage surgery after definitive (radical)chemoradiotherapy

          -  Patients with supracarinal lymph node enlargement on CT scan and/or EUS

          -  Patients intraoperatively detected to have grossly enlarged supracarinal lymph nodes

          -  Patients with Siewert's type III CO junction growths

          -  Patients above the age of 70 years

          -  Patients unreliable for follow up
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

        Previously untreated, resectable, loco-regionally advanced, stage III &amp; IV, biopsy-proven
        squamous cell carcinoma of the oral cavity. (Clinically lower stage patients will also be
        included if upstaged to pathological stage III or IV after Surgery)

        One or more of the following must be present:

        extracapsular nodal extension, involvement of &gt; 2 regional lymph nodes, margin of
        resection with invasive cancer (on histopathology) Extensive soft tissue and / or skin
        infiltration requiring major reconstructive procedure.

        Peri-neural invasion with positive lymph node(s). Lymphovascular embolisation with
        positive lymph node(s). Age &gt; 18. Karnofsky performance status of &gt; 60. WBC &gt; 3500,
        platelets &gt; 100,000 Serum creatinine &lt; 1.2 mg / m2 Signed study-specific informed consent
        form. Protocol treatment must begin within 8 weeks surgery.

        Exclusion Criteria:

        Gross (visible or palpable) residual disease left after surgery. Prior chemotherapy or
        radiation therapy to the head and neck region.

        Evidence of distant metastasis. Any post-operative complication which will delay starting
        of adjuvant treatment for more than 8 weeks.

        Presence of synchronous or concurrent head and neck primary tumors. Prior malignancy
        within the previous 5 years. Patients who because of their medical status are not
        candidates for the proposed treatment.

        KPS &lt; 60. Age &gt; 65 years. Poor expected follow up.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  65 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Histologically proven SCC

          -  Patients have undergone either:

               -  Resection of the primary lesion

               -  Any type of parotidectomy (superficial, total, partial, etc.)

               -  Any type of neck dissection(s)

          -  High risk feature(s); Advanced primary disease or high risk nodal disease

        High Risk Nodal Disease

          -  Intra-parotid nodal disease (any number or size, with/without extracapsular
             extension, with/without an identifiable index lesion)

          -  Cervical nodal disease with a synchronous index lesion or previously resected
             cutaneous primary tumour (&lt;5 years) within the corresponding nodal drainage and a
             mucosal primary has been excluded with at least a CT +/- MRI and panendoscopy* *For
             cervical nodal disease to be eligible there must be at least one of the following
             criteria:

               -  &gt; 2 nodes

               -  largest node &gt; 3 cm

               -  Extracapsular extension

        Advanced Primary Disease (TNM 6th Edition 2002) (Appendix 1)

          -  T3-4  primary disease (cartilage, skeletal, muscle, bone involvement, &gt; 4 cm) of the
             head and neck including lip, nose and external auditory canal with or without nodal
             disease

          -  In transit metastases (metastases between the primary site and the adjoining nodal
             basin)

               -  Age &gt; 18 years

               -  Written informed consent

               -  ECOG &lt;= 2

               -  Absolute neutrophil count &gt; 1.5 X 10^9/L, platelet count &gt; 100 X 10^9/L, and
                  haemoglobin &gt; 10 g/dL (pre-radiotherapy blood transfusion to elevate the
                  haemoglobin &gt; 10 g/dL is permissible)

               -  Calculated creatinine clearance (Cockcroft-Gault) &gt;= 40 mL/min

               -  Available for follow-up for up to 5 years

               -  Life expectancy greater than 6 months

        Exclusion Criteria:

          -  Intercurrent illness that will interfere with either the chemotherapy or radiotherapy
             such as immunosuppression due to medication or medical condition

          -  Metastasis(es) below the clavicles

          -  Previous radical radiotherapy to the head and neck, excluding treatment of an early
             glottic cancer greater than or equal to 2 years ago and superficial radiotherapy to
             cutaneous SCC or Basal cell carcinoma

          -  High risk for poor compliance with therapy or follow-up as assessed by investigator

          -  Pregnant or lactating women

          -  Patients with prior cancers, except: those diagnosed &gt; 5 years ago with no evidence
             of disease recurrence and clinical expectation of recurrence of less than 5%; or
             successfully treated Level 1 cutaneous melanomas or early glottic cancer &gt; 2 years
             ago; or non-melanoma skin cancer; or carcinoma in situ of the cervix.

          -  Low risk cervical nodal disease* without advanced primary disease

             *Low risk cervical nodal disease is defined as the presence of all of the following
             criteria:

          -  single nodal metastasis

          -  greater then or equal to 3cm,

          -  no extracapsular extension
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Patients must have histologically confirmed breast malignancy that is:

               -  High risk stage II breast cancer (4 positive lymph nodes),

               -  Stage III breast cancer, including inflammatory breast cancer

               -  Stage IV breast cancer in a complete remission (bone only not allowed unless the
                  bone scan is normal).

          2. The patient must have had what is considered standard adjuvant systemic therapy that
             may include chemotherapy, hormonal therapy and radiation therapy.  They may have
             undergone high dose chemotherapy with stem cell support as part of their therapy in
             the adjuvant or metastatic setting. The patient is allowed to continue to take
             adjuvant hormonal therapy (for high risk adjuvant patients) and may be allowed to be
             on hormonal consolidation post transplant if they are without evidence of disease
             after a transplant for metastatic breast cancer. The patient cannot be actively
             receiving chemotherapy or any biologic agent to treat their breast cancer.

          3. Six weeks must elapse from last chemotherapy or radiation therapy.

          4. The patient must have had definitive surgical therapy for their breast cancer. This
             includes lumpectomy and axillary dissection or mastectomy.

          5. No clinical or radiologic evidence of disease after surgery and/or systemic treatment
             (by CT scan of chest, abdomen and pelvis and bone scan or PET scan prior to
             enrollment)

          6. Because no dosing or adverse event data are currently available on the use of TM in
             patients &lt; 18 years of age, children are excluded from this study.

          7. ECOG performance status &lt; 1

          8. Life expectancy of greater than 3 months.

          9. Patients must have normal organ and marrow function as defined below:

               -  hemoglobin &gt;10mg/dL

               -  absolute neutrophil count &gt;1,500/mL

               -  platelets &gt;100,000/mL

               -  total bilirubin &lt; 1.5 x normal institutional limits

               -  AST(SGOT)/ALT(SGPT) &lt;1.5 X institutional upper limit of normal

         10. Erythropoietin alpha is allowed, as indicated.

         11. Bisphosphonates may be administered if they were started prior to starting this
             therapy.

         12. Patients must be on stable medical therapy for at least 2 weeks if they are being
             treated medically for their peripheral neuropathy.

         13. Concurrent herceptin is not allowed.

         14. The effects of TM on the developing human fetus are unknown.  For this reason, women
             of child-bearing potential and men must agree to use adequate contraception (hormonal
             or barrier method of birth control; abstinence) prior to study entry and for the
             duration of study participation.  Should a woman become pregnant or suspect she is
             pregnant while participating in this study, she should inform her treating physician
             immediately.

         15. Ability to understand and the willingness to sign a written informed consent
             document.

        Exclusion Criteria:

          1. Patients who have had chemotherapy or radiotherapy within 6 weeks prior to entering
             the study.

          2. Objective evidence of breast cancer.

          3. Carcinomatous meningitis or history of neoplastic parenchymal brain disease.

          4. Serum creatinine &gt;1.5 x normal.

          5. History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to TM.

          6. Pregnant women are excluded from this study because TM has the potential to have
             teratogenic or abortifacient effects.  Because there is an unknown but potential risk
             for adverse events in nursing infants secondary to treatment of the mother with TM,
             breastfeeding should be discontinued if the mother is treated with TM.

          7. Because patients with immune deficiency are at increased risk of lethal infections
             when treated with marrow-suppressive therapy, HIV-positive patients receiving
             combination anti-retroviral therapy are excluded from the study because of possible
             pharmacokinetic interactions with TM.
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion criteria :

          1. Female gender

          2. Post-menopausal(no age limit) defined as:

               1. Radiation-induced menopause or surgical bilateral oophorectomy, or

               2. Women with an intact uterus and

             i. &gt; 55 years of age or ii. without menses for the last 5 years or iii.  55 years of
             age and has not had menses for at least the last 12 months (but has had menses in the
             last 5 years) and has postmenopausal levels of FSH c. Women without an intact uterus
             and i. &gt; 55 years of age or ii.  55 years of age and has postmenopausal levels of
             FSH

          3. Contraindications for the use of neoadjuvant/adjuvant chemotherapy, refusal by the
             patient to receive chemotherapy or if the investigator believes the patient is a
             suitable candidate for this protocol.

          4. WHO performance status &lt; 1

          5. Histologically-confirmed ductal or lobular operable adenocarcinoma of the breast
             (stage I, II and III)

          6. Confirmed absence of liver, lung and bone metastases.

          7. Primary tumor of at least 2 cm, measured clinically and/or radiologically

          8. Multifocal invasive tumors are not eligible, unless a biopsy showing ER positivity
             can be obtained from each tumor lesion.

          9. ER-positive and/or PgR-positive tumors, defined according to immunohistochemistry
             (i.e. &gt; 10% of positive cells after immunostaining), if woman younger 70 years;
             ER-positive or PgR-positive tumors if woman older than 70 years.

         10. Fixed and frozen samples from the primary tumor, obtained before treatment, must be
             available for evaluation of biological markers (cDNA microarrays, EGFR, HER-2,
             intra-tumoral aromatase).

         11. No concurrent second malignancy, including contralateral breast cancer (exceptions
             are: adequately treated basal cell carcinoma of the skin and in situ carcinoma of the
             cervix). Any prior second malignancy must be in remission for  5 years.

         12. No other serious illness or medical condition including:

               -  History of documented congestive heart failure; angina pectoris requiring
                  antianginal medication; evidence of recent (&lt; 6 months) transmural infarction on
                  ECG; poorly controlled hypertension (e.g. systolic &gt;180 mm Hg or diastolic
                  greater than 100 mm Hg); clinically significant valvular heart disease; or
                  high-risk uncontrolled arrhythmias.

               -  Chronic lung disease

               -  History of significant neurological or psychiatric disorders that would prohibit
                  the understanding and giving of informed consent, including psychotic disorders,
                  mental retardation, and dementia.

               -  Active concurrent infection

         13. No concurrent or previous anti-cancer treatment is allowed

         14. Adequate organ function as defined by:

               -  Neutrophils  1.5 x 109/L

               -  Platelets  100 x 109/L

               -  Bilirubin  1.5x upper limit of normal (ULN)

               -  Transaminases  2.5x ULN

               -  Creatinine  1.5x ULN

         15. Normal left ventricular ejection fraction by echocardiography or MUGA scan [for
             combination studies only]

         16. Absence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule;
             those conditions should be discussed with the patient before registration in the
             trial.

         17. Before patient registration/randomization, informed consent must be given according
             to ICH/EU GCP, and national/local regulations.

        Exclusion crieria :

        Non specified
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients with tumors of the head and neck who ar ehaving diagnostic biopsy or surgical
        resection of primary lesions or recurrences
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  actual or suspected malignant or non-malignant tumors of the head and neck

          -  planned biopsy and/or resection, or availability of paraffin embedded or stored
             frozen tumor tissue for non-genetic analysis

        Exclusion Criteria:

          -  insufficient tissue available for both standard diagnostic evaluation and study
             specimen
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. All patients must be female.

          2. Signed informed consent.

          3. Primary breast cancers must be of clinical and/or radiologic size &gt;3 cm, and deemed
             surgically operable.

          4. Negative serum pregnancy test (bHCG) within 7 days of starting study, if of
             child-bearing potential.

          5. Adequate bone marrow function:

               -  Hematocrit of greater than 30%,

               -  total neutrophil count must be &gt;1.5 x 10^9/L and

               -  platelets of &gt; 100 x 10^9/L prior to the start of any cycle.

          6. Renal function tests:

               -  creatinine within 1.5 times of the institution's upper limit of normal (ULN).

          7. Liver function tests:

               -  Total serum bilirubin within ULN, and

               -  liver transaminases within 2.5 times ULN, and

               -  alkaline phosphatase within 5 times ULN.

          8. Electrocardiogram showing no acute ischemic changes.

          9. Performance status (World Health Organization [WHO] scale) &lt;2.

         10. Age &gt; 18 years.

         11. Patients older than 70 years of age should have left ventricular ejection fraction
             within ULN by multigated acquisition scan (MUGA) or 2D echocardiogram.

        Exclusion Criteria:

          1. Patients with metastatic breast cancer.

          2. Pregnancy or unwillingness to use a reliable contraceptive method in women of
             child-bearing potential.

          3. Women who are lactating or breastfeeding.

          4. Severe underlying chronic illness or disease.

          5. Peripheral neuropathy - grade 2 or greater.

          6. Patients on other investigational drugs while on study will be excluded.

          7. Severe or uncontrolled hypertension, history of congestive heart failure, acute
             myocardial infarction, or severe coronary arterial disease.

          8. Prior taxane or anthracycline chemotherapy for malignancy.

          9. Patients with a history of severe hypersensitivity reaction to Taxotere or other
             drugs formulated with polysorbate 80.

         10. No previous or current malignancies at other sites within the last 5 years, with
             exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri
             and basal or squamous cell carcinoma of the skin.
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Squamous cell carcinoma of the oral cavity or oropharynx, with the primary lesion &gt;1
             cm from the midline.

          -  Patient has no clinical or radiologic evidence of contralateral neck node metastases.

          -  No evidence of distant metastasis.

          -  No previous history of radiation therapy or chemotherapy

          -  performance status 0-2

          -  Age &gt;= 18

          -  Signed informed consent

          -  Patients must be accessible for treatment and follow-up

        Exclusion Criteria:

          -  HIV positive patients

          -  Pregnancy or any patients not practicing contraception

          -  Active tobacco or alcohol addiction (as assessed by medical caregiver)

          -  Serious comorbid disease which prevents delivery of full treatment including
             psychiatric disorders, cardiopulmonary disease, etc.

          -  Concomitant use of any trial anticancer therapeutic within 30 days of entry

          -  Uncontrolled hypertension

          -  Known hypersensitivity to mammalian cell-derived products
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Male or female

          -  Age 18+

          -  Surgically difficult to access tumors including intracerebral metastases

        Exclusion Criteria:

          -  Patients unwilling or unable to give written consent

          -  Patients at risk for cardiac ischemia

          -  Patients who cannot physically fit in the MRI scanner in the MRI OR

          -  Patients with contraindications to MRI imaging such as pacemakers, non-compatible
             aneurysm clips, shrapnel, and other internal ferromagnetic objects

          -  Patients with coagulopathies, severe medical problems, cardiac arrhythmias or
             abnormal BUN
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Histologically proven mantle cell lymphoma according to the World Health Organization
             (WHO) classification, preferably confirmed by central pathology review before
             entering the study

          -  Clinical stage II, III or IV

          -  Previously untreated patients

          -  Above the age of 65 years and older or patients at the age between 60 and 65, if not
             eligible for high dose chemotherapy

          -  WHO performance grade 0, 1 or 2

          -  Informed consent according to International Conference on Harmonisation of Technical
             Requirements for Registration of Pharmaceuticals for Human Use/European Union Good
             Clinical Practice (ICH/EU GCP) and national/local regulations

          -  Measurable disease. If, for example only bone marrow (BM) infiltration, patients can
             only undergo a second randomization if a CR is obtained.

        Exclusion Criteria:

          -  WHO performance of 3 or more

          -  Known anti-murine antibody (HAMA) reactivity or known hypersensitivity to murine
             antibodies

          -  Leukocytes &lt;2.0x 10^9/l or thrombocytes &lt;100x 10^9/l, unless clearly related to
             mantle cell lymphoma (MCL) bone marrow infiltration

          -  Patients previously treated for lymphoma

          -  Patients without measurable lesions; if, for example only bone marrow infiltration,
             patients may be included, but can only undergo a second randomization in case of a CR

          -  Patients with stage I disease

          -  Patients with central nervous system involvement

          -  Patients with a history of autoimmune hemolytic anaemia or autoimmune
             thrombocytopenia

          -  Patients with serious cardiac disease (uncontrolled arrhythmias, unstable angina,
             severe congestive heart failure)

          -  Patients with serious pulmonary, neurological, endocrinological or other disorder
             interfering with full dosing of CHOP or FC chemotherapy

          -  Liver enzymes &gt;3x normal or bilirubin &gt;2.5x normal (not due to lymphoma)

          -  Creatinine &gt;2x normal value, corrected for age and weight (not due to lymphoma)

          -  Patients with unresolved hepatitis B or C infection or known HIV positive infection

          -  Uncontrolled infection

          -  Patients with a serious depression that needed therapy within the last 5 years

          -  Any psychological, familial, sociological or geographical condition potentially
             hampering compliance with the study protocol and follow-up schedule

          -  Concomitant or previous malignancies other than basal cell or squamous cell skin
             cancer, in situ cervical cancer and other cancer for which the patient has been
             disease-free for at least 5 years
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  60 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Histologically proven diagnosis of mantle cell lymphoma (World Health Organization
             [WHO] classification)

          -  Clinical stage II - IV (Ann Arbor)

          -  Previously untreated patients

          -  Age 18 - 65 years

          -  WHO performance &lt; 2

          -  Measurable disease (also: patients with isolated bone marrow involvement)

          -  Informed consent according to International Conference on Harmonisation of Technical
             Requirements for Registration of Pharmaceuticals for Human Use/European Union Good
             Clinical Practice (ICH/EU GCP) and national/local regulations

        Exclusion Criteria:

          -  Age &gt; 65 years

          -  WHO performance status &gt; 2

          -  Known anti-murine antibody (HAMA) reactivity or known hypersensitivity to murine
             antibodies

          -  Previous lymphoma therapy with radiation, cytostatic drugs, anti-CD20 antibody or
             interferon

          -  Serious disease interfering with a regular therapy according to the study protocol:

               -  cardiac (e.g. manifest heart failure, coronary heart disease, uncontrolled
                  hypertension)

               -  pulmonary (e.g. chronic lung disease with hypoxemia)

               -  endocrine (e.g. severe, not sufficiently controlled diabetes mellitus)

               -  renal insufficiency (unless caused by the lymphoma): creatinine &gt; 2x normal
                  value and/or creatinine clearance &lt; 50 ml/min)

               -  impairment of liver function (unless caused by the lymphoma): transaminases &gt; 3x
                  normal or bilirubin &gt; 2,0 mg/dl

          -  Patients with unresolved hepatitis B or C infection or known HIV infection

          -  Prior organ, bone marrow or peripheral blood stem cell transplantation

          -  Concomitant or previous malignancies within the last 5 years other than basal cell
             skin cancer or in situ uterine cervix cancer.

          -  Pregnancy or lactation

          -  Any psychological, familiar, sociological, or geographical condition potentially
             hampering compliance with the study protocol and follow up schedule
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  65 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  All soft tissue sarcoma types excluding liposarcoma and leiomyosarcoma (L-type soft
             tissue sarcoma) that cannot be surgically removed and is in an advanced stage or has
             spread

          -  Must have relapsed or had progressive disease following standard of care treatment
             prior to enrollment or intolerant to standard of care treatment due to safety issues

          -  Recovery from toxic effects of prior therapies to Grade 1 or better according to
             National Cancer Institute-Common Terminology Criteria of Adverse Events (criteria
             used to grade the severity of toxic effects on a scale from 0 to 5 - Grade 1 = mild
             in severity, Grade 0 = no severity)

          -  Clinical test results within acceptable limits (ie, hematologic, clinical chemistry
             and hepatic function test results)

          -  Male and female patients surgically sterile, abstinent, or practicing an effective
             method of birth control and female patients have a negative urine or serum pregnancy
             test result at screening

        Exclusion Criteria:

          -  Less than 3 weeks from last dose of radiation, systemic cytotoxic therapy (or 4 half
             lives, whichever is longer)

          -  Active symptomatic viral hepatitis or chronic liver disease

          -  Significant uncontrolled cardiac condition, including New York Heart Association
             Class II or greater heart failure, uncontrolled angina pectoris, myocardial
             infarction within 6 months before enrollment, significant pericardial disease, or
             uncontrolled or arrhythmias

          -  Active infection

          -  Female patient who is pregnant or breastfeeding
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  15 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Candidates for bone marrow transplantation

        Exclusion Criteria:

        -
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

               1. MDS with WHO classification of RA, RARS, RCMD-RS, RCUD, and RCMD and RAEB-1 (all
                  subtypes of MDS with the exception of RAEB 2, CMML, and MDS/MPN overlap)

               2. Anemia requiring transfusion support with at least one unit of packed red blood
                  cells per month for greater than or equal to 2 months

                  OR

                  Anemia (hemoglobin less than 9 or a reticulocyte count less than 60,000)

                  OR

                  thrombocytopenia (platelet count less than 50000/ul)

                  OR

                  neutropenia (absolute neutrophil count less than 500/ul).

               3. Off all other treatments for MDS (except filgrastim (G-CSF), erythropoietin, and
                  transfusion support and related medications) for at least four weeks.
                  Filgrastim (G-CSF) can be used before, during and after the protocol treatment
                  for patients with documented neutropenia (less than 500/Ul) as long as they meet
                  the criteria for anemia and/or thrombocytopenia as stated above.

               4. Ages 18-72 (inclusive)

        EXCLUSION CRITERIA:

          1. Chronic myelomonocytic leukemia (CMML), MDS/MPN overlap,  WHO RAEB-2

          2. Secondary MDS

          3. Failure to respond to prior therapy with ATG or ATG/CsA

          4. Prior therapy with combination chemotherapy

          5. Transformation to acute leukemia (FAB sub-group RAEB-T, i.e., greater than 20% blasts
             in marrow aspirate)

          6. Failure to discontinue the herbal supplements Echinacea purpurea or Usnea barbata
             (Old Man's Beard) within 2 weeks of enrollment.

          7. Active infection not adequately responding to appropriate therapy

          8. HIV positive patients

          9. Active malignant disease (excluding non-melanoma skin carcinoma)

         10. Moribund status or concurrent hepatic, renal, cardiac, neurologic, pulmonary,
             infectious, or metabolic disease of such severity that it would preclude the
             patient's ability to tolerate protocol therapy or that death within 7-10 days is
             likely.

         11. Life expectancy less than 6 months

         12. Low predicted probability of response

         13. Previous hypersensitivity to alemtuzumab (Campath[R]) or its components

         14. Current pregnancy, or unwilling to take oral contraceptives or refrain from pregnancy
             if of childbearing potential

         15. Not able to understand the investigational nature of the study or give informed
             consent
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  72 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Any patient with histologically proven operable ,locally advanced and metastatic
             oesophageal or gastric carcinoma.

        Exclusion Criteria:

          -  Second malignancy
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Biochemical relapse (rising PSA) after initial treatment (radiation therapy,
             brachytherapy, or radical prostatectomy) for histologically or cytologically
             confirmed adenocarcinoma of the prostate

          -  Clinical stage A2, B, C, D1

          -  Age: older than 21 years old

          -  Performance status of 0 or 1

          -  Pretreatment serum testosterone, normal range (or no clinical evidence of
             testosterone deficiency).

          -  If less than 30 months since completion of radiation therapy, biopsy of prostate
             suggested within 6 months of study entry.

          -  If more than or equal to 30 months since completion of radiation therapy, biopsy of
             prostate suggested within 1 year.

          -  Written informed consent.

        Exclusion Criteria:

          -  Abnormal bone scan suggestive of metastatic osseous disease.

          -  Previous hormonal manipulation including orchiectomy or any medication with
             significant antiandrogenic activity (combined androgen suppression over 9 months,
             monotherapy antiandrogens, estrogens, ketoconazole).  *Neoadjuvant androgen
             suppression therapy of less than or equal to 3 months is allowed, if this androgen
             suppression therapy was completed more than or equal to 1 year prior to study
             enrollment AND if the Testosterone level is within the normal ranges.

          -  Any systemic chemotherapy or curative radiotherapy within 6 months.

          -  Hepatic dysfunction (bilirubin: greater than 2.0 mg/dl and/or SGOT, LDH: greater than
             3 times the upper limit of normal range).

          -  Renal dysfunction (BUN: greater than 40 mg/dl and/or creatinine: greater than 2.0
             mg/dl).

          -  History or presence of other malignancy within the last 5 years (except treated
             squamous/basal cell carcinoma of the skin or superficial bladder carcinoma).

          -  Hypersensitivity to flutamide or leuprolide.
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  21 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients with hematologic malignancies or bone marrow failure syndrome who are
             candidates for allogeneic bone marrow transplantation are eligible for this study.
             Hematologic malignancies indicated for transplantation:

               -  Acute lymphoblastic leukemia (ALL) in first remission (with high risk feature),
                  2nd or greater remission.

               -  Acute myeloid leukemia (AML) in first remission (with high risk feature), 2nd or
                  greater remission.

               -  Chronic myeloid leukemia (CML) in 2nd chronic phase or accelerated phase.

               -  Juvenile myelomonocytic leukemia (JMML).

               -  Myelodysplastic syndrome.

               -  Biphenotypic leukemia in first (with high risk feature), 2nd or greater
                  remission.

               -  Induction failure leukemia.

               -  Refractory relapsed leukemia.

               -  Bone marrow failure syndrome.

               -  Severe aplastic anemia failed immunotherapy.

          -  Patients who do not have a 6 out of 6 matched related or unrelated donor or 4/6 and
             5/6 matched cord blood will be eligible for this study.

          -  Partially mismatched related donor availability as defined by molecular typing with 3
             to 5 HLA matches.

          -  Patients who are under 22 years of age.

        Exclusion Criteria:

          -  Patients will not be excluded based on sex, racial, or ethnic background.

          -  Patients will be excluded if they demonstrate significant functional deficits in
             major organs, which would obviously interfere with successful outcome following bone
             marrow transplant utilizing the following guidelines.

               -  Evidence of active, deep-seated, life-threatening infections for which there is
                  no known effective therapy (certain fungal species, HIV, etc.).

               -  Patients who have been treated for infections must have appropriate responses as
                  documented by 2 (two) consecutive negative cultures and/or stable radiographic
                  examinations.

               -  Patients who have active central nervous system (CNS) leukemic disease.

          -  Patients will be excluded if they are women of childbearing potential who are
             currently pregnant (beta-HCG+) or who are not practicing adequate contraception.

          -  Patients who have had a previous hematopoietic stem cell transplant will be excluded.

          -  Donors will be excluded if they are sensitive to E. coli-derived protein.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  22 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   All patients undergoing surgery at Stanford University for head and neck cancer.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

        All patients undergoing surgery at Stanford University for head and neck cancer.

        Exclusion Criteria:

        Non-Stanford patients.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients followed in the transplant clinic at Virginia Commonwealth University Health
        System
  </textblock>
 </study_pop>
 <sampling_method>
  Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients followed in the transplant clinic at Virginia Commonwealth University Health
             System
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients with previously untreated prostatic cancer.

          -  Must have PSA 10-20 ng/ml, Gleason 7 to 9

        Exclusion Criteria:

          -  Patients with proven regional lymph node involvement will be excluded.
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  40 Years
 </minimum_age>
 <maximum_age>
  80 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  liver metastases from colorectal cancer undergoing liver resection

        Exclusion Criteria:

          -  contraindication to CT, MRI or PET
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Confirmed diagnosis of AML or high risk MDS in the following disease stages:
             Induction failure, first or subsequent remission, or untreated first relapse.

          2. Patient must have an HLA-compatible donor willing and capable of donating peripheral
             blood stem cells preferably or bone marrow progenitor cells using conventional
             techniques, and lymphocytes if indicated (HLA-compatible defined as 5/6 or 6/6
             matched related or 6/6 molecular matched unrelated donor)

          3. Both patient and donor must sign written informed consent forms.

          4. Patients must have:

               -  ECOG PS &lt;/= 2;

               -  Ejective fraction &gt; 40%;

               -  DLCO &gt; 40% of predicted;

               -  Serum bilirubin &lt;/= 1.5x institutional upper limit of normal;

               -  SGPT (ALT) and SGOT (AST) &lt;/= 2.5x institutional upper limit of normal;

               -  Serum creatinine &lt;/= 2x upper limit of normal;

               -  Creatinine clearance &gt;/= 60mL/min.  However, renal dysfunction is not an
                  absolute contraindication for NMT as dialysis can be performed during NMT.

        Exclusion Criteria:

          1. Not fulfilling any of the inclusion criteria

          2. Active life-threatening infection

          3. Overt untreated infection

          4. HIV positivity, hepatitis B or C antigen positivity with active hepatitis

          5. Pregnant or lactating women

          6. Donor contraindication (HIV seropositive confirmed by Western blot; hepatitis B
             antigenemia)

          7. Unable to donate bone marrow or peripheral blood due to concurrent medical condition
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  21 Years
 </minimum_age>
 <maximum_age>
  90 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Patients with potentially malignant or suspicious lesions, or with biopsy proven lung
        cancers or esophageal cancers, malignant pleural mesotheliomas, mediastinal or chest wall
        neoplasms, thymoma/thymic carcinomas, or thoracic metastases from cancers of non-thoracic
        origin.

        Patients must have an ECOG performance score of 0-2.

        Patients must be 18 years of age or older. Patients under 18 years of age may participate
        if the tissue acquisition is performed during a clinically indicated surgical procedure,
        and the sampling of tissue, blood and urine does not add risk to the clinically indicated
        procedures.

        Patients must be aware of the neoplastic nature of his/her illness. The patient or parent
        must be willing to sign an Informed Consent, and undergo endoscopic biopsies of tumor and
        adjacent normal tissues, and provide blood (30cc) and urine (100cc) samples to support
        ongoing laboratory research endeavors pertaining to the epigenetics of thoracic
        malignancies.

        EXCLUSION CRITERIA:

        Candidates who do not meet the inclusion criteria
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

        Evaluation by the Surgery and/or Liver Transplant Team has been performed and the patient
        is not considered a candidate for either "standard" therapy to target area (upper abdomen)

          -  Adequate liver function defined as:

               -  total bilirubin &lt; 3mg/dl, albumin &gt; 2.5 g/dl

               -  normal PT/PTT unless on anticoagulants

               -  mild elevation of liver enzymes acceptable (must be less than three times upper
                  limit of normal)

          -  Adequate renal function (creatinine &lt; 1.8 mg/dl or creatinine clearance  50 ml/min)

          -  Adequate bone marrow reserve:

               -  ANC count  1500 mm3

               -  Platelets  50,000/mm3

               -  Hemoglobin &gt; 9 g/dL

        NOTE:  Lab values must be obtained within 2 weeks prior to being registered for protocol
        therapy.

        Exclusion Criteria:

          -  No history of systemic lupus erythematous, rheumatoid arthritis, systemic sclerosis
             or scleroderma

          -  No chemotherapy within 14 days before radiotherapy (chemotherapy may cause transient
             hepatitis with hepatomegaly)

          -  No subsequent chemotherapy planned within 2 weeks of radiotherapy

          -  No active liver infection

          -  No acute Hepatitis. Definition of active disease:

               -  Hepatitis A: Acute hepatitis determined by presence of Anti-HAV-
                         IgM

               -  Hepatitis B:

                    1. HBsAg (HB surface Antigen): present in patients with acute and chronic
                       hepatitis

                    2. HBV DNA present in patients with active viral replication in amounts
                       greater than 100,000 copies

                    3. HBeAg is present in wild type HBV infection and suggests active replication

                    4. Anti-HBs: Antibody against HBsAg appears after HBV infections and confers
                       immunity

                    5. Anti-HBc-IgM: Antibody against HBcAg, fraction IgM, present in acute
                       infection and often could be detected during periods of high viral
                       replication in chronic disease

                    6. Anti-HBc-IgG: is present in chronic disease
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Diagnosis of a hematologic malignancy of 1 of the following high-risk types:

               -  Acute lymphoblastic leukemia

               -  Acute myeloid leukemia

               -  Chronic myelogenous leukemia

               -  Chronic lymphocytic leukemia

               -  Myelodysplastic syndromes

               -  Myeloproliferative disorder

               -  Multiple myeloma

               -  Plasma cell dyscrasias

               -  Non-Hodgkin lymphoma

               -  Hodgkin disease

        PATIENT CHARACTERISTICS:

        Performance status

          -  Karnofsky 50-100%

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  No liver failure

          -  No cirrhosis with evidence of portal hypertension

          -  No alcoholic hepatitis

          -  No esophageal varices

          -  No chronic hepatitis

          -  No other liver disease

        Renal

          -  Not specified

        Cardiovascular

          -  Left Ventricular Ejection Fraction (LVEF) &gt; 35%

          -  No symptomatic coronary artery disease or cardiac failure requiring therapy

        Pulmonary

          -  Diffusing capacity of lung for carbon monoxide (DLCO) &gt; 30%

          -  Total lung capacity &gt; 30%

          -  Forced expiratory volume in 1 second (FEV_1) &gt; 30%

          -  No supplementary continuous oxygen

        Other

          -  HIV negative

          -  No active nonhematologic malignancy except localized skin cancer

          -  No overt organ dysfunction

        PRIOR CONCURRENT THERAPY:

          -  Not specified
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  80 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Pathological and radiographic documented stage IIIB/IV NSCLC (squamous,
             adenocarcinoma, bronchioloalveolar, large cell, undifferentiated or not otherwise
             specified non-small cell carcinoma) diagnosed less than two months prior to
             randomization. Patients must have ECOG performance status of 0-1 and life expectancy
             &gt;3 months.

          -  Patients must never have been diagnosed with any malignancy other than the current
             NSCLC, except for non-metastatic non-melanoma skin cancer, or cancer in situ of the
             cervix.

          -  Patients must be &gt;18 years of age.

          -  Patients must demonstrate the ability and willingness to eat solid food and
             SV/placebo.

          -  Patients must demonstrate the ability and willingness to give informed consent.

          -  Patients must demonstrate the ability and willingness to follow the study
             requirements.

        Exclusion Criteria:

          -  Laboratory criteria for exclusion within 14 days prior to randomization.

               -  Liver function: bilirubin &gt; 1.5x upper limit of normal (ULN) and SGOT (AST) &gt;
                  2.5x ULN.

               -  Renal function: Serum creatinine &gt;1.5x ULN

               -  Bone marrow function: white blood cell (WBC) &lt; 4,000/l; platelet count &lt;
                  100,000 mm3; neutrophil count &lt; 1,500/mm3.

               -  Hemoglobin &lt;9 gm/dl for males; &lt; 8.5 gm/dl for females.

          -  Unexplained temperature &gt; 38.5 C for any 7 consecutive days or chronic diarrhea
             defined as &gt; 3 stools/day persisting for 15 consecutive days, within the 30 days
             prior to randomization.

          -  Prior chemotherapy within 5 years.

          -  Prior radiation to the area of measurable or active tumor.

          -  Significant cardiac disease (i.e. uncontrolled high blood pressure, unstable angina,
             congestive heart failure, myocardial infarction within the previous year) or serious
             cardiac arrhythmia requiring medication.

          -  Evidence of clinically significant neuropathy (&gt; Grade 1) by physical exam.

          -  Patients must not be pregnant or breast-feeding.  Female patients of child-bearing
             potential must have a negative pregnancy test performed within 72 hours prior to
             randomization.  Women of child-bearing potential must agree not to become pregnant
             while participating in the study.

          -  Active acute infection, except for Herpes viruses (cytomegalovirus [CMV], Epstein
             Barr virus [EBV], herpes zoster virus [HZV], herpes simplex virus 1 [HSV 1]).

          -  A serious underlying medical condition other than NSCLC such that life expectancy is
             less than 2 years.

          -  Psychiatric illness that may affect the patient's compliance with the treatment.

          -  Current use of illicit drugs, glucocorticoids other than those necessary for
             concurrent radiotherapy, adrenal failure or septic shock, or other immune-suppressing
             or immune-modulating drugs.  Glucocorticoids for anti-emetic prophylaxis and therapy
             should only be used as a last resort.

          -  A known allergy to one or more components of SV, namely soy beans, mushrooms, mung
             beans, red dates, scallion, garlic, lentil beans, leek, hawthorn fruit, onions,
             ginseng, angelica root, Chinese licorice, dandelion root, Senegal root, ginger,
             olives, sesame seed and parsley.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Low risk patients: Gleason score less than or equal to 6, PSA less than or equal to
             10 ng/mL and clinical stage T1b-T2b (2002 AJCC.

          -  An enzymatic prostatic acid phosphatase must be obtained prior to implantation.

          -  No pelvic external beam radiation therapy for either prostate cancer or other
             malignancies.

          -  Androgen deprivation therapy less than 4 month duration for size reduction is
             allowable.

          -  No surgical staging for prostate cancer.

          -  A minimum of 5 year life expectancy.

          -  No other invasive cancer diagnosis other than non-melanoma skin cancer within the
             last 5 years.

        Exclusion Criteria:

          -  Exclusion criteria will be limited to patients who do not meet the above eligibility
             criteria.
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   All patients (male or female) with Lung cancer.
  </textblock>
 </study_pop>
 <sampling_method>
  Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Potential participants in the Lung Cancer Case Registry will be all patients
             diagnosed or evaluated for possible treatment of lung cancer at the CRTC and NMVHCS.
             Recruiting will primarily be performed through the Multidisciplinary Chest Clinics
             held weekly at each hospital. These clinics are staffed by the Principal Investigator
             (PI) and Reza Mehran, MD, a thoracic surgeon at both hospitals and a co-investigator
             on this submission. Approximately 90% of all lung cancer cases diagnosed at the
             NMVHCS, and a somewhat smaller proportion of cases treated in the Cancer Center, are
             seen in these clinics. Additional cases will be identified through review of new
             patient visits to each hospital with a diagnosis of lung cancer; Drs. Crowell and
             Mehran also maintain weekly contact with pathology and oncology services at both
             facilities, which will facilitate case identification at NMVHCS and University
             Hospital. Finally, patient contact records will be correlated with tumor registry
             records at both hospitals, which will identify any cases not captured through the
             above mechanisms. Although these cases may be identified several weeks after initial
             diagnosis, all attempts will still be made to contact the patient and family for
             enrollment into the registry. Most Spanish-speaking patients served by the CRTC and
             the NMVHCS are bilingual, and a language barrier has not been a problem in other
             similar studies conducted by the PI. However, Spanish-speaking personnel are
             available to obtain consent and answer any questions if necessary.

        Exclusion Criteria:

          -  Patients will be excluded if they cannot provide written informed consent.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. histologically proven adenocarcinoma of stomach

          2. Borrmann type 4 or large (&gt;=8 cm) type 3

          3. no evidence of distant metastasis including liver(M0)

          4. no evidence of para-aortic and/or retropancreatic lymph node metastasis(N0-2)

          5. no peritoneal metastasis and negative peritoneal lavage cytology (PLS) with
             laparoscopic confirmation

          6. no involvement of the esophagus with &gt; 3cm

          7. an age of 20-75 years

          8. an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1

          9. no prior chemotherapy, radiotherapy for any malignancy

         10. no prior surgery for gastric cancer except for endoscopic membrane resection (EMR)

         11. no breeding from primary tumor or gastrointestinal stenosis

         12. sufficient oral intake

         13. adequate organ function

         14. written informed consent

        Exclusion Criteria:

          1. synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ

          2. pregnant or breast-feeding women

          3. severe mental disease

          4. systemic administration of corticosteroids, flucytosine, phenytoin or warfarin

          5. other severe complications such as paralytic ileus, intestinal  pneumonitis,
             pulmonary fibrosis, or ischemic heart disease

          6. myocardial infarction within six disease-free months
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  20 Years
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Diagnosis of Rectal Adenocarcinoma

          -  Location of Tumor less than 7cm from Anal Verge

        Exclusion Criteria:

          -  Pregnancy or Nursing

          -  Metastatic Disease (Stage IV disease)

          -  Previous treatment for any cancer

          -  Patients clinically unable to receive neoadjuvant chemoradiotherapy

          -  Hypersensitivity to 18FDG
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Diagnosis of 1 of the following hematologic malignancies:

               -  Acute myeloid leukemia (AML) with or without history of myelodysplastic
                  syndromes, meeting 1 of the following criteria:

                    -  In first complete remission (CR-1) with unfavorable cytogenetics and/or
                       achieved CR-1 after  1 course of induction therapy

                    -  Secondary or treatment-related AML

                    -  In second or further complete remission

                    -  Relapsed with  20% blasts in the bone marrow AND no circulating blasts

               -  Acute lymphoblastic leukemia (ALL), meeting 1 of the following criteria:

                    -  In CR-1 with unfavorable cytogenetics or elevated WBC at presentation OR
                       failed to achieve CR-1 after  4 weeks of induction therapy

                    -  In second or further complete remission

                    -  Relapsed with  20% blasts in the bone marrow AND no circulating blasts

               -  Other acute leukemic variants allowed at the discretion of the principal
                  investigator

               -  Chronic myelogenous leukemia (CML), meeting 1 of the following criteria:

                    -  In first chronic phase AND refractory to or unable to tolerate imatinib
                       mesylate

                    -  In second or further chronic phase

                    -  In first or second accelerated phase

               -  Myelodysplastic syndromes with intermediate 2- or high-risk International
                  Prognosis Scoring System (IPSS) score, including any of the following:

                    -  Refractory anemia

                    -  Refractory anemia with excess blasts

                    -  Chronic myelomonocytic leukemia

               -  Myeloproliferative disorders with poor prognosis, including any of the
                  following:

                    -  Myelofibrosis with myeloid metaplasia

                         -  No  grade 3 myelofibrosis

                    -  Atypical CML

                    -  Juvenile myelomonocytic leukemia

               -  Other clonal hemopathies with an accepted poor prognosis

               -  Multiple myeloma with chromosome 13 abnormalities and/or progression after prior
                  autologous bone marrow transplantation (BMT)

               -  Chronic lymphocytic leukemia, meeting 1 of the following criteria:

                    -  Primary refractory OR relapsed and refractory disease (less than partial
                       remission)

                    -  Relapsed twice on or after prior chemotherapy

               -  Lymphoma, meeting both of the following criteria:

                    -  Hodgkin's or non-Hodgkin's lymphoma in &gt; CR-1 OR failed primary induction

                    -  Chemosensitive disease, defined as &gt; 50% reduction in mass size after the
                       most recent chemotherapy

          -  Must meet  1 of the following criteria:

               -  Over 45 years of age

               -  Has undergone prior autologous or allogeneic BMT

               -  Charlson^ comorbidity score  2

          -  Must have a high degree of tumor control (salvage therapy allowed)

          -  At high risk for treatment-related mortality with a myeloablative conditioning
             regimen

          -  No massive splenomegaly

               -  Patients may become eligible after splenectomy or radiotherapy to the spleen

          -  No 5/6 or 6/6 HLA-matched related donor available

          -  No well-matched (i.e.,  9/10 HLA match by high-resolution typing) unrelated donor
             available

        PATIENT CHARACTERISTICS:

        Performance status

          -  Not specified

        Life expectancy

          -  Not specified

        Hematopoietic

          -  See Disease Characteristics

        Hepatic

          -  Bilirubin  2 times upper limit of normal (ULN)

          -  Transaminases  4 times ULN (unless due to underlying disease)

        Renal

          -  Creatinine clearance  50 mL/min

        Cardiovascular

          -  Ejection fraction  30%

        Pulmonary

          -  DCLO  35%

        Other

          -  Negative pregnancy test

          -  No uncontrolled viral, bacterial, or fungal infection

          -  HIV negative

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  See Disease Characteristics

        Chemotherapy

          -  See Disease Characteristics

        Radiotherapy

          -  See Disease Characteristics

        Other

          -  At least 3 months since prior immunosuppressive therapy

          -  At least 10 days since prior salvage therapy for patients not in at least morphologic
             or radiologic complete remission
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients must be &lt;45 years of age with a diagnosis of Fanconi anemia with:

               -  Biallelic BRCA2 mutations, or

               -  Aplastic anemia, or advanced myelodysplastic syndrome (MDS) (MDS with 5%
                  blasts), or acute leukemia who are ineligible for total body irradiation.
                  Aplastic anemia is defined as having at least one of the following (with or
                  without cytogenetic abnormalities): platelet count &lt;20 * 10^9, - absolute
                  neutrophil count (ANC) &lt;5 * 10^8/L, - Hgb &lt;8 g/dL /

          -  Patients must have an HLA-A, B, DRB1 identical or 1 antigen mismatched related or
             unrelated BM donor or have an HLA-A, B, DRB1 identical, 1 antigen or 2 antigen
             mismatched related or unrelated umbilical cord blood (UCB) donor. Patients and donors
             will be typed for HLA-A and B using serological level typing and for DRB1 using high
             resolution molecular typing.

          -  Adequate major organ function including:

               -  Cardiac: ejection fraction &gt;45%

               -  Hepatic: no clinical evidence of hepatic failure (e.g. coagulopathy, ascites, no
                  cirrhosis)

               -  Karnofsky performance status &gt;70% or Lansky &gt;50%

          -  Women of child bearing potential must be using adequate birth control and have a
             negative pregnancy test.

        Exclusion Criteria:

          -  Active CNS leukemia at time of HSCT.

          -  Active uncontrolled infection within one week of hematopoietic stem cell transplant
             (HSCT).

          -  Pregnant or lactating female.

        Donor Inclusion Criteria:

          -  Donor must be in good health based on review of systems and results of physical
             examination.

          -  Donor must have a normal hemoglobin, white count, platelet count and partial
             thromboplastin time (PTT), and a negative diepoxybutane (DEB) test.

          -  HIV-NAT negative, HTLV-1, HTLV-2 negative, Hepatitis B and C negative.

          -  Female donors of childbearing potential must have a negative pregnancy test.

          -  Unrelated donors must agree to peripheral blood stem cell (PBSC) donation

        Donor Exclusion Criteria:

          -  Donor is a lactating female.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  44 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients seeking surgical resection of their esophagus at the University of Pittsburgh
        Medical Center.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients scheduled for MIE (Minimally Invasive Esophagectomy)

          -  Patients scheduled for open esophagectomy

          -  Signed informed consent

        Exclusion Criteria:

          -  Patients who are unable to comprehend or complete the QOL instruments.

          -  Patients less than 18 years of age.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Eligible patients will be selected from the investigator's clinic.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Known or suspected esophageal or gastroesophageal junction malignancy

          -  Known Barrett's metaplasia

          -  Clinical management of symptomatic gastroesophageal reflux disease

          -  Achalasia

          -  Hiatal hernia

        Exclusion Criteria:

          -  Elevated pre-operative bloodwork will not have the additional biopsies taken.

          -  Platelet count less than 150,000, partial thromboplastin time (PTT) of 50 or above,
             and/or International Normalized Ratio (INR) of 1.8 or above will not have the
             additional biopsies taken.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Any patient that meets the eligibility criteria and maybe attending a genetics clinic at a
        number of international centres that have gone through ethical approval.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Male carriers of a known pathogenic BRCA1/2 mutations or men testing negative for a
             known BRCA1/2 mutation in their family

          -  Aged between 40-69 years old

          -  WHO performance status 0-2

          -  No previous history of prostate cancer

          -  No previous prostate biopsy for raised PSA

          -  Absence of any psychological, familial, sociological or geographical situation
             potentially hampering compliance with the study protocol and follow-up schedule

          -  Fully informed, written consent according to ICH/EU GCP and national/local
             regulations before subject registration.

        Exclusion Criteria:

          -  Previous cancer with terminal prognosis of less than 5 years

          -  Previous prostate cancer
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  40 Years
 </minimum_age>
 <maximum_age>
  69 Years
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   -  Group 1 (experimental group): 250 lung cancer patients undergoing surgery, with
             13-C-glucose infusion);

          -  Group 2 (control group):  250 lung cancer patients undergoing surgery, without
             13-C-glucose infusion); and

          -  Group 3 (healthy subjects): 250 subjects to provide 1 blood sample and 1 urine
             sample.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Lung Cancer Patients (Groups 1 &amp; 2)

        Inclusion Criteria:

          -  patients with suspected, clinically diagnosed, or histologically diagnosed lung
             cancer. Occasionally, other cancers (including metastatic cancers to the lung) may be
             resected for the study as negative controls for NSCLC, as warranted by the
             particulars of the case.

          -  patients must have general medical conditions to allow them to undergo surgical
             resection of their primary tumor

        Exclusion Criteria:

          -  history of diabetes for the experimental group (surgery + glucose); patients with a
             history of diabetes are allowed in the control group (surgery/no glucose)

          -  known hepatitis C or HIV (AIDS)

        Healthy Subjects (Group 3)

        Inclusion Criteria:

          -  at least 30 years of age

          -  preferably be fasting for 12 hours (minimum 8 hours) prior to enrollment

        Exclusion Criteria:

          -  prior history of diagnosed lung cancer

          -  known hepatitis C or HIV (AIDS)
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Suspected or histologically documented new non-small cell carcinoma that have agreed
             to undergo a thoracotomy for segmentectomy, lobectomy, bilobectomy or pneumonectomy
             as recommended by their thoracic surgeon for treatment

          -  Surgically resectable lung cancer

          -  N2 lymph nodes negative on PET scan or mediastinoscopy

          -  Age &gt; or equal to 18 years of age

          -  Men, women of non-child bearing age or women with a negative pregnancy test

        Exclusion Criteria:

          -  Patient does not want to undergo subsequent surgical resection

          -  Medical condition such as uncontrolled infection or cardiac disease that, i the
             opinion of the treating surgeon, makes resection unreasonably hazardous for the
             patient.

          -  T4 or N2 disease

          -  Pre-operative spirometry that suggests they cannot undergo resection of their primary
             tumor by segmentectomy, lobectomy, bilobectomy, or pneumonectomy

          -  Iodide or seafood allergy

          -  Pregnant or lactating women
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Male and female adults over 18 years old

          -  At least one adenocarcinoma of colon and/or rectum, histologically proven.

          -  No local complication at the time of surgery (no occlusion, no sub-occlusion, no
             massive hemorrhage, no abscesses or local invasion)

          -  At least one hepatic metastasis which R0 resection is possible through a conventional
             simple resection

          -  Informed written consent.

        Non inclusion criteria:

          -  Heart, Respiratory or Renal failure

          -  Physical or psychological dependence

          -  Chronic liver disease

          -  Extra-hepatic metastases

        Exclusion Criteria (at time of surgery)

          -  Localized or diffuse peritoneal carcinomatosis

          -  Non resectable lymph node metastases

          -  Colorectal or hepatic tumour extension towards abdominal wall and/or adjacent organ
             making liver R0 resection impossible immediately

          -  Other hepatic lesions diagnosed with ultrasound making liver R0 resection impossible
             immediately
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Positive HIV serology (previous records acceptable)

          -  Diagnosis of Primary Central Nervous System Lymphoma

          -  Confirmed histopathologic diagnosis by NCI Laboratory of Pathology

          -  If tissue diagnosis is not feasible for any reason, such as undue risk to the patient
             to acquire tissue diagnosis, the following will be accepted as confirmed AR-PCNSL
             diagnosis:

          -  Positive brain FDG-PET and

          -  EBV detected in the CSF using PCR

          -  Age 18 years or greater

          -  ECOG performance less than or equal to 0-4

          -  Ability to understand and willing to provide informed consent

          -  If patient unable to understand informed consent, a previously designated durable
             power of attorney for healthcare or an individual with legal authority may substitute
             in this capacity

          -  Assignment of a durable power of attorney for healthcare if not already done

        EXCLUSION CRITERIA:

          -  Prior therapy for CNS lymphoma

          -  Steroids not an exclusion

          -  Evidence of lymphoma outside of the central nervous system

          -  Ocular involvement will not exclude

          -  Multidrug resistant HIV not amenable to long-term suppression based on either or
             both:

          -  Clinical history of poor adherence to multiple antiretroviral drugs deemed sufficient
             to render effective HIV control unattainable;

          -  HIV mutational analysis (genotyping and/or phenotyping) that reveals high-level
             resistance to more than 1 class of anti-HIV drugs such that a combination regimen
             comprised of agents from at least two drug classes can not be devised to suppress HIV
             long-term.

          -  Refusal to adhere to HAART

          -  Concurrent malignancy other than Kaposi sarcoma, resectable squamous cell or basal
             cell skin cancer, or T1 anal cancer amenable to surgical resection.

          -  Heart failure, Class IV by New York Heart Association criteria

          -  Chronic Liver Disease, Child-Pugh class B or C

        Pregnancy

          -  Refusal to practice contraception during chemotherapy.

          -  Any condition or set of circumstances that the Principal Investigator or Protocol
             Chair interprets as creating undue risk to the patient by participating on this study
             or would make the patient unlikely to comply with the study.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   HIGH-RISK NEWLY DIAGNOSED NON-METASTATIC NODE-NEGATIVE DISEASE

        Both:

        At least two of:

          -  Stage T3/4, PSA40ng/ml or Gleason sum score 8-10

          -  Intention to treat with radical radiotherapy (unless there is a contra-indication;
             exemption can sought in advance of consent, after discussion with MRC CTU)

        OR NEWLY DIAGNOSED METASTATIC OR NODE-POSITIVE DISEASE

        At least one of:

          -  Stage Tany N+ M0

          -  Stage Tany Nany M+

        OR PREVIOUSLY TREATED WITH RADICAL SURGERY AND/OR RADIOTHERAPY, NOW RELAPSING1

        At least one of:

          -  PSA 4ng/ml and rising with doubling time less than 6 months

          -  PSA 20ng/ml

          -  N+

          -  M+

        AND FOR ALL PATIENTS I. Histologically confirmed prostate adenocarcinoma

        II. Intention to treat with long-term androgen deprivation therapy

        III. Fit for all protocol treatment2 and follow-up, WHO performance status 0-23

        IV. Have completed the appropriate investigations prior to randomisation

        V. Adequate haematological function: neutrophil count &gt;1.5x109/l and platelets &gt;100x109/l

        VI. Estimated creatinine clearance &gt;30ml/min

        VII. Serum potassium 3.5mmol/L

        VIII. Written informed consent

        IX. Willing and expected to comply with follow-up schedule

        X. Using effective contraceptive method if applicable

        PATIENT EXCLUSION CRITERIA Patients must not fulfil any of the criteria, below. I. Prior
        systemic therapy for locally advanced or metastatic prostate cancer except as listed in
        Section 4.1.3

        II. Metastatic brain disease or leptomeningeal disease

        III. Abnormal liver functions consisting of any of the following:

          -  Serum bilirubin 1.5 x ULN (except for patients with Gilbert's disease, for whom the
             upper limit of serum bilirubin is 51.3mol/l or 3mg/dl)

          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) 2.5 x ULN

        IV. Any other previous or current malignant disease which, in the judgement of the
        responsible physician, is likely to interfere with STAMPEDE treatment or assessment

        V. Patients with contra-indications to prednisolone, including active peptic ulceration or
        a history of gastrointestinal bleeding

        VI. Patients with active inflammatory bowel disease

        VII. Symptomatic peripheral neuropathy grade  (NCI CTC)

        VIII. Any surgery (e.g. TURP) performed within the past 4 weeks

        IX. Patients with significant cardiovascular disease such that, in the investigator's
        opinion, the patient is unfit for any of the study treatments. This might include:

          -  Severe/unstable angina

          -  Myocardial infarction less than 6 months prior to randomisation

          -  Arterial thrombotic events less than 6 months prior to randomisation

          -  Clinically significant cardiac failure requiring treatment (NYHA II-IV)

          -  Cerebrovascular disease (e.g. stroke or transient ischaemic episode) less than 2
             years prior to randomisation

          -  Patients with uncontrolled hypertension defined as systolic BP greater or equal than
             160 mmHg or diastolic BP greater or equal than 95 mmHg

        X. Patients receiving treatment with drugs known to induce CYP3A4 (including phenytoin,
        carbamazepine, Phenobarbital)

        XI. Prior exposure to abiraterone

        XII. Prior exposure to enzalutamide

        XIII. Prior chemotherapy for prostate cancer

        XIV. Prior therapy with zoledronic acid or other bisphosphonates other than treatment for
        hypercalcaemia or low bone density

        XV. Prior exposure to policy of long-term hormone therapy before randomisation (unless as
        described in Section 4.4.2)

        XVI. History of seizure including any febrile seizure, loss of consciousness, or transient
        ischaemic attack within 12 months of randomisation or any condition that may pre-dispose
        to seizure (e.g., prior stroke, brain arteriovenous malformation, head trauma with loss of
        consciousness requiring hospitalization)

        XVII. Unexplained history of loss of consciousness within 12 months of randomisation

        XVIII. Operation of heavy machinery during treatment

        SELECTION CRITERIA FOR COMPARISON OF RESEARCH (M1) RT FOR METASTATIC DISEASE

        All patients meeting criteria in Section 4.1 and 4.2 are eligible for the trial, but not
        all can be allocated to the research (M1) radiotherapy arm. The selection criteria for
        this "RT to the prostate" comparison are:

          -  Newly-diagnosed prostate cancer

          -  Demonstrable M1 disease

          -  No contraindication to radiotherapy e.g. no previous pelvic radiotherapy and no
             history of inflammatory bowel disease

          -  No previous radical prostatectomy

        Any patients meeting these criteria will have a chance to be allocated to Arm H.
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   women diagnosed with invasive breast cancer &lt; 40 years of age
  </textblock>
 </study_pop>
 <sampling_method>
  Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Women diagnosed with invasive breast cancer 40 years of age or younger. If their
             parents are living, the parents are also invited to participate, regardless of their
             history of cancer.

        Exclusion Criteria:

          -  Women diagnosed with in-situ breast cancer.
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  80 Years
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Histologically confirmed aggressive B-cell non-Hodgkin's lymphoma, including the
             following subtypes:

               -  Grade 3 follicular lymphoma

               -  Diffuse B-cell lymphoma, including diffuse large cell lymphoma with the
                  following variants:

                    -  Centroblastic

                    -  Immunoblastic

                    -  Plasmablastic

                    -  Anaplastic large cell

                    -  T-cell-rich B-cell lymphoma

               -  Primary effusion lymphoma

               -  Intravascular B-cell lymphoma

               -  Primary mediastinal B-cell lymphoma

               -  Burkitt's or Burkitt-like lymphoma

               -  Mantle cell lymphoma (blastoid)

               -  Aggressive marginal zone lymphoma (monocytoid)

          -  Previously untreated disease

          -  CD20-positive disease

          -  International prognostic index (IPI) score 0 or 1 (age-adjusted)

               -  Only patients with bulky disease, as defined by largest single or conglomerate
                  tumor  7.5 cm in diameter, are allowed to have an IPI score of 0

          -  No mucosa-associated lymphoid tissue (MALT) lymphoma

          -  No CNS involvement of lymphoma (intracerebral, meningeal, or intraspinal)

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Platelet count  100,000/mm

          -  WBC  2,500/mm

          -  No known hypersensitivity to the study medications

          -  No known HIV-positivity

          -  No active hepatitis infection

          -  Not pregnant or lactating

          -  Negative pregnancy test

          -  No other malignancy within the past 5 years except carcinoma in situ or basal cell
             skin cancer

          -  No impaired left ventricular function

          -  No severe cardiac arrhythmias

          -  No other impaired organ function

          -  No other serious disorder

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy or radiotherapy

          -  No prior immunosuppressive treatment with cytostatics

          -  No concurrent participation in other treatment studies
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  60 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Histologically confirmed aggressive B-cell non-Hodgkin's lymphoma, including the
             following subtypes:

               -  Grade 3 follicular lymphoma

               -  Diffuse B-cell lymphoma, including diffuse large cell lymphoma with any of the
                  following variants:

                    -  Centroblastic

                    -  Immunoblastic

                    -  Plasmablastic

                    -  Anaplastic large cell

                    -  T-cell-rich B-cell lymphoma

               -  Primary effusion lymphoma

               -  Intravascular B-cell lymphoma

               -  Primary mediastinal B-cell lymphoma

               -  Burkitt's or Burkitt-like lymphoma

               -  Mantle cell lymphoma (blastoid)

               -  Aggressive marginal zone lymphoma (monocytoid)

          -  Previously untreated disease

          -  CD20-positive disease

          -  International Prognostic Index (IPI) score 0

          -  No bulky disease

               -  Largest single or conglomerate tumor &lt; 7.5 cm in diameter

          -  No mucosa-associated lymphoid tissue (MALT) lymphoma

          -  No CNS involvement of lymphoma (intracerebral, meningeal, or intraspinal)

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  Platelet count  100,000/mm^3

          -  WBC  2,500/mm^3

          -  Lactate dehydrogenase normal

          -  Not pregnant or lactating

          -  Fertile patients must use effective contraception during and for 1 year after study
             participation

          -  Negative pregnancy test

          -  No known hypersensitivity to the study medications

          -  No known HIV-positivity

          -  No active hepatitis infection

          -  No impaired left ventricular function

          -  No severe cardiac arrhythmias

          -  No other impaired organ function

          -  No other serious disorder

          -  No other malignancy within the past 5 years except carcinoma in situ or basal cell
             skin cancer

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy or radiotherapy

          -  No prior immunosuppressive treatment with cytostatics

          -  No planned radiotherapy to extranodal involvement

          -  No concurrent participation in other treatment studies
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  60 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Eligible patients will be selected from investigator's clinic.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Histologic confirmation of non-small cell lung cancer, mesothelioma or a radiographic
             lesion highly suspicious for malignancy

          -  Written informed consent.

          -  Must be scheduled for a biopsy or surgical resection

        Exclusion Criteria:

          -  Subjects with any "other" prior cancer (other than lung) within 5 years of date of
             surgery are NOT eligible (unless there is preoperative pathologic confirmation that
             the lung mass is a second primary cancer)

          -  Subjects with any type of lung cancer other than non-small cell lung cancer(NSCLC)
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  85 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   All patients (male, female, any ethnic background) with rectal (inferior margin of the
        tumor less than 15cms from anal verge by rigid sigmoidoscopy or below the level of S1-2 at
        operation) or sigmoid-rectal junction carcinomas confirmed by sigmoidoscopy and pathologic
        diagnosis of biopsy sample.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Must have rectal or sigmoid-rectal junction adenocarcinoma confirmed by sigmoidoscopy
             and pathologic diagnosis of biopsy sample

               -  Inferior margin of the tumor less than 15 cm from anal verge by rigid
                  sigmoidoscopy or below the level of S1-2 at surgery

          -  Candidate for chemotherapy and radiotherapy, as defined by any of the following:

               -  Tumor staged as T3 or N1-2 by rectal sonography

               -  Tumor occupying &gt; 40% of circumference of rectum

               -  Tumor fixed to extra colonic structures as determined by digital rectal
                  examination

               -  Tumor &lt; 5 cm from sphincter mechanism

               -  Patient has inoperable disease and is being treated for palliation

               -  Pelvic or anastomotic recurrences of previously resected rectal cancer

          -  Planning to undergo chemotherapy and radiotherapy

          -  No sigmoid carcinoma (carcinoma proximal to the pelvic peritoneal reflection)

        PATIENT CHARACTERISTICS:

          -  Not pregnant

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Children and adolescents aged 1 to 17 years at diagnostic

          -  Documented Ph+ ALL

          -  Eligibility for the current local prospective therapeutic study of childhood ALL

          -  Informed consent given by the parents or by legal guardian

        Exclusion Criteria:

          -  Abnormal hepatic functions

          -  Abnormal renal functions

          -  Active systemic bacterial, fungal or viral infection
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  1 Year
 </minimum_age>
 <maximum_age>
  18 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Individuals with Barrett's esophagus or adenocarcenoma of the esophagus whose medical care
        is at the participating institutions, are referred from outside institutions, or who
        contact the participating institutions.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Eligible cases will be defined as those patients and their family members who meet the
        following criteria:

          -  Barrett's esophagus confirmed by review of pathology and endoscopy report or
             adenocarcinoma of the esophagus or family members of person with Barrett's esophagus
             or adenocarcinoma of the esophagus.

          -  Male or female age 18 or older at time of enrollment or male or female less than 18
             years of age at time of enrollment with parental consent.

          -  Ability to give informed consent, if patient is age 18 or older.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   All female patients undergoing hysterectomy at the Brown Cancer Center
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  all female patients older than 18 years of age who are:

          -  undergoing hysterectomy

          -  excisions of cervical dysplasia and/or venereal warts

          -  therapeutic excisional surgeries for any benign or malignant gynecologic disease

          -  paracentesis procedure for the symptomatic relief of ascites fluid accumulation
             (distention)

        Exclusion Criteria:

          -  women who are pregnant

          -  women who are HIV or Hepatitis C positive

          -  women who are enrolled in a current clinical trial utilizing the specimens
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Self-identified women at high risk for development of breast cancer
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  women with at least 2 times the normal risk of developing breast cancer

          -  between the ages of 30-65 (or within 10 years of youngest age at diagnosis in first
             degree relative)

          -  greater than six months from ingestion of antihormonal therapy

          -  greater than 1 year from pregnancy, lactation, or chemotherapy

          -  willing to have a mammogram within six months prior to RPFNA

          -  willing to discontinue NSAIDS or herbal supplements

          -  willing to have blood drawn

        Exclusion Criteria:

          -  no metastatic malignancy of any kind

          -  no breast implants or tram flap reconstructions

          -  no radiation to both breasts

          -  no women who have a current mammogram or clinical breast exam suspicious for cancer
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  30 Years
 </minimum_age>
 <maximum_age>
  65 Years
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   INCLUSION CRITERIA:

          -  Signed written informed consent form

          -  Histopathologic confirmation of intermediate- or high-grade primary central nervous
             system lymphoma (PCNSL) as documented by brain biopsy or cytology (analysis from
             cerebrospinal fluid [CSF] or vitrectomy

          -  Diagnosed within the past 90 days

          -  CD20-positive disease

          -  No radiographic signs of excessive intracranial mass effect with associated rapid
             neurologic deterioration and/or spinal block

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-3 OR Karnofsky PS
             40-100%

          -  Hematocrit  25% (transfusion allowed)

          -  WBC  2,500/mm^3

          -  Absolute granulocyte count  1,200/mm^3

          -  Platelet count  100,000/mm^3 (or  lower limit of normal)

          -  Creatinine clearance  50 mL/min (eligible for full-dose methotrexate)

          -  Creatinine clearance  30 mL/min (eligible for reduced-dose methotrexate and
             carboplatin)

          -  Bilirubin  2.0 times upper limit of normal

          -  Fertile patients must use effective contraception

          -  Other chemotherapy for PCNSL during the 90 days since diagnosis allowed

          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and at least 10
             days since prior methotrexate)

          -  Available for follow-up for at least one year after completion of treatment

        EXCLUSION CRITERIA:

          -  Prior cranial or spinal radiotherapy

          -  Systemic lymphoma

          -  Seropositive for HIV

          -  Seropositive for hepatitis B or hepatitis C

          -  Uncontrolled, clinically significant confounding medical conditions within the past
             30 days

          -  Pregnant or nursing

          -  Allergy to any of the study agents (rituximab, carboplatin, methotrexate, or sodium
             thiosulfate)

          -  If subject has Congestive Heart Failure (CHF), New York Heart Association class III
             or IV
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Age 18 or above

          2. Current smoker with a history of at least five cigarettes/day for the past year

          3. Motivated to quit within the next 30 days (preparation stage)

          4. Participants must provide a viable home address and a functioning home telephone
             number

          5. Can read and write in English

          6. Register "8" or more on a carbon monoxide breath test

          7. Provide viable collateral contact information

        Exclusion Criteria:

          1. Contraindication for nicotine patch use

          2. Regular use of tobacco products other than cigarettes (cigars, pipes, smokeless
             tobacco)

          3. Use of bupropion or nicotine patch replacement products other than the study patches

          4. Pregnancy or lactation

          5. Another household member enrolled in the study

          6. Active substance dependence (exclusive of nicotine dependence)

          7. Current psychiatric disorder; current use of psychotropic medication

          8. Participation in a smoking cessation program or study during the past 90 days
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   healthy subjects at risk for lung cancer and controls from community, private physician
        referrals, local trade unions, employee health fairs, word of mouth and print
        advertisements.

        patient referrals from physician outpatient offices and inpatients with CT findings
        suspicious for lung cancer.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Screening Cohort

               -  At high- or low-risk for lung cancer

               -  Smoking history  20 pack years*

                    -  With or without workplace exposure to asbestos

          -  NOTE: * Participants with &lt; 20 pack years of smoking are eligible if 50 years of age
             or older

          -  Rule-Out Lung cancer group

               -  Referred for evaluation of suspicious nodules with 1 of the following diagnoses:

                    -  Lung cancer

                    -  Nonmalignant nodules (control group)

        PATIENT CHARACTERISTICS:

          -  Not pregnant

          -  No prior malignancy except nonmelanoma skin cancer

        PRIOR CONCURRENT THERAPY:

          -  Not specified
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  50 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Primary care clinic.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. The diagnosis of cholangiocarcinoma will be established preoperatively by at least
             one of the following criteria:

               1. A positive brush cytology or biopsy result obtained at the time of
                  cholangiography;

               2. Fluorescence in situ hybridization demonstrating aneuploidy;

               3. A serum CA 19-9 value greater than 100 U/mL in the presence of a
                  radiographically characteristic malignant stricture in the absence of
                  cholangitis.

          2. Tumor is above the cystic duct and is unresectable.

          3. Patient is a suitable candidate for OLT and judged a good candidate for the study by
             a radiation oncologist, a medical oncologist, and the liver transplant team.

          4. Maximum Eastern Cooperative Oncology Group performance status of 2 and a minimum
             daily caloric intake of 1200kcal.

          5. No evidence of  metastatic disease.

          6. Between ages 18 - 70.

          7. Patient must provide written informed consent.

        Exclusion Criteria:

          1. Patients with intrahepatic metastasis

          2. Patients with uncontrolled infections (sepsis)

          3. Patients undergoing prior attempts at resection

          4. Prior treatment with either irradiation or chemotherapy for this disease

          5. Evidence of extrahepatic disease, including local lymph node metastasis (except
             peri-hilar nodes).

          6. History of another malignancy diagnosed within 5 years, excluding superficial skin
             and cervical cancers
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Male or female patients of  18 years of age.

          -  Patients with a documented histologic diagnosis of relapsed or refractory
             glioblastoma multiforme (GBM), anaplastic astrocytoma (AA) or anaplastic mixed
             oligoastrocytoma (AOA).  All patients will have samples of their tissue evaluated for
             EGFRvIII overexpression and PTEN loss.

          -  Patients with a histologically confirmed low grade brain tumor who relapse with an
             enhancing tumor on magnetic resonance imaging (MRI) can be evaluated for toxicity
             only.

          -  Patients must have at least one confirmed and evaluable tumor site.*

             *A confirmed tumor site is one which is biopsy-proven.  NOTE: Radiographic procedures
             (e.g., Gd-enhanced MRI or computed tomography [CT] scans) documenting existing
             lesions must have been performed within three weeks of treatment on this research
             study.

          -  Patients must have a Karnofsky performance status  60% (or the equivalent Eastern
             Cooperative Oncology Group [ECOG] level of 0-2) and an expected survival of  three
             months.

          -  No chemotherapy for six weeks prior to treatment under this research protocol and
                                                                               no external beam
             radiation for eight weeks prior to treatment under this research protocol.

          -  Patients must have adequate hematologic reserve with WBC  3000/mm3, absolute
             neutrophils  1500/mm3 and platelets  100,000/mm3.  Patients who are on Coumadin
             must have a platelet count of  150,000/mm3

          -  Pre-enrollment chemistry parameters must show: bilirubin &lt; 1.5X the institutional
             upper limit of normal (IUNL); AST or ALT &lt; 2.5X IUNL and creatinine &lt; 1.5X IUNL.

          -  Pre-enrollment coagulation parameters (PT and PTT) must be  1.5X the IUNL.

          -  Concomitant Medications:

               -  Growth factor(s): Must not have received within 1 week of entry onto this study.

               -  Steroids: Systemic corticosteroid therapy is permissible in patients with
                  centrail nervous system (CNS) tumors for treatment of increased intracranial
                  pressure or symptomatic tumor edema. Patients with CNS tumors who are receiving
                  dexamethasone must be on a stable or decreasing dose for at least 1 week prior
                  to study entry.

               -  Study Specific: Patients on enzyme-inducing anticonvulsants will be changed to
                  non-enzyme inducing anticonvulsants or will not be allowed on this study.
                  Patients receiving proton pump inhibitor or H2 blockers will not be allowed on
                  study. Patients taking antacids will be allowed on study although they should
                  not take the antacid for two hours before or two hours after taking erlotinib.

          -  Patients must agree to use a medically effective method of contraception during and
             for a period of three months after the treatment period.  A pregnancy test will be
             performed on each premenopausal female of childbearing potential immediately prior to
             entry into the research study.

          -  Patients should not have received a CYP3A4 inhibitor within 1 week of study entry and
             should not have received a CYP3A4 inducer within 4 weeks of study entry.

          -  Patients should not have received proton-pump inhibitors within 5 days of study entry
             or H2 blockers within 2 days of study entry.

          -  Patients on steroids must receive prophylaxis for Pneumocystis carinii pneumonia
             (PCP) with Bactrim, unless they have a history of allergy to sulfa drugs.

          -  Patients must be able to understand and give written informed consent.  Informed
             consent must be obtained at the time of patient screening.

        Exclusion Criteria:

          -  Previous treatment with Tarceva.

          -  Women who are pregnant or lactating.

          -  Women of childbearing potential and fertile men will be informed as to the
             potential risk of procreation while participating in this research trial and will be
             advised that they must use effective contraception during and for a period of three
             months after the treatment period.

          -  Patients with significant intercurrent medical or psychiatric conditions that would
                  place them at increased risk or affect their ability to receive or comply with
             treatment or post-treatment clinical monitoring.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

        Standard patients will be enrolled into Arms 1-6. High risk patients (transplant with
        aplasia) will be considered separately in Arm 7.

          -  Age and Graft criteria (all patients)

               -  Patient's &lt; or = 75 years old with a 5/6 or 6/6 related donor match are
                  eligible.

               -  Patient's &lt; or = 75 years who have a 7-8/8 HLA-A,B,C,DRB1 allele matched
                  unrelated volunteer marrow and/or peripheral blood stem cell (PBSC) donor match
                  are eligible.

          -  Disease Criteria (standard risk patients)

               -  Acute myelogenous leukemia

               -  Acute lymphocytic leukemia

               -  Chronic myelogenous leukemia all types except blast crisis (note treated blast
                  crisis in chronic phase is eligible).

               -  Non-Hodgkins lymphoma (NHL), Hodgkins, chronic lymphocytic leukemia, multiple
                  myeloma demonstrating chemosensitive disease

               -  Acquired bone marrow failure syndromes

               -  Myelodysplastic syndrome of all subtypes including refractory anemia (RA) or all
                  IPSS categories if severe pancytopenia, transfusion requirements not responsive
                  to therapy, or high risk cytogenetics. Blasts must be less than 5%. If &gt;5%
                  requires therapy (induction or Hypomethylating agents) pre-transplant to
                  decrease disease burden.

               -  Renal cell cancer,

               -  Chronic myeloproliferative disorder, i.e. myelofibrosis

          -  Disease Criteria (High risk patients on Arm 7)

               -  Patients with refractory leukemia or MDS may be taken to transplant in aplasia
                  after induction or re-induction chemotherapy or radiolabeled antibody. These
                  high risk patients will be analyzed separately in Arm 7.

          -  Adequate organ function and performance status (all patients)

        Exclusion Criteria:

          -  Pregnancy or breast feeding

          -  Evidence of HIV infection or known HIV positive serology

          -  Active serious infection

          -  Congenital bone marrow failure syndrome

          -  Previous irradiation that precludes the safe administration of an additional dose of
             200 cGy of total body irradiation (TBI)

          -  Chronic myelogenous leukemia (CML) in refractory blast crisis

          -  Intermediate or high grade NHL, mantle cell NHL, and Hodgkins disease that is
             progressive on salvage therapy. Stable disease is acceptable to move forward provided
             it is non-bulky.

          -  Multiple Myeloma progressive on salvage chemotherapy.

        DONOR ELIGIBILITY

          -  Related will undergo apheresis - if donor is unable to undergo apheresis, a bone
             marrow harvest is acceptable; unrelated volunteer donors must be able to undergo bone
             marrow harvest or apheresis.

          -  All donors must be able to give informed consent.

          -  Donors weighing less than 40 kg (children) will need evaluation by a pediatrician for
             suitability of the apheresis procedure. Informed consent must be obtained from parent
             or guardian as applicable for minors.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   INCLUSION CRITERIA:

          -  Signed written informed consent in accordance with institutional guidelines

          -  Histologically confirmed anaplastic oligodendroglioma or mixed glioma (i.e.,
             oligoastrocytoma) (At least 25% of oligodendroglial element required to qualify as a
             mixed tumor)

          -  Must have undergone prior surgical procedure, either complete resection, partial
             resection, or biopsy

          -  Prior treatment with temozolomide required and at least 28 days since prior
             temozolomide

          -  Radiation therapy: prior consultation OR at least 14 days since completion of
             radiation

          -  Age 18-75 years old

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 OR Karnofsky PS
              50%

          -  WBC  2,500/mm^3

          -  Absolute granulocyte count &gt; 1,500/mm^3

          -  Platelet count  100,000/mm^3

          -  Creatinine &lt; 1.5 times upper limit of normal (ULN)

          -  Bilirubin &lt; 1.5 times ULN

          -  Serum glutamic oxaloacetic transaminase/Serum glutamic-pyruvic transaminase
             (SGOT/SGPT) &lt; 2.5 times ULN

          -  Fertile patients must use effective contraception prior to and during study treatment

        EXCLUSION CRITERIA:

          -  Radiographic signs of excessive intracranial mass effect and/or spinal cord block

          -  Significant risk for general anesthesia

          -  Uncontrolled clinically significant confounding medical condition within the past 30
             days

          -  Pregnant, positive human chorionic gonadotropin (HCG) or lactating

          -  Contraindications to carboplatin, melphalan, etoposide phosphate, or sodium
             thiosulfate
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

        Age, Graft Cell Dose and Graft HLA Criteria

          -  Subjects must be &lt;70 years old. Subjects ages  70 and  75 may be eligible if they
             have a Co-Morbidity Scoring (HCT-CI) score  2.

          -  The UCB graft is matched at 4-6 HLA-A, B, DRB1 antigens with the recipient.

          -  Patients co-enrolled in MT-2006-01 Phase I Study of Infusion of Umbilical Cord Blood
             Derived CD25+CD4+ T-Regulatory (Treg) Cells after Non-Myeloablative Cord\Blood
             Transplantation will receive grafts composed of 2 UCB units.

        Disease Criteria:

          -  Acute Leukemias:

               -  Acute myeloid leukemia: high risk complete remission 1 (CR1) (as evidenced by
                  preceding myelodysplastic syndrome (MDS), high risk cytogenetics such as those
                  associated with MDS or complex karyotype, &gt; 2 cycles to obtain CR or
                  erythroblastic and megakaryocytic); second or greater CR.

               -  Acute lymphoblastic leukemia/lymphoma: high risk CR1 as evidenced by high risk
                  cytogenetics (e.g. t(9;22), t(1;19),t(4;11), other myeloid/lymphoid or mixed
                  lineage leukemia [MLL] rearrangements, hypodiploidy or Ikaros family zinc finger
                  1 [IKZF1]), &gt; 1 cycle to obtain CR or evidence of minimal residual disease
                  (MRD). Patients in second or greater CR are also eligible.

          -  Burkitt's lymphoma in CR2 or subsequent CR

          -  Natural Killer cell malignancies

          -  Chronic myelogenous leukemia: all types except refractory blast crisis. Chronic phase
             patients must have failed or been intolerant to Gleevec

          -  Myelodysplastic syndrome:

          -  Large-cell lymphoma, Hodgkin lymphoma and multiple myeloma with chemotherapy
             sensitive disease that has failed or patients who are ineligible for an autologous
             transplant.

          -  Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone
             B-cell lymphoma, follicular lymphoma, which have progressed within 12 months of
             achieving a partial or complete remission. Patients who had remissions lasting &gt; 12
             months, are eligible after at least two prior therapies. Patients with bulky disease
             should be considered for debulking chemotherapy before transplant. Patients with
             refractory disease are eligible, unless has bulky disease and an estimated tumor
             doubling time of less than one month.

          -  Lymphoplasmacytic lymphoma, mantle-cell lymphoma, prolymphocytic leukemia are
             eligible after initial therapy if chemotherapy sensitive.

          -  Refractory leukemia or MDS.

          -  Bone marrow failure syndromes, except for Fanconi Anemia

          -  Myeloproliferative syndromes Patients who have undergone an autologous transplant &gt;12
             months prior to allogeneic transplantation

        Adequate Organ Function and Performance Status

        Exclusion Criteria:

          -  &lt; 70 years with an available 5-6/6 HLA-A, B, DRB1 matched sibling donor

          -  Pregnancy or breastfeeding

          -  Evidence of human immunodeficiency virus (HIV) infection or known HIV positive
             serology

          -  Current active serious infection

          -  Unless in post-chemotherapy and radioimmunoconjugated antibody induced aplasia, when
             he/she would be eligible for Arm 3, patients with acute leukemia in morphologic
             relapse/ persistent disease defined as &gt; 5% blasts in normocellular bone marrow OR
             any % blasts if blasts have unique morphologic markers (e.g. Auer rods) or associated
             cytogenetic markers that allows morphologic relapse to be distinguished are not
             eligible.

          -  Chronic myelogenous leukemia (CML) in refractory blast crisis

          -  Large cell lymphoma, mantle cell lymphoma and Hodgkin disease that is progressive on
             salvage therapy. Stable disease is acceptable to move forward provided it is
             non-bulky.

          -  Active central nervous system malignancy
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Acute myeloid leukemia (AML): high risk CR1 (as evidenced by preceding
             myelodysplastic syndrome [MDS], high risk cytogenetics,  2 cycles to obtain complete
             remission [CR], erythroblastic or megakaryocytic leukemia; CR2+.  All patients must
             be in CR as defined by hematological recovery, AND &lt;5% blasts by light microscopy
             within the bone marrow with a cellularity of 15%.

          -  Very high risk pediatric patients with AML.  Patients &lt;21 years, however, are
             eligible with (M2 marrow) with &lt; or = 25% blasts in marrow after having failed one or
             more cycles of chemotherapy. This group of patients will be analyzed separately.

          -  Acute lymphocytic leukemia (ALL): high risk CR1 [t(9;22), t (1:19), t(4;11) or other
             MLL rearrangements] hypodiploidy, or IKZF1 abnormalities), DNA index &lt; 0.81, &gt; 1
             cycle to obtain CR or presence minimal residual disease (MRD). Patients in CR2+ are
             eligible. All patients must be in CR as defined by hematological recovery, AND &lt;5%
             blasts by light microscopy within the bone marrow with a cellularity of 15%.

          -  Very high risk pediatric patients with ALL. patients &lt;21 years are also considered
             high risk CR1 if they had M2 or M3 marrow at day 42 from the initiation of induction
             or M3 marrow at the end of induction. They are eligible once they achieved a complete
             remission

          -  Chronic myelogenous leukemia (CML) excluding refractory blast crisis. To be eligible
             in first chronic phase (CP1) patient must have failed or be intolerant to imatinib
             mesylate.

          -  Plasma Cell leukemia after initial therapy, who achieved at least a partial remission

          -  Advanced myelofibrosis

          -  Myelodysplasia (MDS) IPSS Int-2 or High risk (i.e. RAEB, RAEBt) or refractory anemia
             with severe pancytopenia or high risk cytogenetics. Blasts must be &lt; 10% by a
             representative bone marrow aspirate morphology.

          -  Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone
             B-cell lymphoma or follicular lymphoma are eligible if there was disease
             progression/relapse within 12 of achieving a partial or complete remission. Patients
             who had remissions lasting &gt; 12 months, are eligible after at least two prior
             therapies. Patients with bulky disease (nodal mass greater than 5 cm) should be
             considered for debulking chemotherapy before transplant.

          -  Lymphoplasmacytic lymphoma, mantle-cell lymphoma, prolymphocytic leukemia are
             eligible after initial therapy in CR1+ or PR1+.

          -  Large cell NHL &gt; CR2/&gt; PR2. Patients in CR2/PR2 with initial short remission (&lt;6
             months) are eligible.

          -  Lymphoblastic lymphoma, Burkitt's lymphoma, and other high-grade NHL after initial
             therapy if stage III/IV in CR1/PR1 or after progression if stage I/II &lt; 1 year.

          -  Multiple myeloma beyond PR2. Patients with chromosome 13 abnormalities, first
             response lasting less than 6 months, or -2 microglobulin &gt; 3 mg/L, may be considered
             for this protocol after initial therapy.

          -  Recipients must have a Karnofsky score (adults)  80 % or Lansky score  50%
             (pediatrics), and proper organ function.

        Exclusion Criteria

          -  Active infection at time of transplantation

          -  History of human immunodeficiency virus (HIV) infection

          -  Pregnant or breast feeding.

          -  Chemotherapy refractory large cell and high grade NHL

          -  If &lt; or = 18 years old, prior myeloablative transplant within the last 6 months. If
             &gt;18 years old prior myeloablative allotransplant or autologous transplant

          -  Extensive prior therapy including &gt; 12 months alkylator therapy or &gt; 6 months
             alkylator therapy with extensive radiation.

          -  Patients who have received Y-90 ibritumomab (Zevalin) or I-131 tostumomab (Bexxar),
             as part of their salvage therapy.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  55 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed prostate cancer

               -  High-volume metastatic disease meeting any of the following criteria:

                    -  Visceral metastases (extranodal)

                    -  Bone metastases

                         -  At least 4 bone lesions

                         -  At least 1 bone lesion must be outside of the vertebral column or
                            pelvis

          -  On androgen-deprivation therapy for &lt; 120 days

               -  Prostate-specific antigen (PSA) level may not have risen and met criteria for
                  progression from its lowest point between the start of androgen-deprivation
                  therapy and randomization

        PATIENT CHARACTERISTICS:

          -  ECOG performance status (PS) 0-2

               -  PS 2 eligible only if decline in PS is due to metastatic prostate cancer

          -  Absolute neutrophil count  1,500/mm^3

          -  Platelet count  100,000/mm^3

          -  Bilirubin  upper limit of normal (ULN)

          -  ALT  2.5 times ULN

          -  Creatinine clearance  30 mL/min

          -  PT and INR  1.5 times ULN (unless on therapeutic anticoagulation)

          -  PTT  1.5 times ULN (unless on therapeutic anticoagulation)

          -  No prior malignancy in the past 5 years except for basal cell or squamous cell
             carcinoma of the skin

               -  Other malignancies that are considered to have low potential to progress (e.g.,
                  grade 2, T1a transitional cell carcinoma) may be allowed if approved by study
                  chair

          -  No peripheral neuropathy &gt; grade 1

          -  No history of severe hypersensitivity reaction to docetaxel or other drugs formulated
             with polysorbate 80

          -  No active cardiac disease, including the following:

               -  Active angina

               -  Symptomatic congestive heart failure

               -  Myocardial infarction within the past 6 months

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  At least 4 weeks since prior major surgery and recovered from all toxicity prior to
             randomization

          -  Prior adjuvant or neoadjuvant hormonal therapy allowed provided the following are
             true:

               -  Therapy was discontinued  12 months ago AND there is no evidence of disease, as
                  defined by 1 of the following:

                    -  PSA &lt; 0.1 ng/dL after prostatectomy plus hormonal therapy

                    -  PSA &lt; 0.5 ng/dL and has not doubled above nadir after radiotherapy plus
                       hormonal therapy

               -  Therapy lasted no more than 24 months

                    -  Last depot injection must have expired by the 24-month mark

          -  Prior palliative radiotherapy allowed if commenced within 30 days before starting
             androgen deprivation

          -  Anti-androgen therapy allowed as single-agent therapy  7 days before medial
             castration to prevent flare

          -  No prior chemotherapy in adjuvant or neoadjuvant setting

          -  No prior hormone therapy in the metastatic setting

          -  More than 30 days (or 6 half-lives) (whichever is longer) since prior participation
             in another clinical trial

          -  Patients can not simultaneously enroll on CALGB 90202

          -  Concurrent participation in nontherapeutic trials allowed

          -  Concurrent antiandrogen therapy (e.g., bicalutamide or flutamide) allowed, but not as
             sole hormonal therapy

          -  No concurrent 5-alpha reductase inhibitors
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Histologically proven supratentorial low-grade (grade II) glioma of any of the
             following histologic subtypes:

               -  Oligodendroglioma

               -  Astrocytoma

               -  Oligoastrocytoma

          -  Has undergone surgical resection or biopsy within 35 days after diagnosis of
             low-grade glioma

               -  Study treatment must begin between 14 days and 4 months after surgical resection
                  or biopsy

          -  Evaluable disease by gadolinium-MRI

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status 60-100%

          -  Absolute neutrophil count  1,500/mm^3

          -  Platelet count  100,000/mm^3

          -  Hemoglobin  10 g/dL

          -  Creatinine &lt; 1.5 times upper limit of normal (ULN)

          -  BUN &lt; 1.5 times ULN

          -  Bilirubin &lt; 1.5 times ULN

          -  SGOT &lt; 2.5 times ULN

          -  Alkaline phosphatase &lt; 2 times ULN

          -  Life expectancy &gt; 12 weeks

          -  No nonmalignant systemic disease resulting in the patient being a poor medical risk

          -  No acute infection requiring intravenous antibiotics

          -  No frequent vomiting or medical condition that would interfere with oral medication
             intake (e.g., partial bowel obstruction)

          -  No other concurrent malignancies except surgically cured carcinoma in situ of the
             cervix or basal cell or squamous cell carcinoma of the skin

               -  Prior malignancies must be in remission for  5 years

          -  No known HIV positivity

          -  No AIDS-related illness

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior radiotherapy, interstitial brachytherapy, or radiosurgery for low-grade
             glioma

          -  No prior biological therapy or chemotherapy for low-grade glioma

          -  No other concurrent chemotherapy

          -  No concurrent radiotherapy or biological therapy

          -  No concurrent prophylactic growth factors

          -  No concurrent epoetin alfa

          -  No other concurrent investigational drugs
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Histologically confirmed anal canal or perianal (anal margin) squamous cell carcinoma

               -  Stage I-IIIB (closed to accrual as of 11/3/2008)

               -  Stage II (T3, N0 only), IIIA, or IIIB

               -  Tumors of nonkeratinizing histology, such as basaloid, transitional cell, or
                  cloacogenic histology, allowed

               -  No well-differentiated stage I anal margin cancer

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Hemoglobin  10 g/dL

          -  Platelet count  100,000/mm^3

          -  Absolute neutrophil count &gt; 1,500/mm^3

          -  Creatinine  1.5 times upper limit of normal (ULN) OR creatinine clearance &gt; 60
             mL/min

          -  Bilirubin  2 times ULN

          -  AST and ALT &lt; 3 times ULN

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for  3 months after
             completion of study treatment

          -  No other malignancies except nonmelanomatous skin cancer

               -  Prior malignancies must be in remission for  5 years

          -  None of the following conditions within the past 6 months:

               -  Active infection

               -  Uncontrolled diabetes

               -  New York Heart Association class II-IV congestive heart failure

               -  Cerebrovascular accident

               -  Transient ischemic attack

               -  Uncontrolled hypertension

               -  Unstable angina

               -  Myocardial infarction

          -  No history of rheumatic disorders, irritable bowel syndrome, or inflammatory bowel
             disease

          -  No known HIV positivity

          -  No known risk factors for HIV infection

               -  Patients with a known risk factor for HIV infection must undergo HIV testing
                  within 90 days before study entry AND must be HIV negative by antibody
                  detection, culture, or quantitative assay of plasma HIV RNA

        PRIOR CONCURRENT THERAPY:

          -  No prior radiotherapy or chemotherapy for this malignancy

          -  No prior pelvic radiotherapy

          -  No prior potentially curative surgery (i.e., abdominal or peritoneal resection) for
             anal cancer

          -  No concurrent intensity-modulated radiotherapy
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Male or female greater than or equal to 16 years of age.

          -  If female of child-bearing potential and outside of the window of 10 days since the
             first day of the last menstrual period, a negative pregnancy test is required.

          -  Patients with known primary or suspected metastatic squamous cell carcinoma of the
             head and neck, non-small cell or small cell carcinoma of the lung, lymphoma, GBM
             (greater than or equal to 3 glioma), neuroendocrine tumours, or renal cell carcinoma
             with at least one lesion &gt;1 cm in diameter.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  16 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  &gt; 18 years old

          -  Cancer of head or neck

        Exclusion Criteria:

        -
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  18 years of age or older

          -  newly diagnosed histologically proven CD-20 positive diffuse large B- cell lymphoma
             by tissue biopsy, listed under peripheral B-cell neoplasm according to the WHO/REAL
             classification (diffuse large B-cell lymphoma, mediastinal large B-cell lymphoma,
             T-cell rich B-cell lymphoma, intravascular large B-cell lymphoma)

          -  Advanced stage disease  defined as - patients with stage III or stage IV disease; or
             patients with stage I or stage II disease with one of the following additional
             criteria: B-symptoms, or disease that is not radio- encompassable within a single
             involved field, or not a candidate for brief chemotherapy and irradiation, or the
             presence of bulky disease (any single mass =&gt; 10 cm)

          -  Previously untreated or treated with up to 3 cycles of standard dose 3- weekly R-CHOP
             chemotherapy prior to enrollment (i.e. patients may be enrolled prior to initiation
             of the fourth cycle of R-CHOP chemotherapy)

          -  ECOG Performance Status 0,1 or 2 at time of enrollment

          -  No evidence of progressive disease while on R-CHOP chemotherapy

          -  The patient must sign the consent form prior to registration

        Exclusion Criteria:

          -  Patients with a history of any other lymphoproliferative disorder, including prior
             history of indolent NHL

          -  Patients with a history of prior or concurrent malignancies within 5 years of the
             current diagnosis, except adequately treated non- melanoma skin cancer, and
             curatively treated in-situ cancer of the cervix

          -  Known HIV infection

          -  Known hepatitis B virus infection

          -  Pregnancy or lactation.  Men and women of childbearing age must be using adequate
             contraception.

          -  Significant renal insufficiency (serum creatinine &gt; 200 mmol/L), unless due to
             lymphoma

          -  Significant hepatic insufficiency (serum total bilirubin &gt; 30 mmol/L), unless due to
             lymphoma

          -  Cardiac contraindication to doxorubicin therapy (e.g. abnormal contractility on
             echocardiography). If history of cardiac disease, ejection fraction must be within
             normal limits for age.

          -  Neurologic contraindication to vincristine (e.g. peripheral neuropathy)

          -  Absolute neutrophil count &lt;1.5 x 109/L (unless due to bone marrow involvement with
             lymphoma or due to initiation of R-CHOP chemotherapy)

          -  Platelet count &lt; 100 x 109/L (unless due to splenomegaly, bone marrow involvement
             with lymphoma or due to initiation of R-CHOP chemotherapy)

          -  Evidence of active systemic infection

          -  Any medical condition that in the opinion of the investigator would compromise
             treatment delivery, add toxicity or impair assessment
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

          -  Patients must have histologically or cytologically documented metastatic colorectal
             cancer, which has recurred or progressed following at least one prior chemotherapy
             regimen administered for the treatment of metastatic disease.  The diagnosis should
             be confirmed by the Laboratory of Pathology at the Clinical Center, NIH.

          -  Tumor should express EGFR, defined as any membrane staining for EGFR in tumor cells
             by immunohistochemistry (IHC) done on archival tumor blocks or slides.

          -  Tumor blocks or unstained slides from archival pathological specimen suitable for the
             isolation of genomic DNA must be available to determine the status of mutations in
             KRAS in the tumor. (For the initial 13 evaluable patients already enrolled and
             treated on this study, every effort will be made to re-acquire these blocks from
             patients or their referring physicians for evaluation of KRAS.)

          -  Patients must have measurable disease, defined as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter to be recorded) as
             greater than or equal to 20 mm with conventional techniques or as greater than or
             equal to 10 mm with spiral CT scan.

          -  Patients must have received or been offered and declined at least one prior
             5FU-containing combination chemotherapy regimen for metastatic disease, unless
             available chemotherapy regimens were for some reason contraindicated for a particular
             patient. Patients who have received chemotherapy and/or biologic therapy, excluding
             BAY 43-9006 or cetuximab, are eligible. This therapy must have been completed greater
             than or equal to 4 weeks prior to enrollment on protocol, and the patient must have
             recovered to eligibility levels from prior toxicity. Prior radiation or surgery
             should have been completed greater than or equal to 4 weeks prior to study enrollment
             and all associated toxicities resolved to eligibility levels.

          -  Age greater than or equal to18 years.  Colorectal cancer does not usually occur in
             patients less than 18 years of age.

          -  Life expectancy greater than 3 months.

          -  ECOG performance status 0 or 1.

          -  Patients must have normal organ and marrow function as defined below:

          -  absolute neutrophil count greater than or equal to 1,500/ microliter

          -  platelets greater than or equal to 100,000/ microliter

          -  total bilirubin less than or equal to 1.5 times the institutional upper limits of
             normal

          -  AST(SGOT)/ALT(SGPT) less than or equal to 2.5 times the institutional upper limit of
             normal

          -  creatinine less than or equal to 1.5 times the institutional upper limits of normal

        OR

          -  creatinine clearance greater than or equal to 60 mL/min/1.73 m(2)

          -  PT/PTT less than or equal to 1.5 times the institutional upper limits of normal

          -  Patients must have at least one lesion amenable to biopsy, as determined by an
             associate investigator after discussion with a member of the interventional radiology
             team.  This lesion should be different from target lesion(s) being followed on
             imaging studies to evaluate response to treatment.

          -  The effects of the combination of BAY 43-9006 and cetuximab on the developing human
             fetus at the recommended therapeutic doses are unknown.  For this reason and because
             raf kinase inhibitor agents used in this trial are known to be teratogenic, women of
             child-bearing potential and men must agree to use adequate contraception (hormonal or
             barrier method of birth control; abstinence) prior to study entry, for the duration
             of study participation, and for at least 2 months following completion of study.
             Should a woman become pregnant or suspect she is pregnant while participating in this
             study, she should inform her treating physician immediately.

          -  Ability to understand and the willingness to sign a written informed consent document
             and the ability to comply with daily oral self administration schedule.

          -  Patients must have systolic blood pressure less than or equal to 150 mm Hg and
             diastolic blood pressure less than or equal to 90 mmHg.  Concomitant antihypertensive
             medications to achieve control of blood pressure are allowed.

        EXCLUSION CRITERIA:

          -  Patients who have had chemotherapy, biologic therapy, or radiotherapy within 4 weeks
             prior to entering the study or those who have not recovered to at least eligibility
             levels from adverse events due to agents administered more than 4 weeks earlier.
             Patients must be greater than or equal to 2 weeks since any investigational agent
             administered as part of a Phase    0    study (also referred to as an    early Phase
             I study    or    pre-Phase I study    where a sub-therapeutic dose of drug is
             administered) at the PI   s discretion, and should have recovered to eligibility
             levels from any toxicities

          -  Patients who have received any other investigational agents within 4 weeks prior to
             entering the study or those who have not recovered to at least eligibility levels
             from adverse events due to agents administered more than 4 weeks earlier.

          -  Patients with known brain metastases would be excluded from this clinical trial, with
             the exception of patients whose brain metastatic disease status remains stable for
             greater than or equal to 6 months after treatment of the brain metastases without
             steroids or anti seizure medications. These patients may be enrolled at the
             discretion of the principal investigator.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to BAY 43-9006 (for example, other multi-targeted kinase inhibitors, such
             as sunitinib) or cetuximab (for example, other drugs containing murine proteins, such
             as bevacizumab) used in the study.

          -  Prior therapy with cetuximab or BAY 43-9006.

          -  Patients on therapeutic anticoagulation are excluded.  Prophylactic anticoagulation
             (i.e. low dose warfarin) of venous or arterial access devices is allowed provided
             that the requirements for PT, INR or PTT are met.

          -  Evidence of bleeding diathesis.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             serious infection, symptomatic congestive heart failure, unstable angina pectoris,
             uncontrolled cardiac arrhythmia, uncontrolled hypertension, or psychiatric
             illness/social situations that would limit compliance with study requirements.

          -  Pregnant women are excluded from this study because BAY 43-9006 is a kinase inhibitor
             agent with the potential for teratogenic or abortifacient effects. Because there is
             an unknown but potential risk for adverse events in nursing infants secondary to
             treatment of the mother with BAY 43-9006, breastfeeding should be discontinued if the
             mother is treated with  BAY 43-9006.

          -  HIV-positive patients receiving anti-retroviral therapy are excluded from this study
             due to the possibility of pharmacokinetic interactions between anti-retroviral
             medications and BAY 43-9006.  HIV positive patients not receiving antiretroviral
             therapy are excluded due to the possibility that BAY 43-9006 may worsen their
             condition and the likelihood that the underlying condition may obscure the
             attribution of adverse events with respect to BAY 43-9006.

          -  History of another malignancy within the past 5 years, apart from adequately treated
             non-melanoma skin cancers, superficial bladder cancer or in situ cervical cancer.

          -  Patients with conditions that would impair their ability to swallow tablets are
             excluded.

          -  Use of the following medications will be not be allowed within 4 weeks prior to
             enrollment on the study and during the study: ketoconazole, itraconazole, ritonavir,
             cyclosporine, carbamazepine, phenytoin, phenobarbital, rifampin, St. Johns Wort, and
             prophylactic use of filgrastim and sargramostim. Products containing grapefruit juice
             will not be allowed while on study. BAY 43-9006 tosylate is metabolized by the P450
             CYP3A enzyme; therefore, it is possible that BAY 43-9006 tosylate may interact with
             the above medications.  Efforts should be made to switch patients who are taking
             enzyme-inducing anticonvulsant agents to other medications.

          -  Patients in whom resection is indicated and can be performed safely (unless surgery
             is declined by the patient for other reasons).

          -  For the optional PET/CT imaging with (89)Zr-panitumumab correlative study,
             participants with severe claustrophobia not relieved by oral anxiolytic medication or
             patients weighing &gt; 136 kg (weight limit for scanner table).

        Inclusion of Women and Minorities:

        Both men and women and members of all races and ethnic groups are eligible for this trial.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. A pathologic diagnosis of adenocarcinoma of the prostate

          2. Age greater than 18 years

          3. ECOG performance status of 2 or less.

          4. Presence of any of the following high risk features:

               -  Clinical stage cT3-4 or

               -  Gleason score 8-10 or

               -  Pre-treatment PSA &amp;gt; 20ng/ml or

               -  Clinical N1/N2 or pathologic N1/N2

        Exclusion Criteria:

          1. Patients with contraindication to radical radiation therapy including inflammatory
             bowel disease

          2. Prior or active malignancy except non-melanoma skin carcinoma within 5 years of the
             diagnosis of prostate cancer

          3. Prior pelvic radiotherapy for other malignancies

          4. Prior cytotoxic chemotherapy

          5. Prior orchiectomy, radical prostatectomy, cryotherapy or thermal ablation therapy for
             prostate cancer
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  The patients must have histologically confirmed primary gastric MALT lymphoma with or
             without clustering large cells (extranodal marginal zone lymphoma, and diffuse large
             cell lymphoma with features of MALT by REAL/WHO classification, Harris NL et al.
             1994).

               -  1.1 The diagnosis of primary gastric lymphoma must fulfill the criteria of
                  Dawson [38].

                    -  (1)No enlargement of peripheral or mediastinal lymph node;

                    -  (2)Peripheral blood smear revealing no leukemic or lymphomatous
                       abnormalities;

                    -  (3)Predominant of alimentary tract lesions with any adenopathy
                       corresponding to accepted lymphatic drainage route; and

                    -  (4)No involvement of liver or spleen except by extension of contiguous
                       disease.

               -  1.2 The diagnosis of MALT lymphoma will be made by histopathologists from
                  individual hospitals, in accordance with criteria defined by Isaacson et al. and
                  Chang et al, and will be reviewed by the members of the TCOG Pathology
                  Committee. This pathology review mechanism had been functioned well in the
                  previous T1296 study (see J Natl Cancer Inst. 2005;97:1345-53)

               -  1.3 The patient must have no prior chemotherapy or radiotherapy for his/her
                  gastric lg- or hg-MALToma.

          -  Patients must have evaluable disease by endoscopy and/or the nodal status by computed
             tomography. Endoscopic ultrasonography (EUS) is mandatory to evaluate the depth of
             tumor infiltration and for status of perigastric lymph node enlargement.

          -  Patients must have documented H. pylori infection before treatment, which will be
             evaluated by the following tests: histology, rapid urease test (CLO-test), C-13
             urease breath test and serology.

               -  3.1 The following will be considered to have H. pylori infection: if any of
                  above 4 tests show positive result.

          -  Patients must have either stage IE or IIE-1 disease, according to an adaptation of
             the Ann Abor staging system modified by Musshoff for primary extranodal lymphoma.

               -  4.1 Stage IE : lymphoma confined to the gastric wall without lymph node
                  involvement.

               -  4.2 Stage IIE : localized involvement of one or more GI site(s) on one side of
                  the diaphragm with lymph node involvement, any depth of lymphoma infiltration
                  into the gut wall. 4.21 Stage IIE-1: involvement of perigastric lymph node. 4.22
                  Stage IIE-2: abdominal, but beyond perigastric, lymph nodal involvement.

          -  Patient must have signed the informed consent and agree to provide achieved
             pathologic material for immunohistochemical study and for RT-PCR t(11;18)(q21;q21)
             determination.

        Exclusion Criteria:

          -  Patients with extensive gastrointestinal tract involvement are not eligible.

          -  Patients with previous history of extranodal lymphoma are not eligible.

          -  Patients with stage IIE-2 or beyond disease: infiltration of regional lymph node,
             e.g. paraaortic, renal hilar, retroperitoneal, mesenteric, or lymph node of
             gastrosplenic ligament and of hepatoduodenal ligament; or involvement of lymph node
             above and below diaphragm (Stage III) or other visceral organ involvement (stage IV)
             are not eligible.

          -  Patients with cardiopulmonary status that do not allow repeat endoscopy are not
             eligible.

          -  Patients with prior antibiotics, chemo- or radiotherapy for their gastric lymphoma
             are not eligible.

          -  Patients who had previous anti-H. pylori therapy and without pretreatment pathology
             achieve material for histological review and immunohistochemical study are not
             eligible.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients with paraneoplastic neurologic disease, diagnosed through the research lab of the
        PI, or from third party referrals in the NYC area.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Neurological disease which is suspected to be paraneoplastic

          -  No known active additional malignancy other than non-melanoma skin cancer

        Exclusion Criteria:

          -  Known central nervous system (CNS) metastasis

          -  Known active additional malignancy

        if leukapheresis: No known hepatitis B or C, HIV, or syphilis (by history or prior
        negative tests) no known IV drug users HgB &gt; 8.5 WBC &gt; 3,500 platelets &gt; 100,000 INR &lt; 2

        if large blood draw (1/2 to 1 unit; children 3 ml/kg) in lieu of leukapheresis: no known
        IV drug users HgB &gt; 10 WBC &gt; 3,500 platelets &gt; 100,000 INR &lt; 2 if lumbar puncture:
        platelets &gt; 120,000 INR &lt; 1.2
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  16 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  18-59 years

          -  ALL newly diagnosed (blast &lt; 20%)

          -  Central Nervous System (CNS) positive or negative

          -  Signed written informed consent

          -  For GRAAPH trial only: t(9;22) or BCR- ABL positive

        Exclusion Criteria:

          -  Lymphoblastic lymphoma

          -  ALL 3

          -  Chronic myeloid leukemia

          -  Severe organ condition
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  59 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  must have histologically proven glioma

          -  the patient or legally authorized representative must fully understand all elements
             of informed consent, and sign the consent form

        Exclusion Criteria:

          -  psychiatric conditions precluding informed consent

          -  medical or psychiatric condition precluding MRI or PET studies (e.g. pacemaker,
             aneurysm clips, neurostimulator, cochlear implant, severe claustrophobia/anxiety,
             pregnancy)
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   pregnant women diagnosed with cancer
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

        Patients must meet all of the following inclusion criteria:

          -  Histologically proven cancer

          -  Patients must have adequate bone marrow, renal, hepatic and pulmonary function.

          -  World Health Organization (WHO) performance status of 0 or 1

          -  &gt; 18 years of age

          -  Patients who have given their signed and written informed consent to participate in
             the trial after fully understanding the implication of the protocol

          -  Women receiving any cytotoxic drug during pregnancy are allowed for the assessment of
             the maternal and fetal outcome

          -  Patients are allowed to opt for the pharmacokinetic part or clinical follow-up part
             of the study only and do not need to participate in both; however, preferentially
             both study parts should be performed.

          -  Women receiving any kind of radiotherapy during pregnancy

        Exclusion Criteria:

          -  Mentally disabled or significantly altered mental status that would prohibit the
             understanding and giving of informed consent
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Histologically confirmed (e.g., slide of tissue) breast cancer

          -  HER2/NEU positive or negative

          -  Clinical evidence of metastasis (e.g., biopsy) with at least 1 measurable metastatic
             (M1) lesion prior to starting the current chemotherapy

          -  Received 1st and 2nd line chemotherapy

          -  Hemoglobin (Hb) &lt;= 11g/dL at the time of randomization

          -  planned to receive at least 2 more cycles of chemotherapy

          -  Life expectancy &gt; 6 months

          -  Eastern Cooperative Oncology Group score 0 or 1

          -  At least 18 years old using effective birth control or surgically sterile or
             postmenopausal for 1 year

        Exclusion Criteria:

          -  Active second cancer

          -  no recent history of clinically relevant thrombovascular event

          -  Current treatment with anticoagulants

          -  Brain metastasis or CNS involvement

          -  Anemia secondary to another cause

          -  Recent (within prior 1 months) use of an ESA

          -  Patient pregnant or breast feeding

          -  Progressive disease during adjuvant/neoadjuvant chemotherapy

          -  Rapidly progressive or life-threatening metastatic disease

          -  Concomitant endocrine therapy

          -  Patient in whom the only site of metastasis was local and was successfully treated
             surgically.
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Patients must have metastatic melanoma or stage III in-transit or regional nodal
             disease. (Turnstile I)

          2. Patients must receive an MRI/CT of the brain or PET/CT within 6 months of consenting.
             If new lesions are present, PI or his designee should make final determination
             regarding enrollment. (Turnstile I)

          3. Age greater than or equal to 12 years. (Turnstile I)

          4. Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0-2.
             (Turnstile I)

          5. Patients previously treated with immunotherapy, targeted therapy, or no therapy will
             be eligible. Patients receiving cytotoxic agents will be evaluated by the PI or his
             designee as to suitable eligibility. (Turnstile I)

          6. Patients must be HLA-A2 for cohort A. (Turnstile II-Chemotherapy/Cell
             Infusion-Inclusion Criteria)

          7. Patients must have adequate TIL available. (Turnstile II)

          8. Patients must have measurable metastatic melanoma. (Turnstile II - Chemotherapy/Cell
             Infusion -Inclusion Criteria).

          9. Patients may have brain lesions which measure &lt;/= 1cm each. Lesions that are &gt;1 cm
             that have been treated with SRS and in the opinion of the PI or his designee no
             longer represents active disease will also be allowed. (Turnstile II -
             Chemotherapy/Cell Infusion- Inclusion Criteria).

         10. Patients of both genders must practice birth control for four months after receiving
             the preparative regimen. (Turnstile II - Chemotherapy/Cell Infusion- Inclusion
             Criteria).

         11. Patients must have a documented negative pregnancy test (urine or serum) for women
             who have menstruation in the past 12 months and without sterilization surgery.

         12. Unless surgically sterile by bilateral tubal ligation or vasectomy of partner(s), the
             patient agrees to continue to use a barrier method of contraception throughout the
             study such as: condom, diaphragm, hormonal, intrauterine device (IUD), or sponge plus
             spermicide. Abstinence is an acceptable form of birth control. (Turnstile II)

         13. Pregnancy testing will be performed within 7 days prior to treatment.

         14. Clinical performance status of ECOG 0 - 2 at the time of chemotherapy infusion.
             (Turnstile II - Chemotherapy/Cell Infusion-Inclusion Criteria).

         15. Absolute neutrophil count greater than or equal to 750/mm3. (Turnstile II -
             Chemotherapy/Cell Infusion- Inclusion Criteria).

         16. Platelet count greater than or equal to 75,000/mm3. (Turnstile II - Chemotherapy/Cell
             Infusion- Inclusion Criteria).

         17. Hemoglobin greater than or equal to 8.0 g/dl. (Turnstile II - Chemotherapy/Cell
             Infusion).

         18. Serum ALT less than three times the upper limit of normal. (Turnstile II -
             Chemotherapy/Cell Infusion- Inclusion Criteria).

         19. Serum creatinine less than or equal to 1.6 mg/dl. (Turnstile II - Chemotherapy/Cell
             Infusion-Inclusion Criteria).

         20. Total bilirubin less than or equal to 2.0 mg/dl, except in patients with Gilbert's
             Syndrome who must have a total bilirubin less than 3.0 mg/dl. (Turnstile II -
             Chemotherapy/Cell Infusion - Inclusion Criteria).

         21. Patients in Cohort A will be randomized to receive either TIL alone or TIL plus
             Dendritic cells.

         22. A stress cardiac test (stress thallium, stress MUGA, dobutamine echocardiogram or
             other stress test that will rule out cardiac ischemia) within 6 months of
             lymphodepletion. (Turnstile II - Chemotherapy/Cell Infusion-Inclusion Criteria).

         23. Pulmonary function tests (FEV1&gt;65% or FVC&gt;65%of predicted) within 6 months of
             lymphodepletion. (Turnstile II - Chemotherapy/Cell Infusion - Inclusion Criteria).

         24. MRI/CT of the brain within 42 days of lymphodepletion. CT scan of
             chest/abdomen/pelvis or PET/CT within 30 days of lymphodepletion. Exception: Patients
             randomized to receive dendritic cells may have an MRI of the brain within 30 days of
             lymphodepletion. (Turnstile II-Chemotherapy/Cell Infusion-Inclusion Criteria)

         25. Patients must be receiving a B-RAF inhibitor and failed to achieve PR or CR or have
             progressive disease in response to B-RAF treatment (Cohort C).

        Exclusion Criteria:

          1. Has had prior systemic cancer cytotoxic chemotherapy within the past four weeks at
             the time of the start of the lymphodepletion regimen.

          2. Has had prior B-RAF or MEK targeted therapy within 7 days prior to the start of the
             lymphodepletion regimen (Cohort A and Cohort B).

          3. Is not receiving B-RAF treatment (Cohort C) (Turnstile II - Chemotherapy/Cell
             Infusion Exclusion Criteria)

          4. Achieves PR or CR in response to B-RAF treatment (Cohort C).

          5. Women who are pregnant or nursing will be excluded because of the potentially
             dangerous effects of the preparative chemotherapy on the fetus. (Turnstile II -
             Chemotherapy/Cell Infusion Exclusion Criteria)

          6. Any active systemic infections requiring intravenous antibiotics, coagulation
             disorders or other major medical illnesses of the cardiovascular, respiratory or
             immune system, such as abnormal stress test and/or abnormal PFT. PI or his designee
             shall make the final determination regarding appropriateness of enrollment.(Turnstile
             II - Chemotherapy/Cell Infusion Exclusion Criteria)

          7. Any form of primary or secondary immunodeficiency. Must have recovered immune
             competence after chemotherapy or radiation therapy as evidenced by lymphocyte counts
             (&gt; 500/mm3), white blood cell count (WBC) (&gt; 3,000/mm3) or absence of opportunistic
             infections. (Turnstile II - Chemotherapy/Cell Infusion Exclusion Criteria)

          8. Require steroid therapy or steroid-containing compounds, or have used systemic
             steroids in the past 30 days, or have used topical or inhalational steroids in the
             past 2 weeks prior to lymphodepletion. Exception: Patients on physiologic dose of
             steroid (Turnstile II - Chemotherapy/Cell Infusion Exclusion Criteria)

          9. Presence of a significant psychiatric disease, which in the opinion of the principal
             investigator or his designee, would prevent adequate informed consent or render
             immunotherapy unsafe or contraindicated. (Turnstile II - Chemotherapy/Cell Infusion
             Exclusion Criteria)
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  12 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Individuals with the diagnosis of CMM at the Department of Dermatology, Bufalini Hospital,
        Cesena, Italy who have other family members affected with CMM will be eligible for
        participation.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  10 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Any patients entered on approved trials of cancer therapeutics or agents that are commonly
        administered to patients with cancer at institutions outside of the intramural NCI are
        eligible for inclusion, provided that they have consented to pharmacological analysis in
        the original consent form.

        EXCLUSION CRITERIA:

        None anticipated at this time.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        We will include about 3,000 individuals born in Belarus from April, 26, 1986 through
        March, 31, 1987 who were exposed to internal and external sources of ionizing radiation
        during prenatal and early postnatal periods due to the Chernobyl fallout.

        EXCLUSION CRITERIA:

        For the purpose of individual dose reconstruction we need to establish    child-mother
        pair for each cohort member and conduct personal dosimetric interview with child   s
        mother. We anticipate that some of the eligible subjects will be deceased at the time of
        the cohort construction. Deceased subjects will not be included in the cohort. Excluded
        from the interview study and the subsequent follow-up study will be those who are
        deceased, cannot be located, refuse to participate in the study, or do not provide
        informed consent.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  16 Years
 </minimum_age>
 <maximum_age>
  34 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Case Subject Selection:

        Diagnosis of non-small cell lung cancer made pathologically (with confirmation by a second
        pathologist).

        Must reside in Maryland.

        Have a residential working phone within their home.

        Be born in the United States.

        Speak English well enough to be interviewed.

        Be physically and mentally capable of performing the interview (i.e., must be able to hear
        the interviewer, mentally comprehend the interviewers questions and verbally respond).

        Never have been interviewed as a control for the study.

        Consent by the physician from the clinic where the subject was identified, or listed as
        the treating physician by the tumor registry or surgical pathology report.

        Hospital-Based Control Selection:

        Stratified to frequency match cases by age (5 year intervals), gender, race, smoking (20
        pack year intervals -- non-smokers, 0-20, 20-40, 40-60 and greater than 60 and ex-smokers
        [greater than 5 yrs]) and hospital.

        Must reside in Maryland

        Have a residential working phone within their home.

        Be born in the United States.

        Speak English well enough to be interviewed.

        Be physically and mentally capable of performing the interview (i.e., must be able to hear
        the interviewer, mentally comprehend the interviewers questions and verbally respond).

        Never have been interviewed as a control for the study.

        Physician consent by physician from clinic with subject is identified.

        Selection of Population-Based Controls:

        Stratified to match cases by age (5 year intervals), gender, and race.

        Must reside in Maryland

        Have a residential working phone within their home.

        Be born in the United States.

        Speak English well enough to be interviewed.

        Be physically and mentally capable of performing the interview (i.e., must be able to hear
        the interviewer, mentally comprehend the interviewers' questions and verbally respond).

        Never been interviewed as a control for the study.

        EXCLUSION CRITERIA:

        Case Subject Selection:

        More than 6 months after initial diagnosis.

        Currently residing in an institution such as prison, nursing home or shelter.

        Severely ill in an intensive care unit (after discharge from ICU, then can be
        reconsidered).

        Subjects is unable to give informed consent.

        Hospital-Based Control Selection:

        History of cancer other than non-melanotic skin cancer or in situ cervical cancer.

        Currently residing in an institution such as a prison, nursing home or shelter.

        Severely ill in an intensive care unit (after discharge from ICU, the can be
        reconsidered).

        Subject is unable to give informed consent.

        Selection of Population-Based Controls:

        History of cancer other than non-melanotic skin cancer or in situ cervical cancer.

        Currently residing in an institution such as a prison, nursing home or shelter.

        Subjects unable to give informed consent.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Individuals must meet the following eligibility criteria to be entered into the RDP donor
        pool:

          1. Age 18 or older.

          2. Weight of 110 lb or greater.

          3. Registration for participation in semen donation is limited to males currently
             enrolled in the donor pool.

        EXCLUSION CRITERIA:

        Individuals with any of the following will be excluded from the donor pool:

          1. History of chronic illness which might increase the risk associated with phlebotomy,
             including but not limited to heart, lung, or kidney disease.

          2. Current acute illness.

          3. History of clotting disorders.

          4. Current medications which might increase the risk associated with phlebotomy.

          5. History of syncope or other difficulty with venipuncture.

          6. Anemia, as determined by CBC or hemotacrit:

             Hemotacrit acceptable range for males:  40-51 percent.

             Hemotacrit acceptable range for females:  34-46 percent.

             Hemoglobin acceptable range for males:  12.5-17.0 g/dl

             Hemoglobin acceptable range for females:  11.5-15.2 g/dl

          7. Positive blood test for exposure to HIV-1, HIV-2, HTLV-1, HTLV-2, or HCV or positive
             test for HBV surface antigens.

          8. Individuals will be shown a list of activities and conditions which place them at
             high risk of HIV infection and asked not to donate if any apply.

          9. Males who qualify for participation in the donor pool will be excluded from
             participation in semen donation if they have knowingly had any injury, infection, or
             treatment performed that renders them incapable of producing sperm.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Diagnosis of lymphoid malignancy at one of the LLMPP participating institutions, including
        specimens originating at other clinical sites and submitted to LLMPP participating sites.

        Informed consent for research studies performed on biopsy material or waiver of the
        requirement for informed consent by the clinical research review boards at the LLMPP
        institutions.

        Sufficient frozen biopsy and/or FFPE material from initial biopsy and/or biopsies at
        relapse of disease to obtain adequate RNA and DNA for gene expression profiling and
        analysis of genomic alterations in the malignant cells.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION AND EXCLUSION CRITERIA:

        The only exclusion criteria is age.  Participants must be greater than or equal to 18
        years of age.  Otherwise, there are no health status criteria for participating in this
        study; participants may be healthy or have preexisting conditions.

        Participants will not be excluded based on gender, ethnicity, race or religion.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        All patients over the age of 18 presenting to the SCHI with upper GI signs or symptoms
        requiring upper GI endoscopy over a defined calendar period (depending on prevalence of
        premalignant lesions, but estimated to be approximately 3 years) will be potentially
        eligible for participation in this study.

        Patients are eligible only if they meet one of the following two conditions: (1) a visible
        lesion unlikely to be cancer or (2) no visible lesions on routine endoscopy (without
        mucosal iodine staining) but an unstained (abnormal) lesion following iodine spraying.

        Invitation for participation will be based solely on the visual appearance of an
        esophageal abnormality without or with mucosal iodine staining, but before histologic
        confirmation is obtained, and will occur during the same clinic visit as the qualifying
        endoscopic examination.

        EXCLUSION CRITERIA:

        Patients will not be invited to participate in this study until after they have undergone
        their routine endoscopic evaluation.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        All individuals with a histologically confirmed diagnosis of lung cancer or a family of
        lung cancer are eligible to enroll their family in the study.  Five major histologic types
        of lung cancer, i.e., adenocardinoma, squamous cell, small cell, large cell, and
        unspecified nonsmall cell carcinoma will be included.  In addition to lung cancer
        patients, LSU will also contact patients newly diagnosed with bronchus or tracheal cancer
        in target hospital areas to request their enrollment in their study.  In addition, several
        sites including LSU, Mayo Clinic and Karmanos Cancer Institute also collect DNA samples
        from unaffected, geographically and ethnically matched controls.

        For the purposes of this study, an eligible family must meet the minimum criteria for
        familial lung cancer: at least 2 first-degree relatives in the family have had lung
        cancer.  Priority will be given to more highly loaded pedigrees and to families in which
        the affected persons had onset of the disease at an early age (less than 50 years).  Lung
        cancer cases may be living or deceased.  Relatives with lung cancer are defined as first-
        o second-degree relatives or cousins of index cases will be eligible to participate in the
        study because their familial relationships might provide useful linkage information.

        Adult participants must be physically able to tolerate removal of 25 to 40 ml of blood, or
        buccal brush sampling of their cheek.  Children above 5 years old must be able to
        physically tolerate an amount of blood drawn that is equal to 4ml/kg of their weight.
        Adults must be willing to complete a self-administered environmental exposure
        questionnaire, and all participants must be able to consent to the study procedures (or
        have appropriate assent/parental consent).  Biological specimens, including blood samples,
        archived tumor blocks and other medical records will be obtained from patients treated at
        the various hospitals and collection sites and from individuals with strong family history
        of lung cancer (either affected or unaffected) who have either been self-referred or
        physician referred to the study.

        EXCLUSION CRITERIA:

        Excluded from the study are families or individuals within the family who do not meet the
        minimum criteria described above.  Individuals who do not sign the Consent Form will be
        excluded, and families for whom all necessary members do not sign the Consent Form may be
        excluded.  MAYO also excludes patients who (1) do not speak English, (2) are non-US
        citizens or residents and (3) are diagnosed with an uncommon tumor type that is not among
        the above specified types (e.g.) mixed cell or unspecified non-small cell lung cancer,
        carcinoids, sarcomas and lymphomas of the lung and bronchus).  This is done at MAYO
        because the family study is piggy-backed onto a case-control study.  No fetuses, prisoners
        or institutionalized individuals will be enrolled.  While this study does not target
        pregnant women, because contact with many of the families will be by mail we will not be
        able to exclude pregnant women.  Additionally, the participant's own physician or health
        care clinic will draw blood samples from long-distance participants and therefore can
        determine if there is any risk to the woman or her fetus.  UMHS also excludes children as
        research participants in their site.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  5 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        In this retrospective study, any cancer patients entered on IRB approved clinical trials
        at the National Cancer Institute are eligible.  Studies for which pharmacokinetic analyses
        were/are being performed will be the source of the patient population.  At this time
        enrollment will be limited to patients with pharmacokinetic samples obtained during
        treatment on protocol 00-C-0033, 00-C-0080, 01-C-0049, 01-C-0124, 01-C-0215, 02-C-0061,
        02-C-0083, 02-C-0130, 02-C-0149, 02-C-0215, 02-C-0218, 02-C-0229, 03-C-0030, 03-C-0157,
        03-C-0176, 03-C-0284, 04-C-0132, 04-C-0257, 04-C-0262, 04-C-0273, 04-C-0280, 05-C-0022,
        05-C-0049, 05-C-0167, 05-C-0186, 06-C-0083, 06-C-0088, 06-C-0164, 06-C-0221, 07-C-0047,
        07-C-0059, 07-C-0106, 07-C-0107, 08-C-0030, 08-C-0074, 94-C-0169, 95-C-0015, 97-C-0135,
        97-C-0171, and 98-C-0015.

        EXCLUSION CRITERIA:

        A patient will be excluded if there is an insufficient quantity of sample available to
        perform the genotyping procedure.  This is not anticipated to be of significance for this
        study since the methodology does not require a large serum sample.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Newly diagnosed patients with de novo or secondary AML

          -  Intermediate or poor risk

          -  In first complete remission

          -  Age 51-70 years

          -  Fit for the procedure

          -  Fit for further consolidation chemotherapy

          -  At least one sibling willing to undergo HLA-typing

        Exclusion Criteria:

          -  Planned for a full-dose allogeneic transplant

          -  Planned for a transplant from an unrelated donor
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  51 Years
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Either:

        A. Patients (male or female) who are immunosuppressed with acute pneumonia and are
        undergoing or have undergone a clinically indicated procedure, such as bronchoscopy or
        sputum induction, to obtain a respiratory sample for diagnostic purposes.

        or

        B. Patients (male or female) who are immunosuppressed with acute pneumonia or individuals
        likely to be exposed to environmental or person-to-person sources of organisms, including
        healthy volunteers (with or without respiratory disease), health care professionals,
        patient families, or other patients in health care facilities who are willing to provide
        oral washes, nasal samples or blood samples and to consider providing an induced sputum
        sample.

        All ages greater than or equal to 3 years.

        Only children who will be having a clinically indicated induced sputum or bronchoscopy
        will be included in this study (nasal specimens will not be collected from children).

        Ability of individual or guardian to give informed consent.

        EXCLUSION CRITERIA:

        For enrollment under category B, any individual who cannot safely provide an oral wash or
        nasal samples (nasopharyngeal swabs, or nasal washes) as determined by the health care
        provider.

        Pregnancy and age are not exclusion factors.

        Nasal specimens will not be collected from children.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  3 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  ELIGIBILITY CRITERIA

        CASE SUBJECT SELECTION

        We will recruit incident cases of pathologically confirmed PCa at all stages of the
        disease that are age 40 to 90 years. Treatment can be surgery or therapy. The following
        check list will be used to verify eligibility of a case subject.

        ELIGIBILITY CHECK LIST - PROSTATE CANCER CASES

        CRITERIA (ALL MUST BE CHECKED):

          -  Has been diagnosed with prostate cancer within the last two years

          -  Pathological diagnosis of prostate cancer made at the local hospital pathology
             department

          -  Resides in Baltimore City or contiguous metropolitan counties, Anne Arundel and
             Prince George   s counties, Eastern Shore, western and northern Maryland, or adjacent
             counties in Pennsylvania, Delaware, Virginia, or the Washington Metropolitan area

          -  Has a residential working phone within his home

          -  Born in the United States

          -  Of African-American or Caucasian descent, and age 40 to 90 years

          -  A non-objection statement by the physician from the hospital where the patient was
             identified, or listed as the treating physician by the tumor registry or surgical
             pathology report, to contact the patient

          -  Is not currently residing in an institution, such as a prison, nursing home, or
             shelter

          -  Is not a severely ill patient in the intensive care unit

          -  Speaks English well enough to be interviewed

          -  Is able to give informed consent

          -  Is physically and mentally capable of performing the interview

          -  Has never been interviewed as a control for this study

          -  Subject provides informed consent and signs form.

        Unwilling   Unavailable

        SELECTION OF POPULATION-BASED CONTROLS

        Population-based controls will be identified through the Department of Motor Vehicles
        (DMV), and matched on age (5-year intervals), gender and race to cases. Recruitment of
        controls will start concurrently with case accrual, using the age and race frequency
        distribution of cancer patients in previous years, but recruitment objectives can be
        re-assessed to ensure a frequency-matched study. We will exclude controls that do not have
        a listed home phone number. The following check list will be used to verify eligibility of
        a control subject.

        ELIGIBILITY CHECK LIST - POPULATION-BASED CONTROLS

        CRITERIA (ALL MUST BE CHECKED):

          -  Resides in Baltimore City or contiguous metropolitan counties, Anne Arundel and
             Prince George   s counties, Eastern Shore, western and northern Maryland, or adjacent
             counties in Pennsylvania, Delaware, Virginia, or the Washington Metropolitan area

          -  Has a residential working phone within his home

          -  Born in the United States

          -  Of African-American or Caucasian descent, and age 40 to 90 years

          -  Does not have a personal history of cancer other than basal and non-melanomic skin
             cancer

          -  Have never had radiation therapy or chemotherapy

        Is not currently residing in an institution, such as a prison, nursing home, or shelter

          -  Speaks English well enough to be interviewed

          -  Is able to give informed consent

          -  Is physically and mentally capable of performing the interview

          -  Has never been interviewed as a control for the study

          -  Subject provides informed consent and signs form.

        Unwilling    Unavailable
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  40 Years
 </minimum_age>
 <maximum_age>
  90 Years
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Clinical history supportive of the diagnosis of T-LGL leukemia (i.e. a history of
        cytopenias with peripheral blood morphologic evidence of LGLs)

        Immunophenotypic studies of peripheral blood showing an increased population of T-LGLs
        (suggested by staining with CD3+, CD8+ and CD16+ or CD57+) or gammadelta T cells

        Restricted or clonal rearrangement of the T-cell receptor by PCR AND one or more of the
        following:

        Severe neutropenia (less than 500 neutrophils/microliter); OR

        Severe thrombocytopenia (less than 20,000 platelets/microliter), or moderate
        thrombocytopenia (less than 50,000 platelets/microliter) with active bleeding; OR

        Symptomatic anemia with a hemoglobin less than 9 g/dL or red blood cell transfusion
        requirement of greater than 2 units/month for two months prior to initiation of Campath

        Ages 18-85 (both inclusive)

        EXCLUSION CRITERIA:

        A reactive LGL lymphocytosis to a viral infection

        Serologic evidence of HIV infection

        Infection not adequately responding to appropriate therapy

        Previous immunosuppressive therapy with alemtuzumab

        History of carcinoma that is not considered cured (excluding non-melanoma skin carcinoma)

        Moribund status or concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious,
        or metabolic disease of such severity that it would preclude the subject's ability to
        tolerate protocol therapy or that death within 7-10 days is likely

        Current pregnancy, or unwilling to take oral contraceptives or refrain from pregnancy if
        of childbearing potential

        Not able to understand the investigational nature of the study or give informed consent.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  85 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Karnofsky performance status: &gt;80% (&gt;60% if poor performance status is related to
             lymphoma)

          -  No evidence of serious organ dysfunction that is not attributable to tumor

               -  Central nervous system: Patients with a history of CNS involvement by lymphoma
                  or with relapsed primary lymphoma will be eligible.

               -  Infection: Patients with serious uncontrolled infections at the time of
                  transplant will be excluded.

          -  Hepatitis B: Patients who are carriers of Hepatitis B will be included in this study.
             These patients are not eligible to receive rituximab as a component of their
             chemotherapy mobilization.

          -  HIV disease. Patients with HIV disease are eligible for this study provided that:

               -  Patients will be seen in the infectious disease (ID)/HIV clinic prior to
                  enrollment on study for the purpose of determining eligibility and for local
                  coordination of HIV care during the peri-transplant period.

               -  Must be on a maximally active anti-HIV regimen

               -  CD4+  50/L

               -  HIV RNA viral load  100,000 copies per mL on each of samples 4 weeks apart. The
                  most recent level must be within one month of enrollment.

          -  Non-Hodgkin's lymphoma (NHL). Patients with chemo-sensitive histologically confirmed
             NHL.

               -  Precursor B-cell or Precursor T-cell NHL

                    -  Lymphoblastic lymphoma

                         -  All patients will be eligible in second or greater complete remission
                            (CR) or first or subsequent partial remission (PR)

               -  Mature B-cell Lymphomas:

                    -  Small lymphocytic lymphoma (SLL) or Chronic Lymphocytic Leukemia (CLL)

                    -  Follicular Lymphoma

                    -  Diffuse Large B-cell Lymphoma

                    -  Mantle Cell Lymphoma

                    -  Burkitt's/Burkitt's like

               -  Mature T-cell lymphoma

          -  Hodgkin's lymphoma (HL)

               -  patients with histologically proven HL will be eligible for transplantation
                  after failing prior therapy.

        Exclusion Criteria:

          -  Patients eligible for any higher priority transplant protocols

          -  Women who are pregnant or breast feeding

          -  Patients with chemotherapy resistant disease
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   cancer patients
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   1. Age &gt; or = 18; for the samples collected under the NIH grant, no subjects below the
             age of 20 will be enrolled.

          2. Prior diagnosis of cancer or suspected of having cancer

          3. Karnofsky performance status of greater than 70

          4. Standard pretreatment evaluation

          5. Signed Stanford University Human Subjects Committee consent
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Three groups of caregivers: African American, Latinos, and white non-Latinos.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Caregiver inclusion criteria includes: provides care and/or assistance to a patient
             receiving new or current treatment - Single or combined chemotherapy, radiotherapy,
             and/or targeted therapy for advanced solid tumors (lung, breast, cervical, and
             other).

          2. 18 years of age or older;

          3. self-identified as African-American/Black, Latino, or white, non-Latino;

          4. able to speak English or Spanish (as applicable);

          5. able to read and complete forms or be willing to have the forms read to them by a
             trained interviewer;

          6. accessible through personal or telephone contact for the duration of the study.

          7. Patient inclusion criteria: Receiving new or current treatment - Single or combined -
             chemotherapy, radiotherapy, and/or targeted therapy for advanced solid tumors (lung,
             breast, cervical, and others). Criteria 2-6 are the same as listed under Caregiver
             Criteria.

        Exclusion Criteria: None
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. a diagnosis of NF1 by NIH criteria

          2. between 10 and 50 years of age

          3. no evidence of a comorbid neurological disorder (e.g., epilepsy, encephalitis)

          4. not currently taking a statin medication

          5. not suffering from hypercholesterolemia based on self-report, collateral information
             from physician, or initial medical workup using National Cholesterol Education
             Program (NCEP, JAMA 2001), guidelines accepted by the American College of Cardiology
             (ACC) and the American Heart Association (AHA)

          6. does not have any of the aforementioned conditions that contraindicates use of statin
             medications (such as pregnancy, lactation, liver disease, or use of other medication
             not recommended for use in conjunction with lovastatin).  A negative pregnancy test
             will be required if the patient is a female in reproductive years.

          7. not mentally retardation (i.e., IQ greater than 70)

          8. no evidence of significant and habitual alcohol or drug abuse or dependence

          9. sufficient acculturation and fluency in the English language to avoid invalidating
             research measures of thought, language, and speech disorder, and verbal abilities.

         10. lives in Southern California area (or can arrange ~5 visits to Los Angeles over 14
             weeks)

        Exclusion Criteria:

          1. comorbid neurological conditions

          2. significant drug or alcohol abuse

          3. non-fluency in English
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  10 Years
 </minimum_age>
 <maximum_age>
  50 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Diagnosis of myelofibrosis requiring therapy, including those previously treated and
             relapsed or refractory, or if newly diagnosed, with intermediate or high risk
             according to Lille scoring system (risk factors are: Hb &lt; 10 g/dl, WBC &lt; 4 or &gt; 30 x
             109/L; risk group: 0 factor(s) = low, 1 factor(s) = intermediate, 2 factor(s) = high)
             or with symptomatic splenomegaly

          2. Understanding and voluntary signing an IRB-approved informed consent form.

          3. Age &gt;/= 18 years at the time of signing the informed consent.

          4. Disease-free of prior malignancies for &gt;/= 2-years with exception of basal cell or
             squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast.

          5. ECOG performance status 0 to 2.

          6. Patients must have adequate organ function as demonstrated by the following: Total
             bilirubin &lt;/= 2.0 mg/dL (unless higher due to MF); Serum creatinine &lt;/= 2.0 mg/dL
             (unless higher due to MF); Absolute neutrophil count &gt;/= 1 x 10^9/L; ALT &lt;/= 3 x
             upper limit of normal (unless higher due to MF).

          7. Females of childbearing potential (FCBP) must have a negative serum or urine
             pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to
             and again within 24 hours of starting lenalidomide and must either commit to
             continued abstinence from heterosexual intercourse or begin TWO acceptable methods of
             birth control, one highly effective method and one additional effective method AT THE
             SAME TIME, at least 4 weeks before she starts taking lenalidomide. FCBP must also
             agree to ongoing pregnancy testing.

          8. Continuation of 7. Men must agree to use a condom during sexual contact with a female
             of child bearing potential even if they have had a successful vasectomy. All patients
             must be counseled at a minimum of every 28 days about pregnancy precautions and risks
             of fetal exposure. See Appendix J: Risks of Fetal Exposure, Pregnancy Testing
             Guidelines and Acceptable Birth Control Methods

          9. footnote to no 7.  A female of childbearing potential is a sexually mature woman
             who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not
             been naturally postmenopausal for at least 24 consecutive months (i.e., has had
             menses at any time in the preceding 24 consecutive months).

         10. All study participants must be registered into the mandatory RevAssist program, and
             be willing and able to comply with the requirements of RevAssist.

        Exclusion Criteria:

          1. Use of any other standard (e.g. hydroxyurea, anagrelide, growth factors) or
             experimental drug or therapy within 28 days of starting lenalidomide and/or lack of
             recovery from all toxicity from previous therapy to grade 1 or better.

          2. Known prior clinically relevant hypersensitivity reaction to thalidomide, including
             the development of erythema nodosum if characterized by a desquamating rash.

          3. Prior therapy with lenalidomide.

          4. Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from signing the informed consent form.

          5. Suspected Pregnancy. Pregnant or lactating females.

          6. Any condition, including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if he/she were to participate in the study or confounds
             the ability to interpret data from the study.

          7. Known positive for HIV or infectious hepatitis, type A, B or C.

          8. Known prior clinically relevant hypersensitivity to prednisone.

          9. Participants with a heart rate (HR) of less than or equal to 50, as a HR less than 50
             indicates underlying cardiac abnormalities.

         10. Participants with prior history of thromboembolic disease (i.e.-deep venous
             thrombosis [DVT] or pulmonary embolism [PE]) within the last six months, as
             Lenalidomide has demonstrated a significantly increased risk of DVT or PE.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

        Meeting the definition of standard risk or high risk Fanconi anemia as defined in the next
        two sections:

          -  Standard risk patients must be &lt;18 years of age with a diagnosis of Fanconi anemia
             with aplastic anemia (AA), myelodysplastic syndrome without excess blasts, or high
             risk genotype as defined below:

               -  Aplastic anemia is defined as having at least one of the following when not
                  receiving growth factors or transfusions:

                    -  platelet count &lt;20 * 10^9/L

                    -  ANC &lt;5 * 10^8/L

                    -  Hemoglobin &lt;8 g/dL

               -  Myelodysplastic syndrome (MDS) with multilineage dysplasia with or without
                  chromosomal anomalies

               -  High risk genotype (e.g. IVS-4 or exon 14 FANCC mutations, or BRCA1 or 2
                  mutations)

          -  High risk patients must have one or more of the following high risk features:

               -  Advanced MDS ( 5% blast) or acute leukemia

               -  Require additional HSCT for graft failure

               -  History at any time of systemic fungal or gram negative infection

               -  Severe renal disease with a creatinine clearance &lt;40 mL/min

               -  Age &gt; 18 years

          -  Very high risk patients must have Advanced MDS ( 5% blast) or acute leukemia after
             initial hematopoietic stem cell transplant (HSCT)

          -  Patients must have an appropriate source of stem cells. Patients and donors will be
             typed for HLA-A, B, C and DRB1 using high resolution molecular typing.

          -  Adequate major organ function including:

               -  Cardiac: ejection fraction &gt;45%

               -  Hepatic: bilirubin, AST or ALT, ALP &lt;5 x normal

               -  Karnofsky performance status &gt;70% or Lansky &gt;50 (if &lt; 16 years of age)

          -  Women of child-bearing age must be using adequate birth control and have a negative
             pregnancy test.

          -  Written consent.

        Exclusion Criteria:

          -  Available HLA-genotypically identical related donor in standard risk patients.

          -  Active central nervous system (CNS) leukemia at time of study enrollment.

          -  History of squamous cell carcinoma of the head/neck/cervix within previous 2 years.

          -  Prior radiation therapy that prevents further total body irradiation (TBI).
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Must be newly diagnosed with clinical stage II, III, or IV breast cancer who will
             undergo neoadjuvant chemotherapy (chemotherapy prior to surgery)

          -  Must &gt;= 18 years of age

          -  If female, must not be pregnant

          -  Must be willing and able to sign informed consent document
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients 14 years of age and up with colon cancer recently removed by surgery and
        receiving chemotherapy to try to prevent cancer from returning.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Histologically proven adenocarcinoma of the colon. Those patients that do not have
             tissue available at MDACC for analysis will be eligible to participate in the blood,
             questionnaire and data portion of the study. They will not participate in the tissue
             portion of this study.

          2. AJCC stage II [T3-4(subscript)N0(subscript)M0(subscript)]or stage III
             [TX(subscript)N1-3(subscript)M0(subscript)].

          3. Age &gt;= 14 yrs old.

          4. If the patient elects to receive chemotherapy and it is to be administered outside of
             M. D. Anderson Cancer Center (MDACC), the patient must agree to complete all
             subsequent surveillance at M.D. Anderson Cancer Center if participating in this
             clinical trial.

          5. Ability to understand and the willingness to sign the written informed
             consent/authorization document.

        Exclusion Criteria:

          1. Patients who have initiated adjuvant chemotherapy prior to participating in this
             study will not be included.

          2. Patients with known history of familial adenomatous polyposis (FAP), hereditary
             nonpolyposis colorectal cancer (HNPCC), and any other hereditary polyposis syndrome
             (Muir Torre, Gardner's Syndrome, etc) will be excluded since these patients are at
             increased risk for second primary malignancies and are at higher risk of recurrent
             disease.

          3. No prior malignancies (excluding non-melanomatous skin neoplasms) over the past 5
             years.

          4. Patients with a known diagnosis of HIV/AIDS or Hepatitis C will be excluded from this
             study due to their increased risk of second primary malignancies that may complicate
             appropriate analysis of DFS.

          5. Patients who are unable to self-administer the protocol questionnaire will be
             excluded from this study.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  14 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients on this trial will receive two partially HLA matched umbilical cord blood
             (UCB) units, if available (treatment arm 1).  If two units are not available, then
             single UCB unit transplantation will be allowed (on treatment arm 2).

          -  UCB units will be selected according to the University Of Minnesota UCB Graft
             Selection Algorithm. The unrelated cord blood donor(s) must be 4-6/6 HLA-A, B, DRB1
             matched with the recipient (HLA matching using molecular techniques: A and B to
             antigen level resolution and DR to allele level resolution).

          -  Patients aged  2 years at diagnosis (not age of transplant) with hematological
             malignancy as detailed below:

               -  Acute myeloid leukemia: high risk CR1 as evidenced by:

                    -  High risk cytogenetics t(4;11) or other MLL rearrangements; chromosome 5,
                       7, or 19 abnormalities; complex karyotype (&gt;5 distinct changes);  2 cycles
                       to obtain complete response (CR); CR2 or higher; Preceding myelodysplastic
                       syndrome (MDS); All patients must be in CR or early relapse (i.e., &lt;15%
                       blasts in BM).

                    -  Acute lymphocytic leukemia: high risk CR1 as evidenced by: High-risk
                       cytogenetic: t(4;11) or other MLL rearrangements; hypodiploid; t(9;22); &gt;1
                       cycle to obtain CR; CR2 or higher; All patients must be in CR as defined by
                       hematological recovery, AND &lt;5% blasts by light microscopy within the bone
                       marrow with a cellularity of 15%.

               -  Myelodysplasia (MDS) IPSS Int-2 or High risk (i.e. RAEB, RAEBt) or refractory
                  anemia with severe pancytopenia or high risk cytogenetics. Blasts must be &lt; 10%
                  by a representative bone marrow aspirate morphology.

               -  Minimal Residual Disease (MRD): Patients with evidence of minimal residual
                  disease at the completion of therapy or evidence of rising MRD while on therapy.
                  MRD will be defined by either flow cytometry (&gt;0.1% residual cells in the blast
                  gate with immune phenotype of original leukemic clone), by molecular techniques
                  (PCR or FISH) or conventional cytogenetics (g-banding).

          -  Recipients must have a Lansky score &gt; or = 50% and have acceptable organ function
             defined as:

               -  Renal: glomerial filtration rate &gt; 60ml/min/1.73m^2

               -  Hepatic: bilirubin, AST/ALT, ALP &lt; 5 x upper limit of normal,

               -  Pulmonary function: oxygen saturation &gt;92%

               -  Cardiac: left ventricular ejection fraction &gt; 45%.

          -  Voluntary written informed consent before performance of any study-related procedure
             not part of normal medical care.

        Exclusion Criteria:

          -  Active infection at time of transplantation (including active infection with
             Aspergillus or other mold within 30 days).

          -  History of HIV infection

          -  Prior myeloablative transplant within the last 6 months.

          -  Evidence of active extramedullary disease (including central nervous system
             leukemia).
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  2 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  The subject or the subject's legally authorized representative has provided signed
             informed consent.

          -  The subject is within 18 to 70 years of age.

          -  The subject has severe or moderately severe hemophilia A, defined by a baseline
             factor VIII level &lt;= 2% of normal, as tested at screening. A subset of 15 subjects
             per group must have baseline factor VIII levels &lt; 1% of normal.

          -  The aPTT must be within the range of normal after administration of FVIII
             concentrate, as determined in the preoperative pharmacokinetic evaluation, or as
             documented in the medical history, if available.

          -  The subject is scheduled to undergo an elective unilateral major orthopedic surgery
             that requires drain placement.

          -  The subject was previously treated with factor VIII concentrate(s) for a minimum of
             at least 150 exposure days (as estimated by the investigator) prior to study entry.

          -  Human immunodeficiency virus (HIV) positive subjects must be immunocompetent as
             determined with a CD4 count &gt;= 200 cells/mm (CD4 count at screening), but HIV
             negative subjects with a CD4 count &lt; 200 cells/mm qualify, if immunocompetency is
             documented.

          -  The subject has a life expectancy of at least 28 days from the day of surgery.

        Exclusion Criteria:

          -  The subject has a detectable factor VIII inhibitor at screening, with a titer &gt;= 0.4
             BU (Nijmegen modification of the Bethesda assay) in the central laboratory.

          -  The subject has a history of factor VIII inhibitors with a titer &gt;= 0.4 BU (by
             Nijmegen assay) or &gt;= 0.5 BU (by Bethesda assay) at any time prior to screening.

          -  The subject is scheduled to undergo any other concurrent minor or major surgery
             during the course of the study. The placement of central venous lines and the
             performance of fine needle aspiration biopsies are permitted.

          -  Excluding hemophilia-related physical impairments, the subject is assigned to NYHA
             class &gt;= III according to the New York Heart Association (NYHA).

          -  The subject has an abnormal renal function (serum creatinine &gt; 1.5 mg/dL).

          -  The subject has active hepatic disease (alanine aminotransferase [ALT] or aspartate
             aminotransferase [AST] levels &gt; 5 times the upper limit of normal).

          -  The subject has severe chronic liver disease as evidenced by, but not limited to, any
             of the following: International Normalized Ratio (INR) &gt; 1.4, hypoalbuminemia, portal
             vein hypertension including presence of otherwise unexplained splenomegaly and
             history of esophageal varices.

          -  The subject has clinical and/or laboratory evidence of abnormal hemostasis from
             causes other than hemophilia A (e.g., late-stage chronic liver disease, immune
             thrombocytopenia purpura).

          -  The subject is currently receiving, or is scheduled to receive during the course of
             the study, an immunomodulating drug other than anti-retroviral chemotherapy (e.g.,
             alpha-interferon, corticosteroid agents at a dose equivalent to hydrocortisone
             greater than 10 mg/day).

          -  The subject has a known hypersensitivity to mouse or hamster proteins.

          -  The subject has received another investigational drug study within 30 days prior to
             screening and/or is scheduled to receive additional investigational drug during the
             course of the trial in the context of another investigational study.

          -  The subject is identified by the investigator as being unable or unwilling to
             cooperate with study procedures.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Primary immunodeficiency disorder or other nonmalignant inherited disease (except
             Fanconi anemia) treatable by allogeneic HCT

          -  Patients with pre-existing medical conditions or other factors that renders them at
             high risk for regimen related toxicity or ineligible for conventional myeloablative
             HCT and who do not have HLA-matched related or unrelated donors

          -  Patients with a related donor who is identical for one HLA haplotype

          -  Acquired aplastic anemia: Severe aplastic anemia (SAA) is defined as follows:

               -  Bone marrow cellularity &lt; 25%, or marrow cellularity &lt; 50% but with &lt; 30%
                  residual hematopoietic cells

               -  Two out of three of the following (in peripheral blood): neutrophils &lt; 0.5 x
                  10^9/L; platelets &lt; 20 x 10^9/L; reticulocytes &lt; 20 x 10^9/L

               -  SAA diagnostic criteria may be applied to assessment at initial diagnosis or
                  follow-up assessments

          -  DONOR: Related donors who are identical for one HLA haplotype (bone marrow will be
             the only allowed stem cell source)

        Exclusion Criteria:

          -  Fanconi anemia

          -  Suitably HLA-matched related or unrelated donors

          -  Patients with metabolic storage diseases who have severe central nervous system (CNS)
             involvement of disease, defined as IQ score &lt; 70

          -  Cardiac ejection fraction &lt; 30% (or, if unable to obtain ejection fraction,
             shortening fraction &lt; 26%) on multiple-gated acquisition (MUGA) scan or cardiac echo,
             symptomatic coronary artery disease, or other cardiac failure requiring therapy

          -  Patients with a history of, or current cardiac disease should be evaluated with
             appropriate cardiac studies and/or cardiology consult; patients with a shortening
             fraction of &lt; 26% must be seen by cardiology for approval

          -  Poorly controlled hypertension despite anti-hypertensive medications

          -  Patients with clinical or laboratory evidence of liver disease will need to be
             evaluated for the cause of the liver disease, its clinical severity in terms of liver
             function and the degree of portal hypertension; patients will be excluded if they are
             found to have fulminant liver failure, cirrhosis of the liver with evidence of portal
             hypertension, bridging fibrosis, alcoholic hepatitis, esophageal varices, a history
             of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic
             synthetic dysfunction evidenced by prolongation of the prothrombin time, ascites
             related to portal hypertension, bacterial or fungal liver abscess, biliary
             obstruction, chronic viral hepatitis with total serum bilirubin &gt; 3 mg/dl, or
             symptomatic biliary disease

          -  Seropositive for human immunodeficiency virus (HIV)

          -  Females who are pregnant (beta- human chorionic gonadotropin [B-HCG]+) or
             breast-feeding

          -  Fertile men or women who are unwilling to use contraceptives during HCT and up to 12
             months post-treatment

          -  Patients with fungal pneumonia with radiological progression after receipt of
             amphotericin formulation or mold-active azoles for greater than 1 month will not be
             eligible for this protocol

          -  DONOR: Donor-recipient pairs in which the HLA-mismatch is only in the
             host-versus-graft (HVG) direction; patients are homozygous and donor is heterozygous

          -  DONOR: Donors who are not expected to meet the minimum target dose of marrow cells (1
             x 10^8 nucleated cells/kg recipient Ideal Body Weight)

          -  DONOR: HIV-positive donors

          -  DONOR: A positive anti-donor cytotoxic cross match is absolute donor exclusion

          -  DONOR: &lt; 6 months old and &gt; 75 years old
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  54 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Any patient with a condition or disease whose etiology is unknown.

        Adequate venous access.

        EXCLUSION CRITERIA:

        None
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients must have undergone pancreaticoduodenectomy.

          -  Must have pancreatic remnant remaining in place (body and tail).

          -  Must be candidate for reconstruction by pancreaticojejunostomy by one of the two
             techniques described below.

          -  Must have an identifiable pancreatic duct which can be used for a duct-to-mucosa
             anastomosis.

        Exclusion Criteria:

          -  Patients undergoing total pancreatectomy.

          -  Patients undergoing PD who have had previous left-sided pancreatic resection.

          -  Failure to sign informed consent.

          -  Failure to identify the pancreatic duct.

          -  Pregnant patients.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Individuals visiting the Starr-5 Pulmonary, Critical Care Unit, and 5 West floor for
        standard clinical care will be recruited.  Controls will be obtained from volunteers
        without a history of lung disease.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Must provide informed consent

          -  Males and females, age 18 years and older

          -  Lung disease proven by at least one of the following:

               -  symptoms consistent with pulmonary disease

               -  chest X-rays consistent with lung disease

               -  pulmonary function tests consistent with lung disease

               -  lung biopsy consistent with lung disease

               -  family history of lung disease

               -  disease of organs with know associated with lung disease

               -  individuals suspected of history of lung disease based on history and/or
                  physical examination

               -  normal controls (individuals without history of lung disease) to be sampled to
                  provide a comparison to the lung disease cohort.

        Exclusion Criteria:

          -  Drug and/or alcohol abuse within the past six months

          -  Females who are pregnant or nursing
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Diagnosis of chronic myelogenous leukemia (CML) in chronic phase based on cytogenetic
             detection of the Philadelphia chromosome and/or detection of the BCR-ABL
             rearrangement by any of the following molecular methods:

               -  Recombinant DNA analysis of the BCR-ABL fusion gene

               -  Fluorescence in situ hybridization (FISH)

               -  Polymerase chain reaction detection of the BCR-ABL hybrid mRNA

          -  Documentation of complete cytogenetic response by conventional cytogenetic or FISH
             analysis while on a stable dose of tyrosine kinase inhibitor

          -  No other phase of CML

        PATIENT CHARACTERISTICS:

          -  ECG performance status 0-2

          -  Life expectancy &gt; 24 months

          -  Not pregnant

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Creatinine  2.0 mg/dL

          -  Bilirubin  2.0 times upper limit of normal (ULN)

          -  AST and ALT  2.5 times ULN

          -  No other malignancy within the past 5 years except in situ cervical carcinoma or
             adequately treated nonmelanoma skin cancer

          -  No other disease requiring long-term corticosteroids or immunosuppressants

        PRIOR CONCURRENT THERAPY:

          -  At least 28 days since prior investigational agents

          -  No prior bone marrow transplant or other transplant

          -  No concurrent immunosuppressants (e.g., steroids, cyclosporine, azathioprine,
             mycophenolate mofetil, sirolimus, or tacrolimus)

          -  No concurrent hydroxyurea, busulfan, or cytoreductive agents (other than frontline
             TKI)

          -  No other concurrent anticancer agents or therapies
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients must have locally advanced or metastatic urothelial cancer that is not
             amenable to surgical treatment

          -  Patients must have histologically or cytologically confirmed urothelial tract
             carcinoma

          -  Patients must have measurable disease, defined as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter to be recorded) as &gt;=
             20 mm with conventional techniques or as &gt;= 10 mm with spiral computed tomography
             (CT) scan

          -  All patients may have received up to two prior lines of chemotherapy for
             recurrent/advanced disease

          -  Patients must have received at least one platinum-based chemotherapy for
             recurrent/advanced disease; recurrent disease is defined as having recurred after
             definitive therapy and advanced disease is defined as T4 and/or N2 and/or M1; in
             addition, for completion of Cohort #2, patients must also have received a tubulin
             inhibitor as part of their therapy for urothelial cancer; for purposes of this
             evaluation, treatment with chemotherapy regimens where carboplatin or similar is
             substituted for cisplatin or where a taxane is added or removed will be considered
             the same regimen; tubulin inhibitors in common use include paclitaxel, docetaxel, and
             vinblastine; the exception to this requirement applies to women

          -  Women with and without prior therapy are also eligible; priority will be given to
             those who consent to participating in the pharmacokinetic studies

          -  Life expectancy of greater than 6 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2 and Karnofsky &gt;= 60%

          -  Absolute neutrophil count &gt;= 1,000/mcL

          -  Platelets &gt;= 100,000/mcL

          -  Hemoglobin &gt;= 9 g/dL

          -  Total bilirubin =&lt; 1.5 institutional upper limit of normal (IULN)

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =&lt; 2.5 X IULN

          -  Patients must have either (a) normal kidney function (i.e. creatinine =&lt; 1.5 X upper
             limit of normal [ULN] OR calculated creatinine clearance &gt;= 60 mL/min by the modified
             Cockcroft and Gault Formula OR a creatinine clearance &gt;= 60 mL/min obtained from a
             24-hour urine collection) or (b) moderate or severe renal dysfunction (i.e.
             creatinine clearance &lt; 60 mL/min and &gt;= 20 mL/min)

          -  Patients with symptomatic uremia, uncontrolled edema or unstable serum electrolytes
             should not enter the trial until such time as they have been stabilized - such
             patients should be discussed with the principal investigator

          -  Eligibility of patients receiving any medications or substances known to affect or
             with the potential to affect the activity or pharmacokinetics of E7389 Halichondrin
             analog will be determined following review of their case by the principal
             investigator

          -  Women and men of child-bearing potential must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry and
             for the duration of study participation; should a woman become pregnant or suspect
             she is pregnant while participating in this study, she should inform her treating
             physician immediately

          -  Patients must have the ability to understand and the willingness to sign a written
             informed consent document

        Exclusion Criteria:

          -  Patients may not be receiving any other investigational agents

          -  Patients with brain metastasis that are unstable (i.e. presenting with neurologic
             symptoms that progress or require increasing doses of steroids within a 4-week
             period) or are untreated (i.e. not radiated) should be excluded

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if
             the mother is treated with E7389

          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
             therapy are ineligible; HIV-positive patients with cluster of differentiation (CD)4+
             =&lt; 500/mm^3 are ineligible; appropriate studies will be undertaken in this group of
             patients when indicated

          -  Prior therapy with E7389 Halichondrin analog (eribulin)
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   HIV-positive men who have sex with men
  </textblock>
 </study_pop>
 <sampling_method>
  Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  HIV-infected patients

        Exclusion Criteria:

          -  None
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Individuals who are 18 years of age or older with or without a history of gastrointestinal
        disease and with any of the following:

          1. lymphangioleiomyomatosis, or

          2. asthma, or

          3. sarcoidosis, or

          4. pulmonary fibrosis, or

          5. other chronic or genetic lung diseases (e.g., chronic obstructive pulmonary disease,
             eosinophilic granuloma, cystic fibrosis, Wegener's granulomatosis, chronic
             bronchitis), or

          6. research volunteers without a history of lung disease.

        EXCLUSION CRITERIA:

        Individuals with any of the following:

          1. uncontrolled ischemic heart disease, or

          2. uncorrectable bleeding diathesis, or

          3. pregnancy or lactation, or

          4. inability to give informed consent, or

          5. risk factors for endocarditis (e.g., prosthetic cardiac valve, previous bacterial
             endocarditis, surgically constructed systemic pulmonary shunts or conduits, complex
             cyanotic congenital heart disease [e.g., single ventricle, transposition of great
             arteries, tetralogy of Fallot])
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   INCLUSION CRITERIA:

          1. Any patient, regardless of age or sex, with EBV-positive lymphoma, or
             lymphoepithelioma regardless of the histological subtype or EBV (associated)-T/NK-LPD
             all confirmed on any tissue sample.

             Primary refractory lymphoma or in second or subsequent relapse including after
             autologous or syngeneic stem cell transplant OR patients at a high risk for relapse
             defined as: (i) patients with primary refractory lymphoma or multiply relapsed
             lymphoma who are in remission but not eligible for autologous SCT or (ii) patients
             with relapsed lymphoma after autologous SCT who are in remission but not eligible for
             allogeneic SCT (Group A)

             OR

             Any patient who has received an allogeneic SCT for  EBV Lymphoma or EBV
             (associated)-T/NK-LPD or Lymphoepithelioma (Group B)

          2. Patients with life expectancy 6 weeks or greater from the time of CTL infusion.

          3. Patients with a Karnofsky score of 50 or greater.

          4. If post allogeneic SCT must not have less than 50% donor chimerism in either
             peripheral blood or bone marrow

          5. Patients with bilirubin 3x normal or less, AST 5x normal or less, and Hgb greater
             than 8.0

          6. Patients with a creatinine 2x normal for age or less

          7. Patients with O2 saturations greater than 93% on room air (measured by pulse
             oximetry)

          8. Patient, parent/guardian able to give informed consent.

          9. Patients should have been off other investigational therapy for one month prior to
             entry in this study.

        EXCLUSION CRITERIA:

          1. Patients with a severe intercurrent infection.

          2. Patients with evidence of GVHD greater than Grade II at time of enrollment.

          3. HIV positive at time of procurement cells for CTL generation

          4. Due to unknown effects of this therapy on a fetus, pregnant women are excluded from
             this research. The male partner should use a condom.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   INCLUSION CRITERIA:

          -  Lack of suitable conventional donor (i.e. 5/6 or 6/6 related or 5/6 or 6/6 unrelated
             donor) or presence of a rapidly progressive disease not permitting time to identify
             an unrelated donor

          -  Age less than or equal to 55 years of age

          -  Patients with high risk ALL in CR1 or ALL or high grade (stage III or IV) NHL after
             first relapse or with primary refractory disease or minimal residual diseases.

          -  Myelodysplastic syndrome

          -  Patients with high risk AML in CR1 (complement receptor 1) or after first relapse or
             with primary refractory disease or minimal residual disease.

          -  CML

          -  Hemophagocytic lymphohistiocytosis (HLH), familial hemophagocytic lymphohistiocytosis
             (FLH), viral-associated hemophagocytic syndrome (VAHS), X-linked lymphoproliferative
             disease (XLP)

          -  Donor cells should be collected and frozen before conditioning starts

        EXCLUSION CRITERIA:

          -  Patients with a life expectancy (&lt; / = 6 weeks) limited by diseases other than
             leukemia

          -  Patients with symptomatic cardiac disease, or evidence of significant cardiac disease
             by echocardiogram (i.e., shortening fraction &lt; 25%)

          -  Patients with severe renal disease (i.e., creatinine clearance less than 40 cc/1.73
             m2)

          -  Patients with pre-existing severe restrictive pulmonary disease (FVC less than 40% of
             predicted)

          -  Patients with severe hepatic disease (direct bilirubin greater than 3 ug/dl or SGPT
             (serum glutamic-pyruvic transaminase) greater than 500 ug/dl)

          -  Patients with severe personality disorder or mental illness

          -  Patients with a severe infection that on evaluation by the Principal Investigator
             precludes ablative chemotherapy or successful transplantation

          -  Patients with documented HIV positivity

        'High risk' ALL or AML refers to those acute leukemias identified by the presence of
        specific biologic features, which predict high likelihood of failure to conventional
        chemotherapy.  As biologic features of high risk disease evolve with improvement of
        conventional chemotherapy, it is not practical to define this indication with any further
        specificity.  Therefore, high risk AML/ALL will be determined by the primary physician.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  55 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Have given written informed consent, prior to pre-study screening, with the
             understanding that consent may be withdrawn at any time without prejudice.

          2. A histological diagnosis of nasopharyngeal cancer (NPC) must have been established at
             some time and the investigator must review and confirm the diagnosis prior to
             randomization.

          3. Loco-regional advanced NPC UICC/AJCC Stages IIB, III, IVA or IVB.

          4. No evidence of distant metastases in the staging work up at diagnosis.

          5. Must have detectable plasma EBV-DNA (&gt; 0 copies/ml) at  6-8 weeks after completion of
              primary RT or chemo-RT

          6. No clinical evidence of persistent loco-regional disease after primary treatment

          7. Performance status of ECOG grade 0 or 1.

          8. Patients must have adequate organ and marrow function as defined below:

             leukocytes &gt;3,000/L; absolute neutrophil count &gt;1,500/L; platelets &gt;100,000/L; total
             bilirubin &lt;1.5 X institutional upper limit of normal; AST(SGOT)/ALT(SGPT) &lt;2.5 X
             institutional upper limit of normal; Creatinine clearance &gt; 50 ml/min

          9. At least 18 years of age, of either sex.

         10. If female, must be either (i) post-menopausal or surgically sterilized, or (ii) use a
             hormonal contraceptive, intra-uterine device, diaphragm with spermicide for the
             duration of the study and must be neither pregnant nor breast-feeding.

        Exclusion Criteria:

          1. Hypercalcaemia: calcium &gt;= 2.7 mmol/L (10.8 mg/dL).

          2. Second primary malignancy (except in situ carcinoma of the cervix or adequately
             treated basal cell carcinoma of the skin).

          3. More that 12 weeks after completion of primary radiotherapy.

          4. Had received prior adjuvant chemotherapy.

          5. Other serious concomitant systemic disorders incompatible with the study (at the
             discretion of the investigator).

          6. Have serious active infection.

          7. Patients with peripheral or ototoxicity with a grade of greater than 2.

          8. Pregnant or lactating female subjects and subjects with reproductive potential not
             implementing adequate contraceptive measures.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients scheduled to undergo radical prostatectomy at Stanford
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

        - Patients scheduled to undergo radical prostatectomy at Stanford

        Exclusion Criteria:

        - Patients treated with neoadjuvant or adjuvant hormonal therapy or radiation therapy
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients diagnosed with liver cancer
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:Patients diagnosed with liver cancer based on biopsy or serum AFP
        level, associated with characteristic hypervascular liver tumors on triphasic spiral CT
        scan or MRI.

          -  Patients with non-cancer liver conditions such as cirrhosis, adenoma, cholangioma, or
             nodular hyperplasia.

          -  Patients with hepatitis B or hepatitis C viral infections not associated with liver
             cancer.

        Exclusion Criteria:Patients will be excluded if, upon looking through their medical
        records, information required for data analysis are missing.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  High risk renal cancer per modified UISS criteria

          -  Eastern Cooperative Oncology Group (ECOG) 0-2

          -  predominant clear cell histology

          -  No prior anti-cancer treatment

          -  Kidney tumor has been removed

          -  No evidence of macroscopic disease following surgery

        Exclusion Criteria:

          -  Histologically undifferentiated carcinomas or collecting duct carcinoma, lymphoma,
             sarcoma or subjects with metastatic renal sites.

          -  Diagnosis of any second malignancy within the last 5 years, except basal cell
             carcinoma, squamous cell skin cancer, or in situ carcinoma of the cervix uteri that
             has been adequately treated with no evidence of recurrent disease for 12 months

          -  known HIV or Hepatitis

          -  any severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or study
             drug administration
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  preoperative PSA&gt;20ng/ml

          -  postoperative PSA &gt;0.2 ng/ml

          -  Gleason &gt; 7

          -  pT3b

          -  signated infomed consent

        Exclusion Criteria:

          -  neoadjuvant hormonaltherapy before RP

          -  R1 RP

          -  N+ RP

          -  unstable cncomitant conditions
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  40 Years
 </minimum_age>
 <maximum_age>
  80 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients older than 18-year-old.

          -  Patients must have a diagnosis of cancer.

          -  Patients must understand and voluntarily sign an Informed Consent form after the
             contents have been fully explained to them.

        Exclusion Criteria:

          -  Patients who cannot complete a PET/CT scan.

          -  Pregnant women.

          -  Patients with metallic prosthesis/implants/devices unsafe for MRI imaging.

          -  Healthy volunteers.

          -  Patients participating in other research studies.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Diagnosis of breast cancer

               -  Newly diagnosed disease

               -  Stage I-III disease

          -  No diagnosed lymphedema

          -  Must have arm measurements for axilla, elbow, and wrist that fall within the ranges
             for one of six sleeve sizes (i.e., all three measurments must be found in one column)
             available

          -  Scheduled to undergo axillary node dissection with  10 nodes removed

               -  No sentinel axillary node dissection only

          -  Hormone receptor status not specified

        PATIENT CHARACTERISTICS:

          -  Female

          -  Menopausal status not specified

          -  No documented cardiac conduction disturbances, unstable angina, dementia, or any
             other chronic disease that, in the opinion of the investigator, significantly
             increases mortality over the next 2 years

          -  May not be currently homebound or dependent upon a walker or wheelchair for mobility

          -  Able to participate in a mild exercise program

          -  No prior history of carcinoma in situ, lobular carcinoma in situ, ductal carcinoma in
             situ, or invasive breast cancer

               -  Patients with a history of other invasive malignancies are eligible as long as
                  they have completed treatment and are 5 years post-diagnosis

               -  Patients with basal cell and squamous cell carcinoma of the skin are eligible

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior double mastectomy, axillary node dissection, and/or radiotherapy involving
             both arms

               -  Prior treatment (i.e., surgergy and/or radiotherapy) on the contralateral arm
                  allowed provided it is documented appropriately

          -  May be enrolled on other treatment trials except surgery trials where one treatment
             arm involves full axillary node dissection

               -  Patients enrolled on ACOSOG-Z1071 allowed

          -  Any type of radiotherapy to the breast or axilla allowed

          -  Neoadjuvant treatment for this cancer allowed
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Diagnosis of cerebral metastases meeting the following criteria:

               -  One to three presumed brain metastases

               -  Metastases must be from a histologically confirmed extracerebral site (e.g.,
                  lung, breast, prostate)

                    -  Histologic confirmation may have been from the primary tumor site, from
                       another metastatic site (e.g., osseous metastasis, adrenal metastasis), or
                       from the metastatic brain lesion(s)

               -  Each lesion must measure less than 3.0 cm by contrast MRI of the brain performed
                  within the past 21 days

               -  Lesions must not be within 5 mm of the optic chiasm or within the brainstem

          -  Eligibility for treatment with gamma knife or linear accelerator-based radiosurgery
             confirmed by a radiation oncologist

          -  No primary germ cell tumor, small cell carcinoma, or lymphoma

          -  No leptomeningeal metastases

          -  Hormone receptor status not specified

        PATIENT CHARACTERISTICS:

          -  Male or female

          -  Menopausal status not specified

          -  ECOG performance status 0-2

          -  Not pregnant

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

               -  Male patients must continue to use contraception for 3 months after the
                  completion of radiotherapy

          -  No pacemaker or other MRI-incompatible metal in the body

          -  No known allergy to gadolinium

        PRIOR CONCURRENT THERAPY:

          -  More than 7 days since prior and no concurrent chemotherapy

          -  No prior cranial radiotherapy

          -  No prior resection of cerebral metastases

          -  Concurrent hormonal agents, steroids, and/or anticonvulsants allowed
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients of at least 18 years old with histologically documented non-gastric marginal
             zone lymphoma.

          -  Disease limited to stages I and II after adequate staging (see Appendix II), patients
             with stage IV with extranodal disease confined to paired organs (e.g. salivary
             glands) and including any local extension of this disease into adjacent tissues.
             Patients with involved lymph nodes on the same side of the diaphragm in addition to
             paired organ involvement are also eligible, provided all involved tumour sites, nodal
             and extranodal, can be irradiated to 30 Gy within the tolerance of the relevant
             normal tissues. If paired organ involvement was regarded as a single extranodal site
             (rather than 2 separate sites and hence stage IV), eligible patients would then be
             regarded as having stage IE or IIE disease. Patients with wider dissemination (bone
             marrow, liver etc) are ineligible.

          -  Anticipated life expectancy &gt; 2 years

          -  Given written informed consent

          -  Been assessed by a radiation oncologist

          -  Agree to undergo breath testing for H. pylori and/or oesophagogastroduodenoscopy to
             exclude active infection with helicobacter pylori

          -  Must be available for long-term follow up

        Exclusion Criteria:

          -  Splenic marginal zone lymphoma

          -  Received previous locoregional radiotherapy

          -  A medical contraindication to radiotherapy

          -  Any previous or concurrent malignancy other than curatively treated non-melanoma skin
             cancer, level 1 malignant melanoma, or in situ cervical cancer, unless disease and
             treatment-free for 5 years

          -  Such extensive involvement of the thorax that treatment with radiotherapy alone would
             be hazardous because of excessive lung irradiation, even if a shrinking field
             technique were employed

          -  Suspected or confirmed pregnancy

          -  Transformation to large cell lymphoma or other aggressive histology

          -  Disease that is widely disseminated (bone marrow, liver etc)
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients diagnosed with Paraneoplastic Disorder

        Exclusion Criteria:

          -  Metastasis (spread) of cancer to brain, History of additional active malignancy other
             than non-melanoma skin cancer, History of Hepatitis B, Hepatitis C, HIV or Syphilis.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  16 Years
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Diagnosis of APL based on morphological grounds, which will have to be confirmed by
             the presence of t(15;17) and/or PML-RARA rearrangement with characterization of the
             bcr subtype (PML-RAR characterization).

          -  Untreated patients.

          -  No contraindication to intensive chemotherapy (especially well documented cardiac
             contraindication to idarubicin).

          -  In female patients: absence of pregnancy and adequate contraceptive methods (due to
             teratogenetic effects of ATRA in early pregnancy).

          -  Absence of Hypersensitivity to Arsenic derivatives.

          -  No QT interval prolongation  or complete atria-ventricular block.

          -  Written informed consent.

        Exclusion Criteria:

          -  Patients already treated.

          -  Patients with contraindication to intensive chemotherapy, especially well documented
             cardiac contraindication to Idarubicin.

          -  In female patients: pregnancy or absence of adequate contraceptive Methods

          -  QT interval prolongation or complete atria-ventricular block.

          -  Hypersensitivity to Arsenic derivatives.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  histologically proven nasopharyngeal carcinoma for primary treatment with radical
             intent

          -  non-keratinizing or undifferentiated type

          -  stage III-IVB (by AJCC/UICC 6th edition)

          -  ECOG Performance status less or equal to 2

          -  Marrow: WBC &gt;= 4 and platelet &gt;=100

          -  Renal: creatinine clearance &gt;=60

          -  Informed consent

        Exclusion Criteria:

          -  Primary treatment with palliative intent

          -  WHO type I squamous cell carcinoma or adenocarcinoma

          -  Evidence of distant metastases

          -  Patient is pregnant or lactating

          -  Prior malignancy except adequately treated basal cell or squamous cell skin cancer,
             in-situ cervical cancer or other cancer for which the patient has been disease-free
             for 5 years
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Adrenoleukodystrophy: Patients from 0-55 years of age diagnosed with ALD as
             determined by very long chain fatty acid testing will be eligible for this protocol
             if they have evidence of cerebral or cerebellar disease based on MRI testing, AND
             they are determined high risk for any of the following reasons:

               1. Age &gt;18 years

               2. MRI score &gt;10

               3. Evidence of aggressive disease that in the judgment of the Inherited Metabolic
                  and Storage Disease group is sufficiently concerning to consider transplantation
                  with a reduced intensity regimen instead of a standard full preparative regimen.

          -  Metachromatic Leukodystrophy: Patients from 0-55 years of age diagnosed with MLD as
             determined by determinations of arylsulfatase A testing will be eligible for this
             protocol IF they are determined high risk for any of the following reasons:

               1. Age &gt;18 years

               2. Symptomatic disease, as based on neurologic examination, or evidence of
                  deterioration based on subsequent neuropsychologic evaluations.

               3. Evidence of aggressive disease such as rapidly changing MRI determinations that
                  in the judgment of the Inherited Metabolic and Storage Disease group is
                  sufficiently concerning to consider transplantation with a reduced intensity
                  regimen instead of a standard full preparative regimen.

          -  Globoid Cell Leukodystrophy: Patients from 0-55 years of age diagnosed with GLD as
             determined by determinations of galactocerebrosidase testing will be eligible for
             this protocol IF they are determined high risk for any of the following reasons:

               1. Age &gt;18 years

               2. Symptomatic disease, as based on neurologic examination, or evidence of
                  deterioration based on subsequent neuropsychologic evaluations.

               3. Evidence of aggressive disease such as rapidly changing MRI determinations that
                  in the judgment of the Inherited Metabolic and Storage Disease group is
                  sufficiently concerning to consider transplantation with a reduced intensity
                  regimen instead of a standard full preparative regimen.

          -  Patients with GM1 gangliosidosis, Tay Sachs disease, Sanfilippo syndrome, Wolman
             disease or Sandhoff disease or other inherited metabolic diseases including but not
             limited to I-cell disease (mucolipidosis II) who are determined to be sufficiently
             advanced or high risk based on the following reasons:

               1. Symptomatic disease, as based on neurologic examination, or evidence of
                  deterioration based on subsequent neuropsychologic evaluations.

               2. Evidence of an expected poor outcome based on genetic testing or a prior family
                  history of aggressive disease.

               3. Other metabolic disorders, including but not limited to I-cell disease, that are
                  deemed to be high-risk for a poor outcome with a standard transplant regimen due
                  to anticipated toxicity based on experience gained at the University of
                  Minnesota or other centers.

        Exclusion criteria:

          -  Major organ dysfunction.

          -  Advanced Disease Exclusion: Following evaluation, if a consensus of the members of
             the Inherited Metabolic and Storage Disease Program is that a patient is too advanced
             to benefit in a measurable and meaningful way from transplant, this will be
             communicated to the family, and transplant will not be offered. Measures to assist in
             those determinations may include: neurologic/neurocognitive functions such as
             activities of daily living, motor function, vision, hearing, interaction with
             environment, toileting, swallowing, or other standardized measures
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Patients referred to the surgeons of the Stanford University Breast Cancer Program

          2. Patients will be required to have the capacity to provide informed consent.

          3. All experimental protocols will be reviewed and approved by the Stanford
             Institutional Review Board for  the Protection of Human Subjects.

          4. All of the subjects to be enrolled in the proposed studies will be patients with
             unilateral breast cancer who are scheduled to undergo breast surgery and axillary
             lymph node dissection, with or without breast conserving techniques.

        Exclusion Criteria:

          1. Patients with other serious systemic illness (renal failure, hepatic dysfunction,
             congestive heart failure, neurological or psychological impairment) that would
             confound the study or impair the patients' ability to participate.

          2. Patients with recurrent breast cancer or other forms of pre-existing lymphedema will
             be ineligible.
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Patients &lt; 65 years of age with histologically confirmed refractory or relapsed
             Hodgkin's disease (including patients who fail or relapse after autologous SCT). This
             upper age limit will apply to transplants from both matched related and unrelated
             donors.

          2. Patients should have any of the following disease status: a. responsive or stable
             disease on salvage chemotherapy or radiation therapy. b. untreated, smoldering (i.e.
             not rapidly progressive) relapses.

          3. Patients must have a serum bilirubin equal to or &lt;/=2.0 mg/dl (isolated
             hyperbilirubinemia related to Gilbert's disease allowed), serum transaminase (ALT)
             equal to or &lt;/= 3 times the upper limit of the normal range, serum creatinine &lt;2.0
             mg/dl (provided they also have a glomerular filtration rate of at least 55 ml/min),
             no symptomatic cardiac or pulmonary disease and a performance status equal to or
             &lt;/=2. Left ventricular ejection fraction &gt;/= 40%, FEV1, FVC and corrected DLCO &gt;/=
             50% predicted.

          4. Patients must have an HLA-compatible related or unrelated donor (one-antigen
             mismatched related donors are acceptable) willing to donate marrow or
             rhG-CSF-mobilized peripheral blood stem cells. In the event of transplants from
             matched unrelated donors, a high-resolution allele match for HLA-A, -B, -C, -DRB1 ("8
             of 8 match") is required.

          5. Women of childbearing potential must have a negative serum pregnancy test within two
             weeks of study entry and should be advised to avoid becoming pregnant. Men should be
             advised to not father a child while on treatment. Both women of childbearing
             potential and men must agree to practice effective methods of contraception.

          6. Patients must be capable and willing to sign informed consent.

        Exclusion Criteria:

          1. Patients with documented disease progression on salvage chemotherapy.

          2. Nursing or pregnant females. Should a woman become pregnant or suspect she is
             pregnant while participating in the study, she should inform her treating physician
             immediately.

          3. Severe concomitant medical or psychiatric illness.

          4. Uncontrolled arrhythmia or symptomatic cardiac or pulmonary disease.

          5. Chronic active hepatitis or cirrhosis.

          6. Active or uncontrolled infection.

          7. Radiation therapy involving chest (axilla excluded), mediastinum, or abdomen (i.e.,
             small or large bowel) completed within 10 weeks of transplant admission. Radiation
             therapy shortly before the start of the preparative regimen is allowed.

          8. Prior or concurrent malignancies (including myelodysplasia) except resected basal
             cell carcinoma or treated carcinoma in-situ. Cancer treated with curative intent &lt; 5
             years previously will not be allowed unless approved by the Protocol Chair. Cancer
             treated with curative intent &gt; 5 years previously will be allowed.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  65 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Women diagnosed with metastatic breast cancer and their male spouse or significant other
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. For Patients: Being a female patient diagnosed with metastatic breast cancer.

          2. For Patients: Initiating treatment for metastatic breast cancer

          3. For Patients: Having and ECOG Performance Status Score of 2 or less

          4. For Spouses: Being the male spouse or significant other of a female patient diagnosed
             with metastatic breast cancer

          5. For Spouses: Having the patient's consent to be contacted

          6. For Patients and Spouses: Having the ability to read and speak English well enough to
             understand the consent form and complete the questionnaires

          7. For Patients and Spouses: Being able to provide informed consent

        Exclusion Criteria:

          1. For Patients and Spouses: Not being able to provide informed consent.

          2. For Patients: Rating average pain as 0 on the BPI
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Participants must be 18 years of age or older.

          2. Histologically documented malignant melanoma of the conjunctiva/eyelid greater than
             or equal to 1 millimeter in thickness, or those less than 1 mm thick that have
             evidence of ulceration, mitotic figures or are Clark IV.

          3. A CXR, liver enzymes, and a head and neck computed tomography (CT) or magnetic
             resonance imaging (MRI) negative for evidence of metastasis.

          4. Participant must have a negative ultrasound of regional lymph nodes (i.e., within 6
             weeks of study enrollment).

          5. Patient provided written informed consent. In the event that non-English speaking
             participants are eligible for this study, a short form (if applicable) or an ICD in
             their language, will be utilized and completed in accordance with the MDACC Policy
             for Consenting Non-English Speaking Participants.

        Exclusion Criteria:

        1) Pregnant or nursing females.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  PLT &gt;= 100,000/uL

          -  Must have central review prior to registration

          -  Candidate for gross total or subtotal resection

          -  Ability to provide informed consent

          -  Willing to provide biological specimens as required by the protocol

          -  Normal serum CEA level (&lt; ng/ml) at the time of registration

          -  Recurrent grade 4 astrocytoma and grade 4 gliosarcoma with histological confirmation
             at primary diagnosis and/or recurrence

          -  Negative serum pregnancy test done =&lt; 7 days prior to registration (for women of
             childbearing potential only)

          -  Anti-measles virus immunity as demonstrated by IgG anti-measles antibody levels of &gt;=
             20 EU/ml as determined by Enzyme Immunoassay

          -  Grade 3 astrocytoma patients with clinical or imaging characteristics suggestive of
             progression to grade 4 are eligible, provided that the diagnosis of grade 4
             astrocytoma is confirmed by biopsy (including confirmation in frozen section) prior
             to viral administration

          -  Total bilirubin =&lt; 1.5 x upper normal limit (ULN)

          -  AST =&lt; 2 x ULN

          -  Creatinine =&lt; 2.0 x ULN

          -  Hgb &gt;= 9.0 gm/dL

          -  PT and aPTT =&lt; 1.3 x ULN

          -  ECOG performance status (PS) 0, 1 or 2

          -  ANC &gt;= 1500/uL

        Exclusion Criteria:

          -  Pregnant women

          -  Nursing women

          -  Radiation therapy =&lt; 6 weeks prior to registration

          -  Any viral or gene therapy prior to registration

          -  Failure to fully recover from acute, reversible effects of prior chemotherapy
             regardless of interval since last treatment

          -  New York Heart Association classification IV

          -  Requiring blood product support

          -  Inadequate seizure control

          -  Expected communication between ventricles and resection cavity as a result of surgery

          -  History of organ transplant

          -  History of chronic hepatitis B or C

          -  Exposure to household contact =&lt; 15 months old or household contact with known
             immunodeficiency

          -  Allergy to measles vaccine or history of severe reaction to prior measles vaccination

          -  Chemotherapy =&lt; 4 weeks prior to registration (6 wks for nitrosourea-based
             chemotherapy)

          -  Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy
             considered investigational (utilized for a non-FDA -approved indication and in the
             context of research investigation)

          -  History of tuberculosis or history of PPD positivity

          -  Biologic therapy =&lt; 4 weeks prior to registration

          -  Non-cytotoxic antitumor drugs (i.e., small molecular cell cycle inhibitors) =&lt; 2
             weeks prior to registration

          -  HIV-positive test result or history of other immunodeficiency

          -  Men or women of childbearing potential who are unwilling to employ adequate
             contraception

          -  Active infection =&lt; 5 days prior to registration

          -  Immunotherapy =&lt; 4 weeks prior to registration
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Newly diagnosed, previously untreated: (1) M0 medulloblastoma with &gt; 1.5 cm^2
             residual; (2) M+ medulloblastoma; patients with diffusely anaplastic medulloblastoma
             are eligible regardless of M-stage or residual tumor

               -  As of amendment # 2, enrollment of patients with supratentorial PNET has been
                  discontinued

               -  All patients with M4 disease are not eligible

          -  A pre-operative magnetic resonance imaging (MRI) scan of the brain with and without
             contrast is required; NOTE: computed tomography (CT) scans are NOT sufficient for
             study eligibility

               -  Post-operative head MRI scan with and without contrast (preferably within 72
                  hours post-surgery); for patients who undergo stereotactic biopsy only, either a
                  pre or post-operative MRI is sufficient; for patients with M2 and M3 disease, a
                  post-op MRI is strongly encouraged, but not mandatory

               -  Spinal MRI imaging with and without gadolinium is required within 10 days of
                  surgery if done pre-operatively or within 28 days of surgery if done
                  post-operatively; for posterior fossa tumors, pre-operative MRI scans are
                  preferred

          -  Lumbar cerebrospinal fluid (CSF) cytology examination must be obtained
             pre-operatively or within 31 days following surgery; the optimal time for obtaining
             CSF is prior to surgery or 1-3 weeks following surgery; ventricular CSF (either pre-
             or post-op) may be used only if a post-operative spinal tap is contraindicated; if a
             spinal tap is contraindicated and there is no ventricular CSF available, then CSF
             cytology can be waived for patients with supratentorial tumors or if there is
             documentation of spinal subarachnoid metastases (M3); patients who are categorized as
             M1 must have either an intra-operative positive CSF (via lumbar puncture at the end
             of the procedure) or a positive lumbar CSF obtained &gt; 7 days post-operatively

          -  Patients must have a Karnofsky performance level of &gt;= 30 for patients &gt; 16 years of
             age or a Lansky performance scale of &gt;= 30 for patients =&lt; 16 years of age and life
             expectancy &gt; 8 weeks

          -  No previous chemotherapy or radiation therapy

          -  Patients taking Accutane (isotretinoin) for acne must discontinue drug use with this
             indication prior to enrollment; corticosteroids should not be used during
             chemotherapy administration as an antiemetic

               -  Isotretinoin is contraindicated in patients with parabens allergy and patients
                  with soybean allergy; concurrent use with tetracyclines should be avoided;
                  intake of vitamin A should be limited for the duration of isotretinoin treatment

          -  Selected strong inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4
             (cytochrome P450 3A4) include azole antifungals, such as fluconazole, voriconazole,
             itraconazole, ketoconazole, and strong inducers include drugs such as rifampin,
             phenytoin, phenobarbitol, carbamazepine, and St. John's wort; the use of these drugs
             should be avoided with vincristine (vincristine sulfate)

          -  CYP450 3A4 stimulators or inhibitors should be avoided or used with great caution
             when taking cyclophosphamide; aprepitant should also be used with caution with
             etoposide or vincristine chemotherapy

          -  Cisplatin should be used with caution with nephrotoxic drug; aminoglycoside should be
             avoided or used with caution during or shortly after cisplatin administration and
             concomitant use with amphotericin B should probably also be avoided; patients
             receiving cisplatin and other potentially ototoxic drugs such as aminoglycoside or
             loop diuretics concomitantly should be closely monitored for signs of ototoxicity

               -  Plasma levels of anticonvulsant agents should be monitored and doses adjusted
                  during therapy with cisplatin

          -  No other experimental therapy is permitted while on study

          -  Creatinine clearance or radioisotope glomerular filtration rate (GFR) &gt;= 70
             mL/min/1.73 m^2 OR a serum creatinine based on age/gender as follows:

               -  0.4 mg/dL (1 month to &lt; 6 months of age)

               -  0.5 mg/dL (6 months to &lt; 1 year of age)

               -  0.6 mg/dL (1 to &lt; 2 years of age)

               -  0.8 mg/dL (2 to &lt; 6 years of age)

               -  1.0 mg/dL (6 to &lt; 10 years of age)

               -  1.2 mg/dL (10 to &lt; 13 years of age)

               -  1.5 mg/dL (male) or 1.4 mg/dL (female) (13 to &lt; 16 years of age)

               -  1.7 mg/dL (male) or 1.4 mg/dL (female) (&gt;= 16 years of age)

          -  Total bilirubin &lt; 1.5 x upper limit of normal (ULN) for age

          -  Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or
             serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) &lt; 2.5 x
             upper limit of normal (ULN) for age; for patients on anti-seizure medications, SGOT
             (AST) or SGPT (ALT) must be &lt; 5 x ULN

          -  Absolute neutrophil count (ANC) &gt;= 1,000/uL

          -  Platelets &gt;= 100,000/uL (untransfused)

          -  Hemoglobin &gt;= 8 g/dl (may be transfused)

          -  Female patients who are post-menarchal must have a negative pregnancy test; lactating
             female patients must agree not to breast-feed while on this trial; males or females
             of reproductive potential may not participate unless they have agreed to use an
             effective contraceptive method

          -  All patients and/or their parents or legal guardians must sign a written informed
             consent

          -  All institutional, Food and Drug Administration (FDA), and National Cancer Institute
             (NCI) requirements for human studies must be met
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  3 Years
 </minimum_age>
 <maximum_age>
  21 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Age &gt; 12 months and &lt; 30 years at the time of study entry

          -  Diagnosis of autoimmune cytopenias requiring treatment with medications

          -  At least one of the following: Autoimmune Neutropenia, Autoimmune Hemolytic Anemia,
             and/or Autoimmune Thrombocytopenia

          -  Must be proven autoimmune by either a documented autoantibody (positive direct anti
             globulin test, positive anti-neutrophil, and/or anti-platelet antibody) and/or a
             documented clinical response to immunosuppression

          -  Autoimmune Cytopenias can be idiopathic (Idiopathic Thrombocytopenic Purpura (ITP),
             Autoimmune Hemolytic Anemia (AIHA), Autoimmune Neutropenia (AIN), or Evans syndrome)
             or secondary to one of following conditions: Lupus, Rheumatoid Arthritis (RA), ALPS
             (Autoimmune Lymphoproliferative Syndrome), or Inflammatory bowel disease (IBD)

          -  Patients must have chronic disease diagnosed by either a documented cytopenia
             syndrome (Lupus, ALPS, RA, or IBD), or by having Evans syndrome defined as idiopathic
             destruction of multiple blood cell types, and/or by having disease &gt;6 months

          -  Patients must be refractory to or unable to tolerate standard front-line therapies
             for autoimmune cytopenias (corticosteroids and/or IVIG)

          -  Patients may be taking second-line agents for autoimmune cytopenias (mycophenolate
             mofetil, cyclosporine, tacrolimus, mercaptopurine, and/or methotrexate) at time of
             study entry; however, attempts should be made to wean these agents. Patients may not
             stay on a combination of sirolimus and a calcineurin inhibitor for greater than 4
             weeks

          -  Informed consent/assent MUST be obtained prior to initiating treatment

          -  Patient must be able to consume oral medication in the form of tablets or solution

        Exclusion Criteria:

          -  Pregnancy or breast feeding

          -  Uncontrolled infection

          -  Known allergy to Sirolimus or its components

          -  Patients with a documented malignancy on therapy or not in remission

          -  Patients who do not meet organ function requirements listed in protocol

          -  Patients with a documented history of severe combined immunodeficiency or human
             immunodeficiency virus infection (HIV)
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  1 Year
 </minimum_age>
 <maximum_age>
  30 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients receiving chemoradiation for abdominal-pelvic tumors and healthy controls.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Patients receiving 5 to 6-week course of chemoradiation for abdominal-pelvic tumors
             (gastric cancers, gastro-esophageal (GE) junction, pancreatic, cervix, vulvar,
             endometrial, or anal) using conventional fractionation [(180cGy-200cGy per day)]

          2. Patients receiving concurrent abdominal-pelvic radiation and single agent or
             combination of cisplatin, paclitaxel, CPT-11, oxaliplatin or 5-FU, capecitabine,
             gemcitabine, or bevacizumab (Avastin).

          3. Patients must be least 18 years of age

          4. Controls must be individuals with no prior cancer diagnosis

          5. Controls must be at least 18 years of age

          6. Controls must be the caregivers of patients on this study

        Exclusion Criteria:

          1. Patients who do not have a diagnosis of cervix, endometrial, vulvar or anal cancer

          2. Patients who are not scheduled to receive chemoradiation treatment

          3. Patients who are not at least 18 years of age

          4. Controls - individuals who have a prior diagnosis of cancer (with the exception of
             non-melanoma skin cancer)

          5. Controls - individuals who are not at least 18 years of age
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Diagnosis of 1 of the following:

               -  Histologically or morphologically confirmed acute myeloid leukemia (AML),
                  meeting 1 of the following criteria:

                    -  Relapsed or refractory AML after treatment with  1 prior conventional
                       induction therapy

                         -  Patients in early first relapse must not have a matched donor
                            available and/or be ineligible for allogeneic stem cell
                            transplantation

                    -  Poor-risk AML, as defined by any of the following criteria:

                         -  Treatment-related AML, unless associated with favorable cytogenetics
                            (e.g., inversion 16, t[16;16], t[8;21], t[15;17]), and ineligible for
                            stem cell transplantation

                         -  Antecedent hematological disease (e.g., myelodysplastic syndromes,
                            myelofibrosis, or polycythemia vera) that evolved to AML ( 20%
                            blasts) and ineligible for stem cell transplantation

                         -  De novo AML (must be &gt; 70 years of age)

                         -  AML with unfavorable cytogenetics (e.g., abnormalities of chromosomes
                            -7, -5, 7q-, or 5q-; complex [ 3] abnormalities; or abnormalities of
                            11q23, excluding t[9;11], t[9;22], inversion 3, t[3;3], and t[6;9]),
                            regardless of age, and ineligible for allogeneic stem cell
                            transplantation

               -  High-risk myelodysplastic syndromes diagnosed by morphologic, histochemical, or
                  cell surface marker criteria

                    -  Resistant or intolerant to chemotherapy

                    -  Ineligible for or unwilling to undergo immediate allogeneic stem cell
                       transplantation

          -  Bone marrow index (i.e., percent cellularity  percent blasts)  40% at time of
             treatment

          -  No active CNS leukemia

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Bilirubin  1.5 mg/dL

          -  ALT and AST &lt; 2.5 times upper limit of normal

          -  Albumin  3 mg/dL

          -  Creatinine  1.5 mg/dL

          -  LVEF  50%

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 2 weeks after
             completion of study treatment

          -  No complicated medical or psychiatric problems that would preclude study compliance

          -  No concurrent serious uncontrolled infection or disseminated intravascular
             coagulation

          -  No myocardial infarction within the past 6 months

          -  No allergies to diphtheria toxin

          -  No requirement for oxygen

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No other concurrent antineoplastic drugs

          -  No concurrent radiotherapy

          -  No concurrent corticosteroids as antiemetics

          -  No concurrent hematopoietic growth factors (e.g., epoetin alfa, interleukin-11,
             filgrastim [G-CSF], or sargramostim [GM-CSF])

          -  No concurrent intravenous immunoglobins
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients aged &gt;= 50 and &lt; 75 years (yrs) with CMML, or previously untreated MDS or
             MPD

          -  Patients aged &lt; 50 yrs at high risk for regimen related toxicity using standard high
             dose regimens; factors considered high risk include pre-existing conditions such as a
             chronic disease affecting kidneys, liver, lungs, or heart or previous failed HCT

          -  An human leukocyte antigen (HLA)-identical related or an HLA-matched unrelated donor
             (Fred Hutchinson Cancer Research Center [FHCRC] matching allowed will be Grade 1.0 to
             2.1) is available

          -  Recovery from the effects of previous chemotherapy, with a minimum of 21 days from
             initiation of last therapy; hydroxyurea or anagrelide may be used to manage elevated
             cell counts in patients up to the time they begin therapy under this protocol

          -  Patients &lt; 12 yrs of age must be discussed on a case by case basis with the primary
             investigator (PI) of the protocol prior to registration

          -  A signed informed consent form or minor assent form

          -  MDS: MDS classifiable by the World Health Organization (WHO) system as RA, RARS,
             refractory cytopenia with multilineage dysplasia (RCMD), RCMD and ringed sideroblasts
             (RCMD-RS) or RAEB

          -  MDS: No previous myelosuppressive therapy; for the purpose of this protocol
             myelosuppressive chemotherapy will be defined as chemotherapy given with the intent
             of inducing a complete remission (e.g., standard 7+3, high dose intermittent ARA-C
             [HIDAC], or Mylotarg)

          -  MDS: Patients must have &lt; 10% marrow blasts; fewer than 10% marrow blasts must be
             documented by marrow examination within 3 weeks of initiation of conditioning

          -  CMML: Patients with CMML1 who have not received myelosuppressive therapy must have &lt;
             10% marrow blasts; fewer than 10% marrow blasts must be documented by marrow
             examination within 3 weeks of initiation of conditioning; OR patients with CMML who
             have progressed beyond CMML1 and have received myelosuppressive chemotherapy must
             have &lt; 5% marrow blasts; fewer than 5% marrow blasts must be documented by marrow
             examination within 3 weeks of initiation of conditioning

          -  MPD: Patients with polycythemia vera with persistent thrombotic or hemorrhagic
             complications despite conventional therapy, or who have progressed to
             postpolycythemic marrow fibrosis

          -  MPD: Patients with essential thrombocythemia with persistent thrombotic or
             hemorrhagic complications despite conventional therapy, or who have progressed to
             myelofibrosis

          -  MPD: Chronic idiopathic myelofibrosis with peripheral blood cytopenias

          -  MPD: Patients must have &lt; 10% marrow blasts; fewer than 10% marrow blasts must be
             documented by marrow examination within 3 weeks of initiation of conditioning

          -  MPD: No previous myelosuppressive therapy; for the purpose of this protocol
             myelosuppressive chemotherapy will be defined as chemotherapy given with the intent
             of inducing a complete remission (e.g., standard 7+3, HIDAC, or Mylotarg)

          -  Atypical chronic myeloid leukemia (CML): Philadelphia chromosome-negative patients
             with a diagnosis of atypical CML

          -  Atypical CML: Patients must have &lt; 10% marrow blasts; fewer than 10% marrow blasts
             must be documented by marrow examination within 3 weeks of initiation of conditioning

          -  Atypical CML: No previous myelosuppressive therapy; for the purpose of this protocol
             myelosuppressive chemotherapy will be defined as chemotherapy given with the intent
             of inducing a complete remission (e.g., standard 7+3, HIDAC, or Mylotarg)

          -  Paroxysmal nocturnal hemoglobinuria (PNH): Patients with the non-aplastic form of PNH
             (cellular bone marrow) who have had a history of life-threatening complications of
             their disease including thrombotic events, severe hemolysis or Budd Chiari syndrome
             are eligible; other patients may be considered following approval at PCC and approval
             by the Principal investigator

          -  Matched Related Donor: Related to the patient and is genotypically or phenotypically
             HLA-identical

          -  Matched Related Donor: Donor age &lt; 75 yrs unless cleared by institutional PI

          -  Matched Related Donor: Capable of giving written, informed consent

          -  Matched Related Donor: Donor must consent to PBSC mobilization with G-CSF and
             apheresis

          -  Unrelated Donor: FHCRC matching allowed will be grades 1.0 to 2.1: Unrelated donors
             who are prospectively:

               1. Matched for HLA-A, B, C, DRB1 and DQB1 by high resolution typing;

               2. Only a single allele disparity will be allowed for HLA-A, B, or C as defined by
                  high resolution typing

          -  Unrelated Donor: Patient and donor pairs homozygous at a mismatched allele in the
             graft rejection vector are considered a two-allele mismatch, i.e., the patient is
             A*0101 and the donor is A*0102, and this type of mismatch is not allowed

          -  HLA Matched Related Donor: G-CSF mobilized peripheral blood mononuclear cell (PBMC)
             only will be permitted as a hematopoietic stem cell (HSC) source on this protocol

          -  HLA Matched Unrelated Donor: Donor must consent to PBSC mobilization with G-CSF and
             apheresis; bone marrow unrelated donors are not eligible for this protocol

        Exclusion Criteria:

          -  Organ dysfunction as defined by the following:

               -  Symptomatic coronary artery disease or cardiac ejection fraction &lt; 35% (or, if
                  unable to obtain ejection fraction, shortening fraction of &lt; 26%); if shortening
                  fraction is &lt; 26% a cardiology consult is required with the principal
                  investigator (PI) having final approval of eligibility; ejection fraction is
                  required if age &gt; 50 years or there is a history of anthracycline exposure or
                  history of cardiac disease

               -  Diffusing capacity of the lung for carbon monoxide (DLCO) &lt; 35%, TLC &lt; 35%,
                  forced expiratory volume (FEV)1 &lt; 35% and/or receiving supplementary continuous
                  oxygen; the FHCRC PI of the study must approve of enrollment of all patients
                  with pulmonary nodules

               -  Liver function abnormalities: Patient with clinical or laboratory evidence of
                  liver disease will be evaluated for the cause of liver disease, its clinical
                  severity in terms of liver function, bridging fibrosis, and the degree of portal
                  hypertension; the patient will be excluded if he/she is found to have fulminant
                  liver failure, cirrhosis of the liver with evidence of portal hypertension,
                  alcoholic hepatitis, esophageal varices, a history of bleeding esophageal
                  varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction
                  evinced by prolongation of the prothrombin time, ascites related to portal
                  hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic
                  viral hepatitis with total serum bilirubin &gt; 3mg/dL, or symptomatic biliary
                  disease

          -  Bone marrow documenting blast count &gt;= 10% or &gt;= 5% in CMML patients who have
             progressed beyond CMML1 and received myelosuppressive chemotherapy

          -  Patients with active non-hematologic malignancies (except non-melanoma skin cancers);
             this exclusion does not apply to patients with non-hematologic malignancies that do
             not require therapy

          -  Patients with a history of non-hematologic malignancies (except non-melanoma skin
             cancers) currently in a complete remission, who are less than 5 years from the time
             of complete remission, and have a &gt; 20% risk of disease recurrence

          -  Presence of &gt;= 5% circulating leukemic blasts (in the peripheral blood) detected by
             standard pathology

          -  Active central nervous system (CNS) involvement of disease

          -  Karnofsky performance score &lt; 70% or Lansky-Play Performance score &lt; 70 for pediatric
             patients

          -  Life expectancy severely limited by diseases other than malignancy

          -  Fungal infections with radiological progression after receipt of amphotericin product
             or active triazole for &gt; 1 month

          -  Active bacterial infection

          -  Patients of fertile age who refuse contraception for a twelve month period
             post-transplant

          -  Females who are pregnant or breastfeeding

          -  Human immunodeficiency virus (HIV) seropositivity

          -  Severe psychological illness such as major psychosis (e.g. schizophrenia), major
             bipolar depression, or suicidal situational depression

          -  Matched Related Donor: Identical twin

          -  Matched Related Donor: Any contra-indication to the administration of subcutaneous
             G-CSF at a dose of 16mg/kg/d for five consecutive days

          -  Matched Related Donor: Serious medical or psychological illness

          -  Matched Related Donor: Pregnant or lactating females

          -  Matched Related Donor: Prior malignancy within the preceding five yrs, with the
             exception of non-melanoma skin cancers

          -  Matched Related Donor: HIV seropositivity

          -  Unrelated Donor: A positive anti-donor cytotoxic crossmatch is an absolute donor
             exclusion; donors are excluded when preexisting immunoreactivity is identified that
             would jeopardize donor hematopoietic cell engraftment; this determination is based on
             the standard practice of the individual institution; the recommended procedure for
             patients with 10 of 10 HLA allele level (phenotypic) match is to obtain a panel
             reactive antibody (PRA) screens to class I and class II antigens for all patients
             before HCT; if the PRA shows &gt; 10% activity, then flow cytometric or B and T cell
             cytotoxic cross matches should be obtained; the donor should be excluded if any of
             the cytotoxic cross match assays are positive; for those patients with an HLA class I
             allele mismatch, flow cytometric or B and T cell cytotoxic cross matches should be
             obtained regardless of the PRA results

          -  Unrelated Donor: Marrow donors

          -  Unrelated Donor: Donors who are HIV-positive and/or medical conditions that would
             result in increased risk to the donor G-CSF mobilization and G-PBMC collections

          -  Unrelated Donor: Serious medical or psychological illness

          -  Unrelated Donor: Pregnant or lactating females

          -  Unrelated Donor: Prior malignancy within the preceding five yrs, with the exception
             of non-melanoma skin cancers

          -  Unrelated Donor: HIV seropositivity
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Any type of NHL or Hodgkin's disease.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:- Any type of NHL or Hodgkin's disease.

        Exclusion Criteria:- Patients without NHL or Hodgkin's disease
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

               1. At least 18 years of age and able to give informed consent

               2. In overall good health;

               3. Able to exercise on a treadmill (if participating in the treadmill exercise
                  portion).

               4. Able to perform hand or leg exercises (if participating in the MRS Portion)

        EXCLUSION CRITERIA:

          1. Blood pressure higher than 190/100 mmHg

          2. Diabetes requiring medical treatment

          3. Anemia

          4. Tobacco use within the past three months

          5. Symptomatic heart disease, heart failure or poor blood circulation

          6. Undergone stem cell transplantation

          7. Inflammatory disease or immunosuppressive therapy

          8. Claustrophobia and/or unable to lie on your back in the MRI machine

          9. Pregnant or breast feeding

         10. Body mass index under 19 or over 45

         11. Metal medical implantable device or other MRI incompatible materials

        Additional Exclusion Criteria for the Muscle Biopsy:

        Coagulopathy
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Age  75 years.

          -  ECOG  3.

          -  Morphologic Diagnosis of LPA (FAB M3 or variant M3). Those cases without typical
             morphology but with PML-RAR reordering also must be including.

          -  Genetic Diagnosis: t (15; 17) demonstrated by cariotipo conventional, FISH, PML-RAR
             reordering detected by RT-PCR or a pattern microspeckled demonstrated with antibody
             anti-PML (positive PGM3). Obvious, it will be had the result of these tests once
             initiated the treatment on the basis of a suspicion diagnoses morphologic

        Exclusion Criteria:

          -  Age &gt;75 years (the treatment with this protocol can be considered individually)

          -  Absence of PML-Rare reordering.

          -  To have received previously some type of treatment for LPA, including chemotherapy or
             retinoides. The previous treatment with corticoids, hidroxiurea or leucoafresis is
             not reason for exclusion.

          -  To have received chemotherapy or x-ray for the treatment of a disease vitiates
             previous.

          -  Associate Neoplasia.

          -  Serious psychiatric Disease.

          -  Seropositividad for VIH.

          -  Contraindication to receive intensive chemotherapy, specially antraciclinas.

          -  Srica Creatinina  2,5 mg/dL ( 250 mol/l).

          -  Bilirrubina, fosfatasa alkaline, or GOT &gt; 3 times the normal limit

          -  Test of positive pregnancy.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Histologically proven rectum cancer

          -  UICC TNM I-III

          -  WHO performance status 0-2

          -  Less than 10% weight loss the last 6 months

          -  No recent (&lt; 3 months) severe cardiac disease

          -  Normal serum bilirubin and serum creatinin

        Exclusion Criteria:

          -  Concurrent chemotherapy with radiation

          -  History of prior pelvis radiotherapy

          -  Recent (&lt;3 months) myocardial infarction

          -  Uncontrolled infectious disease

          -  Concurrent medication known as inhibitors of CYP3A4 susceptible to increase
             Rapamycin blood concentrations
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Female subject is either post-menopausal or surgically sterilized or willing to use
             an acceptable method of birth control (ie, a hormonal contraceptive, intra-uterine
             device, diaphragm with spermicide, condom with spermicide, or abstinence) for the
             duration of the study.

          -  Male subject agrees to use an acceptable method for contraception for the duration of
             the study.

          -  Patients who have had a diagnosis of Acute Myeloid Leukemia (AML) or Acute
             Lymphoblastic Leukemia (ALL) will be eligible for the study.

               -  Patients must have failed initial therapy that may manifest in either  of the
                  following ways:

                    -  Demonstration of Primary Refractory Disease (Primary Induction Failure) as
                       evidenced by a mid-cycle bone marrow analysis showing lack of complete
                       tumor clearance (CTC).

                    -  Relapse of initial disease after a period of attaining complete remission.

          -  Patients must be &gt; 18 years of age, with no upper age limit.

          -  ECOG performance status of 0 or 1.

          -  Patients have no symptomatic cardiac or pulmonary disease and adequate hepatic and
             renal function as measured by the following criteria:

               -  Cardiac: Left ventricular ejection fraction at rest must be &gt;40% (MUGA
                  preferred)

               -  Hepatic: ALT and AST &lt; 3x the upper limits of normal range as specified by the
                  institution's clinical laboratory.

               -  Renal: Serum creatinine within the normal range (&lt; 1.4 mg/dL) or if creatinine
                  outside normal range then creatinine clearance &gt; 60 mL/min/m2

          -  Patients who have had a diagnosis of Acute Myeloid Leukemia (AML) or Acute
             Lymphoblastic Leukemia (ALL) will be eligible for the study.

          -  Patients must have failed initial therapy that may manifest in either of the
             following ways:

               -  Demonstration of Primary Refractory Disease (Primary Induction Failure) as
                  evidenced by a mid-cycle bone marrow analysis showing lack of complete tumor
                  clearance (CTC).

               -  Relapse of initial disease after a period of attaining complete remission.

          -  Patients must be &gt; 18 years of age, with no upper age limit.

          -  ECOG performance status of 0 or 1.

          -  Patients have no symptomatic cardiac or pulmonary disease and adequate hepatic and
             renal function as measured by the following criteria:

               -  Cardiac: Left ventricular ejection fraction at rest must be &gt;40% (MUGA
                  preferred)

               -  Hepatic: ALT and AST &lt; 3x the upper limits of normal range as specified by the
                  institution's clinical laboratory.

               -  Renal: Serum creatinine within the normal range (&lt; 1.4 mg/dL) or if creatinine
                  outside normal range then creatinine clearance &gt; 60 mL/min/m2

        Exclusion Criteria:

          -  Patient has &gt; Grade 2 peripheral neuropathy within 14 days before enrollment.

          -  Myocardial infarction within 6 months prior to enrollment or has New York Hospital
             Association (NYHA) Class III or IV heart failure (see section 8.4), uncontrolled
             angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence
             of acute ischemia or active conduction system abnormalities.  Prior to study entry,
             any ECG abnormality at screening has to be documented by the investigator as not
             medically relevant.

          -  Patient has hypersensitivity to bortezomib, boron or mannitol.

          -  Female subject is pregnant or breast-feeding.  Confirmation that the subject is not
             pregnant must be established by a negative serum or urinary pregnancy test result
             obtained during screening.  Pregnancy testing is not required for post-menopausal or
             surgically sterilized women.

          -  Patient has received other investigational drugs within 14 days before enrollment

          -  Serious medical or psychiatric illness likely to interfere with participation in this
             clinical study.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   INCLUSION CRITERIA :

          1. Histological evidence of non-small cell lung cancer (NSCLC)

          2. Complete resection by lobectomy, bilobectomy or pneumonectomy (i.e patients with
             positive margins) or extra-capsular mediastinal nodal extension breaching the surface
             of the pathological specimen should not to be included

          3. Mediastinal lymph node exploration (lymph node sampling or systematic dissection of
             lymph nodes at stations 2, 4 and 7 in case of upper/middle right-sided lung cancer;
             4, 7, 8 and 9 in case of lower right-sided lung cancer; 5, 6 and 7 in case of upper
             left -sided lung cancer; 7, 8 and 9 in case of lower left-sided lung cancer is
             recommended)

          4. Pathologically or cytologically documented N2 mediastinal nodal involvement, at the
             time of surgery if no preoperative chemotherapy or before preoperative chemotherapy,
             according to the criteria of the joint AJCC and UICC classification, clinical N2
             patients without cytological or histological documentation of mediastinal node
             involvement before preoperative chemotherapy can be included in the study if and only
             if, they have histologically confirmed N2 disease at the time of surgery

          5. Prior chemotherapy is allowed (pre-operative or post-operative adjuvant chemotherapy,
             or both)

          6. Patient aged  18 years

          7. Good Performance status (WHO  2)

          8. Fit enough to receive curative radiotherapy

          9. Adequate pulmonary function with post-operative FEV1 after surgery &gt; 1 l or over 35%
             theoretical value

         10. Signed informed consent form

        EXCLUSION CRITERIA:

          1. Documented metastases, (except for ipsilateral nodule(s) in a different lobe after
             pneumonectomy or bi-lobectomy)

          2. Major pleural or pericardial effusion

          3. Synchronous contra-lateral lung cancer

          4. Clinical progression during post-operative chemotherapy

          5. Previous chest radiotherapy

          6. Intention of concomitant chemotherapy during radiotherapy

          7. Weight loss in the previous 6 months before surgery  10 %

          8. Evidence of severe or uncontrolled systemic disease as judged by the investigator

          9. Recent (&lt; 6 months) severe cardiac disease (arrhythmia, congestive heart failure,
             infarction, pace-maker) or pulmonary disease

         10. Current or past history of neoplasm other than non-small cell lung cancer diagnosed
             within the last 5 years, except :

               -  basal cell carcinoma of the skin

               -  in situ carcinoma of the cervix A patient diagnosed for another neoplasm 5 years
                  ago or more, treated and considered as cured may be included in the study if all
                  the other criteria are respected.

         11. Pregnancy or breast feeding or inadequate contraceptive measures during treatment

         12. Patients who, for family, social, geographic or psychological reasons, cannot be
             adequately followed up and/or are incapable of undergoing regular controls

         13. Patient deprived of freedom or under guardianship
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Orthopaedic clinic
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  All patients seen in the UF&amp;Shands Orthopaedics and Sports Medicine Institute will be
             asked to sign an informed consent.

        Exclusion Criteria:

          -  No exclusions, all patients interested in participation will be asked to sign an
             informed consent.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Histological diagnosis of breast cancer

          -  Surgical resection of breast cancer (breast conserving surgery or mastectomy)

          -  No evidence of disease

          -  Indication for adjuvant hormonal therapy (ER and/or PgR positive with IHC exam in at
             least 1% of primary tumor cells, according to St. Gallen criteria)

          -  Patient age at least 18 years

          -  Written informed consent .       Premenopausal status defined as LMP within 12 months
             of randomization (FSH, LH will not be considered as determinants of menopausal status
             due the chemotherapy induced reversible ovarian suppression)

        Please note that patients who have received neoadjuvant or adjuvant chemotherapy and/or
        locoregional radiation therapy may be included in the study

        Exclusion Criteria:

          -  Performance status (ECOG)&gt;2.

          -  Previous or concomitant malignancy (with the exception of adequately treated
             nonmalignant skin cancer and carcinoma in situ of the uterine cervix

          -  Metastatic breast cancer

          -  Creatinine &gt; 1.25 times the value of upper normal limit

          -  Pregnant or lactating females

          -  Clinical or radiologic evidence of bone fractures

          -  Treatment with systemic cortisone therapy within 12 months prior to randomization

          -  Treatment with drugs that could alter bone metabolism (calcitonin, mithramycin,
             gallium nitrate) within 2 weeks prior to randomization

          -  Previous treatment with tamoxifen or aromatase inhibitors

          -  AST and/or ALT &gt; 3 times the value of upper normal limit with clinical and laboratory
             findings that indicate a grade of hepatic insufficiency that could potentially
             increase the risk of assuming letrozole

          -  Any concomitant conditions that would, in the Investigator's opinion, contraindicate
             the use of any of the drugs used in this study

          -  Inability to provide informed consent

          -  Inability to comply with followup

          -  Patient undergoing invasive dental work at time of baseline evaluation or foreseen
             during the course of adjuvant therapy
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Age 18 years and older

          2. Diagnosis of HCL established by bone marrow examination

          3. Patients with relapsed disease are eligible if they have had no more than one prior
             therapy

          4. Women of child-bearing potential must use birth control (oral contraceptive, barrier,
             abstinence or any other acceptable method) for the duration of the study

          5. Performance status &lt;/= 3

          6. Adequate renal function: creatinine less than or equal to 2.0 unless related to the
             disease

          7. Adequate liver function: bilirubin less than or equal to 3.0, transaminases less than
             or equal 3 x upper limit of normal unless related to the disease

          8. No prior investigational agent in the 4 weeks prior to initiation of therapy

        Exclusion Criteria:

          1. Unable or unwilling to sign the consent form

          2. Known infection with HIV, hepatitis B or C

          3. Presence of active infection

          4. Presence of CNS metastases

          5. New York Heart Association Classification III or IV heart disease (See Appendix I)

          6. Prior chemotherapy (last 4 weeks)
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients with candidemia or with an invasive Candida infection

          -  Presence of fever, hypothermia or other appropriate local sign of infection

          -  Female patients must be non-lactating and at no risk of pregnancy

        Exclusion Criteria:

          -  Patients with a sole diagnosis of mucocutaneous candidiasis, i.e. oropharyngeal,
             esophageal or genital candidiasis; or candidal lower urinary tract infection or
             Candida isolated solely from respiratory tract specimens

          -  Patients with candidemia who failed a previous antifungal therapy for the same
             infection

          -  Patients previously enrolled in a phase III study with isavuconazole

          -  Patients with a body weight &lt;40kg
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  women tested positive of BRCA1 or BRCA2 gene mutations

          -  referred for screening

          -  aged 25 - 70 years

        Exclusion Criteria:

          -  general contraindications for MR

          -  pregnant or lactating

          -  men

          -  bilateral mastectomy

          -  ongoing treatment with chemotherapy

          -  metastatic breast cancer

          -  previous breast surgery less than 6 months before MR

          -  previous radiation therapy of the breast less than 1 year before

          -  incapable of managing her own affairs
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  25 Years
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  male or female  18 years of age.  If female of child bearing potential and outside
             of the window of 10 days since the first day of the last menstrual period, a negative
             pregnancy test

          -  patients with known locally advanced or metastatic carcinoma of the pancreas

          -  planned gemcitabine treatment

          -  calculated creatinine clearance &gt;50ml/min (calculated by Crockcraft and Gault
             equation)

          -  able and willing to follow instructions and comply with the protocol

          -  provide written consent prior to participation in this study

          -  Karnofsky Performance Scale Score 60-100

        Exclusion Criteria:

          -  Bilirubin 200 umol/L

          -  AST or ALT 5 times the upper limits of normal

          -  Serious medical conditions which may prevent a patient from tolerating experimental
             chemotherapy such as: congestive heart failure, unstable angina, unstable ventricular
             arrhythmia, uncontrolled psychiatric conditions, serious infections, uncontrolled
             diabetes

          -  uncontrolled brain metastasis.  Patients who have stable brain metastasis treated
             with radiation or surgery who are symptomatic and a stable dose of dexamethasone are
             eligible

          -  nursing females
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Subjects presenting to Indiana University for treatment of biliary tract disease.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Presenting to IU for treatment of biliary tract disease; Age greater than or equal to
             18

        Exclusion Criteria:

          -  Problems other than biliary tract disease
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Primary breast cancer without known extension beyond the breast and axillary nodes
             (i.e. believed to be Tumor Stage 1-3, Nodes 0-2)

          -  Scheduled for unilateral or bilateral mastectomy with or without implant (isolated
             "lumpectomy" will not qualify)

          -  Isolated "lumpectomy" with axillary node dissection (anticipated removal of at least
             five nodes)

          -  Written informed consent, including willingness to be randomized to morphine or
             regional analgesia

        Exclusion Criteria:

          -  Previous surgery for breast cancer (except diagnostic biopsies)

          -  Inflammatory breast cancer

          -  Age &lt; 18 or &gt; 85 years old

          -  Scheduled free flap reconstruction

          -  ASA Physical Status  4

          -  Any contraindication to epidural or paravertebral anesthesia and analgesia (including
             coagulopathy, abnormal anatomy)

          -  Any contraindication to midazolam, propofol, sevoflurane, fentanyl, or morphine

          -  Other cancer not believed by the attending surgeon to be in long-term remission

          -  Systemic disease believed by the attending surgeon to present  25% two-year
             mortality
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  85 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   HIV-infected men who have sex with men
  </textblock>
 </study_pop>
 <sampling_method>
  Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  HIV-infected men who have sex with men

        Exclusion Criteria:

          -  None
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Histologically confirmed diagnosis of 1 of the following:

               -  Acute myeloid leukemia meeting the following criteria:

                    -  M0-M7 histologic subtypes by French-American-British classification

                    -  Previously treated disease

                    -  Meets 1 of the following criteria:

                         -  Persistent disease as evidenced by 5-30% persistent blasts in bone
                            marrow after induction or salvage therapy

                         -  In second or subsequent complete remission (CR)

                         -  In first CR with 1 of the following high-risk features:

                              -  Philadelphia chromosome present

                              -  Noncore-binding factor type of chromosomal abnormalities

               -  Myelodysplastic syndromes with 1 of the following International Prognostic
                  Scoring System (IPSS) scores:

                    -  Intermediate-1

                    -  Intermediate-2

                    -  High-risk score with transfusion dependence

               -  Chronic myelogenous leukemia meeting 1 of the following criteria:

                    -  In accelerated or blastic phase

                    -  Failed prior imatinib mesylate therapy

               -  Acute lymphoblastic leukemia meeting 1 of the following criteria:

                    -  In first CR with any of the following high-risk features:

                         -  Philadelphia chromosome present

                         -  Translocation t(4;11) present

                         -  WBC &gt; 30,000/mm (adult patients)

                         -  More than 4 weeks from initiation of treatment was required to achieve
                            CR (adult patients)

                         -  DNA index of near haploid (N=23 chromosomes) (pediatric patients)

                    -  In second or subsequent CR

                    -  Persistent disease as evidenced by 5-20% persistent blasts in bone marrow
                       after induction or salvage therapy

               -  Hodgkin's or non-Hodgkin's lymphoma meeting the following criteria:

                    -  Recurrent or refractory disease

                    -  Tumor  5 cm in diameter

               -  Myeloma or plasma cell neoplasm meeting 1 of the following staging criteria:

                    -  Stage III at presentation

                    -  Stage I-II at presentation

                         -  Not responding OR progressed after first-line therapy

               -  Chronic lymphocytic leukemia or Waldenstrom's macroglobulinemia with refractory
                  or progressive disease after first-line therapy

          -  No 5-6/6 HLA-matched related or 7-8/8 HLA-matched unrelated marrow or peripheral
             blood stem cell donor available

          -  No single 4-6/6 HLA-A, -B, or -DRB1-matched umbilical cord blood unit  3.5 x 10^7
             nucleated cells/kg available

        PATIENT CHARACTERISTICS:

          -  ECOG performance status (PS) 0-2 OR Karnofsky or Lansky PS 70-100%

          -  Not pregnant

          -  Fertile patients must use effective contraception prior to and during study
             participation

          -  HIV negative

          -  Bilirubin &lt; 3.0 mg/dL

          -  AST and ALT  3 times upper limit of normal

          -  Creatinine &lt; 2.0 mg/dL OR creatinine clearance &gt; 50 mL/min

          -  Cardiac ejection fraction &gt; 50% by echocardiogram OR shortening fraction &gt; 27%

          -  No uncontrolled symptomatic congestive heart failure

          -  No unstable angina pectoris

          -  No cardiac arrhythmia

          -  FEV_1 &gt; 50% of normal

          -  Forced vital capacity &gt; 50% of normal

          -  DLCO normal

          -  Oxygen saturation &gt; 92% on room air (for patients &lt; 5 years of age)

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biological composition to busulfan and fludarabine phosphate

          -  No ongoing or active infection

          -  No psychiatric illness or social situation that would preclude study compliance

          -  No other uncontrolled illness

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  At least 4 weeks since prior and no concurrent surgery

          -  At least 4 weeks since prior and no other concurrent investigational or commercial
             agents or therapies for the malignancy, including chemotherapy, biologic therapy, or
             radiotherapy
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  69 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Age between 18 and 76 years

          -  Histological or cytological proven primary epithelial ovarian carcinoma or peritoneal
             cancer (PPSC) or fallopian tube carcinoma FIGO stage III, including serous papillary
             adenocarcinoma, mucinous adenocarcinoma and endometrioid adenocarcinoma.

          -  In case of pleural effusion cytology should be negative for tumour cells

          -  In case diagnosis is made based on cytology only (i.e. patients treated by primary
             chemotherapy) additional criteria apply:

               -  Normal mammogram (&lt; 6 weeks before first registration) and

               -  Presence of pelvic mass and

               -  CA 125 &gt; 200 kU/l and

               -  Serum CA125/CEA ratio &gt; 25. If the serum CA125/CEA ratio is &lt; 25, a barium enema
                  or colonoscopy and gastroscopy or radiological examination of the stomach should
                  be negative for the presence of a primary tumour of the digeste tract (&lt; 6 weeks
                  before registration) and

               -  Omental cake or other metastases larger than 2 cm in the upper abdomen and/or
                  regional lymph node metastasis irrespective of size (CT/MRI or ultrasound or
                  laparoscopy)

          -  Patients eligible for interval debulking for the following 2 reasons:

               -  Primary debulking surgery not feasible due to tumour extension or general
                  condition (patients treated by primary chemotherapy) or

               -  Incomplete primary debulking with residual disease &gt; 1 cm

          -  In case of primary chemotherapy:

               -  Chemotherapy consists of 3 courses of carboplatin or cisplatin combined with
                  taxol

               -  Following 2 cycles of chemotherapy at least a 30% decrease in the sum of largest
                  diameter (LD) of target lesions taking as reference the baseline sum LD (RECIST
                  criteria, see appendix 1)

          -  In case of an incomplete primary debulking as indicated under 5 followed by
             chemotherapy:

               -  Chemotherapy consists of 3 courses of carboplatin or cisplatin combined with
                  taxol

          -  General criteria:

               -  Fit for major surgery, ASA 1 or ASA 2

               -  WHO performance status 0-2

               -  Written informed consent

               -  Laboratory values: serum creatinine &lt; 140 mol/L; creatinine clearance &gt; 60
                  ml/min   (Cockroft formula); white blood cell count &gt; 3.5 x 109/l; platelets &gt;
                  100 x 109 /l

          -  For quality of life studies:

               -  Baseline questionnaires should be filled in before randomization

        Exclusion Criteria:

          -  History of breast cancer or previous malignancies within 5 years prior to inclusion,
             with the exception of radically excised basal cell or squamous cell skin cancer or
             carcinoma in situ of the cervix
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  76 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the prostate

               -  No small cell, neuroendocrine, or transitional cell carcinoma

          -  Clinically localized, stage T1-3a disease

          -  No radiographic evidence of metastatic disease*, as demonstrated by all of the
             following:

               -  No pelvic lymph nodes &gt; 1.5 cm by CT scan or MRI of the abdomen and pelvis or
                  endorectal MRI of the pelvis

                    -  A negative biopsy required for lymph node(s) that measure &gt; 1.5 cm

                         -  If &gt; 1 lymph node is &gt; 1.5 cm, the largest or most accessible node is
                            biopsied

               -  Negative bone scan with plain films and/or MRI/CT scan confirmation, if
                  necessary NOTE: *Positive positron emission tomography scan and Prostascint
                  scans are not considered proof of metastatic disease

          -  Serum prostate-specific antigen level  100 ng/mL within the past 6 weeks

          -  Patients must have a known Gleason sum based on biopsy or TURP at study entry

          -  High-risk disease, meeting 1 of the following criteria:

               -  Probability of biochemical progression-free survival at 5 years after surgery &lt;
                  60% by Kattan nomogram prediction

               -  Biopsy Gleason score 8 to 10

          -  Deemed an appropriate candidate for radical prostatectomy

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Life expectancy &gt; 10 years

          -  Absolute neutrophil count  1,500/mm^3

          -  Platelet count  150,000/mm^3

          -  Creatinine  2.0 mg/dL

          -  Bilirubin normal ( 2.5 times upper limit of normal [ULN] for patients with Gilbert's
             disease)

          -  AST and ALT  1.5 times ULN

          -  Fertile patients must use effective contraception during and for  2 months after
             completion of study treatment

          -  Not at high risk for cardiac complications

               -  Prior deep venous thrombosis, pulmonary embolism, and/or cerebrovascular
                  accident allowed

        PRIOR CONCURRENT THERAPY:

          -  No prior treatment for prostate cancer, including surgery, pelvic lymph node
             dissection, radiotherapy, or chemotherapy

               -  Prior transurethral resection of prostate allowed

          -  Prior androgen-deprivation therapy (e.g., luteinizing hormone-releasing hormone
             agonists, antiandrogens, or both) lasting  4 months allowed

          -  Concurrent systemic anticoagulation allowed

          -  No other concurrent systemic therapy, including androgen-deprivation therapy for the
             treatment of the prostate cancer

          -  No concurrent oral antiandrogens

          -  No concurrent aprepitant

          -  No other concurrent chemotherapeutic agents except for any of the following:

               -  Steroids given for adrenal failure

               -  Hormones administered for nondisease-related conditions (e.g., insulin for
                  diabetes)

               -  Intermittent use of dexamethasone as an antiemetic or as pretreatment for
                  patients receiving docetaxel
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Histological or cytological diagnosis of breast cancer

          -  Stage IV disease

          -  None or at most one prior treatment for metastatic disease (prior treatment with
             trastuzumab for metastatic disease is not permitted)

          -  Overexpression of HER-2 (immunohistochemistry 3+) or genetic amplification of
             c-erbB2/neu (FISH+)

          -  ECOG  Performance Status 0-2

          -  Age &gt;18 and &lt; 75 years

          -  Left Ventricular Ejection Fraction (LVEF) &gt;50%

          -  Life expectancy &gt;3 months

          -  Signed informed consent

        Exclusion Criteria:

          -  Absence of measurable or evaluable disease

          -  Life expectancy &lt; 3 months

          -  ECOG performance status &gt; 2

          -  History of prior malignancy in the last 5 years (other than adequately treated
             non-melanoma skin cancer or excised cervical carcinoma in situ).

          -  Previous chemotherapy with vinorelbine or carboplatin (as adjuvant therapy or for
             metastatic disease)

          -  Previous therapy with trastuzumab for metastatic disease  (previous adjuvant therapy
             with trastuzumab is permitted)

          -  Neutrophil &lt; 2000/mm3, platelets &lt; 100,000/mm3, haemoglobin &lt; 9 g/dl

          -  Creatinine &gt; 1.5 x the upper normal limits

          -  GOT and/or GPT &gt; 2.5 x the upper normal limits  and/or Bilirubin &gt; 1.5  x the upper
             normal limits in absence of hepatic metastases

          -  GOT and/or GPT  &gt; 5 x the upper normal limits and/or Bilirubin &gt; 3 x  the upper
             normal limits in presence of hepatic metastases

          -  Congestive hearth failure or history of congestive heart failure, unstable angina
             pectoris even if it is medically controlled, myocardial infarction, clinically
             significant valve disease, uncontrolled  arrhythmia

          -  Any concomitant pathology that would, in the investigator's opinion, contraindicate
             the use of the drugs in this study

          -  Male gender

          -  Pregnant or lactating women

          -  Refusal or incapacity to provide informed consent

          -  Inability to comply with follow up
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   People who have esophageal cancer, Barrett's esophagus or gastro-esophageal reflux disease
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  People who are undergoing upper endoscopy as part of their medical care with a
             history of esophageal cancer, Barrett's esophagus, or upper gastrointestinal
             symptoms.

        Exclusion Criteria:

          -  People who are are currently having chemotherapy, or who have completed chemotherapy
             within the last 4 weeks.

          -  People who have ever had radiation treatments to their chest.

          -  People who have ever had photodynamic therapy or other mucosal ablation in the past.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  95 Years
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Diagnosis: Poor Prognosis Non-Seminomas Germ Cell Tumor in  PR1/CR1 or Good or
             Intermediate Prognosis Seminomas and Non- Seminomas Germ Cell Tumor in  PR1 or  CR2
             as defined by the International Germ Cell Cancer Consensus Classification.  Patients
             with increasing tumor markers only (i.e. no imaging evidence of progressive disease)
             are eligible for transplant.

          -  Age:  10 years and &lt; 70 years of age.

          -  Performance status: Karnofsky  80% (subjects  16 years of age) Lansky  80% for
             subject 10 - 15 years of age

          -  Life expectancy: Greater than 8 weeks.

          -  Patients must have normal organ function as defined below:

               -  Hematologic:

                    -  Hemoglobin &gt; 8 gm/dL without transfusion and off erythropoietin for 14 days
                       or Aranesp for 21 days

                    -  White blood cells (WBC) &gt; 2.5 x 10^9/L with an absolute neutrophile count
                       (ANC) &gt; 1.5 x 10^9/L and off G-CSF or GM-CSF for 10 days or Neulasta for 21
                       days

                    -  Platelets &gt; 100 x 10^9/L without transfusion and/or a bone marrow
                       cellularity of  20%

               -  Renal: Creatinine  2.0 mg/dl or creatinine clearance &gt; 50 ml/min.

               -  Hepatic: Total bilirubin  2.0 mg/dl, AST and alkaline phosphatase &lt; 5 x upper
                  limit of normal. No history of severe prior or ongoing chronic liver disease.

               -  Cardiac: Patients must be free of symptoms of uncontrolled cardiac disease
                  including unstable angina, decompensated congestive heart failure, or
                  arrhythmia. LVEF 45% by MUGA/ECHO.

               -  Pulmonary: Patients must have no significant obstructive airways disease (FEV1
                  must be  50% of predicted) and must have acceptable diffusion capacity
                  (corrected DLCO &gt; 50% of predicted).

          -  Patients with a history of CNS tumor involvement are eligible if they have completed
             treatment for CNS disease (radiotherapy or surgery or chemotherapy), have recovered
             from or stabilization of the side effects associated with the therapy and have no
             evidence of progressive CNS disease at the time of enrollment.

        Exclusion Criteria:

          -  Patients with serious uncontrolled infections will not be eligible.

          -  Male and female patients of reproductive potential must use an approved contraceptive
             method if appropriate (for example, intrauterine device [IUD], birth control pills,
             or barrier device) during and for the duration of study participation. The drugs used
             in this study are pregnancy category D - clear evidence of risk in pregnancy.

          -  Pregnant and breast feeding women will not be eligible.

        Voluntary written informed consent before performance of any study-related procedure not
        part of normal medical care, with the understanding that consent may be withdrawn by the
        subject at any time without prejudice to future medical care.

        Additional Eligibility prior to Transplant Two:

          -  Total Collection of  4 x 10^6 CD34 cells/kg prior to transplant one

          -  Transplant able to occur between day +30 and day +90 from transplant one

          -  Recovery of blood counts as demonstrated by:

               -  WBC &gt; 2.5 x 10^9/L with an ANC &gt; 1.5 x 10^9/L and off G-CSF for 3 days

               -  Platelets &gt; 50 x 10^9/L without transfusion in the prior 7 days

               -  Renal: Creatinine  2.0 mg/dl or creatinine clearance &gt; 50 ml/min

               -  Hepatic: Total bilirubin  2.0 mg/dl, AST and alkaline phosphatase &lt; 5 x upper
                  limit of normal

          -  Infection: Patients with serious uncontrolled infections at the time of planned
             transplant will be excluded

          -  Patients with progressive disease by Response Evaluation Criteria in Solid Tumors
             (RECIST) criteria by imaging techniques are not eligible to proceed to the second
             transplant. Tumor marker increase alone is not sufficient to diagnose disease
             progression.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  10 Years
 </minimum_age>
 <maximum_age>
  69 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Patients who will be undergoing surgery to remove a region of skin suspected of
             containing non-melanoma skin cancer will be eligible to participate in this study.
             The proposed resection should be equal or greater than 1 cm in diameter.

          2. In addition, patients undergoing induction chemotherapy or biologic therapy prior to
             surgical resection are also eligible.

          3. Patients must sign an informed consent indicating awareness of the investigational
             nature of this study.

        Exclusion Criteria:

          1. Patients with non-melanoma skin cancer lesion at eyelid, or in case that the lesion
             extends to superior or inferior eyelid, this area will not be imaged.

          2. Persons who are medically unfit to undergo resection of skin lesions.

          3. Persons under the age of 18.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Histologically* or cytologically* confirmed small bowel adenocarcinoma

               -  Metastatic or unresectable locally advanced disease NOTE: *Biopsy may be of
                  primary tumor or from a metastatic site if there is a primary small bowel tumor
                  or currently or previously present.

          -  Measurable disease

               -  For patients with lesions  1 cm but &lt; 2 cm, spiral CT scan imaging must be used
                  for tumor assessments

          -  Confirmed UGT1A1 TA indel genotype of 6/6, 6/7, or 7/7

          -  No periampullary carcinoma or appendiceal cancer

          -  No known CNS metastases or carcinomatous meningitis

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Life expectancy  12 weeks

          -  Absolute neutrophil count  1,500/mm

          -  Platelet count  100,000/mm

          -  AST  2.5 times upper limit of normal (ULN) (5 times ULN if liver metastasis is
             present)

          -  Bilirubin normal for patients with 6/6 genotype (&lt; 2 times ULN for patients with 6/7
             or 7/7 genotype)

          -  Hemoglobin  9.0 g/dL

          -  Creatinine  1.5 times ULN OR creatinine clearance  60 mL/min

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No active or uncontrolled infection

          -  No other concurrent malignancy, except for nonmelanoma skin cancer

          -  No preexisting sensory neuropathy  grade 2

          -  No evidence of serious intercurrent illness, including any of the following:

               -  Unstable angina

               -  Symptomatic congestive heart failure

               -  Serious uncontrolled cardiac arrhythmia

        PRIOR CONCURRENT THERAPY:

          -  At least 2 weeks since prior radiotherapy

          -  At least 4 weeks since prior major surgery

          -  No prior chemotherapy for advanced small bowel cancer

               -  Prior adjuvant fluorouracil/leucovorin calcium allowed provided last dose was 
                  3 months ago

               -  No prior adjuvant oxaliplatin or irinotecan hydrochloride

          -  No prior radiotherapy to &gt; 25% of bone marrow

          -  No concurrent sorivudine, brivudine, lamivudine, or stavudine

          -  No concurrent sargramostim (GM-CSF) or pegfilgrastim
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Participants with precancerous or cancerous oral lesions.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Patients with a lesion or history of a lesion of the oral mucosa.

          2. Subjects with the ability and willingness to sign an informed consent and
             authorization.

        Exclusion Criteria:

          1. Persons who are medically unfit to undergo surgery.

          2. Persons under the age of 18.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Breast cancer cases diagnosed after 1994 and equal number of frequency-matched (by age
        within 2 years and ethnicity) controls. Cases and eligible controls with at least 3
        screening mammograms since 1994 will be recruited through the University Hospitals Breast
        Center, and primary care clinics within the University Hospitals Health System (UHHS). The
        restriction of 3 or more screening mammograms will allow us to adequately model the
        longitudinal change patterns.
  </textblock>
 </study_pop>
 <sampling_method>
  Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Meets 1 of the following criteria:

               -  Patient at the University Hospitals Breast Center and primary care clinics
                  within the University Hospitals system AND meets the following criteria:

                    -  Histologically confirmed breast cancer that was diagnosed between the years
                       2002-2004

                         -  Known tumor stage

               -  Healthy participant who is receiving routine medical care (e.g., screening
                  mammograms) at the University Hospitals Health System

          -  Underwent  4 prior screening mammograms at the Breast Center since 1994

          -  No known carriers of BRCA1 or BRCA2 genes

          -  Hormone receptor status:

               -  Known estrogen and/or progesterone receptor status

        PATIENT CHARACTERISTICS:

          -  Female

          -  Menopausal status not specified

          -  No breast implants

        PRIOR CONCURRENT THERAPY:

          -  Not currently taking tamoxifen citrate, raloxifene, or aromatase inhibitors
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  50 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Meets 1 of the following criteria:

               -  Newly diagnosed primary invasive melanoma (patient group)

                    -  Lentigo maligna malignant melanoma allowed

                    -  Rare variants of melanoma allowed, including any of the following:

                         -  Acral lentiginous

                         -  Subungual

                         -  Ear, nose, and throat

                         -  Oropharyngeal

                         -  Perineal

                         -  Vaginal

                         -  Vulval

                         -  Rectal

                         -  Nodal with no known primary

                    -  Patients undergoing sentinel node biopsy are eligible

                    -  No in situ melanoma, melanocytic intraepidermal neoplasia, or ocular
                       melanoma

               -  Healthy participant meeting either of the following criteria (control group):

                    -  Relative of a patient who was diagnosed with melanoma after September 2005

                    -  Healthy volunteer who is age- and sex-matched for patients who were
                       diagnosed with melanoma before October 2005

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  Not specified
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Histologically confirmed GD2-expressing malignancy, including the following:

               -  Medulloblastoma or primitive neuroectodermal tumor of the CNS

               -  High-grade astrocytoma

               -  Malignant glioma

               -  Neuroblastoma

               -  Retinoblastoma

               -  Ependymoma

               -  Rhabdoid tumors

               -  Sarcomas

               -  Melanoma

               -  Small cell lung carcinoma

               -  Desmoplastic small round cell tumor

               -  Other tumor types with GD2 expression confirmed by immunohistochemical staining
                  and assessed by the Memorial Sloan-Kettering Department of Pathology using prior
                  frozen tissue, bone marrow, or cerebrospinal fluid cytology

          -  Must meet 1 of the following criteria:

               -  Refractory to conventional therapies

               -  Disease for which no conventional therapy exists

               -  Recurrent brain tumors with a predilection for leptomeningeal dissemination
                  (e.g., medulloblastoma, supratentorial primitive neuroectodermal tumor, rhabdoid
                  tumor)

          -  Patients with active malignancy outside the central nervous system are eligible

               -  No obstructive or symptomatic communicating hydrocephalus

        PATIENT CHARACTERISTICS:

          -  Absolute neutrophil count &gt; 1,000/mm

          -  Platelet count &gt; 50,000/mm

          -  No uncontrolled life-threatening infection

          -  No rapidly progressing or deteriorating neurologic examination

          -  No severe major organ toxicity (i.e., renal, cardiac, hepatic, pulmonary, and
             gastrointestinal system toxicity  grade 2)

          -  Stable neurological deficits (due to brain tumor) allowed

          -  No hearing loss &gt; 3

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

          -  No cranial or spinal irradiation within the past 3 weeks

          -  No prior craniospinal radiation &gt; 45 Gy or focal brain radiation &gt; 72 Gy

          -  No systemic chemotherapy within the past 3 weeks (corticosteroids allowed)

          -  Programmable shunt allowed
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Patients must have: IIIA or IIIB non-small cell lung cancer by radiographic or
             surgical staging, excluding: superior sulcus tumors, tumors with associated
             atelectasis or obstructive pneumonitis of the entire lung, and tumors with a
             malignant pleural effusion.

          2. Patients will be included in the study based on the following criteria:

               -  Patients must be older than 18 years old.

               -  Patients must have a Zubrod performance status of 0 to 2

               -  Patients with adequate bone marrow function

               -  Patients with adequate renal function

               -  Patients with adequate hepatic function

               -  Patients of childbearing potential must have a negative serum pregnancy test and
                  use an effective form of contraception.

               -  Patients who are suitable for treatment with radical intent using concurrent
                  chemotherapy and radiation.

               -  Patients who have signed an approved informed consent and authorization
                  permitting release of personal health information.

        Exclusion Criteria:

          1. Disease-Specific Exclusions

               -  Superior sulcus tumors

               -  Atelectasis or obstructive pneumonitis of the entire lung

               -  Malignant pleural effusion

          2. General Medical Exclusions

               -  Surgical candidates

               -  Patients who are pregnant at the time of diagnosis

               -  Serious concomitant systemic disorders incompatible with the study

               -  Inability to comply with study and/or follow-up procedures

               -  Life expectancy of less than 12 weeks

               -  Current, recent (within 4 weeks of the first infusion of this study), or planned
                  participation in an experimental drug study

               -  Patients with septicemia or severe infection.

               -  Patients who have circumstances that will not permit completion of this study or
                  the required follow-up

               -  Patients with any contraindication to gemcitabine, carboplatin, or paclitaxel
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients at high risk for complications from lung resection.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Patient's age is between 18-90.

          2. Patient has been referred for an oxygen consumption exercise test because they are
             considered high risk for morbidity and/or mortality post lung resection

          3. Patient must be able to read, understand and provide informed consent.

        Exclusion Criteria:

          1. Patients diagnosed with angina pectoris

          2. Patients diagnosed with critical aortic stenosis

          3. Patients with unstable gait that persists with use of assistive device

          4. Patients unable to walk
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  90 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   This is a combined eligibility criteria for both bevacizumab comparison and the lapatinib
        feasibility study. Please note the bevacizumab comparison closed to recruitment on 28th
        March 2014.

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed gastric or type I, II or III gastroesophageal junction
             adenocarcinoma or lower oesophageal

        Gastric and Type III junctional tumours should be Stage Ib (T1 N1, T2a/b N0), II, III or
        stage IV (T4 N1 or N2) with no evidence of distant metastases (M0)

        Lower oesophageal and Type I and II junctional tumours should be Stage II to Stage IVa (T1
        N1, T2 N1, T3 N0-1, but not T2N0). T4 (N0 or N1) tumours are also eligible providing that
        they involve only the crura OR invade only the mediastinal pleura. Patients with nodal
        disease affecting the origin of the left gastric and splenic artery or coeliac axis
        (staged as M1a) are also eligible.

          -  Resectable disease

          -  Previously untreated disease

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0 or 1

          -  Absolute neutrophil count  1,500/mm^3

          -  Platelet count  100,000/mm^3

          -  Hemoglobin  9 g/dL (can be post transfusion)

          -  WBC  3,000/mm^3

          -  Glomerular filtration rate  60 mL/min

          -  Proteinuria  1 g by 24-hour urine collection

          -  Bilirubin  1.5 times upper limit of normal (ULN)

          -  ALT and AST  2.5 times ULN

          -  Alkaline phosphatase  3 times ULN (in the absence of liver metastases)

          -  INR  1.5

          -  PTT  1.5 times ULN

          -  FEV_1  1.5 L

          -  Cardiac ejection fraction  50% by MUGA scan or echocardiogram

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Must be fit enough to receive protocol treatment

          -  No other malignancies within the past 5 years except for curatively treated basal
             cell carcinoma of the skin and/or in situ carcinoma of the cervix

          -  No prior or concurrent significant medical conditions, including any of the
             following:

               -  Cerebrovascular disease (including transient ischemic attack and stroke) within
                  the past year

               -  Cardiovascular disease, including the following:

                    -  Myocardial infarction within the past year

                    -  Uncontrolled hypertension while receiving chronic medication

                    -  Unstable angina

                    -  New York Heart Association class II-IV congestive heart failure

                    -  Serious cardiac arrhythmia requiring medication

               -  Major trauma within the past 28 days

               -  Serious nonhealing wound, ulcer, or bone fracture

               -  Evidence of bleeding diathesis or coagulopathy

               -  Recent history of any active gastrointestinal inflammatory condition (e.g.,
                  peptic ulcer disease, diverticulitis, or inflammatory bowel disease)

                    -  If patients have a known diagnosis of any of the above, evidence of disease
                       control is required by negative endoscopy within the past 28 days

          -  No severe tinnitus

          -  No lack of physical integrity of the upper gastrointestinal tract, malabsorption
             syndrome, or inability to take oral medication

          -  No known peripheral neuropathy  1 (absence of deep tendon reflexes as the sole
             neurological abnormality does not render the patient ineligible)

          -  No known dihydropyrimidine dehydrogenase deficiency

          -  No history of interstitial lung disease or radiological evidence of lung fibrosis

          -  No known allergy to any of the following:

               -  Chinese hamster ovary cell proteins

               -  Other recombinant human or humanized antibodies

               -  Any excipients of bevacizumab formulation or platinum compounds

               -  Any other components of the study drugs

        Due to an increase in perforations associated with self-expandable metal stents in
        patients with colorectal cancer receiving bevacizumab, patients with an oesophageal or
        gastric stent (metal or biodegradable) in situ are ineligible for the study.

        PRIOR CONCURRENT THERAPY:

          -  No prior anthracycline

          -  More than 28 days since prior major surgery or open biopsy

          -  More than 10 days since prior thrombolytic therapy

          -  No concurrent thrombolytic therapy

          -  No concurrent dipyridamole

          -  No concurrent capecitabine or sorivudine (or sorivudine analogues [e.g., brivudine])

          -  No chronic, daily high-dose acetylsalicylic acid (&gt; 325 mg/day) or nonsteroidal
             anti-inflammatory drugs

          -  No chronic corticosteroids ( 10 mg/day methylprednisolone equivalent)

               -  Inhaled steroids allowed

          -  No other concurrent cytotoxic agents

          -  No other concurrent investigational drugs

          -  No concurrent radiotherapy

          -  Low molecular weight heparin allowed

          -  More than 7 days since prior CYP3A4 inhibitor therapy

          -  More than 14 days since prior CYP3A4 inducer therapy

          -  More than 6 months since prior amiodarone therapy

          -  More than 14 days since prior St John's Wort, modafinil, ginkgo biloba, kava, grape
             seed, valerian, ginseng, echinacea and evening primrose oil
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Diagnosis of diffuse large B-cell lymphoma, meeting 1 of the following staging
             criteria:

               -  Limited stage I disease that is bulky (i.e., more than 10 cm) or with
                  International Prognostic Index &gt; 1

               -  Stage II-IV disease

          -  CD20-positive disease

          -  Paraffin-embedded tumor specimen must be available

          -  No active CNS lymphoma

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-3

          -  WBC &gt; 2,500/mm

          -  Absolute neutrophil count &gt; 1,000/mm (unless due to disease in marrow)

          -  Platelet count &gt; 100,000/mm (unless due to disease in marrow)

          -  Creatinine &lt; 2.0 mg/dL

          -  Bilirubin &lt; 1.5 mg/dL (1.5-3.0 mg/dL if due to liver involvement by lymphoma)

          -  AST and ALT &lt; 3 times upper limit of normal

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  LVEF &gt; 45%

          -  No HIV positivity

          -  No other malignancy except for basal cell carcinoma of the skin or in situ carcinoma
             of the cervix (unless the tumor was treated with curative intent  2 years ago and
             the patient continues to be free of evidence of recurrence)

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy, radiotherapy, or immunotherapy

               -  A prior short course (i.e., &lt; 2 weeks) of corticosteroids allowed
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Meets one of the following criteria:

               -  Prior multiple primary melanomas

                    -  Histological samples available

               -  Family history of melanoma, with melanoma in two first-degree relatives (e.g.,
                  cases of melanoma in both a mother and son or in two brothers but not in two
                  cousins)

               -  Family history of melanoma, where three or more individuals (of any
                  relationship) have had melanoma

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  Not specified
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Relapsed or refractory myeloma that with evidence of progression on an IMiD, a
             proteasome inhibitor, and an alkylator.

        NOTE: Progression within 1 year post-high-dose chemotherapy with autologous stem    cell
        support would qualify as alkylator refractory

          -  Absolute neutrophil count (ANC) &gt;= 1000/uL

          -  Platelets (PLT) &gt;= 50,000/uL

          -  Hemoglobin &gt;= 8.5 g/dl

          -  Aspartate aminotransferase (AST) =&lt; 2 times upper limit of normal

          -  Creatinine &lt; 2 times upper limit of normal

          -  Total bilirubin =&lt; 1.5 x upper limit of normal

          -  International normalized ratio (INR) =&lt; 1.4 x ULN at the time of registration

          -  Ability to provide informed consent

          -  Willingness to return to Mayo Clinic Rochester for follow-up

          -  Life expectancy &gt;= 12 weeks

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2

          -  Willingness to provide all biological specimens as required by the protocol

          -  Negative serum pregnancy test done =&lt; 7 days prior to registration for women of
             childbearing potential only

          -  Measles virus titers (measles neutralizing antibody) &lt; 0.5

        Exclusion Criteria:

          -  Availability of known standard therapy that is definitely capable of extending life
             expectancy (patients who are on maintenance therapy with bisphosphonates are not
             excluded)

          -  Uncontrolled infection

          -  Active tuberculosis

          -  Chemotherapy =&lt; 3 weeks prior to study registration

          -  Immunotherapy =&lt; 4 weeks prior to study registration

          -  Biologic therapy =&lt; 4 weeks prior to study registration

          -  New York Heart Association classification III or IV, known symptomatic coronary
             artery disease, or symptoms of coronary artery disease on systems review, or known
             cardiac arrhythmias (atrial fibrillation or supraventricular tachycardia [SVT])

          -  Active central nervous system (CNS) disorder or seizure disorder

          -  Human immunodeficiency virus (HIV) positive test result

          -  Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy
             considered investigational

          -  Allergy to iodine (this does not include reactions to intravenous contrast materials)

          -  Previous exposure to heat inactivated measles virus vaccine (this vaccine was given
             to some individuals between the years of 1963-1967)

          -  Any of the following:

               -  Pregnant women or women of reproductive ability who are unwilling to use
                  effective contraception

               -  Nursing women

               -  Men who are unwilling to use a condom (even if they have undergone a prior
                  vasectomy) while having intercourse with any woman, while taking the drug and
                  for 4 weeks after stopping treatment

          -  Prior allogeneic hematopoietic stem cell transplantation

          -  Exposure to household contacts =&lt; 15 months old or household contact with known
             immunodeficiency
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Subjects who received poxviral vectors (vaccinia and/or fowlpox) or other vaccines
        utilizing gene transfer or any other immunotherapeutic agent through an LTIB affiliated
        trial at the National Cancer Institute. These studies include (but are not limited to):
        00-C-0137, 00-C-0154, 02-C-0218, 03-C-0176, 04-C-0167, 04-C-0246, 05-C-0017, 05-C-0167,
        05-C-0229, 07-C-0106, 07-C-0107, 07-C-0188, 08-C-0166, 09-C-0101, 11-C-0225,12-C-0056,
        13-C-0146, 13-C-0153, 13-C-0095 and 14-C-0142. Upon termination of the above protocols,
        available stored specimens obtained in each of the protocols listed above will be
        transferred to this protocol for future research use.

        EXCLUSION CRITERIA:

        Patients unwilling to participate.  (Please note, patients may participate in this
        protocol and, at the same time, participate in an active treatment or continuing care
        study.)
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

        Patients fulfilling all the following criteria will be eligible:

          -  Male or female aged &gt;18years;

          -  Newly diagnosed with acute myeloid leukaemia and undergoing first   induction
             chemotherapy regimen;

          -  Expected to have absolute neutrophil counts of &lt;0.5x109/L for at least 2 weeks;

          -  Normal high resolution chest and sinus CT scan at baseline;

          -  No signs or symptoms of invasive fungal infections

          -  No prior diagnosis of proven or probable invasive fungal infection within the last 6
             months;

          -  Females of childbearing potential must be: surgically incapable of pregnancy; or
             practicing an acceptable mode of birth control and have a negative pregnancy test
             (blood or urine) at baseline;

          -  Give written informed consent prior to any study-specific procedures;

          -  Must have the ability and must agree to comply with all study requirements.

        Exclusion Criteria:

        Patients with any of the following will be ineligible

          -  Known hypersensitivity to amphotericin B, in particular known history of anaphylactic
             reaction to amphotericin B;

          -  Patients undergoing any transplantation;

          -  Creatinine clearance &lt;60mL/min/1.72 m2;

          -  Patients with moderate or severe liver disease as defined by aspartate
             aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 5 times the upper limit of
             normal (ULN)

          -  Patients who are unlikely to survive more than one month;

          -  Patients who have received systemic antifungal therapy within the last 15 days

          -  Any severe cardiovascular disease ( in particular arrhythmias) which may constitute a
             contra-indication to LAB (AmBisome) administration;

          -  Any severe diseases other than acute myeloid leukaemia which in the investigator's
             judgement may interfere with study evaluations or affect the patients safety;

          -  Pregnant or nursing females;

          -  Patients previously included in this study;

          -  Patients who have taken an investigational drug in the last 30 days prior to the
             inclusion.

          -  Patients enrolled in a pre-emptive treatment strategy trial
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  80 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Histological or cytological documented diagnosis of inoperable, locally advanced,
             recurrent or metastatic (Stage IIIB or Stage IV) NSCLC.

          -  Chemo-nave patients.

          -  Patients who are in the investigator's opinion not medically suitable for
             chemotherapy.

          -  Measurable disease according to the RECIST criteria.

          -  ECOG performance status of 0 - 3.

          -  Life expectancy of at least 12 weeks.

          -  Patients must be able to take oral medication.

          -  Serum calcium within normal ranges

          -   4 weeks since prior surgery or radiation therapy

          -  For all females of childbearing potential a negative pregnancy test must be obtained
             within 48 hours before starting therapy and must use effective contraception

          -  18 years of age or older

          -  Written (signed) Informed Consent to participate in the study

        Exclusion Criteria:

          -  Prior systemic antitumor therapy

          -  Any unstable systemic disease which according to the investigator contraindicates the
             use of the study drug render the subject at high risk from treatment complications
             (including active infection, unstable angina, myocardial infarction within the
             previous month, inflammatory bowel disease, hepatic disease with serum bilirubin  2
             upper limit of normal (ULN) or AST and/or ALT   2 x ULN (or    5 x ULN if  clearly
             attributable to liver metastasis), renal disease with acute renal failure or serum
             creatinine   5 x ULN.

          -  Any other malignancies within 5 years (except for adequately treated carcinoma in
             situ of the cervix or basal or squamous cell skin cancer).

          -  Nursing mothers or pregnant woman.

          -  Hypersensitivity to Tarceva or co-formulants.

          -  Patients with brain metastasis or spinal cord compression that has not yet been
             definitively treated with surgery and/or radiation.

          -  Patients with brain metastasis or spinal cord compression that  not are in a stable
             condition despite treatment with steroids.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   patients received bone marrow transplantation in Tokyo Metropolitan Komagome Hospital
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  After allogeneic bone marrow transplantation

        Exclusion Criteria:

          -  Contraindication for gastrointestinal endoscopy
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  20 Years
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Histologically confirmed marginal zone lymphoma (MZL)

               -  Extranodal, splenic, or nodal MZL

               -  All stages allowed

          -  Meets 1 of the following criteria:

               -  Previously untreated nongastric MZL

               -  Gastric MZL that did not respond to antibiotic therapy given 2-6 months ago

          -  Measurable or evaluable disease

          -  Must not have  25% bone marrow involvement by MZL

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Life expectancy  6 months

          -  Platelet count  100,000/mm

          -  Absolute neutrophil count  1,500/mm

          -  No known HIV positivity

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 6 months after
             completion of study treatment

          -  No physical or mental condition that precludes study compliance

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior or concurrent chemotherapy

          -  No prior radiotherapy, immunotherapy, systemic corticosteroids, or systemic biologic
             anticancer therapy

          -  No concurrent corticosteroids

          -  No other concurrent systemic antineoplastic therapy
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients with dyskeratosis congenita (DC) or severe aplastic anemia (SAA) 0-70 years
             of age with an acceptable hematopoietic stem cell (HSC) donor

               -  HSC source

                    -  HLA identical or 1 antigen mismatched sibling or other relative eligible to
                       donate bone marrow (BM), umbilical cord blood (UCB) or mobilized peripheral
                       blood (PB) at cell doses that meet current institutional standards.

                    -  HLA identical or up to a 1 antigen mismatched unrelated donor.

                    -  Two units of unrelated umbilical cord blood (UCB) that are (a) up to 2 HLA
                       antigens mismatched to the patient (b) up to 2 HLA antigens mismatched to
                       each other, (c) minimum cell dose of  3.5 x 10^7 nucleated cells/kg and
                       optimal cell dose  5 x 10^7 nucleated cells/kg.

                    -  If two units are not available: single unrelated UCB unit selected
                       according to Minnesota Bone Marrow Transplant (BMT) program guidelines

               -  Disease Characteristics for DC (both of the following):

                    -  Evidence of BM failure:

                         -  Requirement for red blood cell and/or platelet transfusions,

                         -  Requirement for granulocyte colony-stimulating factor (G-CSF) or
                            granulocyte-macrophage colony-stimulating factor (GM-CSF) or
                            erythropoietin, or

                         -  Refractory cytopenias defined as two out of three: platelets
                            &lt;40,000/uL or transfusion dependent, Absolute neutrophil count &lt;500/uL
                            without hematopoietic growth factor support, Hemoglobin &lt;9g/uL or
                            transfusion dependent

                    -  Diagnosis of DC:

                         -  A triad of mucocutaneous features: oral leukoplakia, nail dystrophy,
                            abnormal reticular skin hyperpigmentation.

                         -  Or one of the following:  Short telomeres (under a research study),
                            Dyskerin mutation, TERC mutation

               -  Disease Characteristics for SAA (both of the following):

                    -  Evidence of BM failure:

                         -  Refractory cytopenia defined by bone marrow cellularity &lt;25-50% (with
                            &lt; 30% residual hematopoietic cells)

                    -  Diagnosis of SAA:

                         -  Refractory cytopenias defined as two out of three: Platelets
                            &lt;20,000/uL or transfusion dependent, Absolute neutrophil count &lt;500/uL
                            without hematopoietic growth factor support, Absolute reticulocyte
                            count &lt;20,000/uL

               -  Patients with early myelodysplastic features.

               -  Patients with or without clonal cytogenetic abnormalities.

        Patient Exclusion Criteria:

          -  Patients with one or more of the following:

               -  Decompensated congestive heart failure; left ventricular ejection fraction &lt;35%

               -  Acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis
                  on biopsy

               -  Carbon Monoxide Diffusing Capacity (DLCO) &lt;30% predicted, and oxygen requirement

               -  Glomerular filtration rate (GFR) &lt;30% predicted

               -  Pregnant or lactating female

               -  Active serious infection whereby patient has been on intravenous antibiotics for
                  at least one week prior to study entry. Any patient with AIDS or HIV
                  seropositivity. If recent mold infection e.g. Aspergillus - must have &gt;30 days
                  of appropriate treatment before HSC transplantation and infection must be
                  controlled and cleared by the Infectious Disease consultant.

               -  Cannot receive TBI due to prior radiation therapy

               -  Diagnosis of Fanconi anemia based on diepoxybutane (DEB).

               -  DC patients with advanced myelodysplastic syndrome (MDS) or acute myeloid
                  leukemia with &gt;30 blasts.

               -  History of non hematopoietic malignancy within 2 years except resected basal
                  cell carcinoma or treated carcinoma in situ.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patient is considered a poor surgical candidate for removal of renal mass as
             determined by anesthesiology pre-operative assessment or the surgical team, medical
             team. (No major psychiatric illnesses.)

          -  Patient is able to give and sign study specific informed consent

          -  No prior radiation to the treatment field

          -  Negative serum or urine pregnancy test within 72 hours prior to registration for
             women of childbearing potential

          -  Patient has a radiologically and /or pathologically confirmed diagnosis of a renal
             tumor

          -  Karnofsky status of &gt;= 60%

          -  Signed study-specific informed consent prior to study entry

        Exclusion Criteria:

          -  Any patient not meeting the eligibility criteria.

          -  Any patient with active connective tissue disease such as lupus, dermatomyositis.

          -  Any patient with active Crohn's disease or active ulcerative colitis.

          -  Major psychiatric illness, which would prevent completion of treatment or interfere
             with follow-up.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

        This trial includes only patients who have relapsed after an allogeneic transplant, who
        have either:

          1. No response to conventional DLI given for at least one dose, or

          2. No possibility of access to large number of donor lymphocyte for repeated doses of
             DLI, This applies to cases of unrelated transplant or cord blood transplant

          3. Patients who developed significant GVHD to conventional DLI, but had no other
             therapeutic option. In such cases the rationale is based on mice studies of
             mismatched CIK producing much less GVHD than mismatched unmanipulated splenocytes.

        In view of the period taken to culture the cell to maturity, patient must have a life
        expectancy of more than one month. Interim measures eg chemotherapy or conventional DLI
        will be given during the interval so that ongoing treatment will not be compromised in any
        way.

        Exclusion Criteria:

          1. Uncontrolled infection or significant bleeding

          2. Unstable vital signs

          3. Any degree of hypoxia requiring oxygen therapy.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  12 Years
 </minimum_age>
 <maximum_age>
  60 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:  Part 1 and Part 2 prior to Amendment 13:

          -  Age 18 years.

          -  Karnofsky Performance Status (KPS) score 70%.

          -  All patients must have histologic evidence of multiple myeloma.  Evidence of relapsed
             or relapsed/refractory disease for which no other approved treatment is available and
             clinically indicated.  In addition, patients may have undergone prior bone marrow
             transplantation.  For patients treated at the Recommended Phase 2 Dose patients are
             required to have measurable relapsed or relapsed/refractory disease.  Disease must be
             assessed within 28 days prior to treatment initiation.

               1. Measurable disease is defined as one of the following:

                    -  Serum M-protein 0.5 g/dL

                    -  Urine M-protein 200 mg/24 hours

                    -  Involved serum free light chain (FLC) level 10 mg/dL, provided the serum
                       FLC ratio is abnormal

               2. Relapsed and Refractory are defined as:

                    -  Must have received at least 2 prior treatment regimens.

                    -  Must have received prior treatment with at least 2 cycles of lenalidomide
                       and at least 2 cycles of bortezomib (either in separate regimens or within
                       the same regimen).

                    -  Must have received a cytotoxic chemotherapy agent (eg, alkylating agent).

                    -  Relapsed Disease:  Must have progressive disease after having achieved at
                       least stable disease for at least one cycle of treatment during at least
                       one prior regimen.

                    -  Refractory Disease:  Must have documented evidence of progressive disease
                       during or within 60 days (measured from the end of the last cycle) of
                       completing the most recently received anti-myeloma drug regimen prior to
                       study entry

          -  All AEs resulting from prior chemotherapy, surgery, or radiotherapy must have
             resolved to NCI-CTCAE Grade 1 (except for hematologic parameters outlined below).

          -  The following laboratory results, within 7 days prior to NPI-0052 administration
             (transfusions and/or growth factor support may be used with discretion by the
             Investigator during Screening):

               -  Hemoglobin 8 g/dL

               -  Absolute neutrophil count 0.5  109/L

               -  Platelet count 30  109/L

               -  Serum bilirubin 1.5  ULN

               -  AST 2.5  ULN

               -  Serum creatinine 1.5  ULN

               -  Creatinine clearance 40 mL/min

          -  Signed informed consent.

        For patients in Part 2 only:

        -Must have previously received at least 2 cycles of carfilzomib (as a single agent or in
        combination with other agents) and subsequently had disease progression during or within
        60 days of carfilzomib therapy.  Carfilzomib does not have to be the most recent therapy
        that the patient has received, but patients must have documented disease progression
        during or within 60 days of their last anti-myeloma therapy

        Inclusion Criteria Part 2 Amendment 13:

          -  Age 18 years.

          -  Karnofsky Performance Status score 70%.

          -  All patients must have histologic evidence of multiple myeloma and evidence of
             relapsed or relapsed/refractory disease as defined below  Patients are required to
             have measurable relapsed or relapsed/refractory disease.  Disease must be assessed
             within 28 days prior to treatment initiation.

               1. Measurable disease defined as one of the following:

                    -  Serum M-protein 0.5 g/dL

                    -  Urine M-protein 200 mg/24 hours

                    -  Involved serum free light chain (FLC) level 10 mg/dL provided the serum
                       FLC ratio is abnormal

               2. Relapsed and Refractory are defined as:

                    -  Must have received at least 2 prior treatment regimens.

                    -  Must have received prior treatment with at least 2 cycles of an
                       immunomodulator (lenalidomide or pomalidomide or thalidomide).

                    -  Must have previously received at least 2 cycles of carfilzomib (as a single
                       agent or in combination with other agents) and subsequently had disease
                       progression during or within 60 days of carfilzomib therapy.  Carfilzomib
                       does not have to be the most recent therapy that the patient has received,
                       but patients must have documented disease progression during or within 60
                       days of their last anti-myeloma therapy. Patients may also have received
                       bortezomib.

        In addition, patients may have undergone prior cytotoxic chemotherapy, bone marrow
        transplantation and previously participated in other clinical trials.

          -  Relapsed Disease: Must have progressive disease after having achieved at least stable
             disease for at least one cycle of treatment during at least one prior regimen.

          -  Refractory Disease: Must have documented evidence of progressive disease during or
             within 60 days (measured from the end of the last cycle) of completing the most
             recently received anti-myeloma drug regimen prior to study entry.

               -  All Adverse Events resulting from prior chemotherapy, surgery, or radiotherapy,
                  must have resolved to CTCAE Grade 1 (except for hematologic parameters outlined
                  below).

               -  The following laboratory results, within 7 days of NPI-0052 administration
                  (transfusions and/or growth factor support may be used with discretion by the
                  Investigator during the screening period):

          -  Hemoglobin 8 g/dL

          -  Absolute neutrophil count 0.5 x 109/L

          -  Platelet count 30 x 109/L

          -  Serum bilirubin 1.5 x ULN

          -  AST 2.5 x ULN

          -  Serum creatinine 1.5 x ULN

          -  Creatinine clearance 40 mL/min -Signed informed consent.

        Exclusion Criteria:  Part 1 and Part 2

          -  Administration of chemotherapy, biological, immunotherapy, or investigational agent
             (therapeutic or diagnostic) within 14 days prior to receipt of study medication (this
             washout period can be reduced to 7 days for biologically targeted therapies (eg,
             bortezomib, carfilzomib, thalidomide, lenalidomide, pomalidomide, and dexamethasone
             or equivalent), provided the patient has recovered from the toxicity from these
             regimens per Inclusion Criterion #4).  Patients must be 6 weeks from last dose of
             nitrosourea and 12 weeks from BMT.  Patients must be 2 weeks from last dose of
             radiation.

          -  Patients with Grade &gt;1 proteinuria (1 g/24 hour excluding M proteins = urine
             paraprotein subtracted from total urine protein), untreated urinary tract infection,
             as well as any pre existing kidney disease (acute or chronic) that in the
             Investigator's assessment would impose excessive risk to the patient.

          -  Patients with evidence of mucosal or internal bleeding and/or platelet refractory
             (ie, unable to maintain platelet count 30  109/L).

          -  Significant cardiac disease defined as:

               -  Patients with congenital long QT syndrome;

               -  Congestive heart failure of Class III or IV of the NYHA classification;

               -  History of myocardial infarction or ischemia within 12 months of study
                  enrollment.

          -  For patients in Part 2 only:  abnormal left ventricular ejection fraction (LVEF) (&lt;
             lower limit of normal as defined by the study site for a patient of that age) by
             echocardiogram (ECHO) or multiple-gated angiography (MUGA).

          -  Patients with a prior hypersensitivity reaction of CTCAE Grade &gt;3 to therapy
             containing propylene glycol or ethanol.

          -  Pregnant or breast-feeding women.  Female patients must be postmenopausal or
             surgically sterile, or they must agree to use acceptable methods of birth control
             (ie, a hormonal contraceptive with barrier method, intra-uterine device, diaphragm
             with spermicidal or condom with spermicide, or abstinence) for the duration of the
             study and for one month following study completion.  Female patients with
             childbearing potential must have a negative serum pregnancy test within the 7 days
             before the first NPI-0052 administration.  Male patients must be surgically sterile
             or agree to use an acceptable method of contraception.

          -  Active uncontrolled bacterial or fungal infection requiring systemic therapy;
             infection requiring parenteral antibiotics.

          -  Known to be HIV positive or positive and active for hepatitis A, B, or C.

          -  Any medical conditions that, in the Investigator's opinion, would impose excessive
             risk to the patient.  Examples of such conditions include infection requiring
             parenteral or oral anti-infective treatment or any altered mental status or
             psychiatric condition that would interfere with an understanding of the informed
             consent.

          -  Unwilling or unable to comply with procedures required in this protocol.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   pituitary disease patients
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Familial acromegaly or other type of pituitary tumour OR

          -  Early onset acromegaly or

          -  Sporadic pituitary tumour

        Exclusion Criteria:

          -  Do not consent
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  6 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Polycystic ovary syndrome (using ESHRE/ARSM 2004 criteria)

        Exclusion Criteria:

          -  Age &lt;18 or &gt;35 years

          -  Severe obesity (BMI &gt;35)

          -  Neoplastic, metabolic, hepatic, and cardiovascular disorders or other concurrent
             medical illnesses

          -  Hypothyroidism, hyperprolactinemia, Cushing's syndrome, and non-classical congenital
             adrenal hyperplasia

          -  Current or previous (within the last six months) use of oral contraceptives,
             glucocorticoids, antiandrogens, antidiabetic and anti-obesity drugs or other hormonal
             drugs

          -  Previous use of ovulation induction agents

          -  Intention to start a diet or a specific program of physical activity

          -  No uterine bleeding after progesterone challenge test

          -  Organic pelvic diseases

          -  Previous pelvic surgery

          -  Suspected peritoneal factor infertility

          -  Tubal or male factor infertility or sub-fertility
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  35 Years
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Biopsy proven, clinical stage 1-3 prostate carcinomas

          2. Prostatectomy at M. D. Anderson within 3 months from the time of MRSI

          3. An interval of &gt; 6 weeks between the biopsy and MRSI

          4. Signed informed consent form

        Exclusion Criteria:

          1. Contraindications for MRI (e.g. cardiac pacemaker)

          2. Allergy to Latex

          3. Contraindications for MRS (e.g. history of abdomino-perineal resection of rectum)

          4. Metals or any conditions (e.g. hip prosthesis) that can distort the local magnetic
             field

          5. Previous prostate surgery for prostate carcinoma (including, Transurethral resection
             of the prostate (TURP) and cryosurgery), local or systemic treatment for prostate
             carcinoma (e.g. radiation, androgen deprivation), pelvic radiation (e.g. rectal
             cancer), rectal surgery, Bacillus Calmette-Guerin (BCG) for bladder cancer
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Clinics from Children's Hospital of Wisconsin.
  </textblock>
 </study_pop>
 <sampling_method>
  Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Study Population Inclusion Criteria:

          -  No limit to age

          -  Diagnosis of infantile hemangioma and/or vascular anomaly

          -  Unaffected twin sibling

          -  Each patient's authorized legal guardian must understand the nature of the study and
             must provide written informed consent. Each patient must also give assent to study
             participation.

        Study Population Exclusion Criteria:

          -  Diagnosis other than infantile hemangioma or vascular anomaly

          -  If the lesion has resolved and cannot be confirmed as a hemangioma by clinical exam

          -  If the biologic parents are unwilling or unable to submit DNA samples the child will
             be excluded from the DNA study. Therefore, if DNA samples cannot be or are not
             obtained from both biologic parents, the child and family will be excluded from the
             study.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion:

         Patients must have the following CD19+ B cell leukemia or lymphoma either with relapsed
        or chemotherapy-refractory disease or with evidence of residual disease following therapy.

        In all cases, patient's disease must be confirmed at MSKCC.

          -  CLL: Patients must have a diagnosis of CLL as evidenced by flow cytometry, bone
             marrow histology, and/or cytogenetics.

          -  Other low grade B-cell neoplasms are eligible for study, such as small lymphocytic
             lymphoma (SLL), follicular lymphoma, Waldenstrom's macroglobulinemia, hairy cell
             leukemia, marginal zone lymphomas, and mantle cell lymphomas.

          -  Creatinine 2.0 mg/100 ml, bilirubin 2.0 mg/100 ml, AST and ALT 3.0x normal, PT and
             PTT  2x normal outside the setting of stable chronic anticoagulation therapy,
             granulocytes 1,000/mm3, platelets 50,000/mm3, hemoglobin 8.0g/dl with transfusion
             support

          -  Adequate cardiac function (LVEF 40%) as assessed by ECHO or MUGA scan performed
             within 1 month of treatment.

          -  Adequate pulmonary function as assessed by 92% oxygen saturation on room air by
             pulse oximetry.

          -  Life expectancy of &gt; 3 months.

        Exclusion:

          -  Karnofsky performance status &lt;70.

          -  CLL patients with active transformed disease (Richter's transformation) are
             ineligible for enrollment on this study.

          -  Patients with following cardiac conditions will be excluded:

          -  New York Heart Association (NYHA) stage III or IV congestive heart failure

          -  Myocardial infarction 6 months prior to enrollment

          -  History of clinically significant ventricular arrhythmia or unexplained syncope, not
             believed to be vasovagal in nature or due to dehydration

          -  History of severe non-ischemic cardiomyopathy with EF 20%

          -  Patients with HIV, hepatitis B or hepatitis C infection are ineligible.

          -  Patients with any concurrent active malignancies as defined by malignancies requiring
             any therapy other than expectant observation.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

        Patients must fulfill all of the following criteria for admission to study:

          -  Women  18 years.

          -  Histologically proven DCIS of the breast without an invasive component.

          -  Bilateral mammograms performed within 6 months prior to randomization.

          -  Clinically node-negative.

          -  Treated by breast conserving surgery (primary excision or re-excision) with complete
             microscopic excision and clear radial margins of 1 mm* (*Patients with superficial
             or deep resection margin of &lt;1 mm are eligible if surgery has removed all of the
             intervening breast tissue from the subcutaneous tissue to the pectoralis fascia).

          -  Women who are at high risk of local recurrence due to:

               -  Age &lt; 50 years; OR

               -  Age  50 years plus at least one of the following:

                    -  Symptomatic presentation

                    -  Palpable tumour

                    -  Multifocal disease

                    -  Microscopic tumour size  1.5 cm in maximum dimension

                    -  Intermediate or high nuclear grade

                    -  Central necrosis

                    -  Comedo histology

                    -  Radial* surgical resection margin &lt; 10 mm. (*Patients with superficial or
                       deep resection margin of &lt; 10 mm are eligible if surgery has not removed
                       all of the intervening breast tissue from the subcutaneous tissue to the
                       pectoralis fascia.)

          -  Assessed by surgeon and radiation oncologist to be suitable for breast conserving
             therapy including whole breast RT.

          -  Ability to tolerate protocol treatment.

          -  Protocol RT should preferably commence within 8 weeks but must commence no later than
             12 weeks from the last surgical procedure.

          -  ECOG performance status 0, 1 or 2.

          -  Patient's life expectancy &gt; 5 years.

          -  Availability for long-term follow-up.

          -  Written informed consent.

        Exclusion Criteria:

        Patients who fulfill any of the following criteria are not eligible for admission to
        study:

          -  Multicentric disease or extensive microcalcifications that could not be completely
             excised by breast conserving surgery with radial margins of 1 mm*.

             *Patients with superficial and/or deep margin of &lt;1 mm are eligible if surgery has
             removed all of the intervening breast tissue from the subcutaneous tissue to the
             pectoralis fascia.

          -  Presence of tumour cells in lymph nodes detected using H&amp;E or immunohistochemical
             examination (if lymph node biopsy or dissection has been performed).

          -  Locally recurrent breast cancer.

          -  Previous DCIS or invasive cancer of the contralateral breast.

               -  Bilateral DCIS of the breasts

               -  Synchronous invasive carcinoma of the contralateral breast

          -  Other concurrent or previous malignancies except:

               -  Non-melanomatous skin cancer;

               -  Carcinoma in situ of the cervix or endometrium; and

               -  Invasive carcinoma of the cervix, endometrium, colon, thyroid and melanoma
                  treated at least five years prior to study admission without disease recurrence.

          -  Serious non-malignant disease that precludes definitive surgical or radiation
             treatment (e.g., scleroderma, systemic lupus erythematosus,
             cardiovascular/pulmonary/renal disease).

          -  ECOG performance status  3.

          -  Women who are pregnant or lactating.
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

        Any patient who has rejected a previous allogeneic transplant (related or unrelated)
        rejection based on chimerism data from peripheral blood specimens showing loss of donor T
        Cells.

          1. Available HLA-identical, a one-antigen mis-matched sibling donor, a phenotypically
             HLA-matched family member, a phenotypically matched unrelated donor, or a 9/10
             matched unrelated donor with a negative cross-match.

          2. Age  75 years.

          3. Patients who fail to engraft or have signs of early relapse after an autologous
             transplant may be considered for this protocol as salvage treatment if they are
             presented to the RMBMTP Clinical Care meeting and the majority of the group agrees
             that this a reasonable treatment option.

        Exclusion Criteria:

          1. Patients whose low donor chimerism is felt to be due to rapidly progressive
             hematological malignancies, unless they can be treated into a minimal disease state
             with additional treatment.

          2. Patients with active uncontrolled CNS involvement with malignancy.

          3. Fertile men or women unwilling to use contraceptive techniques during and for 12
             months following treatment.

          4. Females who are pregnant.

          5. Patients who are HIV positive

          6. Organ dysfunction felt to be due to the conditioning for the first transplant
             including the following:

               -  Left ventricle ejection fraction &lt; 35%.

               -  DLCO &lt;35% of predicted, or receiving continuous supplementary oxygen.

               -  Karnofsky score &lt;50 for patients &lt; 60 years, or &lt;70 for patients aged 60 - 69
                  years (see appendix B).

               -  Creatinine clearance &lt; 40 ml/min.

               -  Patients with these end-organ toxicities may be presented to the RMBMTP Patient
                  Care Conference. If the majority opinion is that this treatment is the safest
                  option for a patient who has rejected their first transplant, they will be
                  allowed to undergo the treatment, after informed consent has been signed.

                    -  Patients with a positive PRA or anti-donor T or B cell (+) will be
                       considered for this treatment protocol only if no other option is
                       available. They should not be eligible for another research study. The
                       transplantation group must have a majority opinion that this is the best
                       available option for the patient in question. In patients with either
                       condition, the only acceptable stem cell source will be peripheral blood.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  74 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   New patients presenting with HME will be identified through the offices and clinics of
        British Columbia Children's Hospital Orthopaedic Department.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Diagnosed with HME
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion criteria:

        Women who satisfy the following conditions are the only subjects who will be eligible for
        this study:

          -  Normal volunteers

          -  Subjects with known or suspected breast disease

          -  Subjects must have signed an approved consent form.

          -  Subjects must be  18 years old.

          -  The protocol nurse will check with the patient that there is no h/o kidney disease

          -  Normal creatinine and estimated GFR* within 30 days under the following circumstances

               -  Had abnormal creatinine in the last 60 days

               -  Are over 60 years of age

               -  Has received chemotherapy within the past 30 days

               -  Has diabetes, HIV, renal disease or hx of renal cancer

          -  * GFR will be calculated using:
             http://www.kidney.org/professionals/kdoqi/gfr_calculator.cfm

          -  Patients with an eGFR&gt;90ml/min reported within 30 days, and who have not had
             intervening chemotherapy or other treatment or condition that might deteriorate renal
             function, may receive any gadolinium agent.

        Exclusion Criteria:

          -  Children will be excluded from this study.

          -  Pregnant women and women who are breast feeding will be excluded from this study.
             (The Vanderbilt University Medical Center radiology "MRI Procedure Screening Form"
             will be used to identify and exclude subjects who are pregnant or breastfeeding. A
             urine pregnancy test/or serum beta HCG will also be performed for each pre-menopausal
             subject.)

          -  Subjects found to have any constitutionally present non-MR compatible ferromagnetic
             materials will be excluded from this study.

          -  Patients who are acutely ill who are deemed by their treating physician as not
             suitable candidates for this study

          -  Subjects for whom an MRI is technically not feasible (e.g. breast volume, obesity)

          -  Subjects who have vascular access ports or other implanted devices rated as anything
             other than "Safe" or "Conditional 6"
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients with completely resected non-small cell lung cancer of stage I, II, or IIIA
             T3N1 confirmed by histology can be included in the study

          -  Patients who had preoperative chemotherapy, those who are selected for adjuvant
             chemotherapy and those who are not candidates for adjuvant chemotherapy (because they
             have a contraindication to chemotherapy or they have a stage I cancer) are eligible
             for the study

          -  Written informed consent

          -  age &gt; 18 years

        Exclusion Criteria:

          -  Previous heparin induced thrombocytopenia

          -  Allergy to tinzaparin

          -  Allergy to sulfites

          -  Renal failure with a creatinin clearance &lt; 30 ml/min according to COCKROFT formula

          -  Prothrombin time &lt; 50%

          -  Platelet count &lt; 100 G/L

          -  Increased bleeding risk: ongoing hemorrhage, major bleeding within 10 days, previous
             intracerebral bleeding, uncontrolled hypertension (SAP &gt; 180 mmHg or DAP &gt; 120 mmHg)

          -  Indication for curative anticoagulant treatment on inclusion

          -  More than 6 weeks between surgery and inclusion

          -  Known pregnancy or no efficient contraception for women of childbearing age

          -  Breast feeding

          -  Previous malignant disease diagnosed within 5 days except in situ carcinoma of the
             uterine cervix or spinal-cellular or baso-cellular cutaneous carcinoma

          -  Inclusion in another therapeutic trial at the time of inclusion

          -  Treatment with an experimental drug within 30 days before inclusion in the study
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Age &gt; 60 years old

          -  Cytomorphologic and immunophenotypic diagnosis of ALL (all FAB groups except L3 and
             all immunophenotypes except SmIg+ B-ALL)

          -  Signed informed consent

        Exclusion Criteria:

          -  Age &lt;=  60 years old

          -  Ph+ ALL

          -  Refuse to sign informed consent
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  60 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Subject is overweight or obese (BMI &gt; 25 kg/m2)

          -  Patient with pathologically confirmed adenocarcinoma of the prostate and has elected
             to undergo radical prostatectomy

          -  Willing to delay radical prostatectomy for 5 to 8-weeks if randomized to the weight
             loss intervention group.

          -  Able to adhere to physical activity intervention (able to walk for 30 minutes without
             rest)

          -  Able to come to the VA for weight loss visits during the 5 to 8-wk study

        Exclusion Criteria:

          -  Any one of the following: Gleason grade &gt; 4+4, PSA &gt; 20.

          -  History of ever receiving androgen deprivation therapy, antiandrogen therapy, or
             finasteride

          -  Prior prostate radiotherapy (external beam or brachytherapy) or prior cryotherapy

          -  Diagnosis of diabetes mellitus and on insulin**

          -  Current use of weight loss medications or enrolled in a diet/weight loss program

          -  Current use of lycopene supplements*** Significant co-morbidities (i.e. cardiac,
             pulmonary, liver disease, ongoing alcohol/drug abuse) Cardiac pacemaker
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Functioning kidney allograft (with estimated (e) GFR by MDRD &gt;20) and be &gt;6/12
             post-transplantation

          -  Deteriorating allograft function as defined by linear regression of reciprocal
             creatinine plot. Deterioration will be defined as a negative slope over at least the
             preceding 3 months (with at least 6 creatinines included) with an adjusted r2 &gt;0.35
             and a p value of 0.05 compared to horizontal baseline. Deterioration will be
             confirmed by reduction in Cockcroft-Gault (CG) eGFR over the same period (to exclude
             increases in body mass as a cause of a negative slope on reciprocal creatinine plots)
              OR significant proteinuria as assessed by a urine protein/creatinine ratio of 50

          -  CAN, by Banff '97 criteria, and/or transplant glomerulopathy on renal allograft
             biopsy performed within 6/12 of enrolment

          -  Diffuse, linear C4d deposition on at least 25% of peritubular capillary (PTC) and/or
             glomerular EC of renal transplant biopsy when assessed by immunoperoxidase or &gt;50% of
             PTC (alone) when assessed by immunofluorescence OR PTCitis OR glomerulitis with
             combined PTC/g score of 2.

        Exclusion Criteria:

          -  Ages below 18 years of age

          -  Suspicion of pregnancy confirmed by positive HCG pregnancy test

          -  Untreated ureteric obstruction on ultrasound of allograft

          -  History of acute allograft rejection in preceding 3/12

          -  History of MI in preceding 3/12

          -  History of malignancy in previous 5 years (excluding tumours limited to skin)

          -  Symptomatic IHD

          -  Recipient of simultaneous pancreas/kidney transplant

          -  Recipient of ABO-incompatible kidney

          -  Recipient who underwent an HLA desensitisation procedure prior to transplantation

          -  Evidence, on examination of renal allograft biopsy specimen, of recurrent or de-novo
             disease (except IgA deposition in absence of mesangial proliferation)

          -  Evidence, on examination of renal allograft biopsy specimen, of CNI toxicity IF
             ACCOMPANIED by mostly supra-therapeutic CNI trough levels in the 6 month period
             preceding biopsy.

          -  Documented allergy to mouse or chimeric human/mouse proteins

          -  HepBsAg+, HepBcAb+, HCV Ab+ or HIV+.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Sri Lankan Sinhalese adults (18 years of age or older) living in the greater Houston area,
        but born in Sri Lanka. Siblings or the first cousins of the study participants living in
        Sri Lanka of same sex and of an age plus or minus 10 years.
  </textblock>
 </study_pop>
 <sampling_method>
  Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Sri Lankan Sinhalese adults (18 years of age or older) living in the greater Houston
             area but born in Sri Lanka

          2. Siblings or the first cousins of the study participants living in Sri Lanka of same
             sex and of an age plus or minus 10 years

        Exclusion Criteria:

          1. Sri Lankan Sinhalese born in the US

          2. Sri Lankan Sinhalese under 18 years of age

          3. Participation in a M. D. Anderson sponsored focus group or survey regarding health
             within the past 6 months
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients with recently diagnosed inflammatory breast cancer (IBC).
  </textblock>
 </study_pop>
 <sampling_method>
  Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Patients with new clinical diagnosis of primary inflammatory breast cancer (IBC),
             second primary IBC, or highly suspicious for IBC.

          2. Histological diagnosis of invasive breast cancer, or highly suspicious for IBC but
             pending breast cancer diagnosis.

          3. Be either newly diagnosed, or highly suspicious for IBC (Cohort I) or have paraffin
             blocks or up to 20 unstained slides of each representative block(s) from the time of
             initial diagnosis of IBC, i.e. core biopsy, punch biopsy or lymph node biopsy (Cohort
             II).

          4. Age &gt; 18 years

          5. Able to provide informed consent

        Exclusion Criteria:

        1) Have had mastectomy/axillary dissection for primary or secondary IBC without core
        biopsy performed at initial diagnosis.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Pathologically confirmed cancer

               -  Receiving chemotherapy for either adjuvant treatment or metastatic disease prior
                  to beginning a new chemotherapy regimen

        PATIENT CHARACTERISTICS:

          -  Must be able to understand English

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior enrollment in this trial

          -  No concurrent enrollment on a phase I clinical trial
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  65 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients with SCLC and gynecologic (breast or ovarian) tumors and patients with unrelated
        cancers.  Also healthy volunteers will be included as a comparison group in this study.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Males and females ages 25 -75

          2. If leukapheresis:

             Hepatitis B surface antigen negative if tested* Hepatitis C antibody negative if
             tested* HIV antibody negative if tested* VDRL negative if tested* No known IV drug
             users HgB &gt; 8.5 WBC &gt; 3,800 Platelets &gt; 120,000 INR &lt; 2 (verified only if clinically
             indicated)

          3. If large blood draw (1/2 to 1 unit) in lieu of leukapheresis:

        Hepatitis B surface antigen negative if tested* Hepatitis C antibody negative if tested*
        HIV antibody negative if tested* VDRL negative if tested* No known IV drug users HgB &gt;
        10.0 WBC &gt; 3,800 Platelets &gt; 120,000 INR &lt; 2 (verified only if clinically indicated)

        Exclusion Criteria:

        No known neurologic disease 2. No known CNS metastasis on clinical exam 3. No chemotherapy
        within 1 month 4. No NYHA class III/IV status 5. No pulmonary disease which limits daily
        activities 6. No anticoagulation therapy
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:- Age 18 to 70 years.

          -  Histologically proven non-Hodgkin's lymphoma

          -  Relapse after achieving initial remission or failure to achieve initial remission.
             Patients with residual radiographic abnormalities after primary therapy are eligible
             if abnormalities are FDG-PET positive.  Eligible patients must have 1) transformed
             lymphoma, 2) mycosis fungoides that is resistant or refractory to therapy, 3) other
             histological subtypes in patients that do not have adequate cytoreduction to salvage
             chemotherapy to reach a minimal disease state, 4) patients in 2nd or greater relapse
             or 3 or subsequent remission, or 5) other patients with non-Hodgkin's lymphoma felt
             to have less than a 20% chance of event-free survival  with autologous transplant
             after discussion with the BMT Faculty and the Principal Investigator

               -  Definition of Minimal Disease State- No individual lymph nodes greater than 2
                  cm, greater than &gt;75% reduction in a bulky mass (&gt; 10 cm) and &lt; 10% bone marrow
                  involvement with lymphoma.

          -  ECOG performance status &lt; 2

          -  Matched related or unrelated donor identified and available.  Donor must be a
             complete match or have only a single allele mismatch.

          -  Bone marrow biopsy and cytogenetic analysis within 8 weeks of registration

          -  Women of child-bearing potential and sexually active males must use an accepted and
             effective method of birth control.

          -  Patients must have a pretreatment serum bilirubin &lt; 2 x the institutional ULN, a
             serum creatinine &lt; 2 x the institutional ULN and measured or estimated creatinine
             clearance &gt; 60 cc/min by the following formula (all tests must be performed within 28
             days prior to registration):

               -  Estimated Creatinine Clearance = (140age)X WT(kg) X 0.85 if female 72X serum
                  creatinine(mg/dl).

          -  Patients must have an EKG within 42 days prior to registration that shows no
             significant abnormalities that are suggestive of active cardiac disease.

          -  Patients must have an echocardiogram or MUGA scan within 42 days of registration. If
             the ejection fraction is &lt; 40%, the patient will not be eligible. If the ejection
             fraction is 40-50%, patients must have an exercise echocardiogram or dobutamine-echo
             with a normal response to exercise.

          -  Patients must have a corrected diffusion capacity &gt; 50% prior to the autologous
             transplant and &gt; 40% prior to the allogeneic transplant.

          -  Patients with known allergy to etoposide or a history of Grade 3 hemorrhagic cystitis
             with cyclophosphamide are not eligible.

          -  Patients must be informed of the investigational nature of this study and must sign
             and give written informed consent in accordance with institutional and federal
             guidelines.

        Exclusion Criteria:- Pregnant or breast-feeding women are ineligible due to the known
        birth defects association with the treatments used in this study.

          -  Patients known to be human immunodeficiency virus (HIV)-positive are ineligible
             because the concern for opportunistic infection and hematologic reserve are
             considered to be significantly greater in this population. The antibody test for HIV
             must be performed within 42 days of registration.

          -  No chemotherapy other than corticosteroids should be administered within 2 weeks of
             the initiation of protocol therapy.

          -  No prior malignancy is allowed except adequately treated basal cell or squamous cell
             skin cancer, in situ cervical cancer or other cancer for which the patients has been
             disease-free for five years.

          -  Patients with active infection requiring oral or intravenous antibiotics are
             excluded.

          -  No prior autologous or allogeneic hematopoietic cell transplantation.

          -  No prior radioimmunotherapy

          -  Patient with recurrent/refractory diffuse large B cell lymphoma.

        Donor Selection/Evaluation:

          -  Related or unrelated HLA identical donors who are in good health and have no
             contra-indication to donation.

          -  No contra-indication for the donor to collection by apheresis of mononuclear cells
             mobilized by G-CSF at a dose of 16 g/kg of body weight.

          -  Virology testing including CMV, HIV, EBV, HTLV, RPR, Hepatitis A, B and C will be
             performed within 30 days of donation.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Histologically* or radiologically confirmed primary adenocarcinoma of the colon or
             rectum

               -  Advanced and/or metastatic disease NOTE: *Liver metastases should not be
                  biopsied

          -  Must have potentially resectable liver metastases present, as defined by any of the
             following:

               -  Metachronous metastases AND complete resection of the primary tumor without
                  gross or microscopic evidence of residual disease (R0)

               -  Synchronous metastases AND R0 resection of the primary tumor &gt; 1 month before
                  study entry

               -  Synchronous metastases with sufficient evidence (e.g., by CT scan or diagnostic
                  laparoscopy) that both the primary tumor and the liver metastases can be
                  completely resected during the same procedure and resection of primary tumor can
                  be delayed for 3-4 months

               -  Suboptimally resectable disease (i.e., potentially resectable disease with
                  compromise of the resection margins)

          -  No detectable extrahepatic tumor that cannot be completely resected

          -  Unidimensionally measurable disease

          -  No brain metastases

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-2

          -  WBC  4,000/mm

          -  ANC  1,500/mm

          -  Platelet count &gt; 150,000/mm

          -  Bilirubin  1.25 times upper limit of normal (ULN)

          -  Alkaline phosphatase  5 times ULN

          -  AST or ALT  3 times ULN

          -  Creatinine clearance &gt; 50 mL/min OR glomerular filtration rate &gt; 50 mL/min

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for  3 months after
             completion of study treatment

          -  No psychiatric or neurological condition that would preclude study compliance

          -  No partial or complete bowel obstruction

          -  No preexisting neuropathy &gt; grade 1

          -  No other prior or concurrent malignant disease that, in the opinion of the
             investigator, would preclude study treatment

          -  No concurrent severe uncontrolled medical illness (including poorly-controlled angina
             or myocardial infarction within the past 3 months) that would preclude study
             treatment

          -  No known hypersensitivity reaction to any of the components of the study drugs

        PRIOR CONCURRENT THERAPY:

          -  No prior systemic chemotherapy for metastatic disease

          -  More than 6 months since prior adjuvant chemotherapy comprising fluorouracil,
             leucovorin calcium, capecitabine, or irinotecan hydrochloride

          -  More than 1 month since prior rectal chemoradiotherapy comprising fluorouracil and
             leucovorin calcium

          -  No concurrent contraindicated medication
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients with hepatic neoplasms who undergo Image-guided Therapy
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Undergoing concurrent image-guided therapy for hepatic malignancies using any of the
             following imaging techniques:

               -  X-ray

               -  Ultrasound

               -  MRI

               -  CT scan

               -  Nuclear medicine imaging

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients  18 years

          -  Histologically-proven, locally advanced, or metastatic STS (excluding extraosseus
             Ewing sarcoma)

          -  Patients not amenable to surgery, radiotherapy, or combined-modality therapy with
             curative intent

          -  Patients untreated or previously treated with one or more systemic regimen

          -  ECOG Performance status 0-2 (Appendix A)

          -  At least one untreated (not previously irradiated) target lesion that could be
             measured in one dimension, according to RECIST criteria

          -  A life expectancy of 12 weeks or more

          -  Adequate baseline bone marrow, hepatic and renal function, defined as follows:

               -  Neutrophils &gt; 1.5 x 109/L and platelets &gt; 100 x 109/L

               -  Bilirubin &lt; 1.5 x ULN

               -  AST and/or ALT &lt; 2.5 x ULN in absence of liver metastasis or &lt; 5 x ULN in
                  presence of liver metastasis

               -  Serum creatinine &lt; 1.5 x ULN

               -  Creatinine clearance (estimated according to Cockcroft-Gault formula)  50
                  ml/min

          -  Patients may have had prior treatment providing the following conditions are met
             before treatment start:

               -  Surgery and radiation therapy: wash-out period of 14 days

               -  Systemic therapy: wash-out period of 21 days

               -  Patients must give written informed consent

        Exclusion Criteria:

          -  Patients may not receive any other investigational agents while on study

          -  Patients with myocardial infarction within the last six (6) months, unstable angina,
             New York Heart Association (NYHA) grade II or greater congestive heart failure, or
             serious cardiac arrhythmia requiring medication

          -  LVEF &lt; 55% (only for patients candidate for doxorubicin treatment)

          -  Uncontrolled hypertension

          -  Prolonged QTc interval (congenital or acquired) &gt; 450 ms

          -  History or evidence upon physical examination of CNS disease unless adequately
             treated (e.g., primary brain tumor, any brain metastasis, seizure not controlled with
             standard medical therapy) or history of stroke

          -  Patients with active or uncontrolled systemic disease/infections or with serious
             illness or medical conditions, which is incompatible with the protocol

          -  Known hypersensitivity/allergic reaction or contraindications to human albumin
             preparations or to any of the excipients

          -  Any psychological, familial, sociological or geographical condition potentially
             hampering compliance with the study protocol

          -  Pregnancy or lactation. Patients - both males and females - with reproductive
             potential (i.e. menopausal for less than 1-year and not surgically sterilized) must
             practice effective contraceptive measures throughout the study. Women of
             child-bearing potential must provide a negative pregnancy test (serum or urine)
             within 14 days prior to registration
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Diagnosis of cancer

          -  Must be receiving single-agent capecitabine either in the adjuvant/neoadjuvant or
             palliative setting at a dose of  1000 mg/m twice daily on days 1-14 (given in
             3-week courses)

        PATIENT CHARACTERISTICS:

          -  Life expectancy &gt; 12 weeks

          -  No preexisting neuropathy

          -  No known allergy to pyridoxine hydrochloride and its incipients

          -  No other dermatologic condition that, in the opinion of the physician, may affect the
             hands or feet or may complicate evaluation during study treatment

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior capecitabine

          -  Concurrent radiotherapy, steroids, and/or biological therapy (e.g., trastuzumab
             [Herceptin] or bevacizumab) allowed provided they do not cause hand-foot syndrome
             (HFS)

          -  No other concurrent drugs (e.g., docetaxel or doxorubicin hydrochloride liposome)
             that can cause HFS

          -  No concurrent drugs (e.g., oxaliplatin or taxanes) that can cause neuropathy

          -  No concurrent pyridoxine hydrochloride-containing preparations (e.g., multivitamins
             or vitamin B complex)

          -  No concurrent over-the-counter products that contain urea or lactic acid

          -  No concurrent drugs reported to have drug interactions with pyridoxine hydrochloride
             (e.g., cycloserine; hydralazine; immunosuppressants; isoniazid; levodopa; estrogen or
             estrogen-containing contraceptives; penicillamine; phenobarbitone; phenytoin; or
             pyrazinamide)
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Histologically confirmed follicular lymphoma

          -  Patients with relapsed follicular lymphoma achieving at least a PR following their
             most recent systemic chemotherapy and/or immunotherapy regimen.

          -  Lymphoma accessible for sampling or existing cryopreserved lymphoma tumor judged
             suitable for vaccine preparation.

          -  4 weeks must have elapsed between the completion of the the last chemotherapy,
             immunotherapy, glucocorticoid therapy, radiotherapy, or experimental therapy.

          -  ECOG Performance Status 0 or 1

          -  Estimated life expectancy of &gt; 6 months

          -  35 years of age or older

          -  Adequate recovery of drug related toxicities, surgery or radiation therapy

          -  Greater than 6 months since autologous stem cell transplantation

          -  Laboratory parameters as outlined in the protocol

        Exclusion Criteria:

          -  Uncontrolled active infection or illness

          -  Psychiatric illness/social situation that would limit study compliance

          -  Pregnancy or nursing mothers

          -  Evidence of infection with HIV or viral hepatitis

          -  Other invasive malignancy

          -  Existing autoimmune cytopenia

          -  Previous allogeneic stem cell transplant

          -  Pre-existing autoimmune disease requiring anti-inflammatory therapy

          -  Participation in previous vaccine trial

          -  Any component of grade 3 follicular lymphoma or transformed follicular lymphoma
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  35 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Department of Gynecologic Oncology or the Department of Gynecologic Medical Oncology at UT
        MD Anderson Cancer Center in Houston, Texas
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

        1) All patients seen at M.D. Anderson Cancer Center with the following tumor types or
        diagnosis are eligible for inclusion in this database. This includes patients whose
        disease progressed to a higher-grade carcinoma since the time of original diagnosis:
        Ovarian tumor of low malignant potential, Low-grade serous carcinoma of the ovary, Primary
        peritoneal tumor of low malignant potential, Low-grade serous carcinoma of the peritoneum,
        Psammocarcinoma

        Exclusion Criteria:

        1) None
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Any woman treated in the Breast Clinic of WFUBMC with a diagnosis of stage 0-IV breast
        cancer and identified as a candidate by their surgeon.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Diagnosis of breast cancer

               -  Stage I-IV disease

          -  Planning to undergo surgery at the Comprehensive Cancer Center Breast Clinic at Wake
             Forest University Baptist Medical Center
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Diagnosis of 1 of the following sickle cell anemias (Hb SS):

               -  Hb S/ thalassemia

               -  Hb S/+ thalassemia

               -  Hb SC disease

               -  Hb SE disease

               -  Hb SD disease

               -  Hemoglobin SO-Arab disease

               -  Hb S/hereditary persistence of fetal hemoglobin

          -  Meets 1 of the following criteria:

               -  History of invasive pneumococcal disease

               -  Stroke or CNS event lasting &gt; 24 hours

               -  MRI changes indicative of brain parenchymal damage

               -  Evidence of cerebrovascular disease by magnetic resonance angiography

               -  Acute chest syndrome requiring exchange transfusion or hospitalization

               -  Recurrent vaso-occlusive pain crisis (&gt; 2 per year for the last 2 years)

               -  Stage I or II sickle lung disease

               -  Sickle retinopathy

               -  Osteonecrosis

               -  Red cell alloimmunization (&gt; 2 antibodies) during long-term transfusion

               -  Constellation of dactylitis in the first year of life AND a baseline hemoglobin
                  &lt; 7 g/dL and leukocytosis (WBC &gt; 13.4/mm^3) in the absence of infection during
                  the second year of life

               -  Pitted RBC count &gt; 3.5% during the first year of life

          -  Ineligible for or refused bone marrow transplantation from an HLA-matched sibling
             donor

          -  Partially mismatched (at least haploidentical) first-degree relative donor available

               -  No minor (donor anti-recipient) ABO incompatibility if an ABO compatible donor
                  is available

        PATIENT CHARACTERISTICS:

          -  ECOG performance status (PS) 0-1 OR Karnofsky or Lansky PS 70-100%

          -  LVEF  35%

          -  FEV_1 and forced vital capacity  40% predicted

          -  Direct bilirubin &lt; 3.1 mg/dL

          -  No moderate to severe pulmonary hypertension by ECHO

          -  No debilitating medical or psychiatric illness that would preclude study
             participation

          -  No HIV positivity

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

          -  No prior transfusions from donor

          -  No immunosuppressive agents, including steroids as antiemetics, within 24 hours after
             the last dose of post-transplantation cyclophosphamide
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  2 Years
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   All patients who had or will have laparoscopic surgery in the Department of Gynecologic
        Oncology (Gynecologic Oncology and General Gynecology) since January 1, 1990 forward.
  </textblock>
 </study_pop>
 <sampling_method>
  Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

        1. All patients who had or will have laparoscopic surgery in the Department of Gynecologic
        Oncology (Gynecologic Oncology and General Gynecology) since January 1, 1990 forward.

        Exclusion Criteria: None
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  5 children with any type of cancer in the initial stages of chemotherapy and/or
             cranial radiation.

          -  10 children with any type of cancer who have completed chemotherapy and cranial
             radiation.

        Exclusion Criteria:

          -  Children with pre-cancer/pre-chemotherapy history of brain injury, neurological,
             psychiatric, neurodevelopmental and/or learning disorders including attention deficit
             hyperactivity disorder will be excluded.

          -  Participants will be excluded for MRI contraindications such as orthodontia and
             biomedical implants.

          -  Non-English speaking participants will be excluded due to the unavailability at this
             time of translated cognitive testing and MRI assessments.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  9 Years
 </minimum_age>
 <maximum_age>
  16 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients must be newly diagnosed with MCL, have an accessible disease site for
             excisional biopsy or sufficient peripheral blood tumor burden to safely leukapherese.

          -  By standard clinical criteria be medically appropriate to receive induction
             chemotherapy and high-dose chemotherapy with AHCT.

          -  Must be between 18 to 70 years of age.

          -  Serum creatinine &lt;2.0 or 24-hour creatinine clearance &gt;60 ml/min.

          -  Patients must be HIV negative.

          -  ECOG performance status 0, 1, or 2.

          -  Patients must be capable of signing an informed consent.

        Exclusion Criteria:

          -  Patients who are currently taking immunosuppressive medications.

          -  Severe psychological or medical illness.

          -  Patients may not be receiving any other investigational agents.

          -  Pregnant or lactating women.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Study participants with low-risk prostate cancer who choose to undergo active
        surveillance.
  </textblock>
 </study_pop>
 <sampling_method>
  Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Patients will have histologic proof of adenocarcinoma of the prostate within six
             months of study entry.

          2. Patients must agree to have repeat extended 11-core multisite biopsy (sextant
             locations, midline, and 2 cores each from the left and right anterior horn) of the
             prostate at study entry. A baseline prostate biopsy is not indicated if a repeat
             biopsy following the extended biopsy scheme (at least 10 biopsy cores) was performed
             at The University of Texas M. D. Anderson Cancer Center (MDACC) within 6 months of
             study entry.

          3. Patients who have clinically localized cancer defined by pathologic and PSA criteria
             to be very low-risk/low-risk, patients with clinically localized cancer [not
             low-risk] who have refused early intervention or chosen active surveillance as a
             management option, and patients with clinically localized cancer who are precluded
             from local therapy because of comorbidities.

          4. Patients must agree to comply with the surveillance schedule.

          5. Non-English speaking patients may participate in the study, but they will not be
             required to complete the surveys.

          6. Patients must sign an informed consent indicating that they are aware of the
             investigational nature of this study.

        Exclusion Criteria:

          1. Active noncutaneous malignancy at any site.

          2. Prior radiation therapy for treatment of the primary tumor.

          3. Planned concomitant immunotherapy, hormonal therapy, chemotherapy, or radiation
             therapy while on protocol.
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Patients with CD20 positive diffuse large B-cell lymphoma as confirmed by a
             pathological biopsy report.

          2. Patients who are candidates for autologous stem-cell transplantation due to primary
             refractory or first relapse of disease.

          3. Patients must have chemo-sensitive disease achieving at least partial response
             (Cheson 2007 criteria) to last chemotherapy.

          4. Age  18 years and age  70

          5. Patients with adequate autologous stem cell collection for transplantation (target 
             2.5 x 106 CD34+ cells/kg).

          6. Patients must sign written informed consent.

          7. Adequate birth control in fertile patients.

          8. All prior chemotherapy completed at least three weeks before study treatment.

          9. Marrow involvement less than 25% at transplantation, no limitation on blood counts
             (low platelet count allowed).

         10. Negative HIV antibody.

        Exclusion Criteria:

          1. 1. Chemo-refractory disease as determined by less than partial response (Cheson 2007
             Criteria) to last chemotherapy.

          2. Two or more relapses after initial response to induction chemotherapy.

          3. High-grade transformation from earlier diagnosis of low-grade lymphoma. Patients with
             "De Novo" Transformed DLBCL, defined as DLBCL only on lymph node biopsy and a
             discordant marrow with para-trabecular small cells at first diagnosis of lymphoma,
             are eligible if adherent all other selection criteria.

          4. Bilirubin   &gt; 3.0 mg/dl, transaminases &gt; 3 times upper normal limit.

          5. Creatinine &gt; 2.0 mg/dl.

          6. ECOG Performance status &gt; 2.

          7. Uncontrolled infection.

          8. Pregnancy or lactation.

          9. Abnormal lung diffusion capacity (DLCO &lt; 40% predicted).

         10. Severe cardiovascular disease; New York Heart Association (NYHA) Functional
             Classification 2.

         11. Active CNS disease involvement.

         12. Presence of any other malignancy or history of prior malignancy within 5 years of
             study entry. Within 5 years, patients treated for Stage I or II cancers are eligible
             provided they have a life expectancy  &gt; 5 years in relation to this prior malignance.
             The 5-year exclusion rule does not apply to-non melanoma skin tumors and in situ
             cervical cancer.

         13. Pleural effusion or ascites &gt; 1 liter.

         14. Known hypersensitivity to rituximab.

         15. Psychiatric conditions/disease that impair the ability to give informed consent or to
             adequately co-operate.

         16. Prior radioimmunotherapy.

         17. Prior autologous or allogeneic HSCT.

         18. Active evidence of Hepatitis B or C infection; Hepatitis B surface antigen positive.

         19. Patients who have had prior radiation to the lung will be excluded from the study,
             although mediastinal irradiation will be permitted if minimal lung is in the
             treatment volume.

         20. Patients who have received &gt;500cGy radiation to the kidneys will be excluded from the
             study.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Histologically confirmed diagnosis of endometrial cancer, including the following
             histological subtypes:

               -  Adenocarcinoma

               -  Adenocarcinoma with squamous differentiation

               -  Mucinous adenocarcinoma

               -  Squamous cell carcinoma

               -  Mixed carcinoma

               -  Undifferentiated carcinoma

               -  Clear cell adenocarcinoma

               -  Serous adenocarcinoma

          -  Must have undergone prior complete hysterectomy and bilateral salpingo-oophorectomy
             at the time of original therapy

          -  Recurrent disease confined to the pelvis and/or vagina

               -  No evidence of extrapelvic disease, including positive periaortic or
                  inguino-femoral nodes by chest x-ray or CT scan

          -  Primary surgical debulking before protocol therapy is permissible; this would include
             removal of gross symptomatic disease in the pelvis and/or vagina; exenterative
             surgery is not permissible; patients enrolled subsequent to revision 11 with complete
             resection of gross recurrent disease are eligible (05/14/2012)

               -  Patients enrolled prior to revision 11 who have undergone complete surgical
                  resection of the recurrent tumor and have no evidence of residual disease
                  evaluable clinically and by CT or MRI imaging, following resection are not
                  eligible

          -  Patients with ureteral obstruction must undergo stent or nephrostomy tube placement
             prior to study entry

          -  GOG performance status 0-2

          -  Life expectancy  3 months

          -  Absolute neutrophil count  1,500/mm

          -  Platelet count  100,000/mm

          -  Creatinine normal OR creatinine clearance &gt; 50 mL/min

          -  Bilirubin  1.5 times upper limit of normal (ULN)

          -  SGOT  2.5 times ULN

          -  Alkaline phosphatase  2.5 times ULN

          -  No sensory or motor neuropathy &gt; grade 1

          -  No septicemia or severe infection

          -  No circumstances that would preclude study participation

          -  No renal abnormalities (i.e., pelvic kidney, horseshoe kidney, or prior renal
             transplantation) that would require modification of radiation fields

          -  No other invasive malignancies within the past 5 years except nonmelanoma skin cancer

          -  No significant history of cardiac disease, including uncontrolled hypertension,
             unstable angina, congestive heart failure, or uncontrolled arrhythmias within the
             past 6 months

          -  No history of active collagen vascular disease

          -  At least 6 months since prior hormone therapy and/or systemic chemotherapy

          -  No prior neoadjuvant chemotherapy for recurrent disease

          -  No prior exenterative surgery

          -  No prior vaginal, pelvic, or abdominal irradiation

          -  No prior chemotherapy directed at the present recurrent disease

          -  No prior cancer treatment that would preclude study treatment
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Female patient diagnosed with stage I-III breast cancer (AJCC 6), undergoing breast
             irradiation as part of her adjuvant therapy.

          2. The patient must be a carrier of a deleterious mutation in BRCA 1/2.

          3. Age above 30 years.

          4. The patient may receive any regimen of adjuvant chemotherapy, according to the
             treating physician. All cycles of chemotherapy must be completed at least 3 weeks
             prior to the start of radiation therapy.

          5. The patient may be treated with hormonal therapy before, during or after study entry,
             according to the guidelines of her treating center.

          6. The patient must have negative gadolinium based MRI of the contralateral breast, no
             more than 6 months prior to study entry.

          7. The patient refused prophylactic contralateral mastectomy.

          8. The patient is aware that subsequent breast cancer in the irradiated breast will
             probably mandate mastectomy.

          9. The patient consent for contralateral prophylactic irradiation. -

        Exclusion Criteria:

          1. Metastatic breast cancer.

          2. Previous irradiation of the breast or chest wall.

          3. Pregnancy.

          4. No concurrent chemotherapy is allowed

          5. Patients with active connective tissue diseases are excluded due to the potential
             risk of significant radiotherapy toxicity.

          6. Patients who are unable to lie on their back and raise their arms above their heads
             in the treatment planning position for radiotherapy are excluded -
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  30 Years
 </minimum_age>
 <maximum_age>
  90 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Primary breast cancer &gt;4cm in diameter and / or lymph node status N2-3.

          -  Age 65 years or younger

          -  "Limited" distant metastases allowed, but patients with massive distant metastases
             should be excluded

          -  Willing to participate in the study

        Exclusion Criteria:

          -  Known allergy toward any of the cytotoxic compounds to be administered (epirubicin
             and doxorubicin)

          -  Liver enzymes &gt; 2 times upper normal limit or bilirubin &gt; 3 times upper normal limit

          -  Other medical conditions making them unfit for dose-dense therapy

          -  Cardiac insufficiency; for patients not to receive trastuzumab, decision whether to
             exclude such patients will be at the physicians discretion. Considering patients with
             HER-2 positive tumors who should have trastuzumab, exclusion criteria will be
             according to the NBCG (Norwegian Breast Cancer Group) general guidelines
             (www.NBCG.net).
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  65 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Early laryngeal cancer

        Exclusion Criteria:

          -  No history of radiotherapy and collagen vascular disease
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Patients must have one of the following hematologic malignancies: Acute Myelogenous
             Leukemia (AML), induction failure, high-risk for relapse first remission (with
             intermediate-risk or high-risk cytogenetics, flt3 mutation positive and/or evidence
             of minimal residual disease by flow cytometry), secondary leukemia from prior
             chemotherapy and/or arising from MDS, Langerhan's cell histiocytosis, any disease
             beyond first remission; or,

          2. Myelodysplastic Syndrome (MDS): Primary or therapy related; or,

          3. Acute Lymphoblastic Leukemia (ALL): induction failure, primary refractory to
             treatment (do not achieve complete remission after first course of therapy) or are
             beyond first remission including second or greater remission or active disease.

          4. #3, continued: Patients in first remission are eligible if they are considered high
             risk, defined as any of the following detected at any time: with translocations 9;22
             or 4;11, hypodiploidy, complex karyotype, secondary leukemia developing after
             cytotoxic drug exposure, and/or evidence of minimal residual disease, or acute
             biphenotypic leukemia, or double hit non-Hodgkin's lymphoma; or,

          5. Non-Hodgkin's Lymphoma (NHL) in second or third complete remission, or relapse
             (including relapse post autologous hematopoietic stem cell transplant). Double hit
             lymphomas in first remission or more advanced disease; or,

          6. Small Lymphocytic Lymphoma (SLL), or Chronic Lymphocytic Leukemia (CLL) with
             progressive disease following standard therapy; or,

          7. CML second chronic phase or accelerated phase; or,

          8. Hodgkin's Disease (HD): Induction failures, second or third complete remission, or
             relapse (including relapse post autologous hematopoietic stem cell transplant); or,

          9. Multiple Myeloma: stage II or III, symptomatic, secretory Multiple Myeloma requiring
             treatment.

         10. Age greater than or equal to 1 year but less than or equal to 55 years (Myeloablative
             Regimen 4). Eligibility for pediatric patients will be determined in conjunction with
             an MDACC pediatrician. Patients &gt;55 but &lt; 65 years who have a Performance Status of 0
             or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion
             of the investigator(s).

         11. Age greater than 55 years and less than or equal to 80 years (Nonmyeloablative
             Regimen 2)

         12. Age greater than or equal to 1 but less than or equal to 80 years old that in the
             opinion of the investigator(s) would preclude myeloablative therapy and who cannot
             receive Total Body Irradiation (TBI) may receive reduced intensity regimen 3.

         13. Performance score of at least 60% by Karnofsky or PS less than 3 (ECOG) (age greater
             than or equal to 12 years), or Lansky Play-Performance Scale of at least 60% or
             greater (age &lt;12 years)

         14. Left ventricular ejection fraction of at least 40% (Myeloablative Regimen 4, Reduced
             Intensity Regimen 3) or 30% (Nonmyeloablative Regimen 2)

         15. Pulmonary function test demonstrating a diffusion capacity of least 50% predicted
             (Myeloablative Regimen 4, Reduced Intensity Regimen 3) or at least 40% predicted
             (Nonmyeloablative Regimen 2). For children &lt; 7 years of age who are unable to perform
             PFT, oxygen saturation &gt; 92% on room air by pulse oximetry.

         16. Creatinine &lt; 1.6 mg/dL (Myeloablative Regimen 4, Reduced Intensity Regimen 3) or &lt;
             3.0 mg/dL (Nonmyeloablative Regimen 2).

         17. SGPT/bilirubin &lt; / = to 2.0 x normal (Myeloablative Regimen 4, Reduced Intensity
             Regimen 3) or &lt; / = 4.0 x normal (Nonmyeloablative Regimen 2)

         18. Negative Beta HCG test in a woman with child bearing potential defined as not
             post-menopausal for 12 months or no previous surgical sterilization and willing to
             use an effective contraceptive measure while on study.

         19. Unrelated Cord Blood will be used as a source of hematopoietic support if a 5 or 6/6
             related or 6/6 unrelated bone marrow donor is not available, or if the tempo of a
             patient's disease dictates it is not in the patient's best interest to wait for an
             unrelated marrow donor to be procured.

         20. Patients must have two Cord Blood units available which are matched with the patient
             at 4, 5, or 6/6 HLA class I (serological) and II (molecular) antigens. Each cord must
             contain at least 10 million total nucleated cells/Kg recipient body weight (pre-thaw)

         21. Patients must have a family member who is matched at 2, 3, or 4 HLA antigens typed as
             described above and willing to donate 80-100 ml or bone marrow for MSC generation or
             the Angioblast Mesenchymal Precursor Cells will be used for the cord blood
             co-cultures. Patients that are high risk for relapse are eligible to use the
             Angioblast "off-the-shelf" Mesenchymal Precursor Cells.

         22. Have identified a back-up cell source in case of engraftment failure. The source can
             be autologous, related, or unrelated.

        Exclusion Criteria:

          1. HIV positive

          2. Positive beta HCG in female of child-bearing potential defined as not post-menopausal
             for 12 months or no previous surgical sterilization or breast-feeding.

          3. Uncontrolled serious medical condition such as persistent septicemia despite adequate
             antibiotic therapy, decompensated congestive heart failure despite cardiac
             medications or pulmonary insufficiency requiring intubation. (excluding primary
             disease for which CB transplantation is proposed), or psychiatric condition that
             would limit informed consent.

          4. Active CNS disease in patient with history of CNS malignancy.

          5. Availability of appropriate, willing, HLA-matched related marrow donor.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  1 Year
 </minimum_age>
 <maximum_age>
  80 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Suspected or proven non-small cell lung cancer (NSCLC), meeting both preoperative and
             intraoperative criteria:

               -  Preoperative criteria

                    -  Peripheral lung nodule  2 cm by CT scan

                         -  Center of the tumor must be located in the outer third of the lung in
                            either the transverse, coronal, or sagittal plan

                         -  Tumor location must be suitable for either lobar or sublobar resection
                            (wedge resection or segmentectomy)

                    -  No pure ground opacities or pathologically confirmed N1 or N2 disease

               -  Intraoperative criteria

                    -  Histologically confirmed NSCLC

                    -  Confirmation of N0 status by frozen section examination of nodal levels 4,
                       7, and 10 on the right side and 5, 6, 7, and 10 on the left side*

                         -  Levels 4 and 7 nodes may be sampled by mediastinoscopy, endobronchial
                            ultrasound (EBUS), and/or endoscopic ultrasound (EUS), or at the time
                            of thoracotomy or video-assisted thoracoscopic surgery (VATS)
                            exploration* NOTE: *Nodes previously sampled by mediastinoscopy (or
                            EBUS and/or EUS) either immediately before or within 6 weeks of the
                            definitive surgical procedure (thoracotomy or VATS) do not need to be
                            resampled

          -  No evidence of locally advanced or metastatic disease

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  No other malignancy within the past 3 years except for nonmelanoma skin cancer,
             superficial bladder cancer, or carcinoma in situ of the cervix

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy or radiotherapy for this malignancy
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients diagnosed with heart disease and that may be at a high risk for the development
        of heart failure.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients who are at high risk for developing Cardiomyopathy or Congestive Heart
             Failure.

          -  Patients two months of age and older.

        Exclusion Criteria:

          -  Those that are not willing to sign an informed consent.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  2 Months
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  The primary inclusion criteria are all patients with operable Periampullary cancer
             and jaundice who have not previously undergone bile flow drainage.

        Exclusion Criteria:

          -  Define as failed ERCP, patients who have previously undergone bile flow drainage or
             radical surgery is not possible.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  20 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Previously untreated T cell ALL including T cell lymphoblastic lymphoma. Failure to
             one induction course of chemotherapy are eligible. Patients in CR after &lt;/= 2 courses
             are also eligible.

          2. ECOG performance status less than or equal to 3.

          3. Serum bilirubin less than or equal to 2.0 mg/dL unless considered due to involvement
             by tumor when an upper limit of 5.0 mg/dL is acceptable. SGOT or SGPT less than or
             equal to 4 x ULN.

          4. Serum creatinine less than or equal to 2.0 mg/dL unless considered due to involvement
             by tumor when an upper limit of 2.5 mg/dL is acceptable.

        Exclusion Criteria:

        1) Pregnant or nursing women.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Polycystic ovary syndrome (using  NIH criteria)

          -  Anovulatory infertility (using WHO criteria)

          -  Ovulatory cycles under metformin (three cycles)

        Exclusion Criteria:

          -  Age &lt;18 or &gt;35 years

          -  Severe obesity (BMI &gt;35)

          -  Neoplastic, metabolic, hepatic, and cardiovascular disorders or other concurrent
             medical illnesses

          -  Hypothyroidism, hyperprolactinemia, Cushing's syndrome, and non-classical congenital
             adrenal hyperplasia

          -  Current or previous (within the last six months) use of oral contraceptives,
             glucocorticoids, antiandrogens, antidiabetic and anti-obesity drugs or other hormonal
             drugsPrevious use of ovulation induction agents

          -  Intention to start a diet or a specific program of physical activity

          -  Organic pelvic diseases

          -  Previous pelvic surgery

          -  Suspected peritoneal factor infertility

          -  Tubal or male factor infertility or sub-fertility
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  35 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients undergoing continuous hyperthermic peritoneal perfusion with cisplatin and their
        parents/caregivers.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. All participants must be English or Spanish speaking.

          2. A patient enrolled on Protocol 2009-0528, and/or one parent or adult non-parent
             primary caretaker of the child enrolled on Protocol 2009-0528.

          3. Patients greater than or equal to 1 year.

        Exclusion Criteria:

          1. Patients not enrolled on Protocol 2009-0528 will be excluded from this study.

          2. Patients less than 1 year.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  1 Year
 </minimum_age>
 <maximum_age>
  18 Years
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Women that are scheduled to undergo surgery of a single, stage I-III, invasive ductal
             or lobular carcinoma tumor with curative intent

          -  No evidence of metastatic disease prior to surgery. Minimal workup would include
             chest XR, abdominal ultrasound and bone scan.

          -  Age between 20 and 70 year old.

          -  ASA score of 1-2

          -  The patient is able to understand the study objectives and procedures, able to comply
             with the protocol, and is capable to sign an informed consent.

        Exclusion Criteria:

          -  Patients with metastatic disease, known prior to surgery.

          -  Patients in whom surgical resection is planned without curative intent.

          -  Patients who have undergone neoadjuvant treatment.

          -  Patients with renal failure, measured by creatinine level &gt;1.5

          -  Patients with significant heart failure (NYHA functional class 3 or higher)

          -  Patients with significant liver failure (known cirrhosis, Bilirubin level&gt;2)

          -  Patients suffering from asthma

          -  Patients with known allergy to one or more of the study medications

          -  Patients with known allergy to any medication from the non-steroidal
             anti-inflammatory drug group.

          -  Patients with diabetes mellitus (type 1 or 2).

          -  Patients treated chronically with one or more of the study medications

          -  Patients treated chronically with any type of Beta adrenergic blocker.

          -  Patients treated chronically with any type of COX inhibitor.

          -  Patients with second or third degree AV block.

          -  Patients with sinus bradycardia (patients with heart rate of less than 50).

          -  Patients with sick sinus syndrome.

          -  Patients with current atrial fibrillation/flutter.

          -  Patients with Printzmetal's angina

          -  Patients with hypertension

          -  Patients with right sided heart failure owing to pulmonary hypertension.

          -  Patients with significant cardiomegaly

          -  Patients with (current) pheochromocytoma

          -  Patients with chronic Digoxin treatment

          -  Patients with active peptic disease

          -  Patients with peripheral vascular disease

          -  Patients with history or concomitant malignant disease of any type other than breast
             cancer.

          -  Patients who were treated with chemotherapy in the last 10 years for any reason
             besides neo-adjuvant therapy for breast cancer within the last six months.

          -  Pregnant woman.

          -  Patients currently participating in any other clinical trial
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  20 Years
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Painful bone metastasis of solid tumors

          -  A maximum number of bone metastases less or equal to 3

          -  Life expectancy &gt; 6 months

          -  Minimum age 21 years

          -  Signed informed consent

        Exclusion Criteria:

          -  Previous radiotherapy to the painful site

          -  Bone metastasis from malignant melanoma or renal cell carcinoma

          -  Associated fracture or extra-osseous component
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  21 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients with familial and sporadic Wilm's tumor, genitourinary anomalies,
        Beckwith-Wiedemann hemihypertrophy and/or aniridia, and family members of patients.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

        1. Patients with familial and sporadic Wilm's tumor, genitourinary anomalies,
        Beckwith-Wiedemann hemihypertrophy and/or aniridia, and family members of patients.

        Exclusion Criteria:

        1. Patients who do not meet inclusion eligibility criteria are excluded.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

          -  Age greater than or equal to 2 years.

          -  History of diagnosis of childhood malignancy or HSCT and completion of therapy prior
             to entering the study. In order to be eligible for the study, patients must have been
             diagnosed with cancer prior to the age of 18.  Eligible patients must be free of
             their underlying malignancy for at least one year prior to entering the study, as
             confirmed by records from the referring oncologist.

          -  We will request permission to administer the Child Health Questionnaires (PF 50 and
             CF87) to all patients who are enrolled in this protocol. Patients who do not speak
             and read English will be excluded from the questionnaire. This instrument has been
             validated for use in children ages five and older. Children 10 years and older will
             complete the child version. The Child Health Questionnaire (CHQ) has been normed in a
             representative sample in the US, and is being used in large population studies in
             Australia, Ireland, and the UK. Additionally, it has been rigorously translated into
             a number of languages using international guidelines including American-Spanish,
             Canadian French, Dutch, Finnish, French, German, Italian, Greek, Honduran- Spanish,
             Mexican-Spanish, Norwegian, Portuguese, and Swedish. For this study will purchase the
             CHQ in American- Spanish in order to include Spanish-speaking subjects in this part
             of the study. The costs to purchase the CHQ in numerous languages would be
             prohibitive for this pilot study. However, if a significant number of subjects in a
             specific language are recruited, we will consider the purchase of the CHQ for that
             group of subjects.

        EXCLUSION CRITERIA:

        -None besides not meeting the inclusion.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  2 Years
 </minimum_age>
 <maximum_age>
  24 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  ECOG  3.

          -  Patients in first or subsequent hematological or molecular relapse of APL

          -  Persistence of a positive PCR (positive PCR after 3 consolidation cycles of first
             line therapy).

          -  Diagnostic measures Confirmation of relapse by RT-PCR of PML/RARa, cytogenetics, FISH
             or positive PGM3.

          -  Age over 18 years (No upper age limit)

          -  Informed consent of the patient

        Exclusion Criteria:

          -  ECOG 4.

          -  Heart failure NYHA grade III and IV.

          -  Renal or hepatic failure WHO grade III

          -  Positive HIV.

          -  Psychological dysfunction

          -  Associated active neoplasia

          -  Pregnancy.

          -  Arsenic Hypersensibility.

          -  QTc-interval prolonged over 460 msec before therapy (normal electrolytes, no other
             drugs prolonging the QT-interval )
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Individuals, over 18 years of age, diagnosed with an advanced cancer.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

        1) 1.) Normal Samples: Community dwelling adults &gt; 18 years of age. 2.) Patient Samples:
        In patients and out patients &gt; 18 years of age, being followed at UT M.D. Anderson or a
        collaborating site. Diagnosis of cancer confirmed by pathology.

        Exclusion Criteria:

        1) Those who refuse to participate or are determined incapable of completing the research.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patient diagnosed with cancer or a participant with a family member who has had cancer.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Members of families who have participated in the p53 project through Dr. Strong's lab
             are eligible, via protocol P90-001.  There are at least 115 kindreds including at
             least  800 participants living who may be at risk of carrying a p53 germline
             mutation.

          -  The participants must provide an informed consent and be 18 years or older.

          -  We will include English and non-English speaking participants.  For non-English
             speaking participants to be recruited, the consent documents has been translated into
             the language of the target population in accordance with the IRB procedures.

        For the survey portion of this study, we will invite individuals who:

          1. are already enrolled in the present study (protocol BS99-038),

          2. are at risk for carrying a p53 mutation, and

          3. have children who are less than 27 years old. -Patients who agree to enroll in the
             survey portion of the study will sign a specific informed consent form (Transition
             from Research to Disclosure in Human Genetics, BS99-038, Subtitle: Optional Survey).
             The informed consent document for the survey portion of the study will be translated
             into the language of the target population for non-English speaking participants in
             accordance with the IRB procedures.

        Exclusion Criteria:

        N/A
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Study participants with a pathological diagnosis of cancer and community dwelling adults
        who attend a meeting of a designated service organization.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Outpatient or inpatient receiving evaluation, treatment, or follow-up care at MDACC
             or a collaborating site.

          2. Has a pathological diagnosis of cancer.

          3. 18 years of age or older.

          4. Able to understand English.

          5. Gives informed consent to participate.

          6. Community sample eligibility: Community dwelling adult who attends a meeting of a
             designated service organization.

          7. Community sample eligibility: 18 years of age or older

          8. Community sample eligibility: Gives Informed Consent to participate.

          9. Community sample eligibility: Able to understand English.

        Exclusion Criteria:

          1. Cannot understand the intent of the study.

          2. Patient feels too ill to complete the surveys.

          3. Refuses to participate.

          4. Community sample exclusion criterion: Unable to complete the surveys.

          5. Community sample exclusion criterion: Refuses to participate.

          6. Community sample exclusion criterion: Cancer diagnosis (past or present)
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

        1.  Any person 18 years of age or older with a lesion of the oral mucosa.   Persons with
        changes in existing lesions or those who develop new lesions can be re-evaluated, but it
        is not required.

        Exclusion Criteria:

        NA
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Study participants that are or were pregnant when diagnosed with cancer.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. All pregnant patients with cancer and patients known to have been pregnant with a
             diagnosis of cancer are eligible, regardless of their diagnosis or treatment plan.

          2. Patients may receive prenatal care from any obstetrician, but a consult with a
             Maternal Fetal Medicine physician is encouraged.

        Exclusion Criteria:

        N/A
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Women, 18 years or older, that have or are at risk for Lynch Syndrome.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Women who meet one or more of the following criteria:

             A. Lynch syndrome mutation, including those at risk for cancer, those who have had
             cancer, and those who have had prophylactic surgery.

             B. Family history meets Amsterdam II criteria, defined as the following: At least 3
             relatives with an HNPCC-associated cancer (colorectal.endometrial cancer, small
             bowel, ureter, or renal pelvis). One is a first-degree relative of the other two. At
             least 2 successive generations affected. One cancer diagnosed before age 50.

             C. Tumor studies (MSI, IHC) are suggestive for Lynch Syndrome.

             D. Female family members who are at 25% or 50% risk for a lynch syndrome mutation may
             also be enrolled in the registry. 25% risk is defined as women with second degree
             family member grandmother, aunt, uncle, niece, and grandchild. 50% risk is defined as
             women with first degree family member being parent, child, sibling.

          2. Subjects must be 18 or older and able to give informed consent.

        Exclusion Criteria:

        1)  None
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed myelodysplastic
             syndromes (MDS), including any of the following:

               -  Secondary MDS

               -  MDS/myeloproliferative disorders (MPD) (e.g., chronic myelomonocytic leukemia or
                  atypical chronic myeloid leukemia)

               -  IPSS scores of 0.5 or greater ( INT-1) OR transfusion dependent despite use of
                  growth factors

               -  No more than 20% blasts in the marrow

               -  Patients who have not responded after 3 courses of hypomethylating agents
                  (azacitidine or decitabine) OR; who are unable to tolerate hypomethylating
                  agents OR who refused to receive hypomethylating agents are eligible for this
                  study

          -  ECOG performance status  2 (Karnofsky  60%)

          -  Total bilirubin  1.5 x upper limit of normal (ULN)

          -  AST/ALT  2.5 x ULN

          -  Creatinine  1.5 x ULN OR creatinine clearance  60 mL/min

          -  Urine protein:creatinine ratio &lt; 1 OR urine protein &lt; 500 mg by 24-hour urine
             collection

          -  PT INR  1.5

          -  Patients with PT INR &gt; 1.5 on full-dose anticoagulants (e.g., warfarin) are eligible
             provided both of the following criteria are met:

               -  Patient has an in-range INR (usually between 2 and 3) and is on a stable dose of
                  oral anticoagulant or low molecular weight heparin

               -  Patient has no active bleeding or pathological condition that carries a high
                  risk of bleeding (e.g., tumor involving major vessels or known varices)

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for at least 6 months
             after completion of study treatment

          -  Prior DNA-demethylating agent therapy or lenalidomide therapy allowed

          -  Prior treatment with other molecular agents, such as thalidomide, valproic acid, or
             imatinib mesylate allowed

        Exclusion Criteria:

          -  Evidence of active malignancies other than squamous cell or basal cell carcinoma of
             the skin

          -  Known hypersensitivity to Chinese hamster ovary cell products or other recombinant
             human antibodies

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to agents used in the study

          -  Serious or non-healing wound, ulcer, or bone fracture

          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
             abscess within the past 28 days

          -  Significant traumatic injury within the past 28 days

          -  Clinically significant cardiovascular disease, including any of the following:

               -  History of cerebrovascular accident (CVA) within the past 6 months

               -  Uncontrolled hypertension, defined as blood pressure &gt; 150/100 mm Hg or systolic
                  BP &gt; 180 mm Hg if diastolic blood pressure &lt; 90 mm Hg (on at least 2 repeated
                  determinations on separate days) within the past 3 months

               -  Myocardial infarction or unstable angina within the past 6 months

               -  New York Heart Association class III or IV congestive heart failure, serious
                  cardiac arrhythmia requiring medication, or unstable angina pectoris within the
                  past 6 months

          -  Clinically significant peripheral vascular disease within the past 6 months

          -  Pulmonary embolism, deep vein thrombosis (DVT), or other thromboembolic event within
             the past 6 months

          -  Evidence of bleeding diathesis or coagulopathy

          -  Concurrent uncontrolled illness including, but not limited to, ongoing or active
             infection or psychiatric illness/social situation that would limit compliance with
             study requirements

          -  Prior cytotoxic chemotherapy for MDS

          -  Molecular therapy or immunosuppressive agents (including steroids) within the past 3
             weeks

          -  Other prior antiangiogenesis agents

          -  Coronary artery bypass graft (CABG) within the past 6 months

          -  Valproic acid should be discontinued at least 24 hours before aflibercept
             administration, unless needed for seizure control

          -  Major surgical procedure or open biopsy within the past 28 days

          -  Core biopsy (other than bone marrow biopsy) within the past 7 days

          -  Anticipation of need for major surgical procedures during the course of the study

          -  Patients may not be receiving any other investigational agents
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

         All patients with primary breast cancer occurring during pregnancy will be eligible for
        enrollment.

        Exclusion Criteria:

          -  Patients presenting with systemic metastases at time of diagnosis.

          -  Patients unwilling or unable to give informed consent.

          -  Patients who have received radiation therapy while pregnant

          -  Patients who have received chemotherapy during the first trimester of pregnancy or
             chemotherapy other than FAC.
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Eligible subjects must be 3 to 70 years of age

          -  Must have a diagnosis of chronic ITP

          -  Must have a a platelet count  20 x 10(9)/L
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  3 Years
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients, 18 years or older, with advanced cancer experiencing cancer therapy-induced
        pain.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Since moderate pain, albeit brief, will be induced, this feasibility project will be
             limited to consenting adults, 18 years old or older, in which there is also a well
             established QST database.

          2. The subjects must be able to understand the nature of the study and have signed
             consent.

          3. The patients must either: a) have pain that has developed as a consequence of cancer
             therapy with either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based
             compounds or ionizing irradiation. OR b) have no pain that has developed as a
             consequence of cancer therapy, and are just entering chemotherapy with taxanes, vinka
             alkaloids, bortezomib, thalidomide, or platinum-based compounds

          4. (For Healthy Controls) Willing to participate and have signed an informed consent.

        Exclusion Criteria:

          1. Patients who refuse to participate or who are determined incapable of completing the
             research.

          2. (For Healthy Controls) Receiving anti-coagulants, immunosuppressed or diabetic.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed metastatic or
             unresectable gastric or gastroesophageal junction (GEJ) adenocarcinoma.  GEJ
             adenocarcinoma may be classified according to Siewert's classification type I, II, or
             III[43].

          -  Histological documentation of local recurrence or metastasis is strongly encouraged,
             unless the risk of such a procedure outweighs the potential benefit of confirming the
             metastatic disease.

          -  If no histologic confirmation, then the metastases or recurrence will require
             documentation by a 2nd radiographic procedure (eg. PET/CT scan or MRI in addition to
             the CT scan).  If the imaging procedure does not confirm recurrent or metastatic
             disease, biopsy confirmation will be required.

          -  Patients must have disease that can be evaluated radiographically.  This may be
             measurable disease or non-measurable disease.  Measurable disease is defined as that
             which can be measured in at least one dimension as &gt; 20 mm with conventional
             techniques, or &gt;10 mm by high resolution imaging. Disease that is identified on
             radiology studies, but does not meet the criteria for measurable disease, is
             considered non-measurable.

          -  Patients may have received no prior chemotherapy for metastatic or unresectable
             disease.  Patients may have received prior adjuvant therapy (chemotherapy and/or
             chemoradiation) if more than 6 months have elapsed between the end of adjuvant
             therapy and registration.  Patients may not have received prior docetaxel or
             cisplatin.

          -  Age 18 years or older.

          -  Karnofsky performance status &gt; than or = to 70% (ECOG performance status 0-1).

          -  Peripheral neuropathy &lt; than or = to grade 1.

          -  Hematologic (minimal values):

               -  White blood cell count &gt; than or = to 3000/mm3

               -  Absolute neutrophil count &gt; than or = to 1500 cells/ mm3

               -  Hemoglobin &gt; than or = to 9.0 g/dl

               -  Platelet count &gt; than or = to 100,000 / mm3

          -  Hepatic (minimal values):

          -  Total bilirubin &lt; or = to  1.5

             * * AST and ALT and Alkaline phosphatase must be within the eligible range. In
             determining eligibility, the more abnormal of the two values (AST or ALT) should be
             used. Patients with alkaline phosphatase elevation secondary to the bony metastases
             rather than liver dysfunction may proceed with treatment on protocol after discussion
             with the principal investigator.

          -  Kidney function (minimal values):

             * Serum creatinine &lt; than or = to 1.5 mg/dl - if serum creatinine is 1.2-1.5 mg/dl,
             the creatinine clearance (either measured or calculated) must be 50 ml/min or greater

          -  The patient has a PT (INR) &lt; than or = to 1.5 and an PTT &lt; than or = to 3 seconds
             above the upper limits of normal if the patient is not on anticoagulation. If a
             patient is on full-dose anticoagulants, the following criteria should be met for
             enrollment:

               -  The patient must have an in-range INR (usually between 2 and 3) on a stable dose
                  of warfarin or on stable dose of LMW heparin

               -  The patient must not have active bleeding or pathological conditions that carry
                  high risk of bleeding (e.g. tumor involving major vessels, known varices)

          -  Women of childbearing potential have a negative pregnancy test.

          -  Men and women of childbearing potential must be willing to consent to using effective
             contraception while on treatment and for at least 3 months thereafter.

          -  Ability to understand informed consent and signing of written informed consent
             document prior to initiation of protocol therapy.

          -  Patients must have HER2-positive (FISH+ or IHC 3+) metastatic or unresectable gastric
             or gastroesophageal junction (GEJ) adenocarcinoma to be eligible for trastuzumab. For
             the purposes of this protocol, FISH+ is defined as HER2:CEP17 ratio  2.0. Biopsy
             samples with cohesive IHC3+ or FISH+ clones are considered HER2 positive irrespective
             of size, i.e.&lt;10%. FISH+ defined as &gt;2 HER2:CEP17.

          -  Patients who are receiving trastuzumab must have a left ventricular ejection fraction
             of  50%.

        Exclusion Criteria:

          -  Patients who have received previous chemotherapy for the treatment of metastatic or
             unresectable gastric or GEJ adenocarcinoma are ineligible.

          -  Patients who have received previous pre- or post-operative chemotherapy or
             chemoradiation are ineligible if therapy was completed less than 6 months prior to
             study registration. Patients must have recovered from adverse events from any
             previous therapy.

          -  Patients who have received previous docetaxel or cisplatin.

          -  Patients with a history of another neoplastic disease within the past three years,
             excluding basal cell carcinoma of the skin, cervical carcinoma in situ, or
             nonmetastatic prostate cancer.

          -  Patients with brain or central nervous system metastases, including leptomeningeal
             disease.

          -  Pregnant (positive pregnancy test) or breast feeding.

          -  Serious, non-healing wound, ulcer, or bone fracture.

          -  Significant cardiac disease as defined as:

        unstable angina, New York Heart Association (NYHA) grade II or greater, congestive heart
        failure, history of myocardial infarction within 6 months

          -  Evidence of bleeding diathesis or coagulopathy.

          -  History of a stroke or CVA within 6 months

          -  Clinically significant peripheral vascular disease.

          -  Clinically significant hearing loss or ringing in the ears.

          -  Patients with a history of severe hypersensitivity reaction to Taxotere or other
             drugs formulated with polysorbate 80.

          -  Inability to comply with study and/or follow-up procedures.

          -  Patients with any other medical condition or reason, in that investigator's opinion,
             makes the patient unstable to participate in a clinical trial.

          -  For patients who are Her2 positive and will be treated on the trastuzumab + mDCF
             cohort, prior trastuzumab treatment is not allowed.

          -  For patients who are Her2 positive and will be treated on the trastuzumab+mDCF
             cohort, left ventricular function &lt;50%
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Hodgkin Lymphoma (histologically proven)

          -  CS (PS) IIB with one or both of the risk factors:

               -  bulky mediastinal mass (&gt; 1/3 of maximum transverse thorax diameter)

               -  extranodal involvement

          -  CS (PS) III, IV

          -  Written informed consent

        Exclusion Criteria:

          -  Leucocytes &lt; 3000/l

          -  Platelets &lt; 100000/l

          -  Hodgkins lymphoma as "composite lymphoma"

          -  Activity index (WHO) &lt; grade 2
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  60 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  ELIGIBILITY CRITERIA     RECIPIENT ON STANDARD CARE THERAPY:

          -  The patient is 18     74 years of age.

          -  The patient has a potentially suitable 8/8  donor if they are between the ages of
             69-74 years of age or a potentially suitable 8/8 or 7/8 unrelated donor(s) in the
             National Marrow Registry or Other Available Registry if they are between the ages of
             18-74.

          -  The patient currently does not meet the protocol   s eligibility/enrollment criteria
             for any reason.

          -  There is a high likelihood that the patient, in the opinion of the PI or LAI, will
             meet the protocol   s eligibility/enrollment criteria to proceed to transplant after
             standard therapy is completed.

          -  The patient or legal guardian is able to give informed consent.

        EXCLUSION CRITERIA     RECIPIENT ON STANDARD CARE THERAPY:

          -  HIV infection.  There is theoretical concern that the degree of immune suppression
             associated with the treatment may result in progression of HIV infection.

          -  Pregnant or lactating.  Patients of childbearing potential must use an effective
             method of contraception. The effects of the chemotherapy, the subsequent transplant
             and the medications used after the transplant are highly likely to be harmful to a
             fetus.  The effects upon breast milk are also unknown and may be harmful to the
             infant.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  74 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Eligibility Criteria:

          -  Cytologically or histologically confirmed "COX dependent" non-small cell lung cancer.

          -  COX dependency is defined by change in urinary PGE-M levels following a "run-in"
             phase of celecoxib.

          -  Previous treatment with 2 different chemotherapy regimens one of which must have
             been platinum-based (cisplatin or carboplatin) chemotherapy.

          -  Age 18 years

          -  ECOG PS 0, 1 or 2.

          -  Measurable or evaluable disease.

          -  At least 3 weeks post major surgery, chemotherapy or radiotherapy &amp; recovered from
             all toxicities.

          -  Expected survival of at least 2 months.

          -  CNS metastases permitted provided the patient has adequately recovered from
             radiotherapy includes stereotactic therapy) or surgery.

          -  Adequate renal function: serum creatinine 1.8 mg/dl &amp;/or CrCl &gt;50 cc/min

        Eligibility According to Liver Function:

        AST:

        &lt;/= 1.5 ULN-Docetaxel; &lt;/= 2.5 ULN-Pemetrexed (Liver parameters to be used for pemetrexed
        in the absence of proven or radiographically suspected liver metastases.); &lt;/= 5.0
        ULN-Pemetrexed (Liver parameters to be used for pemetrexed only in the presence of proven
        or radiographically suspected liver metastases.)

        Alk Phosphatase:

        &lt;/= 2.5 ULN-Docetaxel; &lt;/= 2.5 ULN-Pemetrexed (Liver parameters to be used for pemetrexed
        in the absence of proven or radiographically suspected liver metastases.); &lt;/= 5.0
        ULN-Pemetrexed (Liver parameters to be used for pemetrexed only in the presence of proven
        or radiographically suspected liver metastases.)

        Total Bilirubin:

        &lt;/= 1.5 ULN-Docetaxel; &lt;/= 1.5 ULN-Pemetrexed (Liver parameters to be used for pemetrexed
        in the absence of proven or radiographically suspected liver metastases.); &lt;/= 2.5
        ULN-Pemetrexed (Liver parameters to be used for pemetrexed only in the presence of proven
        or radiographically suspected liver metastases.)

          -  Adequate hematologic function: ANC1500/mm3 &amp; platelets 100,000/mm3

          -  Female patients cannot be pregnant and must use contraception if of childbearing age

          -  Lactating women are excluded.

          -  Peripheral neuropathy must be CTC grade 2

          -  Patients must not currently be on non-steroidal anti-inflammatory agents or other
             COX-2 inhibitors (Must be off for at least 7 days)

          -  Written informed consent.

        Exclusion Criteria:

          -  More than two prior chemotherapy regimens for recurrent or relapsed NSCLC.

          -  COX Independent as defined by change in urinary PGE-M levels following a "run-in"
             phase of celecoxib.

          -  Previous treatment with both docetaxel and pemetrexed

          -  History of greater than grade 2 allergic reaction to celecoxib or any other
             non-steroid anti-inflammatory agent including aspirin, ibuprofen, or indomethacin.

          -  History of allergy to compounds containing boron or mannitol.

          -  History of allergy to sulfonamides.

          -  Concomitant use of Warfarin, but low dose Coumadin allowed for port prophylaxis

          -  Recent (past 4 weeks) coronary artery bypass graft (CABG) surgery.

          -  Inadequate organ function:

          -  Serum creatinine 1.8 mg/dl or a calculated CrCl &lt;45 cc/min.

          -  AST &gt;1.5 upper limits of normal (ULN); alkaline phosphatase &gt;2.5 ULN; &amp; bilirubin
             &gt;1.5 ULN

          -  ANC&lt;1500/mm3 &amp; platelets &lt;100,000/mm3

          -  Active pregnancy or inability or unwillingness to employ appropriate contraception.

          -  Small cell carcinoma histology.

          -  Prior malignancy within 5 years of diagnosis of NSCLC. Exceptions include basal cell
             or non-metastatic squamous cell carcinomas of the skin, cervical carcinoma in situ or
             FIGO stage I cervical carcinoma, or other cancer history considered not clinically
             significant by the principal investigator.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients above 12 years of age with performance status (PST)score of 0-2

          -  Unresectable HCC with underlying Child's A/B cirrhosis

          -  Normal Main portal vein and its branches

          -  Normal Inferior vena cava

          -  No history of drug allergy

          -  Informed written consent of patient.

          -  Less than 50% involvement of liver by HCC

        Exclusion Criteria:

          -  Unresectable HCC with underlying Child's C cirrhosis

          -  Performance status 3-5

          -  Extrahepatic disease

          -  Vascular involvement

          -  Co-morbid illness like coronary artery disease, congestive heart failure, chronic
             renal failure etc

          -  Previous history of encephalopathy/ upper gastrointestinal bleed in the last six
             months

          -  HCC in a female of child bearing age
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  12 Years
 </minimum_age>
 <maximum_age>
  80 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

          -  HIV+ adults and children greater than 8 years of age

        EXCLUSION CRITERIA:

          -  Inability or unwillingness to give consent or assent or to comply with study
             requirements

          -  Unable to return to NIH or Washington Hospital Center for two follow-up visits over a
             9-month period

          -  New opportunistic or bacterial infection within past 3 months or active opportunistic
             infection.

          -  Active malignancy, other than non-melanoma skin cancer and cutaneous Kaposi sarcoma
             not requiring treatment. Rationale: systemic inflammation may induce
             microalbuminuria.

          -  Diabetes by history

          -  IL-2, IL-7 or IFN-alpha therapy within past 3 months.  Rationale: IL-2 and IFN-alpha
             therapy induce renal dysfunction and IL-7 may be associated with systemic
             inflammation.

          -  Non compliance, alcohol use, and drug use are conditions that make study completion
             unlikely or difficult.

          -  Diabetes (fasting glucose greater than 125 mg/dL or 2 hour oral glucose tolerance
             value greater than or equal to 200 mg/dL or current diagnosis of diabetes).

          -  Serum creatinine greater than 1.4 mg/dL.

          -  Urine protein/creatinine ratio greater than 0.5 and sustained on at least 2
             measurements.

          -  Pregnant Women
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  8 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Participants, 18 years or older, with a confirmed diagnosis of AML or MDS (cases), or
        treated for a primary malignancy (controls).
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Age 18 years or older

          2. Willing and able to provide written informed consent and authorization

          3. Willing to donate a saliva sample or 10 ml of blood and to complete a
             self-administered or personal interview

          4. A histologically confirmed diagnosis of AML or MDS (cases only)

          5. A history of a previous primary malignancy that was treated with chemotherapy and/or
             radiation therapy (cases only)

          6. Enrolled in leukemia/MDS studies under protocol ID00-173 or ID03-0250 (cases only)

          7. Treated for a primary malignancy at MDACC (controls only)

          8. Matched to cases (2:1) by cases' prior malignancy (site, treatment (chemo and/or
             radiation), year of diagnosis (+/- 3 years)), age (+/- 5 years), sex, and ethnicity
             (controls only)

        Exclusion Criteria:

          1. Under 18 years of age

          2. History of second primary malignancy (controls only)
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Diagnoses of low risk acute lymphoblastic leukemia in children no treated previously

        Exclusion Criteria:

          -  Mature B-ALL (FABL3) or with cytogenetic ALL "Burkitt-like" alterations (t[8;14],
             t[2;8], t[8;22])

          -  Mixed forms of ALL

          -  Acute Leukemia no differentiate

          -  Patients with coronary disorders, valvular or hypertensive cardiopathy

          -  Patients with chronic liver disorders

          -  Chronic pulmonary disorders

          -  Renal insufficiency

          -  Neurologic disfunctions

          -  ECOG 3 and 4

          -  No signed consent form
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  15 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Cytologic or histologic diagnosis of small cell lung cancer

          -  Extensive disease according to VALG classification

          -  One or more target lesions.

          -  Performance status (ECOG) 0 or 1

          -  Age &lt;70 years.

          -  Patients with asymptomatic cerebral metastases are eligible

          -  Patients who have completed treatment with radiation therapy at least 4 weeks prior
             to enrollment are eligible

          -  Written informed consent

        Exclusion Criteria:

          -  Previous chemotherapy

          -  Previous or concomitant malignant neoplasm (excluding adequately treated baso or
             spinocellular skin carcinoma or carcinoma in situ of the cervix)

          -  Neutrophil &lt; 2000/mm3, platelets &lt; 100,000/mm3, haemoglobin &lt; 10 g/dl

          -  Creatinine &gt; 1.5 x the upper normal limits

          -  GOT and/or GPT   &gt; 2.5 and/or Bilirubin &gt; 1.5 times the upper normal limits in
             absence of hepatic metastases

          -  GOT and/or GPT &gt; 5  and/or Bilirubin &gt; 3 times the upper normal limits in presence of
             hepatic metastases

          -  Any concomitant pathology that would, in the investigator's opinion, contraindicate
             the use of the drugs in this study

          -  Hypersensitivity to darbepoetin alpha, to  r-HuEPO or their components

          -  Uncontrolled hypertension.

          -  Inability to provide informed consent.

          -  Inability to comply with follow-up
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  High risk children with acute lymphoblastic leukemia

        Exclusion Criteria:

          -  Mature B-ALL (FABL3)

          -  Mixed forms of ALL

          -  Patients with coronary disorders, valvular or hypertensive cardiopathy

          -  Patients with chronic liver disorders

          -  Chronic pulmonary disorders

          -  Renal insufficiency

          -  Neurologic disfunctions

          -  ECOG 3 and 4
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  16 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients with unresectable cancer primarily in the liver with the liver being the only
        site of disease or the dominant site of disease
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Confirmed diagnosis of intrahepatic carcinoma

               -  Histopathology confirmation may be waived in patients with a radiographically
                  identifiable liver mass AND known laboratory or clinical risk factors for cancer
                  or elevated tumor markers such as AFP

          -  Unresectable disease

          -  No portal hypertension with portal venous shunt away from the liver

          -  No significant extrahepatic disease representing an imminent life-threatening outcome

          -  No evidence of potential delivery of &gt; 16.5 mCi (30 Gy absorbed dose) radiation to
             the lungs on either of the following:

               -  First yttrium Y 90 glass microspheres (TheraSphere) administration

               -  Cumulative delivery of radiation to the lungs over multiple treatments

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  ECOG performance status 0-2

          -  Absolute granulocyte count  1,500/L

          -  Platelet count &gt; 25,000/L

          -  Serum creatinine &lt; 2.0 mg/dL (unless using non-iodinated contrast or on dialysis)

          -  Serum bilirubin  3.0 mg/dL (in some cases where there is an elevated bilirubin and
             the tumor may be isolated from a vascular standpoint, treatment may proceed)

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        Exclusion criteria:

          -  Any of the following contraindications to angiography and selective visceral
             catheterization:

               -  History of severe allergy or intolerance to any contrast media, narcotics,
                  sedatives, or atropine, that cannot be controlled using basic angiographic
                  techniques

               -  Bleeding diathesis, not correctable by usual forms of therapy

               -  Severe peripheral vascular disease that would preclude catheterization

          -  Evidence of any detectable Tc-99 macroaggregated albumin flow to the stomach or
             duodenum, after application of established angiographic techniques to stop such flow

          -  Severe liver dysfunction or pulmonary insufficiency

          -  Active uncontrolled infection

          -  Significant underlying medical or psychiatric illness

        PRIOR CONCURRENT THERAPY:

          -  At least 4 weeks since prior and no other concurrent anticancer therapy
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Potential research subjects will be identified by a member of the patient's treatment
        team, the protocol investigator, or research team at Memorial Sloan-Kettering Cancer
        Center (MSKCC), or specified plastic surgeon at outside institution.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Age 18 to 99 years.

          -  Patients who have altered facial appearance secondary to an oncologic head and neck
             surgical resection and reconstruction. Reconstruction will be defined as complex
             linear closures, skin grafts, local flaps or free tissue transfer (oncologic Post-op
             cohort).

          -  Patients who have undergone cosmetic plastic surgery procedures to the head and neck
             unrelated to a diagnosis of cancer (non-oncologic Post-op cohort).

        Patients who have completed surgery at MSKCC between 1 week to 7 years ago (Post-op
        cohorts).

          -  Patients who have completed facial surgery 6 weeks (+/- 1 week) ago (early
             postoperative subset-Phase I).

          -  Patients who are scheduled to undergo oncologic head and neck resection and
             reconstruction with anticipated altered facial appearance (Pre-op).

        Exclusion Criteria:

          -  Active psychiatric illness, cognitive or sensory impairment that in the opinion of
             the investigator is severe enough to preclude participation in the study.

          -  Moderate to severe cognitive impairment.

          -  Blindness.

          -  Physical impairment that may prevent the respondent from filling out the paper and
             pencil survey.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria: at least one of the following:

          -  FLIPI score 3 thru 5 at diagnosis and/or at relapse

          -  First complete response shorter than 3 years, if no maintenance (Interferon,
             Rituximab, etc) treatment was administered, or than 5 years if maintenance treatment
             was administered

          -  No treatment has been able to induce complete response until autologous stem cell
             transplant

          -  Poor-prognosis genomic profiling

        Exclusion Criteria: any of the following:

          -  Unavailability of a harvestable lymph node of at least cm 2x2x2

          -  Life expectancy &lt; 1 year

          -  Abnormal heart or liver or kidney function

          -  ECOG Performance Status &gt; 2

          -  Failure to sign informed consent before enrollment
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  65 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Stage T1 (only)

          -  Over 18 years old

          -  Patient's consent

          -  Previous R0 resection of rectal tumor

        Exclusion Criteria:

          -  Metastases (M1)

          -  Neoadjuvant chemotherapy or radiotherapy

          -  Meta- or synchronous tumors
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients with AML in 1st &amp; 2nd complete remission w/no HLA matched related donor
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  85 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients with metastatic cancer of the liver who are not surgical resection candidates.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Confirmed diagnosis of metastatic intrahepatic carcinoma

               -  Histopathology confirmation may be waived in patients with a radiographically
                  identifiable liver mass AND known laboratory or clinical risk factors for cancer
                  or elevated tumor markers such as AFP

          -  Unresectable disease

          -  No portal hypertension with portal venous shunt away from the liver

          -  FDA approval to receive compassionate use of yttrium Y 90 glass microspheres

          -  No significant extrahepatic disease representing an imminent life-threatening outcome

          -  No evidence of potential delivery of &gt; 16.5 mCi (30 Gy absorbed dose) of radiation to
             the lungs on either of the following:

               -  First administration of yttrium Y 90 glass microspheres (TheraSphere )

               -  Cumulative delivery of radiotherapy to the lungs over multiple treatments

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Life expectancy  3 months

          -  Absolute granulocyte count  1,500/L

          -  Platelet count  25,000/L

          -  Creatinine  2.0 mg/dL (unless using non-iodinated contrast or on dialysis)

          -  Serum bilirubin  3.0 mg/dL (in some cases where there is an elevated bilirubin, and
             the tumor may be isolated from a vascular standpoint, treatment may proceed)

          -  No contraindication to angiography or selective visceral catheterization, including
             any of the following:

               -  History of severe allergy or intolerance to any contrast media, narcotics,
                  sedatives, or atropine, that cannot be controlled using basic angiographic
                  techniques

               -  Bleeding diathesis, not correctable by usual forms of therapy

               -  Severe peripheral vascular disease that would preclude catheterization

          -  No severe liver dysfunction or pulmonary insufficiency

          -  No active uncontrolled infection

          -  No significant underlying medical or psychiatric illness

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No evidence of any detectable technetium-99 macroaggregated albumin (Tc-99 MAA) flow
             to the stomach or duodenum after application of established angiographic techniques
             to stop such flow

          -  No comorbid disease or condition that would preclude safe delivery of yttrium Y 90
             glass microspheres and place patient at undue risk

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  More than 4 weeks since prior radiotherapy

          -  More than 2 weeks since prior surgery

          -  At least 2 weeks since prior radiosensitizing chemotherapy

          -  More than 6 weeks since prior carmustine (BCNU) or mitomycin C

          -  No other concurrent cancer therapy
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Study participants who the investigator or delegate believes that they and/or their
             parents/legally acceptable representative can and will comply with the requirements
             of the protocol (e.g. completion of the diary cards, return for follow-up visits)
             should be enrolled in the study.

          -  A male or female between, and including, 12 and 15 years of age at the time of the
             first vaccination.

        A written informed assent must be obtained from all study participants prior to enrolment.
        In addition, a written informed consent must be obtained from the study participants'
        parent or legally acceptable representative.

        Note: As according to the Finnish law legal age of consent is 15 years, a written informed
        consent form can be obtained from study participants aged 15 years old and their
        parent(s)/legally acceptable representative(s) will receive a letter informing them of
        their child participation to the study.

          -  Healthy male and female study participants as established by medical history before
             entering into the study. If needed, a history-directed clinical examination will be
             performed by the investigator or delegate (e.g. study nurse).

          -  Study participants must not be pregnant. Absence of pregnancy should be verified
             (e.g. urine pregnancy test) as per investigator's or delegate's clinical judgement.

          -  If the study participant is female, she must be of non-childbearing potential, i.e.
             be abstinent, have a current tubal ligation, hysterectomy, ovariectomy or be
             post-menopausal or pre-menarcheal, or if she is of childbearing potential, she must
             use adequate contraception for 30 days prior to vaccination and continue for 2 months
             after completion of the vaccination series.

        Exclusion Criteria:

          -  Previous vaccination against HPV or Hepatitis B virus.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccines.

          -  Acute disease at the time of enrolment. (Acute disease is defined as the presence of
             a moderate or severe illness with or without fever. All vaccines can be administered
             to persons with a minor illness such as diarrhoea, mild upper respiratory infection
             with or without low-grade febrile illness, i.e. Oral temperature &lt;37.5C (99.5F) /
             Axillary temperature &lt;37.5C (99.5F) / Rectal temperature &lt;38C (100.4F).)

          -  Pregnant or lactating female.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  12 Years
 </minimum_age>
 <maximum_age>
  15 Years
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients with breast cancer
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed androgen-independent adenocarcinoma of the
             prostate

               -  Advanced or recurrent disease for which standard curative or reliable palliative
                  therapy does not exist or is no longer effective

          -  Measurable disease with elevated prostate-specific antigen (PSA) or evaluable disease
             (PSA elevation will constitute evaluable disease)

          -  Patients who have received prior antiandrogens or progestational agents as therapy
             for prostate cancer must discontinue therapy and demonstrate a rising PSA  28 days*
             after discontinuation NOTE: *At least 42 days for bicalutamide or nilutamide

          -  Patients undergoing androgen deprivation using luteinizing hormone-releasing hormone
             (LHRH) analogues must continue therapy or undergo orchiectomy to maintain castrate
             levels of testosterone

          -  Patients with brain metastases which are stable and have been treated for surgery or
             irradiation are eligible

        PATIENT CHARACTERISTICS:

          -  ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%

          -  Life expectancy &gt; 3 months

          -  Leukocytes  3,000/mm^3

          -  Hemoglobin  8 g/dL

          -  Absolute neutrophil count  1,500/mm^3

          -  Platelet count  75,000/mm^3

          -  Total bilirubin normal

          -  AST/ALT  2.5 x upper limit of normal

          -  Creatinine  2 mg/dL

          -  Calcium normal

          -  Must be able to receive oral medications, including oral capsules

          -  No known severe hypersensitivity to ketoconazole, calcitriol, or any of the
             excipients of these products

          -  No history of allergic reaction attributed to compounds of similar chemical or
             biologic composition to calcitriol, ketoconazole, or other agents used in the study

          -  No evidence of any other significant clinical disorder or laboratory finding that
             would make it undesirable for the patient to participate in the trial

          -  No history of kidney, ureteral, or bladder stones within the past 5 years

          -  No incomplete healing from prior oncologic treatments or other major surgery

          -  No unresolved chronic toxicity &gt; grade 2

          -  No heart failure or significant heart disease, including any of the following:

               -  Significant arrhythmias

               -  Myocardial infarction within the past 3 months

               -  Unstable angina pectoris

               -  Documented ejection fraction &lt; 30%

          -  No other severe or uncontrolled systemic disease (e.g., unstable or compensated
             respiratory, cardiac, hepatic, or renal disease) or intercurrent illness including,
             but not limited to any of the following:

               -  Ongoing or active infection

               -  Symptomatic congestive heart failure

               -  Psychiatric illness/social situation that would limit compliance with study
                  requirements

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Recovered from prior anticancer therapy

          -  At least 7 days since prior thiazide therapy

          -  At least 30 days since prior treatment with a non-approved or investigational drug or
             agent

          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)

          -  At least 4 weeks since prior radiotherapy or cytotoxic therapy

          -  No more than 2 prior cytotoxic chemotherapy regimens

               -  Retinoids, vitamin D analogues, PPAR agonists or antagonists, antiandrogens,
                  progestational agents, estrogens, PC-SPES, LHRH analogues, vaccines, and
                  cytokines are not considered cytotoxics

               -  Prior ketoconazole and glycocorticoids allowed

          -  Concurrent megestrol acetate for hot flashes at a dose of  40 mg/day allowed

          -  No concurrent digoxin therapy

          -  No concurrent systemic glucocorticoid therapy at greater than physiologic replacement
             doses

          -  No concurrent calcium supplementation

          -  No concurrent combination antiretroviral therapy for HIV-positive patients

          -  No concurrent proton pump inhibitors or H2 blockers

          -  No concurrent use of any of the following:

               -  Phenytoin

               -  Carbamazepine

               -  Barbiturates

               -  Rifampicin

               -  Phenobarbital

               -  Hypericum perforatum (St. John wort)

               -  Alfentanil

               -  Alfuzosin

               -  Almotriptan

               -  Alprazolam

               -  Amiodarone

               -  Amitriptyline

               -  Aprepitant

               -  Amprenavir

               -  Aripiprazole

               -  Bepridil

               -  Bortezomib

               -  Bosentan

               -  Budesonide

               -  Buprenorphine

               -  Buspirone

               -  Cilostazol

               -  Cisapride

               -  Cyclosporine

               -  Delavirdine

               -  Didanosine

               -  Digoxin

               -  Disopyramide dofetilide

               -  Donepezil

               -  Eletriptan

               -  Eplerenone

               -  Fluticasone

               -  Fosamprenavir

               -  Galantamine

               -  Systemic griseofulvin

               -  Indinavir

               -  Levobupivacaine

               -  Lopinavir

               -  Midazolam

               -  Mifepristone

               -  Modafinil

               -  Nateglinide

               -  Nefazodone

               -  Nelfinavir

               -  Oxcarbazepine

               -  Pimozide

               -  Quetiapine

               -  Quinidine

               -  Repaglinide

               -  Rifabutin

               -  Rifampin

               -  Rifapentine

               -  Ritonavir

               -  Saquinavir

               -  Valdecoxib

               -  Vardenafil

               -  Ziprasidone

               -  Statins

               -  Calcium channel blockers

               -  Macrolides

               -  Sildenafil

               -  Sirolimus

               -  Tacrolimus

               -  Tadalafil

               -  Tolterodine

               -  Theophyllines

               -  Triazolam

               -  Zonisamide

               -  Other agents that would be significantly perturbed in a clinically important way
                  by the P450 inhibitory properties of ketoconazole
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Lymphoma database
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients with newly diagnosed Hodgkin's Disease and Non-Hodgkin's Lymphoma

        Exclusion Criteria:

          -  Patients with diagnosis other than HD and NHL.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  14 Years
 </minimum_age>
 <maximum_age>
  85 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Study participants considered to be at low risk for ovarian cancer.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Female, &gt;/= 50 years old or less than 75 years old

          2. Postmenopausal (&gt;/= 12 months amenorrhea)

          3. Have at least one ovary

          4. Cancer-free and have not received any chemotherapy or radiation therapy for &gt;/=12
             months prior to enrolling on this study

          5. Willingness to return to UTMD Anderson Cancer Center (UTMDACC)for CA 125 blood tests
             annually or earlier if indicated

          6. 6) Willingness to return to UTMDACC to undergo transvaginal ultrasound if indicated.

          7. Women need to provide the name of a gynecologist or qualified healthcare professional
             willing to provide appropriate follow-up care if indicated

        Exclusion Criteria:

          1. Female: Less than 50 years old or older than 75 years

          2. Psychiatric or psychological or other conditions which prevent a fully informed
             consent.

          3. Prior removal of both ovaries.

          4. Active non-ovarian malignancy.

          5. Women who have a history of non-ovarian malignancy will be eligible if they have no
             persistent or recurrent disease and have not received treatment for &gt;12 months. If
             they are on SERM (i.e. tamoxifen or aromatase inhibitors) they will not be excluded.
             Women maybe undergoing or have had treatment &lt;12 months prior to study entry for
             basal cell carcinoma only.

          6. High risk for ovarian cancer : a. known mutation in BRCA1 of BRCA2.

          7. Two 1st or 2nd degree relatives of same lineage who have: two ovarian cancers; one
             ovarian cancer and one pre-menopausal breast cancer; two pre-menopausal breast
             cancers; one pre-menopausal and one post menopausal breast cancer. These conditions
             can also be met using the participant and one 1st or 2nd degree female relative.

          8. Ashkenazi Jewish descent with one 1st degree or two 2nd degree relatives with
             pre-menopausal breast or ovarian cancer or participant has had pre-menopausal breast
             cancer.

          9. 1st or 2nd degree male relative with breast cancer diagnosed at any age. First degree
             relative defined as: children, siblings and parents. Second degree relative defined
             as half-siblings, aunts, uncles, nieces, nephews, grandparents, and grandchildren.

         10. HNPCC/Lynch Syndrome: known genetic mutation, presumed HNPCC carrier, Amsterdam
             criteria.
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  50 Years
 </minimum_age>
 <maximum_age>
  74 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   primary care clinic, community sample
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Non-pregnant woman age 18 yrs and older.

        Exclusion Criteria:

          -  pregnant woman and younger than 18 yrs of age.
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Histologically confirmed invasive breast cancer completely removed by surgery

               -  Any T, any N

               -  No recurrent or metastatic disease

          -  Estrogen or progesterone receptor-positive disease in primary tumor, as defined by 1
             of the following:

               -  At least 10% of tumor cells positive by immunohistochemistry

               -  At least 10 fmol/mg cytosol protein by ligand binding assay

          -  Patients with HER-2/neu positive tumors are eligible provided they receive
             trastuzumab (Herceptin) according to the registered schedule

        PATIENT CHARACTERISTICS:

          -  Female

          -  Postmenopausal, defined by  1 of the following:

               -  Age  60 years

               -  Age 45-59 and satisfying 1 or more of the following criteria:

                    -  Amenorrhea for  12 months AND intact uterus

                    -  Amenorrhea (secondary to hysterectomy, hormone replacement therapy (HRT),
                       or chemotherapy) for &lt; 12 months AND follicle-stimulating hormone within
                       the postmenopausal range

               -  Underwent prior bilateral oophorectomy at any age &gt;18 years

          -  No concurrent illness that contraindicates adjuvant endocrine treatment

          -  No other invasive breast cancer or invasive malignancy within the past 10 years,
             except adequately cone-biopsied squamous cell or basal cell skin cancer or carcinoma
             in situ of the cervix

          -  No concurrent disease that would place the patient at unusual risk

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Adjuvant or neoadjuvant chemotherapy must be completed prior to study entry

          -  At least 1 month since prior and no concurrent HRT

          -  More than 30 days since prior systemic investigational drugs

          -  No prior tamoxifen as part of any breast cancer prevention study

          -  Prior or concurrent locoregional radiotherapy allowed

          -  No other concurrent experimental drugs

          -  No concurrent bisphosphonates, unless indicated as treatment for osteoporosis
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Women with Estrogen Receptor (ER), Progesterone Receptor (PR),and HER2 negative
             invasive breast cancer confirmed on core biopsy.(Note: HER2 negative by FISH
             preferred; HER2 0 or 1+ by IHC acceptable)

          -  Primary tumor size 2cm or greater by physical exam or radiographic
             measurements.(Note: Locally advanced T4 or inflammatory breast cancer is eligible.)

          -  Assessment of pre-treatment axillary lymph nodal status (Note: FNA biopsy if palpable
             or sentinel lymph node biopsy (SLNB) if not palpable preferred; clinical exam
             acceptable.)

          -  Absolute neutrophil count &gt; 1500 mm3 and platelet count &gt; 100,000 mm3

          -  Normal myocardial left ventricular function

          -  Serum creatinine &lt; 2.0 mg/dl

          -  Total bilirubin and AST &lt; 3X upper limits normal

        Exclusion Criteria:

          -  Recurrent or metastatic breast cancer findings (Note: If oncologically felt to be a
             second breast primary, patient eligible for this protocol)

          -  Another active cancer present

          -  Medical contraindications to chemotherapy or surgery

          -  First trimester pregnancy

          -  Breast feeding
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Subjects with premalignant lesion of the oral cavity mucosa (leukoplakia or
             erythroplakia).

          2. Patients with a history of head and neck cancer or oral premalignant disease but
             without any clinical evidence of disease.

          3. Persons with any other condition (such as lichen planus, Fanconi anemia, heavy
             tobacco use, etc) making them at higher risk for oral cancer development.

          4. Patients with either pre-malignant or a history of oral cancer based on patient
             history and clinical presentations

        Exclusion Criteria:

          1. Subjects under the age of 18.

          2. Subjects that are unable or unwilling to give informed consent.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Group 1. Non-oncologic patients from VAMC in Houston:

          2. Biopsy proven or clinically suspected advanced parenchymal liver disease

          3. Core biopsies obtained within 1-month of MRI/MRE

          4. No treatment affecting the status of liver between MRI/MRE and post-imaging biopsy

          5. Signed consent

          6. Group 2. Oncologic patients at MDACC:

          7. Clinically or radiographically suspected liver damage, hepatic steatosis, hepatitis,
             hepatic fibrosis or cirrhosis

          8. Surgical or core biopsy scheduled within 4 weeks of MRI/MRE

          9. Signed consent

        Exclusion Criteria:

          1. Claustrophobia

          2. Contraindications for MRI

          3. Unable to hold a breath

          4. Ascites or other clinical or radiographical signs of portal hypertension
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Participant has a confirmed diagnosis of precursor B-cell or precursor T-cell acute
             lymphocytic leukemia (ALL)  by immunophenotyping

          -  Participant is less than or equal to 18 years of age

          -  Limited prior therapy, including systemic glucocorticoids for one week or less, one
             dose of vincristine, emergency radiation therapy to the mediastinum and one dose of
             intrathecal chemotherapy. Other circumstances must be cleared by principal
             investigator (PI) or co-PI.

          -  Written, informed consent and assent following Institutional Review Board, NCI, FDA,
             and Office for Human Research Protections (OHRP) Guidelines.

        Exclusion Criteria:

          -  Participants with prior therapy, other than that listed above

          -  Pregnant or lactating

          -  Inability or unwillingness of research participant or legal guardian/representative
             to give written informed consent.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  18 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Have a diagnosis of advanced cancer with an estimated prognosis of less than 1 year
             but more than 3 days.

          2. Describe their nausea as at least moderate on a Likert scale OR at have had at least
             one vomit per day for the last three days.

          3. Have an underlying cause for their nausea which is thought to be irreversible OR the
             patient has made an autonomous choice not to proceed with treatment for any
             potentially reversible cause (for example surgery for obstruction or drainage of
             ascites).

          4. Can be male or female patients but must be over the age of 18.

          5. Have signed a consent form prior to entering the study.

          6. If patients are taking corticosteroids the dosage should be stable for 3 days before
             and during the trial.

          7. Be thought to be well enough to complete the 3 day trial.

        Exclusion criteria:

          1. Arm lymphoedema.

          2. Weakness, fatigue or confusion sufficient that patient is unable to take part.

          3. Previous history of acupuncture/acupressure for nausea or vomiting, or history of use
             of acupressure by a close relative.

          4. History of Parkinsonism or Parkinsonism on examination.

          5. Patients will not be enrolled if they are sharing a room with another patient taking
             part in the study.

          6. Patients who are unable to read or comprehend the questionnaire or Visual Analogue
             Scale.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

        Inclusion criteria:

          -  Diagnosis of acute lymphoblastic leukemia (ALL) or biphenotypic leukemia meeting the
             following criteria:

               -  Based on European Group for the Classification of Acute Leukemia (EGIL)
                  diagnostic criteria

               -  Newly diagnosed disease

               -  Verified by morphology and confirmed by cytochemistry and immunophenotyping

                    -  Trephine biopsy is recommended (unless diagnosis can be confirmed by
                       peripheral blood examination) in the event that bone marrow aspiration
                       results in a "dry tap"

          -  Must have MLL gene rearrangements documented by split-signal fluorescence in situ
             hybridization and meets 1 of the following risk criteria:

               -  Low-risk disease, defined as all MLL germline cases

               -  Medium-risk disease, defined by 1 of the following criteria:

                    -  MLL status unknown

                    -  MLL rearranged AND age &gt; 6 months

                    -  MLL rearranged AND age &lt; 6 months AND WBC &lt; 300 x 10^9/L AND prednisone
                       good response

               -  High-risk disease, defined by MLL rearrangement AND meets the following
                  criteria:

                    -  Age at diagnosis &lt; 6 months (i.e., &lt; 183 days)

                    -  WBC  300 x 10^9/L AND/OR prednisone poor response

          -  Minimum donor and stem cell requirements for high-risk patients undergoing stem cell
             transplantation:

               -  Donor meeting 1 of the following criteria:

                    -  HLA-identical sibling

                    -  Very well-matched related or unrelated donor

                    -  Must be HLA compatible in 10/10 or 9/10 alleles by 4 digit/allele
                       high-resolution molecular genotyping

               -  Stem cell source

                    -  Bone marrow (preferred source) OR peripheral blood stem cells of filgrastim
                       [G-CSF]-stimulated donors OR cord blood

                         -  Highly-matched unrelated umbilical cord blood (UCB) (&gt; 7/8 matches
                            identified by high-resolution typing) accepted if a sibling donor is
                            not able to donate bone marrow AND UCB with a sufficient number of
                            nucleated cells (NCs) (i.e., &gt; 1.5 x 10^7/kg recipient body weight
                            [BW]) is cryopreserved

               -  Must have  3 x 10^8 NCs/kg BW OR 3 x 10^6/kg BW CD34-positive cells available
                  for transplantation

          -  CNS or testicular leukemia at diagnosis allowed

        Exclusion criteria:

          -  Mature B-ALL, defined by the immunophenotypical presence of surface immunoglobulins
             or t(8;14) and breakpoint as in B-ALL

          -  Presence of the t(9;22) (q34;q11) or bcr-abl fusion in the leukemic cells (if data
             are not known, patient still may be eligible)

          -  Relapsed ALL

        PATIENT CHARACTERISTICS:

          -  See Disease Characteristics

        PRIOR CONCURRENT THERAPY:

          -  More than 4 weeks since prior systemic corticosteroids

               -  Corticosteroids by aerosol are allowed
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  1 Year
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Primary immunodeficiency disorder or other nonmalignant inherited disease (except
             aplastic anemia and Fanconi anemia) treatable by allogeneic HCT

          -  Patients with pre-existing medical conditions or other factors that renders them at
             high risk for regimen related toxicity or ineligible for a conventional myeloablative
             HCT

          -  Donors: Related donor who is human leukocyte antigen (HLA) genotypically identical at
             least at one haplotype and may be genotypically or phenotypically identical for
             serological typing for HLA-A, B, -C, and at the allele level for -DRB1 and -DQB1;
             related donors must be a match or a single allele mismatch at HLA-A, B, and C (at
             highest resolution available at the time of donor selection) and matched at DRB1 and
             DQB1 by deoxyribonucleic acid (DNA) typing

          -  Donors: Unrelated donors who are prospectively:

               -  Matched for HLA-A, B, C, DRB1 and DQB1 by DNA typing at the highest resolution
                  routinely available at the time of donor selection

               -  Only a single allele disparity will be allowed for HLA-A, B, or C as defined by
                  high resolution typing (no mismatching for DRB1 or DQB1 is allowed)

        Exclusion Criteria:

          -  Patients with Aplastic anemia and Fanconi anemia

          -  Patients with metabolic storage diseases who have severe central nervous system (CNS)
             involvement of disease, defined as intelligence quotient (IQ) score &lt; 70

          -  Cardiac ejection fraction &lt; 30% or, if unable to obtain ejection fraction, shortening
             fraction of &lt; 26%) on multi-gated acquisition (MUGA) scan or cardiac echo,
             symptomatic coronary artery disease, other cardiac failure requiring therapy;
             patients with a history of, or current cardiac disease should be evaluated with
             appropriate cardiac studies and/or cardiology consult; patients with a shortening
             fraction &lt; 26% may be enrolled if approved by a cardiologist

          -  Poorly controlled hypertension despite anti-hypertensive medications

          -  Patients with clinical or laboratory evidence of liver disease will need to be
             evaluated for the cause of the liver disease, its clinical severity in terms of liver
             function and the degree of portal hypertension; patients will be excluded if they are
             found to have: fulminant liver failure, cirrhosis of the liver with evidence of
             portal hypertension, bridging fibrosis, alcoholic hepatitis, esophageal varices, a
             history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic
             synthetic dysfunction evidenced by prolongation of the prothrombin time, ascites
             related to portal hypertension, bacterial or fungal liver abscess, biliary
             obstruction, chronic viral hepatitis with total serum bilirubin &gt; 3mg/dl, or
             symptomatic biliary disease (Patients will be allowed on to the protocol with liver
             problems if gastroenterology approves the patient for HCT)

          -  Patients who are seropositive for human immunodeficiency virus (HIV)

          -  Females who are pregnant or breast-feeding

          -  Fertile men or women who are unwilling to use contraceptives during HCT and up to 12
             months post-treatment

          -  Patients with fungal pneumonia with radiological progression after receipt of
             amphotericin formulation or mold-active azoles for greater than 1 month will not be
             eligible for this protocol (either regimen A or B)

          -  Donors: Identical twin

          -  Donors: Pregnancy

          -  Donors: HIV seropositive

          -  Donors: A positive anti-donor cytotoxic cross match is absolute donor exclusion

          -  Donors: If a patient is homozygous at a particular loci, mismatching at that loci is
             not allowed due to an isolated graft rejection vector, i.e., patient A*0101 and the
             donor is A*0101, A*0201; such a mismatch may increase the risk of graft rejection; if
             patient and donor pairs are both homozygous at a mismatched loci, they are considered
             a two-HLA antigen mismatch, i.e., the patient is A*0101 and the donor is A*0201, and
             this type of mismatch is not allowed

          -  Donor: Donor &lt; 6 months old, &gt; 75 years old
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  54 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients must fulfill one of the following criteria:

          -  T4 NO MO - Deep primary melanoma (&gt; 4.0 mm) with or without lymphadenectomy.

          -  T1-4 N1-3 MO - Primary melanoma with regional lymph node metastases found at
             lymphadenectomy or sentinel lymph node sampling, but clinically undetectable
             (occult).

          -  T1-4 N1-3 MO - Primary melanoma with clinically apparent (overt) regional lymph node
             metastases confirmed by lymphadenectomy.

          -  T1-4 N1-3 MO - Recurrence of melanoma at the proximal regional lymph node(s).

          -  Patients must have undergone a wide excision of the primary and, if &gt;1mm in depth,
             have completed sentinel lymph node sampling or lymphadenectomy as is standard of
             practice.  Patients must have confirmation of adequate surgical margins around the
             primary lesion (1 or 2 cm minimum, for primary lesions of 1-2 mm depth; 2 cm for
             primary lesions equal to or greater than 2 mm depth). When entering this study with
             recurrent regional lymph node disease, the patient must be enrolled no later than 90
             days from the date of lymphadenectomy.

          -  For subungual melanomas a distal interphalangeal. amputation is required.  For
             patients with regional lymph node recurrence, the same evidence for adequate margins
             around the primary are required as for patients at initial presentation.

          -  For safety reasons, patients must be of age between 18 and 85.

          -  Patients must have ECOG performance status 0-2.

          -  Patients must have WBC &gt;3,000, platelet count &gt;100,000, and hematocrit &gt;33.

          -  Patients must have SGOT and bilirubin &lt;2x normal; creatinine &lt;2.3; BUN &lt;33.

          -  Patients must have no active medical or psychiatric disorders requiring therapy that
             would prevent completion of the protocol.

          -  Patients must give written informed consent.

        Exclusion Criteria:

          -  Patients for whom histopathologic examination of the primary or metastatic
             melanoma is not positive are ineligible.

          -  Patients who have clinical, radiological, laboratory, or pathological evidence of
             incompletely resected melanoma or any distant metastatic disease are ineligible.

          -  Patients with an active second cancer (except in situ cervical cancer, or basal or
             squamous skin cancer) are ineligible.  Exceptions may be discussed with the principal
             investigator.

          -  Patients with organic brain syndrome or significant impairment of basal cognitive
             function or any psychiatric disorder that might preclude participation in the full
             protocol, are ineligible.

          -  Patients who have had prior adjuvant chemotherapy, immunotherapy, including
             preoperative infusion or perfusion therapy are ineligible.

          -  Patients with recurrent melanoma at regional lymph nodes must not have been
             previously entered into this study.

          -  Patients with more than one lymph node group involved are ineligible.

          -  Women of child bearing age who are not on adequate birth control are ineligible.

          -  Women who are pregnant or breast feeding are ineligible.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients must have histologic or cytologic verification of extra-ocular
             retinoblastoma; extra-ocular disease includes orbital disease, optic nerve
             involvement at the surgical margin, regional nodal disease, and/or overt distant
             metastatic disease (at sites such as bone, bone marrow, liver and/or the central
             nervous system); patients with trilateral retinoblastoma will also be included in
             this protocol

               -  Patients with a CNS lesion consistent with trilateral or stage 4b disease may be
                  enrolled without tissue confirmation if (1) unequivocal leptomeningeal disease
                  is present on brain or spine magnetic resonance imaging (MRI) scan and/or (2)
                  the primary tumor is at least 2 cm in diameter, predominantly solid, and
                  demonstrates enhancement on the post-gadolinium images; however, even in such
                  cases surgery should be given serious consideration

          -  Patients must have a performance status corresponding to Eastern Cooperative Oncology
             Group (ECOG) scores of 0, 1, or 2; use Karnofsky for patients &gt; 16 years of age and
             Lansky for patients =&lt; 16 years of age

          -  No prior chemotherapy or radiotherapy for the extra-ocular retinoblastoma may have
             been administered prior to entering this study; prior treatment (chemotherapy and/or
             radiation therapy) for intra-ocular retinoblastoma is permissible

          -  Peripheral absolute neutrophil count (ANC) &gt;= 750/uL

               -  If the ANC and/or platelet count are not adequate, but due to bone marrow
                  metastatic disease, these criteria will be waived

          -  Platelet count &gt;= 75,000/uL (transfusion independent)

               -  If the ANC and/or platelet count are not adequate, but due to bone marrow
                  metastatic disease, these criteria will be waived

          -  Creatinine clearance OR radioisotope glomerular filtration rate &gt;= 70 mL/min/1.73 m^2
             or a serum creatinine based on age/gender as follows:

               -  0.4 mg/dL (1 month to &lt; 6 months of age)

               -  0.5 mg/dL (6 months to &lt; 1 year of age)

               -  0.6 mg/dL (1 years to &lt; 2 years of age)

               -  0.8 mg/dL (2 years to &lt; 6 years of age)

               -  1.0 mg/dL (6 years to &lt; 10 years of age)

               -  1.2 mg/dL (10 years to &lt; 13 years of age)

               -  1.5 mg/dL (male) or 1.4 mg/dL (female) (13 years to &lt; 16 years of age)

               -  1.7 mg/dL (male) or 1.4 mg/dL (female) (&gt;= 16 years of age)

          -  Total bilirubin =&lt; 1.5 times upper limit of normal (ULN)

          -  Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or
             serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) &lt; 2.5 x
             upper limit of normal (ULN)

          -  All patients and/or their parents or legal guardians must sign a written informed
             consent

          -  All institutional, Food and Drug Administration (FDA), and National Cancer Institute
             (NCI) for human studies must be met
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  10 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA RECIPIENT:

        Under this protocol, cell recipients must fulfill all of the following characteristics and
        conditions:

        Greater than or equal to 18 years old

        Ability to sign informed consent

        For women of child-bearing potential, negative result on a serum or urine pregnancy test;
        in addition, men and women of childbearing potential must agree to practice abstinence or
        use two methods of birth control/contraception (condoms, diaphragm or cervical cap with
        spermicide, IUD, or hormonal-based contraception) for at least 4 weeks after each cell
        infusion

        Willingness to comply with study requirements and procedures including storage of blood
        for possible future use to study HIV/AIDS, related diseases, or the immune system

        Willingness to permit HLA testing

        Hematocrit greater than or equal to 27 percent, platelets greater than or equal to
        25,000/mm (3)

        No significant underlying cardiac, renal, or hepatic disease (Creatinine less than 2.0
        mg/dL; aspartate aminotransferase  (AST) and alanine aminotransferase (ALT) less than 150
        U/mL)

        HIV infection must be confirmed by ELISA and western blot if not previously documented,
        and patients must be under the care of a primary care physician.

        Viral load greater than 10,000 copies/mL on available optimized combination antiretroviral
        therapy, to include at least 3 drugs, one of which is a non-nucleoside reverse
        transcriptase inhibitor (NNRTI), integrase inhibitor, or protease inhibitor. Patients not
        on combination antiretroviral therapy will be eligible, but must be willing to resume
        combination antiretroviral therapy and to have had a viral load greater than 10,000
        copies/mL after at least 2 weeks of therapy.

        Failure or intolerance of at least two previous combination antiretroviral regimens.
        Failure will be defined as an HIV viral load greater than 400 copies/mL while taking a
        given regimen.

        Recipient must be taking appropriate prophylaxis for opportunistic infections, as per
        Public Health Service (PHS) guidelines, unless there is intolerance to available
        medications.

        Screening CD4+ cell count less than or equal to 200 cells/mm(3) obtained within 6 weeks
        prior to study entry.

        EXCLUSION CRITERIA FOR RECIPIENT:

        An individual will be ineligible to receive cells if one or more of the following
        conditions are present:

        Discordance with donor on antibody status of EBV, CMV, or HHV-8 if donor is antibody
        positive for EBV, CMV, or HHV-8.

        Malignancy requiring systemic therapy, or a history of  malignancy that required
        myelotoxic chemotherapy.

        Active untreated opportunistic infection that requires systemic therapy. Patients with
        opportunistic infections who have received greater than 2 weeks of therapy will be
        eligible.

        Is pregnant or breast feeding.

        Severe psychiatric disorder that would interfere with adherence to protocol requirements.
        Individuals who have a stable psychiatric condition may be eligible.

        Current use or a history of treatment with investigational agent(s) within 3 months of
        protocol enrollment. ARVs obtained through expanded access programs are permitted.

        Current use or a history of treatment with a systemic corticosteroid, immunosuppressive,
        or cytotoxic agent within 30 days of protocol enrollment.

        Any other medical condition for which the investigator believes cell transfer may be
        contraindicated.

        Ever been diagnosed with autoimmune vasculitis.

        INCLUSION CRITERIA DONOR:

        Donor eligibility criteria as specified by the FDA will be followed, except for HIV
        testing. All donors will be HIV positive as per protocol and as described in the IND
        application. Under this protocol, cell donors must fulfill all of the following
        characteristics and conditions:

        Greater than or equal to 18 years old.

        Ability to sign informed consent.

        For women of child-bearing potential, negative result on a serum or urine pregnancy test.

        Willingness to comply with study requirements and procedures including storage of blood
        for possible future use to study HIV/AIDS, related diseases, or the immune system.

        Willingness to permit HLA testing.

        Matched to at least one HLA-B allele of the potential recipient. The

        match will be at a two-digit resolution HLA allele level of typing or higher.

        Hematocrit greater than or equal to 30 percent, platelets greater than or equal to
        100,000/mm(3), white blood cells greater than or equal to 3.0 times 10(9)/L.

        No underlying cardiac, pulmonary, renal, or hepatic disease that would preclude patient
        from undergoing apheresis.

        HIV infection must be confirmed by ELISA and western blot if not previously on record, and
        patients must be under the care of a primary care physician.

        CD4+ cell count greater than or equal to 400 cells/mm(3) and HIV viral load less than 50
        copies/mL, with no recorded HIV viral load obtained after acute HIV infection greater than
        2,500 copies/mL. HIV viral loads obtained during acute HIV infection (within 6 months of
        the estimated date of seroconversion) will not be utilized for study

        inclusion/exclusion.

        HIV infection for greater than or equal to 7 years.

        Minimum wt of 110 lbs

        From 1980 through 1996, did not spend time that adds up to three (3) months or more in the
        United Kingdom.

        From 1980 to the present, did not spend time that adds up to five (5) years or more in
        Europe.

        From 1980 to the present, did not receive a blood transfusion in the United Kingdom.&lt; TAB&gt;
        &lt; TAB&gt;

        EXCLUSION CRITERIA FOR DONOR:

        An individual will be ineligible to donate cells if one or more of the following
        conditions are present:

        Ever having been diagnosed with any AIDS-defining illnesses

        Ever being on antiretroviral therapy other than one or two nucleotide reverse
        transcriptase inhibitor (NRTI) drugs; no NRTI therapy during the previous year

        Positive results on screening test for any of the following tests: HCV enzyme immunoassay
        (EIA) repeat reactive/ recombinant immunoblot (RIBA) confirmed, HBV/HCV NAT, HTLV-I/II
        antibodies, T.cruzi antibodies, HBsAg, or serologic test for syphilis (with positive
        confirmatory treponemal-based assay), unless the patient has received adequate therapy for
        syphilis. Donors with a positive West Nile Virus NAT are deferred for 120 days.

        Is pregnant or breast feeding

        HLA homozygous donor who is haplo-identical to recipient

        History of malignancy other than basal cell carcinoma of the skin, or in situ carcinoma of
        cervix or colon

        ALT or AST greater than 2 times the upper limit of normal

        Been diagnosed with malaria

        Been diagnosed with Chagas    disease

        Been diagnosed with babesiosis

        Received a dura mater (or brain covering) graft

        Been diagnosed with any neurological disease

        Relative had Creutzfeldt-Jakob disease

        Had a transplant or other medical procedure that involved being exposed to live cells,
        tissues, or organs from an animal

        Had a sexual partner or a member of the household have a transplant or other medical
        procedure that involved being exposed to live cells, tissues, or organs from an animal

        Severe psychiatric disorder that would interfere with adherence to protocol requirements.
        Individuals who have a stable psychiatric condition may be eligible.

        Current use or a history of treatment with investigational agent(s) within 3 months of
        protocol enrollment.

        Current use or a history of treatment with a systemic corticosteroid, immunosuppressive,
        or cytotoxic agent within 30 days of protocol enrollment.

        Any other medical condition for which the investigator believes apheresis may be
        contraindicated.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients diagnosed with prostate cancer.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Primary treatment at MD Anderson for prostate cancer using: radical retropubic
             prostatectomy, robotic prostatectomy, photon external beam radiation, photon external
             beam radiation with hormone therapy, proton radiation, radioisotopic implant,
             cryotherapy, or active surveillance.

          2. Neoadjuvant, concurrent and adjuvant androgen ablation in conjunction with photon
             external beam radiation is allowed if not greater than 6 months total duration.
             Hormone therapy will be given as an LHRH agonist with or without an antiandrogen.

          3. Pathologic diagnosis of prostate adenocarcinoma

          4. AJCC (VI) stage T1-T3b N0M0

          5. Ability to read, write, and fill out the self-survey questionnaires

          6. Patients may be simultaneously enrolled on other MD Anderson treatment or laboratory
             protocols. The EPIC Survey will be used for both this protocol and for protocol
             2007-0209 such that patients enrolled on both protocols will complete only one
             document at each survey point. Simultaneous enrollment on other survey protocols will
             be handled in a similar manner.

        Exclusion Criteria:

          1. Histology other than adenocarcinoma

          2. Stage T4, nodal or distant metastasis

          3. Prior treatment for prostate cancer except for neoadjuvant, concurrent and adjuvant
             androgen deprivation of 6 months or less duration in patients treated with photon
             radiation. Hormone therapy in all other modalities is not allowed.

          4. Chemotherapy or molecular targeting therapy as primary, neoadjuvant or adjuvant
             treatment

          5. Treatment for another pelvic malignancy, to include surgery or radiation

          6. Treatment for another malignancy with chemotherapy completed within one year or less
             of treatment for prostate cancer.

          7. Inflammatory bowel disease (eg. Crohn's or Ulcerative Colitis)

          8. Patients 18 years or younger.
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patient is, in the investigator's opinion, willing and able to comply with the
             protocol requirements.

          -  Patient has given voluntary written informed consent before performance of any
             study-related procedure not part of normal medical care, with the understanding that
             consent may be withdrawn by the patient at any time without prejudice to their future
             medical care.

          -  Age over 18 and under 67 years old.

          -  Patient diagnosed with symptomatic Multiple Myeloma based on standard criteria with
             bad prognosis. This factor is associated with at least one of the clinical
             alterations defined as follows:

        Patient who displayed a Monosomy of chromosome 13 or other adverse cytogenetic
        abnormality.

        Patient in first relapse. Patient with relapsed multiple myeloma after autologous
        transplantation.

          -  Patient has a ECOG performance status &lt;= 2.

          -  Patient has a life-expectancy &gt;3 months.

          -  Patients who are candidates for autologous transplantation.

          -  Patients must have HLA-identical sibling donors.

          -  Patient has the following laboratory values before Baseline visit:

        Platelet count  30000/mm3 (transfusion allowed), hemoglobin  8 g/dl (transfusion
        allowed) and absolute neutrophil count (ANC)  0.750/mm3. Lower values are accepted if
        they are caused by bone marrow infiltration.

        Aspartate transaminase (AST):  2.5 x the upper limit of normal. Alanine transaminase
        (ALT): ):  2.5 x the upper limit of normal. Total bilirubin:  1.5 x the upper limit of
        normal. Serum creatinine value  2mg/dl

        Exclusion Criteria:

          -  Patient present serious pathologies that make impossible chemotherapy treatments:

               1. Congestive heart failure, angina or heart attack during last 12 months.

               2. Uncontrolled arterial hypertension.

               3. Uncontrolled supraventricular arrhythmias during last 3 last months.

               4. Ventricular arrhythmia.

               5. Hepatic disease (Cirrhosis).

          -  Patient has  Grade 2 peripheral neuropathy within 14 days before enrollment.

          -  Patient with serious psychiatric disorders that make impossible comply satisfactorily
             with the protocol requirements.

          -  Personal medical history of neoplasia of other type, except:  carcinoma in situ,
             other curatively treated malignancy in complete remission for more than 10 years.

          -  Patient has hypersensitivity to bortezomib, boron or mannitol.

          -  Fertile patient is not going to use a medical effective contraceptive method during
             the trial.

          -  Patient has received other investigational drugs within 30 days before enrollment

          -  Patient is known to be seropositive for the human immunodeficiency virus (HIV),
             Hepatitis B surface antigen-positive or active hepatitis C infection.

          -  Patient had a myocardial infarction within 6 months of enrollment or has New York
             Heart Association (NYHA) Class III or IV, heart failure, uncontrolled angina, severe
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
             ischemia or active conduction system abnormalities.

          -  Patient is enrolled in another clinical research study and/or is receiving an
             investigational agent for any reason.

          -  Patient participated in clinical study VISTA.

          -  Pregnant or breast-feeding women.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  66 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria

          -  Male or female outpatient of  18 years of age or  country's legal age  for adult
             consent

          -  Dukes C colon cancer, high risk Dukes B colon cancer, Dukes B rectal cancer or Dukes
             C rectal cancer (see Appendix 1 for definition of High Risk Dukes B)

          -  Undergone complete resection of primary tumour

          -  Completed standard therapy ( at least 3 months of chemotherapy  radiotherapy )

          -  Within 120 days of completion of standard therapy (surgery, chemotherapy 
             radiotherapy)

          -  ECOG performance status 0 to 2

          -  Satisfactory haematological or biochemical functions (tests should be carried out
             within 8 weeks prior to randomisation): Results of clinical investigations carried
             out within 8 weeks prior to randomisation can be used in place of the required
             screening investigations. Patients with mild laboratory abnormalities can be included
             at the discretion by the site principal investigator,  and after approval by ASCOLT
             Trial Management Group

          -  ANC  1.0 x 109/L

          -  Platelets  100 x 109/L

          -  Creatinine clearance  30 mL/min

          -  Total bilirubin  2.0 x the upper limit normal

          -  AST &amp; ALT  5 x the upper limit normal

          -  Completed the following investigations

          -  Colonoscopy(or CT colonogram(within 16 months prior to randomization)

          -  Imaging of abdomen (CT or CT colonogram or MRI or PET or Ultrasound) within 16 months
             prior to randomization

          -  Written informed consent

        Exclusion Criteria

          -  Pre-existing Familial adenomatous polyposis, inflammatory bowel disease or ulcerative
             colitis

          -  Active gastritis or active peptic ulcer

          -  History of continuous daily use of PPI more than 1 year prior to consent

          -  Gastrointestinal bleeding within the past one year

          -  Haemorrhagic diathesis (i.e. haemophilia)

          -  Uncontrolled hypertension (untreated systolic blood pressure &gt; 160 mmHg, or diastolic
             blood pressure &gt; 95 mmHg)

          -  History of recent cancers (except for colorectal cancers, non-melanoma skin cancers,
             basal cell carcinomas, squamous cell carcinomas) in the past 5 years

          -  History of stroke, coronary arterial disease, angina, or vascular disease

          -  Patients who are on current long term treatment ( 4 consecutive weeks) with Aspirin,
             NSAID or Cox-2 inhibitors

          -  History of erosive GERD or active erosive GERD on gastroscopy.

          -  Patient on active current treatment of antiplatelet agents (i.e. off-study Aspirin,
             clopidogrel, ticlopidine)

          -  Patient receiving active treatment of anticoagulants (i.e. warfarin, low molecular
             weight heparins)

          -  Pregnant, lactating, or not using adequate contraception

          -  Patient having known allergy to NSAID or Aspirin

          -  Unexplained rise of CEA (i.e. smoker with elevated CEA will not be excluded)

          -  Patient on other investigational drug

          -  Patients with HNPCC (Lynch Syndrome)
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Recipients age 18 or older of an HLA-non-identical,living or deceased donor kidney
             transplant.

          -  A willing renal donor who consents for subsequent donation of donor blood for testing
             throughout the follow-up period and for use of his/her kidney in this experimental
             study.

        Exclusion Criteria:

          -  Immunosuppressive drug therapy within 1 year prior to enrollment.

          -  Active malignancy or history of malignancy within 5 years of enrollment.

          -  Any history of blood malignancy or lymphoma.

          -  Any known immunodeficiency syndrome, including HIV infection.

          -  Absence of EBV or CMV specific antibodies in cases with evidence of EBV and/or CMV
             infection.

          -  Women of child-bearing potential unwilling or unable to use an acceptable method of
             birth control.

          -  Women who are pregnant or breastfeeding at the time of enrollment or study drug
             administration.

          -  Donor age &lt;18 years.

          -  Subjects with protocol-specific etiologies of underlying renal disease.

          -  Subjects with a positive T-cell lymphocytic crossmatch or historical evidence of
             donor specific alloantibody by solid phase or flow-based detection methods.

          -  Prior solid organ transplant or potential to require a concurrent organ or cell
             transplant.

          -  Positive Hepatitis B or C antibodies and PCR positive for the same.

          -  Active (tuberculosis) TB requiring treatment within the previous 3 years.

          -  Known positive PPD unless chest x-ray is negative or treatment for latent TB has been
             completed.

          -  Active infection or other contraindications.

          -  History of drug or alcohol abuse within the past 5 years.

          -  Psychotic disorders which would interfere with adequate study follow-up.

          -  Active peptic ulcer disease, chronic diarrhea, or gastric malabsorption.

          -  All women 40 years or older with first degree family history of breast cancer will be
             required to have a screening mammogram within 6 months of study enrollment.

          -  Subjects with suspicion of breast malignancy which cannot be ruled out will be
             excluded.

          -  Belatacept use within 30 days prior to the day 1 visit.

          -  Prisoners or individuals who are involuntarily incarcerated.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients must have histologic diagnosis of ovarian epithelial carcinoma, peritoneal
             primary or fallopian tube carcinoma, which is now recurrent

          -  The following histologic epithelial cell types are eligible:

               -  Serous adenocarcinoma

               -  Endometrioid adenocarcinoma

               -  Mucinous adenocarcinoma

               -  Undifferentiated carcinoma

               -  Clear cell adenocarcinoma

               -  Mixed epithelial carcinoma

               -  Transitional cell carcinoma

               -  Malignant Brenner Tumor

               -  Adenocarcinoma not otherwise specified

          -  Patients must have had a complete response to front-line platinum-taxane therapy (at
             least 3 cycles) and a treatment-free interval without clinical evidence of
             progressive disease lasting at least 6 months

               -  A complete response to front-line chemotherapy must include the following:

                    -  Negative physical exam

                    -  Negative pelvic exam

                    -  Normalization of CA125, if elevated at baseline

                    -  Negative radiographic assessment of disease

               -  All patients must have also had a treatment-free interval without clinical
                  evidence of progressive disease of at least 6 months from completion of
                  front-line chemotherapy (both platinum and taxane); front-line therapy may have
                  included a biologic agent

               -  Front-line treatment may include maintenance therapy following complete clinical
                  or pathological response; however, maintenance cytotoxic chemotherapy must be
                  discontinued for a minimum of 6 months prior to documentation of recurrent
                  disease; patients receiving maintenance biological therapy or hormonal therapy
                  are ELIGIBLE provided their recurrence is documented more than 6 months from
                  primary cytotoxic chemotherapy completion (includes maintenance chemotherapy)
                  AND a minimum 4 weeks has elapsed since their last infusion of biological
                  therapy

          -  Patients must have clinically evident recurrent disease for the purpose of this
             study,

               -  Measurable disease (RECIST) is defined as at least one lesion that can be
                  accurately measured in at least one dimension (longest dimension to be
                  recorded); each lesion must be more than or equal to 20 mm when measured by
                  conventional techniques, MRI or CT, or more than or equal to 10 mm when measured
                  by spiral CT

          -  Absolute neutrophil count (ANC) &gt;= 1,500/mm^3 equivalent to Common Toxicity Criteria
             for Adverse Events v3.0 (CTCAE) Grade1

          -  Platelet count &gt;= 100,000/mm^3 (Common Terminology Criteria for Adverse Events
             [CTCAE] Grade 0-1)

          -  Creatinine (non-isotope dilution mass spectrometry [IDMS]) =&lt; 1.5 times upper limit
             of normal (ULN)

          -  Total bilirubin =&lt; 1.5 times ULN

          -  Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) =&lt;
             2.5 times ULN (&lt; 5.0 times ULN in the presence of liver metastasis)

          -  Alkaline phosphatase =&lt; 2.5 times ULN (&lt; 5.0 times ULN in the presence of liver
             metastasis)

          -  Patients must have a urine protein-to-creatinine ratio (UPCR) &lt; 1.0 mg/dL

          -  Patients who are not candidates for surgical cytoreduction are eligible for the
             chemotherapy randomization; patients are not considered candidates for surgical
             cytoreduction if complete cytoreduction in the estimation of the investigator is
             impossible or a medical infirmity precludes exploration and debulking

          -  Patients must have signed an approved informed consent and authorization permitting
             release of personal health information

          -  Gynecologic Oncology Group (GOG) performance status of 0, 1, or 2

        Exclusion Criteria:

          -  Patients who have more than one previous regimen of chemotherapy (maintenance therapy
             is not considered a second regimen)

          -  Patients receiving concurrent immunotherapy, or radiotherapy

          -  Patients who have received prior radiotherapy to any portion of the abdominal cavity
             or pelvis are excluded

          -  Patients whom have already undergone secondary cytoreduction for recurrent disease
             are excluded

          -  Patients with a prior histologic diagnosis of borderline, low malignant potential
             (grade 0) epithelial carcinoma that was surgically resected and who subsequently
             developed an unrelated, new invasive epithelial ovarian or peritoneal primary cancer
             are eligible provided they meet the inclusion criteria above

          -  Patients who require parenteral hydration or nutrition and have evidence of partial
             bowel obstruction or perforation

          -  Patients with synchronous primary endometrial cancer, or a past history of primary
             endometrial cancer are excluded, unless all of the following conditions are met:

               -  Stage not greater than I-B;

               -  No more than superficial myometrial invasion, without vascular or lymphatic
                  invasion;

               -  No poorly differentiated subtypes, including papillary serous, clear cell or
                  other International Federation of Gynecology and Obstetrics (FIGO) Grade 3
                  lesions

          -  Patients with uncontrolled infection

          -  Patients with concurrent severe medical problems unrelated to the malignancy that
             would significantly limit full compliance with the study or expose the patient to
             extreme risk or decreased life expectancy

          -  Patients with peripheral neuropathy &gt;= grade 2

          -  Patients with a history of allergic reactions to carboplatin and/or paclitaxel or
             chemically similar compounds; patients with allergic (hypersensitivity) reactions  to
             these chemotherapeutic agents are NOT excluded IF they were successfully  retreated
             following a desensitization program or protocol

          -  Patients with known hypersensitivity to Chinese hamster ovary cell products or other
             recombinant human or humanized antibodies

          -  Patients of childbearing potential, not practicing adequate contraception, patients
             who are pregnant or patients who are nursing are not eligible for this trial; to
             date, no fetal studies in animal or humans have been performed; the possibility of
             harm to a fetus is likely; bevacizumab specifically inhibits VEGF, which is
             responsible for the formation of new blood vessels during development, and antibodies
             can cross the placenta; therefore, bevacizumab should not be administered to pregnant
             women; in addition, there are unknown immediate and long-term consequences of
             chemotherapy administration to these women; in addition, surgical exploration as
             mandated by randomization during pregnancy may cause imminent mortal consequences;
             further, it is not known whether bevacizumab is excreted in human milk; because many
             drugs are excreted in human milk, bevacizumab should not be administered to nursing
             women; subjects will be apprised of the large potential risk to a developing fetus

          -  Patients with other invasive malignancies, with the exception of nonmelanoma skin
             cancer, or patients who had (or have) any evidence of the other cancer present within
             the past 5 years or whose previous cancer treatment contraindicates this protocol
             therapy

          -  Patients with active bleeding or pathologic conditions that carry high risk of
             bleeding such as a known bleeding disorder, coagulopathy, or tumor involving major
             vessels

          -  Patients with a history or evidence upon physical examination of central nervous
             system (CNS) disease, including primary brain tumor, seizures not controlled with
             standard medical therapy, any brain metastases, or a history of stroke within the
             past  5 years of the first date of treatment on this study

          -  Patients with clinically significant cardiovascular disease including any of the
             following:

               -  Significant cardiac conduction abnormalities (e.g., PR interval &gt; 0.24 sec or
                  2nd or 3rd degree atrioventricular [AV] block )

               -  Uncontrolled hypertension, defined as systolic blood pressure (BP) &gt; 150 mm Hg
                  or diastolic BP &gt; 90 mm Hg

               -  Myocardial infarction, cardiac arrhythmia, or unstable angina within the past 6
                  months

               -  New York Heart Association (NYHA) grade II or greater congestive heart failure

               -  Serious cardiac arrhythmia requiring medication

               -  Grade II or greater peripheral vascular disease except  episodes of ischemia &lt;
                  24 hrs in duration that are managed non-surgically and without permanent deficit

               -  History of cerebrovascular accident (CVA) within the past 6 months

          -  Patients who have had a major surgical procedure, open biopsy, dental extractions or
             other dental surgery/procedure that results in an open wound, or significant
             traumatic injury within 28 days prior to the first date of treatment on this study,
             or anticipation of need for major surgical procedure during the course  of the study;
             patients with placement of vascular access device or core biopsy within 7 days prior
             to the first date of treatment on this study:

               -  Patients undergoing pre-treatment secondary cytoreduction will undergo therapy
                  with bevacizumab on cycle 2

               -  Patients undergoing pre-treatment surgery for purposes other than cytoreduction
                  may also participate provided they meet eligibility; patients randomized to arms
                  containing bevacizumab must wait a minimum of 28 days since that procedure to
                  begin protocol treatment; patients who undergo an uncomplicated port placement
                  must wait a minimum of 7 days to begin protocol treatment
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Families who have a child or adult with pleuropulmonary blastoma or cystic nephroma are
        invited to participate.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  child or adult diagnosed with pleuropulmonary blastoma or cystic nephroma.

        Exclusion Criteria:

          -  child or adult who does not have a confirmed diagnosis of pleuropulmonary blastoma or
             cystic nephroma.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  95 Years
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:(transplant recipient)

          -  Patients less than or equal to 21 years of age; may be greater than 21 years old if a
             current St. Jude patient or previously treated St. Jude patient within 3 years of
             completion of prior treatment.

          -  Must have one of the following diagnosis:

               -  ALL high risk in second remission.  Examples include relapse on therapy, first
                  remission duration of less than or equal to 30 months, or relapse within 12
                  months of completing therapy.

               -  ALL in third or subsequent remission.

               -  ALL high risk in first remission.  Examples include:  induction failure, minimal
                  residual disease greater than or equal to 1% marrow blasts by morphology after
                  induction, persistent or recurrent cytogenetic or molecular evidence of disease
                  during therapy requiring additional therapy after induction to achieve
                  remission.

               -  High-risk AML in first remission.  Examples include monosomy 7, M6, M7, t(6;9),
                  FLT3-ITD, or patients who have greater than or equal to  25% blasts by
                  morphology after induction or who do not achieve CR after 2 courses of therapy.

               -  Relapsed or persistent AML (less than or equal to 25% blasts in marrow by
                  morphology).

               -  AML in second or subsequent morphologic remission.

               -  CML in first chronic phase with detectable molecular or cytogenetic evidence of
                  disease despite medical therapy; or CML with a history of accelerated or blast
                  crisis, now in chronic phase; or unable to tolerate tyrosine kinase inhibitor
                  therapy.

               -  Juvenile myelomonocytic leukemia (JMML).

               -  Myelodysplastic syndrome (MDS).

               -  Therapy related (secondary) AML, ALL, or MDS.

               -  Hodgkin lymphoma in second or subsequent complete remission (CR) after prior
                  autologous HSCT transplant or will be unable to have hematopoietic stem cells
                  collected for autologous HSCT.

               -  Non-Hodgkin lymphoma (NHL) in second or subsequent CR after prior autologous
                  HSCT or unable to have stem cells collected for autologous HSCT.

          -  Has not received a prior allogeneic hematopoietic stem cell transplant.

          -  Does not have a suitable HLA-matched sibling donor available for stem cell donation.

          -  Does not have a suitable cord blood product or volunteer matched unrelated donor
             (MUD) available in the necessary time for stem cell donation.

          -  Has a suitable HLA partially matched family member available for stem cell donation.

          -  Cardiac shortening fraction greater than or equal to 25%.

          -  Creatinine clearance or glomerular filtration rate (GFR) greater than or equal to 40
             ml/min/1.73 m^2.

          -  Forced vital capacity (FVC) greater than or equal to 40% of predicted value or a
             pulse oximetry value of greater than or equal to 92% on room air.

          -  Direct bilirubin less than or equal to 3 mg/dl.

          -  Age-dependent performance score of greater than or equal to 50.

          -  Serum glutamic pyruvic transaminase (SGPT) less than 3 times the upper limit of
             normal for age.

          -  Karnofsky or Lansky (age-dependent) performance score of greater than or equal to 50.

          -  No known allergy to murine products or human anti-mouse antibody (HAMA) results
             within normal limits.

          -  Not pregnant (confirmed by negative serum or urine pregnancy test within 14 days
             prior to enrollment).

          -  Not breast feeding.

        Inclusion criteria (stem cell donor):

          -  Partially HLA matched family member.

          -  At least 18 years of age.

          -  Human immunodeficiency virus (HIV) negative.

          -  Not pregnant (confirmed by negative serum or urine pregnancy test within 7 days prior
             to enrollment).

          -  Not breast feeding.

        Inclusion criteria (transplant recipient - stem cell boost)

        Has experienced one of the following disorders post-transplant:

          -  graft failure

          -  graft rejection

          -  delayed hematopoietic and/or immune reconstitution.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  21 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Adenocarcinoma of the prostate treated primarily with radical prostatectomy

               -  Pathologically proven to be lymph node-negative by pelvic lymphadenectomy (N0)
                  or lymph node status pathologically unknown (Nx [undissected pelvic lymph nodes
                  because lymph node dissection is not required])

               -  Any type of radical prostatectomy allowed, including retropubic, perineal,
                  laparoscopic, or robotically assisted

               -  Meets 1 of the following pathologic classifications:

                    -  T3 N0/Nx disease with or without positive prostatectomy margins

                    -  T2 N0/Nx disease with or without positive prostatectomy margins

               -  N1 patients are ineligible, as are those with pelvic lymph node enlargement 
                  1.5 cm in greatest dimension by CT scan or MRI of the pelvis, unless the
                  enlarged lymph node is negative

               -  Prostatectomy Gleason score of 9 or less

          -  A post-radical prostatectomy entry PSA of  0.1 and  1.0 ng/mL at least 6 weeks
             after prostatectomy and within 30 days of registration

          -  Serum total testosterone  40% of the lower limit of normal (patients who have had a
             unilateral orchiectomy are eligible as long as this requirement is met)

          -  No distant metastases based on history/physical examination, CT scan or MRI of the
             abdomen and pelvis, and bone scan

          -  No palpable prostatic fossa abnormality/mass suggestive of recurrence, unless shown
             by biopsy under ultrasound guidance not to contain cancer

        PATIENT CHARACTERISTICS:

          -  Zubrod performance status 0-1

          -  Platelets  100,000/mm^3

          -  Hemoglobin  10.0 g/dL (the use of transfusion or other intervention to achieve this
             is allowed)

          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &lt; 2 x upper limit
             of normal

          -  No prior invasive malignancy (except nonmelanoma skin cancer) or superficial bladder
             cancer unless disease free for a minimum of 5 years (e.g., carcinoma in situ of the
             oral cavity is permissible)

          -  No severe, active co-morbidity, including any of the following:

               -  History of inflammatory bowel disease

               -  History of hepatitis B or C

               -  Unstable angina and/or congestive heart failure requiring hospitalization within
                  the past 6 months

               -  Transmural myocardial infarction within the past 6 months

               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the
                  time of registration

               -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness
                  requiring hospitalization or precluding study therapy at the time of
                  registration

               -  Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects

               -  Acquired immune deficiency syndrome (AIDS) based upon current Centers for
                  Disease Control (CDC) definition

                    -  HIV testing is not required for entry

          -  No prior allergic reaction to the study drug(s) involved in this protocol

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  More than 5 years since prior chemotherapy for any other disease site

          -  No androgen-deprivation therapy started prior to prostatectomy for &gt; 6 months
             duration

               -  The use of finasteride or dutasteride ( tamsulosin) for longer periods prior to
                  prostatectomy is acceptable

          -  No androgen-deprivation therapy started after prostatectomy and prior to registration

               -  The use of finasteride or dutasteride ( tamsulosin) after prostatectomy is not
                  acceptable, it must be stopped within 3 months after prostatectomy

          -  No neoadjuvant chemotherapy before or after prostatectomy

          -  No prior cryosurgery or brachytherapy of the prostate (prostatectomy should be the
             primary treatment and not a salvage procedure)

          -  No prior pelvic radiotherapy
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Patients who will undergo IVU using digital tomosynthesis and staging abdomino-pelvic
             CT as part of their routine care, will be invited to participate in this study.

          2. Patients who have been referred for CTU will also be invited to participate in the
             study.

          3. Patients who have histologically proven transitional cell carcinomas (TCC); or

          4. Patients who have bladder tumors of Stage &gt;/= T3; or

          5. Patients who have had cystectomies for bladder cancer; or

          6. Patients who have upper tract TCC.

          7. Patients who are &gt; 18 years of age.

          8. Written informed consent will be obtained from patients.

        Exclusion Criteria:

          1. Elevated serum creatinine of &gt;2.

          2. Allergy to intravenous CT contrast media.

          3. Ureteral stint present or removed within six weeks

          4. Women of child bearing potential.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients with advanced stage NSCLC who are either newly diagnosed, or who have evidence of
        disease progression.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:Inclusion Criteria:Inclusion Criteria (Cases):

          1. Advanced stage (IIIB with malignant effusion or IV) histologically or cytologically
             confirmed NSCLC

          2. Patients must be newly diagnosed (untreated) or have evidence of disease progression
             at the time of sample collection

          3. ability to sign informed consent

          4. at least 18 years of age

        Inclusion Criteria (Controls):

          1. no known prior or active malignancy

          2. ability to sign informed consent

          3. at least 18 years of age Exclusion Criteria:1. history of any other cancer other than
             non-melanoma skin cancer within the last 5 years

        Exclusion Criteria:1. history of any other cancer other than non-melanoma skin cancer
        within the last 5 years

        2. pregnant women
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Cases will be identified from clinic patient medical records and linked to pathology
        reports. The surgical pathology record number will thus be obtained and used to retrieve
        the archival blocks and slides. In addition, all these participants will be clinical
        patients of the Protocol Director, thus the Physician will always be familiar with the
        participants.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Patient must be over the age of 18.

          2. Patients must have benign and malignant breast and thyroid cancer.

          3. Patient mus sign consent form.

        Exclusion Criteria:

        1. No children will be allowed.
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Newly diagnosed patients with head and neck cancer
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:Newly diagnosed patients with head and neck cancer who has tumor
        accessible to tumor oxygenation measurement with a microelectrode.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Children (ages 2-17 years)
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  males and females

          -  greater than or equal to 2 years and less than or equal to 17 years at enrollment

          -  diagnosis of atopic dermatitis (confirmed by treating physician)

          -  applied pimecrolimus cream 1 % 6 weeks out of past 24 weeks

        Exclusion Criteria:

          -  past or present history of systemic malignancy, skin malignancy, or
             lymphoproliferative disease

          -  past or present use of oral immunosuppressive therapy
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  2 Years
 </minimum_age>
 <maximum_age>
  17 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients must have histologically documented AML, ALL, MDS, CML,

          -  Identification of haploidentical donor

          -  LVEF &gt; 45% corrected

          -  DLCO &gt; 50% predicted

          -  Serum Creatinine &lt;= 2 mg/dL

          -  Bilirubin &lt; 2 x ULN

          -  AST, ALT &lt; 2 x ULN

          -  Age  65 years

          -  Performance Status 0-1

        Exclusion Criteria:

          -  Patients relapsing &lt;6 months after autologous SCT are not eligible.

          -  Patients with active infections requiring oral or intravenous antibiotics are not
             eligible for enrollment until resolution of infection

          -  No HIV disease

          -  Non-pregnant and non-nursing
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  65 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)

               -  Recurrent, refractory, or metastatic disease after  1 prior first-line regimen
                  (chemotherapy or radiotherapy)

          -  Documented EGFR-positive disease (any expression level) by immunohistochemistry (IHC)
             (may be based on archival sample)

          -  Measurable or evaluable disease by radiograph, CT scan, MRI, and/or physical exam

          -  Appropriate slides of the primary lesion must be available for review of IHC staining
             assessment by a central pathology team

          -  No clinical evidence of active brain metastases

               -  Patients with brain metastases are eligible provide they have received
                  definitive radiotherapy or chemotherapy and/or have undergone surgical resection
                  for brain metastases

          -  No prior hematological malignancy

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status (PS) 60-100% OR ECOG PS 0-2

          -  Life expectancy  3 months

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Granulocytes  1,000/mm^3

          -  Platelet count  50,000/mm^3

          -  Hemoglobin  8 g/dL

          -  BUN  2.0 times normal

          -  Serum creatinine  2.0 mg/dL

          -  Bilirubin  1.5 times normal

          -  SGOT  1.5 times normal (with or without liver metastases)

          -  Hepatitis B surface antigen and HIV negative

          -  LVEF  45 % at rest (by MUGA)

               -  No evidence of depressed left ventricular function

          -  FEV_1, DLCO, and FVC  50% of the predicted value

          -  No other malignancy, except for the following:

               -  History of curatively treated in situ squamous cell carcinoma or basal cell
                  carcinoma of the skin

               -  History of other curatively treated malignancy (except those with a hematologic
                  origin) for which the patient has remained in complete remission &gt; 5 years after
                  completing therapy (as documented by history, physical exams, tumor markers, and
                  radiology scanning)

          -  No serious medical or psychiatric illness that would preclude giving informed consent
             or receiving intensive treatment

          -  No recent myocardial infarction (within the past year)

          -  No current angina/coronary symptoms requiring medications

          -  No clinical evidence of congestive heart failure requiring medical management
             (irrespective of MUGA results)

          -  No systolic blood pressure (BP)  130 mm Hg or diastolic BP  80 mm Hg

               -  Patients with elevated BP must have it controlled by anti-hypertensive
                  medications for at least 7 days prior to the first infusion

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  More than 4 weeks since prior chemotherapy or radiotherapy

          -  At least 4 weeks since prior cetuximab or small molecule EGFR-inhibitors including,
             but not limited to, gefitinib or erlotinib hydrochloride

          -  No concurrent radiotherapy

          -  No concurrent steroids except for treatment of adrenal failure, septic shock, or
             pulmonary toxicity or hormones for non-disease-related conditions (e.g., insulin for
             diabetes)
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  All subjects must be female.

          -  Postmenopausal status, defined as any one of the following criteria:

               -  Documented history of bilateral oophorectomy.

               -  Age 60 years or more.

               -  Age 45 to 59 and satisfying one or more of the following criteria:

                    -  Amenorrhea for at least 12 months and intact uterus.

                    -  Amenorrhea for less than 12 months and a follicle stimulating hormone (FSH)
                       and estradiol concentration within postmenopausal range including: patients
                       who have had a hysterectomy and patients who have received hormone
                       replacement.

          -  Patients must have histologically confirmed invasive breast cancer with a primary
             tumor of 3 cm or more in greatest dimension as measured by clinical examination.

          -  Estrogen receptor and/or progesterone receptor positive disease.

          -  Patients must not have received any prior treatment for current or newly diagnosed
             breast cancer.

          -  Patients must have not received previous treatment with any of the study medications
             or similar drugs.

          -  No use of selective estrogen receptor modulators (SERM) such as raloxifene or similar
             agents in the past 2 years.

          -  WHO performance status of 0, 1, or 2.

          -  Adequate organ function defined as follows:

               -  Adequate renal function, defined by a serum creatinine within 3 times the upper
                  limits of normal.

               -  Adequate liver function, defined by total bilirubin, AST, ALT, and alkaline
                  phosphatase within 3 times the upper limits of normal.

               -  Adequate bone marrow function, defined as a WBC greater than 3.0 ml, PLT greater
                  than 75,000/ul, Hb greater than 9 gm/l.

          -  Willing to undergo breast core biopsies as required by the study protocol.   -
             Ability to understand and sign a written informed consent for participation in the
             trial.

          -  Life expectancy of at least 1 year.

        Exclusion Criteria:

          -  Premenopausal status.

          -  Other coexisting malignancies with the exception of basal cell carcinoma or cervical
             cancer in situ.

          -  Patients with brain metastasis.

          -  WHO performance status of 3 or 4.

          -  Is judged by the investigator, uncontrolled intercurrent illness including, but not
             limited to, ongoing or active infection, symptomatic congestive heart failure,
             unstable angina pectoris, significant cardiac arrhythmia, or psychiatric
             illness/social situations that would limit compliance with study requirements.

          -  Evidence of any other significant clinical disorder or laboratory finding that makes
             it undesirable for the subject to participate in the clinical trial.   - Concurrent
             treatment with estrogens or progestins. Patients must stop these drugs at least two
             weeks prior to study entry.

          -  Treatment with a non-approved or investigational drug within 30 days before Day 1 of
             study treatment.

          -  Platelet count less than 75,000.

          -  In the opinion of the investigator, bleeding diathesis or anticoagulation therapy
             that would preclude intramuscular injections.

          -  History of hypersensitivity to castor oil.

          -  Any evidence of clinically active interstitial lung disease (patients with chronic
             stable radiographic changes who are asymptomatic need not be excluded)   - Patients
             with recurrent breast cancer.

          -  Patients with contralateral second primary breast cancers are eligible.
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Patients with oral squamous cell carcinoma measuring 1 to 3 cm at the primary site

          -  No clinical or preoperative imaging evidence of nodal involvement in the neck (N0)

          -  Surgery is the primary mode of treatment

               -  Dose not need reconstruction that necessitates opening the neck, as assessed by
                  the surgeon

          -  No cancer of the lip

          -  No prior head and neck tumor

        PATIENT CHARACTERISTICS:

          -  No technical, medical, or anaesthetic difficulties that preclude patients being
             entered into one of the trial arms

          -  Not considered to be medically, socially, or psychiatrically unfit for surgery as
             first-line treatment by the multidisciplinary team

          -  No other synchronous tumor

          -  No preference for non-surgical treatment

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  16 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Samples will be studied in the laboratory and in experimental animal models. These
        analyses and animal models may help to better understand multiple myeloma and to better
        select the appropriate treatment for all participants with multiple myeloma.
  </textblock>
 </study_pop>
 <sampling_method>
  Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Any subject evaluated for a MIRT protocol

        Exclusion Criteria:

          -  Subjects who have not been evaluated for a MIRT protocol
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  18-100 years old

          -  Not pregnant or breastfeeding

          -  Breast cancer requiring lymph node evaluation for the ipsilateral or contralateral
             breast OR prophylactic mastectomy

          -  Willing participation following an informed consent process

        Exclusion Criteria:

          -  Patient &lt; 18 y/o or &gt; 100 y/o

          -  Pregnant or breastfeeding

          -  If a pregnant female should be diagnosed with breast cancer an exception would be
             considered on a case to case basis.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients must have a diagnosis of Philadelphia chromosome positive (Ph+) chronic
             myeloid leukemia in chronic phase by having met all of the following criteria at the
             time of their initial diagnosis:

          -  Cytogenetic confirmation of Philadelphia chromosome or variants of the t(9;22)
             translocations. Patients may have secondary chromosomal abnormalities in addition to
             the Philadelphia chromosome.

          -  Peripheral blood or bone marrow blast count &lt; 10%.

          -  Peripheral blood basophil count &lt; 20%.

          -  Platelet count  100,000 x 109/L.

          -  If the peripheral blood counts are unavailable from the time of their original
             diagnosis, but there is no evidence of accelerated- or blast-phase disease from prior
             clinical or other medical records, then they will be allowed to participate.

          -  Patients must be eighteen years of age or older.

          -  Patients must be actively receiving treatment for their CML with a a tyrosine kinase
             inhibitor, either imatinib or nilotinib.

          -  Patients may be receiving imatinib mesylate. Patients must be on imatinib mesylate
             for a minimum of 2 years, and be on a stable dose for at least one consecutive year
             leading up to enrollment.

          -  Patients may be receiving nilotinib (Tasigna) as frontline therapy or as second line
             therapy if the reason for the switch from imatinib to nilotinib was intolerance to
             imatinib. Patients cannot have been switched from imatinib to nilotinib because of a
             concern or demonstration for resistance to frontline imatinib. Patients must be on
             nilotinib for a minimum of 2 years, and be on a stable does for at least one
             consecutive year leading up to enrollment.

          -  Patients must have an ongoing complete hematologic response (CHR) on a a TKI
             (imatinib or nilotinib), defined as follows:

          -  WBC  10 x 109/L.

          -  Platelet count &lt; 450,000 x 109/L.

          -  No blasts or promyelocytes in peripheral blood.

          -  No evidence of disease-related symptoms and extramedullary disease, including the
             liver and spleen.

          -  Patients must have a complete cytogenetic response (CCyR) on  a TKI (imatinib or
             nilotinib) for a minimum of 1 year leading up to enrollment. Complete cytogenetic
             response is defined as 0% Ph+ cells in metaphase, in the bone marrow and/or a
             negative peripheral blood FISH analysis for the Bcr-Abl  gene fusion, and an ongoing
             CCyR must be confirmed by bone marrow aspirate cytogenetics and/or peripheral blood
             FISH for Bcr-Abl within 4 weeks of starting treatment.

          -  Patients may have a negative quantitative RT-PCR (qPCR) for BCR-ABL at the time of
             enrollment, but if the qPCR is positive, patients cannot have greater than 1% bcr-ABl
             / Abl /ABL transcript, present in 2 consecutive qPCR analyses, performed at least 3
             months apart, in the 6 to 12 months leading up to enrollment.

          -  Patients must have an ECOG performance status of 0-2 (Appendix 13.1).

          -  All patients must be informed of the investigational nature of this study and
             standard alternative therapy.  All patients must sign and give written informed
             consent in accordance with institutional and federal guidelines.

        Exclusion Criteria:

          -  Patients who have had prior progression of their CML to accelerated phase or blast
             crisis.

          -  Patients who have previously undergone hematopoietic stem cell transplantation.

          -  Patients who have previously been treated with interferon-.

          -  Patients with an absolute neutrophil count (ANC) &lt; 1500/mm3 and/or a platelet count &lt;
             100,000/mm3.

          -  Patients with serum bilirubin, SGOT[AST], SGPT[ALT], or serum creatinine &gt; 1.5 x the
             upper limit of normal (ULN).

          -  Patients with an INR or PTT &gt; 1.5 x ULN, with the exception of patients on treatment
             with oral anticoagulants.

          -  Patients with uncontrolled medical diseases such as diabetes mellitus,
             neuropsychiatric disorders, infection, angina, severe hypertension, pulmonary disease
             (chronic obstructive pulmonary disease [COPD] with hypoxemia), major organ
             malfunction (liver, kidney) or class III or IV cardiac disease as defined by the New
             York Heart Association Criteria.

          -  Patients who are (a) pregnant, (b) breast feeding, (c) of childbearing potential
             without a negative pregnancy test prior to Study Day 1, and (d) male or female of
             childbearing potential unwilling to use barrier contraceptive precautions throughout
             the trial (postmenopausal women must be amenorrheic for at least 12 months to be
             considered of non-childbearing potential).

          -  Patients with a history of another active malignancy within the last five years,
             which required treatment with chemotherapy, hormonal therapy, or radiation therapy.
             Exceptions to this rule include basal cell and squamous cell skin carcinomas or
             cervical carcinoma in situ.

          -  Patients with a history of non-compliance to medical regimens or who are considered
             potentially unreliable.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion:

        * Histologically or cytologically confirmed diagnosis of recurrent or second primary
        squamous cell carcinoma (SCC) of the head and neck, including any of the following:

          -  Oral cavity

          -  Oropharynx

          -  Hypopharynx

          -  Larynx

          -  Recurrent neck metastases with unknown primary

        Exception from pathology confirmation of tumor recurrence is accepted for patients who
        originally had pathologically confirmed SCC of the Head and Neck, the new tumor is located
        in the head and neck area and it is clinically considered as a recurrence of the original
        tumor, and a tumor biopsy is technically difficult and would expose the patient to
        unjustified risk. The treating physicians should agree and document the clinical
        definition of tumor recurrence and should document the increased risk for biopsy.

          -  Measurable disease by CT scan or MRI OR evaluable disease

          -  No definitive evidence of distant metastasis

          -  Unresectable disease by a preliminary ENT evaluation OR refused surgery

          -  Patients may have received chemotherapy as a component of their primary tumor
             treatment but not for recurrent or metastatic disease. No prior treatment with
             systemic anti-EGFR inhibitors or Pemetrexed is permitted

          -  Has undergone prior head and neck radiotherapy (for SCC of the head and neck) to a
             dose of  72 Gy that involved most of the recurrent tumor (&gt; 75%) OR has a second
             primary tumor volume in areas previously irradiated to &gt; 45 Gy

          -  The entire tumor volume must be included in a treatment field that limits the total
             spinal cord dose to 54 Gy (prior plus planned dose)

          -  Must have disease recurrence or persistence for  6 months after completion of prior
             radiotherapy

          -  ECOG performance status 0-1

          -  Age  18 years

          -  ANC &gt; 1,500/L

          -  Platelet count &gt; 100,000/L

          -  Total bilirubin &lt; 1.5 times upper limit of normal (ULN)

          -  AST/ALT &lt; 2 times ULN

          -  Creatinine &lt; 1.5 times ULN

          -  Willing and able to take folic acid and vitamin B12 supplementation

          -  Recovered from prior surgery, chemotherapy, or radiotherapy

          -  At least 6 months since prior radiotherapy

          -  At least 5 days since prior aspirin or other non-steroidal anti-inflammatory agents
             (8 days for long acting agents [e.g., piroxicam])

          -  Fertile patients must use effective contraception

        Exclusion:

          -  Nasopharyngeal carcinoma

          -  Concurrent uncontrolled illness, including, but not limited to, any of the following:

               -  Ongoing or active infection

               -  Psychiatric illness or social situation that would limit compliance with study
                  requirements

               -  Significant history of uncontrolled cardiac disease (i.e., uncontrolled
                  hypertension; unstable angina; recent myocardial infarction [within the past 3
                  months]; uncontrolled congestive heart failure; or cardiomyopathy with decreased
                  ejection fraction)

          -  Active interstitial lung disease

          -  Presence of third space fluid that cannot be controlled by drainage

          -  Other concurrent investigational agents

          -  Pregnant or nursing

          -  HIV positive
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   All patients must be eligible for care at the Kansas City VA Medical Center. Those
        presenting to the Kansas City VA endoscopy laboratory for their "standard BE surveillance"
        endoscopy. Patients with a history of BE will be identified and contacted from the
        existing databank. Patients with newly diagnosed BE in the endoscopy laboratory after
        their procedure is completed and biopsy results are available. Patients undergoing upper
        endoscopy for evaluation of GERD symptoms. Control group of patients undergoing upper
        endoscopy for any reason other than the ones stated above.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   All patients must be eligible for care that the Kansas City VA Hospital where this study
        was approved for enrollment.

        Inclusion Criteria:

          -  Kansas City VA Patients with confirmed BE with and without dysplasia and patients
             with reflux disease (patients/cases); patients with other indicators for endoscopy
             such as anemia,  weight loss, diarrhea, but without GERD and PE (controls).

        Exclusion Criteria:

          -  Patients with uncontrolled significant comorbidities such as cardiovascular,
             pulmonary, renal, hepatic or metabolic diseases.

          -  Presence of anticoagulation that would increase risk from biopsies

          -  Patients unable to provide history

          -  Patients with dyspepsia
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Able to provide written informed consent

          -  Histologically confirmed diagnosis of Stage 2 or Stage 3 rectal carcinoma requiring
             preoperative radiation, chemotherapy or both, per treating physician

          -  18 years of age or older

          -  Karnofsky performance status  or = to 70

        Exclusion Criteria:

          -  Women who are pregnant (confirmed by serum b-HCG in women of reproductive age) or
             breast feeding
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Histologically confirmed classical Hodgkin lymphoma, including CD20+ disease

               -  No lymphocyte predominant histology

          -  Primary refractory or relapsed disease with all 3 risk factors, failed platinum-based
             chemotherapy, or disease relapsed more than 100 days after autologous stem cell
             transplantation, proven by biopsy or fine-needle aspiration (cytology) of an involved
             site

               -  Risk factors are defined as B-symptoms, extranodal sites of disease, and disease
                  remission lasting &lt; 1 year after first-line therapy

          -  Failed doxorubicin hydrochloride or mechlorethamine hydrochloride-containing
             front-line therapy

          -  Fludeoxyglucose F 18-PET scan demonstrating PET-avid disease

          -  No more than 2 prior salvage chemotherapy regimens (for patients proceed to
             allogeneic hematopoietic stem cell transplantation [AHSCT])

          -  Donor available meeting 1 of the following criteria (for patients proceed to AHSCT):

               -  HLA-matched or one allele mismatched related donor

                    -  Genotypically or phenotypically matched at  9/10 of the A, B, C, DRB1, and
                       DQB1 loci, as tested by high resolution

                    -  Peripheral blood stem cells (PBSC) collected

               -  HLA-matched unrelated donor

                    -  Matched at  9/10 (allele mismatch only) of the A, B, C, DRB1, and DQB1
                       loci, as tested by high resolution

                    -  PBSC or bone marrow collected

               -  Umbilical cord blood (2 units)

                    -  must be  4/6 HLA-A, B antigen, and DRB1 allele matched with recipient

        PATIENT CHARACTERISTICS:

          -  Platelet count &gt; 50,000/mm^3

          -  ANC &gt; 1,000/mm^3

          -  Cardiac ejection fraction &gt; 50% (for patients  18 years of age)

          -  Fractional shortening &gt; 50% by echocardiogram* (for patients &lt; 18 years of age)

          -  Adjusted diffusing capacity &gt; 50% on pulmonary function testing*

          -  Serum creatinine &lt; 1.5 mg/dL

          -  Creatinine clearance  50 mL/min

          -  Total bilirubin &lt; 2.0 mg/dL in the absence of a history of Gilbert disease

          -  HIV I and II negative

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Karnofsky performance status (PS)  70% or Lansky PS  70% (for patients proceed to
             AHSCT)

          -  No active and uncontrolled infection at time of transplantation including active
             infection with Aspergillus or other mold (for patients proceed to AHSCT) NOTE:
             *measured since last chemotherapy

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior allogeneic transplantation

          -  No more than 1 prior autologous transplantation

          -  No inability to complete planned cytoreduction due to therapy complications
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  13 Years
 </minimum_age>
 <maximum_age>
  65 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   All patients diagnosed with Multifocal lymphangioendotheliomatosis with thrombocytopenia
        (MLT) or with a vascular anomaly with coagulopathy
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Subjects with a vascular anomaly with coagulopathy

        Exclusion Criteria:

          -  Subjects without a vascular anomaly with coagulopathy
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Histologically proven nasopharyngeal carcinoma

          -  Non-keratinizing or undifferentiated type Stage III-IVB (by AJCC/UICC 6th edition)

          -  Essential staging investigations: CT or MRI of nasopharyngeal region Chest x-ray (or
             CT thorax)

          -  Liver function test, alkaline phosphatase Liver and bone scan if alkaline phosphatase
             exceeds the institutional upper limit of normal, or if clinically indicated.

          -  Liver scan if SGOT exceeds the institutional upper limit of normal

          -  Adequate marrow: WBC &gt; 4 and platelet &gt; 100

          -  Adequate renal function: creatinine clearance &gt; 60 ml/min.

          -  Satisfactory performance status: &gt; 2 by ECOG System.

        Exclusion Criteria:

          -  WHO Type I squamous cell carcinoma or adenocarcinoma

          -  Age &gt; 70

          -  Treatment with palliative intent (including those with tumor extent mandating the use
             of AP opposing facio-cervical field technique)

          -  Prior malignancy except adequately treated basal cell or squamous cell skin cancer,
             in-situ cervical cancer, or other cancer for which the patient has been disease-free
             for five years.

          -  Pregnancy or lactation (consider pregnancy test in women of child-bearing age and
             emphasize effective contraception during the treatment period).

          -  History of previous RT (except for non-melanomatous skin cancers outside intended RT
             treatment volume).

          -  Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  6/6/human leukocyte antigen (HLA) matched sibling donor or related donor, or
             acceptable matched unrelated donor

          -  Biopsy (Bx) proven diagnosis of LG (including small lymphocytic lymphoma
             [SLL]/chronic lymphocytic leukemia [CLL], lymphoplasmacytic lymphoma, marginal zone,
             mucosa-associated lymphoid tissue [MALT] lymphoma and follicular lymphoma [FL] grade
             1 and 2), IG (FL grade 3 and DLCL) or MCL NHL

          -  Prior demonstrated monoclonal CD20+ malignant B-Cell population in lymph nodes and/or
             BM Bx specimen

          -  LG NHL; must have relapsed after achieving a complete response (CR) or partial
             response (PR) to prior therapy or have never responded to prior therapy, including
             chemotherapy and/or MAb therapy

          -  MCL NHL in any disease state

          -  Other aggressive B-cell lymphomas (excluding Burkitt lymphoma or Burkitt-like
             lymphoma) having had at least one relapse or having been refractory to chemotherapy

          -  Bone marrow (BM) aspiration and Bx ( =&lt; 42 days prior to imaging dose) which show &lt;
             25% lymphomatous involvement of total cellularity; in CLL, peripheral lymphocyte
             count &lt; 5000/mm^3

          -  Salvage chemotherapy/MAbs to reduce BM lymphomatous involvement and reduce disease
             bulk allowed

          -  Normal renal function test with serum creatinine of =&lt; 1.5 mg/dl, or a creatinine
             clearance of &gt;= 60 ml/min

          -  Adequate pulmonary function as measured by forced expiratory volume in one second
             (FEV1) &gt; 65% of predicted measured, or a diffusing capacity of carbon monoxide (DLCO)
             &gt;= 50% of predicted measured

          -  Cardiac Ejection fraction of &gt; 50% by Echocardiogram (ECHO) or multi gated
             acquisition (MUGA)

          -  Adequate liver function tests with a bilirubin of =&lt; 1.5 x normal and serum glutamic
             oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT) =&lt; 2 x
             normal

          -  Negative Human Immunodeficiency Virus (HIV) antibody

          -  Karnofsky Performance Status (KPS) &gt; 80

          -  No active Central Nervous System (CNS) disease or prior history of CNS disease

          -  Involved field External Beam Therapy (EBT) to area excluding lung, heat, liver, and
             kidney allowed, but evaluated on a case-by-case basis

          -  Recovery from last therapy and therapy dose (Y-90 Zevalin) must be &gt;= 4 weeks from
             prior systemic chemotherapy

          -  DONOR: Age &lt; 75 years

          -  DONOR: HLA genotypically identical related donor or acceptable matched unrelated
             donor

          -  DONOR: Must consent to G-CSF administration and leukapheresis for matched sibling
             donor, but for unrelated donor, the donor will sign a standard consent for donation
             at their designated donor or collection center

          -  DONOR: Must have adequate veins for leukapheresis or agree to placement of a Central
             Venous Catheter (CVC [femoral, subclavian])

        Exclusion Criteria:

          -  Presence of Human Anti-Zevalin Antibody (HAZA)

          -  Prior radioimmunotherapy (RIT)

          -  Prior AHSCT; but prior aHSCT is allowed; prior fractionated total body irradiation
             (FTBI) in the conditioning regimen will be evaluated on an individual basis

          -  Prior malignancy, except for: adequately treated basal cell or squamous cell skin
             cancer; adequately treated noninvasive carcinomas; or other cancer from which the
             patient has been disease-free for at least 5 years; myelodysplastic syndromes (MDS)
             is excluded from this criterion

          -  Active evidence of Hepatitis B or C infection; hepatitis B surface antigen positive

          -  Total peripheral lymphocyte count &gt; 5,000/mm^3 if SLL/CLL

          -  Burkitt lymphoma or Burkitt-like lymphoma

          -  DONOR: Age &lt; 12 years

          -  DONOR: Identical twin

          -  DONOR: Pregnancy

          -  DONOR: HIV infection

          -  DONOR: Inability to achieve adequate venous access

          -  DONOR: Known allergy to G-CSF

          -  DONOR: Current serious systemic illness or any disease that may preclude the use of
             G-CSF (eg, recent thromboembolic event); for unrelated donors, considered ineligible
             by National Marrow Donor Program (NMDP) donor evaluation center
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  69 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients with head and and neck malignancies hat require simultaneous surgical resection
        and reconstruction of the ablative defect will be eligible to participate.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients undergoing surgical resection and reconstruction for every stage head and
             neck malignancies at Memorial Sloan-Kettering Cancer Center.

          -  Patients at least 21 years of age

        Exclusion Criteria:

          -  Patients who are less than 21 years old

          -  Patients who do not speak the English language

          -  Patients who are unable to comprehend the content of the questionnaires due to
             psychiatric disorders or cognitive impairment

          -  Patients who cannot complete the pre-operative questionnaires during consent
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  21 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   All patients meeting the eligibility criteria and receiving or seeking prostate cancer
        treatment in the Genitourinary Oncology/Urology Services will be approached by a
        consenting professional at a suitable point in their clinical course prior to biospecimen
        collection.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

        Men with prostate conditions representing the following disease states:

          -  No Cancer Diagnosis

          -  Clinically Localized Disease

          -  Rising PSA

          -  Clinical Metastases: Noncastrate

          -  Clinical Metastases: Castrate (Testosterone  50 ng/ml)

          -  Signed informed consent

        Exclusion Criteria:

        -Patients without any prostate related problems.
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   All Pediatric Oncology and Bone Marrow Transplantation Service patients with a
        histologically proven tumor for whom there is an intent to treat with chemotherapy
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  All Pediatric Oncology and Bone Marrow Transplantation Service patients with a
             histologically proven tumor for whom there is an intent to treat with chemotherapy
             are eligible for participation in this study. The patient does not need to be newly
             diagnosed for enrollment on this protocol.

          -  All patients or their guardians must provide written informed consent. Minors will be
             required to provide assent.

        Exclusion Criteria:

          -  None
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Subjects must be 18-80 years of age with a history of surgically removed colon or
             rectal cancer, and have received treatment for their disease using drugs (adjuvant
             chemotherapy)

          -  Subjects must have colon or rectal cancer with stage I, II, or III disease

          -  Subjects should not have further treatment with radiation therapy. Subjects having
             already received adjuvant (i.e., post-operative) radiation therapy to the colon or
             rectum will be excluded. However, subjects receiving radiation therapy prior to
             surgery for rectal cancer are eligible for enrollment.

          -  Subject's tumor must have been completely removed within the past 12 months, with
             first surveillance colonoscopy anticipated 12 weeks after study treatment start date
             (i.e. one-year after surgical removal).

          -  Subjects must be in good physical status

          -  If subjects are premenopausal and perimenopausal women, they must be using adequate
             birth control methods.

          -  Subjects must have no history of another invasive cancer within 5 years

          -  Subjects must have no further chemotherapy anticipated.

          -  Subjects don't have special dietary requirements or additives.  Subjects must not be
             consuming a diet that would preclude taking the study medication.

          -  Subjects must have no concomitant use of calcium supplements (&gt; 520mg/day).

          -  Subjects must have no history of abnormal wound healing or repair, or conditions that
             predispose to the same.

          -  Subjects don't have personal history of colon resection of or inflammatory bowel
             disease.

          -  Subjects must give informed consent via consent form approved by the local Human
             Subjects Committee (Institutional Review Board).

          -  If subjects are taking aspirin 81mg by mouth daily they will be eligible

          -  Subjects must have no history of allergies or adverse reactions to aspirin.

          -  Subjects don't have documented history of gastric/duodenal ulcer within the last 12
             months.

        Exclusion Criteria:

          -  Subjects already received radiation therapy to the colon or rectum.

          -  Subjects adhering to vegetarian diets.

          -  Subjects are pregnant or lactating women.

          -  Subjects are breastfeeding

          -  Subjects are already taking aspirin 325mg by mouth daily.

          -  Subjects are taking combination medication with more than 81mg aspirin.

          -  Subjects are currently being treated for gastric/duodenal ulcer or experiencing
             symptoms at study entry.

          -  Subjects have a history of any medical condition that would place them at risk as a
             result of a blood donation, they will be excluded from the study.

          -  Subjects are taking blood-thinning drugs as warfarin (Coumadin)

          -  Subjects are allergic to fenoprofen, ibuprofen, indomethacin, ketoprofen,
             meclofenamate sodium, naproxen, sulindac, tolmetin, or an orange food coloring known
             as tartrazine.

          -  Subjects have liver damage or severe kidney failure
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  80 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Prostate Cancer Patients
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria is the same at both sites, and is outlined below:

        Inclusion Criteria:

        Comparison Androgen Ablation Group

          1. Diagnosis of prostate cancer

          2. Age 65 or older

          3. Ability to converse, write and read English

          4. Able to provide informed consent

          5. Have been on continuous androgen ablation therapy for 6 months to-3 years

        Androgen Ablation Subgroup

          1. Diagnosis of prostate cancer

          2. Age 65 or older

          3. Ability to converse, write and read English

          4. Able to provide informed consent

          5. Starting androgen ablation therapy

          6. No androgen ablation therapy within the past year

        No Androgen Ablation Subgroup

          1. Diagnosis of prostate cancer

          2. Age 65 or older

          3. At least 1-year post definitive localized treatment

          4. Ability to converse, write and read English

          5. Able to provide informed consent

          6. Not anticipated to start androgen ablation therapy

        Exclusion Criteria:

        All Groups

        2) Previous or current treatment with chemotherapy 3) History of neurological brain damage
        4) History of untreated psychiatric disease 5) Previous head traumas 6) Current use of
        opioids 7) History of developmental disorders 8) Current history of alcohol or substance
        abuse

        Androgen Ablation Subgroup and No Androgen Ablation Subgroup Only

        1)      History of androgen ablation therapy within the past year of the date of consent
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  65 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Leukemias/lymphomas:

               1. Acute myeloid leukemia, primary or secondary: Disease status: remission or &lt;10%
                  peripheral blasts

               2. Myelodysplasia

               3. Acute lymphoblastic leukemia Disease status: in remission

               4. Chronic myelogenous leukemia:  Disease status: chronic phase, accelerated phase
                  or blast crisis now in second chronic phase.

               5. Mixed lineage or biphenotypic acute leukemia

               6. Lymphoblastic lymphoma:  Disease status: remission

               7. Burkitt's lymphoma/leukemia:  Disease status: in remission

          2. Non-malignant diseases:

               1. Bone marrow failure, including severe aplastic anemia

               2. Immunodeficiencies

        Exclusion Criteria:

        1.  Patients who have had prior stem cell transplant (SCT) and bone marrow transplant
        (BMT) are excluded for study enrollment.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  22 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Primary care clinic
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients accepted for referral to the Cancer Family Clinic of the Department of
             Medicine at Memorial Sloan-Kettering Cancer Center are eligible for participation in
             this study. Such patients should have a history of cancers of the breast, ovary,
             colon, prostate, uterus, non-Hodgkin's lymphoma, leukemia, soft tissue sarcoma,
             endocrine neoplasms, or other malignancies presenting in first degree relatives or in
             successive generations as part of a suspected cancer family syndrome.

          -  Family members of probands including parents, sisters, brothers, half-brothers and
             sisters, sons, daughters, grandparents, as well as aunts and uncles are also
             eligible.

          -  This study involves research which presents no greater than minimal risk to children.
             The assent of any minor should be obtained before the patient is entered into this
             study.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Primary Care Clinic
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Families referred for genetic counseling consultation at Memorial Hospital

          -  Individuals self-referred or physician referred for genetic counseling due to a
             concern about increased risk for breast cancer, regardless of family history or
             ethnic origin.

          -  Individuals enrolled in MSK protocol 97-029 "Germline BRCA1 and BRCA2 mutations in
             Jewish Women Affected by Breast Cancer" who wish to have full sequencing or who wish
             to have commercial testing in addition to testing done as part of that study.

          -  Individuals who present for genetic counseling consultation at Memorial Hospital
             after undergoing genetic testing at an outside institution.

          -  Member of a family with breast cancer who wishes to provide a DNA sample for research
             purposes

        Exclusion Criteria:

        -Patients will be excluded from this study if: he/she has physical, cognitive or
        psychiatric conditions that interfere with ability to give meaningful informed consent;
        he/she cannot read, write or communicate in English; he/she is less than 18 years of age.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients with a histologic diagnosis of cancer of the colon, breast, bladder, kidney,
             testicles, lungs, prostate, head and neck, or lymphoid organs, who have donated a
             diagnostic blood sample as either an inpatient or outpatient at MSKCC.

          -  All patients who have two or more histologic diagnoses of the same primary tumor type
             involving the above sites.

          -  Patients of Ashkenazi Jewish ancestry with a histologic diagnosis of cancer of any
             type.

          -  Samples ascertained as part of protocol 98-024A(1) are also eligible for
             ascertainment in this study.

        Exclusion Criteria:

          -  MSKCC patients without a histologic diagnosis of cancer of the breast, bladder,
             kidney, colon, testicles, lungs, prostate, or lymphoid malignancy (including all
             types of lymphoma) will not be eligible for the AMDeC sponsored component of the
             study.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients seen or referred by Memorial Sloan-Kettering Cancer physicians
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  All patients with known or suspected sarcoma who will have or have had tissue removed
             for therapeutic or diagnostic purposes.

          -  Patients will be entered without preference for any particular racial/ethnic group or
             gender.

          -  Patients may have received prior hormonal therapy, cytotoxic chemotherapy,
             irradiation, immunotherapy or surgical therapy.

          -  Tissue specimens must be large enough in quantity to allow routine pathologic
             analysis, with the research laboratory specimen removed from the residual specimen,
             which would otherwise be discarded. Optimal tissue amounts for snap freeze: Core
             biopsy - 2 tissue cores Incisional biopsy- 0.5 to 1.5 grams Resected sarcoma
             specimen- 1.0 to 50 grams depending on size of specimen Normal fat or muscle tissue -
             0.5 to 4.0 grams (if available from resected sarcoma specimen) Optimal tissue amounts
             for RNA later Core biopsy - 2 tissue cores Incisional biopsy- 30 mg (three 3 x 3 x 3
             mm cubes) Resected sarcoma specimen - 30 mg (three 3 x 3 x 3 mm cubes) Normal fat or
             muscle tissue - 30 mg (three 3 x 3 x 3 mm cube

        Exclusion Criteria:

        - None
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Nursing homes, senior centers, health fairs or other community organizations.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Eligible subjects must be non-cancer affected volunteers of either gender who are 60
             years of age or older at the time of saliva/blood donation.

          -  Subjects will self-identify religion and country of origin of grandparents.

          -  Volunteers will have (by self report) no history of cancer other than nonmelanoma
             skin cancer. It is recognized that there may be some errors in self report, however,
             the literature reports a very low error rate for self reported disease reporting for
             cancer as assessed by interview.

        Exclusion Criteria:

          -  Subjects with mental impairment will be excluded from this study.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  60 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Unresectable or metastatic non-small cell lung cancer (NSCLC)
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

        Patients diagnosed with unresectable or metastatic non-small cell lung cancer (NSCLC) and
        who fulfill the following eligibility criteria will be considered eligible for this study.

          -  Patient must have previously received treatment with small molecule kinase inhibitors
             targeting at least, in part, EGFR patients may have received other treatments since
             treatment with small molecule kinase inhibitors including radiation or chemotherapy)

          -  Development of disease progression while actively receiving tyrosine kinase inhibitor

          -  Signed informed consent

        Exclusion Criteria:

          -  None
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  All patients with a presumed or known diagnosis of a primary or secondary bone cancer
             or other solid tumor who are having or have had a biopsy or surgery  to remove tumor
             for diagnostic or therapeutic reasons. No tumors will be obtained solely for research
             purposes.

          -  All adult patients (&gt; or = to 18 yrs.) will have given written informed consent.

          -  All minor patients (&lt;18 yrs.) will have given assent to the best of their ability to
             understand, and their parent or guardian will have given written informed consent

        Exclusion Criteria:

          -  N/A
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Age  18 years old and  75 years old (*)

          -  Chronic Obstructive Pulmonary Disease with FEVs/VC &lt; 70% (**)

          -  Respiratory pulmonary hypertension with mean pulmonary arterial pressure  25 mmHg
             (**) related to normal pulmonary capillary pressure assessed by catheterization of
             the right side of the heart (pulmonary capillary wedge pressure 12mmHg)

          -  PO2  60 mmHg assessed by arterial gazometry at ease (**) or PO2 &gt; 60 mmHg, but
             related with high hypoxemia after  exercise  (six-minute walk test )

          -  Oxygenotherapy more than 6 months before pre-screening

          -  Written informed consent

        (*)  Inclusion of young adults concerns COPD related to asthma or cystic fibrosis (**)
        Criteria assessed from last health check or the last exams for COPD diagnosis

        Exclusion Criteria:

          -  clinical instability and/or respiratory exacerbation within the previous three months

          -  clinical instability and/or respiratory exacerbation dangerous for catheterization

          -  Pregnancy (HCG &gt; 20 UI /l) or breastfeeding on going

          -  General corticotherapy &gt; 0,5 mg/kg/day prdnisolone equivalent

          -  Hepatic insufficiency (TP &lt; 50%) or renal insufficiency (creatininemia &gt; 130 mol/l)
             or diabetes mellitus type I or II (treated by oral antidiabetic or insulin)

          -  Left-heart failure (coronary heart disease and/or left valvulopathy)

          -  High level of prostatic specific antigen (PSA) (&gt; 2,5ng/ml)

          -  Cancer antecedent or treatment on going
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Black men with prostate cancer
  </textblock>
 </study_pop>
 <sampling_method>
  Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  18 years of age or older

          -  Patients who are being monitored by PSA tests, who will have a PSA test done on the
             day of their current clinic visit or prior to their clinic visit, but prior to being
             informed of the results

          -  Diagnosis of prostate cancer

          -  Ethnicity: Black, African-American, or of African descent (and will include those men
             who identify as Black and Hispanic).

          -  Ability to comprehend and complete questionnaires in English

        Exclusion Criteria:

          -  Major psychopathology or cognitive impairment likely, in the judgment of the research
             staff, to interfere with the participation or completion of the protocol

          -  Other non-Black or non-African-American ethnic groups
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Women seen at MSKCC breast clinic
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  multifocal lobular carcinoma in situ treated with prophylactic mastectomy or
             lumpectomy

          -  invasive breast cancer (lobular or ductal) with coexisting lobular carcinoma in situ
             treated with mastectomy or lumpectomy

          -  biopsy proven, untreated lobular carcinoma in situ

          -  invasive lobular cancer with or without coexisting lobular carcinoma in situ treated
             with mastectomy or lumpectomy

        Exclusion Criteria:

          -  no paraffin blocks available

          -  no residual lobular carcinoma in situ in paraffin blocks
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Potential research subjects will be identified by a member of the patient's treatment
        team, the protocol investigator, or research team at Memorial Sloan-Kettering Cancer
        Center (MSKCC).
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients with histologically proven diagnosis of head and neck cancer or patients
             with tumors strongly suspicious for head and neck cancer due to clinical features or
             FNA (fine needle aspiration) cytology assessment.

          -  Will undergo surgery or chemo-radiation treatment

          -  Presence of evaluable primary tumor

          -  Patients must be 18 years or older and have the ability to give informed consent

        Exclusion Criteria:

          -  Claustrophobia

          -  Absence of evaluable primary tumor

          -  Known reaction to Gd-DTPA

          -  Pre-operative radiation to primary tumor site

          -  Contraindication to MRI

               1. Pacemaker

               2. Aneurysmal clips

               3. Metal implants in field of view

               4. Pregnant or nursing women

               5. Age and mental status wherein he/she is unable to cooperate for MRI study
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients greater than 4 years of age at Memorial Sloan-Kettering Cancer Center

          -  Must be undergoing hematopoietic stem cell transplantation (either autologous or
             allogenic) in conjunction with a conditioning regimen that includes TBI (single or
             multiple fraction)

          -  Functional central venous catheter

        Exclusion Criteria:

          -  No subjects will be excluded from the proposed research study for demographic
             reasons. Treatment with growth factors, such as keratinocyte growth factor (KGF),
             will not be grounds for exclusion.

          -  Subjects who will receive radiation therapy within 5 days prior to TBI will be
             excluded.

          -  Subjects who will receive systemic antineoplastic chemotherapy within 7 days prior to
             TBI not have research bloods collected. Only urine will be collected from these
             patients.

          -  Based on current knowledge, we will not a priori exclude patients based on disease
             status (ie, patients in or out of remission will be included in this study), type of
             disease(ie, chromosomal breakage syndromes), or previous therapies (unless exclusion
             criteria is met).
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  4 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Potential research subjects will be identified by a member of the patient's treatment
        team, the protocol investigator, or research team at MSK or collaborating centers. If the
        investigator is a member of the treatment team, s/he will screen their patient's medical
        records for suitable research study participation and discuss the study and their
        potential for enrolling in the research study. Potential subjects contacted by their
        treating physician will be referred to the investigator/research staff of the study.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

        Patient/Relative Cohort:

        Must meet one or more criteria below:

          1. A person with a diagnosis of gastric or gastroesophageal junction (GEJ)
             adenocarcinoma.

          2. A person without gastric or GEJ adenocarcinoma who has or had a first degree relative
             eligible for a High Risk Genetic sub-group (EOGC/FGC).

               1. Early Onset Gastric Cancer - diagnosis of gastric cancer before the age of 50
                  without a family history of the disease.

               2. Familial Gastric Cancer - having a family history of gastric cancer as defined
                  as one first degree relative or 2 second degree relatives.

          3. A person without gastric or GEJ adenocarcinoma who has a personal family history of a
             genetic mutation associated with the development of gastric or GEJ adenocarcinoma
             (i.e. family history of CDH1 mutation).

        These individuals will sign the "Patient/Relative Consent". Following enrollment, we will
        assign individuals to the appropriate High Genetic Risk or Low Genetic Risk groups based
        on the age of diagnosis and their family history.

        Control Cohort

        Must meet all criteria below:

          1. Does not have gastric cancer.

          2. Not a blood relative of patient or relative participants.

          3. No family history of a mutation in the CDH1 gene.

        These individuals will sign the "Control consent". Note: A participant's genetic risk
        group is subject to change due to change in their diagnosis, family history, or genetic
        test results.

        Subject Exclusion Criteria

        Patients are ineligible for the study if they:

          -  Have any condition, which in the opinion of the primary MSKCC clinician or
             investigators precludes their ability to provide informed consent.

          -  Relatives of patients that are not eligible for the High Genetic Risk Cohorts who are
             less than 18 years of age are excluded.

          -  Relatives of patients eligible for the High Genetic Risk Cohorts who do not have a
             proband available to join the study are excluded. (Unless there is a known CDH1
             mutation in the family).

          -  Control participants who are less than 18 years of age are excluded.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria: Part 3

          -  Histologically or cytologically documented NSCLC with measurable of disease

          -  Disease is evaluable by CT scan

          -  At least 18 years old. Women cannot be pregnant or breastfeeding

          -  Karnofsky score &gt;/= to 60

          -  Adequate renal/hepatic function

          -  Adequate blood cell count levels

        Exclusion Criteria:

          -  Concomitant infection

          -  Other active cancers
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients seeking genetic counseling with or without genetic testing for colorectal cancer
        risk and/or suspected Lynch Syndrome will be recruited and offered enrollment during their
        first counseling visit at the Clinical Genetics Service at MSKCC
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  A patient will be eligible for enrollment if he/she is self-referred or
             physician-referred for genetic counseling at Memorial Sloan-Kettering Cancer Center's
             (MSKCC) Clinical Genetics Service due to a concern about increased risk for colon
             cancer or;

          -  An individual who presents for genetic counseling at MSKCC's Clinical Genetics
             Service after undergoing genetic testing at an outside institution with a documented
             mutation in any gene associated with Lynch Syndrome or;

          -  An individual who in the context of genetic counseling has received stricter
             colorectal and/or gynecologic screening recommendations than that of the general
             population regardless of genetic test results.

          -  DNA of patients who have been consented to protocol 93-102 ("Ascertainment of
             Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial
             Cancers"), who meet the eligibility criteria listed above, will also be eligible for
             inclusion in this study.

        Exclusion Criteria:

          -  Patients will be excluded from this study if: he/she has physical, cognitive or
             psychiatric conditions that interfere with ability to give meaningful informed
             consent; he/she cannot read, write or communicate in English; he/she is less than 18
             years of age; he/she has received a diagnosis of FAP.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Clinical Genetics Service at MSKCC or to the MSKCC outpatient clinics of the Lymphoma or
        Leukemia Services in the Department of Medicine.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients with lymphoma or lymphoproliferative disease accepted for referral to the
             Cancer Family Clinic of the Department of Human Genetics for genetic counseling, or
             to the MSKCC outpatient clinics of the Lymphoma or Leukemia Services in the
             Department of Medicine in consultation for treatment who are found on routine history
             or through a Family History Questionnaire (FHQ) (Appendix A) to have relatives or
             members of successive generations of the family affected with Hodgkin's disease,
             non-Hodgkin's lymphoma, lymphoid leukemia, multiple myeloma or other
             lymphoproliferative disease. Patients with lymphoma, associated with colon and renal
             cancer will be eligible for DNA storage through this protocol. Family members or
             probands with Hodgkin's disease who are women who received therapeutic irradiation
             for Hodgkin's disease" or who developed secondary cancers after Hodgkin's disease are
             also eligible for participation.

          -  The criteria for eligibility are broad because the ascertainment by the computerized
             FHQ does not allow for resolution of different types of lymphoma or different types
             of leukemia. Patient recall of this information is also imprecise. More accurate
             family history information will be obtained upon contact of family members and
             diagnoses will be verified by obtaining pathologic documentation. The spectrum of
             familial lymphoproliferative syndromes (LPS) may include all types of lymphoma as
             well as chronic lymphocytic leukemia. This is an additional reason to have a broad
             eligibility. Subset analysis will be performed on specific types of lymphoid
             neoplasms. DNA of patients with a family history of lymphoma who have consented to
             protocol 93-102 ("Ascertainment of Peripheral Blood or Saliva Samples for Genetic
             Epidemiology Studies of Familial Cancers") will also be eligible for inclusion in
             this study.

          -  Family members of probands including patients, sisters, brothers, halfbrothers and
             sisters, sons, daughters, grandparents, as well as aunts and uncles are also
             eligible. An effort will be made to ascertain all living affected and unaffected
             living relatives in the affected lineage. An emphasis will be on affected sibling
             pairs and both parents, if alive.

          -  Also eligible for inclusion are up to 2000 anonymized familial lymphoma/leukemia
             samples from Montefiore Medical Center, with information on age of onset, gender,
             lymphoma or leukemia type, familial relationship, and year of sample collection. No
             PHI will be used and therefore these samples will be fully and permanently anonymized
             to MSKCC.

          -  As this study involves research that presents no greater than minimal risk to
             children (see Sec. 46.404 of Federal Regulations part 46), minors are also eligible
             for participation. The assent of any minor should be obtained before the patient is
             enrolled into this study, as well as the consent of the legal guardian.

        Exclusion Criteria:

          -  N/A
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Primary Care Clinic
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

        For patients:

          -  All patients with benign or malignant tumors of the soft tissues, gastrointestinal
             tract, and other intra-abdominal sites who will have or have had tissue, peritoneal,
             pleural, cyst, urine, and/or other gastrointestinal fluid removed for therapeutic or
             diagnostic purposes.

          -  Patients will be entered without preference for any particular racial/ethnic group.

          -  Patients may have received prior hormonal therapy, cytotoxic chemotherapy,
             irradiation, immunotherapy or surgical therapy.

          -  Tissue and body fluid specimens must be a large enough quantity to allow routine
             pathological analysis, with the research laboratory specimen removed from the
             residual specimen which would otherwise be discarded.

        Healthy Control Subjects:

          -  Any male or female with no concurrent malignancies (except for localized basal cell
             or squamous cell skin cancer) within 5 years of enrollment.

          -  &gt; or = to 18 years of age

          -  Any MSKCC employee will be allowed to participate as a healthy control, provided they
             fulfill the above inclusion criteria and they enroll willfully and voluntarily

        Exclusion Criteria:

        Healthy Control Subjects:

          -  Attending physicians authorized to obtain informed consent may exercise discretion in
             excluding individuals for appropriate medical or other (e.g. mentally impaired)
             reasons.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients with primary refractory AML (that is no prior remission). Patients who have
             greater than 10% AML blasts in the bone marrow or blood upon recovery from two cycles
             of standard cytarabine- and anthracycline-based induction chemotherapy are eligible.
             Patients who have received etoposide and/or 6-thioguanine during remission induction
             will be eligible.

          -  Patients with relapsed AML. Patients must have had a documented remission lasting &gt;
             30 days at some point during their prior therapy. Their current relapse must be
             untreated. Relapse is defined as the presence of greater than 10% AML blasts in the
             bone marrow or blood after having had a documented remission.

          -  Patients who have received a high-dose cytarabine containing regimen (&gt;2 g/m2/dose)
             within 3 months prior to registration on this protocol are not eligible.

          -  No active CNS involvement. A lumbar puncture prior to treatment is not required and
             should not be performed in the absence of significant CNS symptoms or signs.

          -  Non-pregnant and non-nursing. Treatment under this protocol would expose an unborn
             child to significant risks. Women and men of reproductive potential should agree to
             use an effective means of birth control.

        Exclusion Criteria:

        Although NOT considered formal Exclusion Criteria, study physicians are strongly
        encouraged as part of this decision-making process to recognize that the following may
        increase the risks to a subject entering this protocol:

          -  Other serious illnesses which would limit survival to &lt;2 years, or a psychiatric
             condition which would prevent compliance with treatment or informed consent.

          -  Performance Status &gt; 2.

          -  Uncontrolled or severe cardiovascular disease, diabetes, pulmonary disease, or
             infection, which in the opinion of the treating physician, would make this protocol
             treatment unreasonably hazardous for the patient.

          -  Patients with a "currently active" second malignancy other than non-melanoma skin
             cancers. Patients are not considered to have a "currently active" malignancy if they
             have completed therapy and considered by their physician to be at less than 30% risk
             of relapse within one year.

          -  Patients who have received any investigational agent within the prior 4 weeks.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients must have a diagnosis of transitional cell carcinoma (TCC) of the urinary
             bladder confirmed at the study institution.  The patient must have demonstrated
             superficial recurrent bladder cancer refractory to standard intravesical therapy.
             This will include stage Ta, T1, Tis and exclude all patients with muscle invasion
             (T2).  All patients with stage Ta will require documentation of high-grade histology.
              All grossly visible disease must be fully resected and pathologic stage will be
             confirmed at the institution where the patient is enrolled.  Patients must exhibit
             disease recurrence after receiving some form of standard intravesical therapy,
             including BCG, mitomycin, interferon or any combination thereof.

          -  Age &gt; 18 and must be able to read, understand and sign informed consent

          -  Performance Status: ECOG 0,1 (See Appendix II )

          -  Peripheral neuropathy: must be &lt; grade 1

          -  Hematologic-Inclusion within 2 weeks of start of treatment

               -  Absolute neutrophil count &gt; 1,500/mm3

               -  Hemoglobin &gt;9.0 g/dl

               -  Platelet count &gt; 100,000/mm3

          -  Hepatic-Inclusion within 2 weeks of entry

               -  Total Bilirubin must be within normal limits.

               -  Adequate renal function with serum creatinine  2.0 mg/dL

               -  Aspartate transaminase (AST) and alanine transaminase (ALT)  2.5 x ULN for the
                  institution, Alkaline phosphatase   2.5 x ULN for the institution, unless bone
                  metastasis is present in the absence of liver metastasis

          -  Women of childbearing potential must have a negative pregnancy test.

          -  All patients of childbearing potential must be willing to consent to using effective
             contraception, i.e., IUD, Birth control pills, Depo-Provera, and condoms while on
             treatment and for 3 months after their participation in the study ends.

          -  No intravesical therapy within 6 weeks of study entry

          -  No prior radiation to the pelvis

        Exclusion Criteria:

          -  Prior systemic docetaxel or paclitaxel therapy.

          -  Any other malignancy diagnosed within 2 years of study entry (except basal or
             squamous cell skin cancers or non-invasive cancer of the cervix) is excluded.

          -  Concurrent treatment with any chemotherapeutic agent.

          -  Women who are pregnant or lactating.

          -  History of vesicoureteral reflux or an indwelling urinary stent.

          -  Participation in any other research protocol involving administration of an
             investigational agent within 3 months prior to study entry aside from the phase I
             segment of this study.

          -  History of neuropathy of any cause
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Men with prostate cancer who have received prior local therapy (radical prostatectomy
             or definitive radiation therapy) and have biochemical (PSA)    relapse without
             evidence of radiographic or clinical metastatic disease.

          -  For men who had prior prostatectomy, the surgery must have occurred at least 6 months
             prior to initiation of treatment.

          -  For men who had prior definitive radiation therapy, radiation must have been
             completed at least 1 year prior to initiation of treatment.

          -  Exhibit at least three separate rises in serum PSA, at least one month apart with
             differences &gt;/= 0.03 ng/ml and a total PSA of &gt;0.2 ng/ml.

          -  Have a PSA doubling time of &gt;/= 6 months if the baseline serum PSA was &gt;2 ng/ml.

          -  Negative bone scans.

          -  Negative CT scans of abdomen and pelvis (no evidence of soft tissue lesions &gt;/= 1
             cm).

          -  Scans must be obtained within 6 weeks of entry into the trial (initiation of
             treatment).

          -  Written informed consent.

          -  Age &gt;/= 18 years.

          -  Required laboratory values [obtained within 2 weeks of study entry (initiation of
             treatment)].

          -  Serum creatinine &lt;/= 2.0 mg/dL

          -  Adequate hematologic function: granulocytes &gt;/= 1800 per mm3, platelets &gt;/= 100,000
             per mm3, WBC &gt;/= 3700, and lymphocytes &gt;/= 590.

          -  Adequate hepatocellular function: AST &lt;3x upper limit of normal and bilirubin &lt;1.5
             mg/dl (unless bilirubin elevation is consistent with Gilbert's syndrome).

          -  PSA used as an eligibility criterion must be drawn within 42 days prior to injection
             number 1 and will be redrawn on Day 1 for use as a baseline value.

        Exclusion Criteria:

          -  Candidates for salvage radiation therapy unless the patient refuses.

          -  Active or unresolved clinically significant infection.

          -  Parenteral antibiotics &lt;7 days prior to initiation of treatment.

          -  Evidence of prior or current CNS metastases. Specific imaging is not necessary in the
             absence of signs or symptoms.

          -  Co-morbid medical conditions which would result in a life expectancy (participation)
             of less than 1 year.

          -  Patients with compromised immune systems; congenital, acquired, or drug-induced
             (immunosuppressive agents) will be excluded from the study. Use of prednisone at
             doses higher than 10 mg daily (or equipotent steroid doses) for more than 7 days
             within the last 3 months is not allowed.

          -  No-pre-existing malignancies that required treatment within the past 5 years except
             for basal or squamous cell cancers of the skin.

          -  Prior systemic therapies for prostate cancer not allowed (hormonal therapy, including
             but not limited to LHRH agonists, antiandrogens, ketoconazole or chemotherapy -
             mitoxantrone/taxanes/estramustine, etc.) except when patients stopped hormone therapy
             two or more years prior to enrollment and currently have normal testosterone levels;
             patients in Arm B, undergoing androgen depletion therapy during the vaccination will
             be eligible.

          -  Prior participation in any vaccine studies for non-infectious diseases.

          -  The inability to understand the language and the clinical protocol.

          -  Allergy or religious objection to pork products; Gelfoam is produced from pork.
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  90 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Adults 19 years of age or older, pancreatic cancer patients at the University of Alabam at
        Birmingham.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Person over  19 years of age, patient with a tissue-proven diagnosis of pancreatic
             cancer at the University of Alabama at Birmingham (UAB) University Hospital during
             the period, and cognitive ability to provide informed consent

        Exclusion Criteria:

          -  Person not 19 or older and have not had a tissue-proven diagnosis of pancreatic
             cancer.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  19 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Advanced malignancies (except leukemias), histologically proven at diagnosis;
             Histologically confirmed advanced malignancies that are known to be sensitive to
             PF-03241066 inhibition, e.g. ALK, c-MET and ROS

          -  Solid tumors must have measurable disease (Recommended Phase 2 Dose Cohort patients
             with non-measurable disease may enter on a case-by-case basis); not required for DDI
             sub-studies.

          -  Adequate blood cell counts, kidney function, liver function and Eastern Cooperative
             Oncology Group (ECOG) score of 0 or 1 (for the Recommended Phase 2 Cohort, a ECOG
             score of 2 may be allowed on a case-by-case basis)

        Exclusion Criteria:

          -  Major surgery, radiation therapy or anti-cancer therapy within 2 to 4 weeks of
             starting study treatment, depending on the patient cohort

          -  Prior stem cell transplant except of patients with neuroblastoma, lymphoma or myeloma

          -  Active or unstable cardiac disease or heart attack within 3 months of starting study
             treatment
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   INCLUSION CRITERIA:

        Patients must meet the following eligibility criteria to be included:

          1. Recurrent low grade or intermediate grade B cell lymphoma or leukemia (ALL or CLL),
             or newly diagnosed patients unable to receive or complete standard therapy OR
             diagnosis of intermediate B cell lymphoma with a treatment plan that will include
             high dose therapy and autologous stem cell transplantation. If a patient is less than
             18, the lymphoma/leukemia is highly aggressive (i.e. lymphoblastic, Burkitt, ALL).

          2. Life expectancy of at least 12 weeks

          3. Recovered from the toxic effects of all prior chemotherapy before entering this study

          4. ANC greater than 500, HgB greater than 8.0

          5. Bilirubin less than 3 times the upper limit of normal

          6. AST less than 5 times the upper limit of normal

          7. Serum creatinine less than 3 times upper limit of normal

          8. Pulse oximetry of greater than 90% on room air

          9. Karnofsky/Lansky score of greater than 60%

         10. Available autologous transduced peripheral blood T-cells with greater than/=15%
             expression of CD19CAR determined by flow-cytometry

         11. Patients or legal guardians must sign an informed consent indicating that they are
             aware this is a research study and have been told of its possible benefits and toxic
             side effects. Patients or their guardians will be given a copy of the consent form

         12. Sexually active patients must be willing to utilize one of the more effective birth
             control methods during the study and for 3 months after the study is concluded. The
             male partner should use a condom

        EXCLUSION CRITERIA:

          1. History of hypersensitivity reactions to murine protein-containing products

          2. Pregnant or lactating

          3. Tumor in a location where enlargement could cause airway obstruction

          4. Currently receiving any investigational agents or have not received any tumor
             vaccines within the previous six weeks
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients who have histologically confirmed Barrett's Esophagus
  </textblock>
 </study_pop>
 <sampling_method>
  Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Sex: Male and female

          -  Age: 18-80 years

          -  Confirmed BE.

        Exclusion Criteria:

          -  Columnar mucosa in the distal esophagus but no intestinal metaplasia on biopsy.

          -  Patients with BE who have undergone endoscopic ablation therapy or enrolled in
             chemoprevention trials.  Since this is a natural history study, patients enrolled in
             intervention trials (e.g. those undergoing endoscopic ablation of their BE) will be
             excluded.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  80 Years
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   patients who have had endoscopic mucosal resection
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Barrett's Esophagus Early Esophageal Adenocarcinoma History of Endoscopic Mucosal
             Resection

        Exclusion Criteria:

          -  NA
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients who have had or qualify for ablation therapy for treatment of their barrett's
        esophagus
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients who have had or qualify for ablation therapy for treatment of their
             barrett's esophagus with high grade dysplasia or early esophageal adenocarcinoma

          -  Ability to provide informed consent

        Exclusion Criteria:

          -  Eastern Cooperative Oncology Group performance status 3 or 4

          -  Inability to tolerate endoscopic procedures

          -  Pregnancy:  Females of child-bearing age will be screened with pregnancy test.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  90 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Breast cancer patients seen at Memorial Sloan-Kettering Cancer Center
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  For acquisition of existing breast cancer tissue specimens from the MSKCC Tissue
             Procurement Service, the only criteria are a pathologically-confirmed diagnosis of
             invasive breast cancer and the availability of corresponding nonmalignant tissue from
             each case.

          -  For the prospective acquisition of blood or saliva from control subjects without
             breast cancer, eligibility criteria include:

          -  Any patient with a previous diagnosis of invasive breast cancer who undergoes a
             palliative procedure related to the presence of a pleural effusion is eligible for
             the pleural fluid collection aspect of this protocol.

          -  Any female patient, or any female over the age of 18 accompanying a patient under the
             care of a physician in the Department of Urology, Department of Surgery, or
             Department of Medicine.

          -  Subjects will have no history of preinvasive (carcinoma in situ) or invasive breast
             cancer.

          -  Subjects will be eligible without regard to racial, or ethnic status. Attending
             physicians authorized to obtain informed consent may exercise discretion in excluding
             individuals for appropriate medical or other (e.g., mentally impaired) reasons.

          -  For the prospective acquisition of blood, saliva, pleural fluid or cerebrospinal
             fluid from patients who have or are suspected of having breast cancer or carcinoma
             in-situ, eligibility criteria include:

          -  Any patient at MSKCC with a previously confirmed or suspected diagnosis of malignant
             or premalignant (e.g., carcinoma in situ) breast disease is eligible for inclusion in
             the blood acquisition aspect of this protocol.

          -  Any patient with a previous diagnosis of invasive breast cancer who undergoes a
             palliative procedure related to the presence of a pleural effusion is eligible for
             the pleural fluid collection aspect of this protocol.

          -  Any patient with a previous diagnosis of invasive breast cancer with leptomeningeal
             metastasis who undergoes a routine procedure associated with the collection of
             cerebrospinal fluid is eligible for the cerebrospinal fluid collection aspect of this
             protocol.

          -  All subjects must be under the care of one or more members of the MSKCC Breast
             Disease Management Team at the time of enrollment.

          -  Subjects may have received prior hormonal therapy, cytotoxic chemotherapy, radiation
             therapy, or surgical therapy at MSKCC or another institution.

          -  All subjects must be 18 years or older

          -  Subjects will be eligible without regard to sex, racial, or ethnic status.   It is
             anticipated that approximately 99% of the patients will be female. Attending
             physicians authorized to obtain informed consent may exercise discretion in excluding
             individuals for appropriate medical or other (e.g., mentally impaired) reasons.

          -  If, after pathologic diagnosis, preinvasive or invasive breast disease is not found,
             patients previously consented for the blood collection aspect of this protocol will
             not be included.

        Exclusion Criteria:

          -  For the prospective acquisition of blood or saliva from control subjects without
             breast cancer, ineligibility criteria include:

               -  A first degree relative (mother, daughter, sister, father, brother or son) who
                  has been diagnosed with breast cancer.

               -  A personal history of breast cancer, lobular carcinoma in situ or atypia.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients will be offered participation in this study by their attending oncologist in the
        Department of Pediatrics at Memorial Sloan-Kettering Cancer Center.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Neuroblastic tumors diagnosed in accordance with the International Neuroblastoma
             Staging System viz., either (a) histologic confirmation (by the MSKCC Department of
             Pathology) which may involve immunohistochemical, ultrastructural, or cytogenetic
             studies, or (b) elevated urinary catecholamines plus tumor cells/clumps in the bone
             marrow.

        OR

          -  Clinically suspected neuroblastic tumors prior to diagnostic surgery.

        Exclusion Criteria:

          -  None
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients with histologically confirmed prostate cancer.

          -  Progressive disease manifest by either:

          -  Imaging modalities:

          -  Bone Imaging: New osseous lesions on bone imaging (bone scintigraphy or NaF PET scan)
             and/or MRI or CT: An increase in measurable soft tissue disease, or the appearance of
             new sites of disease. Or

          -  Biochemical progression: A minimum of three rising PSA values from a baseline that
             are obtained 1 week or more apart, or 2 measurements 2 or more weeks apart.

          -  Visible lesions by either CT, bone imaging, or MRI consistent with disease.

          -  Informed consent.

        Exclusion Criteria:

          -  Previous anaphylactic reaction to either FDHT or FDG

          -  Hepatic: Bilirubin &gt; 1.5 x upper limit of normal (ULN), AST/ALT &gt;2.5 x ULN, albumin &lt;
             2 g/dl, and GGT &gt; 2.5 x ULN IF Alkaline phosphatase &gt; 2.5 x ULN

          -  Renal: Creatinine &gt;1.5 x ULN or creatinine clearance &lt; 60 mL/min
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Cases will be identified in one of two ways. Pathology records will be reviewed for the
        years 1985-present. All patients with diagnoses of pancreatic cancer, uterine
        cancer,lymphoma, melanoma, cancer of the gallbladder and bile duct, stomach cancer, brain
        cancer, ovarian cancer, colon cancer, head and neck cancer, lung cancer and breast
        cancer(including DCIS) from 1985 to the present at MSKCC will be identified.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Diagnosis of cancer made at MSKCC or collaborating institutions, AND

          -  Tissue block of tumor or normal margin or extracted DNA available for study and
             sufficient material present to allow study without exhausting block or DNA,

          -  Individual self-identified as Jewish on intake.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients of the Dermatology and Clinical Immunology Services and Pediatrics that are
        determined to have a skin lesion with anticipated epidermal and superficial dermal
        histologic alterations amenable to visualization by surface confocal microscopy will be
        offered the opportunity to participate in the study.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients older than or equal to 10 years of age.

          -  Patients with a skin lesion with anticipated epidermal and superficial dermal
             histologic alterations amenable to visualization by surface confocal microscopy.

          -  Healthy volunteer subjects older than or equal to 10 years old.

          -  Ability to give informed consent.

        Exclusion Criteria:

          -  Patients who are allergic to fluorescein sodium.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  10 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patient must have clinically suspected or biopsy proven prostate cancer.    If a
             patient has been diagnosed with prostate cancer an official report of biopsy from
             MSKCC or outside site is required. All outside pathology reports will be confirmed at
             MSKCC.

          -  For those patients who have undergone prostate biopsy it is recommended that the
             interval between biopsy and protocol MRI/MRSI should be at least 8 weeks.

          -  Patient is a potential surgical candidate for treatment of prostate cancer

          -  Patient is willing to undergo an endorectal MRI/MRSI exam on the 3.0T MR scanner

        Exclusion Criteria:

          -  Patients who because of general medical or psychiatric condition, or physiologic
             status unrelated to the presence of prostate cancer cannot give valid informed
             consent.

          -  Patients who are unwilling or unable to undergo MRI/MRSI (including patients with
             contra-indications to MRI such as the presence of cardiac pacemakers or
             non-compatible intracranial vascular clips.

          -  Patients who cannot tolerate or have contra-indications to endorectal coil insertion;
             for example, patients who have had a prior abdominoperineal resection of the rectum
             or have Crohn's disease, patients with severe hemorrhoids, patients who have had
             prior radiation to the pelvis to treat a malignancy, or patients who have had minor
             rectal surgery within the previous 8 weeks.

          -  Patients with an allergic reaction to latex.

          -  Patients with a metallic hip implant or any other metallic implant or device in the
             pelvis that might distort local magnetic field and compromise quality of MRI/MRSI.
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  21 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed squamous cell cancer of
             the head and neck (SCCHN), from any primary site, including unknown primary cancers
             of the head and neck; patient must not have nasopharyngeal carcinoma of histologic
             types World Health Organization (WHO) 2 or 3 or squamous cell carcinoma that
             originated in the skin

          -  Patients must have SCCHN that is either (a) recurrent, judged incurable by surgery or
             radiation or (b) metastatic; NOTE: Patients who refuse radical resection for
             recurrent disease are eligible; NOTE: A second primary squamous cell carcinoma of the
             head and neck is allowed if eligibility is based on a recurrent or metastatic first
             primary squamous cell carcinoma of the head and neck

          -  No prior chemotherapy or biologic/molecular targeted therapy for recurrent or
             metastatic SCCHN

               -  Patients may have received one regimen of induction, concomitant
                  chemoradiotherapy and/or adjuvant chemotherapy as part of initial potential
                  curative therapy but must not have received prior chemotherapy for recurrent or
                  metastatic disease

               -  A minimum of 4 months is required between last dose of chemotherapy or
                  chemoradiotherapy and study treatment; in addition patients must be
                  progression-free for at least 4 months after completion of chemotherapy or
                  chemoradiotherapy or radiation plus cetuximab given with a curative intent;
                  (cetuximab therapy: 4 months is required between last dose of chemotherapy or
                  chemoradiotherapy and study treatment if part of concurrent regimen, 8 weeks if
                  part of adjuvant regimen post radiation)

               -  Patients having progression after 2 cycles of induction chemotherapy are not
                  eligible for the study

          -  No prior bevacizumab is allowed

          -  A maximum of one prior radiotherapy regimen, curative or palliative, to the head and
             neck is allowed; if the radiation is combined with chemotherapy and/or cetuximab, a
             minimum of 4 months must elapse between the end of radiotherapy and registration; if
             the radiation is given alone, a minimum of 8 weeks must elapse between the end of
             radiotherapy and registration; a minimum of 3 weeks must elapse between prior
             radiation to other areas and registration

          -  Patients must not be receiving any other investigational agent while on the study

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

          -  Patients must have recovered to grade 1 or better from any acute effects of prior
             surgery, chemotherapy, or radiation therapy, and should be &gt; 4 weeks post surgery;
             chronic late xerostomia, speech and swallowing abnormalities resulting from prior
             radiation or surgery are permitted if nutritional status is stable

          -  Patients must have measurable disease based on Response Evaluation Criteria in Solid
             Tumors (RECIST); baseline measurements and evaluations of all sites of disease must
             be obtained =&lt; 4 weeks prior to randomization; disease in previously irradiated sites
             is considered measurable if there has been unequivocal disease progression or
             biopsy-proven residual carcinoma following radiation therapy; persistent disease
             after radiotherapy must be biopsy proven at least 8 weeks after completion of
             radiation therapy; (radiographic findings are acceptable providing that clear-cut
             measurements can be made)

          -  Absolute neutrophil count (ANC) &gt;= 1500/mm^3

          -  Hemoglobin (Hgb) &gt;= 8.0 g/dL

          -  Platelet count &gt;= 100,000/mm^3

          -  Creatinine clearance of &gt;= 60 ml/min; creatinine clearance may be measured or
             calculated; if calculating, creatinine clearance, use the Cockroft-Gault formula

          -  Total bilirubin within normal limits (must be obtained =&lt; 2 weeks prior to
             randomization)

          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) must be within the
             range allowing for eligibility

               -  Alkaline phosphatase normal AND AST or ALT =&lt; 5 x upper limit of normal (ULN)

               -  Alkaline phosphatase &gt; 1 but =&lt; 2.5 x ULN AND AST or ALT &gt; 1 but =&lt; 1.5 x ULN

               -  Alkaline phosphatase &gt; 2.5 but =&lt; 5 x ULN AND AST or ALT normal

          -  Alkaline phosphatase must be within the range allowing for eligibility

          -  Urine dipstick must be =&lt; 0-1+ within 2 weeks (14 days) of randomization; if urine
             dipstick result is &gt; 1+, a calculation of urine protein creatinine (UPC) ratio is
             required; patients must have a UPC ratio &lt; 1.0 to participate in the study; NOTE: UPC
             ratio of spot urine is an estimation of the 24 urine protein excretion - a UPC ratio
             of 1 is roughly equivalent to a 24-hour urine protein of 1 gm

          -  No known brain metastases

          -  Patients who meet the following criteria will be excluded:

               -  Tumors that invade major vessels (e.g. the carotid) as shown unequivocally by
                  imaging studies

               -  Central (i.e. within 2 cm from the hilum) lung metastases that are cavitary as
                  shown unequivocally by imaging studies

               -  Any prior history of bleeding related to the current head and neck cancer

               -  History of gross hemoptysis (bright red blood of 1/2 teaspoon or more per
                  episode of coughing) =&lt; 3 months prior to enrollment

          -  No history of coagulopathy or hemorrhagic disorders

          -  Patients should not have a history of thrombosis (e.g. pulmonary embolism or deep
             venous thrombosis) currently requiring therapeutic anticoagulation (prophylactic use
             of warfarin 1 mg per day is allowed) and international normalized ratio (INR) should
             be &lt; 1.5 at registration

          -  Patients must not be receiving chronic daily treatment with aspirin (&gt; 325 mg/day) or
             non-steroidal anti-inflammatory agents (NSAID's) known to inhibit platelet function;
             the use of anti-platelet agents (e.g. dipyridamole [Persantine], ticlopidine
             [Ticlid], clopidogrel [Plavix]) is allowed only if patient is not receiving aspirin
             or NSAID's known to inhibit platelet function

          -  No hypercalcemia related to head and neck cancer

          -  Patients with a prior history of squamous cell or basal carcinoma of the skin or in
             situ cervical cancer must have been curatively treated; patients with a history of
             other prior malignancy must have been treated with curative intent and must have
             remained disease-free for 3 years post diagnosis

          -  No current peripheral neuropathy &gt;= grade 2 at time of randomization

          -  Patients must not have any co-existing condition that would preclude full compliance
             with the study

          -  No prior history of severe hypersensitivity reaction to docetaxel or other drugs
             formulated with polysorbate 80, if the physician's choice of chemotherapy regimen is
             docetaxel

          -  All patients must have blood pressure =&lt; 150/90 =&lt; 2 weeks prior to randomization;
             patients with history of hypertension must be well-controlled upon study entry (=&lt;
             150/90) on a stable regimen of anti-hypertensive therapy

          -  No major surgical procedure, open biopsy, or significant traumatic injury within 28
             days prior to study enrollment, or anticipation of need for major surgical procedure
             during the course of the study

          -  No unstable angina or myocardial infarction within the previous 6 months; no
             symptomatic congestive heart failure, New York Heart Association (NYHA) grade II or
             greater; no history of aortic dissection or presence of aneurysm &gt; 6 cm (or at high
             risk for rupture); no serious cardiac arrhythmia requiring medication (history of
             chronic atrial fibrillation or other atrial arrhythmia with controlled rate on
             medication is allowed); no clinically significant peripheral vascular disease
             manifested by intermittent claudication or need for vascular intervention; no history
             of aortic dissection; no history of any central nervous system (CNS) cerebrovascular
             ischemia or stroke within the last 6 months; no active serious infection

          -  Patients should not have prior history of a serious human anti-human antibody (HAHA)
             reaction; patients with known hypersensitivity to Chinese hamster ovary cell products
             or other recombinant human antibodies are not eligible

          -  Women must not be pregnant or breast feeding; pregnant women are excluded from this
             study; women of child-bearing potential and men must agree to total abstinence or to
             use adequate hormonal or barrier method of birth control prior to study entry and for
             the duration of study participation; should a woman become pregnant or suspect she is
             pregnant while in this study, she should inform her treating physician immediately;
             all females of childbearing potential must have a blood test or urine study within 2
             weeks prior to randomization to rule out pregnancy

          -  Human immunodeficiency virus (HIV)-positive patients receiving combination
             anti-retroviral therapy are excluded from the study; appropriate studies will be
             undertaken in patients receiving combination anti-retroviral therapy when indicated

          -  No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal
             abscess within 6 months prior to registration
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients with advanced AML or ALL defined as beyond first remission, primary
             refractory disease, or evolved from myelodysplastic or myeloproliferative syndromes;
             or patients with MDS expressed as refractory anemia with excess blasts (RAEB),
             refractory cytopenia with multilineage dysplasia (RCMD), RCMD with ringed
             sideroblasts (RCMD-RS), or chronic myelomonocytic leukemia (CMML)

          -  Patients not in remission must have cluster of differentiation (CD)45-expressing
             leukemic blasts; patients in remission do not require phenotyping and may have
             leukemia previously documented to be CD45 negative (because in remission patients,
             virtually all antibody binding is to non-malignant cells which make up &gt;= 95% of
             nucleated cells in the marrow)

          -  Patients should have a circulating blast count of less than 10,000/mm^3 (control with
             hydroxyurea or similar agent is allowed)

          -  Patients must have a creatinine clearance greater than 50/ml per minute by the
             following formula (test must be performed within 28 days prior to registration):

               -  Creatinine clearance (CrCl) = (140-age) (Wt in Kg) x 0.85 (female) OR 1.0
                  (male)/72 x serum Cr

          -  Bilirubin &lt; 2 times the upper limit of normal

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 2 times the
             upper limit of normal

          -  Karnofsky score &gt;= 70 or Eastern Cooperative Oncology Group (ECOG) =&lt; 2

          -  Patients must have an expected survival of &gt; 60 days and must be free of active
             infection

          -  Patients must have a related donor who is identical for one HLA haplotype and
             mismatched at the HLA-A, -B or class II, DR beta 1 (DRB1) loci of the unshared
             haplotype with the exception of single HLA-A, -B or DRB1 mismatches

          -  DONOR: Related donor who is identical for one HLA haplotype and mismatched at the
             HLA-A, -B, or DRB1 loci of the unshared haplotype with the exception of single HLA-A,
             -B, or DRB1 mismatches

        Exclusion Criteria:

          -  Circulating antibody against mouse immunoglobulin (HAMA)

          -  Prior radiation to maximally tolerated levels to any critical normal organ

          -  Cross-match positive with donor

          -  Patients may not have symptomatic coronary artery disease and may not be on cardiac
             medications for anti-arrhythmic or inotropic effects

          -  Left ventricular ejection fraction &lt; 35%

          -  Corrected diffusion capacity of carbon monoxide (DLCO) &lt; 35% and/or receiving
             supplemental continuous oxygen

          -  Liver abnormalities: fulminant liver failure, cirrhosis of the liver with evidence of
             portal hypertension, alcoholic hepatitis, esophageal varices, hepatic encephalopathy,
             uncorrectable hepatic synthetic dysfunction as evidenced by prolongation of the
             prothrombin time, ascites related to portal hypertension, bacterial or fungal liver
             abscess, biliary obstruction, chronic viral hepatitis, or symptomatic biliary disease

          -  Patients who are known seropositive for human immunodeficiency virus (HIV)

          -  Perceived inability to tolerate diagnostic or therapeutic procedures, particularly
             treatment in radiation isolation

          -  Central nervous system (CNS) involvement with disease refractory to intrathecal
             chemotherapy and/or standard cranial-spinal radiotherapy

          -  Women of childbearing potential who are pregnant (beta-human chorionic gonadotropin
             positive [b-HCG+]) or breast feeding

          -  Fertile men and women unwilling to use contraceptives during and for 12 months
             post-transplant

          -  Inability to understand or give an informed consent
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Histologically confirmed seminoma of the testis

               -  Stage I disease, as determined by clinical examination and CT scan of the chest,
                  abdomen, and pelvis

          -  No evidence of any non-seminoma germ cell tumor elements

          -  Has undergone orchidectomy within the past 8 weeks

               -  Normal serum alpha-fetoprotein pre-orchidectomy and at study randomization

               -  Normal serum beta human chorionic gonadotrophin at study randomization (may have
                  been elevated pre-orchidectomy)

          -  Not planning to undergo adjuvant therapy

        PATIENT CHARACTERISTICS:

          -  Able to attend regular surveillance

          -  No other malignancy within the past 10 years expect successfully treated nonmelanoma
             skin cancer

          -  No contraindication to MRI (i.e., ferrous metal implants of any type, cardiac
             pacemaker or defibrillator, or history of injury by metal fragments)

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  16 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   The study population is a Veteran population presenting to a VA Hospital upper endoscopy
        unit
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  18-80 years

          -  Patients must be able to provide written informed consent

          -  Patients referred for endoscopy for screening/surveillance of BE or for endoscopic
             treatment of BE with early mucosal neoplasia

        Exclusion Criteria:

          -  Current use of aspirin, non-steroidal anti-inflammatory agents(NSAIDs),or chronic
             anticoagulants that cannot be discontinued prior to the procedure.

          -  Inability to provide written informed consent

          -  Significant thrombocytopenia or coagulopathy

          -  Any significant co-morbid condition that would prevent the safe administration of
             conscious sedation
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  malignant colonic obstruction localized between splenic flexure and 15 cm from anal
             margin diagnosed by CTScan.

          -  Possibility of endoscopy and stent location during next 24 h after diagnostic.

          -  Clinical occlusion to gas and faeces.

          -  Informed consent obtained from the patient or from a relative in case of inability.

        Exclusion Criteria:

          -  Bowel perforation diagnosed by clinical exploration and complementary studies.

          -  Associated pathologies contraindicating general anaesthesia and/or haemodynamic
             instability.

          -  Impossibility to gain a valid informed consent or refusal from the patient.

          -  Patients with multiple liver metastases diagnosed by CTScan at the moment of
             diagnostic and not considered operable with curative intention following the
             standards of every center.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   ELIGIBILITY:

        Inclusion Criteria

          -  Histologically confirmed non-small cell cancer by biopsy or cytology.  Squamous cell
             carcinoma, adenocarcinoma, large cell carcinoma, bronchioalveolar carcinoma, or
             non-small cell carcinoma (not otherwise specified) are allowed.

          -  Staging studies must identify patient as AJCC Stage I or II based on only 1 of
             following combinations of TNM staging:

               -  T1, N0, M0

               -  T2 (&lt;=7cm), N0, M0

               -  T3 (&lt;=7cm), N0, M0

          -  Primary tumor must be arising in one of the following central chest locations:

               -  Within or touching the zone of the proximal bronchial tree (a volume 2cm in all
                  directions around the proximal bronchial tree [carina, R &amp; L main bronchi, R &amp; L
                  upper lobe bronchi, intermedius bronchus, R middle lobe bronchus, lingular
                  bronchus, R &amp; L lower lobe bronchi])

               -  Adjacent to (within 5 mm) or invading the mediastinal pleura

               -  Adjacent to (within 5 mm) or invading the parietal pericardium

          -  To differentiate T3 lesions involving the mediastinal pleura from T4 lesions
             involving major vessels or organs, a chest MRI will be obtained. If any uncertainty
             remains, the patient will have four-dimensional CT scans (4DCT) in an effort to
             determine the degree of tumor motion.  A freely mobile tumor during ventilation will
             be judged to be T3 disease.

          -  Patients with hilar or mediastinal lymph nodes &lt;=1cm and no abnormal hilar or
             mediastinal uptake on PET will be considered N0.  Patients with &gt;1cm hilar or
             mediastinal lymph nodes on CT or abnormal PET (including suspicious but
             non-diagnostic uptake) may be eligible if directed tissue biopsy of all abnormally
             identified areas are negative for cancer.

          -  Primary tumor must be technically resectable by an experienced thoracic cancer
             clinician, with a reasonable possibility of obtaining a gross total resection with
             negative margins (potentially curative resection, PCR).  However, patients must have
             underlying physiological medical problems prohibiting PCR (i.e., problems with
             general anesthesia, the operation, the post-op recovery period, or removal of
             adjacent functioning lung) or refuse surgery.  Deeming a patient medically inoperable
             based on pulmonary function for surgical resection may include any of the following:
             baseline FEV1 &lt;40% predicted; post-operative predicted FEV1 &lt;30% predicted; severely
             reduced diffusion capacity; baseline hypoxemia and/or hypercapnia; exercise oxygen
             consumption &lt;50% predicted; severe pulmonary hypertension; diabetes with severe end
             organ damage; severe cerebral, cardiac, or peripheral vascular disease; or severe
             chronic heart disease.  Any one of these problems will qualify a patient for this
             trial.

          -  Age &gt;=18.

          -  Zubrod performance status 0-2.

          -  Women of childbearing potential must use effective contraception.

          -  No direct evidence of regional or distant metastases after appropriate staging
             studies.  No synchronous primary or prior malignancy in past 2 years except
             non-melanoma skin cancer or in situ cancer.

          -  No previous lung or mediastinal radiation therapy.

          -  No plans for concomitant antineoplastic therapy (including standard fractionated RT,
             chemo, biologic, vaccine therapy, or surgery) while on this protocol except at
             disease progression.

          -  No active systemic, pulmonary, or pericardial infection.

          -  No pregnant or lactating women.

          -  PRESTUDY REQUIREMENTS:

               -  History and Physical Examination, Weight, Zubrod performance status (within 4
                  weeks pre-study entry)

               -  Evaluation by thoracic cancer clinician (within 8 weeks pre-study entry)

               -  Pregnancy test, if applicable (serum or urine, within 72 hours prior to
                  treatment start.)

               -  CT (preferably with contrast unless medically contraindicated; both lungs,
                  mediastinum, liver, adrenals)

               -  PET (using FDG with visualization of primary tumor and draining lymph node
                  basins in hilar and mediastinal regions)

               -  Brain MRI or head CT with contrast

               -  PFTs  - include routine spirometry, lung volumes, diffusion capacity

               -  Signed informed consent.

        Exclusion Criteria:

        There is no exclusion criteria associated with this protocol.  Please see the above
        inclusion criteria.-
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Biopsy proven NRSTS or bone sarcoma

          -  Less than or equal to 30 years of age

          -  Patients must have been treated with a standardly accepted chemotherapy regimen if
             chemotherapy is indicated

          -  Patients must be willing to receive follow-up care for a minimum of five years after
             treatment at MGH and annual visits unless it is too difficult to return to MGH for
             follow-up care.  In that event, the patient or guardian must be willing to have their
             outside medical information released in order to track the results of treatment

          -  Timing of radiation may be according to concurrent protocol

        Exclusion Criteria:

          -  Co-morbidities that would make the use of radiation too toxic to deliver safely, such
             as serious local injury of collagen vascular disease

          -  Patients who are pregnant

          -  Previous treatment with radiation therapy

          -  Concurrent adriamycin or gemcitabine chemotherapy is planned, unless on a concurrent
             protocol
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  30 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients with biopsy proven newly diagnosed rhabdomyosarcoma.

          -  Patients less than or equal to 21 years of age.

          -  Patients must be treated with a standardly accepted chemotherapy regimen.

          -  May not have metastatic disease unless aged 2-10 with embryonal histology.

          -  Must be willing to receive follow-up care for a minimum of five years after treatment
             at MGH and annual visits unless it is too difficult to return to MGH for follow-up
             care.  In that event, they must be willing to have their outside medical information
             released to us to track the results.

          -  Timing of radiation must be according to the IRB protocol upon which the patient is
             treated within either 35 days of last chemotherapy or surgery.

        Exclusion Criteria:

          -  Life expectancy of less than 2 years.

          -  Co-morbidities that would make the use of radiation too toxic to deliver safely, such
             as serious local injury or collagen vascular disease.

          -  Patients who are pregnant

          -  Previous treatment with radiation therapy.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  21 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients must have histologically documented AML, ALL, MDS, CML, Acute myeloid
             leukemia (AML) with one or more of the following criteria

               -  CR 1 with poor risk features

               -  CR 2, or higher order CR

          -  Acute lymphoblastic leukemia (ALL) with one of the following criteria

               -  CR 1 with poor risk features

               -  CR 2, or higher order CR

          -  Myelodysplasia, RAEB I

          -  Donor has been identified

          -  Age  65 years.

          -  Performance Status 0-1.

        Exclusion Criteria:

          -  Patients relapsing &lt;6 months after autologous SCT are not eligible.

          -  Patients with active infections requiring oral or intravenous antibiotics are not
             eligible for enrollment until resolution of infection.

          -  Non-pregnant and non-nursing
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  65 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Patient has provided a written informed consent prior to study-specific screening
             procedures, with the understanding that she has the right to withdraw from the study
             at any time, without prejudice.

          2. Woman  &gt; 18 years of age.

          3. Histologically confirmed invasive breast cancer.

          4. HER2-positive breast cancer (preferably assessed with CISH or FISH; if not available
             with  immunohistochemistry 3+)

          5. A high risk of breast cancer recurrence  with one of the following:

               -  Pathological N0 with the longest invasive tumor diameter &gt;5 mm

               -  Histologically confirmed regional node positive disease (pN+; nodal isolated
                  tumor cells/cell clusters &lt; 0.2 mm in diameter (ITP) are not counted as a
                  metastasis)

        Exclusion Criteria:

          1. Presence of distant metastases.

          2. Inflammatory breast cancer.

          3. pT1bN0M0 (i.e. the longest tumor diameter 6 to 10 mm, node-negative) and histological
             grade 1.

          4. Clinically significant (i.e. active) cardiac disease (e.g. congestive heart failure,
             symptomatic coronary artery disease and cardiac arrhythmia not well controlled with
             medication) or myocardial infarction within the last 12 months.

          5. Left ventricular ejection fraction less than 50% (or under the institutional normal
             reference range) assessed by echocardiography or isotope cardiography.

          6. ER, PgR and HER-2 status (via in situ hybridization or immunohistochemistry) not
             determined.

          7. Primary systemic cancer therapy (neoadjuvant chemotherapy or endocrine therapy) has
             been administered prior to breast surgery.

          8. The WHO performance status &gt; 1.

          9. Pregnant or lactating women.

         10. Women of childbearing potential unless using a reliable and appropriate contraceptive
             method. Women must have been amenorrheic for at least 12 months prior to study entry
             to be considered postmenopausal and to have no childbearing potential. Women of
             childbearing potential (menstruating within 12 months of study entry), or with no
             hysterectomy and age &lt; 55, must have a negative pregnancy test at baseline.

         11. More than 12 weeks between breast surgery and date of randomization.

         12. Organ allografts with immunosuppressive therapy required.

         13. Major surgery (except breast surgery) within 4 weeks prior to study treatment start,
             or lack of complete recovery from the effects of major surgery.

         14. Participation in any investigational drug study within 4 weeks preceding treatment
             start.

         15. Patients with a history of uncontrolled seizures, central nervous system disorders or
             psychiatric disability judged by the investigator to be clinically significant
             precluding study participation.

         16. History of another malignancy within the last five years except cured basal cell
             carcinoma of skin or carcinoma in situ of the uterine cervix.

         17. One or more of the following:

               -  Blood hemoglobin &lt; 10.0 g/dL, neutrophils &lt; 1.5 x 109/L, platelet count &lt; 120 x
                  109/L

               -  Serum/plasma creatinine &gt; 1.5 x Upper Limit of Normal (ULN)

               -  Serum/plasma bilirubin &gt; ULN

               -  Serum/plasma ALT and/or AST &gt; 1.5 x ULN

               -  Serum/plasma alkaline phosphatase &gt; 2.5 x ULN

         18. Serious uncontrolled infection or other serious uncontrolled concomitant disease.

         19. Unwilling or unable to comply with the protocol for the duration of the study.

         20. History of hypersensitivity to the investigational products or to drugs with similar
             chemical structures.

         21. Pre-existing motor or sensory neurotoxicity of a severity  grade 2 by CTCAE version
             3, unless related to mechanical etiology.
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Female gender

          -  Age  18 years

          -  Invasive primary female breast cancer

          -  Pathologically proven regional nodal metastasis

          -  Status post mastectomy or partial mastectomy with an assessment of axillary nodes via
             sentinel lymph node biopsy and/or axillary lymph node dissection.

          -  Signed study specific consent form

        Exclusion Criteria:

          -  Distant metastasis

          -  Currently Pregnant

          -  Psychiatric or addictive disorders that preclude informed consent

          -  Time from initial diagnosis to the start of radiation therapy &gt; one year

          -  Estimated life expectancy judged to be &lt; one year

          -  Prior radiation to the ipsilateral breast or chest wall

          -  Primary breast cancer is lymphoma or sarcoma

          -  Patients being treated with concurrent chemotherapy.
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients are recruited from the general practice of 3 of our investigators.  Patients will
        have received an structural allograft or vascularized autograft for the treatment of bone
        cancer.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  male or female

          -  all races will be included

          -  autograft or allograft of long bone as part of treatment for bone tumor

        Exclusion Criteria:

          -  pregnancy

          -  patients with a history of IV contrast reactions

          -  contraindication to use of epinephrine or diphenhydramine

          -  hypertyroidism or history of sensitivity to iodine

          -  kidney disease (abnormal urinalysis or calculaged GFR) or poor hydration due to poor
             intake or other causes
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  10 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   All Medical Center including personal breast clinic, general hospital, university
        hospital, cancer institute in Korea
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Over 19 years old

          -  Agree to this study

          -  Breast cancer patient with family history of breast/ovarian cancer (1 subgroup)

          -  Breast cancer patient; young age (&lt;40), bilateral, male, combined ovarian (2
             subgroup)

          -  Family members with 1, 2 subgroups (3 subgroup)

        Exclusion Criteria:

          -  Under 20 years old

          -  Unable to decide for oneself
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  20 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   People who live in Iijima town
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  People who live in Iijima town at their age  of  19  to 69 years
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  19 Years
 </minimum_age>
 <maximum_age>
  69 Years
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   MSKCC's Clinics and Moffitt Cancer Center, Tampa, Florida
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  All patients (male and female) who are scheduled to undergo total, anterior or
             posterior pelvic exenteration for pelvic malignancies arising in gynecologic,
             colorectal or urologic organs are eligible for participation in the study. Anterior
             or posterior pelvic exenteration must involve formation of a permanent ostomy
             (urostomy or colostomy).

          -  Participants must be able to speak and read English proficiently.

          -  Participants must be able to provide written informed consent.

          -  Patients must be 18 years of age or older to enroll.

        Exclusion Criteria:

          -  Subjects may be excluded or withdrawn from the study based on the following criteria.

          -  Development of a cognitive or psychiatric deficit resulting in an inability to
             provide meaningful informed consent

          -  Inability to speak or read in English.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed relapsed or refractory HIV-associated
             non-Hodgkin lymphoma (NHL)

               -  Must have histologic or cytologic documentation of prior AIDS-associated NHL
                  (i.e., at time of diagnosis) for clinically relapsed and/or refractory disease
                  for which biopsy is not feasible

               -  Must have documented HIV seropositivity

               -  Must have documentation of Epstein-Barr Virus (EBV)- and/or human herpes virus-8
                  (HHV-8)- positive infection within the lymphoma (i.e., LMP-1, LANA expression,
                  or positive Epstein-Barr-encoded RNAs [EBERs])

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  ECOG performance status (PS) 0-2 OR Karnofsky PS 50-100%

          -  Life expectancy &gt; 2 months

          -  ANC  1,000/mm* (growth factor support allowed)

          -  Hemoglobin  8.0 g/dL* (growth factor support allowed)

          -  Platelet count  100,000/mm

          -  Total bilirubin  1.5 mg/dL

          -  AST/ALT  2.5 times institutional upper limit of normal (ULN)

          -  Serum creatinine  ULN

          -  Creatinine clearance  50 mL/min

          -  Negative pregnancy test

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception NOTE: *Patients with lymphomatous
             involvement of the bone unable to meet hematologic criteria are allowed

        Exclusion criteria:

          -  Peripheral neuropathy  grade 2

          -  Uncontrolled intercurrent illness including, but not limited to, any of the
             following:

               -  Ongoing or active infection

                    -  Opportunistic infections controlled by antimicrobial or suppressive therapy
                       allowed, unless the investigator judges the infection likely to become
                       life-threatening in the setting of multi-agent chemotherapy

               -  Symptomatic congestive heart failure

               -  Unstable angina pectoris

               -  NYHA class III or IV heat failure

               -  Myocardial infarction within the past 6 months

               -  Uncontrolled angina

               -  Severe uncontrolled ventricular or other cardiac arrhythmias

               -  Acute ischemia or active conduction system abnormalities by ECG

               -  Serious psychiatric or medical illness, that would interfere with study
                  compliance

          -  Social situations that would interfere with study compliance

          -  Acute active HIV-associated opportunistic infection requiring antibiotic treatment

               -  Mycobacterium avium or candidiasis allowed unless concurrent therapy with
                  moderate-to-strong CYP3A4 inducers or inhibitors is required

               -  Chronic myelosuppressive agent therapy allowed provided hematologic criteria are
                  met

          -  Hypersensitivity to compounds of similar chemical or biological composition to
             bortezomib, boron, mannitol, ifosfamide, carboplatin, or etoposide

          -  Concurrent malignancy except carcinoma in situ of the cervix, in situ anal cancer,
             nonmetastatic nonmelanoma skin cancer, or Kaposi's sarcoma not requiring systemic
             chemotherapy

          -  Active hepatitis B infection (hepatitis B surface antigen-positive), unless 1 of the
             following criteria are met:

               -  Able to start dual anti-hepatitis B adefovir and telbivudine therapy prior to
                  study

               -  Receiving dual anti-hepatitis B therapy for at least 12 weeks prior to study
                  with either agent active against HIV (i.e., entecavir, tenofovir, lamivudine, or
                  emtricitabine)

          -  Concurrent grapefruit juice/fruit or green tea

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Recovered from prior adverse effects due to agents administered more than 3 weeks
             earlier

          -  Glucocorticoid therapy within the past 3 weeks allowed

          -  More than 3 weeks since prior chemotherapy

          -  More than 2 weeks since prior radiotherapy

          -  More than 14 days since prior and no other concurrent investigational agents (other
             than bortezomib)

          -  No concurrent moderate-to-strong CYP3A4 inducers or inhibitors other than protease
             inhibitors

          -  Concurrent stable (at least 12 weeks) antiretroviral regimen allowed
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients with thyroid cancer or benign thyroid disease (nodules or goiter) who underwent
        thyroidectomy and/or neck dissection as standard of care.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Age 1 - 100

          -  Benign or malignant thyroid lesion, other malignancy or no thyroid abnormality

          -  Pathologic specimen available for analysis

          -  Ability to provide informed consent (for prospective study, Part Two)

          -  Age greater than age 18 (for normal controls)

        Exclusion Criteria:

          -  Patients without adequate data for analysis

          -  Histopathologic or cytopathologic diagnosis of for medullary thyroid carcinoma (not
             derived from the thyroid follicular epithelium), thyroid lymphoma

          -  Unwilling to participate or unable to provide informed consent
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  1 Year
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Women with endometrial carcinoma that undergo an endometrial biopsy before treatment with
        hysterectomy with bilateral salpingoophorectomy with or without  pelvic lymph node
        staging.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Women with endometrial carcinoma

          -  Available endometrial biopsy

          -  Informed consent

        Exclusion Criteria:

          -  No informed consent
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   tertiary referral center
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  patients harboring secretory or non-secretory adenomas and/or siblings and/or spouses

        Exclusion Criteria:

          -  patient without consenting siblings and/or siblings and/or spouses
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Clinic
  </textblock>
 </study_pop>
 <sampling_method>
  Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Age &gt; 18 years.

          -  Newly diagnosed patient (within 3 months from the date of the diagnostic  bone marrow
             aspirate).

          -  MDS classified according to WHO criteria (2001).

          -  IPSS Risk group Low or Intermediate-1 .

          -  Able and willing to provide the written informed consent.

        Exclusion Criteria:

          -  Age &lt;18 years

          -  Patient unwilling or unable to give consent

          -  intermediate-2 or high risk MDS, or in case the IPSS group cannot be defined  5%
             bone marrow blasts.

          -  secondary/therapy-related MDS.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Age: 0-21 years at the time of diagnosis.

          -  Diagnosis: Histologic verification at either the time of original diagnosis       or
             relapse of neuroblastoma or medulloblastoma.

          -  Disease Status: Refractory or first or multiple relapsed neuroblastoma, or
             medulloblastoma that has relapsed after, or is refractory to, a
             chemotherapy-containing treatment regimen.

          -  Measurable disease, including at least one of the following:

               -  Measurable tumor by CT or MRI

               -  For neuroblastoma patients only, a positive MIBG (MIBG not required if subject's
                  neuroblastoma is previously determined to not uptake MIBG), abnormal urinary
                  catecholamine levels, or positive bone marrow biopsy/aspirate.

               -  For medulloblastoma patients only, positive CSF cytology

          -  Current disease state must be one for which there is currently no known curative
             therapy.

          -  A negative urine pregnancy test is required for female participants of child bearing
             potential (13 years of age).

          -  Organ Function Requirements Patients without bone marrow metastases must have an ANC
             &gt; 500/l and platelet count &gt;50,000/l.

          -  Patients must have adequate liver function as defined by AST or ALT &lt;10x normal

          -  Informed Consent: All patients and/or legal guardians must sign informed written
             consent.  Assent, when appropriate, will be obtained according to institutional
             guidelines

        Exclusion Criteria:

          -  Life expectancy &lt;2 months or Lansky score &lt;50%

          -  Investigational Drugs: Patients who are currently receiving another investigational
             drug are excluded from participation.

          -  Anti-cancer Agents: Patients who are currently receiving other anticancer agents are
             not eligible.  Patients must have fully recovered from the effects of prior
             chemotherapy, generally at least 3 weeks from the most recent administration (6 weeks
             for nitrosoureas).

          -  Infection: Patients who have an uncontrolled infection are not eligible until the
             infection is judged to be well controlled.

          -  Patients who, in the opinion of the investigator, may not be able to comply with the
             safety monitoring requirements of the study, or in whom compliance is likely to be
             suboptimal, should be excluded.

        Compensation for travel related expenses may be available
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  21 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients undergoing shave-biopsy on an anatomical site that is readily accessible to
             the VivaScope 1500 (for example, chest, back, legs, arms, cheek, forehead).

          -  The additional 30 patients for this amendment will be imaged with the newly developed
             Vivascope 3000 handheld confocal microscope.

          -  Ability to sign informed consent.

          -  Age &gt; 18 years.

        Exclusion Criteria:

          -  Shave-biopsy located on a site that is not amenable to confocal imaging (for example,
             adjacent to the nose, ears or eyes, fingers, toes).

          -  Inability to give informed consent.

          -  Known hypersensitivity to adhesive rings.

          -  Inability to tolerate imaging procedure (i. e., remain relatively still for multiple
             short durations of 3-4 minutes).
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  80 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Rectal cancer can be resected by curative and elective surgery.

          -  Rectal adenocarcinoma below peritoneal reflection

          -  American Society of AnesthesiologyASA class to  lesions

        Exclusion Criteria:

          -  Cancer located at upper rectum above peritoneal reflection

          -  Distant metastasis

          -  Adjacent organ invasion

          -  Intestinal obstruction

          -  Past colonic surgery

          -  Body mass indexBMI35 kg/m2

          -  Patients who can not complete the whole treatment protocol of concurrent
             chemoradiation therapy.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  85 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed squamous cell carcinoma (SCC) of the oral
             cavity, oropharynx, hypopharynx, or larynx

               -  SCC of the base of the tongue, pharynx, larynx, or hypopharynx are eligible
                  provided additional biopsy tissue has been already saved in the Tumor Tissue
                  Core Laboratory for research purposes

               -  SCC of the oral cavity or tonsils are eligible only if they already have or
                  agree to have additional biopsies of tumor with adjacent normal tissue available
                  for molecular studies

          -  Candidate for surgical treatment with an established date for surgery with  a 15 day
             window of opportunity

          -  Measurable disease by CT scan or MRI

          -  No nasopharyngeal carcinoma

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  ECOG performance status 0-2

          -  ANC &gt; 1,500/L

          -  Platelet count &gt; 100,000/L

          -  Total bilirubin &lt; 1.5 mg/dL

          -  AST/ALT &lt; 2 times upper limit of normal

          -  Creatinine &lt; 1.5 mg/dL

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        Exclusion criteria:

          -  Uncontrolled intercurrent illness including, but not limited to, any of the
             following:

               -  Ongoing or active infection or psychiatric illness/social situations that would
                  limit compliance with study requirements

               -  Significant history of uncontrolled cardiac disease (i.e., uncontrolled
                  hypertension, unstable angina, or myocardial infarction within the past 3
                  months)

               -  Uncontrolled congestive heart failure

               -  Cardiomyopathy with decreased ejection fraction

          -  History of interstitial lung disease (e.g., pneumonitis or pulmonary fibrosis) or
             evidence of interstitial lung disease on chest CT scan

          -  Clinically significant ophthalmologic abnormalities

          -  HIV positivity

        PRIOR CONCURRENT THERAPY:

          -  More than 1 year since prior chemotherapy, biologic therapy, or hormonal therapy

          -  No prior radiotherapy or chemotherapy for this tumor

          -  No prior EGFR inhibitors

          -  No concurrent grapefruit or grapefruit juice

          -  No other concurrent investigational agents
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Criteria:

        Inclusion criteria:

          -  Included subjects will be 18 years old.

          -  Included subjects will not be pregnant.

          -  Included subjects will have a negative urine pregnancy test.

          -  Included subjects will be scheduled for colposcopy and/or LEEP treatment at the VGH
             Women's Clinic.

          -  Included subjects will indicate understanding of the study.

          -  Included subjects will provide informed consent to participate.

        Exclusion criteria:

          -  Individuals &lt;18 years old will be excluded.

          -  Pregnant individuals will be excluded.

          -  Individuals that have had an operation to remove their cervix will be excluded.

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  19 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Histologically confirmed newly diagnosed CNS tumors of any of the following :

          -  Medulloblastoma (all histologic subtypes, including medullomyoblastoma and melanotic
             medulloblastoma)

          -  Supratentorial primitive neuroectodermal tumor (PNET) (including CNS neuroblastoma or
             ganglioneuroblastoma, medulloepithelioma, and ependymoblastoma)

          -  Pineoblastoma

          -  Atypical teratoid rhabdoid tumor (ATRT)

          -  Choroid plexus carcinoma

          -  High grade glioma (including anaplastic astrocytoma, anaplastic oligodendroglioma,
             anaplastic ganglioglioma, pleomorphic xanthoastrocytoma with anaplastic features,
             high-grade astroblastoma , anaplastic pilocytic astrocytoma, malignant glioneuronal
             tumor, glioblastoma multiforme), or gliosarcoma,

          -  Ependymoma (including all ependymoma histological variants)

          -  Age &lt; 3 years at time of diagnosis for all histological diagnosis. Medulloblastoma
             patients  3 and &lt; 5years old at diagnosis who have non-metastatic disease with no
             more than 1cm2 of residual tumor are also eligible.

               -  Meets criteria for 1 of the following risk groups:

          -  Low-risk group:

               -  Histologically confirmed nodular desmoplastic medulloblastoma, including
                  medulloblastoma with extensive nodularity

                    -  Focal areas of anaplasia or other atypical features suggesting more
                       aggressive phenotype in a tumor otherwise considered nodular desmoplastic
                       should be treated on the intermediate-risk group, with final risk
                       stratification at the discretion of principal investigator and study
                       pathologist

               -  No evidence of CNS metastasis 7 to 28 days after surgery by MRI and cytologic
                  examination of lumbar cerebrospinal fluid (CSF)

                    -  Ventricular CSF from a shunt or Ommaya reservoir may be used to rule out M1
                       disease when lumbar puncture is medically contraindicated

                    -  Intermediate-risk group assignment when there is no other evidence of
                       metastasis and CSF sampling is not possible

               -  Gross total resection, defined as residual tumor or imaging abnormality (not
                  definitive for residual tumor) with a size of &lt; 1 cm2 confirmed on postoperative
                  CT scan or MRI

               -  Brain stem invasion by the tumor in the absence of imaging evidence of residual
                  tumor (tumor size &lt; 1 cm2) and otherwise meets criteria for the low-risk group,
                  the patient will be classified as low-risk

               -  Desmoplastic medulloblastoma patients who are 3 -&lt;5 years of age will NOT be
                  eligible for the low risk arm of the protocol.

          -  Intermediate-risk group:

               -  Histologically confirmed nodular desmoplastic medulloblastoma with less than
                  gross total resection and no evidence of metastasis

               -  Any eligible histologic diagnosis other than desmoplastic medulloblastoma with
                  no evidence of CNS metastasis

               -  Medulloblastoma patients who are 3 and &lt; 5 yrs of age irrespective of histology
                  and with no evidence of CNS metastasis

          -  High-risk group:

               -  Any eligible histologic diagnosis with evidence of CNS metastasis

               -  Patients with extraneural metastasis are eligible for treatment on the high-risk
                  group

        PATIENT CHARACTERISTICS:

          -  Lansky performance status  30 (except for posterior fossa syndrome)

          -  WBC &gt; 2,000/mm3

          -  Platelets &gt; 50,000/mm3 (without support)

          -  Hemoglobin &gt; 8 g/dL (with or without support)

          -  ANC &gt; 500/mm3

          -  Serum creatinine &lt; 3 times upper limit of normal (ULN)

          -  ALT &lt; 5 times ULN

          -  Total bilirubin &lt; 3 times ULN

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No more than 31 days since prior definitive surgery

          -  No prior radiotherapy or chemotherapy other than corticosteroid therapy
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  5 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Ages 18 to 75 years old

          -  Eligible for and co-enrolled on protocol UMN-2005LS036, for treatment of any of the
             following advanced hematologic malignancies:

               -  Acute leukemias in complete remission (high risk CR1 or subsequent CR); chronic
                  myelogenous leukemia (except refractory blast crisis); myelodysplastic syndrome
                  with severe pancytopenia or complex cytogenetics, large-cell lymphoma, Hodgkin's
                  lymphoma and multiple myeloma, chronic lymphocytic leukemia/small lymphocytic
                  lymphoma, marginal zone b-cell lymphoma, follicular lymphoma, lymphoplasmacytic
                  lymphoma, mantle-cell lymphoma, prolymphocytic leukemia may be eligible after
                  initial therapy.

          -  Have three partially HLA matched umbilical cord blood (UCB) units (1-2 units for UCB
             transplantation per MT2005-02 and 1 unit for the Treg cell infusion.)

          -  Adequate organ function

        Exclusion Criteria:

          -  Patients not exposed to highly immunosuppressive single agent or multi-agent
             chemotherapy within 3 months, or an ablative preparative regimen for autologous
             hematopoietic stem cell transplant (HCT) within 1 year.

          -  Pregnancy or breastfeeding

          -  Current active serious infection

          -  Evidence of human immunodeficiency virus (HIV) or known HIV positive serology

          -  Patients with acute leukemia in morphologic relapse/persistent disease defined as &gt;5%
             blasts in a &gt; or = 15% cellular bone marrow or any % blasts if blasts have unique
             morphologic markers (e.g., Auer rods) or associated cytogenetic markers that allows
             morphologic relapse to be distinguished are not eligible.

          -  Chronic myelogenous leukemia in refractory blast crisis.

          -  Active central nervous system malignancy.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Pathologically proven non-small cell lung cancer with evidence of distant
             metastases/malignant pleural effusion

          -  Measurable disease on imaging studies in 2 dimensions

          -  No previous therapy with either paclitaxel or vinorelbine, or any chemotherapy for
             the past five years

          -  Patients who have had a previous resection for their lung cancer and present with
             recurrent disease will be eligible

          -  Patients with other prior malignancies will be included, provided they have been
             disease-free for at least five years

          -  Patients with adequately treated basal cell or squamous cell carcinoma of the skin,
             adequately treated carcinoma in-situ of the cervix and hormone sensitive prostate
             cancer will be eligible

          -  Karnofsky score &gt;= 70 (Eastern Cooperative Oncology Group [ECOG] 0-2)

          -  White blood cell (WBC) count &gt;= 3,500/mm^3, OR

          -  Absolute neutrophil count (ANC) &gt;= 1,500/ul

          -  Platelet count &gt;= 100,000/mm^3

          -  Serum creatinine less than 1.5 times the upper limits of normal

          -  Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than
             1.5 times the upper limits of normal

          -  Serum alkaline phosphatase less than 2.5 times the upper limits of normal

          -  No active serious infections or other condition precluding chemotherapy

          -  Non-pregnant and non-nursing

          -  Men and women of reproductive potential may not participate unless they have agreed
             to use an effective contraceptive method while on the study

          -  Able to give informed consent

          -  Able to return for treatment and follow-up as specified in the protocol

        Exclusion Criteria:

          -  Known hypersensitivity to any component of vinorelbine or paclitaxel or other
             required drugs in the study

          -  Any comorbidity or condition which, in the opinion of the investigator, may interfere
             with the assessments and procedures of this protocol

          -  Inability to fulfill the requirements of the protocol
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  70 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA - RECIPIENT:

          -  Diagnosed with severe aplastic anemia characterized by all of the following:

               1. Bone marrow cellularity less than 30 percent (excluding lymphocytes)

               2. Transfusion dependence for platelets and/or RBCs

               3. Neutropenia (absolute neutrophil count less than 500 cells/microL) OR for
                  patients receiving granulocyte transfusions, absolute neutrophil count &lt;  500
                  cells/microL before beginning granulocyte transfusions].)

        OR

          -  Diagnosed with myelodysplastic syndrome characterized by Refractory Cytopenia with
             Unilineage Dysplasia (RCUD) or (Refractory anemia with ringed sideroblasts (RARS), or
             Refractory cytopenia with multi-lineage dysplasia (RCMD) or refractory anemia with
             excess blasts (RAEB) type I or type II, MDS-imc;assofoed (MDS-U) and at least one of
             the following:

               1. Neutropenia [(absolute neutrophil count &lt;  500 cells/microL) OR for patients
                  receiving granulocyte transfusions, absolute neutrophil count &lt;  500
                  cells/microL before beginning granulocyte transfusions]) and history of 1 or
                  more opportunistic infections related to neutropenia. OR

               2. History of severe aplastic anemia transformed to MDS

          -  Intolerance of or failure to respond standard immunosuppressive therapy.

          -  Availability of at least one HLA-haploidentical (i.e. greater than or equal to  5/10
             and less than or equal to 8/10 HLA match) related donor (HLA-A, B, C, DR, and DO
             loci) who is available to donate CD34+ cells (6-75 years old).

          -  Availability of at least one 4/6 HLA-matched (HLA-A, B, and DR loci) cord blood unit
             from the National Marrow Donor Program (NMDP). The cord blood unit must contain a
             minimum TNC (prior to thawing) of at least 1.5 x 10(7) cells per kilogram of
             recipient body weight with the following exception: if the minimum criterion of TNC
             is not met the cord unit must contain at least 1.7 x 10(5) CD34 plus cells/kg (prior
             to thawing).

          -  Ages 4-55 years inclusive.

          -  Ability to comprehend the investigational nature of the study and provide informed
             consent.  The procedure will be explained to subjects aged 4-17 years with formal
             consent being obtained from parents or legal guardian.

          -  Genetic testing for genes associated with bone marrow failure syndromes (BMFS) -
             telomere length, TERC and TERT mutations was done on protocol 04-H-0012 at the NIH or
             performed elsewhere prior to enrolling to protocol 04-H-0012.

        EXCLUSION CRITERIA - RECIPIENT:

          -  Availability of an HLA identical or 9/10 HLA matched(HLA A, B, C, DR, and DO
             loci-relative to serve as a stem cell donor.

          -  The patient is deemed to be a candidate for a 6/6 HLA matched unrelated stem cell
             transplant (availability of a donor and resources required for such a transplant).

          -  ECOG performance status of 2 or more.

          -  Major anticipated illness or organ failure incompatible with survival from transplant

          -  Severe psychiatric illness. Mental deficiency sufficiently severe as to make
             compliance with the transplant treatment unlikely and making informed consent
             impossible.

          -  Positive pregnancy test for women of childbearing age.

          -  HIV positive

          -  Diagnosis of Fanconi's anemia or dyskeratosis congenita.

          -  Diffusion capacity of carbon monoxide (DLCO) less than 40 percent predicted (patients
             under the age of 10 may be excluded from this criterion if they have difficulty
             performing the test correctly and thus are unable to have their DLCO assessed).

          -  Left ventricular ejection fraction less than 40 percent (evaluated by ECHO) or less
             than 30 percent (evaluated by MUGA)

          -  Transaminases greater than 5x upper limit of normal (when transaminases are elevated,
             the subject may be excluded at the discretion of the PI).

          -  Serum bilirubin greater than 4 mg/dl

          -  Creatinine clearance less than 50 cc/min by 24 hr urine collection (adjusted for body
             surface area, i.e.50 ml/min/1.73m(2))

          -  Failure to collect an adequate number of CD34+ cells (i.e. greater than or equal 2 x
             10(6) CD34+ cells/kg) for transplantation from the subject   s haploidentical
             relative.

          -  Presence of an active infection not adequately responding to appropriate therapy

          -  History of a malignant disease liable to relapse or progress within 5 years

        INCLUSION CRITERIA     RELATED HAPLOIDENTICAL DONOR DONATING PURIFIED CD34 PLUS CELLS:

          -  HLA mismatched family donor (greater than or equal to 5/10 and less than or eqhal to
             8/10 HLA matched (HLA-A, B, C, DR and DO loci) who is available to donate CD34+
             cells.

          -  Ages 6-75 inclusive

          -  Weight greater than or equal to 18 kg.

          -  For adults: Ability to comprehend the investigational nature of the study and provide
             informed consent.  For minors: Written informed consent from one parent or guardian
             who is not the recipient of the transplant and informed assent: The process will be
             explained to the minor on a level of complexity appropriate for their age and ability
             to comprehend.

          -  Genetic testing for genes associated with bone marrow failure syndromes (BMFS) -
             telomere length, TERC and TERT mutations was done on protocol 04-H-0012 at the NIH or
             performed elsewhere prior to enrolling to protocol 04-H-0012.

        EXCLUSION CRITERIA     RELATED DONOR (ANY OF THE FOLLOWING):

          -  Pregnant or lactating.

          -  A pediatric haploidentical donor will be excluded if a suitable adult haploidentical
             donor is available.

          -  Unfit to receive filgrastim (G-CSF) and undergo apheresis (history of stroke, MI,
             unstable angina, uncontrolled hypertension, severe heart disease or palpable spleen).

          -  HIV positive (Donors who are positive for HBV, HCV or HTLV I/II, T. cruzi [Chagas]
             may be used at the discretion of the investigator following counseling and approval
             from the recipient).

          -  Sickling hemoglobinopathies including HbSS, HbAS, HbSC

          -  Severe psychiatric illness. Mental deficiency sufficiently severe as to make
             compliance with the BMT treatment unlikely and making informed consent impossible.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  4 Years
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Histologically confirmed diagnosis of head and neck carcinoma (excluding nasopharynx,
             paranasal sinus, salivary, and thyroid malignancies)Any unknown primary squamous cell
             carcinoma of head and neck with gross nodes is allowed (2002 AJCC)

          -  18 years of age or older

          -  Must not have received prior radiation therapy or chemotherapy for this diagnosis.
             Patients who have had their primary site tumor removed by surgery but still present
             with grossly enlarged lymph nodes are eligible for this study.

          -  Karnofsky performance status  70.

        Exclusion Criteria:

          -  all nasopharyngeal, paranasal sinus, salivary cancer, and thyroid malignancies

          -  prior chemotherapy or radiotherapy within the last three years

          -  patients that underwent surgical resection for the same disease (except for biopsy or
             surgery removing primary site tumor but still present with grossly enlarged lymph
             nodes)

          -  any prior radiotherapy to the head and neck region

          -  pregnant (confirmed by serum b-HCG in women of reproductive age) or breast feeding
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Radiologically diagnosed hepatocellular carcinoma

          -  Child classification A or B

          -  Aged 20 to 80

          -  Informed consent taken

        Exclusion Criteria:

          -  Child classification C

          -  Extrahepatic metastasis

          -  Tumor located in central area or adjacent to middle hepatic vein

          -  Recurred hepatocellular carcinoma

          -  Critically ill patient

          -  Patient with psychiatric disease
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  20 Years
 </minimum_age>
 <maximum_age>
  80 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Aged between 0-21 years

          -  Patients suffering from either refractory de novo AML or relapsed AML or patients
             with very high risk AML in CR1

          -  In sexually active patients two reliable contraception methods are used. This
             includes every combination of a hormonal contraceptive (such as injection,
             transdermal patch, implant, cervical ring) or of an intrauterine device(IUD) with a
             barrier method (e.g. diaphragm, cervical cap, or condom) or with a spermicide.

          -  Written informed consent of patient, parents or legal guardians

        Exclusion Criteria:

          -  Severe renal impairment

          -  Pregnant or lactating females

          -  Current participation in another clinical trial
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  21 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Patients must be recipients of allogeneic bone marrow or stem cell grafts.

          2. Patient must weigh above 40 kg

          3. Patients must have new onset, clinical grade II-III acute or late-acute GVHD of the
             GI tract or liver, or the skin that developed post transplantation. The diagnosis of
             GVHD must be pathologically confirmed in at least one organ or highly suspected
             clinically. Pathological confirmation may occur after registration and after the
             start of therapy. Definition of Late Acute GVHD vs Acute GVHD: The diagnosis of Late
             Acute GVHD includes clinical features that are identical to Acute GVHD, however, Late
             Acute GVHD is diagnosed on or after day 100 post transplantation.

          4. Continued from #3: These manifestations include a maculopapular rash, abnormal liver
             studies (cholestatic jaundice) and/or nausea/vomiting / diarrhea. Patients must not
             have any concurrent classical features of chronic GVHD in addition to the above
             manifestations. Features of chronic GVHD include dry eyes and mouth, contractures,
             and/ or sclerodermal, lichenoid skin changes.

          5. In the clinical judgment of the PI, patients must be able to sustain a platelet count
             and a hematocrit &gt;/= 20,000/mL and &gt;/= 27% respectively, with or without
             transfusions.

          6. The absolute WBC must be &gt;1500/mL

          7. Patient must be willing to comply with all study procedures.

          8. All patients with childbearing potential, including males and females, must commit to
             using adequate contraceptive precautions throughout their participation in the study
             and for 3 months following the last ECP treatment.

        Exclusion Criteria:

          1. Patients developing chronic GVHD following immune modulation with immunosuppression
             withdrawal or donor lymphocyte infusion (DLI).

          2. Any clinical Manifestation consistent with de novo chronic GVHD or overlapped
             syndrome of acute and chronic GVHD.

          3. Patients who are unable to tolerate the volume shifts associated with ECP treatment
             due to the presence of any of the following conditions: uncompensated congestive
             heart failure, pulmonary edema, severe asthma or chronic obstructive pulmonary
             disease, hepatorenal syndrome.

          4. Active bleeding

          5. International normalized ration (INR) &gt;2

          6. Patients cannot have received methylprednisolone &gt; 2mg/kg/day for more than 72 hours
             prior to registration.

          7. Patients cannot have received any other immunosuppression for treatment of GVHD but
             calcineurin inhibitors and corticosteroids. Patients are allowed to have had any GVHD
             prophylaxis with the exception of ECP

          8. Patients with known hypersensitivity or allergy to psoralen

          9. Patients with known hypersensitivity or allergy to both citrate and heparin

         10. Patients with co-existing photosensitive disease (e.g. porphyria, systemic lupus
             erythematosus, albinism) or coagulation disorders.

         11. Uncontrolled, persistent hypertriglyceridemia, with levels &gt; 800 mg%
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Practitioners specialized in oncology and urology in Germany
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients with metastatic or locally advanced Renal Cell Carcinoma requiring therapy

          -  Start of first palliative therapy within 1 year before enrollment of patient to
             registry; since enrollment of 1000 Patients: start of first palliative therapy within
             4 weeks before enrollment

        Exclusion Criteria:

        -
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. A female older than 21 years of age,

          2. Have suspicious imaging findings suggesting a possibility of breast cancer, or
             biopsy-proven breast cancer.

        Exclusion Criteria:

          1. Pregnant,

          2. Unwilling to give informed consent,

          3. Have implanted prosthetic heart valves, pacemaker, neuro-stimulation devices,
             surgical clips (hemostatic clips) or other metallic implants,

          4. Have engaged in occupations or activities which may cause accidental lodging of
             ferromagnetic materials, or have imbedded metal fragments from military activities,

          5. Have received orthodontic work involving ferromagnetic materials,

          6. Claustrophobic,

          7. Have had allergic response to contrast agents (such as iodine or gadolinium)
             previously,

          8. Have known history of severe renal insufficiency, asthma, allergic conditions, sickle
             cell anemia, chronic hemolytic anemia, and gastrointestinal disorders.
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  21 Years
 </minimum_age>
 <maximum_age>
  90 Years
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Secondary resectable hepatic metastasis converted by FOLFOX-4 regimen.

          2. age between 18-80 y/o.

          3. no extra-hepatic disease

          4. life expectancy  3 months

          5. Karnofsky performance status  50%.

          6. WBC count  4,000/l, platelet count  100,000/l, serum bilirubin  2.0 mg/dl and
             normal serum glucose and electrolyte levels.-

        Exclusion Criteria:

          1. Secondary resectable hepatic metastasis with extra-hepatic disease

          2. poor liver function including: serum bilirubin &gt; 2.0 mg/dl, GOT,GPT &gt;100 U/L

          3. severe steatosis hepatitis or sinusoidal dilation

          4. Karnoofsky performance status &lt;50%.-
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  80 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Histologically confirmed malignant solid tumor

               -  Advanced or unresectable disease

          -  No standard therapeutic option available

          -  Evaluable disease (according to RECIST criteria) that has not been previously
             irradiated

               -  Prior radiotherapy to the marker lesion(s) allowed provided there is evidence of
                  progression since radiotherapy

          -  Brain metastases allowed provided the following criteria are met:

               -  CNS-directed treatment was given and was completed &gt; 3 months ago

               -  CNS disease has been clinically and radiographically stable for  8 weeks

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Absolute neutrophil count  1,500/L

          -  Platelet count  100,000/L

          -  Creatinine clearance  60 mL/min

          -  Total bilirubin  1.2 mg/dL

          -  Transaminases  5 times upper limit of normal (ULN)

          -  Magnesium  lower limit of normal

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 24 weeks (females)
             or for 4 weeks (males) after completion of study therapy

          -  Willing to avoid pregnancy for 3 months after completion of study therapy

          -  No neuropathy  grade 2

          -  No concurrent life-threatening acute medical illness

          -  No impairment of gastrointestinal function or gastrointestinal disease that may
             significantly alter the absorption of everolimus (e.g., ulcerative disease,
             uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel
             resection)

          -  No active bleeding diathesis

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  At least 3 weeks since prior major surgery, radiotherapy (including radiotherapy
             involving the abdomen or spine), chemotherapy, or other systemic anticancer therapy
             and recovered

          -  At least 4 weeks since prior investigational drugs

          -  No concurrent CYP3A4 inducers or inhibitors that cannot be substituted by a different
             agent

          -  No concurrent oral anti-vitamin K medication (except for low-dose warfarin)

          -  No concurrent colony stimulating factors during the first course of treatment
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients must have signed the current Institutional Review Board (IRB) approved
             informed consent prior to registration (see Informed Consent).

          -  All patients must have CTCL diagnosed by morphologic, histochemical or cell surface
             marker criteria with stage never exceeding IB / IIB disease and mSWAT &lt; 50%. CTCL
             patients with stage IA disease are not eligible for enrollment. CTCL patients with
             stage IB disease are eligible provided that they have failed a systemic treatment
             (this includes radiation). CTCL patients with bone marrow involvement but without
             lymph node involvement are eligible. Patients with a diagnosis of angioimmunoblastic
             T cell lymphoma are eligible, even with lymph node involvement. Age  18 years.
             Patients must have a performance status of &lt; 2 on Eastern Cooperative Oncology Group
             scale (see Appendix). Patients must have fully recovered from toxicity of prior
             chemotherapy or radiation therapy.

          -  Patients must have bilirubin &lt; 1.5 mg/dL, transaminases &lt; 2.5 X ULN, albumin &gt; 3
             gm/dL, creatinine &lt; 2.0 mg/dL. Patients who have had albumin &lt; 3 gm/dL boosted by an
             albumin infusion must be observed to maintain albumin at &gt; 3gm dL for 30 days without
             an additional infusion.

          -  Patients must have a normal echocardiogram (EF &gt; 50% normal) without any evidence of
             cardiac chamber hypertrophy, dilatation or hypokinesis. The Sponsor must be provided
             with copies of these tests BEFORE Sponsor will approve enrollment. In addition, the
             sponsor must receive a list of current medications taken by the patient before
             Sponsor will approve enrollment.

          -  Females and males must be willing to use an approved form of birth control while on
             this study and for 2 weeks after completion.

        Exclusion Criteria:

          -  Failure to meet any of the criteria set forth in Section 3.1.

          -  Inability to give informed consent because of psychiatric problems, or complicated
             medical problems.

          -  Allergic to diphtheria toxin a component of the study drug A-dmDT390-bisFv(UCHT1).

          -  Serious concurrent medical problems, uncontrolled infections, or disseminated
             intravascular coagulopathy (DIC), hepatic cirrhosis, or chronic kidney disease.

          -  CNS leukemia.

          -  Preexisting cardiovascular disease. The only exception being well controlled
             essential hypertension with a sitting blood pressure (B.P.) of &lt; 160 systolic and &lt;
             90 diastolic without any evidence of structural heart disease or one episode of
             myocardial infarction &gt; 8 months ago. A past history of any of the following
             conditions is considered as exclusions to study participation:

               -  Congestive heart failure,

               -  Atrial fibrillation,

               -  Pulmonary hypertension,

               -  Anticoagulant drug therapy,

               -  Thromboembolic events,

               -  Cardiomyopathy or a myocardial infarction within the past 8 months.

               -  The PI and the Clinical Coordinator will be asked to verify that their referred
                  patients do not have these exclusionary histories listed in 3.2 and a copy of
                  this verification must be sent to the Sponsor before the Sponsor will approve of
                  enrollment. Referring physicians will not need to sign. (Template for
                  verification letter Appendix C).

          -  Pregnant or nursing women will be excluded from study.

          -  History of cirrhosis of the liver based on the Child-Pugh score of Class B or C are
             not eligible to participate. (Appendix B.)

          -  Prior treatment with alemtuzumab (Campath) or similar agents or procedures that
             depress blood T cell counts to below 50% of the lower limit of normal.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Donors will be &lt;55 years of age and in good health as approved by the National Marrow
             Donor Program (NMDP) donor and collection centers. Related donors will be &lt; 70 years
             of age.

          -  Recipients will be &lt;55 years, will have satisfactory organ function (excluding bone
             marrow) and will have a Karnofsky activity assessment &gt;90% and will have:

               -  Creatinine &lt;2.0 mg/dl.

               -  Bilirubin, Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)
                  &lt;2 x normal.

               -  Pulmonary function test and Carbon Monoxide Diffusing Capacity (DLCO) &gt; 50% of
                  normal.

               -  Multi Gated Acquisition Scan (MUGA) &gt;45% injection fraction.

          -  Recipients with unrelated donor matched at the HLA A, B, DRBI loci, or if &lt; 35 years
             mismatched at a single HLA A or B, or DRBI locus.

          -  Umbilical cord blood (5) used as an unrelated stem cell source will provide &gt; 2.0 x
             10^7 cells/kg and will be matched at 4 - 6 of 6 HLA A, B, and DRBI loci. Cord blood
             grafts may include a single or pair of cord units depending on the cell dose.

          -  Partially matched related donors will be at least haploidentical (matched at &gt;3 of 6
             HLA A, B, DRB1 loci).

          -  Recipients will fall under one of the following disease categories

               -  Chronic lymphocytic leukemia -- must have all three:

                    -  Rai Stage III/IV

                    -  Progression after previous Complete Response (CR) or Partial Response (PR)
                       including purine antagonist (i.e. fludarabine).

                    -  Recent chemotherapy responsiveness

               -  Advanced non-Hodgkin's lymphoma(NHL).

                    -  Low-grade NHL (Working Formulation A, B, C) following progression after
                       initial therapy if asymptomatic at diagnosis (&gt;CR2, &gt;PR2; response duration
                       &lt; 1 year from last therapy) or if no CR was achieved (&gt;PR1). At least one
                       prior therapy of intermediate intensity (e.g. CHOP).

                    -  Mantle zone lymphoma after any progression following initial therapy (&gt;CR1,
                       &gt; PR1). At least one prior therapy of intermediate intensity (e.g. CHOP).

                    -  Intermediate grade lymphoma (&gt;PR2). Response duration &lt;1 year from prior
                       therapy.

                    -  High-grade Non-Hodgkin's Lymphoma (NHL) (IWF H, I, J) after initial therapy
                       if &gt;stage III at diagnosis; after any progression even if localized (stage
                       I, II) at diagnosis with prior response duration &lt; 1 year.

                    -  Recent chemotherapy responsiveness after treatment with &gt; 3 intermediate
                       intensity regimens.

               -  Advanced Hodgkin's disease beyond PR2 (&gt;CR3, &gt;PR3).

                    -  Recent chemotherapy responsiveness

               -  Multiple Myeloma (&gt;CR2, &gt;PR2) or after initial therapy if no prior PR.

                    -  Recent chemotherapy responsiveness

          -  Recipients will sign informed consent approved by the Committee on the Use of Human
             Subjects at the University of Minnesota.

        Exclusion Criteria:

          -  No available histocompatible related donor; 2nd bone marrow transplant (BMT), HIV-1
             positive; active uncontrolled infection; or resistant malignancy.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  55 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Histologically confirmed primary adenocarcinoma, squamous cell carcinoma or
             adenosquamous carcinoma of the uterine cervix;

          -  Patients with Histologically confirmed stage IA1 (with lymph vascular invasion),
             stage IA2, or stage IB1 disease

          -  Patients undergoing either a Type II or III radical hysterectomy (Piver
             Classification)

          -  Patients with adequate bone marrow, renal and hepatic function:

          -  ECOG Performance Status of 0 or 1.

          -  Patient must be suitable candidates for surgery.

          -  Patients who have signed an approved Informed Consent

          -  Patients with a prior malignancy allowed if &gt; 5 years ago with no current evidence of
             disease

          -  Females, aged 18 years or older

          -  Negative serum pregnancy test within &lt;30 days of surgery in pre-menopausal women and
             women &lt; 2 years after the onset of menopause

        Exclusion Criteria:

          -  Any histology other than adenocarcinoma, squamous cell carcinoma or adenosquamous
             carcinoma of the uterine cervix;

          -  Tumor size greater than 4 cm;

          -  FIGO stage II-IV;

          -  Patients with a history of pelvic or abdominal radiotherapy;

          -  Patients who are pregnant;

          -  Patients with contraindications to surgery;

          -  Patients with evidence of metastatic disease by conventional imaging studies,
             enlarged pelvic or aortic lymph nodes &gt; 2cm; or histologically positive lymph nodes

          -  Unfit for Surgery: serious concomitant systemic disorders incompatible with the study
             (at the discretion of the investigator);

          -  Patients unable to withstand prolonged lithotomy and steep Trendelenburg position

          -  Patient compliance and geographic proximity that do not allow adequate follow-up
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Patient Inclusion Criteria:

          -  Timing of relevant evaluations: Taking in account the need for rapid intervention, if
             white blood count is less than 200 on day +20, bone marrow aspirate should be
             performed on day +21. Unless there is an increase in absolute neutrophil count (ANC)
             to &gt; 500 in the following 7 days, bone marrow aspirate should be repeated on day +28.
             If the white blood count is still less than 200 and bone marrow is acellular, bone
             marrow (BM) or peripheral blood stem cell (PBSC) donor should be reactivated and
             availability of cord blood (CB) units assessed. If the BM or PBSC donor is not
             confirmed within 14 days of the request for the donation (typically second donation
             from the same donor), CB unit should be used instead.

        Primary or secondary graft failure after hematopoietic stem cell transplantation defined
        as a &gt; 50% loss of donor chimerism from previous maximum or less than 25% donor beyond day
        +42 with pancytopenia and no evidence of relapse. Patients with any diagnosis, type of
        donor, hematopoietic cell graft or conditioning regimen should be considered for this
        study.

          -  primary graft failure is defined as:

               -  ANC &lt; 500

               -  BM &lt; 10% on two occasions (Day +21 and Day +28)

               -  Donor chimerism need not to be considered, provided there is no evidence of
                  malignancy

          -  secondary graft failure is defined as &lt; 5% cellularity and ANC &lt; 500 for more than 7
             days any time after primary engraftment).

               -  Women of childbearing potential must agree to use adequate contraception
                  (diaphragm, birth control pills, injections, intrauterine device [IUD], surgical
                  sterilization, subcutaneous implants, or abstinence, etc.) for the duration of
                  treatment.

               -  Patients or their guardian are able and willing to provide written informed
                  consent.

        Patient Exclusion Criteria:

        The presence of any of the following excludes a patient from study enrollment:

          -  Uncontrolled active infection defined as more than one week with no response to
             appropriately chosen antibiotics

          -  Evidence of recurrence of primary malignancy.

          -  Pregnant or lactating. The agents used in this study may be teratogenic to a fetus
             and there is no information on the excretion of agents into breast milk. All females
             of childbearing potential must have a blood test or urine study within 2 weeks prior
             to registration to rule out pregnancy. Women of childbearing age must use appropriate
             methods as described.

          -  Allergy to rituximab.

          -  Evidence of HIV infection or positive HIV serology.

          -  Autologous recovery defined as defined as greater than 90% recipient PCR product in
             the competitive VNTR PCR performed on gradually increasing white blood cell count.

        Donor Inclusion Criteria:

          -  Related donors must be 2-75 years of age and in good health.

          -  Meets match criteria

          -  Able and willing to undergo cell collection procedures (bone marrow cell collection
             or leukapheresis)

          -  Not pregnant or lactating.

          -  HIV-1, HIV-2 negative; HTLV-1, HTLV-2 negative, Hepatitis B and C negative.

          -  Patients or their guardian are able and willing to provide informed consent
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  Patients must be women with a histologically confirmed diagnosis of breast cancer
             that is more than 1 cm and or lymph node positive

          -  Physical examination, and scans needed for tumor assessment must be performed within
             90 days prior to registration

          -  Patients with the clinical diagnosis of congestive heart failure or angina pectoris
             are NOT eligible

          -  Serum creatinine within normal limits within 90 days prior to registration

          -  Bilirubin within normal limits within 90 days prior to registration

          -  Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate
             transaminase (SGPT) =&lt; 2 x the institutional upper limit of normal within 90 days
             prior to registration

          -  Absolute neutrophil count (ANC) of &gt;= 1,500/microliters within 90 days prior to
             registration

          -  Platelet count of &gt;= 100,000/microliters within 90 days prior to registration

          -  Patients must have a performance status of 0-2 by Zubrod criteria

          -  Pregnant or nursing women may not participate; women of reproductive potential may
             not participate unless they have agreed to use an effective contraceptive method;
             pregnancy test required for women of childbearing potential

          -  In calculating days of tests and measurements, the day a test or measurement is done
             is considered day 0; therefore, if a test is done on a Monday, the Monday four weeks
             later would be considered day 28; this allows for efficient patient scheduling
             without exceeding the guidelines; if day 28 or 42 falls on a weekend or holiday, the
             limit may be extended to the next working day

          -  All patients must be informed of the investigational nature of this study and must
             sign and give written informed consent in accordance with institutional and federal
             guidelines
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  21 Years
 </minimum_age>
 <maximum_age>
  90 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Age between 18 years and 75 years.

          -  one of these diagnoses: acute myeloid leukemia in remission or relapse, acute
             lymphocytic leukemia in remission or relapse, chronic myeloid leukemia, chronic
             lymphocytic leukemia, Hodgkin's disease or non-Hodgkin's lymphoma, multiple myeloma,
             myelodysplastic syndrome, severe aplastic anemia, or paroxysmal nocturnal
             hemoglobinuria.

          -  Subjects with hematologic malignancies must have received at least one previous
             course of chemotherapy or biological therapy (i.e., a subject cannot be enrolled on
             this study for initial treatment of the malignancy).

          -  Absence of a healthy related or unrelated volunteer allogeneic donor with whom the
             subject is either completely HLA matched at HLA-A, -B, -C and -DRB1 (8/8 HLA match)
             or mismatched at no more than one HLA locus (7/8 HLA match).

          -  Availability of a healthy haploidentical relative (parent, sib or child) who is able
             to donate peripheral blood stem cells by apheresis.

        Exclusion Criteria:

          -  Eligibility for another clinical therapeutic protocol or standard-of-care treatment
             that offers higher probability of cure or long-term control of subject's malignancy.

          -  Availability of a related or unrelated 7/8 or 8/8 HLA-matched allogeneic donor.

          -  Severe organ dysfunction

          -  Untreated or progressive central nervous system involvement by malignancy.

          -  Subject is pregnant or breast feeding.

          -  Karnofsky score below 50.

          -  Seropositivity for human immunodeficiency virus (HIV).

          -  Life expectancy less than 12 weeks with conventional treatments.

          -  For subjects who are fertile, refusal to practice contraception upon entering this
             study and for at least 12 months after PBSCT or after cessation of post-transplant
             immunosuppressive treatments, whichever occurs later.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patient fully informed, signed dated Institutional Review Board (IRB)-approved
             informed consent form obtained directly by the P.I., Co-P.I., or Res. Nurse, and
             willing to follow study procedures for the duration of study (3 yrs).

          -  Recipient: a hematocrit of  33%, and a hemoglobin of  11.0 g/dL.

          -  Weight &gt; 40 kg.

          -  Primary renal allograft: living related (HLA-identical donor-recipient sibling pairs)

          -  Negative B-cell and T-cell cytotoxic cross-match, and a low ( 10%) Panel Reactive
             Antibody (PRA) using cytotoxicity.

          -  Women of childbearing potential: negative qualitative serum pregnancy test.

          -  Patients studied equivalently as available for transplant using criteria, w/out
             regard to gender, race, or ethnicity.

          -  Normal echocardiogram w/ ejection fraction &gt;50%.

          -  Male participants w/ reproductive potential agree to use approved methods of birth
             control during treatment w/ Campath-1H and for minimum of 6 months following last
             dose. Female participants of childbearing potential agree to use approved methods of
             birth control for duration of participation in study.

          -  Patient agrees to follow-up every 2 months after year 3, up to 10 years.

        Exclusion Criteria:

          -  Patient previously received/receiving transplant other than kidney.

          -  Patient receiving ABO (blood type) incompatible donor kidney.

          -  Recipient/donor is ELISA positive for human immunodeficiency virus (HIV), antibody
             positive for hep. C, or surface antigen positive for hep. B.

          -  Patient has current malignancy or history of malignancy (within past 5 years), except
             non-metastatic basal or squamous cell carcinoma of the skin, or carcinoma in situ of
             the cervix that has been treated successfully.

          -  Patients w/ significant liver disease, defined as having during past 28 days
             continuously elevated aspartate aminotransferase (AST (SGOT)) and/or Alanine
             Aminotransferase (ALT (SGPT)) levels greater than 3 times the upper value of the
             normal range at this center.

          -  Patient has uncontrolled concomitant infections and/or severe diarrhea, vomiting,
             active upper gastro-intestinal tract malabsorption or active peptic ulcer or other
             unstable medical condition that could interfere w/ study objectives.

          -  Patient currently receiving investigational drug or received an investigational drug
             within 30 days pre-transplant.

          -  Patient currently receiving immunosuppressive agent.

          -  In investigator's judgment, anticipated that patient unable to take medications
             orally or via nasogastric tube by morning of second day (i.e., skin closure).

          -  Concurrent use of warfarin, fluvastatin, astemizole, pimozide, cisapride,
             terfenadine, or ketoconazole.

          -  Patient hypersensitivity to tacrolimus, Campath-1H, Thymoglobulin, daclizumab
             (Zenapax), sirolimus, MMF or corticosteroids.

          -  Patient pregnant or lactating.

          -  Patients w/ screening/baseline total white blood cell count &lt;4000/mm3; platelet count
             &lt;100,000/mm3; fasting triglycerides &gt;400 mg/dl (&gt;4.6 mmol/L); fasting total
             cholesterol &gt;300 mg/dl (&gt;7.8 mmol/L); fasting HDL-cholesterol &lt;30 mg/dl; fasting
             LDL-cholesterol &gt;200 mg/dl.

          -  Patient unlikely to comply w/ visits.

          -  Patient w/ any form of substance abuse, psychiatric disorder or condition that, in
             investigator's opinion, may invalidate communication.

          -  Expected that tacrolimus cannot be instituted for over 5 days post-operatively.

          -  Patients w/ cytotoxic PRA value &gt;10% any time pre-enrollment.

          -  Patients w/ Graves disease, unless previously treated w/ radioiodine ablative
             therapy.

          -  History of idiopathic thrombocytopenic purpura (ITP) or thrombotic thrombocytopenic
             purpura (TTP)
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  65 Years
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Malignant Disease

               -  Chronic myleogenous leukemia in chronic or accelerated phase

               -  Acute lymphoblastic leukemia (ALL)

                    -  First remission high-risk ALL (Ph+, t( 4-11) infants).

                    -  Second remission ALL, after a short first remission (&lt;36 mos from Dx).

                    -  3rd or greater remission ALL.

               -  Acute myelogenous leukemia (AML)

                    -  First remission high risk acute nonlymphoblastic (ANLL) (as defined by
                       cytogenetics), if a matched sibling donor is available.

                    -  Initial partial remission AML (&lt;20% blasts in the bone marrow).

                    -  AML that is refractory to two cycles of induction therapy.

                    -  Second or greater remission AML

               -  Myelodysplastic/Myeloproliferative Disease

                    -  Juvenile Myelomonocytic Leukemia (JMML)

                    -  Myelosplastic syndrome and/or pre-leukemia at any stage

               -  Lymphoma

                    -  Relapsed lymphoma with residual disease that appears to be chemo-sensitive
                       and non-bulky (&lt;5 cm at largest diameter)

          -  Venous Access: Three lumens of central vascular access will be required for all
             patients entered on protocol due to the need for a dedicated line for continuous
             infusion cyclosporine.

          -  Informed Consent: The patient and/or the patient's legally authorized guardian must
             acknowledge in writing that consent to become a study subject has been obtained in
             accordance with the institutional policies approved by the U.S. Department of Health
             and Human Services.

          -  Patient organ function requirements:

               -  Adequate renal function: Serum Creatinine &lt;~1.5 x normal, or Creatinine
                  clearance of 70 mL/min/1.73 mE2 or an equivalent GFR as determined by the
                  institutional normal range

               -  Adequate liver function: Total bilirubin &lt;1.5 x normal; and SGOT (AST) or SGPT
                  (ALT) &lt;~2.5 x normal

               -  Adequate cardiac function: Shortening fraction of &gt;/=27% by echocardiogram

               -  Adequate pulmonary function: FEV1/FVC &gt;/=60% by pulmonary function test; for
                  children who are uncooperative, no evidence of dysnpea at rest, or exercise
                  intolerance, and must have a pulse oximetry &gt;94% in room air

          -  Performance status: Lansky for children &lt;/= 16 years &gt;/= 60; Karnofsky status for
             those &gt; 16 years of age &gt;/= 70

          -  Effective Contraceptive Use: Women of childbearing potential and sexually active
             males should use effective contraception while on study.

        Exclusion Criteria:

          -  Patients who are pregnant or lactating

          -  Inability to find a suitable donor for the patient

          -  Patient is HIV-positive

          -  Patient has active Hepatitis B

          -  Disease progression or relapse prior to HPC infusion
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  21 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Histologically or cytologically confirmed NSCLC: it is recommended to obtain adequate
             tissue samples for EGFR mutation analysis.

          2. Unresectable stage IIIA (N2) or stage IIIB NSCLC defined as:unresectability confirmed
             by Surgeon /Stage IIIa T1-3 N2/Stage IIIb T1-4 N3/Stage IIIb T4 N2

          3. Age 18 years over.

          4. ECOG performance status of 0 or 1.

          5. Tumor work-up: within 4 weeks prior 1st day of treatment: chest X-ray; CT of chest,
             liver, and adrenal glands; bone scan; brain MRI

          6. Measurable or un-measurable disease (according to RECIST criteria), documented by CT,
             MRI, X-ray, or physical exam, as appropriate.

          7. Hematology (within 1 week before 1st day of treatment)Absolute Neutrophil Count 2.0
             x 109/L; Platelet 100 x 109/L; Hemoglobin 10 g/dl

          8. Liver function test (within 1 week before 1st day of treatment)Serum bilirubin 1 x
             UNL; AST &amp; ALT 2.5 x UNL

          9. Renal function (within 1 week before 1st day of treatment)Serum creatinine 1 x UNL.
             In case of borderline value, 24h creatinine clearance should be &gt; 60 mL/min.

         10. Pulmonary function (within 4 weeks before 1st day of treatment)FEV1  1 Liter

         11. ECG without significant abnormalities within 4 weeks before 1st day of treatment.

         12. Written informed consent.

        Exclusion Criteria:

          1. T4 with malignant pleural effusion.

          2. Any prior therapy (chemotherapy, immunotherapy, biologic therapy such as
             EGFR-targeted therapy, radiotherapy) for lung cancer.

          3. History of prior malignancies, except for cured non-melanoma skin cancer, curatively
             treated in-situ carcinoma of the cervix or other cancer curatively treated and with
             no evidence of disease for at least 5 years.

          4. Unintended weight loss &gt; 10% within the last 3 months.

          5. Other serious concomitant illness or medical conditions:

          6. Congestive heart failure or angina pectoris except if it is medically controlled.
             Previous history of myocardial infarction within 1 year from study entry,
             uncontrolled hypertension or arrhythmia.

          7. History of significant neurological or psychiatric disorders including dementia or
             seizures.

          8. Active infection requiring IV antibiotics.

          9. Active ulcer, unstable diabetes mellitus or other contra-indication of corticosteroid
             therapy.

         10. Significant gastrointestinal abnormalities, including requirement for intravenous
             nutrition, active peptic ulcer disease, prior surgical procedures affecting
             absorption.

         11. Pregnant or lactating women-Patients (male or female) with reproductive potential not
             implementing adequate contraceptive measures.

         12. Concurrent treatment with any other experimental anti-cancer drugs.

         13. Concurrent use of phenytoin, carbamazepin, barbiturates, or rifampin.

         14. Mental condition rendering the patient unable to understand the nature, scope, and
             possible consequence of the study.

         15. Patient unlikely to comply with protocol, i.e., uncooperative attitude, inability to
             return for follow-up visits, and not likely to complete the study.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Prior to receiving treatment, some patients may undergo diagnostic and/or other
             testing of their WT1 malignancies to determine if their disease is likely to respond
             to treatment with WT1 specific T cells. Alternatively, blood samples may be required
             for research tests to ascertain that the WT1-specific T-cells do not contain any
             cells that could react against the patient. These patients will sign a separate
             pre-treatment consent. If it is determined that a patient will qualify for and might
             benefit from infusions of WT1 CTLs, he/she will go on to sign the standard treatment
             consent for MSKCC IRB # 07-055 and be enrolled and treated on trial, if all other
             eligibility criteria are met.

          -  Patients eligible for this trial will include patients with a pathologically
             confirmed diagnosis of leukemia or myelodysplastic syndrome (MDS) who, following an
             allogeneic hematopoietic cell transplant, have relapsed with leukemia as demonstrated
             morphologically on peripheral blood smear or bone marrow aspirate, or have recurrent
             persistent minimal residual disease as demonstrated by at least 2 sequential testings
             separated by at least 1 week demonstrating molecular evidence of residual leukemia or
             MDS by FISH or cytogenetics. In addition, patients who are to receive an allogeneic
             hematopoietic cell transplant as treatment for a leukemia or myelodysplastic syndrome
             that has an expected of risk of relapse post transplant of &gt;30% will be eligible to
             have donor-derived WT1 peptide specific T cells generated prior to or at the time of
             transplant for immediate use post transplant at such time that the patient is found
             to have minimal residual disease or relapse. This includes patients with AML or ALL
             that is either refractory to primary induction therapy or is at any stage later than
             first relapse for AML or ALL, CML in a secondary chronic phase, accelerated disease
             or after treatment for blast crisis or RAEB or RAEBT stages of MDS which have not
             responded to or recurred following induction therapy. Furthermore, the patient's
             leukemic or MDS blasts should be documented to express the WT1 protein detectable by
             immunohistopathologic analysis of diagnostic paraffin embedded marrow biopsies,
             obtained at diagnosis of relapse or be of a type known to commonly express WT1 at
             high frequency. Expression of WT1 will be assessed by a modification of the technique
             of Dupont and Soslow (36) and graded according to an adaptation of the German
             Immunoreactive Score (IRS) which is the product of subscores for intensity of
             immunoreactivity (0-3+) and distribution of immunoreactivity (0-4+). For this study,
             leukemic blasts with IRS scores of 4-12 will be considered positive.

          -  A pathologically confirmed diagnosis of leukemia or MDS.

          -  Patients who have already received an allogeneic hematopoietic cell transplant and
             have either a documented relapse of leukemia or MDS or have recurrent persistent
             minimal residual disease as documented by at least 2 sequential testings, separated
             by 1 week, demonstrating molecular evidence of leukemia or MDS by FISH, cytogenetics
             or fluorescent immunocytometry.

          -  Patients who are to receive an allogeneic hematopoietic cell transplant as treatment
             for a leukemia or myelodysplastic syndrome that has an expected risk of relapse
             exceeding 30% will be eligible to have donor-derived WT1 peptide sensitized T cells
             generated prior to or at the time of transplant for immediate use post transplant at
             such time that the patient is found to have minimal residual disease or relapse. This
             includes patients with:

          -  ALL, AML or MDS refractory to primary induction therapy

          -  ALL or AML at any stage later than 1 relapse

          -  CML in 2 or greater chronic phase after chemotherapy

          -  CML in persistent accelerated phase or blast crisis

          -  High risk MDS (RAEB and RAEB+) which has failed to respond or has recurred following
             induction chemotherapy

          -  The patients' leukemia or MDS blasts must express the WT1 protein detectable by
             immunohistopathologic analysis, or; if an adequate sample is not available for
             testing, , must have a form of leukemia (ALL, AMLs other than M5) or MDS (2 MDS,
             RAEB, RAEBT) known to over express WT1 in a high proportion of cases (&gt;60%). For
             patients who develop a documented relapse of leukemia or MDS following transplant,
             marrow aspirates should be evaluated for the proportion of blasts expressing WT1 by
             immunohistology or FACS whenever possible.

          -  The patient's hematopoietic cell transplant donor must consent to a 2 volume
             leukapheresis or whole blood donations obtained at one phlebotomy which, will total
             approximately 250 ml from which the WT-1 specific T cells to be used for adoptive
             transfer will be generated

          -  KPS or Lansky score &gt; or equal to 40

          -  Adequate bone marrow, renal and hepatic function at the time of treatment with WT1
             specific T cells:

          -  Absolute neutrophil count (ANC) &gt; or equal to  1000/mm3, with or without G-CSF
             support.

        This requirement may be waived if the patient has hematologic relapse of disease or if
        patient has not yet recovered counts from chemotherapy.

          -  Platelets &gt; or equal to  20,000/mm3. This requirement may be waived if patient has
             hematologic relapse of disease or if patient has not yet recovered counts from
             chemotherapy.

          -  Creatinine &lt; than or equal to 2.0mg/dL

          -  ALT, AST &lt;3.0 and total bilirubin all &lt; 2.5 x the institutional ULN

          -  There are no age restrictions to this protocol.

          -  Patients with relapse also detected in the CNS may be treated on this protocol.
             However, if intrathecal chemotherapy is being administered, T cells should not be
             administered until at least 24 hours thereafter.

        Exclusion Criteria:

          -  Patients with active (grade 2-4) acute graft vs. host disease (GVHD), chronic GVHD or
             an overt autoimmune disease (e.g. hemolytic anemia) requiring high doses of
             glucocorticosteroid (&gt;0.5 mg/kg/day prednisone or its equivalent) as treatment.

          -  Patients with other conditions not related to leukemic relapse (e.g. veno-occlusive
             disease or uncontrolled bacterial, viral or invasive fungal infection) which are also
             life-threatening and which would preclude evaluation of the effects of a T cell
             infusion.

          -  Patients who are pregnant.

        Donor Eligibility for Donation of Blood Lymphocytes for Generation of Donor-Derived
        WT-1-Specific T Cells.

        The eligibility criteria for the donor of blood to be used to generate WT1 peptide
        sensitized T cells are:

          -  The donor of WT-1 specific T. lymphocytes will be the same donor who provided the
             patient's hematopoietic stem cell transplant (HSCT). These normal donors will be
             evaluated for evidence of prior sensitization to EBV by EBV serology. If the donor is
             seropositive, and donor T cells are sensitized with the donor's WT-1 peptide- loaded
             EBV transformed B cells, EBV-specific T-cells will also be generated from
             seropositive donors generating WT-1 specific T-cells, and their growth and
             persistence post transfer will be compared to that of the WT 1 specific T-cells.

          -  Since the donor will have already undergone an extensive evaluation of his/her health
             to ascertain eligibility for donating the patient's HSCT, re-evaluation for this
             blood donation will be limited to a clinical history, physical examination and blood
             tests to insure against any new condition which, in the opinion of the donor's
             physician, preclude the donor from donating the blood required.

          -  New health conditions which would exclude a transplant donor from a second blood
             donation are limited, but include:

          -  New onset of an HIV infection

          -  Other uncontrolled infection which could be transmitted to the patient by blood cells
             and would place the patient at significant increased risk of severe morbidity or
             death.

          -  Significant anemia with Hgb &lt; than or equal to 10 gm/dl, persisting since the time of
             the original transplant donation.

          -  History of myocardial infarction or stroke since the time of HSCT donation which
             might increase the risk of blood donation. A perspective donor will be informed of
             the purposes of this study, and its requirements. If he/she consents, the donor will
             be requested to provide two blood samplings.

          -  An initial donation of 25ml blood anticoagulated with heparin or ACD. This blood is
             used to establish a B cell line transfused transformed with the B95.8 laboratory
             strains of EBV. This EBV+ B cell line/ (EBVBLCL) will be used as an
             antigen-presenting cell. When loaded with the pool of WT-1 pentadecapeptides, the
             EBVBLCL efficiently sensitize T cells from the same donors against WT-1 as well as
             EBV.

        Because the establishment and testing of an EBV transformed B cell line suitable for use
        as an antigen-presenting cell require 4-5 weeks of in vitro culture, it is important that
        this sample be obtained as early as possible for patients at risk for leukemic relapse,
        since disease relapse most frequently occurs 2-6 months post transplant. Accordingly, this
        blood sample should be obtained from the donor prior to donation of the hematopoietic
        progenitor cell transplant whenever possible.

          -  A donation of either a single standard 2 blood volume leukapheresis collected in
             standard ACD anticoagulant. If it is impossible to collect a leukapheresis from some
             of the donors, a unit of whole blood will be accepted by the AICTF (Adoptive Immune
             Cell Therapy Facility manufacturing the clinical grade cell products under GMP
             conditions in MSKCC) for the generation of limited number of T cells. This blood is
             required for isolation of the T cells to be sensitized with the pool of WT-1 15-mers
             loaded on autologous dendritic cells or autologous EBVBLCL, and propagated in vitro.
             In addition, it is required to provide autologous feeder cells essential to sustain
             T-cell growth without the risk of stimulating the growth of alloreactive T-cells
             capable of inducing GVHD.

          -  This donation of a leukapheresis or a unit of blood will be obtained from unrelated
             HSCT donors at least 2 weeks after their donation of an HSCT, but soon thereafter as
             possible.

        In addition to providing written consent to these donations of blood for the purpose of
        generating WT-1-specific T-cells for potential use in the treatment of recurrent leukemia
        or persistent residual disease developing in the patient for whom the donor has provided
        an HSCT, each donor will be informed of and asked to provide separate consent to each of
        the following potential applications of the blood cells donated:

          -  The use of a fraction of the cells isolated to generate immune T-cells specific for
             viruses, such as Epstein-Barr virus (EBV) and cytomegalovirus (CMV) ,that can cause
             lethal infections or lymphomas in transplant recipients. Such T-cells could then be
             used, under separate protocols, to treat EBV-associated diseases (IRB 95-024) and/or
             to treat CMV infections (IRB 05-065) in the patient receiving the donor's
             hematopoietic progenitor cell transplant.

        Consenting to this application will limit the number of blood donations that would be
        required of any donor, since the white cells donated in a leukapheresis should provide
        enough cells to grow immune T-cells against WT-1, EBV and CMV.

        The donation of immune T-cells specific for EBV or CMV generated from the donor that are
        not used for or required by the patient for whom they were originally intended to a bank
        of immune cells that will be started and maintained cryopreserved under GMP conditions in
        the Adoptive Immune Cell Therapy Facility at MSKCC, for potential use in the treatment of
        other patients with EBV lymphomas or cytomegalovirus infections that express HLA alleles
        shared by the donor.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   All patients receiving surgical, medical, or radiological services at University Hospitals
        Case Medical Center,Richmond,or Geauga campuses.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  All patients receiving surgical,medical,or radiological services at University
             Hospitals Case Medical Center,Richmond,or Geauga campuses.

        Exclusion Criteria:

          -  None
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  14 Years
 </minimum_age>
 <maximum_age>
  95 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients eligible for the study must have a human leukocyte antigen (HLA)-identical
             sibling or HLA-matched unrelated bone marrow donor available and willing to donate.

          -  Patients  with severe SSc as defined by the American College of Rheumatology and at
             high-risk for a fatal outcome based on the following prognostic factors in groups
             1-5:

          -  Group 1: Patients must have 1) both a and b below; and 2) at least one of c, d or e:

               -  a. diffuse cutaneous scleroderma with skin score of greater than or equal to 16
                  (modified Rodnan scale [mRSS]).

               -  b. duration of systemic sclerosis less than or equal to  7 years from the onset
                  of first non-Raynaud's symptom.

               -  c. presence of interstitial lung disease (either forced vital capacity [FVC] or
                  corrected diffusing capacity of the lung for carbon monoxide [DLCOcorr] less
                  than 70 % of predicted) and evidence of alveolitis (abnormal bronchoalveolar
                  lavage (BAL) or high resolution chest computed tomography [CT] scan) after
                  treatment with intravenous cyclophosphamide greater than or equal 2 grams given
                  over at least a 3 month period; for patients not able to adequately complete
                  pulmonary function tests (PFT), there must be evidence of progressive disease on
                  chest CT.

               -  d. left heart failure with left ventricular ejection fraction (LVEF) &lt; 50% (that
                  has responded to treatment targeted to scleroderma); 2nd or 3rd atrioventricular
                  (AV) block with other evidence of cardiomyopathy related to SSc; myocardial
                  disease not secondary to SSc must be excluded by a cardiologist.

               -  e. history of SSc-related renal disease that is not active at the time of
                  screening; history of scleroderma hypertensive renal crisis is included in this
                  criterion.

          -  Group 2: Progressive pulmonary disease as defined by a decrease in the FVC or
             DLCOcorr by 15 percent or greater compared to a prior FVC or DLCOcorr in the previous
             twelve month period; in addition, patients may have either less skin involvement than
             group 1 (mRSS less than 16) and the FVC or DLCOcorr is less than 70% or both FVC and
             DLCOcorr greater than or equal to 70% if they have diffuse cutaneous disease (mRSS
             greater than 16) at screening for the study; patients must also have evidence of
             alveolitis as defined by abnormal chest CT or BAL; for patients not able to
             adequately complete PFT, there must be evidence of progressive disease on chest CT.

          -  Group 3: Have progressive active SSc after prior autologous transplant based on the
             presence of progressive pulmonary disease; this will be defined by a decrease in the
             FVC or DLCO adjusted since prior autologous transplant of 15 percent or greater of
             the pre-transplant percent predicted value, in addition to evidence of alveolitis as
             defined by chest CT changes or BAL. If patients had prior autologous HCT on the
             "Scleroderma: Cyclophosphamide Or Transplantation" (SCOT) clinical trial, they must
             have failed based on the defined study endpoints and be approved by the protocol
             principal investigator (PI).

          -  Group 4: Patients who meet group 1 inclusion criteria but may have FVC or
             DLCO-adjusted less than 70% plus have had an adverse event on cyclophosphamide
             preventing its further use (specifically hemorrhagic cystitis, leukopenia with white
             blood cell [WBC]&lt; 2000 or absolute neutrophil count [ANC] &lt; 1000 or platelet count &lt;
             100,000).

          -  Group 5: Diffuse scleroderma with disease duration less than or equal to 2 years
             since development of first sign of skin thickening plus modified Rodnan skin score
             greater than or equal to 25 plus erythrocyte sedimentation rate (ESR) &gt; 25 mm/1st
             hour and/or hemoglobin (Hb) &lt; 11 g/dL, not explained by causes other than active
             scleroderma.

          -  Unless patients have a DLCO-adjusted less than 45%, patients in all groups must have
             failed either oral or intravenous cyclophosphamide regimen defined as: IV
             cyclophosphamide administration for at least &gt; 3 months between first and last
             cyclophosphamide dose at a total cumulative IV dose of at least 2 grams, oral
             cyclophosphamide administration for &gt; 4 months regardless of dose, or combination of
             oral and IV cyclophosphamide for at least &gt; 6 months independent of dose.

          -  DONOR: HLA genotypically identical sibling or unrelated donor; unrelated donors are
             required to be matched by standard molecular methods at the intermediate resolution
             level at HLA-A, B, C and DRB1 and the allele level at DQB1.

          -  DONOR: Donors must meet the selection criteria as defined by the Foundation for the
             Accreditation of Cell Therapy (FACT) and will be screened per the American
             Association of Blood Banks (AABB) guidelines

          -  DONOR: Bone marrow is the preferred cell source

        Exclusion Criteria:

          -  Fertile men or women unwilling to use contraceptive techniques during and for 12
             months following transplant

          -  Evidence of ongoing active infection

          -  Pregnancy

          -  Patients with a creatinine clearance &lt; 60 ml/min/1.73 m^2 body surface area

          -  Uncontrolled clinically significant arrhythmias

          -  Clinical evidence of significant congestive heart failure (CHF) (New York Heart
             Association [NYHA] Class III or IV)

          -  LVEF &lt; 45% by echocardiogram

          -  Severe pulmonary dysfunction with a hemoglobin corrected DLCO &lt; 30% or FVC &lt; 40% of
             predicted or O2 saturation &lt; 92% at rest without supplemental oxygen

          -  Significant uncontrolled pulmonary hypertension defined as: Pulmonary artery peak
             systolic pressure &gt; 55 mmHg by echocardiogram, or pulmonary artery peak systolic
             pressure 45-55 mmHg by echocardiogram and mean pulmonary artery pressure by right
             heart catheterization exceeding 25 mmHg at rest (or 30 mmHg with exercise); or
             NYHA/World Health Organization (WHO), Class III or IV

          -  Active hepatitis or liver biopsy evidence of cirrhosis or periportal fibrosis; liver
             function tests: total bilirubin &gt; 2 x the upper limit of normal and/or serum glutamic
             pyruvate transaminase (SGPT) and SGPT &gt; 4 x the upper limit of normal

          -  Patients with poorly controlled hypertension

          -  Patients whose life expectancy is severely limited by illness other than autoimmune
             disease

          -  Patients with poorly controlled bleeding from gastric antral vascular ectasia (GAVE)
             or other gastrointestinal (GI) sites

          -  Untreated psychiatric illness, drug/alcohol abuse

          -  Inability to give voluntary informed consent or guardian's informed consent

          -  Demonstrated lack of compliance with prior medical care

          -  Malignancy within the 2 years prior to treatment, excluding adequately treated
             squamous cell skin cancer, basal cell carcinoma, and carcinoma in situ; treatment
             must have been completed (with the exception of hormonal therapy for breast cancer)
             with cure/remission status verified for at least 2 years at time of treatment

          -  Human immunodeficiency virus (HIV) seropositivity

          -  DONOR: Identical twin

          -  DONOR: Current pregnancy

          -  DONOR: HIV seropositivity

          -  DONOR: Deemed medically unable to undergo bone marrow harvesting

          -  DONOR: Current serious systemic illness including uncontrolled infections

          -  DONOR: Failure to meet institutional criteria for donation as described in the
             Standard Practice Guidelines
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients, who are participating in a previous Bayer/Onyx sponsored study that has
             reached its endpoint (statistical and regulatory or study end), and who are, in the
             opinion of the Investigator, expected to continue to have an overall positive
             benefit/risk from continuing treatment.

          -  Patients who have signed informed consent for this long term extension program.

          -  Women of childbearing potential and men must agree to use adequate contraception
             prior to study entry and for the duration of study participation, including the 30
             days period after last study drug dosing.  The investigator should advise the patient
             how to achieve an adequate contraception.

          -  Women of childbearing potential who have a negative pregnancy test within 7 days of
             the first dose of sorafenib in this long term extension program.

          -  Patient is receiving sorafenib (Nexavar) as a monotherapy in their originating
             protocol.  Patients who were being treated with sorafenib (Nexavar) in combination
             with other chemotherapies in the original study, but continued on single agent
             sorafenib (Nexavar) after discontinuation of the combination agent will be eligible.

          -  Patient who are receiving concurrent combination with sorafenib (Nexavar) and TACE
             (transarterial chemoembolization) in their originating study will be eligible.

          -  Patients who have completed the End of Treatment assessments in their originating
             study.  Every effort should e made to conduct the End of Treatment visit such that
             the patient does not have any interruption in sorafenib dosing.

        Exclusion Criteria:

          -  Any condition that is unstable or which could jeopardize the safety of the patient
             (please refer to the Investigator Brochure and product labeling safety sections).

          -  History of cardiac disease:  congestive heart failure&gt;NYHA Class 2 or uncontrolled
             hypertension

          -  Myocardial infarction (MI) within the last 3 months

          -  Symptomatic metastatic brain or meningeal tumors

          -  Previous or concurrent cancer that is distinct in primary site or histology from the
             cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal
             cell carcinoma, superficial bladder tumors ( Ta, Tis &amp;T1) or any cancer curatively
             treated &gt; 5 years prior to study entry.

          -  Patients with seizure disorder requiring medication (such as steroid
             anti-epileptics)

          -  Substance abuse, medical, psychological or social conditions that may interfere with
             the patient's participation in the study or evaluation of the study results

          -  Any condition which could jeopardise the safety of the patient and his/her compliance
             in the study

        Excluded therapies and medications, previous and concomitant:

          -  Concurrent anti-cancer chemotherapy, except TACE (transarterial chemoembolization),
             during or within 30 days prior to start of study drug

          -  Concurrent immunotherapy (including monoclonal antibodies),during or within 30 days
             prior to start of study drug

          -  Concurrent hormonal therapy, except for bisphosphonates,during or within 30 days
             prior to start of study drug

          -  Concomitant Rifampicin and St John's Wort (Warfarin may be used only with very close
             monitoring.)

          -  Radiotherapy during study or within 3 weeks of start of study drug.  [Palliative
             radiotherapy will be allowed]

          -  Concomitant use of potent inhibitors of CYP 3A4 including ketoconazole, itraconazole
             and ritonavir.  Consumption of grapefruit juice should also be avoided.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  16 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Histopathologically confirmed glioblastoma multiforme

               -  WHO grade IV disease

          -  Must undergo leukapheresis  4 weeks after definitive resection

          -  Residual radiographic contrast enhancement on post-resection CT scan or MRI must not
             exceed 1 cm in diameter in two perpendicular axial planes

               -  Patients with evidence of contrast enhancement exceeding 1 cm in diameter in two
                  perpendicular axial planes after radiation will not be a candidate for the
                  vaccine despite being previously enrolled and will be removed from the study and
                  replaced

          -  No radiographic or cytologic evidence of leptomeningeal or multicentric disease

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status 80-100%

          -  Curran Group status I-IV

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No active infection requiring treatment

          -  No unexplained febrile (&gt;101.5F) illness

          -  No known immunosuppressive disease or known HIV infection

          -  No unstable or severe intercurrent medical conditions such as severe heart or lung
             disease

          -  No allergy to temozolomide (TMZ) or otherwise unable to tolerate TMZ for reasons
             other than lymphopenia

               -  Patients who are found after enrollment to be unable to tolerate TMZ will not be
                  a candidate for the vaccine despite being previously enrolled and will be
                  removed from the study and replaced

          -  No prior allergic reaction to daclizumab or one of its components

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior daclizumab

          -  No other prior conventional therapeutic intervention except for steroids, radiation,
             or temozolomide

          -  No prior inguinal lymph node dissection, radiosurgery, brachytherapy, or radiolabeled
             monoclonal antibodies

          -  No concurrent corticosteroids, with the exception of nasal or inhaled steroids, at a
             dose above physiologic levels

               -  Patients requiring an increase in corticosteroids, with the exception of nasal
                  or inhaled steroids, such that at the time of first vaccination they require a
                  dose above physiologic levels, will be removed from the study and replaced
                  (physiologic dose will be defined as &lt; 2 mg of dexamethasone/day)

               -  Once vaccinations have been initiated, if patients subsequently require
                  increased steroids, they will still be permitted to remain on the study, but
                  every effort will be made to minimize steroid requirements

          -  No prior allogeneic solid organ transplantation
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Adults over the age of 18 who have a family history of a blood or lymph node disorder.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   At least 2 living, blood related relatives, affected with a lymphoproliferative disorder.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Histologically confirmed diagnosis of 1 of the following:

               -  Anaplastic oligodendroglioma

               -  Anaplastic oligoastrocytoma

               -  Anaplastic astrocytoma

          -  Newly diagnosed disease

          -  Prior surgery for a low grade tumor is allowed, provided histological confirmation of
             an anaplastic tumor is present at the time of progression

          -  Absence of combined 1p/19q loss

          -  Tumor material available for central 1p/19q assessment, central O6-methylguanine-DNA
             methyltransferase promoter methylation status assessment, isocitrate dehydrogenase
             mutation analysis, and central pathology review

          -  Patients must be on a stable or decreasing dose of steroids for at least two weeks
             prior to randomization

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-2

          -  ANC  1.5 x 10^9 cells/L

          -  Platelet count  100 x 10^9 cells/L

          -  Bilirubin &lt; 1.5 x upper limit of normal (ULN)

          -  Alkaline phosphatase &lt; 2.5 x ULN

          -  AST and ALT &lt; 2.5 x ULN

          -  Serum creatinine &lt; 1.5 x ULN

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No known HIV infection or chronic hepatitis B or hepatitis C infection

          -  No other serious medical condition that would interfere with follow-up

          -  No medical condition that could interfere with oral medication intake (e.g., frequent
             vomiting or partial bowel obstruction)

          -  No other prior malignancies except for any malignancy which was treated with curative
             intent more than 5 years prior to registration and adequately controlled limited
             basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma
             in situ of the cervix

          -  No prior or concurrent malignancies at other sites except for surgically cured
             carcinoma in situ of the cervix or nonmelanoma skin cancer

          -  No psychological, familial, sociological, or geographical condition that would
             potentially hamper compliance with the study protocol and follow-up schedule

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior chemotherapy, including carmustine-containing wafers (Gliadel)

          -  No prior radiotherapy to the brain

          -  No concurrent growth factors unless vital for the patient

          -  No other concurrent investigational treatment

          -  No other concurrent anticancer agents
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  At least 18 years f age

          -  Indications for diagnostic or therapeutic approaches for benign or malignant disease
             of the head and neck

          -  Written informed consent

        Exclusion Criteria:

          -  Unexplained fever and/or untreated, active infection

          -  Pregnancy

          -  Previous head and neck surgery precluding transoral/endoscopic/robotic procedures

          -  Presence of medical conditions contraindicating general anesthesia or transoral
             surgical approaches
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

        Entry criteria include the following:

          1. Clinical diagnosis of VOD, made by Baltimore Criteria, Modified Seattle Criteria, or
             biopsy proven:

             1.1   Baltimore Criteria- Bilirubin 2 mg/dL and at least 2 of the following clinical
             findings:

               -  Ascites (radiographic or physical exam)

               -  Weight gain of 5% compared to the day of conditioning-- if this value is not
                  available,  the weight on the date of admission to the SCT unit may be used)

               -  Hepatomegaly; increased over baseline.

             1.2   Modified Seattle Criteria: At least two of the following

               -  Bilirubin 2 mg/dL

               -  Ascites (radiographic or physical exam) and/or weight gain 5% above baseline
                  weight (defined as weight on the first day of conditioning- if this value is not
                  available, the weight on the date of admission to the SCT unit may be used)

               -  hepatomegaly increased over baseline

             1.3   Patients that do not meet the Baltimore Criteria or Modified Seattle Criteria
             and have biopsy proven VOD are eligible.

          2. Patient must also provide written informed consent.

        Exclusion Criteria:

          -  Use of any medication which increases the risk of hemorrhage is disallowed.  Use of
             heparin or other anticoagulants is disallowed within 12 hours unless being used for
             routine central venous line management, fibrinolytic instillation for central venous
             line occlusion, intermittent dialysis or ultrafiltration of CVVH.

          -  Clinically significant uncontrolled acute bleeding, defined as hemorrhage requiring &gt;
             15 cc/kg of packed red blood cells (e.g., a pediatric patient weighing 20 kg and
             requiring &gt; 300cc of packed red blood cells/24 hours, or an adult patient weighing 70
             kg and requiring &gt;3 units of packed red blood cells/24 hours) to replace blood loss,
             OR bleeding from a site which in the Investigator's opinion constitutes a potential
             life-threatening source (e.g. pulmonary hemorrhage or CNS bleeding), irrespective of
             amount of blood loss, at any point from the date of SCT through the date of severe
             VOD diagnosis.

          -  Hemodynamic instability as defined by a requirement for multiple pressors, or
             inability to maintain mean arterial pressure (for children: to maintain mean arterial
             pressure within 1 standard deviation of age-adjusted levels) with single pressor
             support.

          -  Woman who are pregnant.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   volunteers and patients with ovarian, peritoneal, and fallopian tube cancers
  </textblock>
 </study_pop>
 <sampling_method>
  Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Able to understand consent document for participation in the study

          -  Not pregnant

          -  Negative pregnancy test

        Participants must meet 1 of the following criteria:

          -  Patients scheduled for ovarian surgery for an ovarian mass

          -  Healthy female volunteers with no active cancer or history of cancer
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  21 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Well-dignosed patients with cirrhosis
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Image diagnosis or biochemical diagnosis or presence of portal hypertension

        Exclusion Criteria:

          -  Presence of hepatocellular carcinoma
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Histologically confirmed colorectal cancer with liver metastasis(all patients should
             have the pathological report of colorectal cancer. The chances of hepatocellular
             carcinoma or metastasis from other primary lesions should be excluded. )

          2. Liver metastasis should be resected with R0 resection and to save enough normal liver
             tissue

          3. Anticipated liver resection: for normal liver, 70%; for liver with cirrhosis, 50%

          4. No metastasis of other organs or lymph nodes in abdominal cavity

          5. No previous use of oxaliplatin and capecitabine, or previous adjuvant treatment ended
             more than 6 months

          6. Age 18 to 75 years old

          7. Karnofsky performance status 70

          8. Life expectancy of 3 month

          9. Bilirubin level &lt; 1.5mg/dL

         10. Serum creatinine &lt;1.0 times ULN

         11. Absolute neutrophil count 2000/mm3, platelet&gt;100,000/mm3, Hb&gt;9g/dl

         12. Having signed informed consent

        Exclusion Criteria:

          1. previous use of oxaliplatin or fluorouracil-based chemotherapy in 6 months.

          2. No R0 resection or not enough normal liver tissue left

          3. previous radiotherapy of target lesions

          4. accompanied with unresectable other metastasis or malignant pleural fluids or
             ascites.

          5. complete or uncompleted liver obstruction

          6. peripheral neuropathy(NCI-CTC grade 1 or more)

          7. mental disturbance neuropathy that influence the cognition, including brain
             metastasis

          8. other serious disease such as uncontrollable active infection, heart infarction with
             1 year, un controlled hypertension, arrhythmia with high risk, or unstable heart
             infarction,heart failure, coronary artery disease, myocardial infarction within the
             last 6 months

          9. Other previous malignancy within 5 year, except non-melanoma skin cancer

         10. accompany with other anti-tumor therapies,including immune therapy, intervention or
             injection with chemotherapeutical agents into serous cavity, or participating other
             clinical trials.

         11. Pregnancy or lactation period
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients must be &lt;60 years of age with a diagnosis of Fanconi Anemia (FA).

          -  Patients must have an HLA-A, B, DRB1 identical sibling donor. Patients and donors
             will be typed for HLA-A and B using serological or molecular techniques and for DRB1
             using high resolution molecular typing.

          -  Patients with FA must have moderately severe aplastic anemia (AA), early
             myelodysplastic syndrome (MDS) with no excess blasts with or without chromosomal
             abnormalities.

               -  In patients &lt;18 years of age, moderately severe aplastic anemia is defined as
                  having at least one of the following:

                    -  platelet count &lt;40 x 10^9/L

                    -  absolute neutrophil count (ANC) &lt;10 x 10^8/L

                    -  Hgb &lt;9 g/dL

               -  In patients 18-60 years of age, moderately severe aplastic anemia is defined as
                  having at least one of the following:

                    -  platelet count &lt;20 x 10^9/L

                    -  absolute neutrophil count ANC &lt;5 x 10^8/L

                    -  Hgb &lt;8 g/dL

               -  Early myelodysplastic syndrome, with multilineage dysplasia with &lt; 5% blasts,
                  with or without chromosomal anomalies.

          -  Adequate major organ function including:

               -  Cardiac: ejection fraction &gt;45%

               -  Hepatic: no clinical evidence of hepatic failure (e.g. coagulopathy, ascites)

               -  Karnofsky performance status &gt;70% or Lansky &gt;50%

          -  Women of child bearing age must be using adequate birth control and have a negative
             pregnancy test.

        Exclusion Criteria:

          -  Active bacterial infection within one week of hematopoietic cell transplant (HCT)

          -  Active fungal infection at time of HCT.

          -  Late MDS with greater than 5% blasts in bone marrow.

          -  Acute myelogenous leukemia (AML) or history of AML

          -  Malignant solid tumor (e.g. squamous cell carcinoma of the head/neck/cervix) within 2
             years of HCT.

          -  Pregnant or lactating female.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  59 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

        Children under the age of two are eligible for this protocol, but will not receive total
        body irradiation. Instead, children under the age of two will receive
        Busulfan/Cyclophosphamide (Bu/Cy) conditioning as the preparative regimen in order to
        obviate deleterious effects of radiation at this age. Patients who cannot receive total
        body irradiation (TBI) (for example those with prior radiation therapy) will also receive
        the Bu/CY conditioning.

          -  Acute myeloid leukemia (AML)

               -  All children and adults less than the age of 70 with AML who have achieved a
                  first or second bone marrow remission are eligible for this protocol. Patients
                  must undergo peripheral blood stem cell collection or marrow harvest while in
                  remission and must not be expected to have better outcomes with allogeneic
                  transplantation.

               -  Patients with cytogenetic abnormalities suggesting an improved prognosis
                  [t(8:21), t(15;17) and inv(16)] will be eligible for transplantation in first
                  remission.

          -  Allogeneic transplant with an HLA-identical sibling will be recommended for patients
             &lt;55 years. If the patient refuses allogeneic transplant, they may still be eligible
             for this protocol.

        Exclusion Criteria:

          -  Patients can also be deemed not eligible for transplant because of specific organ
             toxicity. Specifically, patients with pre-existing compromise to the heart, lungs,
             kidney, CNS or liver may be excluded:

               -  Eastern Cooperative Oncology Group (ECOG) Performance status: 0 or 1

               -  Heart - The patient must be free of symptoms of uncontrolled cardiac disease,
                  and must not have compromised cardiac function detected by ECHO or by gated
                  cardiac blood flow scan (MUGA) LVEF &gt;45%).

               -  Kidney - The patient must have a corrected creatinine clearance &gt;50% of normal.

               -  Liver - The total serum bilirubin &lt; 2.5 mg/dL; ALT &lt;2 x upper limit of normal.

               -  Lung - Patients must have no significant obstructive airways disease or resting
                  hypoxemia (PO2 &lt;80), and must have acceptable diffusion capacity (DLCO &gt; 50% of
                  predicted).

               -  Central Nervous System (CNS): Patients must be free of active or ongoing
                  ischemic or degenerative CNS disease and no active or resistant CNS leukemia.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Resides in 1 of 20 geographically defined clusters within the slums of Mumbai, India

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  Not specified
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  35 Years
 </minimum_age>
 <maximum_age>
  64 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   patients of the lung clinic hemer
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Any patient

          -  Ages 18-90 years old
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  90 Years
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Patients should have completed their chemotherapy 3 months prior to start of
             treatment with lenalidomide and not more than 9 months prior to treatment initiation.

          2. Patients with CLL/Small Lymphocytic Lymphoma (SLL) that achieve a complete or stable
             partial remission after combination of chemotherapy. Patients in complete remission
             need to have documentation of residual disease by immunophenotyping and/or PCR
             molecular testing.

          3. Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) status of
             0-2.

          4. Adequate renal and hepatic function (creatinine equal to or less than 2mg/dL - total
             bilirubin equal to or less than 2).

          5. Females of childbearing potential (FCBP). A female of childbearing potential is a
             sexually mature woman who: 1) has not undergone a hysterectomy or bilateral
             oophorectomy; 2) or has not been naturally postmenopausal for at least 24 consecutive
             months (has NOT had menses at any time in the preceding 24 consecutive months).

          6. FCBP must have a negative serum or urine pregnancy test with a sensitivity of at
             least 50 mIU/mL within 10-14 days prior to and again within 24 hours of starting
             lenalidomide and must either commit to continued abstinence from heterosexual
             intercourse or begin TWO acceptable methods of birth control; one highly effective
             and one additional effective method AT THE SAME TIME at least 28 days before starting
             taking lenalidomide.

          7. FCBP must also agree to ongoing pregnancy testing weekly for the first four weeks and
             then every 28 days while on therapy and at discontinuation of treatment.

          8. Men must agree to use a latex condom during sexual contact with a FCBP even if they
             have had a successful vasectomy. All patients must be counseled at a minimum of every
             28 days about pregnancy precautions and risks of fetal exposure.

          9. Age 18 and older.

         10. Signed, written IRB-approved informed consent.

        Exclusion Criteria:

          1. Known sensitivity to lenalidomide or thalidomide or it's derivatives

          2. Known positivity for HIV or active hepatitis B or C.

          3. Pregnant or breast feeding females. Lactating females must agree not to breast feed
             while taking lenalidomide.

          4. History of tuberculosis within the last five years or recent exposure to tuberculosis
             equal to or less than 6 months.

          5. Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from signing the informed consent form.

          6. Any condition, including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if he/she were to participate in the study or confounds
             the ability to interpret data from the study.

          7. Use of any other experimental drug or therapy within 28 days of baseline.

          8. Concurrent use of other anti-cancer agents or treatments
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients with diagnosis of Colorectal Cancer at or before age 60 years, and their First
        Degree Relatives (FDRs) who are age 40 years or older.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Colorectal cancer (CRC) Patients: CRC patients will be eligible if they:

               -  have a diagnosis of colorectal adenocarcinoma at or before age 60, and were
                  diagnosed between 6 and 12 months prior to being contacted about this study (to
                  allow adequate time for dissemination of CRC risk to family members, and to
                  avoid interference with care surrounding the initial diagnosis);

               -  have at least one living FDR age 40 years or older;

               -  can read and speak English.

          2. FDRs of CRC Patients: FDRs will be eligible if they

               -  are age 40 years or older;

               -  can read and speak English.

        Exclusion Criteria:

          1. CRC Patients: CRC patients will be excluded if they:

               -  have a history of a known hereditary CRC syndrome (e.g., HNPCC, familial
                  polyposis) or inflammatory bowel disease (e.g., ulcerative colitis or Crohn's
                  disease); or

               -  have an ECOG PS&gt;1.

          2. FDRs of CRC patients: FDRs will be excluded if they:

               -  have a history of a known hereditary CRC syndrome (e.g., HNPCC, familial
                  polyposis) or inflammatory bowel disease (e.g., ulcerative colitis or Crohn's
                  disease); or

               -  have a personal history of colon polyps or of cancer diagnosed within 5 years
                  prior to entry into the study, with the exception of nonmelanoma skin cancer.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  60 Years
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Histologically or cytologically documented small cell lung cancer (SCLC)

               -  Limited-stage disease

                    -  Disease restricted to one hemithorax with regional lymph node metastases,
                       including ipsilateral hilar, ipsilateral and contralateral mediastinal, and
                       ipsilateral supraclavicular lymph nodes

          -  The following patients are not eligible:

               -  Patients with disease involvement of the contralateral hilar or supraclavicular
                  lymph nodes

               -  Patients with pleural effusions that are visible on plain chest radiographs,
                  whether cytologically positive or not

               -  Patients with cytologically positive pleural or pericardial fluid, regardless of
                  the appearance on plain x-ray

          -  Measurable disease, defined as at least one unidimensionally measurable lesion  2 cm
             by conventional techniques OR  1 cm by spiral CT scan

        PATIENT CHARACTERISTICS:

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Granulocytes  1,500/l

          -  Platelet count  100,000/l

          -  Total bilirubin  1.5 times upper limit of normal (ULN)

          -  AST  2.0 times ULN

          -  Serum creatinine  1.5 times ULN OR creatinine clearance  70 mL/min

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

          -  Patients may have received one and only one course of chemotherapy prior to enrolling
             on CALGB 30610, which must have included cisplatin and etoposide

               -  If a patient has had one course of cisplatin/etoposide prior to registration,
                  the patient must have had all of the prior-to-registration tests prior to
                  starting their first course of chemotherapy

               -  Registration to CALGB-30610 must take place within 14-21 days after the start of
                  the non-protocol therapy; failing to do all of the above will make the patient
                  NOT eligible for CALGB-30610

          -  No prior radiotherapy or chemotherapy (except for the chemotherapy described above)
             for SCLC

          -  No prior mediastinal or thoracic radiotherapy

          -  No prior complete surgical resection of SCLC
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Potential research subjects are first identified by their primary doctor/clinical team.
        The research project will be discussed and mutually agreed upon between the subject and
        his/her caregiver before the research team will contact the subject. Other subjects are
        referred in specifically for possible participation in a particular study which they or
        their physician are aware of based on publications which list clinical trials at UPMCHS.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  histologically confirmed GI malignancy

          -  suspected GI malignancy

          -  high risk individual as assessed by their physician
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   The subjects will be recruited from the pool of the patients seen in the Aesthetic and
        Plastic Surgery Institute clinics, as well as patients initially seen as in-patient
        consultations by the Plastic Surgery Service.  Patients requiring reconstructive surgery
        using either a pedicle or free tissue transfer flap(s) will be identified.  Patients
        requiring emergency reconstructive surgery after acute trauma will be excluded from the
        study as a matter of patient safety.  The location and type of tissue transfer flaps
        enrolled will be dependent on the patient mix that presents during the study enrolment
        period.  After explaining the nature, rationale, objectives, benefits, and risks of the
        study to the patients, they will be asked to consent to the study.
  </textblock>
 </study_pop>
 <sampling_method>
  Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Adult patients planned to undergo reconstructive surgery using either a pedicle or
             free tissue transfer flap seen by The Plastic Surgery Service on either an in-patient
             or outpatient bases.

          -  Adult patients that are planned to undergo reconstructive surgery as above and able
             to receive information regarding the study and provide informed consent to enrollment
             in the study.

        Exclusion Criteria

          -  All emergency reconstructive surgery patients.

          -  Patients planned to undergo radiation therapy in the region of the reconstructive
             surgery within 6 months after surgery.

          -  Patients who develop hypotension requiring the administration of vasopressors either
             intra-operatively or during the post-operative period prior to discharge from the
             hospital.

          -  Patients who develop clinical signs of a surgical site infection at the location of
             the tissue transfer flap(s).

          -  Patients with the development of post-operative anemia requiring a blood transfusion
             during the first 72 hours after surgery.

          -  Patients with tattooing or pigmented lesions on the tissue transfer flap.

          -  Patients who incur injury to the flaps secondary to trauma within 6 months of the
             reconstructive surgery; with trauma defined as either accidental major trauma
             resulting in injury to the tissue transfer flap or surgical trauma as a result of
             further oncologic resection of tissues in close proximity to the tissue transfer
             flap.

          -  Minor under the age of 18 years of age.

          -  Patients deemed unable to comprehend and provide informed consent to enrollment into
             study due to either a cognitive deficit or medical condition.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Histological or cytological diagnosis of non-small cell carcinoma of the lung

          -  Initially unresectable non-metastatic stage III disease

          -  Availability for participating in the detailed follow-up of the protocol

          -  Presence of an evaluable or measurable lesion

          -  Written informed consent

          -  No functional or anatomical contraindication to chest irradiation

        Exclusion Criteria:

          -  Prior treatment with chemotherapy, radiotherapy or surgery

          -  Performance status &lt; 60 on the Karnofsky scale

          -  History of prior malignant tumour, except non-melanoma skin cancer or in situ
             carcinoma of the cervix or cured malignant tumour (more than 5 year disease-free
             interval)

          -  Neutrophils &lt; 2,000/mm

          -  Platelet cells &lt; 100,000/mm3

          -  Serum bilirubin &gt; 1.5 mg/100 ml

          -  Hepatic disease contra-indicating the administration of docetaxel and/or GOT or GPT 
             2.5x the normal value and/or alkaline phosphatase  5x the normal value

          -  Serum creatinine &gt; 1.5 mg/100 ml and/or creatinine clearance &lt; 60 ml/min

          -  Recent myocardial infarction (less than 3 months prior to date of diagnosis) or
             uncontrolled angina pectoris

          -  Congestive cardiac failure or cardiac arrhythmia requiring medical treatment

          -  Uncontrolled infectious disease

          -  Symptomatic polyneuropathy

          -  Auditive impairment contra-indicating cisplatin administration

          -  Serious medical or psychological factors which may prevent adherence to the treatment
             schedule

          -  Malignant pleural or pericardial effusion

          -  Homolateral supraclavicular lymph node excepting upper lobe lesion

          -  Heterolateral supraclavicular lymph node

          -  Known hypersensitivity to docetaxel or cisplatin

          -  Pregnancy or for pre-menopausal patient, incapacity to use adequate contraceptive
             method
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Potential research subjects are first identified by their primary doctor/clinical team.

        First Degree Relatives A Letter of Introduction will be supplied to the participant to
        give to first-degree relatives. If the subject's first degree relative is interested in
        participation in the Hereditary Colorectal Tumor Registry, he/she will be provided with
        the Letter of Introduction. The first degree relative must sign the Letter of Introduction
        and send it back via self-addressed stamped envelope supplied by the initial participant
        to show interest in participation. The Letter of Introduction will inform the first degree
        relative subjects that they were referred to the Hereditary Colorectal Tumor Registry
        because of  a shared family history of colorectal, ovarian, endometrial, gastric, biliary,
        renal pelvis, bladder, and or brain tumor.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  HNPCC- RC less than the age of 50

          -  Colorectal polyps less than the age of 40

          -  HNPCC-RC at any age but a FDR with HNPCC-RC less than 50

          -  Anyone with MSI positive high or Immunohistochemistry - for hMLH1, hSH2, hSH6

          -  Anyone at any age with 2 HNPCC-RC (including synchronous or metachronous CRC)

          -  CRC diagnosed in at least 2 FDR or SDR relatives with HNPCC-RC regardless of age

          -  Anyone who is a FDR(first degree relative) to those who meet the inclusion criteria
             above

          -  Because some of the familial cancers involve children and standard of care involves
             screening of children during puberty, they will also be included but with parental
             consent.

          -  Individuals must be able to complete all questionnaires.

          -  Ability to give informed consent

        Exclusion Criteria

          -  Individuals who do not meet the above criteria

          -  Individuals who do not desire to consent to any part of the registry
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  50 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients must be 3 years of age or older

          -  Patients must be planning to undergo standard of care treatment with surgery and
             radiation therapy.

          -  Patients must have malignant glioma or recurrent ependymoma

          -  Tumor must be accessible for injection and must not be located in the brainstem or
             deep midbrain

          -  Performance Score:  Karnofsky 60% if &gt;10y/o, Lansky 60 if 10y/o

          -  Bone Marrow Function: Patients must have adequate bone marrow function defined as a
             peripheral absolute neutrophil count  1000/l, platelet count  100,000/l
             (transfusion independent) and hemoglobin  8.0 gm/dL

          -  Renal Function: Patients must have serum creatinine  1.5 times upper limit of
             institutional normal for age and/or GFR  70 mL/min/1.73 m2.

          -  Hepatic Function: Bilirubin  1.5 times institutional normal; SGPT (ALT) &lt; 3 times
             institutional normal

          -  Serum electrolyte values (sodium, potassium, magnesium, calcium) must be checked
             prior to enrollment and clinically significant abnormalities corrected prior to
             surgery/AdV-tk injection

          -  Patients with seizure disorder may be enrolled if well controlled

          -  Signed informed consent according to institutional guidelines must be obtained

        Exclusion Criteria:

          -  Prior or ongoing liver disease including known cirrhosis, hepatitis B or C infection
             but not to exclude patients with a distant history of resolved hepatitis A infection

          -  Patients on immunosuppressive drugs (with exception of corticosteroid)

          -  Known history of HIV or underlying immunodeficiency

          -  Patients with acute infections (viral, bacterial or fungal infections requiring
             therapy)

          -  Pregnant or breast-feeding patients. Female patients of childbearing age must have
             negative serum or urine pregnancy test within 1 week of beginning therapy

          -  Other serious co-morbid illness or compromised organ function

          -  No other investigational anti-tumor agents within 30 days prior to study entry or
             during active participation in the study (defined as from study entry until tumor
             progression)
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  3 Years
 </minimum_age>
 <maximum_age>
  21 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Histologically or cytologically confirmed transitional cell carcinoma of the urinary
             bladder.

          -  Metastatic or locally advanced disease.

          -  No prior chemotherapy.

          -  Performance status (World Health Organization) 0-2.

          -  Measurable or evaluable disease.

          -  Measurable disease is defined as at least 1 unidimensional measurable lesion

             20 mm by conventional techniques or 1 bidimensionally measurable lesion  20 X 10
             mm. Lesions that are smaller or uni- or bidimensionally unmeasurable are considered
             as evaluable disease.

          -  Adequate liver (bilirubin  1.5 Upper Normal Limit, serum glutamate-pyruvate
             aminotransferase/serum glutamic pyruvic transaminase  2 Upper Normal Limit, ALP 
             2.5 Upper Normal Limit), renal (creatinine  1.5 Upper Normal Limit) and bone marrow
             (absolute neutrophil count  1,500/mm3, platelet count  100,000/mm3) function.

          -  Life expectancy &gt; 3 months.

          -  Patients must be able to understand the nature of this study and give written
             informed consent.

        Exclusion Criteria:

          -  History of serious cardiac disease (unstable angina, severe congestive heart failure,
             myocardial infarction within the previous 6 months, ventricular arrhythmias).

          -  Second primary malignancy, except for non-melanoma skin cancer and in situ cervical
             cancer.

          -  Active infection.

          -  Uncontrolled inflammation.

          -  Pregnant or lactating women.

          -  Psychiatric illness or social situation that would preclude study compliance.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Psoriasis patients with PASI reduction of less than 75% after at least 6 weeks of
             treatment with adalimumab.

        Exclusion Criteria:

          -  Pregnancy or lactation

          -  History of skin cancer

          -  Presence of or history of malignant skin tumors

          -  Dysplastic melanocytic nevus syndrome

          -  Antinuclear antibodies (ds-DNA, Ro/SSA, La/SSB)

          -  Autoimmune disorders such as Lupus erythematosus or Dermatomyositis

          -  Photosensitive diseases such as porphyria, chronic actinic dermatitis, Xeroderma
             pigmentosum, basal cell nevus syndrome, and others

          -  General poor health status
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients with a diagnosis of MPS IH (Hurler syndrome) are candidates for this
             protocol if they are being considered for hematopoietic stem cell transplantation
             according the University of Minnesota guidelines.

        Exclusion Criteria:

          -  Patients are less than 6 months old, or older than 3 years of age.

          -  There is a history of clinically-severe hypersensitivity to Laronidase.

          -  There is a contraindication for repeated lumbar puncture.

          -  The family is not willing to undergo the necessary procedures and evaluations
             inherent in the study.

          -  Consent has not been signed for participation in the 2004-09 study of intravenous
             Laronidase administration.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  6 Months
 </minimum_age>
 <maximum_age>
  3 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients with familial adenomatous polyposis who have undergone subtotal colectomy
             with ileorectal anastomosis, total coloctomy with ileo-anal pull through (reservoir),
             and patients with intact colons with 5 or more adenomas in the rectum-sigmoid or
             reservoir

          -  Patients with familial adenomatous polyposis (FAP) and duodenal adenomatous polyposis
             without current lower tract adenomatous polyposis i.e. s/p ileostomy

        Exclusion Criteria:

          -  Female patients of childbearing age not on effective birth control

          -  Pregnant women

          -  WBC &lt; 3500/ml

          -  Platelet count &lt; 100,000/ml

          -  BUN &gt; 25mg%

          -  Creatinine &gt; 1.5mg%

          -  Patients unable to stop NSAIDS, aspirin, curcumin, tumeric, calcium, vitamin D, green
             tea, or polyphenol E supplements for the duration of the trial

          -  Malignancy other than nonmelanoma skin cancer

          -  Active bacterial infection

          -  Patients with symptoms of active GERD (symptomatic despite medication or current
             erosive esophagitis on endoscopy)

          -  Patients with a history of peptic ulcer disease

          -  Patients on Warfarin or Plavix
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  85 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  age &lt; 75 years with histologically proven adenocarcinoma of the colon or rectum

          -  no severe major organ dysfunction

          -  WHO performance status of 0 or 1

          -  no prior cancer therapy

          -  Stage II (T3-4, N0, M0) or Stage III (T0-4, N1-2, M0) disease (according to the 1997
             revision of the International Union Against Cancer TNM staging system) as determined
             by a preoperative evaluation that included colonoscopy and an abdominal computed
             tomography (CT) scan

        Exclusion Criteria:

          -  age &gt;= 75

          -  severe major organ dysfunction

          -  WHO performance status of &gt;1

          -  prior cancer therapy

          -  Stage I or Stage IV
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  74 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion criteria

          -  B-CLL

          -  Matutes score 4 or 5

          -  Binet stages B or C

          -  Age &gt; 65 years old

          -  No previous treatment of CLL by chemotherapy, radiotherapy or immunotherapy, except
             glucocorticoids &lt; 1 month

          -  Patient's written informed consent

          -  Life expectancy &gt; 6 months

        Exclusion criteria

          -  Binet stage A

          -  ECOG performance status 0 or 1

          -  Presence of a 17p deletion by FISH (&gt; 10% positive cores)

          -  Clinically significant auto-immune cytopenia, Coombs-positive hemolytic anemia as
             judged by the treating physician

          -  Patients with a history of another malignancy in complete remission less than 5
             years, except basal cell skin cancer or tumor treated curatively by surgery

          -  Concomitant disease requiring prolonged use of corticosteroids (&gt; 1 month)

          -  Any severe co-morbidities such as NYHA Class III or IV heart failure, myocardial
             infarction within 6 months, unstable angina, ventricular tachyarrhythmias requiring
             ongoing treatment, severe uncontrolled myocardiopathy, uncontrolled hypertension,
             severe chronic obstructive pulmonary disease with hypoxemia, or uncontrolled diabetes
             mellitus.

          -  CIRS (Cumulative Illness rating Scale) &gt; 6 (see Appendix 11)

          -  Known hypersensitivity to murine proteins or to any of the study drugs or to their
             components

          -  Transformation into an aggressive B-cell malignancy (e.g. diffuse large cell
             lymphoma, Hodgkin lymphoma) or prolymphocytic leukemia

          -  Active bacterial, viral or fungal infection

          -  Seropositivity HIV, hepatitis C or hepatitis B (unless clearly due to vaccination)

          -  Total bilirubin, alkaline phosphatases and aminotransferases &gt; 2 x ULN

          -  Creatinine clearance &lt; 60 ml/min calculated according to the formula of Cockcroft and
             Gault

          -  Any coexisting medical or psychological condition that would preclude participation
             to the required study procedures

          -  Patient with mental deficiency preventing proper understanding of the requirements of
             treatment

        Inclusion criteria at randomization

          -  Patients having received the full induction phase with 4 FC and 6 rituximab courses
             (with/without dose adjustments as per protocol)

          -  Complete or partial response according to NCI criteria at the end of induction phase

          -  Recovery from FCR toxicities

          -  Patient willingness to continue on protocol
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  66 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

               1. Adult patients who are members of families in which there are at least two
                  immediate relatives from consecutive generations that have been diagnosed with
                  gastrointestinal carcinoid tumors (affected family member) and either have a
                  carcinoid tumor or are at a 50% lifetime risk of developing a carcinoid tumor by
                  virtue of being a first degree relative of an affected family member.  This
                  includes family members of patients with carcinoid tumors even if the patients
                  with tumors are unwilling to participate so long as we have appropriate
                  documentation confirming the diagnosis of the carcinoid tumors in the affected
                  family members.  Adult patients who are unable to provide informed consent but
                  whose wishes suggest they are willing to donate samples for research purposes
                  will be considered for study enrollment.

               2. Unaffected spouses of patients with a carcinoid tumor and who have children.

        EXCLUSION CRITERIA:

          1. Families with multiple endocrine neoplasia (MEN) I, MEN II or other familial tumor
             syndromes such as Von Hippel Lindau Syndrome and Neurofibomatosis for which there is
             a known genetic predisposition to non-carcinoid tumors as well as carcinoid tumors
             will be excluded from the study.

          2. Pregnancy, breastfeeding.

          3. Anticoagulation, seizures, severe systemic disease of any sort, advanced metastatic
             carcinoid may be relative exclusion criteria prohibiting a full evaluation as
             described above under protocol design.  However, these medical conditions should not
             absolutely exclude participation in the protocol.  Participation in each protocol
             delineated evaluation procedure will be judged on a case by case basis with patient
             safety as the paramount consideration.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  5 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Histologically confirmed AJCC/UICC high-risk stage II or stage III colon cancer .
             High-risk stage III  patients (T4, N+, M0, or any T, N2, M0) may also be further
             randomized in the BEV study (plus or minus BEV)

          -  Stage II patients have to be considered at high-risk if they fulfill &gt;1 of the
             following criteria:

               -  T4 tumours,

               -  grade &gt;3,

               -  clinical presentation with bowel obstruction or perforation,

               -  histological signs of vascular or lymphatic or perineural invasion,

               -  &lt;12 nodes examined

          -  Age 18 to 75 years

          -  Curative surgery no less than 3 ( 4 in the BEV study) and no more than 8 weeks prior
             to randomization

          -  ECOG performance Status (ECOG-PS) &lt;1

          -  Signed written informed consent obtained prior to any study specific procedures

        Exclusion Criteria:

          -  Macroscopic or microscopic evidence of residual tumor  (R1 or R2 resections).

          -  Previous anti-angiogenic treatment for any malignancy; cytotoxic chemotherapy,
             radiotherapy or immunotherapy for colon cancer

          -  Other malignancies within the last 5 years (other than curatively treated basal cell
             carcinoma of the skin and/or in situ carcinoma of the cervix)

          -  Lactating women

          -  Fertile women (&lt;2 years after last menstruation) and men of childbearing potential
             not willing to use effective means of contraception

          -  History of clinically relevant psychiatric disability , precluding informed consent

          -  Clinically relevant  cardiovascular disease

          -  History or presence of other diseases

          -  Evidence of bleeding diathesis or coagulopathy

          -  Current or recent (within 10 days prior to study treatment start) use of full-dose
             oral or parenteral anticoagulants or thrombolytic agent for therapeutic purposes

          -  Chronic, daily treatment with high-dose aspirin (&gt;325 mg/day) or clopidogrel (&gt;75
             mg/day)

          -  Current or recent (within the 28 days prior to randomization) treatment with another
             investigational drug or participation in another investigational study
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion criteria:

          -  Previously untreated patients with newly diagnosed peripheral T-cell lymphoma of
             stage I bulk ( 7.5 cm) and stages II to IV.

          -  Patients with a confirmed histologic diagnosis of peripheral T-cell NHL according to
             the WHO classification:

          -  Peripheral T-cell lymphoma, unspecified (PTCL NOS)

          -  Angioimmunoblastic T-cell lymphoma

          -  Enteropathy-type T cell lymphoma

          -  Subcutaneous panniculitis-like T-NHL (gamma-delta T-cell lymphoma)

          -  Hepatosplenic T-cell lymphoma

          -  Extranodal NK/T cell lymphoma, nasal type

          -  Age 18-60 years at time of randomization

          -  Life expectancy of 3 months or longer

          -  ECOG performance status (PS) 0, 1 or 2 at the time of randomization. However, PS 3
             will be acceptable if lymphoma-related.

          -  Measurable disease (defined as at least one lesion with two measurable perpendicular
             diameters of which at least one should be &gt;= 15 mm).

          -  Written informed consent

        Exclusion Criteria:

          -  Patients with NK/T-NHL of the following type:

          -  Precursor T cell lymphoblastic lymphoma/leukemia

          -  All mature T cell leukemias (T-PLL, ATLL, NK cell leukemia, T-LGL, HTLV1-pos ATL)

          -  Alk-positive and negative anaplastic large cell lymphoma

          -  Blastic NK cell lymphoma

          -  Cutaneous T-cell lymphoma, transformed or not

          -  Concurrent severe and/or uncontrolled medical disease (e.g. uncontrolled diabetes,
             congestive heart failure, myocardial infarction within 6 months prior to the study,
             unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled
             infection), which could compromise participation in the study.

          -  Known hypersensitivity to murine or chimeric antibodies or proteins

          -  Severe cardiac dysfunction (NYHA classification II-IV, Appendix H) or LVEF &lt; 45 %

          -  Significant renal dysfunction, i.e. serum creatinin   &gt;2 times upper normal level
             (UNL), unless related to NHL

          -  Significant hepatic dysfunction (total bilirubin &gt;2 times UNL  or transaminases &gt;=
             2.5 times UNL), unless related to NHL

          -  Impaired pulmonary functions; in this case, the patient is to be excluded if the
             resultant pulmonary function test shows FEV1&lt;50% or a diffusion capacity &lt;50% of the
             reference values

          -  Suspected or documented Central Nervous System involvement by NHL

          -  Patients known to be HIV-positive

          -  Patients with active, uncontrolled infections, especially known seropositivity for
             HCV or HbsAg

          -  Patients with uncontrolled asthma or allergy, requiring systemic steroid treatment

          -  Prior treatment with chemotherapy, radiotherapy or immunotherapy for this lymphoma,
             except local radiotherapy in case of extranodal NK/T cell lymphoma, nasal or nasal
             type

          -  History of active cancer during the past 5 years, except basal carcinoma of the skin
             or stage 0 cervical carcinoma

          -  Unwillingness or inability to comply with the protocol

          -  Simultaneous participation in any other study protocol

          -  Pregnant and nursing women (Women of childbearing potential should use safe
             anticonceptives) Contraceptive pills, intrauterine devices, injection of prolonged
             gestagen, subdermal implantation, hormonal vaginal devices and transdermal patches
             are considered as safe contraceptive methods).
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  60 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients with recurrent rectal cancer.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. All patients who have had previous surgical treatment of rectal adenocarcinoma,
             regardless of age, with locally recurrent (pelvic) rectal adenocarcinoma are
             eligible, if a period of at least 3 months exists between initial treatment and
             disease recurrence.

          2. Patients may have local recurrence alone, or concurrent distant metastatic disease.
             Patients must have recurrent rectal cancer present in the bony pelvis.

          3. Patients must be conversant in English in order to complete appropriate questions.

          4. Patients must understand the test and questionnaire parameters, including the need
             for PET testing to assess the correlation between perceived symptoms and PET or other
             diagnostic results. Patients must be able and willing to complete all scheduled
             appointments and complete and return all study questionnaires.

        Exclusion Criteria:

          1. Patients must not have non-adenocarcinoma pathology, i.e., squamous cell carcinoma of
             the anus, cloacogenic tumors, etc.

          2. Patients must not have any concurrent pelvic malignancy in addition to rectal
             carcinoma.

          3. Patients must not have ONLY distant metastases. Recurrence must be present within the
             bony pelvis.

          4. Patients must not have a history of either a documented pelvic pain syndrome or a
             preoperative documented diagnosis of chronic constipation (defined as &lt; 1 BM per 48
             hours, unrelated to rectal cancer or mechanical obstruction) preceding the cancer
             diagnosis.

          5. Patient must not have had solely non-operative therapies in treatment of their
             primary rectal carcinoma.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Diagnosis of invasive breast cancer

               -  Clinical stage I, II, or III disease

               -  Resectable disease

          -  Measurable disease, defined as a mass that can be reproducibly measured by physical
             examination and/or ultrasound and is at least 1 cm in size by ultrasound

               -  Patients with measurable residual tumor at the primary site allowed

          -  Estrogen receptor-positive tumor by immunohistochemistry (IHC)

          -  HER2-negative tumor by Herceptest (0 or +1) OR HER2 not overexpressed by fluorescence
             in situ hybridization (FISH)

          -  Planning to undergo surgical treatment with either segmental resection or total
             mastectomy with or without lymph node evaluation

          -  Must have core biopsies from the time of diagnosis available (may include sections of
             paraffin-embedded material)

          -  Prior contralateral breast cancer allowed provided there is no evidence of recurrence
             of the initial primary breast cancer

          -  Patients with locally advanced disease who are candidates for preoperative
             chemotherapy at the time of initial evaluation are not eligible

               -  Locally advanced disease is defined by any of the following:

                    -  Primary tumor  5 cm (T3)

                    -  Tumor of any size with direct extension to the chest wall or skin (T4a-c)

                    -  Inflammatory breast cancer (T4d)

                    -  Fixed axillary lymph node metastases (N2)

                    -  Metastasis to ipsilateral internal mammary node (N3)

          -  No locally recurrent disease

          -  No evidence of distant metastatic disease (i.e., lung, liver, bone, or brain
             metastases)

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  Postmenopausal, as defined by any of the following:

               -  55 years of age and over

               -  Under 55 years of age and meets 1 of the following criteria:

                    -  Amenorrheic for at least 12 months

                    -  Follicle-stimulating hormone (FSH)  40 IU/L and estradiol levels  20 IU/L

               -  Has undergone prior bilateral oophorectomy or radiation castration AND has been
                  amenorrheic for at least 6 months

          -  Bilirubin  1.5 times upper limit of normal (ULN)

          -  SGOT and SGPT  1.5 times ULN

          -  Creatinine  1.5 t times ULN

          -  Able to swallow and retain oral medication

          -  No serious medical illness that, in the judgment of the treating physician, places
             the patient at high risk for operative mortality

          -  No malabsorption syndrome, ulcerative colitis, or other disease significantly
             affecting gastrointestinal function

          -  No other malignancy within the past 5 years except for completely resected
             nonmelanoma skin cancer or successfully treated in situ carcinoma

          -  No dementia, altered mental status, or any psychiatric condition that would preclude
             the understanding or rendering of informed consent

          -  No severe uncontrolled malabsorption condition or disease (i.e., grade II/III
             diarrhea, severe malnutrition, or short gut syndrome)

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  At least 21 days since prior tamoxifen or raloxifene as a preventive agent

          -  At least 7 days since prior hormone replacement therapy (e.g., conjugated estrogens
             [Premarin])

          -  No prior resection of the stomach or small bowel

          -  More than 30 days or 5 half-lives, whichever is longer, since prior investigational
             drugs

          -  No prior chemotherapy for this primary breast cancer

          -  No other concurrent investigational agents

          -  No other concurrent anticancer therapy (e.g., chemotherapy, radiotherapy,
             immunotherapy, hormonal therapy, or any other biologic therapy)
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Referred for a colposcopy following an abnormal Pap smear test result

               -  Atypical squamous cells of undetermined significance/positive for human
                  papilloma virus or mild to moderate dysplasia

               -  Referred for a second opinion OR patient of record within the medical practice
                  who is undergoing routine recommended follow-up

          -  Recruited from Fox Chase Cancer Center or Thomas Jefferson University Hospital

          -  No history of cervical cancer

          -  No evidence of present invasive carcinoma

        PATIENT CHARACTERISTICS:

          -  Must be able to read and/or communicate in English

          -  Not pregnant

          -  No known HIV positivity

          -  No psychiatric disorder or other disorder that would preclude informed consent

        PRIOR CONCURRENT THERAPY:

          -  Not specified
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Men &gt; 18 and 75 years of age.

          -  WHO/ECOG performance status 0 - 1.

          -  Histological proven adenocarcinoma of the prostate within 12 months prior to
             randomisation

          -  One of the following:

               -  T2 with Gleason score 7(4+3 ) and PSA &gt;10 ng/ml to &lt; 70 ng/ml

               -  T2 with Gleason 8-10, any PSA &lt; 70 ng/ml

               -  any T3 tumour

          -  Prior neoadjuvant hormone therapy is mandatory for all patients

          -  Adequate haematological-, liver- and kidney function. (Hemoglobin &gt; 110 g/l,
             neutrophils &gt; 1.5 x 109/ l, platelets &gt; 150 x 109/ l, ASAT and ALAT &lt; 1.5 x ULN, ALP
             &lt; 1.5 x ULN, creatinine &lt; 1.5 x ULN)

          -  Written informed consent

        Exclusion Criteria:

          -  M+

          -  N+ clinical or pathological

          -  Patients with a history of previous malignant disease. Exceptions should be made for
             basal cell carcinoma (BCC) and squamous cell carcinoma of the skin. Exceptions should
             also be made for curatively treated malignant disease, which has been disease free
             for the past five years.

          -  Previous radiotherapy to the pelvic region.

          -  Previous chemotherapy within 5 years.

          -  Systemic corticosteroids within 6 months prior to randomisation.

          -  Unstable cardiovascular disease, including myocardial infarction, within 6 months
             prior to randomisation.

          -  Active untreated infectious disease, including tuberculosis, MRSA.

          -  Active gastric ulcer.

          -  Known hypersensitivity to Polysorbate 80 (an excipient of docetaxel)

          -  Other serious illness or medical condition
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Histological or cytological diagnosis of ovarian cancer

          -  Disease recurrence between 6 and 12 months after a first-line platinum based therapy

          -  Indication for chemotherapy, but no more than 2 previous lines of previous therapy

          -  Life expectancy of more than 3 months

        Exclusion Criteria:

          -  Previous or concomitant malignant malignancy (excluding adequately treated baso-or
             squamocellular carcinoma of the skin and carcinoma in situ of the cervix)

          -  ECOG Performance Status  at least 3

          -  Previous treatment with stealth liposomal doxorubicin

          -  Residual peripheral neuropathy  Grade 3 or higher

          -  Heart disease (congestive heart failure, myocardial infarction within 6 months from
             study entry, atrioventricular block of any grade, severe arrhythmias)

          -  Neutrophils &lt; 2000 x mm3, platelets &lt; 100000 x mm3

          -  Inadequate renal function (creatinine no greater than 1.25 x normal values) or liver
             function (ALT or AST no greater than 1.25 x normal values)

          -  Present or suspected hemorrhagic syndromes

          -  Inability to comply with protocol and follow-up

          -  Inability to access study site for clinical visits

          -  Refusal of informed consent
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Histological or cytological diagnosis of small-cell lung cancer

          -  Extensive disease (i.e. a disease with distant metastases or that cannot be included
             in a single irradiation field incorporating primary tumour, mediastinum and
             supraclavicular lymph node(s))

          -  Availability for participating in the detailed follow-up of the protocol

          -  Presence of an evaluable or measurable lesion

          -  Informed consent

        Exclusion Criteria:

          -  Prior treatment with chemotherapy, radiotherapy or surgery

          -  Performance status &lt; 60 on the Karnofsky scale

          -  A history of prior malignant tumor, except non-melanoma skin cancer or in situ
             carcinoma of the cervix or a cured cancer (defined as a disease-free interval &gt; 5
             years)

          -  White blood cells &lt; 4000/mm3

          -  Platelets &lt; 100000/mm3

          -  Serum bilirubin &gt; 1.5 mg/100 ml

          -  Serum creatinine &gt; 1.3 mg/100 ml and creatinine clearance &lt;60 ml/min

          -  Recent myocardial infarction (less than 3 months prior to date of diagnosis)

          -  Congestive cardiac failure or cardiac arrhythmia uncontrolled by medical treatment

          -  Uncontrolled infectious disease

          -  Serious medical or psychological factors which may prevent adherence to the treatment
             schedule
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Parents or legal guardian signed-written informed consent

          -  1 to &lt; 18 years of age

          -  Histologically or cytologically confirmed solid tumor that has recurred after
             standard therapy, or for which there is no standard therapy. Subjects with brainstem
             glioma DO NOT need histologic proof of the diagnosis.

          -  Paraffin-embedded tumor tissue from primary tumor or metastasis for determination of
             epidermal growth factor receptor expression and biomarker testing

          -  Central nervous system tumors are allowed

          -  Presence of measurable or non-measurable disease.

          -  Life expectancy of &gt;/= 12 weeks.

          -  Performance status:  Karnofsky &gt;/= 60% for 12 to &lt;18 years of age; Lansky play scale
             &gt;/= 60% for 1 to &lt; 12 years of age.

          -  Adequate hematologic function.

          -  Adequate renal function.

          -  Adequate hepatic function.

          -  Magnesium &gt;/= LLN

          -  Adequate pulmonary function

          -  All previous therapy-related toxicities must have resolved or return to baseline.

        Exclusion Criteria:

          -  Diagnosis of leukemia, non-Hodgkin's lymphoma, Hodgkin's disease or other hematologic
             malignancy.

          -  Any prior allogeneic transplant.

          -  Prior autologous bone marrow or peripheral stem cell transplant less than 3 months
             prior to enrollment.

          -  Substantial radiotherapy to the bone marrow within 6 weeks prior to enrollment.

          -  Prior use of any monoclonal antibodies directly targeting the EGFr.  Subjects who
             have received prior tyrosine kinase inhibitors such as gefitinib or erlotinib are
             eligible.

          -  Immunotherapy, radiotherapy, or chemotherapy &lt;/= 2 weeks prior to enrollment.  (&lt;/= 6
             weeks for nitrosoureas, mitomycin-C, and liposomal doxorubicin, and &lt;/= 6 weeks from
             prior antibody therapy).

          -  Requirement to receive concurrent chemotherapy, immunotherapy, radiotherapy (except
             for pain control) or any other investigational drug while on this study.

          -  Prior seizures &lt; 3 months prior to enrollment.  Subjects with a history of seizure
             disorders &gt;/= 3 months prior to enrollment must be seizure free and on stable
             anticonvulsant medication(s) for &gt;/= 3 months prior to enrollment).

          -  Presence of a serious uncontrolled medical disorder.

          -  Dementia, altered mental status, or any other medical condition or disorder that
             would prohibit the understanding or rendering of assent (if applicable), or ability
             to comply with study procedures.

          -  Major surgery &lt;/= 28 days prior to enrollment.

          -  Known or suspected history of interstitial lung disease.

          -  Active inflammatory bowel disease or other bowel disease causing chronic diarrhea.

          -  Known positive test for human immunodeficiency virus infection, hepatitis C virus,
             acute or chronic hepatitis B infection, or any co-morbid disease that would increase
             risk of toxicity.

          -  Females of childbearing potential not using adequate contraception precautions for
             the duration of the study treatment and for 2 months after the last administration of
             investigational product.

          -  Pregnant or breast-feeding, or planning to become pregnant during study treatment and
             within 2 months after the last administration of investigational product.

          -  Received investigational therapy or procedure &lt;/= 30 days prior to enrollment.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  1 Year
 </minimum_age>
 <maximum_age>
  17 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed primary malignant brain
             tumors or brain metastasis

          -  Patients must have had radiographically evaluable or measurable disease with standard
             MR imaging, and the tumor must have an enhancing component.

          -  Patients may or may not have had prior surgery, radiation therapy, or chemotherapy.

          -  Age &gt;18 years

          -  Men and women and members of all races and ethnic groups will be included.

          -  Life expectancy of greater than 2 weeks.

          -  Eastern Cooperative Oncology Group (ECOG) performance status &lt; 3.

          -  Ability to understand and the willingness to sign a written informed consent
             document, or have a representative able to consent for the patient.

        Exclusion Criteria:

          -  Subjects with clinically significant signs of uncal herniation

          -  Subjects who have a contraindication for MRI

          -  Subjects with known hepatic insufficiency or cirrhosis

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to ferumoxytol

          -  Subjects with known or suspected iron overload (genetic hemochromatosis or history of
             multiple transfusions)

          -  Patients expecting to undergo surgery between the imaging sessions.  Patients may
             undergo surgery at any time before the first, or after the last imaging session.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Pregnant or lactating women are excluded from this study because of possible risk to
             the fetus or infant.

          -  Inability or unwillingness to undergo the complete series of imaging sessions.
             Inability or unwillingness to return to the neuro-oncology clinic at Oregon Health
             and Science University (OHSU) for the one month follow-up.

          -  Known immunosuppression or immunodeficiency.

          -  Patients with stage IV or V renal insufficiency.

          -  Patients may not be receiving any other investigational agents.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients with histological proof (from the primary lesion and/or cervical lymph node)
             of squamous carcinoma of the oral cavity, oropharynx, hypopharynx, larynx, or unknown
             primary.

          -  Patients should have stage III or IV disease

          -  Patients must have ECOG Performance Status of 0-1

          -  Patients must be &gt;/= 18 years of age

          -  Patients must have measurable disease

          -  Patients should have adequate bone marrow function defined as an absolute peripheral
             granulocyte count (AGC) of &gt;/= 1500 cells/mm3, platelet count of &gt;/= 100,000 cells/
             mm3; adequate hepatic function with bilirubin &lt;/= 1.5mg/dl, AST and ALT &lt;/= 2x the
             upper limit of normal; serum creatinine &lt;/= 1.5mg/dl, creatinine clearance  &gt;/= 50
             ml/min and INR 0.8 - 1.2

          -  Patients must sign a study specific informed consent form prior to study entry

          -  Final 20 subjects must be HPV negative

        Exclusion Criteria:

          -  Histology other than squamous cell carcinoma

          -  Evidence of metastases (below the clavicle or distant) by clinical or radiographic
             examinations for phase II study subjects

          -  History of malignancy other than non-melanoma skin cancer

          -  Prior chemotherapy or anticancer biologic therapy for any type of cancer, or prior
             radiotherapy to the head and neck region except for radioactive iodine therapy

          -  Prior history of allergy or hypersensitivity to cetuximab or paclitaxel

          -  Weight loss &gt; 10% in the past three months

          -  Patients with uncontrolled intercurrent disease

          -  Patients with currently active malignancy

          -  Pregnant or lactating women

          -  Female patients of childbearing potential who are unwilling to practice adequate
             contraception during study treatment and for two months after the last administration
             of study drug
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients must have radiologically and histologically confirmed diagnosis of
             glioblastoma multiforme

          -  Patients must have measurable disease, defined as evident tumors with gadolinium
             enhancement on MRI that is measurable in at least one diameter and visible on both
             axial and sagittal or coronal views.

          -  Patients have not had prior chemotherapy and/or radiotherapy

          -  Life expectancy of greater than 6 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status &gt; or = 2 (Karnofsky &gt; or
             =60%)

          -  Patients scheduled for standard therapy (6 weeks RT ~60 gray (Gy), plus temozolomide
             75 mg/m2 during 6w RT, 200 mg/m2 5x wk post RT started 4wk after RT)

          -  Patients must be on a stable dose (up to 8mg daily) of dexamethasone throughout the
             study.

          -  After entry into the study, patients are expected to be followed for at least 1 month
             after the last infusion of ferumoxytol

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry and
             for the duration of study participation.

          -  Ability to understand and the willingness to sign a written informed consent
             document. All patients, or their legal guardians, must sign a written informed
             consent and Health Insurance Portability and Accountability Act (HIPAA) authorization
             in accordance with institutional guidelines.

        Exclusion Criteria:

          -  Patients who have had chemotherapy or radiotherapy.

          -  Patients may not be receiving any other investigational agents.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to ferumoxytol: parenteral iron, parenteral dextran, parenteral
             iron-dextran, or parenteral iron-polysaccharide preparations (Ferumoxytol
             Investigator's Drug Brochure, 2005).  Patients with significant drug or other
             allergies or autoimmune diseases may be enrolled at the Investigator's discretion.

          -  Patients with clinically significant signs of uncal herniation, such as acute
             pupillary enlargement, rapidly developing motor changes (over hours), or rapidly
             decreasing level of consciousness.

          -  Patients who require monitored anesthesia for MRI scanning

          -  Patient with history of hemochromatosis or iron overload

          -  Patients with stage IV or V renal insufficiency

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Pregnant women are excluded from this study. Because there is an unknown but
             potential risk for adverse events in nursing infants secondary to treatment of the
             mother with ferumoxytol, breastfeeding should be discontinued if the mother is
             treated with ferumoxytol

          -  HIV-positive patients on combination antiretroviral therapy are ineligible because of
             the potential for pharmacokinetic interactions with ferumoxytol.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Study participants will be asked to voluntarily participate in this project because they
        have been diagnosed with PC, have a family history of PC, or fulfill the criteria to be
        one of the three different control groups meaning they will either have a diagnosis of
        chronic pancreatitis, acute biliary obstruction, or they are a healthy unaffected
        individual.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Patients must meet 1 of the following criteria:

               -  Histologically confirmed adenocarcinoma of the pancreas

                    -  Resectable stage I-IIA disease or stage IIB or higher disease

                         -  Must have undergone complete surgical resection of the tumor with
                            curative intent

                    -  Pancreatic mass (solid) that is less than 4 cm as determined by any
                       conventional imaging (MRI, EUS, or CT scan)

                    -  No evidence of extension of the mass beyond the pancreas including vascular
                       invasion or invasion into surrounding organs, with the exception of the
                       bile duct

                    -  No imaging evidence of metastatic disease or lymphadenopathy (lymph nodes
                       greater than 1 cm and/or appearance suspicious for an advanced lesion by
                       imaging criteria)

               -  Has a family history of pancreatic cancer and is considered to be an at-risk
                  individual for the disease (i.e., member of a family with 2 or more individuals
                  with pancreatic cancer)

          -  Control participants must meet 1 of the following criteria:

               -  Chronic pancreatitis OR history of exocrine insufficiency meeting the following
                  criteria:

                    -  At least 2 of the following criteria are met (unless patient has a history
                       of pancreatic exocrine insufficiency in which case only 1 criterion must be
                       met):

                         -  Abdominal ultrasound that is consistent with chronic pancreatitis by
                            standard radiological criteria (i.e., echogenic foci in the
                            parenchyma, large or small cavities, calcifications, or dilated
                            pancreatic duct)

                         -  Abdominal CT scan consistent with chronic pancreatitis by standard
                            radiological criteria (i.e., calcifications, dilated pancreatic duct,
                            irregular contour of the gland, or cystic lesions)

                         -  Endoscopic retrograde cholangiopancreatography exam consistent with
                            chronic pancreatitis by standard radiological criteria (i.e., dilated
                            tortuous main pancreatic duct with irregular secondary branches or
                            intraductal calculi)

                         -  Endoscopic ultrasound consistent with chronic pancreatitis by standard
                            radiological criteria (i.e., echogenic foci, focal regions of
                            decreased echogenicity, or pancreatic ductal changes)

                         -  Pancreatic calcifications identified on plain film of the abdomen

                    -  Must have an imaging study of the pancreas within 3 months of study
                       enrollment that does not suggest a pancreatic mass

                    -  Stable clinical history over the past year with no suspicion for cancer due
                       to weight loss, jaundice, or change in abdominal symptoms

                    -  No family history of pancreatic cancer

               -  Acute biliary obstruction (stones) including jaundice of benign etiology meeting
                  the following criteria:

                    -  Elevation of serum bilirubin level greater than 2.0 mg/dL

                    -  Dilated extrahepatic biliary systems demonstrated on US, MRI, or CT scan

                    -  Blood sample available within 72 hours of admission and prior to any
                       corrective intervention

                    -  Biliary obstruction must be of benign etiology such as common bile duct
                       stone or benign biliary stricture

                    -  Must have complete imaging study performed of the pancreas that does not
                       suggest a pancreatic cancer (i.e., discrete mass lesion)

                    -  No family history of pancreatic cancer

               -  Healthy control meeting the following criteria:

                    -  Age, race, and sex-matched to qualified pancreatic cancer cases

                    -  No family history of pancreatic cancer

                    -  No personal history of acute pancreatitis or biliary obstruction (stones)
                       including jaundice of benign etiology

                    -  No concurrent abdominal pain

                    -  No concurrent unexplained weight loss

        PATIENT CHARACTERISTICS:

          -  No prior malignancy, except nonmelanoma skin cancer, for 10 years

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior preoperative chemoradiotherapy (neoadjuvant)
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  19 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Folicular Lymphoma CD20-positive, grade 1, 2 or 3a, confirmed in previous 4 months.

          -  Patients no treated previously.

          -  Ann Arbor Stage II, III o IV.

          -  Symptoms or signes wich indicate necesary treatment (GELF criteria):

               -  Ganglionar or extraganglionar mass

               -  B Symptoms

               -  LDH or B2-microglobuline increased

               -  3 ganglionar territory afected (&gt; 3 cm)

               -  Esplenomegalia

               -  Compresive syndrome

               -  Pleural/peritoneal effusion

               -  Secondary medular insufiency due to infiltration

          -  Age&gt; 18 years and &lt;75 years.

          -  ECOG &lt; 2

          -  Adecuate hematological function: Hemoglobin &gt; 8,0 g/dl (5,0 mmol/L); RAN &gt;1,5 x
             109/L; platelets &gt; 100 x 109/L

          -  No pregnant women. Women and man should use an appropiate anticonceptive method
             during the study and one year after

          -  Informed consent

        Exclusion Criteria:

          -  Transformation in high grade lymphoma

          -  FL grade 3b.

          -  Skin or gastro-intestinal primary lymphoma

          -  History of CNS diseases ( or CNS lymphoma)

          -  Previous treatment

          -  Regulary treatment with corticosteroids (permited &lt; 20 mg/day prednisone or
             equivalent).

          -  Previous cancer diseases

          -  Major surgery in 28 days before inclusion in study.

          -  Creatinine &gt; 2,0 mg/dl (197 mmol/L)

          -  Bilirubin &gt; 2,0 mg/dl (34 mmol/L), AST (SGOT) &gt; 3 x upper normal limit.

          -  HIV infection or active infection VHB o VHC &lt; 4 weeks before inclusion.

          -  Other complicated diseases

        Criteria investigador:

          -  Life expectancy &lt; 6 months.

          -  Hipersensibility to Ibritumomab tiuxetan, rituximab, other murines proteins or any
             excipients.

          -  Treatment in other experimental study in previous 30 days

          -  Any medical o psicologycal condition that can modify the capacity to give the consent
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Histologically confirmed diagnosis of prostate cancer

          2. Elevated PSA

          3. Life expectancy  &gt;  4 months

          4. Performance status 0-1

          5. ANC 1.0

          6. Platelets &gt; 100,000

          7. Hemoglobin &gt; 8.0

          8. Creatinine &lt; 1.5mg/dl

          9. Direct Bilirubin &lt; 1.5 mg/dl

         10. No evidence of CHF, CAD, cardiac arrhythmias, A-fib, A flutter, myocardial
             infarction.

         11. No serious, symptomatic obstructive or emphysematous lung disease

         12. No asthma requiring IV medication during last 12 months, no serious lung disease
             associated with dyspnea at normal activity levels, or at rest due to any cause,
             including cancer metastasis and pleural effusion

         13. Patients must have a biopsy able tumor, and be willing to undergo biopsy (Group 3
             only)

         14. Patient is at least 18 years of age.

        Exclusion Criteria:

          1. Serious or unstable renal, hepatic, pulmonary, cardiovascular, endocrine,
             rheumatologic or allergic disease based on history, labs or physical exam

          2. Active clinical disease caused by CMV, Hepatitis B, or C, HIV, TB

          3. Cytotoxic and/or radiation therapy during last 4 weeks prior to entry

          4. Any concurrent malignancies

          5. Patient requires systemic steroids

          6. Patient has participated in prior investigational therapy

          7. Patient has prior exposure to mouse antibody

          8. Patient has had irradiation to whole pelvis or &gt;25% marrow
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Subjects enrolled in MPD-RC treatment protocols.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients are to be registered to this study if they meet the eligibility criteria for
             one of the MPD-RC treatment protocols linked to this study.

          -  Patients diagnosed with the following Myeloproliferative disorders including:
             polycythemia vera (PV), idiopathic myelofibrosis (IM), and essential thrombocythemia
             (ET) who are participating in treatment protocols of the MPD-RC are eligible.

          -  Patients must have signed an informed consent to participate in a Myeloproliferative
             Disorders Research Consortium (MPD-RC) treatment study to which this protocol is a
             companion study.  The subject must also have signed a consent to participate in this
             mandatory companion study.

        Exclusion Criteria:

        See inclusion criteria.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Treatment experienced, HIV-1 infected patients in routine clinical practice.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Treatment experienced, HIV-1 infected patients

          -  18 years or older

          -  Receive an approved assay for determination of HIV-1 tropism

        Exclusion Criteria:

          -  Pregnant or lactating

          -  Using CCR5 inhibitor other than maraviroc
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients diagnosed with Philadelphia chromosome negative myeloproliferative disorders
        (MPD) polycythemia vera (PV), idiopathic myelofibrosis (IM), and essential thrombocythemia
        (ET) are eligible and not currently participating in any MPD-RC treatment studies.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients diagnosed with Philadelphia chromosome negative myeloproliferative disorders
             (MPD) polycythemia vera (PV), idiopathic myelofibrosis (IM), and essential
             thrombocythemia (ET) are eligible.

          -  Newly diagnose MPD patients as well as previously treated for a MPD are eligible.

          -  Signed informed consent is required from each patient at the time of enrollment.

        Exclusion Criteria:

          -  Patients currently participating in experimental treatment arms of MPD-RC protocols,
             or other experimental treatment protocols are not eligible during the period they are
             on study.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   1. Adult individuals (male and female) who have a personal diagnosis/history of breast
             cancer, atypical hyperplasia, ductal carcinoma in situ (DCIS) or lobular carcinoma in
             situ (LCIS) (as stated in the NCCN Breast and/or Ovarian Genetic Assessment
             Guidelines v.1.2006 (Appendix A)

          2. Adult individuals who have characteristics of hereditary breast cancer, as defined in
             the NCCN Breast and/or Ovarian Genetic Assessment Guidelines v.1.2006 (Appendix A) or
             who have a breast cancer risk of &gt; 1.67% over 5 years as estimated by GAIL Model
             (Appendix C )

          3. Age 19 or greater

          4. Able to provide informed consent
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Recruited by a participating physician and meets at least 1 of the following
             criteria:

               -  Current diagnosis or history of breast cancer, atypical hyperplasia, ductal
                  carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) as defined in the
                  National Comprehensive Cancer Network Breast and/or Ovarian Genetic Assessment
                  Guidelines, v.1.2006

               -  Characteristics of hereditary breast cancer, as defined in the National
                  Comprehensive Cancer Network Breast and/or Ovarian Genetic Assessment
                  Guidelines, v.1.2006 (relatives have been diagnosed with breast and/or ovarian
                  cancer) OR have a breast cancer risk of &gt; 1.67% over 5 years as estimated by the
                  GAIL Model

          -  Hormone receptor status not specified

        PATIENT CHARACTERISTICS:

          -  Male or female

          -  Menopausal status not specified

        PRIOR CONCURRENT THERAPY:

          -  Not specified
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  19 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the prostate

               -  pT3a, pT3b (or pT4 by reaching the bladder neck), or R1 disease (stage III or
                  IV)

               -  Localized disease

               -  pN0 or pNx (lymph nodes resected during negative prostatectomy or lymph nodes
                  not resected)

               -  No histologically confirmed nodal involvement during initial surgery (pN1
                  disease)

               -  No pT2 disease

               -  No tumors of other histology than adenocarcinoma

          -  Must have undergone curative surgery in the past 6 months

               -  Positive margins (tumoral glands in contact with contour ink)

          -  No current clinical or biochemical disease

               -  PSA  0.1 ng/mL after prostatectomy (confirmed at 1 month)

          -  Gleason score &lt; 8 with no seminal vesicles involved

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0 or 1

          -  Life expectancy  10 years

          -  Affiliated with social security program

          -  No history of cancer within 5 years of surgery except basal cell skin cancer

          -  No known severe hypertension uncontrolled by appropriate therapy ( 160 mm Hg
             systolic and/or  90 mm Hg diastolic)

          -  No known hypersensitivity to gonadotropin-releasing hormone or its analogs

          -  No contraindication of intramuscular injection

          -  No patients who are deprived of liberty or under guardianship

          -  Not unable to undergo medical monitoring due to geographical, social, or
             psychological reasons

        PRIOR CONCURRENT THERAPY:

          -  No prior surgical or chemical castration

          -  No prior hormonal therapy

          -  No prior radiotherapy within 3 months after radical prostatectomy

          -  No prior pelvic radiotherapy

          -  No concurrent participation in another study
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Clinical diagnosis of non small cell lung cancer

          -  Eligible for surgical resection

          -  Willingness to adhere to randomized treatment

          -  Availability for follow-up schedule of visits

        Exclusion Criteria:

          -  Taking exogenous melatonin
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

        The study population will consist of men and women with histologically confirmed stage 2
        (younger than 45 years of age), 3 or stage 4 differentiated thyroid cancer (e.g.,
        papillary or follicular thyroid cancer) that has been previously treated with at least one
        course of radioactive iodine therapy and has evidence of residual, recurrent or
        progressive disease documented by any combination of radiologic studies and thyroglobulin
        levels.

        To be eligible for inclusion, patients must fulfill each of the following criteria:

          1. Provide written informed consent prior to study-specific screening procedures, with
             the understanding that the patient has the right to withdraw from the study at any
             time, without prejudice.

          2. Age &gt;18 years.

          3. Histologically confirmed stage 2 (younger than 45 years of age), 3 or stage 4
             differentiated thyroid cancer (i.e., papillary or follicular thyroid cancer).

             a. If a patient has distant metastases, it must be documented by any combination of
             radiographic studies or whole body radioiodine scanning.

          4. Previously treated with at least one course of radioactive iodine (I-131) therapy.

          5. At least one measurable site of disease as defined by the Tumor Assessment Criteria
             in Appendix 3.

          6. Serum thyroglobulin levels inappropriately elevated:

             &gt; 60 ng/mL with thyroid gland &gt; 1 ng/mL without thyroid gland

          7. ECOG performance status 0-2.

          8. Life expectancy  3 months.

          9. Normal organ function.  The definitions of minimum adequacy for organ function
             required prior to study entry are as follows:

               1. Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) less
                  than or equal to 2.5 x upper limit of normal (ULN), or AST and ALT less than or
                  equal to 5 x ULN if liver function abnormalities are due to underlying
                  malignancy.

               2. Total serum bilirubin less than or equal to 1.5 x ULN.

               3. Serum albumin greater than or equal to 3.0 g/dL.

               4. Absolute neutrophil count (ANC) greater than or equal to 1500/uL.

               5. Platelets greater than or equal to 100,000/uL.

               6. Hemoglobin greater than or equal to 9.0 g/dL

               7. Serum creatinine less than or equal to 1.5 x ULN.

         10. Agreement to use contraceptives for women with child bearing potential.  Unless
             surgically sterile, men must agree to use effective contraception during period of
             therapy.

         11. The patient must be aware of the nature of his or her malignancy, understand the
             protocol requirements, risks, discomforts, and be able and willing to sign an
             informed consent.

        Exclusion Criteria:

        Patients who fulfill any of the following criteria will be excluded:

          1. Prior systemic chemotherapy or targeted therapy within 3 months prior to enrollment.

          2. Prior treatment on a Sutent clinical trial or current treatment on another clinical
             trial.

          3. Prior external beam radiation therapy to the target lesion(s).

          4. Life expectancy &lt; 3 months.

          5. History of any other carcinomas within the last 5 years, except cured basal cell
             carcinoma of the skin and cured in-situ cervical cancer.

          6. Serious uncontrolled concomitant disease that the Investigator feels might compromise
             study participation.

          7. Lack of physical integrity of the upper gastrointestinal tract or malabsorption
             syndrome, or the inability to take oral medication.

          8. Any of the following clinical conditions within the 12 months prior to starting study
             treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery
             bypass graft, congestive heart failure, cerebrovascular accident including transient
             ischemic attack, pulmonary embolism, ongoing cardiac dysrhythmias of NCI CTCAE grade
             at least 2, atrial fibrillation of any grade, or QTc interval &gt;450 msec for males or
             &gt;470 msec for females.

          9. Uncontrollable hypertension.

         10. Known human immunodeficiency virus infection.

         11. Current treatment with therapeutic doses of Coumadin-derivative anticoagulants (low
             dose Coumadin up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed).

         12. Patients with a history of uncontrolled seizures, central nervous system disorders of
             psychiatric disability judged by the Investigator to be clinically significant
             precluding informed consent or interfering with compliance for oral drug intake
             should be excluded from study.

         13. Inability to swallow whole tablets.

         14. Unwillingness to participate or inability to comply with the protocol for the
             duration of the study.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Only those patients with adenocarcinoma of the prostate who have undergone a radical
             prostatectomy with pelvic lymph node sampling and found to have high risk
             non-metastatic disease with undetectable, persistent or decreasing post-operative PSA
             levels, or who have subsequently experienced a rise in PSA, will be eligible for the
             trial as described below in the inclusion and exclusion criteria

          -  Histologically documented adenocarcinoma of the prostate.

          -  Status post radical prostatectomy with sampling of the pelvic lymph nodes with
             histologically confirmed adenocarcinoma of the prostate, with the patients falling
             into either the "adjuvant high risk group" or the "salvage high risk group" as
             follows:

               -  a) "Adjuvant High Risk Group" (undetectable, persistent or decreasing PSA levels
                  before starting therapy) who have NO evidence of metastatic disease (i.e. no
                  clinical symptoms or radiologic evidence) who MUST be able to start RT
                  treatments within 6 months of radical prostatectomy with at least one of the 3
                  disease features:

                    1. Pathologic T2N0 disease with positive margins and Gleason score 8, or

                    2. Pathologic T3aN0disease with extracapsular extension and Gleason Score  8,
                       or

                    3. Pathologic T3bN0disease with any Gleason Score

               -  b) "Salvage High Risk Group" are those patients with PSA biochemical failure
                  defined by 2 consecutive increases over baseline PSA levels at least one month
                  apart, who have NO other evidence of metastatic disease (i.e. no clinical
                  symptoms or radiologic evidence), and WITH AT LEAST ONE of the high risk disease
                  features as defined below:

                    1. Pathologic T3bN0 disease with any Gleason score, or

                    2. Pathologic T2-3aN0 disease with Gleason score  8,

                    3. Pathologic T2-3aN0 disease with PSA doubling time 10 months, or

                    4. Pathologic T2-3aN0 disease with Pre-radiation therapy PSA level 1.0 ng/ml

          -  Neoadjuvant hormonal therapy prior to radical prostatectomy is allowed, and
             post-prostatectomy hormonal therapy is allowed as long as it is not within 6 months
             of protocol treatment

          -  No prior chemotherapy, or pelvic irradiation

          -  Karnofsky Performance Status 70

          -  Hematologic parameters must be within the following limits:

               -  WBC  3,000

               -  Platelet Count  130,000/ mm3

               -  Hemoglobin level  11.0 g/dl

               -  Creatinine  2.5 g/dl

          -  Normal liver function defined as the following: Total bilirubin below the upper limit
             of normal AND AST, ALT, and Alkaline Phosphatase must be within a defined range of
             eligibility as noted below:

               -  Alkaline Phosphatase

                    -   ULN - eligible

                    -  &gt; 1x but 1.5x ULN - eligible

                    -  &gt; 2.5x but  5x ULN - eligible

                    -  &gt; 5x ULN - ineligible

               -  AST or ALT

                    -   ULN - eligible

                    -  &gt; 1x but 1.5x ULN - eligible

                    -  &gt; 2.5x but  5x ULN - ineligible

                    -  &gt; 5x ULN - ineligible

          -  Patients with a history of an invasive malignancy within the last 5 years are not
             eligible for the protocol; patients who are NED from a prior invasive malignancy for
             at least 5 years or longer are eligible for the trial.  Patients with history of
             benign tumors such as a pituitary macroadenomas, meningiomas, or craniopharyngiomas
             are eligible as long as the benign tumor is under local control regardless of the
             time frame.  Patients with concurrent adequately treated basal cell or squamous cell
             carcinoma of the skin are also eligible for the protocol.

          -  Patients must be informed of the investigative nature of the treatment, must give
             appropriate informed consent to protocol procedures and must sign an Informed Consent
             Documentation Form.

          -  Must not have concomitant medical, psychological or social circumstances which would
             interfere with compliance with the protocol treatment and follow-up.

          -  Age  18 years

          -  Men of childbearing potential must be willing to consent to using effective
             contraception while on treatment and for a reasonable period thereafter, which should
             be for at least 6 months after the completion of protocol therapy

        Exclusion Criteria:

          -  Patients who have received prior chemotherapy, pelvic irradiation or
             post-prostatectomy androgen ablation within 6 months of protocol therapy.

          -  Any coexisting medical condition precluding full compliance with the study.

          -  Patients with active infections or known infection with HIV.

          -  Psychological, familiar, sociological or geographical conditions which would not
             permit compliance with the study protocol.

          -  Known contraindication to dexamethasone (allergic reaction or systemic fungal
             infection)

          -  Pre-existing Grade  1 peripheral neuropathy

          -  Patients with a history of a hypersensitivity reaction to products containing
             Polysorbate 80 (Tween 80)
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  85 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients with a biopsy confirmed prostate cancer who awaits curative treatment and
             have

          -  An elevated level of prostate-specific antigen PSA&gt;10 ng/mL (nanogram per
             milliliter) or/and

          -  A Gleason score &gt; 6 or/and

          -  A TNM staging of T3

        Exclusion Criteria:

          -  Patients who withdraw their informed consent.

          -  Patients who have a bone scan indicates metastatic prostate cancer.

          -  Patients who have a TNM stage is T4

        In the case we detect a patient having an obvious other major illness e.g. lung cancer,
        the patient is referred to relevant treatment. Depending on the illness the might be
        excluded from the study.
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Able to provide voluntary written informed consent, with the understanding that
             consent may be withdrawn by the subject at any time without prejudice to future
             medical care.

          -  Diagnosed with relapsed or refractory NHL, limited to subtypes listed below. The
             subject must have histologic information of diagnosis according to review at the
             Cleveland Clinic Foundation, either at initial diagnosis or at any subsequent
             relapse. (Biopsy is not required at relapse, but is suggested. Biopsy at outside
             institution, reviewed at the Cleveland Clinic, is acceptable.)

               -  "Relapsed or refractory" refers to patients who have received at least 1 prior
                  treatment regimen for lymphoma (which may include prior autologous stem cell
                  transplantation) and have demonstrated evidence of progressive disease by
                  clinical and/or radiographic characteristics.

               -  "Indolent lymphoma" is included, and refers to small lymphocytic lymphoma/B-cell
                  chronic lymphocytic leukemia (SLL/CLL); lymphoplasmacytic lymphoma (with or
                  without Waldenstrom's macroglobulinemia); hairy cell leukemia; follicular
                  lymphoma (FL) of any grade; marginal zone B-cell lymphoma; or mantle cell
                  lymphoma.

               -  Transformed lymphoma is included if patients are ineligible for (or refuse)
                  hematopoetic stem cell transplant.

               -  In addition, cutaneous B and T cell lymphoma are permitted. Cutaneous T cell
                  lymphoma must be refractory to 1 prior systemic therapy (topical therapy,
                  photopheresis, radiation are not considered systemic therapy). Transformed B and
                  T cell cutaneous lymphoma are also permitted.

               -  Relapsed/refractory diffuse large B cell lymphoma (DLBCL) is allowed if the
                  patient is not eligible for, or refuses, hematopoetic stem cell transplant.

               -  Relapsed/refractory nodal, leukemic, and extranodal T cell lymphomas are
                  eligible. Subtypes eligible include anaplastic large cell lymphoma,
                  angioimmunoblastic T cell lymphoma, PTCL-NOS, nasal or disseminated extranodal
                  T/NK lymphoma, enteropathy-associated T cell lymphoma, hepatosplenic gamma/delta
                  T cell lymphoma, subcutaneous panniculitis-like T cell lymphoma,
                  T-prolymphocytic leukemia, Adult T-cell leukemia/lymphoma, large granular
                  lymphocytic leukemia, aggressive NK leukemia.

               -  Plasma cell myeloma and Hodgkin lymphoma are excluded.

          -  Prior therapy with bortezomib is allowed. Patients who have received prior bortezomib
             therapy must have received bortezomib &gt;6 months ago, and must have shown some
             response. Patients that did not respond to prior bortezomib therapy are not eligible.

          -  Measurable disease by one of the following: radiographic criteria (2 cm by computed
             tomography); lymphoma involving peripheral blood with more than 5000 leukemia
             cells/mm3, or any degree of bone marrow infiltration on bone marrow biopsy. Skin
             involvement with or without nodal or bone marrow involvement permitted for cutaneous
             lymphomas is also permitted. (see section 6.0, Measurement of Effect).

          -  Eastern Cooperative Group (ECOG) Performance Status of 0-2.

          -  Serum bilirubin levels 1.5 times the upper limit of the normal (ULN) range for the
             laboratory. Higher levels are acceptable if these can be attributed to active
             hemolysis or ineffective erythropoiesis. Serum AST or serum ALT levels must be 2.5 x
             ULN, or 5 x ULN for patients with liver involvement by lymphoma.

          -  Must have adequate bone marrow function:

               -  Absolute neutrophil count (ANC) 1,000/uL

               -  Platelet count (Plt)  75,000/uL

               -  Hemoglobin (Hgb)  9.0 g/dL

          -  Must have adequate renal function: Creatinine  1.5 X ULN.

          -  Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy
             test within 7 days of starting study drug. In addition, sexually active WCBP must
             agree to use adequate contraceptive methods (tubal ligation; intrauterine device; or
             barrier contraceptive with spermicide) while on study. Oral, implantable, or
             injectable contraceptives may be affected by cytochrome P450 interactions, and are
             therefore not considered effective for this study. WCBP must agree to have pregnancy
             tests every 4 weeks while on study drug. Male subject agrees to use an acceptable
             method of contraception for the duration of the study.

          -  Female patients who:

               -  Are postmenopausal for at least 1 year before the Screening visit, OR

               -  Are surgically sterile, OR

               -  If they are of childbearing potential, agree to practice 2 effective methods of
                  contraception, at the same time, from the time of signing the informed consent
                  through 30 days after the last dose of study treatment, OR agree to completely
                  abstain from heterosexual intercourse

          -  Male patients, even if surgically sterilized (ie, status post-vasectomy), who:

               -  Agree to practice effective barrier contraception during the entire study
                  treatment period and through 30 days after the last dose of study treatment, OR

               -  Agree to completely abstain from heterosexual intercourse

          -  Able to adhere to the study visit schedule and other protocol requirements.

        Exclusion Criteria:

          -  Prior treatment with any investigational drug, chemotherapy, or monoclonal antibody
             within the preceding 1 month

          -  Chronic treatment with systemic steroids or another immunosuppressive agent.

          -  Patients should not receive immunization with attenuated live vaccines during study
             period.

          -  History of allogeneic stem cell transplantation.

          -  Any patient with known diabetes mellitus currently requiring insulin therapy, or any
             patient with preexisting diabetes mellitus in poor control, defined as a hemoglobin
             A1C (HbA1C) value of over 9% within 4 weeks of starting therapy

          -  Fasting serum cholesterol &gt;300 mg/dL OR &gt;7.75 mmol/L or fasting triglycerides &gt; 2.5 x
             ULN. NOTE: In case one or both of these thresholds are exceeded, the patient can only
             be included after initiation of appropriate lipid lowering medication.

          -  Uncontrolled brain or leptomeningeal metastases, including patients who continue to
             require glucocorticoids for brain or leptomeningeal metastases.

          -  Other malignancies within the past 3 years except for adequately treated carcinoma of
             the cervix or basal or squamous cell carcinomas of the skin, or low-risk prostate
             cancer after curative therapy.

          -  Patients who have any severe and/or uncontrolled medical conditions or other
             conditions that could affect their participation in the study such as:

               -  unstable angina pectoris, any history of congestive heart failure, any history
                  of known myocardial infarction, uncontrolled cardiac arrhythmia

               -  severely impaired lung function

               -  uncontrolled diabetes as defined by fasting serum glucose &gt;1.5x ULN, off
                  medications

               -  any active (acute or chronic) or uncontrolled infection/ disorders.

               -  nonmalignant medical illnesses that are uncontrolled or whose control may be
                  jeopardized by the treatment with the study therapy

               -  liver disease including a known history of viral hepatitis B or C, evidence of
                  cirrhosis, chronic active hepatitis or chronic persistent hepatitis

               -  a known history of HIV seropositivity

               -  Impairment of gastrointestinal function or gastrointestinal disease that may
                  significantly alter the absorption of RAD001 (e.g., ulcerative disease,
                  uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel
                  resection)

          -  Patients with an active, bleeding diathesis

          -  Breast feeding or pregnant females

          -  Patients with a known hypersensitivity to everolimus or other rapamycins (sirolimus,
             temsirolimus) or to its excipients, or to bortezomib, boron, or mannitol

          -  History of noncompliance to medical regimens

          -  Patients unwilling or unable for any reason (personal, medical, or psychiatric) to
             comply with the protocol

          -  Patients with preexisting peripheral neuropathy grade  2 will not be eligible

          -  Patients taking concomitant medications (chronically or within 1 week of study drug
             administration) which are strong inhibitors of hepatic metabolism via P450/CY3PA4
             isoenzyme will be excluded.

          -  Patients who have received hematopoietic growth factors (filgrastim, pegfilgrastim,
             or sargramostim) within 28 days of first dose of screening.

          -  Patient had myocardial infarction within 6 months prior to enrollment or has New York
             Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
             ischemia or active conduction system abnormalities. Prior to study entry, any ECG
             abnormality at screening must be documented by the investigator as not medically
             relevant.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Women who have undergone or will undergo a robotic-assisted gynecologic procedure at M. D.
        Anderson Cancer Center and St. Luke's Episcopal Hospital.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

        1) All women who have undergone or will undergo a robotic-assisted gynecologic procedure
        at MD Anderson Cancer Center and MD Anderson Banner - Arizona are eligible for inclusion
        in this study. They should be able to speak either English or Spanish.

        Exclusion Criteria:

        1) None
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  21 to 65 years of age inclusive

          -  1-36 months after radiation or chemotherapy for non-metastatic breast      cancer and
             on a stable dose of anti-estrogen agent and medications for hot flashes

          -  Meets diagnostic criteria for chronic, secondary insomnia

          -  Speak and write English

        Exclusion Criteria:

          -  Presence of a serious unstable physical illness other than cancer

          -  Presence of dementia, major depression, psychosis or other serious psychiatric
             disorder

          -  Presence of a sleep disorder other than insomnia

          -  Unstable doses of psychotropic medications (excluding hypnotics), opioids,
             anit-endocrine medications, or use of high dose steroids

          -  Current evening/night shift employment
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  21 Years
 </minimum_age>
 <maximum_age>
  65 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Must have cancer of the breast

          -  Must have metastatic or unresectable locally advanced disease

          -  Tumor must express CEA by tumor staining or by elevated serum CEA (&gt;10  ng/ml)

          -  Must have measurable disease radiologically or by physical exam

          -  Must have failed potentially curative standard therapy

          -  Must be 18 years of age or older

          -  Good performance status (PS 0-1)

        Exclusion Criteria:

          -  Requiring systemic steroids

          -  Serious medical conditions

          -  Concurrent malignancies
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

        Age: Greater than or equal to 6 months to 21 years of age

        Diagnosis: Patients with NF1 and an inoperable plexiform neurofibroma that has the
        potential to cause significant morbidity, such as (but not limited to) head and neck
        lesions that could compromise the airway or great vessels, brachial or lumbar plexus
        lesions that could cause nerve compression and loss of function, lesions that could result
        in major deformity (e.g., orbital lesions) or significant cosmetic problems, lesions of
        the extremity that cause limb hypertrophy or loss of function, and painful lesions.
        Histologic confirmation of tumor is not required in the presence of consistent clinical
        and radiographic findings. However, if any clinical observation or scan suggests possible
        malignant transformation, the tumor should be biopsied prior to therapy. Patients without
        biopsy-proof of a plexiform neurofibroma must have at least one other diagnostic criteria
        for NF1 as defined by the NIH Consensus Conference.

          -  Six or more cafe-au-lait spots (greater than 0.5 cm in prepubertal subjects or
             greater than 1.5 cm in postpubertal subjects)

          -  Freckling in the axilla or groin

          -  Optic glioma

          -  Two or more Lisch nodules

          -  A distinctive bony lesion (dysplasia of the sphenoid bone or dysplasia or thinning of
             long bone cortex)

          -  A first degree relative with NF1

        Specific eligibility criteria stratum 1:

        Disease status:

          -  Radiographic disease progression as defined for stratum 3 is not required for trial
             entry.

        Patient does not have clinical symptoms from the plexiform neurofibroma.

        Specific eligibility criteria stratum 2:

        Disease status:

          -  Radiographic disease progression as defined for stratum 3 is not required for trial
             entry.

          -  Patient has clinical symptoms from the plexiform neurofibroma.

        Specific eligibility criteria stratum 3:

        Disease status:

          -  Patients must have a radiographically progressive plexiform neurofibroma(s) with or
             without clinical symptoms. Progression at the time of study entry is defined as:

          -  Presence of new plexiform neurofibromas on MRI within the last 12 months OR

          -  A measurable increase of the plexiform neurofibroma (greater than or equal to 20
             percent increase in the volume, or a greater than or equal to 13 percent increase in
             the product of the two longest perpendicular diameters, or a greater than or equal to
             6 percent increase in the longest diameter) over the last two consecutive scans (MRI
             or CT), or over the time period of approximately one year prior to evaluation for
             this study.

        Surgery/Residual disease: Patients are only eligible if complete tumor resection is not
        feasible, or if a patient with a surgical option refuses surgery. Patients must have
        measurable residual tumor present. For the purpose of this study a measurable lesion will
        be defined as a lesion of at least 3 cm measured in one dimension. Evidence of recurrent
        or progressive disease is NOT necessary. Patients must be at least 21 days from surgery,
        if performed, prior to receiving their first dose of study drug.

        Prior therapy: Since there is no standard effective chemotherapy for patients with
        progressive plexiform neurofibromas, patients may be treated on this trial without having
        received prior therapy. If patients have received prior therapy, they must have recovered
        from all toxic effects prior to entering this study.

        Performance Status: Patients should have a life expectancy of at least 12 months and a
        Karnofsky or Lansky performance score of greater than or equal to 50. Patients who are
        wheelchair bound because of paralysis should be considered    ambulatory    when they are
        up in their wheel chair.

        Organ Function: Subjects must have adequate hepatic, renal and bone marrow function as
        defined by the following parameters:

          -  An absolute granulocyte count greater than 1500/microL, a hemoglobin greater than 10
             gm/dl, and a platelet count greater than 100,000/microL at study entry.

          -  Bilirubin less than 1.5 mg/dl and SGPT less than or equal to 2 times upper limit of
             normal.

          -  An age-adjusted normal serum creatinine (see below) OR a creatinine clearance greater
             than or equal to 70 mL/min/1.73 m(2).

          -  Age less than or equal to 5, Maximum Serum Creatinine - 0.8 (mg/dl)

          -  Age greater than 5 to less than or equal to 10, Maximum Serum Creatinine - 1.0
             (mg/dl)

          -  Age greater than 10 to less than or equal to 15, Maximum Serum Creatinine - 1.2
             (mg/dl)

          -  Age greater than 15, Maximum Serum Creatinine - 1.5 (mg/dl)

        Baseline Clinical and Radiographic Evaluations: MRI scan of the target plexiform
        neurofibroma(s), performed according to study requirements, including axial and coronal
        STIR images within 4 weeks of enrollment on study. Patients with orbital PNF   s must have
        a baseline ophthalmologic evaluation as per Appendix G performed prior to study enrollment
        by an ophthalmologist familiar with the protocol guidelines. Patients with pain associated
        with the target PNF must be able to fill out the Pain Medication Diary with at least one
        week of documentation prior to study enrollment.

        Informed Consent: All patients or their legal guardians (if the patients is less than 18
        years old) must sign an IRB approved document of informed consent indicating their
        understanding of the investigational nature and the risks of this study BEFORE any
        protocol related studies are performed (this does not include routine laboratory tests or
        imaging studies required to establish eligibility). When appropriate, pediatric patients
        will be included in all discussion in order to obtain verbal assent.

        EXCLUSION CRITIERIA:

        Clinically significant unrelated systemic illness (serious infections or significant
        cardiac, pulmonary, hepatic or other organ dysfunction) which in the judgment of the
        Principal or Associate Investigator would compromise the patient   s ability to tolerate
        Pegintron or are likely to interfere with the study procedures or results.

        An investigational agent within the past 30 days

        Evidence of an optic glioma requiring treatment with chemotherapy or radiation therapy at
        the time of study entry

        History of malignant peripheral nerve sheath tumor or other cancer other than surgically
        cured non-melanoma skin cancer or cervical carcinoma in situ

        Ongoing radiation therapy, chemotherapy, hormonal therapy directed at the tumor, or
        immunotherapy

        Inability to return for follow-up visits or obtain follow-up studies required to assess
        toxicity and response to therapy

        Severe cardiovascular disease, i.e., arrhythmias requiring chronic treatment, congestive
        heart failure or symptomatic ischemic heart disease

        Pre-existing severe psychiatric condition or a history of a psychiatric disorder requiring
        hospitalization or a history of suicidal ideation or attempt

        Thyroid dysfunction not responsive to therapy

        Uncontrolled diabetes mellitus

        History of seropositivity for HIV

        Subjects who are pregnant, lactating, or of reproductive potential and not practicing an
        effective means of contraception

        Subjects with a medical condition requiring chronic systemic corticosteroids

        Subjects who are known to be actively abusing alcohol or drugs

        Subjects who have not recovered from the effects of recent surgery

        Prior administration of interferon alfa-2b or Pegintron
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  6 Months
 </minimum_age>
 <maximum_age>
  21 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Ages 0-21

          -  AML in one of the following stages:

               -  Having preceding myelodysplasia (MDS)

               -  High Risk cytogenetics

               -  Requiring &gt; 2 cycles chemotherapy to obtain complete remission

               -  High allelic ratio FLT3/ITD+,

               -  Standard risk cytogenetics with positive MRD at end of Induction

               -  Second or greater CR

               -  First relapse with &lt; 25% blasts in bone marrow

               -  With therapy-related AML whose prior malignancy has been in remission for at
                  least 12 months

          -  ALL in one of the following stages:

          -  High risk first remission, defined as:

               -  Ph+ ALL; or,

               -  MLL rearrangement with slow early response [defined as having M2 (5-25% blasts)
                  or M3 (&gt;25% blasts on bone marrow examination on Day 14 of induction therapy)];
                  or,

               -  Hypodiploidy (&lt; 44 chromosomes or DNA index &lt; 0.81); or,

               -  End of induction M3 bone marrow; or,

               -  End of induction M2 marrow or MRD&gt;1% with M2-3 marrow or MRD&gt;1% at Day 42.

               -  High-risk infant ALL defined as age &lt;6 months at diagnosis with MLL (11q23)
                  translocation.

          -  High risk second remission, defined as:

               -  Bone marrow relapse &lt; 36 months from induction; or &gt;36 mths if a matched sibling
                  donor is available

               -  T-lineage relapse at any time; or,

               -  Very early isolated CNS relapse (&lt;18 months from diagnosis); or,

               -  Slow reinduction (M2-3 at Day 28) after relapse at any time.  Any third or
                  subsequent CR.

          -  Biphenotypic or undifferentiated leukemia in any CR or if in first relapse must have
             &lt; 25% blasts in bone marrow

          -  MDS at any stage; prior therapies allowed

          -  CML in chronic or accelerated phase; prior therapies allowed

          -  Patient also must have the following organ requirements:

               -  Adequate renal function defined as serum creatinine &lt;2x normal, or creatinine
                  clearance &gt; 40 ml/min/m^2 or 70 ml/min.

               -  Adequate liver function as defined by total bilirubin less than or equal to 2
                  times normal and AST and ALT less than or equal to 4 times normal.

               -  Adequate cardiac function as defined by: shortening fraction &gt; 24% by
                  echocardiogram, or ejection fraction &gt; 30% by radionuclide angiogram.

               -  Adequate pulmonary function as defined by DLCO, FEV1/FVC &gt; 60% by pulmonary
                  function tests. For children who are uncooperative for PFTs and have no evidence
                  of dyspnea at rest or exercise intolerance, pulse oximetry &gt; 94% on room air is
                  considered acceptable, with a normal chest xray.

               -  Adequate venous access; a double lumen central vascular access device or its
                  equivalent and an additional PICC line will be required for all patients.

          -  Women of childbearing potential and sexually active males should use effective
             contraception while on study.

        Exclusion Criteria:

          -  Inability to give informed consent or assent

          -  Inability to obtain a suitable donor

          -  Patient who is HIV-positive

          -  Patient who has active Hepatitis B

          -  Patient who is pregnant

          -  Patient who is otherwise considered unsuitable for transplant at the discretion of
             the principal investigator.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  21 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   CURRENTLY ENROLLMENT IS OPEN FOR ADOLESCENT SUBJECTS (12&lt;= subject&lt;18) ONLY

        Inclusion criteria:

          -  Pathologically confirmed giant cell tumor of bone within 1 year before study
             enrollment

          -  Measurable evidence of active disease within 1 year before study enrollment

          -  Subjects with surgically unsalvageable disease (eg, sacral, spinal GCTB, or multiple
             lesions including pulmonary metastases) OR subjects whose planned surgery includes
             joint resection, limb amputation, hemipelvectomy or surgical procedure resulting in
             severe morbidity

          -  Karnofsky performance status equal or greater than 50%

          -  Adults or skeletally mature adolescents (ie, radiographic evidence of at least 1
             mature long bone [eg, humerus with closed growth epiphyseal plate]) equal or greater
             than 12 years of age

          -  Skeletally mature adolescents must weigh at least 45 kg

          -  Before any study-specific procedure is performed, the appropriate written informed
             consent must be obtained

        Exclusion criteria:

          -  Currently receiving other GCTB specific treatment (eg, radiation, chemotherapy, or
             embolization)

          -  Concurrent bisphosphonate treatment

          -  Known or suspected current diagnosis of underlying malignancy including high grade
             sarcoma, osteosarcoma, fibrosarcoma, malignant giant cell sarcoma

          -  Known or suspected current diagnosis of non GCTB giant cell-rich tumors

          -  Known or suspected current diagnosis of brown cell tumor of bone or Paget's disease

          -  Known diagnosis of second malignancy within the past 5 years

          -  Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw

          -  Active dental or jaw condition which requires oral surgery

          -  Non-healed dental/oral surgery

          -  Planned invasive dental procedure for the course of the study

          -  Subject currently is enrolled in or has not yet completed at least 30 days since
             ending other investigational device or drug study(s), or subject is receiving other
             investigational agent(s)

          -  Subject has known sensitivity to any of the products to be administered during dosing

          -  Unstable systemic disease including active infection, uncontrolled hypertension,
             unstable angina, congestive heart failure, or myocardial infarction within 6 months
             before enrollment

          -  Subject is pregnant or breast feeding, or planning to become pregnant within 7 months
             after the end of treatment

          -  Female subject of child bearing potential is not willing to use two methods of highly
             effective contraception during treatment and for 7 months after the end of treatment

          -  Subject has any kind of disorder that compromises the ability of the subject to give
             written informed consent and/or to comply with study procedures
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  12 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Histologically confirmed light-chain deposition disease based on the following
             criteria:

               -  Deposition of granular material containing free light-chain (FLC)
                  immunoglobulins that did not bind Congo red

               -  Evidence of a plasma cell dyscrasia, as defined by any of the following:

                    -  Monoclonal gammopathy in the serum or urine by immunofixation
                       electrophoresis

                    -  Clonal plasmacytosis on bone marrow biopsy by IHC

                    -  Elevated serum levels of FLC

          -  No overt multiple myeloma, as defined by any of the following:

               -  Greater than 30% bone marrow plasmacytosis

               -  Extensive (i.e., &gt; 2) lytic lesions

               -  Hypercalcemia

          -  Patients may enroll after stem cell collection (SCC) if all prestudy requirements are
             completed prior to starting SCC (i.e.,  2.5 x 10^6 cells available for
             transplantation)

        PATIENT CHARACTERISTICS:

          -  Performance status 0-2

          -  LVEF  45% within the past 90 days

          -  No myocardial infarction, congestive heart failure, or arrhythmia refractory to
             therapy within the past 6 months

          -  No prior malignancy except adequately treated basal cell or squamous cell skin
             cancer, carcinoma in situ of the cervix, adequately treated stage I or II cancer from
             which the patient is currently in complete response, or any other cancer from which
             the patient has been disease-free for the past 5 years

          -  No HIV positivity

          -  DLCO  50%

        PRIOR CONCURRENT THERAPY:

          -  Prior chemotherapy with alkylating agent allowed provided there is no evidence of
             myelodysplastic syndromes

          -  Prior total dose of melphalan &lt; 300 mg

          -  More than 4 weeks since prior cytotoxic therapy and recovered
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   AIM 2:

        Inclusion Criteria:

          -  suspected or definitive diagnosis of non-small cell lung cancer (NSCLC)

          -  treatment naive or no treatment within 6 months prior to enrollment

          -  able to swallow pills

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3

          -  absolute neutrophil count (ANC) at least 1500/microl

          -  able to understand and willing to sign a written informed consent document

        Exclusion Criteria:

          -  history of hypersensitivity reactions attributed to beta-glucan

          -  currently receiving continuous corticosteroids or other ongoing immunosuppressive
             therapy

          -  presence of an uncontrolled intercurrent illness including but not limited to:
             ongoing or active infection, symptomatic congestive heart failure, unstable angina
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would
             limit compliance with study requirements

        AIM 3:

        Inclusion Criteria:

          -  resectable non-small cell lung cancer (NSCLC), as determined by a thoracic surgeon

          -  treatment naive

          -  able to swallow pills

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

          -  must be an operative candidate

          -  absolute neutrophil count (ANC) at least 1500/microl

          -  able to understand and willing to sign a written informed consent document

        Exclusion Criteria:

          -  history of hypersensitivity reactions attributed to beta-glucan

          -  currently receiving continuous corticosteroids or other ongoing immunosuppressive
             therapy

          -  presence of an uncontrolled intercurrent illness including but not limited to:
             ongoing or active infection, symptomatic congestive heart failure, unstable angina
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would
             limit compliance with study requirements
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Patients recently diagnosed with Cushing's syndrome, recruited from the clinic.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Written consent

          -  Age between 18 and 70

          -  Diagnosed with Cushing's syndrome

        Exclusion Criteria:

          -  Suspected malignancy
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Unresectable stage III and stage IV M1a/M1b/M1c melanoma including patients with
             uveal melanoma

          -  Age  18 years

          -  Life expectancy  4 months

          -  ECOG performance status 0-2

          -  HLA-A2 positive

          -  gp100 expression &gt; 6% in primary lesion or metastasis

          -  At least 28 days from prior treatment (including adjuvant interferon) except in cases
             of a BRAF inhibitor (such as vemurafenib); concurrent treatment with a BRAF inhibitor
             is permitted

          -  Required initial laboratory values (submitted within 14 days prior to registration):

               -  WBC &gt;3,000/mm3

               -  Hg  9.0 gm/dl Platelets &gt;75,000/mm3 Serum Bilirubin &lt; 2.0 mg/dl Serum
                  Creatinine &lt; 2.0 mg/dl

          -  Sexually active women of childbearing potential must use effective birth control
             during the trial and for at least two months following the trial, and sexually active
             men must be willing to avoid fathering a new child while receiving therapy.

        Exclusion Criteria:

          -  Prior treatment with more than one line of cytotoxic chemotherapy; prior treatment
             with one line of cytotoxic chemotherapy is permitted.  Prior treatment with targeted
             therapy (such as ipilumumab, and BRAF inhibitor) is permitted

          -  Active untreated CNS metastasis

          -  Active infection

          -  Prior malignancy (except non-melanoma skin cancer) within 3 years

          -  Pregnant or nursing

          -  Concurrent treatment with corticosteroids; local (inhaled or topical) steroids are
             permitted.

          -  Inability to provide adequate informed consent

          -  Known allergy to eggs

          -  Prior history or uveitis or autoimmune inflammatory eye disease.

          -  Known positivity for hepatitis BsAg, hepatitis C antibody, or HIV antibody.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Primary colon cancer without known extension beyond colon (T3, N0, M0)

          -  Scheduled for open, laparoscopic assisted and laparoscopic resection of  the colon.

          -  Written informed consent, including willingness to be randomized to epidural
             anesthesia/analgesia or to sevoflurane general anesthesia and postoperative opioid
             analgesia.

        Exclusion Criteria:

          -  Previous surgery for colon cancer;

          -  Any contraindication to epidural anesthesia or analgesia (including coagulopathy,
             abnormal anatomy);

          -  Any contraindication to midazolam, propofol, sevoflurane, fentanyl, or morphine;

          -  Age &lt;18 or &gt;85 years old;

          -  ASA Physical Status 4;

          -  Other cancer not believed by the attending surgeon to be in long-term remission;

          -  Systemic disease believed by the attending surgeon or anesthesiologist to present
             25% two-year mortality.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  85 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   All patients actively being treated and previously treated at St. Jude Children's Research
        Hospital for childhood cancer.
  </textblock>
 </study_pop>
 <sampling_method>
  Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  All St Jude patients actively being followed or treated for childhood cancer

        Exclusion Criteria:

          -  St. Jude consult only patients

          -  St. Jude patients permanently discharged from care and follow-up Permanently
             discharged patients include patients who have electively transferred their oncologic
             care to another institution, those who are noncompliant with recommended follow-up or
             those leaving the institution against medical advice.

          -  Patients referred to St. Jude for limited care on phase 1 protocol.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Subjects willing and able to give written informed consent

          2. Confirmed metastatic castration resistant prostate cancer and rising PSA

          3. ECOG performance status  1

          4. Adequate renal function, hepatic function and bone marrow reserve.

          5. Subjects capable of swallowing.

        Exclusion Criteria:

          1. Hypersensitivity to one or more of the Hamsa-1 active components

          2. Glucose-6-phosphate-dehydrogenase deficiency (G6PD)

          3. Subjects with a clinically significant or unstable medical condition that would
             preclude safe and complete study participation

          4. Subjects who received any investigational medication, antineoplastic therapy, or any
             significant change in treatment within 1 month prior to screening

          5. Subjects with visceral metastases (e.g. liver, lung)

          6. Subjects who received more than 2 prior chemotherapies for the treatment of prostate
             cancer

          7. Subjects suffering from circumstances likely to interfere with absorption of orally
             administrated drugs

          8. Subjects unwilling to or unable to comply with study protocol
  </textblock>
 </criteria>
 <gender>
  Male
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Mothers self-identified as primary caregivers to minor-age children (ages 8-21
             years-old)

          -  Mothers must be undergoing genetic counseling and have provided a blood sample for
             analysis for BRCA1/2 mutations

          -  Mothers must have resided in the same home as the child(ren) for the past 6 months
             and intend to continue to reside with the child(ren) for the next 6 months

        PATIENT CHARACTERISTICS:

          -  At least 21 years old (mothers)

          -  No serious mental illness (e.g., cognitive and psychotic disorders) or developmental
             disability that would limit participation or preclude informed consent

          -  Must be able to adequately understand, speak, and read English

          -  Must have ready and consistent access to a telephone

        PRIOR CONCURRENT THERAPY:

          -  Not specified
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  8 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Subjects must be confirmed Esophageal Carcinoma pathologically

          2. (EUS)IIVa, without contraindication for radical radiotherapy

          3. Subjects haven't been given neither radiotherapy nor chemotherapy before

          4. Age 18-70,behavioral status evaluation ECOG scores 02 and anticipated survival more
             than 6 months

          5. In 7 days after being selected, subjects should follow the status: WBC  4.0 x
             10^9/L; ANC  1.5x 10^9/L; PLT  100 x 10^9/L; Hb  90 g/L; serum Cr  ULN; serum
             bilirubin  1.5 ULN; ALT/AST  1.5 ULN

          6. Subjects should sign for the informed consent

          7. Subjects should perform good compliance

          8. Male and female subjects who have the ability of fertility should take contraception
             during the whole course and also 3 months after last dosage.In 7 days before the
             inclusion, urine pregnancy tests of subjects should be negative.

        Exclusion Criteria:

          1. Patients who have or are currently undergoing additional chemotherapy, radiation
             therapy or targeted therapy

          2. Complete obstruction of the esophagus, or patients who have the potential to develop
             perforation

          3. Patients with a history of malignancy (except that skin carcinomas or in situ breast
             cancer, oral cancer and cervical cancer with expected survival 2 years

          4. Patients who multiple foci esophagus

          5. Patients who are/were given any other medicine tests currently/in last 4 weeks

          6. Experienced hypersensitiveness with similar medicine or other kinds of bio-medicines

          7. Women in status of pregnancy

          8. Patients who have complications exist as following:

        (1)Uncontrolled angina and heart failure, have a history of hospitalization in 3 months;
        (2)A history of myocardial infarction in the past 6 months; (3)There is a need for
        antibiotic treatment of acute bacterial or fungal infection; (4)Chronic obstructive
        pulmonary disease, or other lung disease requiring hospitalization; (5)Drug addiction,
        alcoholism and AIDS disease or long-term virus carriers; (6)Uncontrollable seizures, or
        loss of insight because of mental illness
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Acute lymphoblastic leukemia

               -   Complete remission 2 (CR2) (adults  18 years and  55 years)

               -  CR2 in pediatrics (defined as &lt;18 years) and &lt;12 months duration of first
                  remission

               -   CR3 or not in remission (pediatric patients &lt;18 years)

               -  T cell leukemia  CR2

               -  Evidence of pre-transplant minimal residual disease (MRD) by flow cytometry,
                  FISH or cytogenetics

          -  Myelodysplastic syndrome

               -   55 years of age and  10% blasts, not responsive to hypomethylating agents
                  and/or conventional therapy

          -  Acute myeloid leukemia

               -  Not in remission (pediatric patients &lt;18 years)

               -  Not in remission (10-30% blasts in the bone marrow for adult patients 18 years
                  and  55 years)

               -  Evidence of pre-transplant minimal residual disease (MRD) by flow cytometry,
                  FISH or cytogenetics

          -  Patients with prior CNS involvement are eligible provided that it has been treated
             and is in remission. CNS therapy (chemotherapy or radiation) should continue as
             medically indicated during the protocol.

          -  Have acceptable organ function within 14 days of study registration defined as:

               -  Renal: glomerular filtration rate &gt; 60ml/min/1.73m2

               -  Hepatic: bilirubin, aspartate aminotransferase (AST), alanine aminotransferase
                  (ALT), Alkaline phosphatase (ALP) &lt; 5 x upper limit of normal (ULN)

               -  Pulmonary function: Carbon Monoxide Diffusing Capacity corrected (DLCOcorr) &gt;
                  50% of normal, (oxygen saturation [&gt;92%] can be used in child where pulmonary
                  function tests (PFT's) cannot be obtained)

               -  Cardiac:  left ventricular ejection fraction  45% by echocardiogram (ECHO) or
                  multi gated acquisition scan (MUGA)

          -  Karnofsky performance status (PS) &gt;80% for ages 16 years and older or Lansky Play
             Score &gt;50 for &lt; 16 years

          -  Women of childbearing potential must agree to use adequate contraception (diaphragm,
             birth control pills, injections, intrauterine device [IUD], surgical sterilization,
             subcutaneous implants, or abstinence, etc.) for the duration of treatment.

          -  Voluntary written consent

        Exclusion Criteria:

          -  Active uncontrolled infection at time of enrollment or documented fungal infection
             within 3 months.

          -  Evidence of Human immunodeficiency virus (HIV) infection

          -  Pregnant or breast feeding. The agents used in this study may be teratogenic to a
             fetus and there is no information on the excretion of agents into breast milk.  All
             females of childbearing potential must have a blood test or urine study within 2
             weeks prior to registration to rule out pregnancy.

          -  Prior myeloablative transplant within the last 6 months

          -  Prior total body irradiation (TBI) making total marrow irradiation (TMI) not feasible
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  55 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion criteria:

          1.  18 years old

          2. Patients with advanced (unresectable or metastatic) biopsy proven non-syndromic
             neuro-endocrine carcinoma, low or intermediate grade

          3. Radiological documentation of disease progression within 12 months prior to study
             entry. If patients received anti-tumor therapy during the past 12 months, they must
             have radiological documentation of PD while on or after receiving the therapy

          4. Patients may have received previous treatments (chemotherapy, biotherapy,
             peptide-receptor radionuclide therapy); an overall maximum of 3 systemic treatment is
             allowed

          5. Patients with at least one measurable lesion

          6. Patients with an ECOG Performance Status 0-2

          7. Adequate bone marrow function

          8. Adequate liver function

          9. Adequate renal function

         10. Adequate lipid profile

        Exclusion criteria:

          1. Patients with poorly differentiated neuroendocrine carcinoma, high-grade
             neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoid and small cell
             carcinoma

          2. Patients with carcinoid with hormone related symptoms (diarrhea  4 stools per day
             and/or flushes)

          3. Patients with Islet cell carcinomas or pancreatic NET

          4. Patients who received prior therapy with VEGF pathway inhibitor  within 4 weeks prior
             to study entry

          5. Patients who entered PRRT within 3 months prior to study entry

          6. Patients who received CT, biotherapy or radiotherapy within 4 weeks prior to study
             entry

          7. Patients who have previously received systemic mTOR inhibitors

          8. Patients with a known hypersensitivity to everolimus or other rapamycins or to its
             excipients

          9. Patients with uncontrolled central nervous system (CNS) metastases

         10. Patients receiving chronic systemic treatment with corticosteroids or another
             immunosuppressive agent

         11. Patients with a known history of HIV seropositivity

         12. Patients with autoimmune hepatitis

         13. Patients with an active, bleeding diathesis

         14. Patients who have any severe and/or uncontrolled medical conditions or other
             conditions that could affect their participation in the study

         15. Patients who have a history of another primary malignancy and off  treatment  3
             years, with the exception of non-melanoma skin cancer and carcinoma in situ of the
             uterine cervix

         16. Female patients who are pregnant or breast feeding, or adults of reproductive
             potential who are not using effective birth control methods

         17. Patients who are using other investigational agents or who had received
             investigational drugs  4 weeks prior to study treatment start

         18. Patients unwilling to or unable to comply with the protocol
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion criteria:

          1.  18 years old.

          2. Patients with metastatic papillary renal cell carcinoma, type I or II.

          3. Patients with at least one measurable lesion.

          4. Patients with an ECOG Performance Status 1.

          5. Adequate bone marrow function.

          6. Adequate liver function.

          7. Adequate renal function.

          8. Adequate lipid profile.

        Exclusion criteria:

          1. Patients who had radiation therapy within 28 days prior to start of study.

          2. Patients who have received prior systemic treatment for their metastatic RCC.

          3. Patients who received prior therapy with VEGF pathway inhibitor.

          4. Patients who have previously received systemic mTOR inhibitors.

          5. Patients with a known hypersensitivity everolimus or other rapamycins or to its
             excipients.

          6. Patients with uncontrolled central nervous system (CNS) metastases.

          7. Patients receiving chronic systemic treatment with corticosteroids or another
             immunosuppressive agent.

          8. Patients with a known history of HIV seropositivity.

          9. Patients with autoimmune hepatitis.

         10. Patients with an active, bleeding diathesis.

         11. Patients who have any severe and/or uncontrolled medical conditions or other
             conditions that could affect their participation in the study.

         12. Patients who have a history of another primary malignancy and off  treatment  3
             years, with the exception of non-melanoma skin cancer and carcinoma in situ of the
             uterine cervix.

         13. Female patients who are pregnant or breast feeding, or adults of reproductive
             potential who are not using effective birth control methods.

         14. Patients who are using other investigational agents or who had received
             investigational drugs  4 weeks prior to study treatment start.

         15. Patients unwilling to or unable to comply with the protocol.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Biopsy-proven nasopharyngeal carcinoma (NPC)

               -  WHO type 2/3 disease

               -  Metastatic or locally recurrent disease

          -  Epstein-Barr virus (EBV)-positive disease as confirmed by in situ hybridization assay
             or PCR amplification for EBV-encoded RNA expression

          -  Radiologically measurable disease

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Life expectancy &gt; 3 months

          -  ANC &gt; 1,200/mm^3

          -  Platelet count  100,000/mm^3

          -  Hemoglobin  8 g/dL

          -  Bilirubin &lt; 2 times upper limit of normal (ULN)

          -  AST and ALT &lt; 3 times ULN

          -  Creatinine clearance  40 mL/min

          -  Corrected calcium normal

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No concurrent severe illness, including any of the following:

               -  Chronic obstructive pulmonary disease

               -  Ischemic heart disease

               -  Active congestive cardiac failure

               -  Active angina pectoris

               -  Uncontrolled arrhythmia

               -  Uncontrolled hypertension

          -  No concurrent severe infections

          -  HIV negative

        PRIOR CONCURRENT THERAPY:

          -  No more than one line of prior chemotherapy for metastatic disease

          -  No prior gemcitabine hydrochloride

          -  Prior platinum agents allowed

          -  At least 1 month since prior investigational therapy
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  21 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Pathologically confirmed squamous metaplasia or squamous dysplasia of the lungs by
             autofluorescence bronchoscopy within the past 5 years

          -  Must be a current or former smoker

          -  No evidence of concurrent disease with lung cancer or head and neck cancer

               -  History of treated lung cancer or head and neck cancer treated with curative
                  intent allowed, provided that there has been no evidence of disease for &gt; 1 year

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  Total granulocyte count &gt; 1,500 x 10^9cells/L

          -  Platelet count &gt; 100,000 x 10^9cells/L

          -  Calculated Creatinine clearance &gt; 60 mL/min (using the Cockcroft-Gault formula)

          -  Calcium concentration 50-300 mg/24 hours

          -  Total bilirubin 0.2-1.3 mg%

          -  ALT/AST  2.5 times upper limit of normal (ULN)

          -  Alkaline phosphatase  2.5 times ULN

          -  Albumin  2.5 g/dL

          -  Ionized serum calcium normal (1.19-1.29 mmol/L)

          -  Corrected serum calcium  10.2 mg/dL

          -  Willing to attend all scheduled study visits, complete all study questionnaires, and
             allow biological specimen collection, including a bronchoscopy

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for at least 1 month
             after completion of study therapy

          -  No life-threatening medical conditions that would preclude bronchoscopy, including
             but not limited to, any of the following:

               -  Acute cardiac failure

               -  Uncontrolled hypertension

               -  Uncontrolled diabetes mellitus

               -  Unstable coronary artery disease

          -  No severe metabolic disorders that would preclude calcitriol administration

          -  No history of any other malignancy within 3 years except for nonmelanoma skin cancer
             or cervical carcinoma in situ

          -  No history or evidence of kidney stones

          -  No patients who are susceptible to calcium-related dysrhythmias

          -  No known hypersensitivity to calcitriol

          -  No known allergies to tree nuts (i.e., almonds)

        PRIOR CONCURRENT THERAPY:

          -  At least 2 months since prior and no concurrent calcium supplements

          -  Concurrent multivitamin supplement allowed provided the amount of vitamin D in the
             supplement is not in excess of the recommended daily dose

          -  No concurrent thiazides, phenobarbital, or digitalis

          -  No concurrent digoxin

          -  No concurrent bile acid binding drugs (i.e., cholestyramine, colestipol)

          -  No concurrent danazol or aluminum-based antacids

          -  No concurrent ketoconazole or other azole antifungals
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  40 Years
 </minimum_age>
 <maximum_age>
  79 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Histologically confirmed relapsed or refractory non-Hodgkin's lymphoma   or Hodgkin's
             Disease (WHO criteria), for which they are unwilling or unable to undergo an
             autologous stem cell transplant

          2. Must have received first line chemotherapy. No upper limit to number of prior
             therapies

          3. Evaluable Disease

          4. Age &gt;18 years

          5. ECOG performance status &lt;2

          6. Life expectancy of greater than 3 months

          7. Patients must have adequate organ and marrow function

          8. Adequate Contraception

          9. Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          1. Prior Therapy

               -  Patients who have had chemotherapy or radiotherapy within 2 weeks prior to
                  entering the study or those who have not recovered from adverse events due to
                  agents administered more than 4 weeks earlier

               -  Patient is on any systemic steroids that have not been stabilized to the
                  equivalent of 10 mg/day prednisone during the 7 days prior to the start of the
                  study drugs

               -  No monoclonal antibody within 3 months without evidence of progression

          2. Patients may not be receiving any other investigational agents

          3. Patients with known central nervous system metastases, including lymphomatous
             meningitis

          4. History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to vorinostat, niacinamide or etoposide

          5. Uncontrolled intercurrent illness

          6. Pregnant women

          7. Nursing women

          8. Patient with a history of a prior malignancy

          9. Patient is known to be Human Immunodeficiency Virus (HIV)-positive

         10. Active Hepatitis A, Hepatitis B, or Hepatitis C infection

         11. Patient has a history of surgery that would interfere with the administration or
             absorption of the oral study drugs
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Histologically or cytologically confirmed metastatic breast adenocarcinoma

          -  No HER2 overexpression or gene amplification

          -  Absent or low ER or PR expression

          -  No previous therapy for metastatic breast cancer is allowed

          -  Age 18-75 years

          -  Measurable disease as defined by the presence of at least one measurable       lesion
             (except bone metastases, ascites or pleural effusions)

          -  Performance status (WHO) 0-2

          -  Adequate liver (serum bilirubin &lt;1.5 times the upper normal limit, AST and        ALT
             &lt;2.5 times the upper normal limit in the absence of demonstrable liver metastases, or
             &lt;5 times the upper normal limit in the presence of liver metastases)

          -  adequate renal function (serum creatinine &lt;1.5 times the upper normal limit)

          -  bone marrow (neutrophils  1.5x 109 /L, and platelets  100x 109 /L)

          -  No radiation of measurable disease (except brain metastases)

          -  No progressive brain metastases according to clinical or radiological criteria

          -  No brain metastases without prior radiation therapy

          -  Written informed consent

        Exclusion Criteria:

          -  Active infection

          -  History of significant cardiac disease (unstable angina, congestive heart failure,
             myocardial infarction within the previous 6 months, ventricular arrhythmias)

          -  History of stroke

          -  Anticoagulation therapy (except of low dose aspirin &lt;325mg)

          -  Other invasive malignancy except nonmelanoma skin cancer

          -  Psychiatric illness or social situation that would preclude study compliance

          -  Pregnant or lactating women
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion criteria:

          -  Stage IV cancer (primary or recurrent)

          -  Normal white blood cell count and formula

          -  Normal platelet count

          -  No anemia requiring blood transfusion or erythropoietin

          -  Adequate hepatic function: Total bilirubin  1.5 x upper limit of normal (ULN) for
             the institution; ALT, AST, and alkaline phosphatase  2.5 x ULN for the institution).

          -  Calculated Creatinin clearance at least 60 ml/min

          -  No previous administration of cetuximab
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Recurrent histologically confirmed platinum-sensitive or platinum-resistant ovarian,
             primary peritoneal, or fallopian tube cancer

          -  Subjects may not have had &gt; 3 prior regimens and must not have had a     platinum or
             taxane agent within the past 6 months.  Last chemotherapy must have been &gt; 4 weeks
             prior to enrollment. Subjects may not have had prior whole abdomen or pelvic
             radiation. Patients may not have had &gt; 6 cycles of an alkylating agent or &gt; 450 mg/m2
             of doxorubicin.

          -  ECOG Performance Score of 2 (Appendix A)

          -  Adequate bone marrow as evidenced by:

               -  Absolute neutrophil count &gt; or equal to 1,500/uL

               -  Hemoglobin &gt; or equal to 8 g/dl

               -  Platelet count &gt; or equal to 100,000/uL

          -  Adequate renal function as evidenced by serum creatinine &lt; 1.5 mg/dL

          -  Adequate hepatic function as evidenced by:

               -  Serum total bilirubin &lt; 1.5 mg/dL

               -  Alk Phos, AST/ALT must be &lt; 3x ULN or &lt;5x ULN if hepatic mets.

               -  AST/ALT &lt; 3X the ULN for the reference lab

          -  Patients must be recovered from both the acute and late effects of any prior surgery,
             radiotherapy or other antineoplastic therapy

          -  Patients or their legal representatives must be able to read, understand and provide
             informed consent to participate in the trial.

          -  Patients of childbearing potential and their partners must agree to use an effective
             form of contraception during the study and for 90 days following the last dose of
             study medication (an effective form of contraception is an oral contraceptive or a
             double barrier method)

        Exclusion Criteria:

          -  Patients with an active infection or with a fever &gt; 101.30 F within 3 days of the
             first scheduled day of protocol treatment

          -  Patients with active extra-abdominal metastases

          -  Patients with active CNS metastases.  Patients with stable CNS disease, who have
             undergone radiotherapy at least 4 weeks prior to the planned first protocol treatment
             and who have been on a stable dose of corticosteroids for 3 weeks are eligible for
             the trial

          -  History of prior malignancy within the past 5 years except for curatively treated
             basal cell carcinoma of the skin or cervical intra-epithelial neoplasia

          -  Patients with known hypersensitivity to any of the components of docetaxel or
             oxaliplatin

          -  Patients who received pelvic or abdominal radiotherapy

          -  Patients who are receiving concurrent investigational therapy or who have received
             investigational therapy within 30 days of the first scheduled day of protocol
             treatment (investigational therapy is defined as treatment for which there is
             currently no regulatory authority approved indication)

          -  Peripheral neuropathy  Grade 2

          -  Patients who are pregnant or lactating

          -  Any other medical condition, including mental illness or substance abuse, deemed by
             the Investigator to be likely to interfere with a patient's ability to sign informed
             consent, cooperate and participate in the study, or interfere with the interpretation
             of the results.

          -  History of allogeneic transplant

          -  Known HIV or Hepatitis B or C (active, previously treated or both)
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Adults with thyroid nodules or thyroid cancer
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Meets either of the following criteria:

               -  Diagnosis or history of thyroid cancer

               -  Presence of one or more thyroid nodules

        PATIENT CHARACTERISTICS:

          -  Able to provide written informed consent

        PRIOR CONCURRENT THERAPY:

          -  Not specified
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  19 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Transplant recipient patients
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Has received an integrating retroviral or lentiviral vector based GT/GM product at
             St. Jude Children's Research Hospital within the past 15 year time period. Patient is
             no later than 15 years post receipt of GT/GM product.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  All patients must have biopsy proven diagnosis of low- and intermediate-grade
             non-Hodgkin lymphoma (NHL) working formulation B, C,D, E, F, and G; including mantle
             cell lymphoma; patients with transformed lymphoma are also eligible

          -  Demonstrated monoclonal CD20 positive b-cell population in lymph nodes and/or bone
             marrow

          -  Patients must have relapsed after achieving a complete or partial response to prior
             therapy, have never responded to prior therapy or have poor risk disease

          -  Patients with prior bone marrow involvement must have bone marrow aspiration and
             biopsy within 60 days prior to stem cell collection which shows =&lt; 10% lymphomatous
             involvement of total cellularity; alternatively, patients with prior bone marrow
             involvement should have a normal bone marrow study which shows =&lt; 10% lymphomatous
             involvement within 28 days before salvage chemotherapy

          -  Normal renal function test with serum creatinine of &lt; upper limit of normal (ULN),
             and a creatinine clearance of &gt;= 60 ml/min (measured or calculated)

          -  Adequate pulmonary function as measured by forced expiratory volume in 1 second
             (FEV1) &gt; 60% of predicted measured, or a diffusion capacity of carbon monoxide (DLCO)
             &gt;= 50% of predicted measured

          -  Cardiac ejection fraction of &gt; 50% by echocardiogram or multi gated acquisition
             (MUGA) scan; the left ventricular ejection fraction (LVEF) from the prestudy
             echocardiogram (ECHO) or MUGA may be used for eligibility purposes, even if the
             prestudy stress test indicated a lower LVEF

          -  Adequate liver function tests with a bilirubin of =&lt; 1.5 x ULN and serum glutamic
             oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT) =&lt; 2 x
             ULN

          -  Negative human immunodeficiency virus antibody

          -  Eastern Cooperative Oncology Group (ECOG) performance status = 0 or 1; karnofsky
             performance status (KPS) &gt;= 80

          -  No active central nervous system (CNS) disease or prior history of CNS disease

          -  Patients must have recovered from last therapy and should be at least four weeks from
             prior radiation or systemic chemotherapy on the day of administration of Y2B8

          -  After the last systemic therapeutic chemotherapy (Cytoxan, administered only for stem
             cell mobilization is not considered therapeutic) and prior to initiation of high dose
             treatment, the patient should have a baseline computed tomography (CT) scan and
             positron emission tomography (PET) scan done; an fluorodeoxyglucose-computed
             tomography (FDG/CT) scan is sufficient, however, is clinically indicated, an
             additional diagnostic CT may be ordered; exception: if scans were done and were
             negative for disease just prior to priming chemotherapy (therapeutic or
             nontherapeutic) and subsequent stem cell harvest, they do not need to be repeated
             prior to initiation of high dose treatment

        Exclusion Criteria:

          -  Presence of human anti-Zevalin antibody (HAZA)

          -  Prior radioimmunotherapy

          -  Failure to collect adequate number of CD34+ cells &gt;= 3 x 10^6/kg

          -  Abnormal cytogenetic study not related to the underlying lymphoma on the bone marrow
             aspirate sample prior to stem cell collection; if cytogenetics were not performed on
             the marrow aspirate prior to stem cell collection, cytogenetics on the peripheral
             blood may be performed

          -  Prior bone marrow transplantation

          -  Prior malignancy except for:

               -  Adequately treated basal cell or squamous cell skin cancer

               -  Adequately treated noninvasive carcinoma

               -  Other cancer from which the patient has been disease-free for at least five
                  years

          -  Active evidence of Hepatitis B or C infection; Hepatitis B surface antigen positive

          -  Patients who have had prior radiation to the lung will be excluded from the study,
             although mediastinal irradiation will be permitted if minimal lung is in the
             treatment volume

          -  Patients who have received &gt; 500cGy radiation to the kidneys will be excluded from
             the study

          -  Patients who are pregnant or lactating
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   This study will enroll patients who are study participants on interventional AMC protocols
        for diseases other than HPV-associated neoplasia with an accrual goal of 15 patients or
        more.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Serologic documentation of HIV infection by any FDA-approved tests

          -  Enrolled in an AIDS Malignancy Clinical Trials Consortium (AMC) clinical trial of any
             new or existing pharmacotherapeutic agent for treatment of disease other than human
             papillomavirus (HPV)-associated neoplasia

               -  AMC study must have an accrual target of &gt; 15 patients

        PATIENT CHARACTERISTICS:

          -  ECOG performance status (PS) 0-1 OR Karnofsky PS 60-100%

          -  Life expectancy  3 months

          -  Not pregnant or nursing

          -  Patients receiving myelosuppressive therapy must meet the following criteria:

               -  ANC &gt; 1,000/L

               -  Platelet count &gt; 50,000/L

               -  Evaluated before treatment or completely recovered from their nadir

          -  Able to understand and willing to sign a written informed consent document

          -  No bleeding disorder or requirement for anticoagulation that would contraindicate any
             biopsy of the anal canal

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Clinical diagnosis of PCOS

          -  Obese (BMI of at least 30 kg/m2)

        Exclusion Criteria:

          -  Diagnosis of nonclassic 21-hydroxylase deficiency, Cushing syndrome, hypothyroidism,
             or significant elevations in prolactin

          -  Taking steroid preparations (including oral contraceptives), medications known to
             alter insulin secretion and/or action, or medications known to influence sleep during
             the 2 months prior to starting the study

          -  Positive pregnancy test

          -  Diagnosis of diabetes mellitus

          -  Hypertension (systolic &gt; 140 mmHg and/or diastolic &gt; 90 mmhg) not well-controlled on
             stable medication with either ACE inhibitors or diuretics

          -  Habitual alcohol use

          -  Excessive caffeine intake of more than 300 mg/day

          -  Known peanut allergies, or allergies to medications used in the study

          -  Hemoglobin &lt; 11g/dL and/or hematocrit &lt; 33%

          -  Systemic illnesses, including heart, renal, liver, or malignant disease
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  40 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Advanced metastatic or unresectable malignancy that is refractory to standard therapy
             and/or existing therapies are not likely to achieve clinical benefit, and/or the
             patient declines to receive standard treatment such as chemotherapy.

          -  Evaluable disease;

          -  Last dose of prior chemotherapy, radiation therapy, or investigational agents
             occurred at least 4 weeks before the start of therapy;

          -  Recovery from the adverse effects  grade 1;

          -  Acceptable ECOG status 0, 1, or 2;

          -  Life expectancy greater than 3 months following study entry;

          -  Adequate laboratory values;

          -  For the expansion cohorts, positive for specific activating MET mutations, MET
             amplifications, and/or AXL fusions.

        Exclusion Criteria:

          -  Uncontrolled concurrent illness;

          -  History of cardiovascular illness;

          -  QTc  &gt; 470 msec (including subjects on medication);

          -  Left ventricular ejection fraction (LVEF) &lt; 50%;

          -  Immunocompromised subjects;

          -  History of bone marrow transplant;

          -  Lung tumor lesions with increased likelihood of bleeding;

          -  Symptomatic or uncontrolled brain metastases;

          -  Unable to swallow oral medications or with pre-existing gastrointestinal disorders.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Tumor patients with renal cell carcinoma (RCC), mantle cell lymphoma (MCL) or
        gastro-intestinal stroma tumor (GIST)

        Gastro-Intestinal Stroma Tumor
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients with proven tumor of RCC, MCL or GIST by histology.

          -  Informed consent signed by patient.

        Exclusion Criteria:

          -  Pregnancy
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Age  21 years old at diagnosis of adrenocortical tumor.

        Relatives of the ACT patients of any age with a diagnosis of malignant tumor.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   STRATIFICATION ASSIGNMENT:

          -  Stratum A: participant suspected or confirmed diagnosis of adrenocortical tumor 9ACT)

          -  Stratum R: relative of participant with ACT who has diagnosis of malignancy

          -  Stratum P: biological parent of participant with ACT

        Inclusion Criteria - Stratum A (participant with ACT):

          -  Age  21 years old at diagnosis

          -  Suspected or confirmed diagnosis of adrenocortical tumor (adenoma, carcinoma or
             undefined histology).

          -  Signed informed consent

        Exclusion Criteria - Stratum R (relative):

          -  Any age

          -  Diagnosis of malignant tumor

          -  Signed informed consent

        Inclusion Criteria - Stratum P (parent):

          -  Biological parent of Stratum A participant
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  21 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed melanoma of 1 of the following subtypes:

               -  Acral melanoma (defined as occurring on the palms, soles, or subungual sites)

               -  Melanoma arising from the vagina and/or vulva

               -  Melanoma arising on other mucosal surface (not vagina or vulva)

          -  Unresectable locally advanced or metastatic disease

          -  c-KIT mutation identified by polymerase chain reaction (PCR) and sequencing meeting 1
             of the following criteria:

               -  At least 1 mutation in exon 9, 11, 13, 17, or 18

               -  At least 1 mutation in an exon not listed above

          -  Metastatic tumor blocks are required for the evaluation of KIT mutations or
             amplifications

          -  Measurable disease, defined as at least one measurable lesion by RECIST criteria

               -  Prior radiotherapy to a measurable lesion allowed provided there is radiographic
                  evidence of progression of that lesion

          -  No ocular melanoma

          -  Baseline bone scan required for patients with known bone metastases, elevated
             alkaline phosphatase, or symptoms raising suspicion of bone metastases

          -  History or clinical evidence of brain metastasis allowed provided the following
             criteria are met:

               -  Completed radiotherapy or surgical treatment of brain lesions AND there is no
                  evidence of CNS progression for  8 weeks

               -  Must not require corticosteroids for treatment of cerebral edema from brain
                  metastases

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  WBC  3,000/mm

          -  Absolute granulocyte count  1,500/mm

          -  Platelet count  100,000/mm

          -  Creatinine  2.0 times upper limit of normal (ULN) OR creatinine clearance  40
             mL/min

          -  Total bilirubin  1.5 times ULN (&lt; 3.0 times ULN in the presence of Gilbert disease)

          -  AST and ALT  2.5 times ULN ( 5.0 times ULN in the presence of liver metastases)

          -  Serum potassium and magnesium normal (repletion allowed)

          -  Total serum calcium or ionized calcium normal

          -  INR  1.5 and PTT normal

               -  Therapeutic anticoagulation with warfarin allowed provided INR  1.5 or PTT
                  normal prior to initiating anticoagulation therapy

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No evidence of bleeding diathesis

          -  No other malignancies except basal cell or squamous cell skin cancer, carcinoma in
             situ of the cervix, ductal or lobular carcinoma in situ of the breast, or other
             malignancies from which the patient has been continuously disease-free for  5 years

          -  Patients must not have any clinically significant cardiovascular disease including
             the following:

               -  Myocardial infarction or ventricular tachyarrhythmia within 6 months

               -  Prolonged QTc &gt;480 msec (Fridericia correction)

               -  Ejection fraction less than institutional normal

               -  Major conduction abnormality (unless a cardiac pacemaker is present)

               -  Patients with any cardiopulmonary symptoms of unknown cause (e.g., shortness of
                  breath, chest pain, etc.) are to be evaluated by a baseline echocardiogram with
                  or without stress test as needed in addition to electrocardiogram (EKG) to rule
                  out QTc prolongation

               -  Patients with underlying cardiopulmonary dysfunction are excluded from the study

          -  No uncontrolled hypertension, defined as systolic blood pressure  150 mm Hg or
             diastolic blood pressure  90 mm Hg

               -  Hypertension that is adequately controlled with medication allowed

          -  No QTc prolongation, defined as a QTc interval  450 msecs

          -  No concurrent serious illness including, but not limited to, ongoing or active
             infection requiring parenteral antibiotics

          -  No psychiatric illness or social situation that would limit compliance with study
             requirements

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Recovered from prior therapy

          -  No prior treatment with targeted therapies directed to C-KIT/PDGFR (e.g., imatinib
             mesylate or sunitinib malate)

          -  Prior limb perfusion allowed

          -  Prior systemic therapy allowed

          -  At least 4 weeks since prior chemotherapy or immunotherapy

               -  Prior adjuvant or neoadjuvant chemotherapy or immunotherapy allowed

          -  At least 4 weeks since prior radiotherapy

          -  No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs (i.e., phenytoin,
             carbamazepine, or phenobarbital), rifampin, or Hypericum perforatum (St. John wort)
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Histologically or cytologically confirmed Squamous Cell Carcinoma of the Head and
             Neck.

          -  Locally advanced disease, unresectable disease or resectable disease where
             organ-preservation is intended

          -  Age &gt; 18 years

          -  Adequate performance status of ECOG 0-2

          -  Life expectancy of at least 3 months

          -  Written informed consent to participate in the study

          -  Patients must have measurable disease, defined as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter to be recorded) as
             &gt;20 mm with conventional techniques or as &gt;10 mm with spiral CT scan.

          -  Patients must have normal organ and marrow function as defined below:

               -  leukocytes   &gt;3,000/uL

               -  absolute neutrophil count &gt;1,500/uL

               -  platelets   &gt;100,000/uL

               -  total bilirubin  within normal institutional limits

               -  AST(SGOT)/ALT(SGPT)       &lt; 2.5X normal .     Creatinine   within normal range
                  and CCT(Cockcroft-Gault) &gt; 50 ml/min

        Exclusion Criteria:

          -  Prior treatment with anti-EGFR or chemotherapy/radiotherapy

          -  Evidence of CNS metastases

          -  Poor performance status (ECOG 3-4)

          -  Evidence of severe or uncontrolled systemic disease (eg. unstable or uncompensated
             respiratory disorder, cardiac failure, hepatic decompensation, renal failure,
             nephritic syndrome, uncontrolled metabolic disorders such as diabetes mellitus,
             uncontrolled hypertension or uncontrolled significant infections)

          -  Pregnancy or breast-feeding (women of child-bearing potential)

          -  Prior severe allergic drug reactions

          -  Prior history of cancer in the last 5 years prior to enrollment, other than
             curatively treated cancer of the cervix or non-melanoma skin cancer.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  21 Years
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients must have a histologic or cytologic diagnosis of epithelial ovarian cancer

          -  Patients are eligible if they have failed to enter a complete remission with
             induction therapy or have relapsed after a period of remission and are not eligible
             for otherwise curative therapy

          -  Patients must not have received any antineoplastic chemotherapy or immunotherapy for
             the four weeks preceding tumor excision; six weeks for nitrosoureas and mitomycin-C

          -  Patients must not have received irradiation for the four weeks prior to removal of
             the tumor and no previously irradiated tumor deposits may be used for tumor lysate in
             the development of the dendritic cell vaccine

          -  Age &gt;18 years.  Because no dosing or adverse event data are currently available on
             the use of Ontak in combination with dendritic cell vaccination in patients &lt;18 years
             of age, children are excluded from this study but may be eligible for future
             pediatric phase 2 combination trials

          -  Life expectancy of greater than three months

          -  Karnofsky performance status must be &gt;70%; (see appendix A)

          -  Patients must have adequate baseline hematopoetic function as defined below.  - The
             following labs must be drawn within four weeks of having the tumor harvested and/or
             receiving the dose of Ontak

               -  total white blood cell count &gt; 2,500/mm3

               -  absolute neutrophil count  &gt; 1,000/mm3

               -  absolute lymphocyte count  &gt; 500/mm3

               -  platelet count      &gt; 80,000/mm3

          -  Patients must have adequate baseline organ function as defined below. The following
             labs must be drawn within four weeks of having the tumor harvested and/or receiving
             the dose of Ontak:

               -  total bilirubin  2.0 mg/dl

               -  AST(SGOT)/ALT(SGPT) &lt;2.5 X institutional upper limit of normal

               -  creatinine 2.0 mg/dl

               -  prothrombin time (INR) 1.5 X institutional upper limit of normal

               -  albumin &gt;3.0 mg/dl

          -  If patients have had recent surgery, then they must be fully recovered from the
             effects of that surgery.

          -  The effects of Ontak on the developing human fetus at the recommended therapeutic
             dose are unknown.  Women of child-bearing potential must agree to use adequate
             contraception (hormonal or barrier method of birth control; abstinence) prior to
             study entry and for the duration of study participation.  Should a woman become
             pregnant or suspect she is pregnant while participating in this study, she should
             inform her treating physician immediately.

          -  Patients must have the ability to understand and the willingness to sign a written
             informed consent document.

        Additional eligibility requirements for vaccine therapy initiation:

          -  Patients are eligible after tumor collection for the vaccine strategy, or for those
             selected to receive ONTAK alone (group 3)  because tumor is not available can enroll
             at ay time they fulfill the Eligibility Criteria.  Pre-vaccination the goal is to
             establish a Minimal Residual Disease state (MRD maximum tumor diameter of any
             residual disease  1cm).  This can be achieved with surgery and/or salvage
             chemotherapy.  Ontak administration and/or vaccine therapy will commence at least 4
             weeks after the completion of the last day of any of the aforementioned therapies

          -  Patients to be randomized to groups 1 and 2 must have tumor available for preparation
             of tumor lysate vaccine

          -  Women and members of all races and ethnic groups are eligible for this trial

        Exclusion Criteria:

          -  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
             nitrosoureas or mitomycin C) prior to entering the study or those who have not
             recovered from adverse events due to agents administered more than 4 weeks earlier

          -  Patients may not be receiving any other investigational agents.

          -  Patients who have received prior anti-tumor vaccines are ineligible

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to monocolonal antibodies from Murine sources

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, active bleeding, symptomatic congestive heart failure, unstable angina
             pectoris, cardiac arrhythmia, uncontrolled bronchospasm, hypertension, hyperglycemia,
             or hypercalcemia; or psychiatric illness/social situations that in the opinion of the
             investigators would compromise the patient's ability to tolerate this treatment or
             affect compliance

          -  Pregnant and lactating women are excluded from this study.  Because there is an
             unknown but potential risk for adverse events in nursing infants, breastfeeding
             should be discontinued if the mother is treated with Ontak.  These potential risks
             may also apply to other agents used in this study

          -  Patients with HIV infection, AIDS, or hepatitis B surface antigen positivity, are
             excluded from this trial.  Patients on combination antiretroviral therapy are
             ineligible because of the potential for pharmacokinetic interactions.  In addition,
             these patients are at increased risk of lethal infections when treated with
             marrow-suppressive therapy

          -  History of corticosteroid use in the four weeks preceding entry onto the clinical
             trial, or the requirement for ongoing corticosteroid use during the study period

          -  Patients who are expected to require therapeutic anticoagulation during the trial
             period

          -  Patients with known brain metastases
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Age less than or equal to 21 years at time of study entry.

          -  No prior therapy for this malignancy except for one dose of intrathecal therapy and
             the use of hydroxyurea or low-dose cytarabine (100-200 mg/m2 per day for one week or
             less ) for hyperleukocytosis.

          -  Written informed consent according to institutional guidelines

          -  Female patients of childbearing potential must have a negative serum pregnancy test
             within 2 weeks prior to enrollment

          -  Male and female participants must use an effective contraceptive method during the
             study and for a minimum of 6 months after study treatment.

        Exclusion Criteria:

          -  Down syndrome

          -  Acute Promyelocytic Leukemia (APL)

          -  Juvenile Myelomonocytic Leukemia (JMML)

          -  Fanconi anemia (FA)

          -  Kostmann syndrome

          -  Shwachman syndrome

          -  Other bone marrow failure syndromes

          -  Use of concomitant chemotherapy, radiation therapy, or immunotherapy other than as
             specified in the protocol.

          -  Use of investigational agents within 30 days or any anticancer therapy within 2 weeks
             before study entry with the exception of  IT therapy, hydroxyurea, or low-dose
             cytarabine as stated above. The patient must have recovered from all acute toxicities
             from any previous therapy.

          -  Systemic fungal, bacterial, viral, or other infection not controlled (defined as
             exhibiting ongoing signs/symptoms related to the infection and without improvement,
             despite appropriate antibiotics or other treatment).

          -  Pregnant or lactating patients.

          -  Any significant concurrent disease, illness, or psychiatric disorder that would
             compromise patient safety or compliance, interfere with consent, study participation,
             follow up, or interpretation of study results.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  21 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Be 18 years or older, diagnosed with LEMS

          -  If female, have negative pregnancy test and if premenopausal, be willing    to
             practice an effective form of birth control during the study.

        Exclusion Criteria:

          -  Is known to have a sensitivity to 3, 4 DAP

          -  Has a history of past or current seizures

          -  Has a history of past or current severe asthma

          -  Is believed by the investigator to be unable to comply with the protocol

          -  Unable to give informed consent
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients with newly histologically confirmed nasopharyngeal carcinoma, including WHO
             II or III

          -  Original clinical stage must be T4 or N2-3 UICC 2002

          -  Male and no pregnant female

          -  Age between 18-60

          -  WBC 4,000/mm3 and PLT  100,000/mm3

          -  With normal liver function test (ALTAST2.5ULN)

          -  With normal renal function test (Creatinine  1.5ULN)

          -  Performance status scale ECOG grade 01

          -  Without radiotherapy or chemotherapy

          -  Patients must give signed informed consent

        Exclusion Criteria:

          -  Patients have evidence of relapse or distant metastasis

          -  The presence of uncontrolled life-threatening illness

          -  Receiving other ways of anti-cancer therapy

          -  Receiving radiotherapy or chemotherapy

          -  Investigator consider the patients can't finish the whole study
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  60 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Confirmed locally advanced or metastatic non-small cell lung cancer that is
             unresectable

          -  At least 1 unirradiated target lesion measurable by RECIST

          -  Adequate hematologic, renal and hepatic function

          -  ECOG 0,1

          -  Able to understand and sign an Informed Consent

        Exclusion Criteria:

          -  Presence of brain metastases, unless the patient received brain irradiation,
             including adequate stereotactic radiosurgery, at least 4 weeks prior to
             randomization, and is stable, asymptomatic, and off steroids for at least 3 weeks
             prior to randomization

          -  Received prior systemic anti-cancer therapy for NSCLC

          -  History of allergic reactions to compounds of similar chemical or biologic
             composition to talactoferrin or the chemotherapy drugs

          -  Any gastrointestinal tract disease or other medical condition resulting in the
             inability to take oral medications

          -  History of other malignancies except:  (i) adequately treated basal or squamous cell
             carcinoma of the skin; (ii) curatively treated, a) in situ carcinoma of the uterine
             cervix, b) prostate cancer, or c) superficial bladder cancer; or (iii) other
             curatively treated solid tumor with no evidence of disease for 5 years

          -  Uncontrolled ischemic heart disease, or uncontrolled symptomatic congestive heart
             failure

          -  Serious active infection

          -  Psychiatric illness/social situations that would limit study compliance

          -  Other uncontrolled serious chronic disease or conditions that in the investigator's
             opinion could render compliance or follow-up in the protocol problematic

          -  Concurrent radiotherapy or radiotherapy within 4 weeks prior to randomization or
             previous radiotherapy at the indicator sites (the sites that are to be followed for
             determination of a response)

          -  Concurrent systemic corticosteroid therapy within 4 weeks prior to randomization,
             except prophylactic use of steroids prior to paclitaxel administration

          -  Known HIV positive or on active anti-retroviral therapy

          -  Known Hepatitis B surface antigen positive or hepatitis C positive

          -  Receipt of any investigational medication within 4 weeks prior to randomization

          -  Pregnant or lactating patients, or fertile female patients with a positive pregnancy
             test, or fertile female patients unwilling to use adequate contraception during
             treatment and for 30 days after completion of treatment

          -  Sexually active male patients unwilling to practice contraception while participating
             on the study and up to 30 days after completion of treatment

          -  Legal incapacity or limited legal capacity, unless authorization is granted by a
             legal guardian
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   DISEASE CHARACTERISTICS:

          -  Newly diagnosed acute lymphoblastic leukemia meeting 1 of the following risk
             definitions:

               -  Standard-risk disease:

                    -  Age 1 to 9 years

                    -  WBC &lt; 50/mm^3 OR TEL/AML1-positive disease

                    -  Good response to prior prednisone (day 8 peripheral blood blast &lt;
                       1,000/mm^3)

                    -  None of the following subtypes:

                         -  T-cell

                         -  t(9;22)

                         -  t(4;11)

                         -  t(1;19)

                         -  Molecular

                    -  Bone marrow (BM) M1 or M2 on day 15, BM remission (&lt; 5% blast) on day 33

               -  Intermediate-risk disease:

                    -  Good response to prior prednisone

                    -  BM M1/M2 on day 15

                    -  Meets 1 of the following criteria:

                         -  At least 10 years old

                         -  WBC &gt; 50/mm^3

                         -  Under 1 year old without MLL gene rearrangement

                         -  T-cell OR t(1;19) OR E2A/PBX1

                         -  Standard-risk patient with BM M3 on day 15

                         -  If minimal residual disease (MRD) available, day 33 MRD &lt; 10^-2

               -  High-risk disease, meeting 1 of the following criteria:

                    -  Poor response to prior prednisone

                    -  t(9;22), BCR/ABL, t(4;11), OR MLL/AF4

                    -  Intermediate-risk patient with BM M3 on day 15

                    -  BM M2/M3 on day 33

                    -  If MRD available, flow cytometry/PCR &gt; 10% on days 15 OR MRD &gt; 10^-2 on day
                       33 OR MRD (before mM or M phase) &gt; 10^-3 on day 84

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  17 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Within 12 weeks prior to study entry, patients must have a confirmed cytologic or
             histological diagnosis of locally advanced squamous cell carcinoma and/or poorly
             differentiated carcinoma of the nasal cavity and/or paranasal sinuses. If the biopsy
             was collected outside of MD Anderson Cancer Center (MDACC), the MDACC Pathology
             Department must assess and confirm the SCC diagnosis.

          2. 2. Stage II-IV disease; T 2-4, N any, M0. Measurable disease is required with the
             following criteria: Measurable lesions can be accurately measured, with at least one
             diameter &gt;\= 1.0 cm by spiral CT scan or MRI. Lesions can be bidimensionally
             measurable or unidimensionally measurable. Every effort should be made to measure
             lesions in two dimensions. Measurable disease is present if the patient has one or
             more measurable lesions. Non-measurable lesions/disease are all other lesions,
             including small lesions (those with measurements &lt; 2.0 cm; or &lt; 1.0 cm with spiral
             CT).

          3. Karnofsky performance status of &gt;/= 70 or ECOG PS 0-1.

          4. Age &gt; 16 years.

          5. Patients should have adequate bone marrow function defined as an absolute peripheral
             granulocyte count (AGC) of &gt;/= 1500 cells/mm3 and platelet count of &gt;/= 100,000
             cells/mm3;

          6. Hepatic Parameters: Total Bilirubin &lt;/= ULN AST and ALT and Alkaline Phosphatase must
             be within the range allowing for eligibility. In determining eligibility the more
             abnormal of the two values (AST or ALT) should be used. **Refer to table in protocol
             pg. 10**

          7. Hemoglobin &gt;/= 10.0g/dL

          8. Per MDACC Creatinine clearance guidelines, patients must have a Creatinine clearance
             &gt; 50 ml/min determined by 24 hour collection or nomogram: CrCl male = (140 - age) x
             (wt in kg)/serum Cr x 72 CrCl female = 0.85 x (CrCl male)

          9. Patients should have no substantial concomitant medical illness, which in the opinion
             of the attending medical oncologist, would render the patient unsuitable for the
             study (i.e., preclude safe administration of the prescribed chemotherapy treatment).

         10. Women Of Child Bearing Potential (WOCBP) must have a negative serum or urine
             pregnancy test (i.e., minimum sensitivity 25 IU/L or equivalent units of HCG), within
             72 hours prior to the start of study treatment. Should a woman become pregnant or
             suspect she is pregnant while participating in the study, she should inform her
             treating physician(s) immediately. **Refer to pg. 10 of the protocol for the formal
             definition of a WOCBP.**

         11. Ability to understand and the willingness to sign a written Informed Consent Document
             (ICD). In the event that non-English speaking participants are eligible for this
             study, a short form (if applicable) or an ICD in their language, will be utilized and
             completed in accordance with the MDACC Policy For Consenting Non-English Speaking
             Participants.

         12. Willingness to undergo MDACC Audiology and Ophthalmology Assessment

        Exclusion Criteria:

          1. Histology other than locally advanced squamous cell carcinoma and/or poorly
             differentiated carcinoma of the nasal cavity and paranasal sinuses.

          2. Evidence of distant metastases (below the clavicle) by clinical or radiographic
             measures.

          3. Karnofsky performance status &lt; 70 or ECOG&gt;1 (Appendices B and BB).

          4. Pre-existing peripheral neuropathy CTCAE grade 2 or worse or pre-existing severe
             bilateral hearing deficits.

          5. Prior chemotherapy (i.e., as administered strictly for cancer treatment) within the
             previous 3 years. Use of chemotherapy agents for non-cancer treatment purposes (i.e.,
             arthritis treatment, etc.) are excluded from this criterion.

          6. Prior radiotherapy to the paranasal sinus region or the upper neck (i.e., prior
             radiotherapy to another disease site is acceptable).

          7. Initial surgical resection of the paranasal sinuses or nasal cavity region rendering
             the patient clinically and radiologically disease free.

          8. Simultaneous primary invasive cancers or patients currently receiving any other
             investigational agents at time of study enrollment. Patients may have received
             investigational agents in the past. No washout time period is required.

          9. Patients with a past history of malignancy (excluding non melanoma skin cancers, and
             cancers treated &gt; 3 years prior for which patient remains continuously disease free).

         10. Men and Women of childbearing potential (WOCBP) who are unwilling or unable to use an
             acceptable method to avoid pregnancy for the entire study period and for up to 3
             months after the study. Subjects who are men must also agree to use effective
             contraception. Note: WOCBP must be using an adequate method of contraception
             throughout the study and for up to 3 months after the study. Adequate methods of
             contraception will include (oral, injectable, or implantable hormonal contraceptive;
             tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or
             vasectomized partner).

         11. Women who are pregnant or breastfeeding.

         12. Patients with a history of severe hypersensitivity reaction to docetaxel or other
             drugs formulated with polysorbate 80. Please refer to Study Appendix O for a complete
             list of Polysorbate 80 containing drugs.

         13. Patients with a history of HIV or Hepatitis C.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  17 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Specialty IBD clinics or GI clinical practices
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  CD patients prescribed TYSABRI within the TOUCH prescribing program Exclusion
             Criteria:
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion criteria:  Pre-screening will be conducted to ensure that all subjects are in
        good neurologic health with no history of seizures or other neurological disorders, and
        that they have no ferromagnetic implants or clips in their body. Subjects will be
        right-handed exclusive-English speakers with normal hearing.

        Exclusion criteria:  If a subject is found to have profound or severe depression after the
        Neuropsychological and Cognitive Testing session they may be excluded from the imaging
        portion of the study. This is justified as the imaging session would not be valid as the
        biologic correlates of depression rather than chemobrain would be imaged. Subjects found
        to have profound or severe depression will be notified and appropriate referral made to
        get them the necessary medical care to treat their depression.

        Three cohorts of 8 women each under the age of 65 will be recruited for this exploratory
        pilot study. The "affected patient cohort" will be woman with complaints of cognitive or
        memory dysfunction who have received adjuvant chemotherapy for the treatment of breast
        cancer. These patients will be those being treated at Huntsman Cancer Hospital and be the
        patients of Dr Saundra Buys or Dr John Ward. The second "patient control cohort" will be
        age-matched woman with breast cancer who have undergone similar adjuvant chemotherapy for
        the same amount of time who have no complaints of memory dysfunction. Again these are
        primarily patients of Drs. Buys or Ward. The non-patient cohort will be age-matched woman
        who have not undergone any type of chemotherapy. These individuals will be recruited from
        friends of female family members of the two breast cancer cohorts. All individuals will be
        assessed for dementia and cognitive impairment using the same battery of dementia and
        cognitive/neuropsychological testing. All subjects will be age-matched as close as
        possible to eliminate age related cognitive effects. Subjects will be right-handed
        exclusive-English speakers with normal hearing. Pre-screening will be conducted to ensure
        that all subjects are in good neurologic health with no history of seizures or other
        neurological disorders, and that they have no ferromagnetic implants or clips in their
        body.

        Up to 40 subjects may be enrolled to ensure 24 evaluable subjects.
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  65 Years
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   -  INCLUSION CRITERIA:

          -  Medically indicated hysterectomy, myomectomy or other surgery for uterine fibroids.

          -  Samples from patients with unusual variants of fibroid disease (HLRCC, benign
             metastasizing leiomyomatosis) will be included. These samples may possibly not arise
             from the uterus proper, as the leiomyoma may have become located elsewhere in the
             body.

        EXCLUSION CRITERIA:

          -  Inability to give consent or understand the consent forms.

          -  HIV-infected tissues will be excluded due to concern of equipment contamination.

          -  Hepatitis-infected tissues will be excluded due to concern of equipment
             contamination.
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  21 Years
 </minimum_age>
 <maximum_age>
  80 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Adult community members with an interest in one or more of the following dermatologic
        conditions: Acne, Actinic Keratosis, Blistering Diseases, Dysplastic Nevi (mole), Eczema,
        Psoriasis, Vitaligo, Skin Cancer Prevention, Skin Cancer Treatment, Phototherapy Treatment
        Options, Rosacea, Leg or Foot Ulcers, Lichen Planus, Atopic Dermatosis, Canker
        Sores,others as indicated.
  </textblock>
 </study_pop>
 <sampling_method>
  Non-Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Over 18 years of age

        Exclusion Criteria:

          -  Under 18 years of age
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   Multicenter patients enrollment
  </textblock>
 </study_pop>
 <sampling_method>
  Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  18-75 years old,male or female

          -  R0 surgery

          -  Pathologically approved as stage II or stage III

          -  Enrolled within 3 months from the date of surgery

          -  Upper border of tumor before surgery was under L5

          -  KPS&gt;70% or ECOG 0-2

          -  No prior chemotherapy or radiotherapy in the past 6 months

          -  HGB&gt;100 g/L, WBC3.5x109 /L, PLT100x109 /L; CR&lt;1.5 x Upper normalityTB&lt;2.5 X Upper
             normalityAST or ALT&lt;2.5 x Upper normalityAKP&lt;2.5 X Upper normality

          -  Signed consent

        Exclusion Criteria:

          -  Other malignancies simultaneously except in situ cervix or nonmelanoma skin cancer

          -  Pregnancy or in lactation

          -  HGB&lt;100 g/L, WBC&lt;3.5x109 /L, PLT&lt;100x109 /L; CR1.5 x Upper normalityTB2.5 X Upper
             normalityAST or ALT2.5 x Upper normalityAKP2.5 X Upper normality
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  75 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <study_pop>
  <textblock>
   asymptomatic high risk patients
  </textblock>
 </study_pop>
 <sampling_method>
  Probability Sample
 </sampling_method>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. High Risk Group 1 (familial Peutz-Jeghers syndrome):

               1. At least 30 years old and &lt;100 years old, and

               2. at least 2 of 3 criteria diagnostic of Peutz-Jeghers syndrome (characteristic
                  intestinal hamartomatous polyps, mucocutaneous melanin deposition, or family
                  history of Peutz-Jeghers syndrome)

               3. known STK-11 gene mutation carrier

          2. High Risk Group 2 (familial pancreatic cancer relatives):

               1. &gt; 50 years old or 10 years younger than the age of youngest relative with
                  pancreatic cancer, and &lt; 80 years old

               2. come from a family with 2 or more members with a history of pancreatic cancer (2
                  of which have a first-degree relationship consistent with familial pancreatic
                  cancer), and

               3. have a first-degree relationship with at least one of the relatives with
                  pancreatic cancer.

             If there are 2 or more affected blood relatives, at least 1 must be a first-degree
             relative of the individual being screened

          3. High Risk Group 3 (germline mutation carriers):

               1. &gt; 40 years old or 10 years younger than the age of the youngest relative with
                  pancreatic cancer, and&lt; 80 years old

               2. patient is carrier of a known BRCA1, BRCA2, PALB2, or FAMMM (p16/CDKN2A)
                  mutation, and there is &gt; 1 pancreatic cancer in the family, one of whom is a
                  first- or second-degree relative of the subject to be screened.

               3. Hereditary pancreatitis syndrome

          4. High Risk Group 4 (young-onset pancreatic cancer relative):

               1. &gt; 50 years old or 10 years younger than the age of youngest relative with
                  pancreatic cancer, and &lt; 80 years old

               2. have a first-degree relationship with at least one relative with young-onset
                  pancreatic cancer ( age of onset &lt; 50 years)

          5. High risk group 5 (both parents affected)

               1. &gt; 50 years old or 10 years younger than the age of the youngest relative with
                  pancreatic cancer, and&lt; 80 years old

               2. two parents affected by pancreatic cancer

          6. Control 1 (Negative Controls):

               1. are undergoing EUS and/or ERCP for non-pancreatic indications as part of their
                  standard medical care, and

               2. have no clinical or radiologic suspicion of pancreatic disease (chronic
                  pancreatitis or pancreatic cancer)

          7. Control 2 (Chronic Pancreatitis)

               1. are undergoing EUS and/or ERCP for  evaluation and/or treatment of suspected or
                  proven chronic pancreatitis as part of their standard medical care, and,

               2. have no clinical or radiologic suspicion of pancreatic cancer

          8. Control 3 (Pancreatic Cancer)

             a. are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or
             proven pancreatic ductal adenocarcinoma (based on clinical and radiologic evidence)

          9. Control 4 (Intraductal Papillary Mucinous Neoplasm or IPMN) a.  are undergoing EUS
             and/or ERCP for evaluation and/or treatment of suspected or proven pancreatic cancer
             precursor, intraductal papillary mucinous neoplasm (based on clinical presentation
             and radiologic or prior EUS or radiologic evidence of a dilated main pancreatic duct
             and/or pancreatic cystic lesion communicating with the pancreatic ductal system)

        Additional requirements for eligible high risk patients: i) All persons with known genetic
        mutation must have proof of mutation status.  Those who had research-related genetic
        testing must have confirmation by a clinical CLIA-certified laboratory. ii) A good faith
        attempt should be made to confirm pancreatic cancers in the family members via
        registration in a pancreatic cancer registry iii) The affected first degree relative of
        the person being screened must be confirmed by medical record or death certificate.

        All control patients must be &gt; 18 and &lt; 80 years old and no personal or family history of
        pancreatic cancer or a germline mutation linked to pancreatic cancer.

        Exclusion Criteria:

        Patients will be excluded if they have any of the following:

          1. medical comorbidities or coagulopathy that contraindicate endoscopy,

          2. Karnosfky performance status of &lt; 60,

          3. had partial or complete resection of their pancreas

          4. had a partial or complete gastrectomy with Billroth or Roux-en-Y anastomosis

          5. a stricture or obstruction in the upper GI tract that does not allow passage of the
             echoendoscope

          6. life expectancy less than 5 years due to coexisting advanced cancer or AIDS.

          7. inability to provide informed consent

          8. pregnant patient

          9. history of pancreatic cancer,

         10. suspicion of pancreatic neoplasia based on clinical history (weight loss, unexplained
             abdominal pain), physical examination (obstructive jaundice, cachexia), laboratory
             tests (cholestastic liver function tests, markedly elevated CA19-9), and/or imaging
             studies (pancreatic mass or cyst, dilated pancreatic and/or bile duct);

         11. there is no interest in undergoing treatment of pancreatic neoplasm(s) detected by
             screening.

         12. history of chronic  kidney disease, serum creatinine &gt; 2.0 mg/dl or estimated
             glomerulofiltration rate (eGFR) &lt; 30 ml/min, ongoing acute renal failure, cirrhosis
             of the liver, chronic hepatitis (The estimated glomerulfiltration rate (eGFR) will be
             calculated based on age, race, and serum creatinine, using the on-line calculator at
             nephron.com).

         13. history of dementia
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  Accepts Healthy Volunteers
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients must have a pathologically confirmed diagnosis either at MSKCC or at the
             participating site of malignant pleural mesothelioma.

          -  No evidence of metastatic disease.

          -  No prior chemotherapy for mesothelioma.

          -  No prior radiation therapy except for localized prostate or pelvic radiation

          -  Patient age  or = to 18 years on day of signing informed consent.

          -  Karnofsky performance status  or = to 70%

          -  Patients must have the ability to take folic acid, Vitamin B12, and dexamethasone
             according to protocol.

          -  Patient must have the ability to interrupt NSAIDS 2 days before (5 days for
             longacting NSAIDs), the day of, and 2 days following administration of pemetrexed.

          -  Pulmonary Function Tests:

          -  FEV1  30% of predicted postoperative (ppoFEV1) (as if the patient underwent a
             pneumonectomy) based on the following formula using the quantitative V/Q scan:

          -  Predicted post-resection FEV1 = FEV1 x % perfusion to uninvolved lung from the
             quantitative V/Q scan report.

          -  DLCO &gt; 35% predicted

          -  Patient must have adequate organ function as indicated by the following laboratory
             values:

          -  Hematological:

          -  Absolute neutrophil count  or = to 1,500 /mcL

          -  Platelets  or = to 100,000 / mcL

          -  Renal Calculated creatinine clearance (CrCl)  or = to 45 mL/min (Creatinine
             clearance must be calculated using Cockcroft &amp; Gault method) In cases of concern
             about renal toxicity from IMRT, an optional nuclear medicine kidney function scan may
             be performed prior to radiation therapy to determine the functional contribution of
             each kidney.

          -  Hepatic

          -  Serum total bilirubin  or = to 1.5 X upper limit of normal (ULN) AST (SGOT) or ALT
             (SGPT)  or = to  3.0 X ULN

        Exclusion Criteria:

          -  Pregnant or lactating women, or men or women not using effective contraception.

          -  Patients with resectable disease for whom extrapleural pneumonectomy is necessary.

          -  Patients with an active infection that require systemic antibiotics, antiviral, or
             antifungal treatments.

          -  Patients with a concurrent active malignancy.

          -  Patients with serious unstable medical illness.

          -  Presence of third space fluid that cannot be controlled by drainage. For patients who
             develop or have baseline clinically significant pleural effusions before or during
             initiation of pemetrexed therapy consideration should be given to draining the
             effusion prior to dosing.

          -  No acute congestive heart failure
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Stage IV histologically proven breast cancer as defined by the AJCC Cancer Staging
             Manual (6 th. Edition 2003).

          -  Patients must have completed one prior form of chemo and/or radiation therapy for
             their disease and have failed to achieve remission.

          -  There must be no clinical or radiographic signs of active brain metastases (CT of
             brain), or disease to the brain that is not considered controlled.

          -  At least 4 weeks must have elapsed since chemotherapy or biological therapy and 2
             weeks must have elapsed since radiotherapy

          -  Female patients must be at least 18 years of age

          -  Must be ambulatory with a ECOG performance status of &lt;2

          -  Must have common recall antigen DTH skin reaction &gt;2 mm

          -  Must have lab values as following ANC &gt; 1.5 x 109/L; platelets &gt; 100 x 109/L, Hb&gt; 9
             g/dL, creatinine &lt; 1.8 mg/dL  or a creatinine clearance &gt; 35 mL/min; total bilirubin
             &lt; 2 the upper limit of normal, AST and ALT &lt; 2.5 the upper limit of normal; albumin
             &gt;2.5 g/L

          -  If of child bearing potential, must practice a reliable method of contraception at
                                                     screening and must agree to continue this
             status until 6 months after receiving the last study vaccine injection.  An HCG
             (pregnancy) test will be done monthly until the 3 vaccinations are complete.

          -  Signed informed consent (see Appendix A, Clinical Protocol section 25.1) to be
             obtained according to ICH GCP guidelines before the patient is subjected to any extra
             diagnostic procedures performed for evaluation of eligibility for the trial.

        Exclusion Criteria:

          -  History of other prior malignancy, with the exception of curatively treated basal
             cell or squamous cell carcinoma of the skin or cervical cancer stage IB

          -  Active infection requiring continuous use of antibiotic therapy

          -  Significant cardiac or other medical illness that would limit activity or survival,
             such as severe congestive heart failure, unstable angina, or serious cardiac
             arrhythmia

          -  Autoimmune disease currently treated with steroids

          -  Adverse reactions to vaccines such as anaphylaxis or other serious reactions, e.g.
             life-threatening reactions to medicine

          -  History of immunodeficiency or autoimmune disease such as rheumatoid
             arthritis,systemic lupus erythematosus, scleroderma, polymyositis dermatomyositis,
             juvenile onset, insulin dependent diabetes, or a vasculitic syndrome

          -  Pregnancy or lactation

          -  Any reason why, in the opinion of the investigator, the patient should not
             participate

          -  Patients who have received cytotoxic anti-tumor therapy within 4 weeks prior to
             vaccination

          -  Patients with active hepatitis (B, C) or HIV+ individuals

          -  Patients with more than four different lines of chemotherapy in the metastatic
             setting (excluding adjuvant chemotherapy).
  </textblock>
 </criteria>
 <gender>
  Female
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  85 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          -  Patients with an autoimmune disorder of the central or peripheral nervous system will
             be eligible; this will include:

               -  Primary Central Nervous System (CNS) vasculitis

               -  Rasmussen's encephalitis

               -  Autoimmune peripheral neuropathy (anti-Hu [Anna-1], anti-GM1 [GD1b], anti-MAG,
                  anti-ganglioside, anti-sulfatide)

               -  Autoimmune cerebellar degeneration

               -  Gait Ataxia with Late Age Onset Polyneuropathy (GALOP)

               -  Stiff Person Syndrome

               -  Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

               -  Myasthenia Gravis

               -  Lambert-Eaton myasthenic syndrome

               -  Human T-cell lymphotropic virus (HTLV)-1-associated myelopathy (HAM) / tropical
                  spastic paraparesis (TSP)

               -  Opsoclonus / myoclonus (anti-Ri)

               -  Neuromyelitis optica

               -  Multiple sclerosis

               -  Other central or peripheral nervous system autoimmune diseases as approved by
                  study neurologists and the Fred Hutchinson Cancer Research Center (FHCRC)
                  faculty at Patient Care Conference (PCC)

          -  Patients must satisfy the criteria for a diagnosis of one of the severe neurological
             autoimmune disorders outlined

          -  Evidence of disease activity as outlined (e.g. gadolinium enhancement on magnetic
             resonance imaging of the brain or clinical progression)

          -  Patients must have failed at least 2 lines of stand therapy as outlined for the
             specific diseases

          -  DONOR: Sibling of any patient enrolled on this protocol proven by ABO typing, human
             leukocyte antigen (HLA) typing and variable number tandem repeat (VNTR) analysis to
             be syngeneic with the patient (e.g. identical twin)

          -  DONOR: Willing to undergo multiple apheresis procedures (except donors &lt; 12 years who
             will undergo bone marrow harvests)

        Exclusion Criteria:

          -  Pregnancy or expressed plans to become pregnant within 1 year of the procedure

          -  Patients who are serologically positive for human immunodeficiency virus (HIV)

          -  Patients with pulmonary, cardiac, hepatic or renal impairment that would limit their
             ability to receive cytoreductive therapy and compromise their survival; this should
             include patients with any of the following:

               -  Severe pulmonary dysfunction associated with a carbon monoxide diffusing
                  capacity (DLCO) (corrected for hemoglobin) &lt; 40%, or requires supplemental
                  oxygen

               -  Uncontrolled malignant arrhythmias, or clinical evidence of congestive heart
                  failure (New York class III-IV) or ejection fraction &lt; 50%

               -  Renal disease with estimated glomerular filtration rate (GFR) by creatinine
                  clearance or iothalamate clearance &lt; 30ml/min/1.73 m^2 body surface area

               -  Serum glutamate pyruvate transaminase (SGPT)/aspartate aminotransferase (AST) &gt;
                  3 times normal or direct bilirubin greater than 2.5 mg/dL on two repeated tests

          -  Active uncontrolled infection

          -  Demonstrated lack of compliance with prior medical care

          -  Patients whose life expectancy is limited by illness other than their neurological
             condition

          -  Patients with evidence of myelodysplasia

          -  Active malignancy (excluding localized squamous cell or basal cell carcinoma of the
             skin)

          -  DONOR: Inadequate documentation that donor and recipient are syngeneic

          -  DONOR: Donors who do not fulfill criteria as apheresis donors as established by
             institutional guidelines

          -  DONOR: Concordant for autoimmune neurological disease(s) as determined by
             neurological evaluation
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  N/A
 </minimum_age>
 <maximum_age>
  70 Years
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligibility>



<eligibility>
 <criteria>
  <textblock>
   Inclusion Criteria:

          1. Histologically or cytologically verified SCLC, all stages

          2. WHO performance status 0, 1, 2 or 3

          3. Age 18 years or older

          4. Intention and feasibility to treat with chemotherapy consisting of platinum +
             topoisomerase inhibitor.

          5. Platelets &gt;100 x109 /L

          6. Signed informed consent

          7. PK (prothrombin complex) INR and APTT within normal ranges.

        Exclusion Criteria:

          1. Prior systemic chemotherapy for lung cancer.

          2. Concomitant anticoagulation treatment, except for ASA or clopidogrel

          3. Active overt bleeding of clinical importance or at high risk (e.g. earlier   observed
              haemorrhage in a brain metastasis, severe coagulopathy as haemophilia, severe liver
             dysfunction with impaired coagulation, acute peptic ulcer, and within the last 3
             months suffered from intracranial haemorrhage, or surgery in the central nervous
             system).

          4. Any other known contraindication for enoxaparine ( e.g. Hypersensitivity against
             enoxaparine and its derivatives).

          5. Pregnancy or breast-feeding

          6. Fertile women not using effective contraceptives or men who do not agree to use
             effective contraception during the treatment period.

          7. Treatment with any other investigational agent, or participation in any other
             clinical trial.
  </textblock>
 </criteria>
 <gender>
  Both
 </gender>
 <minimum_age>
  18 Years
 </minimum_age>
 <maximum_age>
  N/A
 </maximum_age>
 <healthy_volunteers>
  No
 </healthy_volunteers>
</eligib